The	O
fluoroquinolones	B
are	O
a	O
rapidly	O
growing	O
class	O
of	O
antibiotics	B
with	O
a	O
broad	O
spectrum	O
of	O
activity	O
against	O
gram	O
-	O
negative	O
and	O
some	O
gram	O
-	O
positive	O
aerobic	O
bacteria	O
.	O

These	O
agents	O
,	O
including	O
norfloxacin	B
,	O
ciprofloxacin	B
,	O
ofloxacin	B
,	O
enoxacin	B
,	O
and	O
lomefloxacin	B
,	O
have	O
been	O
extensively	O
studied	O
and	O
have	O
demonstrated	O
efficacy	O
and	O
safety	O
profiles	O
comparable	O
to	O
those	O
of	O
other	O
traditional	O
agents	O
for	O
the	O
treatment	O
of	O
complicated	O
or	O
uncomplicated	O
urinary	O
tract	O
infections	O
and	O
prostatitis	O
.	O

Advantages	O
offered	O
by	O
this	O
class	O
of	O
antibiotics	B
include	O
optimal	O
pharmacokinetics	O
,	O
effectiveness	O
against	O
multidrug	O
-	O
resistant	O
organisms	O
,	O
and	O
oral	O
administration	O
even	O
when	O
parenteral	O
antibiotics	B
are	O
generally	O
used	O
.	O

In	O
order	O
to	O
provide	O
information	O
for	O
the	O
appropriate	O
package	O
insert	O
labeling	O
of	O
progestin	O
-	O
only	O
oral	B
contraceptives	I
(	O
POC	B
)	O
in	O
the	O
US	O
,	O
a	O
comprehensive	O
review	O
was	O
made	O
of	O
norgestrel	B
(	O
0	O
.	O
075	O
mg	O
)	O
and	O
norethindrone	B
(	O
0	O
.	O
35	O
mg	O
)	O
,	O
with	O
the	O
clinical	O
differences	O
indicated	O
where	O
applicable	O
.	O

Antimicrobial	O
activity	O
of	O
Ganoderma	B
lucidum	I
extract	I
alone	O
and	O
in	O
combination	O
with	O
some	O
antibiotics	B
.	O

To	O
investigate	O
the	O
effects	O
of	O
antimicrobial	O
combinations	O
of	O
GL	B
with	O
four	O
kinds	O
of	O
antibiotics	B
(	O
ampicillin	B
,	O
cefazolin	B
,	O
oxytetracycline	B
and	O
chloramphenicol	B
)	O
,	O
the	O
fractional	O
inhibitory	O
concentration	O
index	O
(	O
FICI	O
)	O
was	O
determined	O
by	O
checkerboard	O
assay	O
for	O
each	O
strain	O
.	O

The	O
antimicrobial	O
combinations	O
of	O
GL	B
with	O
four	O
antibiotics	B
resulted	O
in	O
additive	O
effect	O
in	O
most	O
instances	O
,	O
synergism	O
in	O
two	O
instances	O
,	O
and	O
antagonism	O
in	O
two	O
instances	O
.	O

Synergism	O
was	O
observed	O
when	O
GL	B
was	O
combined	O
with	O
cefazolin	B
against	O
Bacillus	O
subtilis	O
and	O
Klebsiella	O
oxytoca	O
.	O

On	O
the	O
basis	O
of	O
the	O
estimated	O
number	O
of	O
regular	O
users	O
of	O
intravenous	O
amphetamine	B
in	O
Ontario	O
,	O
the	O
mortality	O
rate	O
in	O
such	O
users	O
is	O
at	O
least	O
four	O
times	O
as	O
high	O
as	O
in	O
the	O
general	O
population	O
of	O
the	O
same	O
age	O
,	O
and	O
is	O
comparable	O
to	O
that	O
in	O
alcoholics	O
and	O
heroin	B
addicts	O
.	O

However	O
,	O
the	O
absolute	O
number	O
of	O
alcohol	B
-	O
related	O
deaths	O
is	O
far	O
greater	O
than	O
the	O
number	O
of	O
deaths	O
in	O
amphetamine	B
or	O
heroin	B
users	O
.	O

Differential	O
regulation	O
of	O
tyrosine	O
phosphorylation	O
in	O
tumor	O
cells	O
by	O
contortrostatin	B
,	O
a	O
homodimeric	O
disintegrin	O
,	O
and	O
monomeric	O
disintegrins	O
echistatin	B
and	O
flavoridin	B
.	O

The	O
homodimeric	O
disintegrin	O
contortrostatin	B
was	O
compared	O
directly	O
to	O
the	O
monomeric	O
disintegrins	O
echistatin	B
and	O
flavoridin	B
for	O
the	O
ability	O
to	O
affect	O
protein	O
tyrosine	O
phosphorylation	O
in	O
tumor	O
cells	O
.	O

Echistatin	B
alone	O
had	O
no	O
effect	O
on	O
tyrosine	O
phosphorylation	O
in	O
T24	O
cells	O
,	O
but	O
dose	O
-	O
dependently	O
inhibits	O
the	O
effects	O
of	O
contortrostatin	B
when	O
both	O
are	O
added	O
simultaneously	O
.	O

Flavoridin	B
alone	O
was	O
found	O
to	O
have	O
no	O
effect	O
on	O
CAS	O
,	O
but	O
can	O
completely	O
block	O
contortrostatin	B
-	O
induced	O
phosphorylation	O
of	O
this	O
protein	O
in	O
MDA	O
-	O
MB	O
-	O
435	O
cells	O
.	O

Diethyl	B
pyrocarbonate	I
,	O
at	O
pH	O
7	O
.	O
0	O
,	O
was	O
used	O
to	O
chemically	O
modify	O
exposed	O
histidine	O
residues	O
on	O
toxin	B
A	I
.	O

Modification	O
of	O
toxin	B
A	I
with	O
diethyl	B
pyrocarbonate	I
abolished	O
both	O
its	O
cytotoxic	O
activity	O
and	O
the	O
ability	O
of	O
the	O
toxin	B
to	O
bind	O
Zn	O
-	O
Sepharose	O
gel	O
.	O

Treatment	O
of	O
toxin	B
A	I
with	O
[	O
(	O
14	O
)	O
C	O
]	O
-	O
diethyl	B
pyrocarbonate	I
revealed	O
concentration	O
dependent	O
labelling	O
of	O
histidine	O
residues	O
on	O
the	O
toxin	B
molecules	O
.	O

The	O
effects	O
of	O
diethyl	B
pyrocarbonate	I
could	O
be	O
reversed	O
by	O
hydroxylamine	B
treatment	O
.	O

Exposed	O
histidines	O
on	O
toxin	B
A	I
are	O
available	O
for	O
zinc	B
chelation	O
,	O
and	O
these	O
have	O
been	O
exploited	O
in	O
the	O
development	O
of	O
a	O
novel	O
purification	O
protocol	O
for	O
toxin	B
A	I
using	O
zinc	B
-	O
chelating	O
chromatography	O
.	O

Note	O
:	O
dissolution	O
of	O
aerosol	O
particles	O
of	O
budesonide	B
in	O
Survanta	B
,	O
a	O
model	O
lung	B
surfactant	I
.	O

The	O
effect	O
of	O
a	O
pulmonary	B
surfactant	I
extract	O
from	O
bovine	O
lung	O
,	O
Survanta	B
,	O
on	O
the	O
dissolution	O
rate	O
of	O
aerosol	O
particles	O
of	O
budesonide	B
was	O
determined	O
.	O

Aerosol	O
particles	O
of	O
budesonide	B
were	O
generated	O
from	O
an	O
ethanol	B
solution	O
,	O
dried	O
,	O
and	O
collected	O
by	O
a	O
cascade	O
impactor	O
for	O
characterization	O
or	O
by	O
a	O
liquid	O
impinger	O
for	O
dissolution	O
experiments	O
.	O

Survanta	B
increased	O
the	O
extent	O
of	O
dissolution	O
of	O
budesonide	B
in	O
proportion	O
to	O
the	O
added	O
concentration	O
,	O
which	O
was	O
also	O
verified	O
by	O
equilibrium	O
solubilization	O
studies	O
.	O

Survanta	B
also	O
increased	O
rate	O
of	O
dissolution	O
,	O
in	O
a	O
manner	O
similar	O
to	O
sodium	B
dodecyl	I
sulfate	I
.	O

Analysis	O
of	O
the	O
concentration	O
of	O
budesonide	B
following	O
ultracentrifugation	O
indicated	O
that	O
there	O
is	O
rapid	O
equilibration	O
of	O
budesonide	B
between	O
the	O
Survanta	B
and	O
aqueous	O
phase	O
.	O

As	O
immediate	O
-	O
early	O
genes	O
(	O
IEGs	O
)	O
are	O
thought	O
to	O
play	O
a	O
critical	O
role	O
in	O
mediating	O
stimulus	O
-	O
induced	O
neural	O
plasticity	O
,	O
IEG	O
response	O
induced	O
by	O
methamphetamine	B
(	O
METH	B
)	O
has	O
been	O
characterized	O
to	O
define	O
the	O
changes	O
in	O
gene	O
expression	O
that	O
may	O
underlie	O
its	O
long	O
-	O
lasting	O
behavioral	O
effects	O
.	O

Using	O
in	O
situ	O
hybridization	O
,	O
we	O
observed	O
that	O
METH	B
caused	O
a	O
rapid	O
and	O
transient	O
dose	O
-	O
dependent	O
increase	O
in	O
arc	O
mRNA	O
level	O
in	O
the	O
striatum	O
and	O
cortex	O
that	O
was	O
abolished	O
by	O
pretreatment	O
with	O
the	O
specific	O
dopamine	O
D1	O
receptor	O
antagonist	O
SCH	O
-	O
23390	O
but	O
not	O
by	O
an	O
atypical	B
neuroleptic	I
clozapine	I
.	O

The	O
effects	O
of	O
DCG	O
-	O
IV	O
and	O
L	O
-	O
CCG	O
-	O
1	O
upon	O
phencyclidine	B
(	O
PCP	B
)	O
-	O
induced	O
locomotion	O
and	O
behavioral	O
changes	O
in	O
mice	O
.	O

injection	O
of	O
phencyclidine	B
(	O
PCP	B
)	O
were	O
observed	O
by	O
measuring	O
locomotor	O
activity	O
and	O
stereotyped	O
behavior	O
.	O

Then	O
,	O
the	O
effects	O
of	O
metabotropic	O
glutamate	O
receptor	O
(	O
mGluR	O
)	O
agonists	O
,	O
DCG	O
-	O
IV	O
and	O
L	O
-	O
CCG	O
-	O
1	O
,	O
on	O
the	O
above	O
behavioral	O
changes	O
induced	O
by	O
PCP	B
were	O
found	O
.	O

The	O
effects	O
of	O
DCG	O
-	O
IV	O
were	O
very	O
strong	O
and	O
completely	O
depressed	O
the	O
PCP	B
-	O
induced	O
hyperlocomotion	O
.	O

In	O
order	O
to	O
examine	O
some	O
molecular	O
mechanisms	O
of	O
PCP	B
-	O
induced	O
behavioral	O
changes	O
,	O
Northern	O
blot	O
analysis	O
of	O
total	O
RNA	O
from	O
prefrontal	O
cortical	O
tissues	O
of	O
mice	O
treated	O
with	O
PCP	B
,	O
DCG	O
-	O
IV	O
,	O
and	O
L	O
-	O
CCG	O
-	O
1	O
was	O
carried	O
out	O
.	O

Behavioral	O
responses	O
to	O
repeated	O
cocaine	B
exposure	O
in	O
mice	O
selectively	O
bred	O
for	O
differential	O
sensitivity	O
to	O
pentobarbital	B
.	O

Mice	O
from	O
the	O
20th	O
generation	O
of	O
three	O
lines	O
divergently	O
selected	O
for	O
response	O
to	O
pentobarbital	B
-	O
induced	O
sedation	O
times	O
[	O
long	O
-	O
sedation	O
time	O
(	O
LST	O
)	O
,	O
short	O
sedation	O
time	O
(	O
SST	O
)	O
,	O
and	O
randomly	O
bred	O
control	O
(	O
RBC	O
)	O
]	O
were	O
used	O
to	O
study	O
cocaine	B
-	O
induced	O
behavioral	O
sensitization	O
.	O

18	O
-	O
Methoxycoronaridine	O
(	O
18	O
-	O
MC	O
)	O
and	O
ibogaine	B
:	O
comparison	O
of	O
antiaddictive	O
efficacy	O
,	O
toxicity	O
,	O
and	O
mechanisms	O
of	O
action	O
.	O

Like	O
ibogaine	B
(	O
40	O
mg	O
/	O
kg	O
)	O
,	O
18	O
-	O
MC	O
(	O
40	O
mg	O
/	O
kg	O
)	O
decreases	O
the	O
intravenous	O
self	O
-	O
administration	O
of	O
morphine	B
and	O
cocaine	B
and	O
the	O
oral	O
self	O
-	O
administration	O
of	O
ethanol	B
and	O
nicotine	B
in	O
rats	O
;	O

unlike	O
ibogaine	B
,	O
18	O
-	O
MC	O
does	O
not	O
affect	O
responding	O
for	O
a	O
nondrug	O
reinforcer	O
(	O
water	O
)	O
.	O

Both	O
ibogaine	B
and	O
18	O
-	O
MC	O
ameliorate	O
opioid	B
withdrawal	O
signs	O
.	O

Both	O
ibogaine	B
and	O
18	O
-	O
MC	O
decrease	O
extracellular	O
levels	O
of	O
dopamine	O
in	O
the	O
nucleus	O
accumbens	O
,	O
but	O
only	O
ibogaine	B
increases	O
extracellular	O
levels	O
of	O
serotonin	O
in	O
the	O
nucleus	O
accumbens	O
.	O

Both	O
ibogaine	B
and	O
18	O
-	O
MC	O
block	O
morphine	B
-	O
induced	O
and	O
nicotine	B
-	O
induced	O
dopamine	O
release	O
in	O
the	O
nucleus	O
accumbens	O
;	O

only	O
ibogaine	B
enhances	O
cocaine	B
-	O
induced	O
increases	O
in	O
accumbal	O
dopamine	O
.	O

Both	O
ibogaine	B
and	O
18	O
-	O
MC	O
enhance	O
the	O
locomotor	O
and	O
/	O
or	O
stereotypic	O
effects	O
of	O
stimulants	O
.	O

Ibogaine	B
attenuates	O
,	O
but	O
18	O
-	O
MC	O
potentiates	O
,	O
the	O
acute	O
locomotor	O
effects	O
of	O
morphine	B
;	O

both	O
compounds	O
attenuate	O
morphine	B
-	O
induced	O
locomotion	O
in	O
morphine	B
-	O
experienced	O
rats	O
.	O

Ibogaine	B
,	O
but	O
not	O
18	O
-	O
MC	O
,	O
decreases	O
heart	O
rate	O
at	O
high	O
doses	O
.	O

While	O
18	O
-	O
MC	O
and	O
ibogaine	B
have	O
similar	O
affinities	O
for	O
kappa	O
opioid	O
and	O
possibly	O
nicotinic	O
receptors	O
,	O
18	O
-	O
MC	O
has	O
much	O
lower	O
affinities	O
than	O
ibogaine	B
for	O
NMDA	O
and	O
sigma	O
-	O
2	O
receptors	O
,	O
sodium	O
channels	O
,	O
and	O
the	O
5	O
-	O
HT	O
transporter	O
.	O

Both	O
18	O
-	O
MC	O
and	O
ibogaine	B
are	O
sequestered	O
in	O
fat	O
and	O
,	O
like	O
ibogaine	B
,	O
18	O
-	O
MC	O
probably	O
has	O
an	O
active	O
metabolite	O
.	O

The	O
data	O
suggest	O
that	O
18	O
-	O
MC	O
has	O
a	O
narrower	O
spectrum	O
of	O
actions	O
and	O
will	O
have	O
a	O
substantially	O
greater	O
therapeutic	O
index	O
than	O
ibogaine	B
.	O

Clinical	O
implications	O
of	O
warfarin	B
interactions	O
with	O
five	O
sedatives	B
.	O

The	O
intensity	O
,	O
uniformity	O
and	O
time	O
course	O
of	O
anticoagulant	B
interference	O
by	O
phenobarbital	B
,	O
secobarbital	B
,	O
glutethimide	B
,	O
chloral	B
hydrate	I
and	O
methaqualone	B
were	O
systematically	O
investigated	O
in	O
16	O
patients	O
receiving	O
coumarin	B
therapy	O
.	O

Anticoagulant	O
inhibition	O
was	O
observed	O
during	O
the	O
administration	O
of	O
phenobarbital	B
,	O
secobarbital	B
and	O
glutethimide	B
;	O

there	O
was	O
no	O
significant	O
change	O
in	O
prothrombin	O
test	O
results	O
during	O
the	O
trials	O
of	O
chloral	B
hydrate	I
and	O
methaqualone	B
.	O

Barbiturates	B
and	O
glutethimide	B
should	O
not	O
be	O
administered	O
to	O
patients	O
receiving	O
coumarin	B
drugs	I
.	O

Chloral	B
hydrate	I
and	O
methaqualone	B
interact	O
pharmacologically	O
with	O
orally	O
administered	O
anticoagulant	B
agents	I
,	O
but	O
the	O
effect	O
is	O
not	O
clinically	O
significant	O
.	O

It	O
is	O
concluded	O
that	O
chloral	B
hydrate	I
and	O
methaqualone	B
may	O
be	O
administered	O
safely	O
without	O
additional	O
caution	O
in	O
prothrombin	O
test	O
monitoring	O
during	O
oral	O
anticoagulant	B
therapy	O
.	O

Concomitantly	O
given	O
thiazide	B
diuretics	I
did	O
not	O
interfere	O
with	O
the	O
absorption	O
of	O
a	O
tablet	O
of	O
digoxin	B
.	O

Combinations	O
of	O
clozapine	B
and	O
phencyclidine	B
:	O
effects	O
on	O
drug	O
discrimination	O
and	O
behavioral	O
inhibition	O
in	O
rats	O
.	O

Phencyclidine	B
(	O
PCP	B
)	O
produces	O
psychotomimetic	O
effects	O
in	O
humans	O
that	O
resemble	O
schizophrenia	O
symptoms	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
atypical	B
antipsychotic	I
clozapine	I
was	O
tested	O
in	O
combination	O
with	O
an	O
active	O
dose	O
of	O
PCP	B
in	O
two	O
-	O
lever	O
drug	O
discrimination	O
and	O
mixed	O
signalled	O
-	O
unsignalled	O
differential	O
-	O
reinforcement	O
-	O
of	O
-	O
low	O
-	O
rates	O
(	O
DRL	O
)	O
procedures	O
.	O

PCP	B
produced	O
distinctive	O
effects	O
in	O
each	O
task	O
:	O
it	O
substituted	O
for	O
the	O
training	O
dose	O
in	O
PCP	B
discrimination	O
and	O
it	O
increased	O
the	O
number	O
of	O
responses	O
with	O
short	O
(	O
<	O
3	O
s	O
)	O
interresponse	O
times	O
as	O
well	O
as	O
increasing	O
overall	O
response	O
rates	O
in	O
the	O
DRL	O
schedule	O
.	O

Acute	O
dosing	O
with	O
clozapine	B
failed	O
to	O
alter	O
the	O
behavioral	O
effects	O
of	O
PCP	B
in	O
either	O
procedure	O
even	O
when	O
tested	O
up	O
to	O
doses	O
that	O
produced	O
pharmacological	O
effects	O
alone	O
.	O

These	O
results	O
suggest	O
that	O
acute	O
dosing	O
with	O
clozapine	B
would	O
not	O
affect	O
behaviors	O
most	O
closely	O
associated	O
with	O
PCP	B
intoxication	O
.	O

Since	O
chronic	O
dosing	O
is	O
required	O
for	O
therapeutic	O
efficacy	O
of	O
antipsychotics	B
,	O
future	O
studies	O
should	O
focus	O
on	O
investigation	O
of	O
chronic	O
dosing	O
effects	O
of	O
these	O
drugs	O
in	O
combination	O
with	O
PCP	B
.	O

Resveratrol	B
(	O
5	O
-	O
35	O
micromol	O
/	O
l	O
)	O
induced	O
concentration	O
-	O
dependent	O
relaxation	O
of	O
mesenteric	O
arteries	O
preconstricted	O
with	O
noradrenaline	B
(	O
8	O
micromol	O
/	O
l	O
)	O
or	O
KCl	B
(	O
125	O
mmol	O
/	O
l	O
)	O
from	O
both	O
lean	O
and	O
dietary	O
-	O
obese	O
rats	O
.	O

However	O
,	O
L	O
-	O
NAME	O
(	O
100	O
and	O
300	O
micromol	O
/	O
l	O
)	O
did	O
not	O
alter	O
the	O
effects	O
of	O
reseveratrol	B
on	O
arteries	O
from	O
dietary	O
-	O
obese	O
rats	O
,	O
giving	O
superimposed	O
concentration	O
-	O
responses	O
curves	O
.	O

Indomethacin	B
was	O
also	O
ineffective	O
in	O
altering	O
resveratrol	B
activity	O
in	O
arteries	O
from	O
both	O
lean	O
and	O
dietary	O
-	O
obese	O
rats	O
.	O

In	O
noradrenaline	B
-	O
precontracted	O
arteries	O
from	O
dietary	O
-	O
obese	O
rats	O
,	O
responses	O
to	O
resveratrol	B
were	O
not	O
attenuated	O
by	O
endothelial	O
denudation	O
,	O
indicating	O
an	O
action	O
independent	O
of	O
the	O
endothelium	O
.	O

This	O
study	O
indicates	O
that	O
:	O
(	O
a	O
)	O
the	O
maximal	O
effects	O
of	O
resveratrol	B
on	O
resistance	O
arteries	O
from	O
lean	O
and	O
dietary	O
-	O
obese	O
rats	O
are	O
not	O
effected	O
by	O
endothelial	O
dysfunction	O
,	O
and	O
(	O
b	O
)	O
the	O
effects	O
of	O
resveratrol	B
in	O
lean	O
animals	O
(	O
where	O
endothelial	O
function	O
is	O
not	O
impaired	O
)	O
,	O
but	O
not	O
in	O
dietary	O
-	O
obese	O
rats	O
,	O
are	O
mediated	O
via	O
NO	O
.	O

If	O
taken	O
1	O
hour	O
before	O
indinavir	B
(	O
IDV	B
)	O
,	O
didanosine	B
does	O
not	O
affect	O
IDV	B
exposure	O
,	O
despite	O
persistent	O
buffering	O
effects	O
.	O

Concurrent	O
administration	O
of	O
indinavir	B
and	O
didanosine	B
significantly	O
reduces	O
the	O
level	O
of	O
exposure	O
to	O
indinavir	B
,	O
but	O
it	O
is	O
unclear	O
how	O
soon	O
after	O
didanosine	B
administration	O
indinavir	B
may	O
be	O
given	O
safely	O
.	O

We	O
compared	O
indinavir	B
pharmacokinetics	O
and	O
gastric	O
pH	O
in	O
12	O
human	O
immunodeficiency	O
virus	O
-	O
positive	O
patients	O
by	O
use	O
of	O
800	O
mg	O
of	O
indinavir	B
alone	O
versus	O
800	O
mg	O
of	O
indinavir	B
administered	O
1	O
h	O
after	O
didanosine	B
administration	O
.	O

Median	O
gastric	O
pH	O
was	O
significantly	O
higher	O
when	O
indinavir	B
was	O
taken	O
after	O
didanosine	B
administration	O
;	O

Indinavir	B
may	O
be	O
taken	O
with	O
a	O
light	O
meal	O
1	O
h	O
following	O
the	O
administration	O
of	O
400	O
mg	O
of	O
didanosine	B
.	O

Cytochalasin	B
D	I
at	O
10	O
microM	O
preferentially	O
blocked	O
the	O
secretory	O
effect	O
of	O
carbachol	B
and	O
its	O
synergism	O
with	O
cAMP	O
,	O
whereas	O
it	O
had	O
no	O
effect	O
on	O
histamine	O
-	O
or	O
cAMP	O
-	O
stimulated	O
acid	O
secretion	O
within	O
15	O
min	O
.	O

Cytochalasin	B
D	I
inhibited	O
the	O
carbachol	B
-	O
stimulated	O
intracellular	O
Ca	O
(	O
2	O
+	O
)	O
concentration	O
(	O
[	O
Ca	O
(	O
2	O
+	O
)	O
]	O
(	O
i	O
)	O
)	O
increase	O
due	O
to	O
release	O
from	O
the	O
Ca	O
(	O
2	O
+	O
)	O
store	O
.	O

The	O
percentage	O
of	O
neurons	O
hyperpolarized	O
by	O
mu	O
-	O
,	O
delta	O
(	O
1	O
)	O
-	O
,	O
and	O
kappa	O
-	O
selective	O
opioids	B
was	O
significantly	O
reduced	O
when	O
1	O
%	O
but	O
not	O
<	O

Suppression	O
by	O
verapamil	B
of	O
bombesin	B
-	O
enhanced	O
peritoneal	O
metastasis	O
of	O
intestinal	O
adenocarcinomas	O
induced	O
by	O
azoxymethane	B
in	O
wistar	O
rats	O
.	O

BACKGROUND	O
:	O
The	O
effects	O
of	O
combined	O
administration	O
of	O
bombesin	B
and	O
verapamil	B
hydrochloride	I
(	O
verapamil	B
)	O
,	O
a	O
calcium	B
channel	I
blocker	I
,	O
on	O
the	O
incidence	O
of	O
peritoneal	O
metastasis	O
of	O
intestinal	O
adenocarcinomas	O
induced	O
by	O
azoxymethane	B
(	O
AOM	B
)	O
and	O
the	O
labeling	O
index	O
of	O
intestinal	O
cancers	O
were	O
investigated	O
in	O
male	O
Wistar	O
rats	O
.	O

METHODS	O
:	O
From	O
the	O
beginning	O
of	O
the	O
experiment	O
,	O
rats	O
were	O
given	O
10	O
weekly	O
subcutaneous	O
injections	O
of	O
AOM	B
(	O
7	O
.	O
4	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
and	O
subcutaneous	O
injections	O
of	O
bombesin	B
(	O
40	O
microg	O
/	O
kg	O
body	O
weight	O
)	O
every	O
other	O
day	O
,	O
and	O
from	O
week	O
16	O
,	O
intraperitoneal	O
injections	O
of	O
verapamil	B
(	O
10	O
or	O
20	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
every	O
other	O
day	O
until	O
the	O
end	O
fo	O
the	O
experiment	O
in	O
week	O
45	O
.	O

Although	O
verapamil	B
administered	O
at	O
either	O
dose	O
had	O
little	O
or	O
no	O
effect	O
on	O
the	O
enhancement	O
of	O
intestinal	O
carcinogenesis	O
by	O
bombesin	B
or	O
on	O
the	O
location	O
,	O
histologic	O
type	O
,	O
depth	O
of	O
involvement	O
,	O
labeling	O
index	O
,	O
apoptotic	O
index	O
or	O
tumor	O
vascularity	O
of	O
intestinal	O
cancers	O
,	O
it	O
significantly	O
decreased	O
the	O
incidence	O
of	O
cancer	O
metastasis	O
.	O

Verapamil	B
also	O
significantly	O
decreased	O
the	O
incidence	O
of	O
lymphatic	O
invasion	O
of	O
adenocarcinomas	O
,	O
which	O
was	O
enhanced	O
by	O
bombesin	B
.	O

In	O
vitro	O
interaction	O
of	O
prostaglandin	B
F2alpha	I
and	O
oxytocin	B
in	O
placental	O
vessels	O
.	O

The	O
interaction	O
of	O
prostaglandin	B
F2alpha	I
and	O
synthetic	O
oxytocin	B
on	O
placental	O
vessels	O
was	O
studied	O
in	O
vitro	O
.	O

In	O
seven	O
experiments	O
reactions	O
to	O
norepinephrine	B
and	O
oxytocin	B
were	O
PGF2alpha	B
.	O

PGF2alpha	B
produced	O
significantly	O
increased	O
vasoconstriction	O
after	O
a	O
single	O
administration	O
of	O
oxytocin	B
.	O

There	O
is	O
thus	O
an	O
enhancement	O
effect	O
of	O
PGF2alpha	B
upon	O
the	O
reaction	O
of	O
placental	O
vessels	O
to	O
oxytocin	B
in	O
vitro	O
.	O

Carbamazepine	B
overdose	O
recognized	O
by	O
a	O
tricyclic	B
antidepressant	I
assay	O
.	O

We	O
report	O
the	O
case	O
of	O
an	O
adolescent	O
with	O
altered	O
consciousness	O
caused	O
by	O
carbamazepine	B
overdose	O
with	O
a	O
positive	O
tricyclic	B
antidepressant	I
level	O
to	O
alert	O
clinicians	O
to	O
the	O
cross	O
-	O
reactivity	O
of	O
carbamazepine	B
with	O
a	O
toxicology	O
screen	O
for	O
tricyclic	B
antidepressants	I
.	O

Cypermethrin	B
-	O
induced	O
oxidative	O
stress	O
in	O
rat	O
brain	O
and	O
liver	O
is	O
prevented	O
by	O
vitamin	B
E	I
or	O
allopurinol	B
.	O

Considering	O
that	O
the	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
has	O
been	O
implicated	O
in	O
the	O
toxicity	O
of	O
various	O
pesticides	O
,	O
this	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
possibility	O
of	O
oxidative	O
stress	O
induction	O
by	O
cypermethrin	B
,	O
a	O
Type	B
II	I
pyrethroid	I
.	O

Pretreatment	O
of	O
rats	O
with	O
allopurinol	B
(	O
100	O
mg	O
/	O
kg	O
,	O
ip	O
)	O
or	O
Vitamin	B
E	I
(	O
100	O
mg	O
/	O
kg	O
per	O
day	O
,	O
ig	O
,	O
for	O
3	O
days	O
and	O
a	O
dose	O
of	O
40	O
mg	O
/	O
kg	O
on	O
the	O
4th	O
day	O
)	O
provided	O
significant	O
protection	O
against	O
the	O
elevation	O
of	O
TBARS	O
levels	O
in	O
cerebral	O
and	O
hepatic	O
tissues	O
,	O
induced	O
by	O
single	O
high	O
dose	O
of	O
oral	O
cypermethrin	B
administration	O
within	O
4	O
h	O
.	O

Thus	O
,	O
the	O
results	O
suggest	O
that	O
cypermethrin	B
exposure	O
of	O
rats	O
results	O
in	O
free	O
radical	O
-	O
mediated	O
tissue	O
damage	O
,	O
as	O
indicated	O
by	O
elevated	O
cerebral	O
and	O
hepatic	O
lipid	O
peroxidation	O
,	O
which	O
was	O
prevented	O
by	O
allopurinol	B
and	O
Vitamin	B
E	I
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effect	O
of	O
ginsenosides	B
on	O
high	O
threshold	O
voltage	O
-	O
dependent	O
Ca	O
(	O
2	O
+	O
)	O
channel	B
subtypes	O
using	O
their	O
selective	B
Ca	O
(	O
2	O
+	O
)	O
channel	B
blockers	I
nimodipine	I
(	O
L	O
-	O
type	O
)	O
,	O
omega	O
-	O
conotoxin	O
GVIA	B
(	O
N	O
-	O
type	O
)	O
,	O
or	O
omega	O
-	O
agatoxin	O
IVA	B
(	O
P	O
-	O
type	O
)	O
in	O
bovine	O
chromaffin	O
cells	O
.	O

Nimodipine	B
had	O
no	O
effect	O
on	O
ginsenosides	B
response	O
.	O

These	O
data	O
suggest	O
that	O
ginsenosides	B
are	O
negatively	O
coupled	O
to	O
three	O
types	O
of	O
calcium	O
channels	O
in	O
bovine	O
chromaffin	O
cell	O
,	O
including	O
an	O
omega	O
-	O
conotoxin	O
GVIA	B
-	O
sensitive	O
(	O
N	O
-	O
type	O
)	O
channel	O
,	O
an	O
omega	O
-	O
agatoxin	O
IVA	B
-	O
sensitive	O
(	O
P	O
-	O
type	O
)	O
channel	O
and	O
nimodipine	B
/	O
omega	O
-	O
conotoxin	O
GVIA	B
/	O
omega	O
-	O
agatoxin	O
VIA	B
-	O
resistant	O
(	O
presumptive	O
Q	O
-	O
type	O
)	O
channel	O
.	O

Thus	O
,	O
the	O
selective	O
regulation	O
of	O
voltage	O
-	O
dependent	O
Ca	O
(	O
2	O
+	O
)	O
subtypes	O
by	O
ginsenosides	B
in	O
bovine	O
chromaffin	O
cell	O
could	O
be	O
the	O
cellular	O
basis	O
of	O
antistress	O
effects	O
induced	O
by	O
ginseng	B
.	O

In	O
vitro	O
activity	O
of	O
KRM	O
-	O
1648	O
,	O
either	O
singly	O
or	O
in	O
combination	O
with	O
ofloxacin	B
,	O
against	O
Mycobacterium	O
ulcerans	O
.	O

The	O
antimicrobial	O
effect	O
of	O
a	O
benzoxazinorifamycin	B
,	O
KRM	O
-	O
1648	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
ofloxacin	B
,	O
was	O
evaluated	O
in	O
vitro	O
against	O
two	O
type	O
strains	O
and	O
six	O
clinical	O
isolates	O
of	O
Mycobacterium	O
ulcerans	O
.	O

ulcerans	O
was	O
between	O
0	O
.	O
012	O
and	O
0	O
.	O
025	O
mg	O
/	O
l	O
,	O
while	O
corresponding	O
values	O
for	O
rifampicin	B
and	O
rifabutin	B
were	O
in	O
the	O
range	O
of	O
0	O
.	O
1	O
-	O
0	O
.	O
8	O
mg	O
/	O
l	O
and	O
0	O
.	O
1	O
-	O
0	O
.	O
4	O
mg	O
/	O
l	O
respectively	O
.	O

When	O
combined	O
with	O
ofloxacin	B
,	O
KRM	O
-	O
1648	O
exhibited	O
strong	O
synergistic	O
activity	O
while	O
only	O
additive	O
effects	O
were	O
observed	O
with	O
the	O
combination	O
of	O
rifampicin	B
(	O
or	O
rifabutin	B
)	O
and	O
ofloxacin	B
.	O

The	O
effects	O
of	O
ruthenium	B
red	I
(	O
RR	B
)	O
on	O
inositol	B
1	O
,	O
4	O
,	O
5	O
-	O
trisphosphate	O
(	O
InsP	O
(	O
3	O
)	O
)	O
-	O
induced	O
responses	O
were	O
studied	O
in	O
rat	O
bone	O
marrow	O
megakaryocytes	O
with	O
the	O
patch	O
-	O
clamp	O
whole	O
-	O
cell	O
recording	O
technique	O
in	O
combination	O
with	O
fura	O
-	O
2	O
microfluorometry	O
.	O

Administering	O
InsP	O
(	O
3	O
)	O
together	O
with	O
RR	B
(	O
100	O
-	O
500	O
microM	O
)	O
inhibited	O
InsP	O
(	O
3	O
)	O
-	O
induced	O
responses	O
(	O
both	O
Ca	O
(	O
2	O
+	O
)	O
and	O
current	O
responses	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

Pretreatment	O
of	O
megakaryocytes	O
with	O
extracellular	O
RR	B
(	O
50	O
microM	O
)	O
also	O
inhibited	O
InsP	O
(	O
3	O
)	O
-	O
induced	O
responses	O
.	O

In	O
contrast	O
,	O
in	O
isolated	O
single	O
pancreatic	O
acinar	O
cells	O
,	O
RR	B
had	O
no	O
effect	O
on	O
InsP	O
(	O
3	O
)	O
-	O
induced	O
responses	O
.	O

In	O
addition	O
,	O
we	O
have	O
shown	O
that	O
RR	B
is	O
a	O
useful	O
pharmacological	O
tool	O
with	O
which	O
to	O
examine	O
the	O
InsP	O
(	O
3	O
)	O
-	O
mediated	O
responses	O
of	O
megakaryocytes	O
.	O

Effect	O
of	O
rofecoxib	B
on	O
the	O
pharmacokinetics	O
of	O
digoxin	B
in	O
healthy	O
volunteers	O
.	O

The	O
authors	O
examined	O
the	O
effect	O
of	O
the	O
cyclooxygenase	O
-	O
2	O
(	O
COX	O
-	O
2	O
)	O
inhibitor	O
,	O
rofecoxib	B
,	O
at	O
steady	O
state	O
on	O
the	O
pharmacokinetics	O
of	O
digoxin	B
following	O
a	O
single	O
dose	O
in	O
healthy	O
subjects	O
.	O

Samples	O
for	O
plasma	O
and	O
urine	O
immunoreactive	O
digoxin	B
concentrations	O
were	O
collected	O
through	O
120	O
hours	O
following	O
the	O
digoxin	B
dose	O
.	O

For	O
digoxin	B
AUC	O
(	O
0	O
-	O
infinity	O
)	O
,	O
AUC	O
(	O
0	O
-	O
24	O
)	O
,	O
and	O
Cmax	O
,	O
the	O
geometric	O
mean	O
ratios	O
(	O
90	O
%	O
confidence	O
interval	O
)	O
for	O
(	O
rofecoxib	B
+	O
digoxin	B
/	O
placebo	O
+	O
digoxin	B
)	O
were	O
1	O
.	O
04	O
(	O
0	O
.	O
94	O
,	O
1	O
.	O
14	O
)	O
,	O
1	O
.	O
02	O
(	O
0	O
.	O
94	O
,	O
1	O
.	O
09	O
)	O
,	O
and	O
1	O
.	O
00	O
(	O
0	O
.	O
91	O
,	O
1	O
.	O
10	O
)	O
,	O
respectively	O
.	O

The	O
harmonic	O
mean	O
elimination	O
half	O
-	O
life	O
was	O
45	O
.	O
7	O
and	O
43	O
.	O
4	O
hours	O
for	O
rofecoxib	B
+	O
digoxin	B
and	O
placebo	O
+	O
digoxin	B
treatments	O
,	O
respectively	O
.	O

The	O
mean	O
(	O
SD	O
)	O
cumulative	O
urinary	O
excretion	O
of	O
immunoreactive	O
digoxin	B
after	O
concurrent	O
treatment	O
with	O
rofecoxib	B
or	O
placebo	O
was	O
228	O
.	O
2	O
(	O
+	O
/	O
-	O
30	O
.	O
8	O
)	O
and	O
235	O
.	O
1	O
(	O
+	O
/	O
-	O
39	O
.	O
1	O
)	O
micrograms	O
/	O
120	O
hours	O
,	O
respectively	O
.	O

Rofecoxib	B
did	O
not	O
influence	O
the	O
plasma	O
pharmacokinetics	O
or	O
renal	O
elimination	O
of	O
a	O
single	O
oral	O
dose	O
of	O
digoxin	B
.	O

Concomitant	O
cyclophosphamide	B
,	O
doxorubicin	B
,	O
vincristine	B
,	O
and	O
prednisone	B
chemotherapy	O
plus	O
highly	B
active	I
antiretroviral	I
therapy	O
in	O
patients	O
with	O
human	O
immunodeficiency	O
virus	O
-	O
related	O
,	O
non	O
-	O
Hodgkin	O
lymphoma	O
.	O

To	O
evaluate	O
the	O
impact	O
of	O
chemotherapy	O
plus	O
HAART	O
on	O
the	O
clinical	O
course	O
of	O
patients	O
with	O
HIV	O
-	O
related	O
,	O
systemic	O
,	O
non	O
-	O
Hodgkin	O
lymphoma	O
(	O
HIV	O
-	O
NHL	O
)	O
,	O
the	O
authors	O
compared	O
retrospectively	O
a	O
group	O
of	O
24	O
patients	O
with	O
HIV	O
-	O
NHL	O
who	O
were	O
treated	O
with	O
the	O
cyclophosphamide	B
,	O
doxorubicin	B
,	O
vincristine	B
,	O
and	O
prednisone	B
(	O
CHOP	O
)	O
chemotherapy	O
regimen	O
plus	O
HAART	O
with	O
a	O
group	O
of	O
80	O
patients	O
who	O
were	O
treated	O
with	O
CHOP	O
chemotherapy	O
or	O
a	O
CHOP	O
-	O
like	O
regimen	O
(	O
i	O
.	O
e	O
.	O
,	O
cyclophosphamide	B
,	O
doxorubicin	B
,	O
teniposide	B
,	O
and	O
prednisone	B
with	O
vincristine	B
plus	O
bleomycin	B
)	O
without	O
receiving	O
antiretroviral	B
therapy	O
.	O

Antiretroviral	B
regimens	O
consisted	O
of	O
two	O
reverse	B
transcriptase	I
inhibitors	I
and	O
one	O
protease	B
inhibitor	I
.	O

However	O
,	O
careful	O
attention	O
must	O
be	O
directed	O
to	O
cross	O
toxicity	O
and	O
possible	O
pharmacokinetic	O
interactions	O
between	O
antiretroviral	B
and	O
antineoplastic	B
drugs	I
.	O

Treatment	O
with	O
antidepressant	B
drugs	I
can	O
directly	O
interfere	O
with	O
blood	O
glucose	O
levels	O
or	O
may	O
interact	O
with	O
hypoglycemic	B
agents	I
.	O

Imipramine	B
(	O
5	O
mg	O
/	O
kg	O
)	O
,	O
moclobemide	B
(	O
30	O
mg	O
/	O
kg	O
)	O
,	O
clonazepam	B
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
,	O
fluoxetine	B
(	O
20	O
mg	O
/	O
kg	O
)	O
sertraline	B
(	O
30	O
mg	O
/	O
kg	O
)	O
or	O
vehicle	O
was	O
administered	O
.	O

An	O
oral	O
glucose	B
overload	O
of	O
1	O
ml	O
of	O
a	O
50	O
%	O
glucose	B
solution	O
was	O
given	O
to	O
rats	O
and	O
blood	O
glucose	B
was	O
determined	O
after	O
30	O
,	O
60	O
and	O
90	O
min	O
.	O

Imipramine	B
and	O
clonazepam	B
did	O
not	O
change	O
fasting	O
or	O
overload	O
glycemia	O
.	O

Fluoxetine	B
and	O
moclobemide	B
increased	O
blood	O
glucose	B
at	O
different	O
times	O
after	O
the	O
glucose	B
overload	O
.	O

Sertraline	B
neutralized	O
the	O
increase	O
of	O
glycemia	O
induced	O
by	O
oral	O
glucose	B
overload	O
.	O

In	O
the	O
second	O
experiment	O
,	O
non	O
-	O
diabetic	O
and	O
streptozotocin	O
-	O
induced	O
diabetic	O
rats	O
were	O
fasted	O
,	O
and	O
the	O
same	O
procedures	O
were	O
followed	O
for	O
estimation	O
of	O
glucose	B
tolerance	O
30	O
min	O
after	O
glucose	B
overload	O
.	O

Again	O
,	O
sertraline	B
neutralized	O
the	O
increase	O
in	O
glycemia	O
after	O
glucose	B
overload	O
both	O
in	O
diabetic	O
and	O
non	O
-	O
diabetic	O
rats	O
.	O

Activity	O
of	O
buforin	B
II	I
alone	O
and	O
in	O
combination	O
with	O
azithromycin	B
and	O
minocycline	B
against	O
Cryptosporidium	O
parvum	O
in	O
cell	O
culture	O
.	O

The	O
in	O
vitro	O
anti	O
-	O
cryptosporidial	O
activity	O
of	O
buforin	B
II	I
alone	O
and	O
in	O
combination	O
with	O
azithromycin	B
and	O
minocycline	B
was	O
investigated	O
.	O

Moreover	O
,	O
its	O
activity	O
was	O
enhanced	O
when	O
it	O
was	O
combined	O
with	O
either	O
azithromycin	B
or	O
minocycline	B
with	O
90	O
%	O
parasite	O
reduction	O
at	O
the	O
highest	O
concentration	O
tested	O
.	O

Buforin	B
II	I
may	O
be	O
active	O
in	O
inhibiting	O
Cryptosporidium	O
parvum	O
growth	O
in	O
vitro	O
upon	O
combination	O
with	O
either	O
azithromycin	B
or	O
minocycline	B
.	O

Effect	O
of	O
dofetillide	B
on	O
the	O
pharmacokinetics	O
of	O
digoxin	B
.	O

The	O
effect	O
of	O
dofetilide	B
on	O
the	O
steady	O
-	O
state	O
pharmacokinetics	O
of	O
digoxin	B
was	O
evaluated	O
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
.	O

Five	O
days	O
of	O
dofetilide	B
treatment	O
did	O
not	O
significantly	O
affect	O
steady	O
-	O
state	O
pharmacokinetic	O
variables	O
of	O
digoxin	B
compared	O
with	O
placebo	O
;	O

therefore	O
,	O
the	O
use	O
of	O
dofetilide	B
does	O
not	O
necessitate	O
an	O
adjustment	O
in	O
digoxin	B
dose	O
to	O
maintain	O
therapeutic	O
digoxin	B
levels	O
.	O

Numerous	O
drug	O
interactions	O
are	O
possible	O
with	O
some	O
anticonvulsant	B
agents	I
,	O
such	O
as	O
phenobarbitone	B
and	O
phenytoin	B
,	O
which	O
affect	O
hepatic	O
microsomal	O
enzyme	O
systems	O
.	O

Interaction	O
of	O
ketamine	B
and	O
halothane	B
in	O
rats	O
.	O

The	O
interaction	O
of	O
intramuscularly	O
injected	O
ketamine	B
and	O
its	O
N	O
-	O
demethylated	O
metabolite	O
(	O
metabolite	O
I	O
)	O
with	O
halothane	B
was	O
evaluated	O
in	O
rats	O
.	O

However	O
,	O
halothane	B
anesthetic	O
requirement	O
(	O
i	O
.	O
e	O
.	O
,	O
MAC	O
)	O
was	O
depressed	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
as	O
much	O
as	O
56	O
%	O
1	O
-	O
2	O
hours	O
and	O
as	O
much	O
as	O
14	O
%	O
5	O
-	O
6	O
hours	O
after	O
injection	O
of	O
ketamine	B
,	O
50	O
mg	O
/	O
kg	O
,	O
im	O
.	O

The	O
reduction	O
in	O
MAC	O
was	O
correlated	O
with	O
brain	O
levels	O
of	O
ketamine	B
or	O
metabolite	O
I	O
,	O
suggesting	O
a	O
ketamine	B
:	O
metabolite	O
I	O
potency	O
ration	O
of	O
3	O
:	O
1	O
.	O

The	O
half	O
-	O
life	O
of	O
ketamine	B
in	O
plasma	O
and	O
brain	O
was	O
longer	O
in	O
the	O
presence	O
of	O
halothane	B
than	O
when	O
ketamine	B
was	O
given	O
alone	O
.	O

It	O
is	O
concluded	O
that	O
ketamine	B
is	O
not	O
a	O
short	O
-	O
acting	O
drug	O
and	O
that	O
concomitant	O
use	O
with	O
halothane	B
would	O
be	O
expected	O
to	O
prolong	O
further	O
the	O
duration	O
of	O
its	O
action	O
on	O
the	O
central	O
nervous	O
system	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
sodium	B
carboxymethylcellulose	I
(	O
NaCMC	B
)	O
and	O
carboxymethylcellulose	B
-	O
cysteine	O
(	O
CMC	O
-	O
Cys	O
)	O
conjugates	O
on	O
the	O
intestinal	O
permeation	O
of	O
sodium	B
fluorescein	I
(	O
NaFlu	B
)	O
and	O
model	O
peptide	O
drugs	O
,	O
bacitracin	B
and	O
insulin	B
.	O

Cysteine	B
was	O
covalently	O
linked	O
to	O
carbodiimide	O
activated	O
NaCMC	B
.	O

Unmodified	O
NaCMC	B
(	O
1	O
%	O
m	O
/	O
v	O
)	O
significantly	O
improved	O
the	O
transport	O
ratio	O
(	O
R	O
=	O
P	O
(	O
app	O
)	O
polymer	O
/	O
P	O
(	O
app	O
)	O
control	O
)	O
of	O
NaFlu	B
to	O
1	O
.	O
3	O
and	O
1	O
%	O
(	O
m	O
/	O
v	O
)	O
NaCMC	B
conjugated	O
with	O
cysteine	B
further	O
enhanced	O
the	O
permeation	O
.	O

Decreasing	O
the	O
concentration	O
of	O
CMC	O
-	O
Cys	O
,	O
exhibiting	O
7	O
.	O
3	O
%	O
(	O
m	O
/	O
m	O
)	O
of	O
immobilised	O
cysteine	B
(	O
CMC	O
-	O
Cys7	O
.	O
3	O
)	O
from	O
1	O
%	O
(	O
m	O
/	O
v	O
)	O
to	O
0	O
.	O
5	O
%	O
(	O
m	O
/	O
v	O
)	O
decreased	O
the	O
R	O
-	O
value	O
of	O
NaFlu	B
from	O
1	O
.	O
8	O
to	O
1	O
.	O
2	O
.	O

NaCMC	B
at	O
1	O
%	O
(	O
m	O
/	O
v	O
)	O
in	O
the	O
presence	O
of	O
free	O
cysteine	B
had	O
no	O
significant	O
effect	O
on	O
the	O
R	O
-	O
value	O
of	O
NaFlu	B
compared	O
to	O
NaCMC	B
alone	O
.	O

Formulation	O
of	O
fluorescence	O
labelled	O
bacitracin	B
and	O
insulin	B
in	O
unconjugated	O
NaCMC	B
(	O
1	O
%	O
m	O
/	O
v	O
)	O
did	O
not	O
significantly	O
improve	O
the	O
permeation	O
,	O
however	O
in	O
the	O
presence	O
of	O
1	O
%	O
(	O
m	O
/	O
v	O
)	O
CMC	O
-	O
Cys7	O
.	O
3	O
a	O
significantly	O
improved	O
permeation	O
was	O
observed	O
(	O
R	O
=	O
1	O
.	O
3	O
)	O
.	O

Conjugation	O
at	O
NaCMC	B
with	O
cysteine	B
moieties	O
significantly	O
improves	O
the	O
intestinal	O
permeation	O
of	O
the	O
hydrophilic	O
molecule	O
NaFlu	B
and	O
the	O
model	O
peptide	O
drugs	O
bacitracin	B
and	O
insulin	B
in	O
vitro	O
,	O
therefore	O
this	O
conjugated	O
system	O
maybe	O
useful	O
for	O
peroral	O
administration	O
of	O
peptide	O
drugs	O
in	O
the	O
future	O
.	O

Pharmacokinetic	O
Interaction	O
between	O
amprenavir	B
and	O
rifabutin	B
or	O
rifampin	B
in	O
healthy	O
males	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
there	O
is	O
a	O
pharmacokinetic	O
interaction	O
when	O
amprenavir	B
is	O
given	O
with	O
rifabutin	B
or	O
rifampin	B
and	O
to	O
determine	O
the	O
effects	O
of	O
these	O
drugs	O
on	O
the	O
erythromycin	O
breath	O
test	O
(	O
ERMBT	O
)	O
.	O

All	O
subjects	O
received	O
amprenavir	B
(	O
1	O
,	O
200	O
mg	O
twice	O
a	O
day	O
)	O
for	O
4	O
days	O
,	O
followed	O
by	O
a	O
7	O
-	O
day	O
washout	O
period	O
,	O
followed	O
by	O
either	O
rifabutin	B
(	O
300	O
mg	O
once	O
a	O
day	O
[	O
QD	O
]	O
)	O
(	O
cohort	O
1	O
)	O
or	O
rifampin	B
(	O
600	O
mg	O
QD	O
)	O
(	O
cohort	O
2	O
)	O
for	O
14	O
days	O
.	O

Cohort	O
1	O
then	O
received	O
amprenavir	B
plus	O
rifabutin	B
for	O
10	O
days	O
,	O
and	O
cohort	O
2	O
received	O
amprenavir	B
plus	O
rifampin	B
for	O
4	O
days	O
.	O

Serial	O
plasma	O
and	O
urine	O
samples	O
for	O
measurement	O
of	O
amprenavir	B
,	O
rifabutin	B
,	O
and	O
rifampin	B
and	O
their	O
25	O
-	O
O	O
-	O
desacetyl	O
metabolites	B
,	O
were	O
measured	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
.	O

Rifabutin	B
did	O
not	O
significantly	O
affect	O
amprenavir	B
'	O
s	O
pharmacokinetics	O
.	O

Amprenavir	B
significantly	O
increased	O
the	O
area	O
under	O
the	O
curve	O
at	O
steady	O
state	O
(	O
AUC	O
(	O
ss	O
)	O
)	O
of	O
rifabutin	B
by	O
2	O
.	O
93	O
-	O
fold	O
and	O
the	O
AUC	O
(	O
ss	O
)	O
of	O
25	O
-	O
O	O
-	O
desacetylrifabutin	O
by	O
13	O
.	O
3	O
-	O
fold	O
.	O

Rifampin	B
significantly	O
decreased	O
the	O
AUC	O
(	O
ss	O
)	O
of	O
amprenavir	B
by	O
82	O
%	O
,	O
but	O
amprenavir	B
had	O
no	O
effect	O
on	O
rifampin	B
pharmacokinetics	O
.	O

The	O
results	O
of	O
the	O
ERMBT	O
after	O
2	O
weeks	O
of	O
rifabutin	B
and	O
rifampin	B
therapy	O
were	O
increased	O
187	O
and	O
156	O
%	O
,	O
respectively	O
.	O

Amprenavir	B
plus	O
rifampin	B
was	O
well	O
tolerated	O
.	O

Amprenavir	B
plus	O
rifabutin	B
was	O
poorly	O
tolerated	O
,	O
and	O
5	O
of	O
11	O
subjects	O
discontinued	O
therapy	O
.	O

Rifampin	B
markedly	O
increases	O
the	O
metabolic	O
clearance	O
of	O
amprenavir	B
,	O
and	O
coadministration	O
is	O
contraindicated	O
.	O

Amprenavir	B
significantly	O
decreases	O
clearance	O
of	O
rifabutin	B
and	O
25	O
-	O
O	O
-	O
desacetylrifabutin	O
,	O
and	O
the	O
combination	O
is	O
poorly	O
tolerated	O
.	O

Amprenavir	B
inhibits	O
the	O
ERMBT	O
,	O
and	O
rifampin	B
and	O
rifabutin	B
are	O
equipotent	O
inducers	O
of	O
the	O
ERMBT	O
.	O

The	O
thiazolidinediones	B
(	O
rosiglitazone	B
and	O
pioglitazone	B
)	O
,	O
a	O
new	O
class	O
of	O
oral	O
antidiabetic	B
agents	I
,	O
are	O
"	O
insulin	O
sensitizers	O
"	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
etofibrate	B
upon	O
chylomicron	O
metabolism	O
was	O
tested	O
by	O
determination	O
of	O
the	O
plasma	O
kinetics	O
of	O
a	O
chylomicron	O
-	O
like	O
emulsion	O
model	O
in	O
12	O
patients	O
with	O
coronary	O
artery	O
disease	O
,	O
aged	O
59	O
+	O
/	O
-	O
11	O
years	O
,	O
(	O
total	O
cholesterol	O
:	O
240	O
+	O
/	O
-	O
41	O
mg	O
/	O
dl	O
;	O
triglycerides	O
:	O
188	O
+	O
/	O
-	O
42	O
mg	O
/	O
dl	O
)	O
submitted	O
to	O
a	O
randomized	O
,	O
crossover	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
with	O
administration	O
of	O
1	O
g	O
per	O
day	O
etofibrate	B
or	O
placebo	O
for	O
1	O
-	O
month	O
.	O

Etofibrate	B
elicited	O
62	O
%	O
enhancement	O
of	O
post	O
-	O
heparin	B
lipolytic	O
activity	O
and	O
100	O
%	O
increase	O
of	O
3H	O
-	O
triglyceride	O
fractional	O
clearance	O
rate	O
compared	O
with	O
placebo	O
treatment	O
.	O

The	O
mode	O
of	O
toxic	O
action	O
of	O
the	O
pesticide	O
gliftor	B
:	O
the	O
metabolism	O
of	O
1	O
,	O
3	O
-	O
difluoroacetone	O
to	O
(	O
-	O
)	O
-	O
erythro	O
-	O
fluorocitrate	O
.	O

The	O
biochemical	O
toxicology	O
of	O
1	O
,	O
3	O
-	O
difluoroacetone	O
,	O
a	O
known	O
metabolite	O
of	O
the	O
major	O
ingredient	O
of	O
the	O
pesticide	O
Gliftor	B
(	O
1	O
,	O
3	O
-	O
difluoro	O
-	O
2	O
-	O
propanol	O
)	O
,	O
was	O
investigated	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Rat	O
kidney	O
homogenates	O
supplemented	O
with	O
coenzyme	O
A	O
,	O
ATP	O
,	O
oxaloacetate	O
,	O
and	O
Mg2	O
+	O
converted	O
1	O
,	O
3	O
-	O
difluoroacetone	O
to	O
(	O
-	O
)	O
-	O
erythro	O
-	O
fluorocitrate	O
in	O
vitro	O
.	O

Administration	O
of	O
1	O
,	O
3	O
-	O
difluoroacetone	O
(	O
100	O
mg	O
kg	O
(	O
-	O
1	O
)	O
body	O
weight	O
)	O
to	O
rats	O
in	O
vivo	O
resulted	O
in	O
(	O
-	O
)	O
-	O
erythro	O
-	O
fluorocitrate	O
synthesis	O
in	O
the	O
kidney	O
,	O
which	O
was	O
preceded	O
by	O
an	O
elevation	O
in	O
fluoride	O
levels	O
and	O
followed	O
by	O
citrate	O
accumulation	O
.	O

Animals	O
dosed	O
with	O
1	O
,	O
3	O
-	O
difluoroacetone	O
did	O
not	O
display	O
the	O
2	O
-	O
3	O
hour	O
lag	O
phase	O
in	O
either	O
(	O
-	O
)	O
-	O
erythro	O
-	O
fluorocitrate	O
synthesis	O
or	O
in	O
citrate	O
and	O
fluoride	O
accumulation	O
characteristic	O
of	O
animals	O
dosed	O
with	O
1	O
,	O
3	O
-	O
difluoro	O
-	O
2	O
-	O
propanol	O
.	O

We	O
demonstrate	O
that	O
the	O
conversion	O
of	O
1	O
,	O
3	O
-	O
difluoro	O
-	O
2	O
-	O
propanol	O
to	O
1	O
,	O
3	O
-	O
difluoroacetone	O
by	O
an	O
NAD	O
+	O
-	O
dependent	O
oxidation	O
is	O
the	O
rate	O
-	O
limiting	O
step	O
in	O
the	O
synthesis	O
of	O
the	O
toxic	O
product	O
,	O
(	O
-	O
)	O
-	O
erythro	O
-	O
fluorocitrate	O
from	O
1	O
,	O
3	O
-	O
difluoro	O
-	O
2	O
-	O
propanol	O
.	O

Prior	O
administration	O
of	O
4	O
-	O
methylpyrazole	O
(	O
90	O
mg	O
kg	O
(	O
-	O
1	O
)	O
body	O
weight	O
)	O
was	O
shown	O
to	O
prevent	O
the	O
conversion	O
of	O
1	O
,	O
3	O
-	O
difluoro	O
-	O
2	O
-	O
propanol	O
(	O
100	O
mg	O
kg	O
(	O
-	O
1	O
)	O
body	O
weight	O
)	O
to	O
(	O
-	O
)	O
-	O
erythro	O
-	O
fluorocitrate	O
in	O
vivo	O
and	O
to	O
eliminate	O
the	O
fluoride	O
and	O
citrate	O
elevations	O
seen	O
in	O
1	O
,	O
3	O
-	O
difluoro	O
-	O
2	O
-	O
propanol	O
-	O
intoxicated	O
animals	O
.	O

However	O
,	O
administration	O
of	O
4	O
-	O
methylpyrazole	O
(	O
90	O
mg	O
kg	O
(	O
-	O
1	O
)	O
body	O
weight	O
)	O
to	O
rats	O
2	O
hours	O
prior	O
to	O
1	O
,	O
3	O
-	O
difluoroacetone	O
(	O
100	O
mg	O
kg	O
(	O
-	O
1	O
)	O
body	O
weight	O
)	O
was	O
ineffective	O
in	O
preventing	O
(	O
-	O
)	O
-	O
erythro	O
-	O
fluorocitrate	O
synthesis	O
and	O
did	O
not	O
diminish	O
fluoride	O
or	O
citrate	O
accumulation	O
in	O
vivo	O
.	O

We	O
conclude	O
that	O
the	O
prophylactic	O
and	O
antidotal	O
properties	O
of	O
4	O
-	O
methylpyrazole	O
seen	O
in	O
animals	O
treated	O
with	O
1	O
,	O
3	O
-	O
difluoro	O
-	O
2	O
-	O
propanol	O
derive	O
from	O
its	O
capacity	O
to	O
inhibit	O
the	O
NAD	O
+	O
-	O
dependent	O
oxidation	O
responsible	O
for	O
converting	O
1	O
,	O
3	O
-	O
difluoro	O
-	O
2	O
-	O
propanol	O
to	O
1	O
,	O
3	O
-	O
difluoroacetone	O
in	O
the	O
committed	O
step	O
of	O
the	O
toxic	O
pathway	O
.	O

Green	B
tea	I
polyphenols	I
as	O
potent	O
enhancers	B
of	O
glucocorticoid	O
-	O
induced	O
mouse	O
mammary	O
tumor	O
virus	O
gene	O
expression	O
.	O

n	O
-	O
dodecyl	O
gallate	B
showed	O
the	O
most	O
potent	O
inhibition	O
(	O
66	O
%	O
inhibition	O
at	O
10	O
microM	O
)	O
,	O
which	O
was	O
far	O
more	O
potent	O
than	O
that	O
of	O
crude	O
tannic	B
acid	I
.	O

Pharmacokinetic	O
interaction	O
between	O
single	O
oral	O
doses	O
of	O
diltiazem	B
and	O
sirolimus	B
in	O
healthy	O
volunteers	O
.	O

AIM	O
AND	O
BACKGROUND	O
:	O
The	O
pharmacokinetic	O
interaction	O
between	O
sirolimus	B
,	O
a	O
macrolide	B
immunosuppressant	I
metabolized	O
by	O
CYP3A4	O
,	O
and	O
the	O
calcium	B
channel	I
blocker	I
diltiazem	I
was	O
studied	O
in	O
18	O
healthy	O
subjects	O
.	O

Several	O
clinically	O
important	O
interactions	O
have	O
previously	O
been	O
reported	O
for	O
other	O
immunosuppressive	B
drugs	I
that	O
are	O
metabolized	O
by	O
the	O
same	O
enzyme	O
and	O
for	O
calcium	B
antagonists	I
.	O

METHODS	O
:	O
Healthy	O
subjects	O
who	O
were	O
20	O
to	O
43	O
years	O
old	O
participated	O
in	O
an	O
open	O
,	O
three	O
-	O
period	O
,	O
randomized	O
,	O
crossover	O
study	O
of	O
the	O
pharmacokinetics	O
of	O
a	O
single	O
10	O
-	O
mg	O
oral	O
dose	O
of	O
sirolimus	B
,	O
a	O
single	O
oral	O
120	O
-	O
mg	O
dose	O
of	O
diltiazem	B
,	O
and	O
the	O
two	O
drugs	O
given	O
together	O
.	O

RESULTS	O
:	O
The	O
geometric	O
mean	O
(	O
90	O
%	O
confidence	O
interval	O
)	O
whole	O
blood	O
sirolimus	B
area	O
under	O
the	O
plasma	O
concentration	O
time	O
-	O
curve	O
increased	O
60	O
%	O
(	O
35	O
%	O
-	O
90	O
%	O
)	O
,	O
from	O
736	O
to	O
1178	O
ng	O
x	O
h	O
/	O
mL	O
,	O
and	O
maximum	O
concentration	O
increased	O
43	O
%	O
(	O
14	O
%	O
-	O
81	O
%	O
)	O
,	O
from	O
67	O
to	O
96	O
ng	O
/	O
mL	O
,	O
with	O
diltiazem	B
coadministration	O
,	O
whereas	O
the	O
mean	O
elimination	O
half	O
-	O
life	O
of	O
sirolimus	B
decreased	O
slightly	O
,	O
from	O
79	O
to	O
67	O
hours	O
.	O

Apparent	O
oral	O
clearance	O
and	O
volume	O
of	O
distribution	O
of	O
sirolimus	B
decreased	O
with	O
38	O
%	O
and	O
45	O
%	O
,	O
respectively	O
,	O
when	O
sirolimus	B
was	O
given	O
with	O
diltiazem	B
.	O

The	O
plasma	O
maximum	O
concentration	O
and	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
of	O
diltiazem	B
,	O
desacetyldiltiazem	B
,	O
and	O
desmethyldiltiazem	B
were	O
unchanged	O
after	O
coadministration	O
of	O
sirolimus	B
,	O
and	O
no	O
potentiation	O
of	O
the	O
effects	O
of	O
diltiazem	B
on	O
diastolic	O
or	O
systolic	O
blood	O
pressure	O
or	O
on	O
the	O
electrocardiographic	O
parameters	O
was	O
seen	O
.	O

CONCLUSIONS	O
:	O
Single	O
-	O
dose	O
diltiazem	B
coadministration	O
leads	O
to	O
higher	O
sirolimus	B
exposure	O
,	O
presumably	O
by	O
inhibition	O
of	O
the	O
first	O
-	O
pass	O
metabolism	O
of	O
sirolimus	B
.	O

Because	O
of	O
the	O
pronounced	O
intersubject	O
variability	O
in	O
the	O
extent	O
of	O
the	O
sirolimus	B
-	O
diltiazem	B
interaction	O
,	O
whole	O
blood	O
sirolimus	B
concentrations	O
should	O
be	O
monitored	O
closely	O
in	O
patients	O
treated	O
with	O
the	O
two	O
drugs	O
.	O

Fluvoxamine	B
inhibits	O
the	O
CYP2C9	O
catalyzed	O
biotransformation	O
of	O
tolbutamide	B
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
examine	O
the	O
interaction	O
between	O
fluvoxamine	B
and	O
tolbutamide	B
to	O
confirm	O
that	O
fluvoxamine	B
inhibits	O
CYP2C9	O
.	O

Plasma	O
was	O
analyzed	O
for	O
tolbutamide	B
,	O
and	O
urine	O
was	O
analyzed	O
for	O
tolbutamide	B
and	O
its	O
two	O
metabolites	O
,	O
4	O
-	O
hydroxytolbutamide	O
and	O
carboxytolbutamide	B
by	O
means	O
of	O
HPLC	O
.	O

RESULTS	O
:	O
During	O
treatment	O
with	O
fluvoxamine	B
,	O
there	O
was	O
a	O
statistically	O
significant	O
decrease	O
in	O
the	O
median	O
of	O
the	O
total	O
clearance	O
of	O
tolbutamide	B
,	O
from	O
845	O
mL	O
/	O
h	O
to	O
688	O
mL	O
/	O
h	O
,	O
among	O
the	O
volunteers	O
who	O
received	O
75	O
mg	O
/	O
d	O
.	O

The	O
clearance	O
by	O
means	O
of	O
4	O
-	O
hydroxytolbutamide	O
and	O
carboxytolbutamide	B
was	O
significantly	O
reduced	O
in	O
both	O
groups	O
(	O
ie	O
,	O
from	O
901	O
mL	O
/	O
h	O
to	O
318	O
mL	O
/	O
h	O
in	O
the	O
group	O
that	O
received	O
150	O
mg	O
of	O
tolbutamide	B
per	O
day	O
and	O
from	O
723	O
mL	O
/	O
h	O
to	O
457	O
mL	O
/	O
h	O
in	O
the	O
group	O
that	O
received	O
75	O
mg	O
of	O
tolbutamide	B
per	O
day	O
)	O
.	O

Longitudinal	O
assessment	O
of	O
everolimus	B
in	O
de	O
novo	O
renal	O
transplant	O
recipients	O
over	O
the	O
first	O
post	O
-	O
transplant	O
year	O
:	O
pharmacokinetics	O
,	O
exposure	O
-	O
response	O
relationships	O
,	O
and	O
influence	O
on	O
cyclosporine	B
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
characterize	O
the	O
steady	O
-	O
state	O
pharmacokinetics	O
of	O
everolimus	B
and	O
cyclosporine	B
(	O
INN	O
,	O
ciclosporin	B
)	O
when	O
coadministered	O
in	O
de	O
novo	O
kidney	O
allograft	O
recipients	O
during	O
the	O
first	O
year	O
after	O
transplantation	O
.	O

METHOD	O
:	O
This	O
study	O
was	O
a	O
multicenter	O
randomized	O
double	O
-	O
blind	O
study	O
of	O
101	O
patients	O
who	O
were	O
randomly	O
assigned	O
1	O
:	O
1	O
:	O
1	O
to	O
receive	O
everolimus	B
tablets	O
at	O
doses	O
of	O
0	O
.	O
5	O
mg	O
,	O
1	O
mg	O
,	O
or	O
2	O
mg	O
twice	O
daily	O
with	O
cyclosporine	B
and	O
prednisone	B
.	O

Blood	O
sampling	O
for	O
the	O
pharmacokinetics	O
of	O
everolimus	B
and	O
cyclosporine	B
was	O
performed	O
on	O
day	O
1	O
,	O
on	O
weeks	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
,	O
and	O
on	O
months	O
2	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
.	O

Potential	O
differences	O
in	O
cyclosporine	B
dosing	O
and	O
pharmacokinetics	O
at	O
different	O
levels	O
of	O
everolimus	B
exposure	O
were	O
assessed	O
in	O
the	O
context	O
of	O
ANOVA	O
.	O

Cyclosporine	B
doses	O
,	O
trough	O
concentrations	O
,	O
and	O
AUC	O
exhibited	O
similar	O
temporal	O
patterns	O
during	O
the	O
course	O
of	O
the	O
study	O
regardless	O
of	O
the	O
co	O
-	O
administered	O
everolimus	B
dose	O
level	O
(	O
P	O
=	O
.	O
13	O
,	O
.	O
82	O
,	O
and	O
.	O
76	O
,	O
respectively	O
)	O
.	O

For	O
a	O
4	O
-	O
fold	O
range	O
of	O
everolimus	B
doses	O
there	O
were	O
no	O
differential	O
effects	O
on	O
cyclosporine	B
dosing	O
or	O
pharmacokinetics	O
.	O

ADL	B
8	O
-	O
2698	O
,	O
a	O
trans	O
-	O
3	O
,	O
4	O
-	O
dimethyl	O
-	O
4	O
-	O
(	O
3	O
-	O
hydroxyphenyl	O
)	O
piperidine	O
,	O
prevents	O
gastrointestinal	O
effects	O
of	O
intravenous	O
morphine	B
without	O
affecting	O
analgesia	O
.	O

ADL	O
-	O
8	O
-	O
2698	O
is	O
a	O
novel	O
peripherally	B
restricted	I
opioid	I
antagonist	I
that	O
may	O
selectively	O
prevent	O
opioid	B
-	O
induced	O
gastrointestinal	O
effects	O
without	O
reversing	O
analgesia	O
.	O

Gastrointestinal	O
transit	O
time	O
(	O
lactulose	O
hydrogen	O
breath	O
test	O
)	O
was	O
measured	O
in	O
14	O
volunteers	O
with	O
oral	O
and	O
intravenous	O
placebo	O
,	O
oral	O
placebo	O
and	O
intravenous	O
morphine	B
(	O
0	O
.	O
05	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
)	O
,	O
and	O
oral	O
ADL	B
8	O
-	O
2698	O
(	O
4	O
mg	O
)	O
and	O
intravenous	O
morphine	B
(	O
0	O
.	O
05	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
)	O
in	O
a	O
double	O
blind	O
,	O
cross	O
-	O
over	O
study	O
.	O

Morphine	B
prolonged	O
gastrointestinal	O
transit	O
time	O
from	O
69	O
to	O
103	O
minutes	O
(	O
P	O
=	O
.	O
005	O
)	O
;	O
this	O
was	O
prevented	O
by	O
ADL	B
8	O
-	O
2698	O
(	O
P	O
=	O
.	O
004	O
)	O
.	O

Postoperatively	O
,	O
45	O
patients	O
were	O
randomly	O
assigned	O
in	O
a	O
double	O
-	O
blind	O
fashion	O
to	O
receive	O
ADL	B
8	O
-	O
2698	O
(	O
4	O
mg	O
)	O
or	O
placebo	O
and	O
intravenous	O
morphine	B
(	O
0	O
.	O
15	O
mg	O
/	O
kg	O
)	O
or	O
to	O
receive	O
oral	O
and	O
intravenous	O
placebo	O
.	O

Morphine	B
analgesia	O
and	O
pupil	O
constriction	O
were	O
unaffected	O
by	O
ADL	B
8	O
-	O
2698	O
and	O
differed	O
from	O
placebo	O
(	O
P	O
<	O
.	O
002	O
)	O
.	O

We	O
conclude	O
that	O
ADL	B
8	O
-	O
2698	O
prevents	O
morphine	B
-	O
induced	O
increases	O
in	O
gastrointestinal	O
transit	O
time	O
by	O
means	O
of	O
selective	O
peripheral	O
opioid	O
anitagonism	O
without	O
affecting	O
central	O
opioid	O
analgesia	O
.	O

Rhabdomyolysis	O
secondary	O
to	O
a	O
drug	O
interaction	O
between	O
simvastatin	B
and	O
clarithromycin	B
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
rhabdomyolysis	O
resulting	O
from	O
concomitant	O
use	O
of	O
clarithromycin	B
and	O
simvastatin	B
.	O

DISCUSSION	O
:	O
Clarithromycin	B
is	O
a	O
potent	O
inhibitor	O
of	O
CYP3A4	O
,	O
the	O
major	O
enzyme	O
responsible	O
for	O
simvastatin	B
metabolism	O
.	O

The	O
concomitant	O
administration	O
of	O
macrolide	B
antibiotics	I
and	O
other	O
hydroxymethylglutaryl	B
coenzyme	I
A	I
(	O
HMG	O
-	O
CoA	O
)	O
reductase	B
inhibitors	I
have	O
resulted	O
in	O
previous	O
reports	O
of	O
rhabdomyolysis	O
.	O

CONCLUSIONS	O
:	O
Macrolide	B
antibiotics	I
inhibit	O
the	O
metabolism	O
of	O
HMG	O
-	O
CoA	O
reductase	B
inhibitors	I
that	O
are	O
metabolized	O
by	O
CYP3A4	O
(	O
i	O
.	O
e	O
.	O
,	O
atorvastatin	B
,	O
cerivastatin	B
,	O
lovastatin	B
,	O
simvastatin	B
)	O
.	O

The	O
effects	O
of	O
concomitant	O
phenytoin	B
administration	O
on	O
the	O
steady	O
-	O
state	O
pharmacokinetics	O
of	O
quetiapine	B
.	O

Quetiapine	B
fumarate	I
(	O
'	O
Seroquel	B
'	O
)	O
is	O
a	O
newly	O
introduced	O
atypical	B
antipsychotic	I
with	O
demonstrated	O
efficacy	O
in	O
the	O
treatment	O
of	O
positive	O
and	O
negative	O
symptoms	O
of	O
schizophrenia	O
.	O

This	O
study	O
demonstrated	O
that	O
the	O
potent	O
cytochrome	O
P450	O
enzyme	O
-	O
inducer	O
phenytoin	B
did	O
indeed	O
have	O
a	O
marked	O
effect	O
on	O
the	O
metabolism	O
of	O
quetiapine	B
,	O
resulting	O
in	O
a	O
5	O
-	O
fold	O
increase	O
in	O
clearance	O
when	O
administered	O
concomitantly	O
to	O
patients	O
with	O
DSM	O
-	O
IV	O
-	O
diagnosed	O
schizophrenia	O
,	O
schizoaffective	O
disorder	O
,	O
or	O
bipolar	O
disorder	O
.	O

Acetaminophen	B
,	O
lidocaine	B
,	O
phenobarbital	B
,	O
quinidine	B
,	O
theophylline	B
,	O
and	O
valproic	B
acid	I
were	O
added	O
to	O
pooled	O
human	O
serum	O
at	O
therapeutic	O
concentrations	O
.	O

The	O
following	O
eight	O
target	O
drug	O
/	O
added	O
drug	O
combinations	O
were	O
studied	O
:	O
acetaminophen	B
/	O
phenobarbital	B
.	O

acetaminophen	B
/	O
theophylline	B
,	O
lidocaine	B
/	O
quinidine	B
,	O
phenobarbital	B
/	O
acetaminophen	B
,	O
phenobarbital	B
/	O
valproic	B
acid	I
,	O
quinidine	B
/	O
lidocaine	B
,	O
theophylline	B
/	O
acetaminophen	B
,	O
and	O
valproic	B
acid	I
/	O
phenobarbital	B
.	O

Similarly	O
dialyzed	O
were	O
phenobarbital	B
,	O
quinidine	B
,	O
and	O
theophylline	B
,	O
both	O
alone	O
at	O
therapeutic	O
concentrations	O
in	O
serum	O
and	O
with	O
ethanol	B
at	O
three	O
different	O
concentrations	O
in	O
serum	O
.	O

Acetaminophen	B
diminished	O
the	O
binding	O
of	O
theophylline	B
to	O
human	O
serum	O
by	O
a	O
net	O
change	O
of	O
5	O
.	O
7	O
%	O
(	O
percentage	O
increase	O
in	O
free	O
drug	O
fraction	O
[	O
FDF	O
]	O
,	O
11	O
.	O
0	O
%	O
)	O
at	O
662	O
micromol	O
/	O
L	O
and	O
by	O
a	O
net	O
change	O
of	O
7	O
.	O
1	O
%	O
(	O
percentage	O
increase	O
in	O
FDF	O
,	O
13	O
.	O
7	O
%	O
)	O
at	O
1324	O
micromol	O
/	O
L	O
.	O

Theophylline	B
decreased	O
the	O
binding	O
of	O
acetaminophen	B
by	O
a	O
net	O
change	O
of	O
6	O
.	O
8	O
%	O
(	O
percentage	O
increase	O
in	O
FDF	O
,	O
8	O
.	O
8	O
%	O
)	O
at	O
277	O
.	O
5	O
micromol	O
/	O
L	O
;	O

Valproic	B
acid	I
diminished	O
binding	O
of	O
phenobarbital	B
by	O
a	O
net	O
change	O
of	O
9	O
.	O
9	O
%	O
(	O
percentage	O
increase	O
in	O
FDF	O
,	O
21	O
.	O
2	O
%	O
)	O
at	O
1732	O
micromol	O
/	O
L	O
.	O

Coingestion	O
of	O
acetaminophen	B
with	O
theophylline	B
,	O
phenobarbital	B
with	O
acetaminophen	B
,	O
and	O
valproic	B
acid	I
with	O
phenobarbital	B
at	O
high	O
to	O
toxic	O
concentrations	O
decreases	O
the	O
binding	O
of	O
the	O
target	O
drug	O
.	O

The	O
serum	O
concentration	O
of	O
phenytoin	B
increased	O
dramatically	O
from	O
16	O
.	O
6	O
to	O
49	O
.	O
1	O
microg	O
/	O
mL	O
when	O
fluvoxamine	B
was	O
coadministered	O
,	O
although	O
the	O
daily	O
dosage	O
of	O
phenytoin	B
and	O
other	O
drugs	B
had	O
not	O
changed	O
.	O

During	O
phenytoin	B
and	O
fluvoxamine	O
treatment	O
,	O
ataxia	O
,	O
a	O
typical	O
side	O
effect	O
of	O
phenytoin	B
,	O
was	O
observed	O
.	O

The	O
genotypes	O
of	O
CYP2C9	B
and	O
2C19	O
,	O
the	O
enzymes	O
responsible	O
for	O
phenytoin	O
metabolism	O
,	O
were	O
homozygous	O
for	O
the	O
wild	O
-	O
type	O
alleles	O
(	O
CYP2C9	B
*	O
1	O
/	O
*	O
1	O
and	O
2C19	O
*	O
1	O
/	O
*	O
1	O
)	O
.	O

The	O
interaction	O
may	O
be	O
a	O
result	O
of	O
inhibition	O
of	O
both	O
CYP2C9	B
and	O
2C19	O
by	O
fluvoxamine	B
.	O

Here	O
we	O
show	O
that	O
a	O
combination	O
of	O
galangin	B
or	O
3	O
,	O
7	O
-	O
dihydroxyflavone	O
with	O
vancomycin	B
may	O
be	O
used	O
to	O
sensitize	O
resistant	O
strains	O
of	O
Enterococcus	O
faecalis	O
and	O
Enterococcus	O
faecium	O
to	O
the	O
level	O
of	O
vancomycin	B
-	O
sensitive	O
strains	O
.	O

Glucose	B
and	O
insulin	B
exert	O
additive	O
ocular	O
and	O
renal	O
vasodilator	O
effects	O
on	O
healthy	O
humans	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O
There	O
is	O
evidence	O
that	O
insulin	B
and	O
glucose	B
cause	O
renal	O
and	O
ocular	O
vasodilation	O
.	O

Haemodynamic	O
effects	O
of	O
glucose	B
and	O
insulin	B
were	O
additive	O
when	O
somatostatin	B
was	O
co	O
-	O
administered	O
but	O
not	O
under	O
basal	O
conditions	O
.	O

CONCLUSIONS	O
/	O
INTERPRETATION	O
:	O
Glucose	B
and	O
insulin	B
can	O
exert	O
additive	O
vasodilator	O
properties	O
on	O
renal	O
and	O
ocular	O
circulation	O
.	O

Lack	O
of	O
interaction	O
between	O
levofloxacin	B
and	O
oxycodone	B
:	O
pharmacokinetics	O
and	O
drug	O
disposition	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
a	O
significant	O
reduction	O
in	O
the	O
oral	O
bioavailability	O
of	O
trovafloxacin	B
and	O
ciprofloxacin	B
when	O
administered	O
concomitantly	O
with	O
an	O
intravenous	O
opiate	B
such	O
as	O
morphine	B
.	O

This	O
decrease	O
in	O
absorption	O
results	O
in	O
a	O
36	O
%	O
and	O
50	O
%	O
lower	O
AUC	O
for	O
trovafloxacin	B
and	O
ciprofloxacin	B
,	O
respectively	O
,	O
which	O
could	O
cause	O
clinical	O
failures	O
.	O

The	O
authors	O
investigated	O
the	O
possibility	O
of	O
a	O
similar	O
interaction	O
between	O
oxycodone	B
and	O
levofloxacin	B
.	O

1	O
hour	O
after	O
starting	O
the	O
oxycodone	B
or	O
levofloxacin	B
500	O
mg	O
p	O
.	O
o	O
.	O

There	O
was	O
not	O
a	O
significant	O
difference	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
in	O
AUC	O
(	O
48	O
.	O
59	O
+	O
/	O
-	O
8	O
.	O
52	O
vs	O
.	O
49	O
.	O
9	O
+	O
/	O
-	O
9	O
.	O
93	O
)	O
,	O
Cmax	O
(	O
7	O
.	O
73	O
+	O
/	O
-	O
2	O
.	O
6	O
vs	O
.	O
6	O
.	O
6	O
+	O
/	O
-	O
2	O
.	O
0	O
)	O
,	O
and	O
tmax	O
(	O
1	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
6	O
vs	O
.	O
1	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
1	O
)	O
for	O
levofloxacin	B
versus	O
levofloxacin	B
/	O
oxycodone	B
regimens	O
.	O

It	O
was	O
concluded	O
that	O
oral	O
oxycodone	B
and	O
levofloxacin	B
can	O
be	O
administered	O
concomitantly	O
without	O
a	O
significant	O
decrease	O
in	O
AUC	O
,	O
Cmax	O
,	O
or	O
tmax	O
.	O

Lack	O
of	O
an	O
effect	O
of	O
azithromycin	B
on	O
the	O
disposition	O
of	O
zidovudine	B
and	O
dideoxyinosine	B
in	O
HIV	O
-	O
infected	O
patients	O
.	O

Two	O
studies	O
were	O
conducted	O
in	O
HIV	O
-	O
infected	O
subjects	O
to	O
assess	O
the	O
potential	O
for	O
azithromycin	B
to	O
interact	O
with	O
zidovudine	B
and	O
dideoxyinosine	B
.	O

The	O
zidovudine	B
study	O
dosed	O
subjects	O
with	O
1200	O
mg	O
/	O
day	O
of	O
azithromycin	B
(	O
n	O
=	O
7	O
)	O
(	O
later	O
changed	O
to	O
600	O
mg	O
/	O
day	O
[	O
n	O
=	O
5	O
]	O
)	O
for	O
Days	O
8	O
to	O
21	O
of	O
a	O
21	O
-	O
day	O
course	O
of	O
100	O
mg	O
,	O
five	O
times	O
/	O
day	O
of	O
zidovudine	B
.	O

Subjects	O
treated	O
with	O
200	O
mg	O
of	O
dideoxyinosine	B
twice	O
daily	O
for	O
21	O
days	O
received	O
1200	O
mg	O
of	O
azithromycin	B
or	O
an	O
equivalent	O
amount	O
of	O
placebo	O
/	O
day	O
for	O
Days	O
8	O
to	O
21	O
.	O

Antiretroviral	B
plasma	O
and	O
urine	O
sampling	O
were	O
conducted	O
on	O
Days	O
1	O
,	O
7	O
,	O
and	O
21	O
for	O
zidovudine	B
and	O
on	O
Days	O
7	O
and	O
21	O
for	O
dideoxyinosine	B
.	O

Azithromycin	B
had	O
no	O
significant	O
impact	O
on	O
the	O
Cmax	O
and	O
AUC	O
of	O
zidovudine	B
,	O
although	O
it	O
significantly	O
decreased	O
the	O
zidovudine	B
tmax	O
by	O
44	O
%	O
and	O
increased	O
the	O
intracellular	O
exposure	O
to	O
phosphorylated	O
zidovudine	B
by	O
110	O
%	O
.	O

Azithromycin	B
had	O
no	O
significant	O
effect	O
on	O
dideoxyinosine	B
pharmacokinetics	O
.	O

Based	O
on	O
the	O
results	O
of	O
these	O
studies	O
,	O
it	O
is	O
concluded	O
that	O
azithromycin	B
may	O
be	O
safely	O
coadministered	O
with	O
both	O
zidovudine	B
and	O
dideoxyinosine	B
.	O

Effect	O
of	O
diazepam	B
and	O
midazolam	B
on	O
the	O
antinociceptive	O
effect	O
of	O
morphine	B
,	O
metamizol	B
and	O
indomethacin	B
in	O
mice	O
.	O

The	O
influence	O
of	O
midazolam	B
and	O
diazepam	B
on	O
antinociceptive	O
effect	O
of	O
morphine	B
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
metamizol	B
(	O
500	O
mg	O
/	O
kg	O
)	O
and	O
indomethacin	B
(	O
10	O
mg	O
/	O
kg	O
)	O
was	O
investigated	O
in	O
a	O
mouse	O
model	O
using	O
the	O
tail	O
-	O
flick	O
and	O
hot	O
-	O
plate	O
tests	O
.	O

Benzodiazepines	B
were	O
administered	O
to	O
mice	O
30	O
min	O
before	O
applying	O
the	O
analgesic	B
drugs	I
.	O

Diazepam	B
at	O
doses	O
of	O
0	O
.	O
25	O
mg	O
/	O
kg	O
and	O
2	O
.	O
5	O
mg	O
/	O
kg	O
injected	O
with	O
morphine	B
was	O
found	O
to	O
decrease	O
the	O
antinociceptive	O
effect	O
of	O
morphine	B
.	O

Similarly	O
,	O
diazepam	B
decreased	O
the	O
antinociceptive	O
effect	O
of	O
metamizol	B
(	O
only	O
in	O
the	O
tail	O
-	O
flick	O
test	O
)	O
and	O
indomethacin	B
.	O

Midazolam	B
used	O
at	O
doses	O
of	O
1	O
.	O
25	O
mg	O
/	O
kg	O
and	O
2	O
.	O
5	O
mg	O
/	O
kg	O
decreased	O
the	O
antinociceptive	O
effect	O
of	O
morphine	B
,	O
metamizol	B
(	O
only	O
in	O
the	O
tail	O
-	O
flick	O
test	O
)	O
and	O
indomethacin	B
.	O

Influence	O
of	O
estradiol	B
and	O
progesterone	B
on	O
the	O
sensitivity	O
of	O
rat	O
thoracic	O
aorta	O
to	O
noradrenaline	B
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
low	O
and	O
high	O
doses	O
of	O
estradiol	B
,	O
and	O
of	O
progesterone	B
on	O
the	O
response	O
to	O
noradrenaline	B
in	O
rat	O
thoracic	O
aorta	O
.	O

injection	O
of	O
vehicle	O
(	O
corn	O
oil	O
,	O
0	O
.	O
1	O
mL	O
/	O
day	O
)	O
,	O
estradiol	B
(	O
10	O
microg	O
/	O
kg	O
/	O
day	O
or	O
4	O
mg	O
/	O
kg	O
/	O
day	O
)	O
and	O
/	O
or	O
progesterone	B
(	O
20	O
mg	O
/	O
kg	O
/	O
day	O
)	O
,	O
for	O
eight	O
days	O
.	O

Aortic	O
rings	O
with	O
intact	O
endothelium	O
from	O
the	O
high	O
-	O
dose	O
(	O
4	O
mg	O
/	O
kg	O
/	O
day	O
)	O
estradiol	B
group	O
were	O
supersensitive	O
to	O
noradrenaline	B
compared	O
to	O
the	O
vehicle	O
or	O
low	O
-	O
dose	O
(	O
10	O
microg	O
/	O
kg	O
/	O
day	O
)	O
estradiol	B
groups	O
(	O
pD2	O
values	O
=	O
7	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
09	O
,	O
7	O
.	O
30	O
+	O
/	O
-	O
0	O
.	O
11	O
and	O
7	O
.	O
35	O
+	O
/	O
-	O
0	O
.	O
04	O
,	O
respectively	O
)	O
.	O

Endothelium	O
-	O
intact	O
aortic	O
rings	O
from	O
high	O
-	O
estradiol	B
rats	O
were	O
supersensitive	O
to	O
noradrenaline	B
when	O
compared	O
to	O
vehicle	O
-	O
,	O
progesterone	B
-	O
and	O
progesterone	B
+	O
high	O
-	O
estradiol	B
-	O
treated	O
rats	O
(	O
pD2	O
values	O
=	O
7	O
.	O
77	O
+	O
/	O
-	O
0	O
.	O
12	O
,	O
7	O
.	O
21	O
+	O
/	O
-	O
0	O
.	O
13	O
,	O
6	O
.	O
93	O
+	O
/	O
-	O
0	O
.	O
04	O
and	O
7	O
.	O
22	O
+	O
/	O
-	O
0	O
.	O
18	O
,	O
respectively	O
)	O
.	O

Since	O
the	O
arrival	O
of	O
oral	O
erection	O
-	O
supporting	O
medication	B
,	O
patients	O
want	O
to	O
know	O
how	O
safe	O
sexual	O
activity	O
is	O
in	O
cardiovascular	O
disease	O
in	O
general	O
and	O
during	O
use	O
of	O
erection	O
-	O
supporting	O
medication	B
in	O
particular	O
.	O

Sildenafil	B
is	O
contraindicated	O
in	O
patients	O
using	O
long	O
-	O
acting	O
nitrates	B
or	O
who	O
may	O
need	O
to	O
use	O
short	O
-	O
acting	O
nitrates	B
,	O
because	O
the	O
combination	O
may	O
cause	O
a	O
sharp	O
fall	O
of	O
the	O
blood	O
pressure	O
.	O

No	O
interactions	O
have	O
been	O
observed	O
with	O
beta	O
-	O
receptor	O
blockers	B
,	O
calcium	B
antagonists	I
,	O
thiazide	B
and	O
loop	B
diuretics	I
and	O
ACE	B
inhibitors	I
.	O

Influence	O
of	O
coadministration	O
of	O
fluoxetine	B
on	O
cisapride	B
pharmacokinetics	O
and	O
QTc	O
intervals	O
in	O
healthy	O
volunteers	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
fluoxetine	B
on	O
the	O
pharmacokinetics	O
and	O
cardiovascular	O
safety	O
of	O
cisapride	B
at	O
steady	O
state	O
in	O
healthy	O
men	O
.	O

and	O
phase	O
3	O
(	O
days	O
45	O
-	O
52	O
)	O
:	O
cisapride	B
10	O
mg	O
4	O
times	O
/	O
day	O
(	O
days	O
45	O
-	O
51	O
)	O
plus	O
fluoxetine	B
20	O
mg	O
/	O
day	O
(	O
days	O
45	O
-	O
52	O
)	O
.	O

Coadministration	O
of	O
fluoxetine	B
significantly	O
decreased	O
cisapride	B
plasma	O
concentrations	O
.	O

There	O
were	O
no	O
clinically	O
significant	O
changes	O
in	O
corrected	O
QT	O
intervals	O
during	O
administration	O
of	O
cisapride	B
alone	O
or	O
with	O
fluoxetine	B
.	O

Cisapride	B
was	O
well	O
tolerated	O
when	O
administered	O
alone	O
or	O
with	O
fluoxetine	B
.	O

CONCLUSION	O
:	O
Cisapride	B
can	O
be	O
administered	O
safely	O
to	O
patients	O
receiving	O
low	O
therapeutic	O
dosages	O
of	O
fluoxetine	B
.	O

Olanzapine	B
,	O
a	O
thienobenzodiazepine	B
derivative	I
,	O
is	O
a	O
second	B
generation	I
(	O
atypical	O
)	O
antipsychotic	B
agent	I
which	O
has	O
proven	O
efficacy	O
against	O
the	O
positive	O
and	O
negative	O
symptoms	O
of	O
schizophrenia	O
.	O

In	O
large	O
,	O
well	O
controlled	O
trials	O
in	O
patients	O
with	O
schizophrenia	O
or	O
related	O
psychoses	O
,	O
olanzapine	B
5	O
to	O
20	O
mg	O
/	O
day	O
was	O
significantly	O
superior	O
to	O
haloperidol	B
5	O
to	O
20	O
mg	O
/	O
day	O
in	O
overall	O
improvements	O
in	O
psychopathology	O
rating	O
scales	O
and	O
in	O
the	O
treatment	O
of	O
depressive	O
and	O
negative	O
symptoms	O
,	O
and	O
was	O
comparable	O
in	O
effects	O
on	O
positive	O
psychotic	O
symptoms	O
.	O

The	O
1	O
-	O
year	O
risk	O
of	O
relapse	O
(	O
rehospitalisation	O
)	O
was	O
significantly	O
lower	O
with	O
olanzapine	B
than	O
with	O
haloperidol	B
treatment	O
.	O

In	O
the	O
first	O
double	O
-	O
blind	O
comparative	O
study	O
(	O
28	O
-	O
week	O
)	O
of	O
olanzapine	B
and	O
risperidone	B
,	O
olanzapine	B
10	O
to	O
20	O
mg	O
/	O
day	O
proved	O
to	O
be	O
significantly	O
more	O
effective	O
than	O
risperidone	B
4	O
to	O
12	O
mg	O
/	O
day	O
in	O
the	O
treatment	O
of	O
negative	O
and	O
depressive	O
symptoms	O
but	O
not	O
on	O
overall	O
psychopathology	O
symptoms	O
.	O

In	O
contrast	O
,	O
preliminary	O
results	O
from	O
an	O
8	O
-	O
week	O
controlled	O
study	O
suggested	O
risperidone	B
2	O
to	O
6	O
mg	O
/	O
day	O
was	O
superior	O
to	O
olanzapine	B
5	O
to	O
20	O
mg	O
/	O
day	O
against	O
positive	O
and	O
anxiety	O
/	O
depressive	O
symptoms	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
although	O
consistent	O
with	O
the	O
first	O
study	O
,	O
both	O
agents	O
demonstrated	O
similar	O
efficacy	O
on	O
measures	O
of	O
overall	O
psychopathology	O
.	O

Improvements	O
in	O
general	O
cognitive	O
function	O
seen	O
with	O
olanzapine	B
treatment	O
in	O
a	O
1	O
-	O
year	O
controlled	O
study	O
of	O
patients	O
with	O
early	O
-	O
phase	O
schizophrenia	O
,	O
were	O
significantly	O
greater	O
than	O
changes	O
seen	O
with	O
either	O
risperidone	B
or	O
haloperidol	B
.	O

However	O
,	O
preliminary	O
results	O
from	O
an	O
8	O
-	O
week	O
trial	O
showed	O
comparable	O
cognitive	O
enhancing	O
effects	O
of	O
olanzapine	B
and	O
risperidone	B
treatment	O
in	O
patients	O
with	O
schizophrenia	O
or	O
schizoaffective	O
disorder	O
.	O

Several	O
studies	O
indicate	O
that	O
olanzapine	B
has	O
benefits	O
against	O
symptoms	O
of	O
aggression	O
and	O
agitation	O
,	O
while	O
other	O
studies	O
strongly	O
support	O
the	O
effectiveness	O
of	O
olanzapine	B
in	O
the	O
treatment	O
of	O
depressive	O
symptomatology	O
.	O

Olanzapine	B
is	O
associated	O
with	O
significantly	O
fewer	O
extrapyramidal	O
symptoms	O
than	O
haloperidol	B
and	O
risperidone	B
.	O

In	O
addition	O
,	O
olanzapine	B
is	O
not	O
associated	O
with	O
a	O
risk	O
of	O
agranulocytosis	O
as	O
seen	O
with	O
clozapine	B
or	O
clinically	O
significant	O
hyperprolactinaemia	O
as	O
seen	O
with	O
risperidone	B
or	O
prolongation	O
of	O
the	O
QT	O
interval	O
.	O

In	O
comparison	O
with	O
haloperidol	B
,	O
the	O
adverse	O
events	O
reported	O
significantly	O
more	O
frequently	O
with	O
olanzapine	B
in	O
>	O
or	O
=	O
3	O
.	O
5	O
%	O
of	O
patients	O
were	O
dry	O
mouth	O
,	O
bodyweight	O
gain	O
and	O
increased	O
appetite	O
and	O
compared	O
with	O
risperidone	B
,	O
only	O
bodyweight	O
gain	O
occurred	O
significantly	O
more	O
frequently	O
with	O
olanzapine	B
.	O

Pharmacoeconomic	O
analyses	O
indicate	O
that	O
olanzapine	B
does	O
not	O
significantly	O
increase	O
,	O
and	O
may	O
even	O
decrease	O
,	O
the	O
overall	O
direct	O
treatment	O
costs	O
of	O
schizophrenia	O
,	O
compared	O
with	O
haloperidol	B
.	O

Compared	O
with	O
risperidone	B
,	O
olanzapine	B
has	O
also	O
been	O
reported	O
to	O
decrease	O
overall	O
treatment	O
costs	O
,	O
despite	O
the	O
several	O
-	O
fold	O
higher	O
daily	O
acquisition	O
cost	O
of	O
the	O
drug	O
.	O

Olanzapine	B
treatment	O
improves	O
quality	O
of	O
life	O
in	O
patients	O
with	O
schizophrenia	O
and	O
related	O
psychoses	O
to	O
a	O
greater	O
extent	O
than	O
haloperidol	B
,	O
and	O
to	O
broadly	O
the	O
same	O
extent	O
as	O
risperidone	B
.	O

CONCLUSIONS	O
:	O
Olanzapine	B
demonstrated	O
superior	O
antipsychotic	O
efficacy	O
compared	O
with	O
haloperidol	B
in	O
the	O
treatment	O
of	O
acute	O
phase	O
schizophrenia	O
,	O
and	O
in	O
the	O
treatment	O
of	O
some	O
patients	O
with	O
first	O
-	O
episode	O
or	O
treatment	O
-	O
resistant	O
schizophrenia	O
.	O

The	O
reduced	O
risk	O
of	O
adverse	O
events	O
and	O
therapeutic	O
superiority	O
compared	O
with	O
haloperidol	B
and	O
risperidone	B
in	O
the	O
treatment	O
of	O
negative	O
and	O
depressive	O
symptoms	O
support	O
the	O
choice	O
of	O
olanzapine	B
as	O
a	O
first	O
-	O
line	O
option	O
in	O
the	O
management	O
of	O
schizophrenia	O
in	O
the	O
acute	O
phase	O
and	O
for	O
the	O
maintenance	O
of	O
treatment	O
response	O
.	O

The	O
emerging	O
roles	O
of	O
non	O
-	O
nucleoside	O
reverse	B
transcriptase	I
inhibitors	I
in	O
antiretroviral	B
therapy	O
.	O

The	O
availability	O
of	O
potent	O
non	O
-	O
nucleoside	O
reverse	B
transcriptase	I
inhibitor	I
(	O
NNRTI	B
)	O
-	O
based	O
regimens	O
for	O
antiretroviral	B
therapy	O
and	O
concerns	O
regarding	O
protease	B
inhibitor	I
(	O
PI	B
)	O
-	O
related	O
metabolic	O
disturbances	O
have	O
led	O
to	O
significant	O
shifts	O
in	O
treatment	O
practices	O
in	O
HIV	O
infection	O
.	O

NNRTI	B
-	O
based	O
regimens	O
may	O
have	O
several	O
advantages	O
over	O
PI	B
-	O
based	O
therapy	O
for	O
initial	O
or	O
prolonged	O
therapy	O
,	O
including	O
more	O
convenient	O
administration	O
regimens	O
,	O
lower	O
tablet	O
volume	O
,	O
fewer	O
drug	O
interactions	O
,	O
and	O
central	O
nervous	O
system	O
penetration	O
.	O

No	O
data	O
from	O
prospective	O
clinical	O
trials	O
currently	O
exist	O
comparing	O
the	O
3	O
approved	O
agents	O
(	O
efavirenz	B
,	O
nevirapine	B
or	O
delavirdine	B
)	O
.	O

Both	O
efavirenz	B
and	O
nevirapine	B
have	O
been	O
compared	O
to	O
triple	O
therapy	O
with	O
the	O
PI	B
indinavir	I
over	O
48	O
weeks	O
as	O
initial	O
therapy	O
,	O
with	O
similar	O
responses	O
being	O
observed	O
with	O
nevirapine	B
regimens	O
and	O
superiority	O
observed	O
with	O
efavirenz	B
.	O

A	O
smaller	O
24	O
-	O
week	O
study	O
has	O
suggested	O
nevirapine	B
may	O
be	O
superior	O
to	O
the	O
PI	B
nelfinavir	I
.	O

Limited	O
comparative	O
data	O
in	O
patients	O
with	O
high	O
viral	O
loads	O
treated	O
with	O
nevirapine	B
-	O
or	O
delavirdine	B
-	O
based	O
regimens	O
currently	O
exist	O
.	O

The	O
superiority	O
of	O
efavirenz	B
over	O
indinavir	B
-	O
based	O
regimens	O
has	O
been	O
observed	O
in	O
comparative	O
data	O
in	O
a	O
subset	O
of	O
patients	O
with	O
high	O
viral	O
loads	O
.	O

Efavirenz	B
has	O
demonstrated	O
superiority	O
over	O
nelfinavir	B
in	O
nucleoside	O
-	O
experienced	O
patients	O
,	O
although	O
combining	O
these	O
2	O
agents	O
may	O
represent	O
the	O
best	O
approach	O
in	O
these	O
circumstances	O
.	O

METHODS	O
:	O
Clinical	O
studies	O
,	O
case	O
reports	O
,	O
and	O
commentaries	O
and	O
editorials	O
concerning	O
sildenafil	B
published	O
in	O
the	O
international	O
literature	O
between	O
January	O
1999	O
and	O
August	O
2000	O
were	O
identified	O
through	O
searches	O
of	O
MEDLINE	O
,	O
PREMEDLINE	O
,	O
and	O
International	O
Pharmaceutical	O
Abstracts	O
,	O
using	O
the	O
terms	O
sildenafil	B
,	O
Viagra	B
,	O
and	O
erectile	O
dysfunction	O
.	O

RESULTS	O
:	O
Sildenafil	B
has	O
demonstrated	O
effectiveness	O
in	O
men	O
with	O
erectile	O
dysfunction	O
associated	O
with	O
prostatectomy	O
,	O
radiation	O
therapy	O
,	O
diabetes	O
mellitus	O
,	O
certain	O
neurologic	O
disorders	O
,	O
and	O
drug	O
therapy	O
(	O
eg	O
,	O
selective	B
serotonin	I
reuptake	I
inhibitors	I
[	O
SSRIs	B
]	O
)	O
.	O

however	O
,	O
patients	O
with	O
moderate	O
to	O
severe	O
cardiovascular	O
disease	O
or	O
those	O
taking	O
nitrate	B
therapy	O
are	O
at	O
increased	O
risk	O
for	O
potentially	O
serious	O
cardiovascular	O
adverse	O
effects	O
with	O
sildenafil	B
therapy	O
.	O

In	O
addition	O
,	O
patients	O
taking	O
drugs	O
that	O
inhibit	O
the	O
cytochrome	O
P450	O
3A4	O
isozyme	O
,	O
which	O
metabolizes	O
sildenafil	B
,	O
may	O
experience	O
increased	O
drug	O
concentrations	O
and	O
possible	O
toxicity	O
from	O
normal	O
doses	O
of	O
sildenafil	B
.	O

Acute	O
hydrocortisone	B
administration	O
does	O
not	O
affect	O
subjective	O
responses	O
to	O
d	O
-	O
amphetamine	O
in	O
humans	O
.	O

However	O
,	O
the	O
effects	O
of	O
stress	O
and	O
glucocorticoids	B
on	O
the	O
subjective	O
and	O
behavioral	O
effects	O
of	O
psychostimulants	B
have	O
not	O
been	O
well	O
studied	O
in	O
humans	O
.	O

OBJECTIVES	O
:	O
To	O
examine	O
the	O
effects	O
of	O
acute	O
hydrocortisone	B
pretreatment	O
on	O
the	O
subjective	O
and	O
behavioral	O
effects	O
of	O
d	O
-	O
amphetamine	O
.	O

METHODS	O
:	O
Hydrocortisone	B
(	O
100	O
mg	O
)	O
and	O
d	O
-	O
amphetamine	O
(	O
20	O
mg	O
)	O
were	O
administered	O
orally	O
to	O
16	O
healthy	O
male	O
and	O
female	O
volunteers	O
in	O
a	O
four	O
-	O
session	O
,	O
placebo	O
-	O
controlled	O
,	O
within	O
-	O
subject	O
,	O
crossover	O
design	O
.	O

However	O
,	O
hydrocortisone	B
pretreatment	O
did	O
not	O
affect	O
any	O
of	O
the	O
physiological	O
,	O
behavioral	O
,	O
or	O
subjective	O
effects	O
of	O
d	O
-	O
amphetamine	O
.	O

CONCLUSIONS	O
:	O
In	O
contrast	O
to	O
the	O
effects	O
of	O
glucocorticoids	B
in	O
rodent	O
studies	O
,	O
these	O
results	O
indicate	O
that	O
an	O
acute	O
increase	O
in	O
cortisol	O
does	O
not	O
enhance	O
the	O
psychostimulant	O
effects	O
of	O
d	O
-	O
amphetamine	O
in	O
humans	O
.	O

Interaction	O
of	O
clindamycin	B
and	O
gentamicin	B
in	O
vitro	O
.	O

The	O
minimal	O
inhibitory	O
concentrations	O
of	O
clindamycin	B
and	O
gentamicin	B
alone	O
and	O
in	O
combinations	O
were	O
determined	O
by	O
a	O
microdilution	O
method	O
for	O
163	O
aerobic	O
,	O
facultative	O
,	O
and	O
anaerobic	O
clinical	O
isolates	O
.	O

Gentamicin	B
did	O
not	O
interfere	O
with	O
the	O
activity	O
of	O
clindamycin	B
within	O
the	O
range	O
of	O
concentrations	O
tested	O
(	O
0	O
.	O
1	O
to	O
100	O
mug	O
/	O
ml	O
)	O
;	O

Combinations	O
of	O
clindamycin	B
and	O
gentamicin	B
were	O
indifferent	O
for	O
29	O
strains	O
and	O
synergistic	O
for	O
33	O
strains	O
.	O

All	O
20	O
strains	O
of	O
enterococcus	O
,	O
three	O
strains	O
of	O
Clostridium	O
,	O
three	O
strains	O
of	O
Escherichia	O
coli	O
,	O
and	O
one	O
strain	O
of	O
Proteus	O
rettgeri	O
were	O
resistant	O
to	O
both	O
clindamycin	B
(	O
minimal	O
inhibitory	O
concentration	O
greater	O
than	O
3	O
.	O
1	O
mug	O
/	O
ml	O
)	O
and	O
gentamicin	B
(	O
minimal	O
inhibitory	O
concentration	O
greater	O
than	O
6	O
.	O
2	O
mug	O
/	O
ml	O
)	O
.	O

Combinations	O
of	O
clindamycin	B
and	O
gentamicin	B
were	O
indifferent	O
for	O
16	O
and	O
synergistic	O
for	O
11	O
of	O
the	O
resistant	O
strains	O
.	O

Molecular	O
basis	O
for	O
the	O
selective	O
toxicity	O
of	O
amphotericin	B
B	I
for	O
yeast	O
and	O
filipin	B
for	O
animal	O
cells	O
.	O

Among	O
the	O
polyene	B
antibiotics	I
,	O
many	O
,	O
like	O
filipin	B
,	O
cannot	O
be	O
used	O
clinically	O
because	O
they	O
are	O
toxic	O
;	O

Both	O
the	O
toxicity	O
of	O
filipin	B
and	O
the	O
therapeutic	O
value	O
of	O
amphotericin	B
B	I
can	O
be	O
rationalized	O
at	O
the	O
cellular	O
and	O
molecular	O
level	O
by	O
the	O
following	O
observations	O
:	O
(	O
i	O
)	O
these	O
polyene	B
antibiotics	I
showed	O
differential	O
effects	O
on	O
cells	O
;	O

filipin	B
was	O
more	O
potent	O
in	O
lysing	O
human	O
red	O
blood	O
cells	O
,	O
whereas	O
amphotericin	B
B	I
was	O
more	O
potent	O
in	O
inhibiting	O
yeast	O
cell	O
growth	O
;	O

and	O
(	O
ii	O
)	O
the	O
effects	O
of	O
filipin	B
were	O
more	O
efficiently	O
inhibited	O
by	O
added	O
cholesterol	O
,	O
the	O
major	O
membrane	O
sterol	O
in	O
human	O
cells	O
,	O
whereas	O
the	O
effects	O
of	O
amphotericin	B
B	I
were	O
more	O
efficiently	O
inhibited	O
by	O
ergosterol	O
,	O
the	O
major	O
membrane	O
sterol	O
in	O
yeast	O
.	O

Studies	O
on	O
the	O
mechanism	O
of	O
action	O
of	O
miconazole	B
:	O
effect	O
of	O
miconazole	B
on	O
respiration	O
and	O
cell	O
permeability	O
of	O
Candida	O
albicans	O
.	O

The	O
antifungal	B
drug	I
,	O
miconazole	B
nitrate	I
,	O
inhibits	O
the	O
growth	O
of	O
several	O
species	O
of	O
Candida	O
.	O

Effect	O
of	O
probenecid	B
on	O
the	O
apparent	O
volume	O
of	O
distribution	O
and	O
elimination	O
of	O
cloxacillin	B
.	O

(	O
1968	O
,	O
1970	O
)	O
,	O
the	O
higher	O
serum	O
concentrations	O
of	O
penicillins	B
and	O
cephaloridine	B
reached	O
after	O
administration	O
of	O
probenecid	B
are	O
due	O
not	O
only	O
to	O
slower	O
renal	O
elimination	O
but	O
also	O
to	O
an	O
altered	O
distribution	O
in	O
the	O
body	O
.	O

To	O
determine	O
whether	O
probenecid	B
has	O
a	O
direct	O
effect	O
on	O
the	O
distribution	O
of	O
cloxacillin	B
,	O
the	O
elimination	O
and	O
distribution	O
of	O
cloxacillin	B
was	O
studied	O
in	O
six	O
patients	O
,	O
five	O
lacking	O
kidney	O
function	O
and	O
one	O
with	O
a	O
partially	O
impaired	O
renal	O
function	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
probenecid	B
.	O

No	O
significant	O
difference	O
was	O
found	O
between	O
the	O
mean	O
values	O
of	O
the	O
volume	O
of	O
distribution	O
of	O
cloxacillin	B
with	O
and	O
without	O
probenecid	B
(	O
13	O
.	O
0	O
and	O
12	O
.	O
6	O
liters	O
,	O
respectively	O
)	O
.	O

This	O
might	O
be	O
explained	O
by	O
a	O
blockade	O
by	O
probenecid	B
of	O
the	O
elimination	O
of	O
cloxacillin	B
by	O
the	O
liver	O
.	O

Many	O
people	O
use	O
both	O
alcohol	B
and	O
nicotine	B
(	O
i	O
.	O
e	O
.	O
,	O
cigarettes	O
and	O
other	O
tobacco	O
products	O
)	O
.	O

The	O
initiation	O
of	O
alcohol	B
or	O
nicotine	B
use	O
may	O
be	O
precipitated	O
by	O
similar	O
personality	O
characteristics	O
in	O
the	O
user	O
,	O
such	O
as	O
impulsivity	O
and	O
sensation	O
seeking	O
.	O

Moreover	O
,	O
the	O
mechanisms	O
underlying	O
the	O
development	O
of	O
dependence	O
may	O
be	O
similar	O
for	O
alcohol	B
and	O
nicotine	B
.	O

[	O
Dose	O
-	O
time	O
effects	O
of	O
competitive	O
displacement	O
of	O
radiopertechnetate	O
by	O
sodium	O
perchlorate	O
following	O
oral	O
and	O
intravenous	O
administration	O
]	O

An	O
intravenous	O
dose	O
of	O
50	O
mg	O
perchlorate	B
was	O
in	O
respect	O
of	O
competitive	O
suppression	O
of	O
organs	O
actively	O
concentrating	O
pertechnetate	B
as	O
effective	O
as	O
intravenous	O
1000	O
mg	O
ClO	O
-	O
4	O
-	O
simultaneously	O
or	O
1000	O
mg	O
orally	O
30	O
min	O
before	O
the	O
injection	O
of	O
radiopertechnetate	B
.	O

An	O
intravenous	O
injection	O
of	O
perchlorate	B
given	O
later	O
also	O
produces	O
a	O
complete	O
and	O
immediately	O
beginning	O
depletion	O
of	O
pertechnetate	B
already	O
accumulated	O
in	O
the	O
thyroid	O
,	O
within	O
a	O
period	O
of	O
195	O
min	O
after	O
99m	O
-	O
TcO	O
-	O
4	O
-	O
injection	O
with	O
a	O
corresponding	O
increase	O
in	O
blood	O
levels	O
.	O

Sirolimus	B
:	O
mammalian	O
target	O
of	O
rapamycin	B
inhibitor	O
to	O
prevent	O
kidney	O
rejection	O
.	O

Sirolimus	B
works	O
differently	O
from	O
the	O
immunosuppressants	B
currently	O
available	O
,	O
and	O
except	O
for	O
increased	O
lipid	O
levels	O
,	O
the	O
adverse	O
reaction	O
profile	O
of	O
sirolimus	B
does	O
not	O
appear	O
to	O
overlap	O
to	O
any	O
great	O
extent	O
with	O
that	O
associated	O
with	O
cyclosporine	B
or	O
tacrolimus	B
.	O

While	O
additional	O
research	O
is	O
needed	O
,	O
the	O
initial	O
clinical	O
data	O
in	O
kidney	O
recipients	O
suggest	O
that	O
sirolimus	B
,	O
in	O
combination	O
with	O
cyclosporine	B
or	O
tacrolimus	B
,	O
might	O
have	O
the	O
potential	O
to	O
reduce	O
the	O
frequency	O
of	O
rejection	O
episodes	O
,	O
permit	O
reductions	O
in	O
cyclosporine	B
or	O
tacrolimus	B
dosage	O
,	O
and	O
permit	O
steroid	O
withdrawal	O
(	O
Kelly	O
,	O
1999	O
)	O
.	O

The	O
effects	O
of	O
chlordiazepoxide	B
,	O
amphetamine	B
and	O
cocaine	B
on	O
bar	O
-	O
press	O
behavior	O
in	O
normal	O
and	O
genetically	O
nervous	O
dogs	O
.	O

Studies	O
on	O
two	O
strains	O
of	O
pointer	O
dogs	O
have	O
demonstrated	O
that	O
administration	O
of	O
a	O
benzodiazepine	B
(	O
chlordiazepoxide	B
)	O
facilitates	O
acquisition	O
of	O
goal	O
-	O
directed	O
behavior	O
in	O
"	O
genetically	O
nervous	O
"	O

The	O
concomitant	O
administration	O
of	O
either	O
cocaine	B
or	O
amphetamine	B
,	O
compounds	O
which	O
inhibit	O
neuronal	O
reuptake	O
of	O
norepinephrine	O
,	O
disrupts	O
the	O
behavioral	O
response	O
of	O
the	O
genetically	O
nervous	O
E	O
-	O
strain	O
subjects	O
to	O
a	O
far	O
greater	O
extent	O
than	O
the	O
stable	O
A	O
-	O
strain	O
subjects	O
.	O

Fluvastatin	B
is	O
the	O
first	O
synthetic	B
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
coenzyme	B
A	I
(	O
HMGCoA	O
)	O
reductase	B
inhibitor	I
to	O
be	O
approved	O
for	O
clinical	O
use	O
,	O
and	O
has	O
been	O
studied	O
extensively	O
in	O
humans	O
since	O
1986	O
.	O

It	O
is	O
structurally	O
distinct	O
from	O
the	O
other	O
currently	O
available	O
HMGCoA	B
reductase	I
inhibitors	I
(	O
lovastatin	B
,	O
simvastatin	B
,	O
and	O
pravastatin	B
)	O
,	O
leading	O
to	O
unique	O
biopharmaceutical	O
properties	O
relative	O
to	O
the	O
other	O
agents	O
of	O
this	O
class	O
.	O

Cholestyramine	B
,	O
an	O
anionic	O
-	O
binding	O
resin	O
,	O
has	O
a	O
considerable	O
effect	O
in	O
lowering	O
the	O
rate	O
and	O
extent	O
of	O
fluvastatin	B
bioavailability	O
.	O

Although	O
this	O
effect	O
was	O
noted	O
even	O
when	O
cholestyramine	B
was	O
given	O
4	O
hours	O
prior	O
to	O
fluvastatin	B
,	O
this	O
regimen	O
did	O
not	O
result	O
in	O
diminished	O
efficacy	O
.	O

Further	O
,	O
no	O
effects	O
on	O
either	O
warfarin	B
levels	O
or	O
prothrombin	O
times	O
were	O
observed	O
in	O
a	O
study	O
involving	O
concomitant	O
administration	O
of	O
warfarin	B
and	O
fluvastatin	B
.	O

Moreover	O
,	O
additional	O
interaction	O
studies	O
with	O
niacin	B
and	O
propranolol	B
have	O
not	O
demonstrated	O
any	O
effect	O
on	O
fluvastatin	B
plasma	O
levels	O
,	O
and	O
administration	O
to	O
a	O
patient	O
population	O
chronically	O
receiving	O
digoxin	B
resulted	O
in	O
no	O
difference	O
in	O
the	O
extent	O
of	O
bioavailability	O
of	O
digoxin	B
relative	O
to	O
control	O
data	O
.	O

Repeated	O
oral	O
administration	O
of	O
coumaphos	B
in	O
sheep	O
:	O
interactions	O
of	O
coumaphos	B
with	O
bishydroxycoumarin	B
,	O
trichlorfon	B
,	O
and	O
phenobarbital	B
sodium	I
.	O

Interactions	O
between	O
treatments	O
with	O
coumaphos	B
,	O
bishydroxycoumarin	B
(	O
an	O
anticoagulant	B
)	O
,	O
trichlorfon	B
(	O
an	O
organophosphorous	B
compound	I
)	O
,	O
and	O
phenobarbital	B
sodium	I
(	O
an	O
inducer	O
of	O
microsomal	O
enzymes	O
)	O
were	O
investigated	O
in	O
sheep	O
.	O

A	O
daily	O
dose	O
of	O
2	O
mg	O
of	O
coumaphos	B
/	O
kg	O
of	O
body	O
weight	O
for	O
6	O
days	O
did	O
not	O
affect	O
the	O
plasma	O
enzymes	O
or	O
the	O
antiprothrombinemic	O
effect	O
of	O
bishydroxy	O
-	O
coumarin	O
in	O
wethers	O
.	O

The	O
treatment	O
of	O
ewes	O
with	O
an	O
intravenous	O
(	O
IV	O
)	O
injection	O
of	O
trichlorfon	B
,	O
insufficient	O
to	O
produce	O
significant	O
inhibition	O
of	O
erythrocyte	O
acetylcholinesterase	O
(	O
AChE	O
)	O
activity	O
,	O
appeared	O
to	O
produce	O
additive	O
effects	O
with	O
those	O
produced	O
by	O
subsequent	O
treatment	O
with	O
4	O
mg	O
of	O
coumaphos	B
/	O
kg	O
/	O
day	O
.	O

In	O
ewes	O
given	O
40	O
mg	O
of	O
phenobarbital	B
sodium	I
/	O
kg	O
for	O
5	O
days	O
intraperitoneally	O
(	O
IP	O
)	O
,	O
the	O
anticholinesterase	O
effect	O
of	O
4	O
mg	O
of	O
coumaphos	B
/	O
kg	O
was	O
significantly	O
reduced	O
and	O
signs	O
of	O
toxicity	O
were	O
not	O
present	O
.	O

Interaction	O
of	O
gentamycin	B
and	O
atracurium	B
in	O
anaesthetised	O
horses	O
.	O

Evoked	O
hind	O
limb	O
digital	O
extensor	O
tension	O
(	O
hoof	O
twitch	O
)	O
was	O
maintained	O
at	O
40	O
%	O
of	O
baseline	O
for	O
1	O
h	O
by	O
atracurium	B
infusion	O
in	O
7	O
horses	O
anaesthetised	O
with	O
halothane	B
.	O

Atracurium	B
was	O
again	O
given	O
by	O
infusion	O
to	O
maintain	O
40	O
%	O
twitch	O
for	O
a	O
second	O
hour	O
,	O
then	O
2	O
mg	O
gentamycin	B
/	O
kg	O
bwt	O
were	O
given	O
i	O
.	O
v	O
.	O

Recovery	O
of	O
hoof	O
twitch	O
from	O
50	O
%	O
to	O
75	O
%	O
took	O
7	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
7	O
min	O
for	O
atracurium	B
alone	O
and	O
11	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
7	O
min	O
for	O
atracurium	B
plus	O
gentamycin	B
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

Recovery	O
from	O
50	O
%	O
twitch	O
to	O
75	O
%	O
fade	O
recovery	O
took	O
13	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
8	O
min	O
for	O
atracurium	B
alone	O
and	O
13	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
2	O
min	O
for	O
atracurium	B
plus	O
gentamycin	B
.	O

At	O
75	O
%	O
recovery	O
of	O
fade	O
,	O
hoof	O
twitch	O
was	O
87	O
+	O
/	O
-	O
3	O
%	O
for	O
atracurium	B
alone	O
and	O
82	O
+	O
/	O
-	O
4	O
%	O
for	O
atracurium	B
plus	O
gentamycin	B
.	O

It	O
was	O
concluded	O
that	O
,	O
although	O
gentamycin	B
did	O
augment	O
the	O
neuromuscular	O
blockade	O
of	O
atracurium	B
,	O
the	O
effect	O
was	O
minimal	O
.	O

Acid	O
-	O
catalyzed	O
ethanolysis	O
of	O
temazepam	B
in	O
anhydrous	O
and	O
aqueous	O
ethanol	B
solutions	O
.	O

The	O
benzodiazepines	B
are	O
a	O
family	O
of	O
anxiolytic	B
and	O
hypnotic	B
drugs	I
.	O

In	O
addition	O
to	O
this	O
pharmacological	O
interaction	O
,	O
this	O
report	O
describes	O
a	O
novel	O
chemical	O
reaction	O
between	O
temazepam	B
(	O
a	O
benzodiazepine	B
)	O
and	O
ethanol	B
under	O
acidic	O
conditions	O
similar	O
to	O
those	O
found	O
in	O
vivo	O
,	O
resulting	O
in	O
a	O
3	O
-	O
ethoxylated	O
product	O
.	O

The	O
results	O
raise	O
the	O
possibility	O
that	O
the	O
ethanolysis	O
reaction	O
may	O
occur	O
in	O
the	O
stomach	O
of	O
people	O
who	O
consume	O
alcohol	B
and	O
3	O
-	O
hydroxy	O
-	O
1	O
,	O
4	O
-	O
benzodiazepine	O
on	O
a	O
regular	O
basis	O
.	O

Laboratory	O
Tests	O
Response	O
to	O
Plenaxis	B
should	O
be	O
monitored	O
by	O
measuring	O
serum	O
total	O
testosterone	B
concentrations	O
just	O
prior	O
to	O
administration	O
on	O
Day	O
29	O
and	O
every	O
8	O
weeks	O
thereafter	O
.	O

Population	O
pharmacokinetic	O
analyses	O
revealed	O
that	O
MTX	B
,	O
NSAIDs	B
,	O
corticosteroids	B
,	O
and	O
TNF	B
blocking	I
agents	I
did	O
not	O
influence	O
abatacept	B
clearance	O
.	O

The	O
majority	O
of	O
patients	O
in	O
RA	O
clinical	O
studies	O
received	O
one	O
or	O
more	O
of	O
the	O
following	O
concomitant	O
medications	O
with	O
ORENCIA	B
:	O
MTX	B
,	O
NSAIDs	B
,	O
corticosteroids	B
,	O
TNF	B
blocking	I
agents	I
,	O
azathioprine	B
,	O
chloroquine	B
,	O
gold	B
,	O
hydroxychloroquine	B
,	O
leflunomide	B
,	O
sulfasalazine	B
,	O
and	O
anakinra	B
.	O

Concurrent	O
administration	O
of	O
a	O
TNF	B
antagonist	I
with	O
ORENCIA	B
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
infections	O
and	O
no	O
significant	O
additional	O
efficacy	O
over	O
use	O
of	O
the	O
TNF	B
antagonists	I
alone	O
.	O

Concurrent	O
therapy	O
with	O
ORENCIA	B
and	O
TNF	B
antagonists	I
is	O
not	O
recommended	O
.	O

There	O
is	O
insufficient	O
experience	O
to	O
assess	O
the	O
safety	O
and	O
efficacy	O
of	O
ORENCIA	B
administered	O
concurrently	O
with	O
anakinra	B
,	O
and	O
therefore	O
such	O
use	O
is	O
not	O
recommended	O
.	O

These	O
medications	O
have	O
included	O
heparin	B
,	O
warfarin	B
,	O
beta	O
-	O
adrenergic	O
receptor	B
blockers	I
,	O
calcium	B
channel	I
antagonists	I
,	O
angiotensin	B
converting	I
enzyme	I
inhibitors	I
,	O
intravenous	O
and	O
oral	O
nitrates	B
,	O
ticlopidine	B
,	O
and	O
aspirin	B
.	O

Heparin	B
,	O
other	O
anticoagulants	B
,	O
thrombolytics	B
,	O
and	O
anti	B
platelet	I
agents	I
are	O
associated	O
with	O
an	O
increase	O
in	O
bleeding	O
.	O

Patients	O
with	O
HACA	O
titers	O
may	O
have	O
allergic	O
or	O
hypersensitivity	O
reactions	O
when	O
treated	O
with	O
other	O
diagnostic	B
or	O
therapeutic	B
monoclonal	I
antibodies	I
.	O

The	O
concomitant	O
intake	O
of	O
alcohol	B
and	O
Acamprosate	B
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
either	O
alcohol	B
or	O
acamprosate	B
.	O

Pharmacokinetic	O
studies	O
indicate	O
that	O
administration	O
of	O
disulfiram	B
or	O
diazepam	B
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
acamprosate	B
.	O

Co	O
-	O
administration	O
of	O
naltrexone	B
with	O
Acamprosate	B
produced	O
a	O
25	O
%	O
increase	O
in	O
AUC	O
and	O
a	O
33	O
%	O
increase	O
in	O
the	O
Cmax	O
of	O
acamprosate	B
.	O

The	O
pharmacokinetics	O
of	O
naltrexone	B
and	O
its	O
major	O
metabolite	O
6	O
-	O
beta	O
-	O
naltrexol	O
were	O
unaffected	O
following	O
co	O
-	O
administration	O
with	O
Acamprosate	B
.	O

Other	O
concomitant	O
therapies	O
:	O
In	O
clinical	O
trials	O
,	O
the	O
safety	O
profile	O
in	O
subjects	O
treated	O
with	O
Acamprosate	B
concomitantly	O
with	O
anxiolytics	B
,	O
hypnotics	B
and	O
sedatives	B
(	O
including	O
benzodiazepines	B
)	O
,	O
or	O
non	O
-	O
opioid	O
analgesics	B
was	O
similar	O
to	O
that	O
of	O
subjects	O
taking	O
placebo	O
with	O
these	O
concomitant	O
medications	O
.	O

Patients	O
taking	O
Acamprosate	B
concomitantly	O
with	O
antidepressants	B
more	O
commonly	O
reported	O
both	O
weight	O
gain	O
and	O
weight	O
loss	O
,	O
compared	O
with	O
patients	O
taking	O
either	O
medication	O
alone	O
.	O

These	O
drugs	B
include	O
the	O
thiazides	B
and	O
other	O
diuretics	B
,	O
corticosteroids	B
,	O
phenothiazines	B
,	O
thyroid	B
products	I
,	O
estrogens	B
,	O
oral	O
contraceptives	B
,	O
phenytoin	B
,	O
nicotinic	B
acid	I
,	O
sympathomimetics	B
,	O
calcium	B
channel	O
-	O
blocking	O
drugs	B
,	O
and	O
isoniazid	B
.	O

When	O
such	O
drugs	O
are	O
withdrawn	O
from	O
patients	O
receiving	O
Acarbose	B
in	O
combination	O
with	O
sulfonylureas	B
or	O
insulin	B
,	O
patients	O
should	O
be	O
observed	O
closely	O
for	O
any	O
evidence	O
of	O
hypoglycemia	O
.	O

Intestinal	B
adsorbents	I
(	O
e	O
.	O
g	O
.	O
,	O
charcoal	B
)	O
and	O
digestive	B
enzyme	I
preparations	I
containing	O
carbohydrate	O
-	O
splitting	O
enzymes	O
(	O
e	O
.	O
g	O
.	O
,	O
amylase	B
,	O
pancreatin	B
)	O
may	O
reduce	O
the	O
effect	O
of	O
Acarbose	B
and	O
should	O
not	O
be	O
taken	O
concomitantly	O
.	O

Acarbose	B
has	O
been	O
shown	O
to	O
change	O
the	O
bioavailabillty	O
digoxin	B
when	O
they	O
are	O
co	O
-	O
administered	O
,	O
which	O
may	O
require	O
digoxin	B
dose	O
adjustment	O
.	O

Studies	O
in	O
healthy	O
volunteers	O
have	O
shown	O
that	O
Acarbose	B
has	O
no	O
effect	O
on	O
either	O
the	O
pharmacokinetics	O
or	O
pharmacodynamics	O
of	O
digoxin	B
,	O
nifedipine	B
,	O
propranolol	B
,	O
or	O
ranitidine	B
.	O

Acarbose	B
did	O
not	O
interfere	O
with	O
the	O
absorption	O
or	O
disposition	O
of	O
the	O
sulfonylurea	B
glyburide	I
in	O
diabetic	O
patients	O
.	O

Acarbose	B
may	O
affect	O
digoxin	B
bioavailabillty	O
and	O
may	O
require	O
dose	O
adjustment	O
of	O
digoxin	B
by	O
16	O
%	O
(	O
90	O
%	O
confidence	O
interval	O
:	O
8	O
-	O
23	O
%	O
)	O
,	O
decrease	O
mean	O
C	O
max	O
digoxin	B
by	O
26	O
%	O
(	O
90	O
%	O
confidence	O
interval	O
:	O
16	O
-	O
34	O
%	O
)	O
and	O
decrease	O
mean	O
trough	O
concentrations	O
of	O
digoxin	B
by	O
9	O
%	O
(	O
90	O
%	O
confidence	O
limit	O
:	O
19	O
%	O
decrease	O
to	O
2	O
%	O
increase	O
)	O
.	O

The	O
amount	O
of	O
metformin	B
absorbed	O
while	O
taking	O
Acarbose	B
was	O
bioequivalent	O
to	O
the	O
amount	O
absorbed	O
when	O
taking	O
placebo	O
,	O
as	O
indicated	O
by	O
the	O
plasma	O
AUC	O
values	O
.	O

However	O
,	O
the	O
peak	O
plasma	O
level	O
of	O
metformin	B
was	O
reduced	O
by	O
approximately	O
20	O
%	O
when	O
taking	O
Acarbose	B
due	O
to	O
a	O
slight	O
delay	O
in	O
the	O
absorption	O
of	O
metformin	B
.	O

There	O
is	O
little	O
if	O
any	O
clinically	O
significant	O
interaction	O
between	O
Acarbose	B
and	O
metformin	B
.	O

Catecholamine	O
-	O
depleting	O
drugs	B
,	O
such	O
as	O
reserpine	B
,	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	O
-	O
blocking	O
agents	B
.	O

Patients	O
treated	O
with	O
acebutolol	B
plus	O
catecholamine	B
depletors	I
should	O
,	O
therefore	O
,	O
be	O
observed	O
closely	O
for	O
evidence	O
of	O
marked	O
bradycardia	O
or	O
hypotension	O
which	O
may	O
present	O
as	O
vertigo	O
,	O
syncope	O
/	O
presyncope	O
,	O
or	O
orthostatic	O
changes	O
in	O
blood	O
pressure	O
without	O
compensatory	O
tachycardia	O
.	O

Exaggerated	O
hypertensive	O
responses	O
have	O
been	O
reported	O
from	O
the	O
combined	O
use	O
of	O
beta	O
-	O
adrenergic	O
antagonists	B
and	O
alpha	O
-	O
adrenergic	O
stimulants	B
,	O
including	O
those	O
contained	O
in	O
proprietary	O
cold	O
remedies	O
and	O
vasoconstrictive	O
nasal	O
drops	O
.	O

Blunting	O
of	O
the	O
antihypertensive	O
effect	O
of	O
beta	O
-	O
adrenoceptor	O
blocking	B
agents	I
by	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
drugs	B
has	O
been	O
reported	O
.	O

No	O
significant	O
interactions	O
with	O
digoxin	B
,	O
hydrochlorothiazide	B
,	O
hydralazine	B
,	O
sulfinpyrazone	B
,	O
oral	O
contraceptives	B
,	O
tolbutamide	B
,	O
or	O
warfarin	B
have	O
been	O
observed	O
.	O

DIAMOX	B
modifies	O
phenytoin	B
metabolism	O
with	O
increased	O
serum	O
levels	O
of	O
phenytoin	B
.	O

By	O
decreasing	O
the	O
gastrointestinal	O
absorption	O
of	O
primidone	B
,	O
DIAMOX	B
may	O
decrease	O
serum	O
concentrations	O
of	O
primidone	B
and	O
its	O
metabolites	O
,	O
with	O
a	O
consequent	O
possible	O
decrease	O
in	O
anticonvulsant	O
effect	O
.	O

Caution	O
is	O
advised	O
when	O
beginning	O
,	O
discontinuing	O
,	O
or	O
changing	O
the	O
dose	O
of	O
DIAMOX	B
in	O
patients	O
receiving	O
primidone	B
.	O

Acetazolamide	B
may	O
increase	O
the	O
effects	O
of	O
other	O
folic	B
acid	I
antagonists	I
.	O

Acetazolamide	B
decreases	O
urinary	O
excretion	O
of	O
amphetamine	B
and	O
may	O
enhance	O
the	O
magnitude	O
and	O
duration	O
of	O
their	O
effect	O
.	O

Acetazolamide	B
reduces	O
urinary	O
excretion	O
of	O
quinidine	B
and	O
may	O
enhance	O
its	O
effect	O
.	O

Acetazolamide	B
may	O
prevent	O
the	O
urinary	O
antiseptic	O
effect	O
of	O
methenamine	B
.	O

Acetazolamide	B
increases	O
lithium	B
excretion	O
and	O
the	O
lithium	B
may	O
be	O
decreased	O
.	O

Acetazolamide	B
and	O
sodium	B
bicarbonate	I
used	O
concurrently	O
increases	O
the	O
risk	O
of	O
renal	O
calculus	O
formation	O
.	O

Acetazolamide	B
may	O
elevate	O
cyclosporine	B
levels	O
.	O

Concomitant	O
use	O
with	O
iron	B
supplements	O
may	O
result	O
in	O
the	O
reduced	O
absorption	O
of	O
iron	B
.	O

Co	O
-	O
administration	O
of	O
probenecid	B
with	O
acyclovir	B
has	O
been	O
shown	O
to	O
increase	O
the	O
mean	O
half	O
-	O
life	O
and	O
the	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
.	O

Ethanol	B
:	O
Clinical	O
evidence	O
has	O
shown	O
that	O
etretinate	B
can	O
be	O
formed	O
with	O
concurrent	O
ingestion	O
of	O
acitretin	B
and	O
ethanol	B
.	O

Glibenclamide	B
:	O
In	O
a	O
study	O
of	O
7	O
healthy	O
male	O
volunteers	O
,	O
acitretin	B
treatment	O
potentiated	O
the	O
blood	O
glucose	O
lowering	O
effect	O
of	O
glibenclamide	B
(	O
a	O
sulfonylurea	B
similar	O
to	O
chlorpropamide	B
)	O
in	O
3	O
of	O
the	O
7	O
subjects	O
.	O

Repeating	O
the	O
study	O
with	O
6	O
healthy	O
male	O
volunteers	O
in	O
the	O
absence	O
of	O
glibenclamide	B
did	O
not	O
detect	O
an	O
effect	O
of	O
acitretin	B
on	O
glucose	O
tolerance	O
.	O

Hormonal	B
Contraceptives	I
:	O
It	O
has	O
not	O
been	O
established	O
if	O
there	O
is	O
a	O
pharmacokinetic	O
interaction	O
between	O
acitretin	B
and	O
combined	B
oral	I
contraceptives	I
.	O

However	O
,	O
it	O
has	O
been	O
established	O
that	O
acitretin	B
interferes	O
with	O
the	O
contraceptive	O
effect	O
of	O
microdosed	O
progestin	B
minipill	O
preparations	O
.	O

Microdosed	O
minipill	O
progestin	B
preparations	O
are	O
not	O
recommended	O
for	O
use	O
with	O
Soriatane	B
.	O

It	O
is	O
not	O
known	O
whether	O
other	O
progestational	B
contraceptives	I
,	O
such	O
as	O
implants	O
and	O
injectables	O
,	O
are	O
adequate	O
methods	O
of	O
contraception	O
during	O
acitretin	B
therapy	O
.	O

Methotrexate	B
:	O
An	O
increased	O
risk	O
of	O
hepatitis	O
has	O
been	O
reported	O
to	O
result	O
from	O
combined	O
use	O
of	O
methotrexate	B
and	O
etretinate	B
.	O

Consequently	O
,	O
the	O
combination	O
of	O
methotrexate	B
with	O
acitretin	B
is	O
also	O
contraindicated	O
.	O

Phenytoin	B
:	O
If	O
acitretin	B
is	O
given	O
concurrently	O
with	O
phenytoin	B
,	O
the	O
protein	O
binding	O
of	O
phenytoin	B
may	O
be	O
reduced	O
.	O

Tetracyclines	B
:	O
Since	O
both	O
acitretin	B
and	O
tetracyclines	B
can	O
cause	O
increased	O
intracranial	O
pressure	O
,	O
their	O
combined	O
use	O
is	O
contraindicated	O
.	O

Vitamin	B
A	I
and	O
oral	O
retinoids	B
:	O
Concomitant	O
administration	O
of	O
vitamin	B
A	I
and	O
/	O
or	O
other	O
oral	O
retinoids	B
with	O
acitretin	B
must	O
be	O
avoided	O
because	O
of	O
the	O
risk	O
of	O
hypervitaminosis	O
A	B
.	O

Other	O
:	O
There	O
appears	O
to	O
be	O
no	O
pharmacokinetic	O
interaction	O
between	O
acitretin	B
and	O
cimetidine	B
,	O
digoxin	B
,	O
or	O
glyburide	B
.	O

Investigations	O
into	O
the	B
effect	O
of	B
acitretin	I
on	O
the	B
protein	O
binding	O
of	B
anticoagulants	I
of	I
the	I
coumarin	I
type	I
(	O
warfarin	B
)	O
revealed	O
no	O
interaction	O
.	O

Methotrexate	B
:	O
HUMIRA	B
has	O
been	O
studied	O
in	O
rheumatoid	O
arthritis	O
patients	O
taking	O
concomitant	O
MTX	B
.	O

The	O
data	O
do	O
not	O
suggest	O
the	O
need	O
for	O
dose	O
adjustment	O
of	O
either	O
HUMIRA	B
or	O
MTX	B
.	O

Anakinra	B
:	O
Concurrent	O
administration	O
of	O
anakinra	B
(	O
an	O
interleukin	O
-	O
1	O
antagonist	B
)	O
and	O
another	O
TNF	O
-	O
blocking	O
agent	B
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
infections	O
,	O
an	O
increased	O
risk	O
of	O
neutropenia	O
and	O
no	O
additional	O
benefit	O
compared	O
to	O
these	O
medicinal	O
products	O
alone	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
anakinra	B
used	O
in	O
combination	O
with	O
HUMIRA	B
has	O
not	O
been	O
studied	O
.	O

Therefore	O
the	O
,	O
combination	O
of	O
anakinra	B
with	O
other	O
TNF	O
-	O
blocking	O
agents	B
,	O
including	O
HUMIRA	B
,	O
may	O
also	O
result	O
i	O
n	O
similar	O
toxicities	O
.	O

Particular	O
caution	O
should	O
be	O
exercised	O
in	O
using	O
preparations	O
containing	O
sulfur	B
,	O
resorcinol	B
,	O
or	O
salicylic	B
acid	I
in	O
combination	O
with	O
DIFFERIN	B
Gel	O
.	O

Before	O
using	O
this	O
medication	O
,	O
tell	O
your	O
doctor	O
or	O
pharmacist	O
of	O
all	O
prescription	O
and	O
nonprescription	O
products	O
you	O
may	O
use	O
,	O
especially	O
of	O
:	O
aminoglycosides	B
(	O
e	O
.	O
g	O
.	O
,	O
gentamicin	B
,	O
amikacin	B
)	O
,	O
amphotericin	B
B	I
,	O
cyclosporine	B
,	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
e	O
.	O
g	O
.	O
,	O
ibuprofen	B
)	O
,	O
tacrolimus	B
,	O
vancomycin	B
.	O

Intravenous	O
Adenocard	B
(	O
adenosine	B
)	O
has	O
been	O
effectively	O
administered	O
in	O
the	O
presence	O
of	O
other	O
cardioactive	O
drugs	O
,	O
such	O
as	O
quinidine	B
,	O
beta	O
-	O
adrenergic	O
blocking	B
agents	I
,	O
calcium	B
channel	I
blocking	I
agents	I
,	O
and	O
angiotensin	B
converting	I
enzyme	I
inhibitors	I
,	O
without	O
any	O
change	O
in	O
the	O
adverse	O
reaction	O
profile	O
.	O

Digoxin	B
and	O
verapamil	B
use	O
may	O
be	O
rarely	O
associated	O
with	O
ventricular	O
fibrillation	O
when	O
combined	O
with	O
Adenocard	B
.	O

The	O
use	O
of	O
Adenocard	B
in	O
patients	O
receiving	O
digitalis	B
may	O
be	O
rarely	O
associated	O
with	O
ventricular	O
fibrillation	O
.	O

The	O
effects	O
of	O
adenosine	B
are	O
antagonized	O
by	O
methylxanthines	B
such	O
as	O
caffeine	B
and	O
theophylline	B
.	O

In	O
the	O
presence	O
of	O
these	O
methylxanthines	B
,	O
larger	O
doses	O
of	O
adenosine	B
may	O
be	O
required	O
or	O
adenosine	B
may	O
not	O
be	O
effective	O
.	O

Adenosine	B
effects	O
are	O
potentiated	O
by	O
dipyridamole	B
.	O

Thus	O
,	O
smaller	O
doses	O
of	O
adenosine	B
may	O
be	O
effective	O
in	O
the	O
presence	O
of	O
dipyridamole	B
.	O

As	O
the	O
primary	O
effect	O
of	O
adenosine	B
is	O
to	O
decrease	O
conduction	O
through	O
the	O
A	O
-	O
V	O
node	O
,	O
higher	O
degrees	O
of	O
heart	O
block	O
may	O
be	O
produced	O
in	O
the	O
presence	O
of	O
carbamazepine	B
.	O

Co	O
-	O
administration	O
with	O
antifungal	B
agents	I
such	O
as	O
ketoconazole	B
or	O
itraconazole	B
is	O
not	O
recommended	O
.	O

Nafazodone	B
,	O
fluvoxamine	B
,	O
cimetidine	B
(	O
consider	O
Xanax	B
dose	O
reduction	O
)	O
.	O

Fluoxetine	B
,	O
OCs	B
,	O
sertraline	B
,	O
diltiazem	B
,	O
macrolide	B
antibiotics	I
(	O
exercise	O
caution	O
)	O
.	O

Dexamethasone	B
:	O
Steady	O
-	O
state	O
trough	O
concentrations	O
of	O
albendazole	B
sulfoxide	I
were	O
about	O
56	O
%	O
higher	O
when	O
8	O
mg	O
dexamethasone	B
was	O
coadministered	O
with	O
each	O
dose	O
of	O
albendazole	B
(	O
15	O
mg	O
/	O
kg	O
/	O
day	O
)	O
in	O
eight	O
neurocysticercosis	O
patients	O
.	O

Praziquantel	B
:	O
In	O
the	O
fed	O
state	O
,	O
praziquantel	B
(	O
40	O
mg	O
/	O
kg	O
)	O
increased	O
mean	O
maximum	O
plasma	O
concentration	O
and	O
area	O
under	O
the	O
curve	O
of	O
albendazole	B
sulfoxide	I
by	O
about	O
50	O
%	O
in	O
healthy	O
subjects	O
(	O
n	O
=	O
10	O
)	O
compared	O
with	O
a	O
separate	O
group	O
of	O
subjects	O
(	O
n	O
=	O
6	O
)	O
given	O
albendazole	B
alone	O
.	O

The	O
pharmacokinetics	O
of	O
praziquantel	B
were	O
unchanged	O
following	O
coadministration	O
with	O
albendazole	B
(	O
400	O
mg	O
)	O
.	O

Cimetidine	B
:	O
Albendazole	B
sulfoxide	I
concentrations	O
in	O
bile	O
and	O
cystic	O
fluid	O
were	O
increased	O
(	O
about	O
2	O
-	O
fold	O
)	O
in	O
hydatid	O
cyst	O
patients	O
treated	O
with	O
cimetidine	B
(	O
10	O
mg	O
/	O
kg	O
/	O
day	O
)	O
(	O
n	O
=	O
7	O
)	O
compared	O
with	O
albendazole	B
(	O
20	O
mg	O
/	O
kg	O
/	O
day	O
)	O
alone	O
(	O
n	O
=	O
12	O
)	O
.	O

Theophylline	B
:	O
The	O
pharmacokinetics	O
of	O
theophylline	B
(	O
aminophylline	B
5	O
.	O
8	O
mg	O
/	O
kg	O
infused	O
over	O
20	O
minutes	O
)	O
were	O
unchanged	O
following	O
a	O
single	O
oral	O
dose	O
of	O
albendazole	B
(	O
400	O
mg	O
)	O
in	O
6	O
healthy	O
subjects	O
.	O

Therefore	O
,	O
interactions	O
could	O
occur	O
following	O
concomitant	O
administration	O
of	O
psychotropic	B
drugs	I
(	O
e	O
.	O
g	O
.	O
,	O
narcotics	B
,	O
analgesics	B
,	O
antiemetics	B
,	O
sedatives	B
,	O
tranquilizers	B
)	O
.	O

Concurrent	O
administration	O
of	O
drugs	O
possessing	O
nephrotoxic	O
(	O
e	O
.	O
g	O
.	O
,	O
aminoglycosides	B
,	O
indomethacin	B
)	O
,	O
myelotoxic	O
(	O
e	O
.	O
g	O
.	O
,	O
cytotoxic	B
chemotherapy	O
)	O
,	O
cardiotoxic	O
(	O
e	O
.	O
g	O
.	O
,	O
doxorubicin	B
)	O
or	O
hepatotoxic	O
(	O
e	O
.	O
g	O
.	O
,	O
methotrexate	B
,	O
asparaginase	B
)	O
effects	O
with	O
PROLEUKIN	B
may	O
increase	O
toxicity	O
in	O
these	O
organ	O
systems	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
PROLEUKIN	B
in	O
combination	O
with	O
any	O
antineoplastic	B
agents	I
have	O
not	O
been	O
established	O
.	O

Hypersensitivity	O
reactions	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
combination	O
regimens	O
containing	O
sequential	O
high	O
dose	O
PROLEUKIN	B
and	O
antineoplastic	B
agents	I
,	O
specifically	O
,	O
dacarbazine	B
,	O
cis	O
-	O
platinum	O
,	O
tamoxifen	B
and	O
interferon	O
-	O
alfa	O
.	O

Myocardial	O
injury	O
,	O
including	O
myocardial	O
infarction	O
,	O
myocarditis	O
,	O
ventricular	O
hypokinesia	O
,	O
and	O
severe	O
rhabdomyolysis	O
appear	O
to	O
be	O
increased	O
in	O
patients	O
receiving	O
PROLEUKIN	B
and	O
interferon	O
-	O
alfa	O
concurrently	O
.	O

Exacerbation	O
or	O
the	O
initial	O
presentation	O
of	O
a	O
number	O
of	O
autoimmune	O
and	O
inflammatory	O
disorders	O
has	O
been	O
observed	O
following	O
concurrent	O
use	O
of	O
interferon	O
-	O
alfa	O
and	O
PROLEUKIN	B
,	O
including	O
crescentic	O
IgA	O
glomerulonephritis	O
,	O
oculo	O
-	O
bulbar	O
myasthenia	O
gravis	O
,	O
inflammatory	O
arthritis	O
,	O
thyroiditis	O
,	O
bullous	O
pemphigoid	O
,	O
and	O
Stevens	O
-	O
Johnson	O
syndrome	O
.	O

Although	O
glucocorticoids	B
have	O
been	O
shown	O
to	O
reduce	O
PROLEUKIN	B
-	O
induced	O
side	O
effects	O
including	O
fever	O
,	O
renal	O
insufficiency	O
,	O
hyperbilirubinemia	O
,	O
confusion	O
,	O
and	O
dyspnea	O
,	O
concomitant	O
administration	O
of	O
these	O
agents	O
with	O
PROLEUKIN	B
may	O
reduce	O
the	O
antitumor	O
effectiveness	O
of	O
PROLEUKIN	B
and	O
thus	O
should	O
be	O
avoided	O
.	O
12	O
Beta	O
-	O
blockers	O
and	O
other	O
antihypertensives	B
may	O
potentiate	O
the	O
hypotension	O
seen	O
with	O
PROLEUKIN	B
.	O

Delayed	O
Adverse	O
Reactions	O
to	O
Iodinated	B
Contrast	I
Media	I
:	O
A	O
review	O
of	O
the	O
literature	O
revealed	O
that	O
12	O
.	O
6	O
%	O
(	O
range	O
11	O
-	O
28	O
%	O
)	O
of	O
501	O
patients	O
treated	O
with	O
various	O
interleukin	O
-	O
2	O
containing	O
regimens	O
who	O
were	O
subsequently	O
administered	O
radiographic	B
iodinated	I
contrast	I
media	I
experienced	O
acute	O
,	O
atypical	O
adverse	O
reactions	O
.	O

The	O
duration	O
of	O
the	O
period	O
following	O
treatment	O
with	O
AMEVIVE	B
before	O
one	O
should	O
consider	O
starting	O
other	O
immunosuppressive	B
therapy	O
has	O
not	O
been	O
evaluated	O
.	O

Since	O
the	O
effect	O
of	O
AMEVIVE	B
on	O
pregnancy	O
and	O
fetal	O
development	O
,	O
including	O
immune	O
system	O
development	O
,	O
is	O
not	O
known	O
,	O
health	O
care	O
providers	O
are	O
encouraged	O
to	O
enroll	O
patients	O
currently	O
taking	O
AMEVIVE	B
who	O
become	O
pregnant	O
into	O
the	O
Biogen	O
Pregnancy	O
Registry	O
by	O
calling	O
1	O
-	O
866	O
-	O
AMEVIVE	B
(	O
1	O
-	O
866	O
-	O
263	O
-	O
8483	O
)	O
.	O

An	O
immune	O
response	O
to	O
Campath	B
may	O
interfere	O
with	O
subsequent	O
diagnostic	O
serum	O
tests	O
that	O
utilize	O
antibodies	B

Intravenous	O
ranitidine	B
was	O
shown	O
to	O
double	O
the	O
bioavailability	O
of	O
oral	O
alendronate	B
.	O

Products	O
containing	O
calcium	B
and	O
other	O
multivalent	B
cations	I
likely	O
will	O
interfere	O
with	O
absorption	O
of	O
alendronate	B
.	O

Both	O
the	O
magnitude	O
and	O
duration	O
of	O
central	O
nervous	O
system	O
and	O
cardiovascular	O
effects	O
may	O
be	O
enhanced	O
when	O
ALFENTA	B
is	O
administered	O
in	O
combination	O
with	O
other	O
CNS	B
depressants	I
such	O
as	O
barbiturates	B
,	O
tranquilizers	B
,	O
opioids	B
,	O
or	O
inhalation	O
general	O
anesthetics	B
.	O

Limited	O
clinical	O
experience	O
indicates	O
that	O
requirements	O
for	O
volatile	B
inhalation	I
anesthetics	I
are	O
reduced	O
by	O
30	O
to	O
50	O
%	O
for	O
the	O
first	O
sixty	O
(	O
60	O
)	O
minutes	O
following	O
ALFENTA	B
induction	O
The	O
concomitant	O
use	O
of	O
erythromycin	B
with	O
ALFENTA	B
can	O
significantly	O
inhibit	O
ALFENTA	B
clearance	O
and	O
may	O
increase	O
the	O
risk	O
of	O
prolonged	O
or	O
delayed	O
respiratory	O
depression	O
.	O

Cimetidine	B
reduces	O
the	O
clearance	O
of	O
ALFENTA	B
.	O

Therefore	O
smaller	O
ALFENTA	B
doses	O
will	O
be	O
required	O
with	O
prolonged	O
administration	O
and	O
the	O
duration	O
of	O
action	O
of	O
ALFENTA	B
my	O
be	O
extended	O
.	O

Drug	O
-	O
Drug	O
Interactions	O
:	O
The	O
pharmacokinetic	O
and	O
pharmacodynamic	O
interactions	O
between	O
UROXATRAL	B
and	O
other	O
alpha	O
-	O
blockers	O
have	O
not	O
been	O
determined	O
.	O

However	O
,	O
interactions	O
may	O
be	O
expected	O
,	O
and	O
UROXATRAL	B
should	O
NOT	O
be	O
used	O
in	O
combination	O
with	O
other	O
alpha	O
-	O
blockers	O
.	O

Effects	O
of	O
Other	O
Drugs	O
on	O
Aliskiren	B
Based	O
on	O
in	O
-	O
vitro	O
studies	O
,	O
aliskiren	B
is	O
metabolized	O
by	O
CYP	O
3A4	O
.	O

Co	O
-	O
administration	O
of	O
lovastatin	B
,	O
atenolol	B
,	O
warfarin	B
,	O
furosemide	B
,	O
digoxin	B
,	O
celecoxib	B
,	O
hydrochlorothiazide	B
,	O
ramipril	B
,	O
valsartan	B
,	O
metformin	B
and	O
amlodipine	B
did	O
not	O
result	O
in	O
clinically	O
significant	O
increases	O
in	O
aliskiren	B
exposure	O
.	O

Co	O
-	O
administration	O
of	O
irbesartan	B
reduced	O
aliskiren	B
Cmax	O
up	O
to	O
50	O
%	O
after	O
multiple	O
dosing	O
.	O

Co	O
-	O
administration	O
of	O
atorvastatin	B
resulted	O
in	O
about	O
a	O
50	O
%	O
increase	O
in	O
aliskiren	B
Cmax	O
and	O
AUC	O
after	O
multiple	O
dosing	O
.	O

Ketoconazole	B
:	O
Co	O
-	O
administration	O
of	O
200	O
mg	O
twice	O
-	O
daily	O
ketoconazole	B
with	O
aliskiren	B
resulted	O
in	O
an	O
approximate	O
80	O
%	O
increase	O
in	O
plasma	O
levels	O
of	O
aliskiren	B
.	O

Effects	O
of	O
Aliskiren	B
on	O
Other	O
Drugs	O
Aliskiren	B
does	O
not	O
inhibit	O
the	O
CYP450	O
isoenzymes	O
(	O
CYP1A2	O
,	O
2C8	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
2E1	O
,	O
and	O
CYP	O
3A	O
)	O
or	O
induce	O
CYP	O
3A4	O
.	O

Co	O
-	O
administration	O
of	O
aliskiren	B
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
of	O
lovastatin	B
,	O
digoxin	B
,	O
valsartan	B
,	O
amlodipine	B
,	O
metformin	B
,	O
celecoxib	B
,	O
atenolol	B
,	O
atorvastatin	B
,	O
ramipril	B
or	O
hydrochlorothiazide	B
.	O

Warfarin	B
:	O
The	O
effects	O
of	O
aliskiren	B
on	O
warfarin	B
pharmacokinetics	O
have	O
not	O
been	O
evaluated	O
in	O
a	O
well	O
-	O
controlled	O
clinical	O
trial	O
.	O

Furosemide	B
:	O
When	O
aliskiren	B
was	O
co	O
-	O
administered	O
with	O
furosemide	B
,	O
the	O
AUC	O
and	O
Cmax	O
of	O
furosemide	B
were	O
reduced	O
by	O
about	O
30	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O

Patients	O
who	O
are	O
applying	O
Panretin	B
gel	O
should	O
not	O
concurrently	O
use	O
products	O
that	O
contain	O
DEET	B
(	O
N	O
,	O
N	O
-	O
diethyl	O
-	O
m	O
-	O
toluamide	O
)	O
,	O
a	O
common	O
component	O
of	O
insect	O
repellent	O
products	O
.	O

Animal	O
toxicology	O
studies	O
showed	O
increased	O
DEET	B
toxicity	O
when	O
DEET	B
was	O
included	O
as	O
proof	O
of	O
the	O
formulation	O
.	O

Although	O
there	O
was	O
no	O
clinical	O
evidence	O
in	O
the	O
vehicle	O
-	O
controlled	O
studies	O
of	O
drug	O
interactions	O
with	O
systemic	O
antiretroviral	B
agents	I
,	O
including	O
protease	B
inhibitors	I
,	O
macrolide	B
antibiotics	I
,	O
and	O
azole	B
antifungals	I
,	O
the	O
effect	O
of	O
Panretin	B
gel	O
on	O
the	O
steady	O
-	O
state	O
concentrations	O
of	O
these	O
drugs	O
is	O
not	O
known	O
.	O

Mercaptopurine	B
/	O
Azathioprine	B
:	O
Allopurinol	B
inhibits	O
the	O
enzymatic	O
oxidation	O
of	O
mercaptopurine	B
and	O
azathioprine	B
to	O
6	O
-	O
thiouric	O
acid	B
.	O

In	O
patients	O
receiving	O
mercaptopurine	B
(	O
Purinethol	B
)	O
or	O
azathioprine	B
(	O
Imuran	B
)	O
,	O
the	O
concomitant	O
administration	O
of	O
300	O
-	O
600	O
mg	O
of	O
allopurinol	B
per	O
day	O
will	O
require	O
a	O
reduction	O
in	O
dose	O
to	O
approximately	O
one	O
-	O
third	O
to	O
one	O
-	O
fourth	O
of	O
the	O
usual	O
dose	O
of	O
mercaptopurine	B
or	O
azathioprine	B
.	O

Subsequent	O
adjustment	O
of	O
doses	O
of	O
mercaptopurine	B
or	O
azathioprine	B
should	O
be	O
made	O
on	O
the	O
basis	O
of	O
therapeutic	O
response	O
and	O
the	O
appearance	O
of	O
toxic	O
effects	O
.	O

Dicumarol	B
:	O
It	O
has	O
been	O
reported	O
that	O
allopurinol	B
prolongs	O
the	O
half	O
-	O
life	O
of	O
the	O
anticoagulant	B
,	O
dicumarol	B
.	O

The	O
clinical	O
basis	O
of	O
this	O
drug	O
interaction	O
has	O
not	O
been	O
established	O
but	O
should	O
be	O
noted	O
when	O
allopurinol	B
is	O
given	O
to	O
patients	O
already	O
on	O
dicumarol	B
therapy	O
.	O

Uricosuric	B
Agents	I
:	O
Since	O
the	O
excretion	O
of	O
oxipurinol	B
is	O
similar	O
to	O
that	O
of	O
urate	O
,	O
uricosuric	B
agents	I
,	O
which	O
increase	O
the	O
excretion	O
of	O
urate	O
,	O
are	O
also	O
likely	O
to	O
increase	O
the	O
excretion	O
of	O
oxipurinol	B
and	O
thus	O
lower	O
the	O
degree	O
of	O
inhibition	O
of	O
xanthine	O
oxidase	O
.	O

The	O
concomitant	O
administration	O
of	O
uricosuric	B
agents	I
and	O
allopurinol	B
has	O
been	O
associated	O
with	O
a	O
decrease	O
in	O
the	O
excretion	O
of	O
oxypurines	O
(	O
hypoxanthine	O
and	O
xanthine	O
)	O
and	O
an	O
increase	O
in	O
urinary	O
uric	O
acid	O
excretion	O
compared	O
with	O
that	O
observed	O
with	O
allopurinol	B
alone	O
.	O

Although	O
clinical	O
evidence	O
to	O
date	O
has	O
not	O
demonstrated	O
renal	O
precipitation	O
of	O
oxypurines	O
in	O
patients	O
either	O
on	O
allopurinol	B
alone	O
or	O
in	O
combination	O
with	O
uricosuric	B
agents	I
,	O
the	O
possibility	O
should	O
be	O
kept	O
in	O
mind	O
.	O

Thiazide	B
Diuretics	I
:	O
The	O
reports	O
that	O
the	O
concomitant	O
use	O
of	O
allopurinol	B
and	O
thiazide	B
diuretics	I
may	O
contribute	O
to	O
the	O
enhancement	O
of	O
allopurinol	B
toxicity	O
in	O
some	O
patients	O
have	O
been	O
reviewed	O
in	O
an	O
attempt	O
to	O
establish	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
and	O
a	O
mechanism	O
of	O
causation	O
.	O

Although	O
a	O
causal	O
mechanism	O
and	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
have	O
not	O
been	O
established	O
,	O
current	O
evidence	O
suggests	O
that	O
renal	O
function	O
should	O
be	O
monitored	O
in	O
patients	O
on	O
thiazide	B
diuretics	I
and	O
allopurinol	B
even	O
in	O
the	O
absence	O
of	O
renal	O
failure	O
,	O
and	O
dosage	O
levels	O
should	O
be	O
even	O
more	O
conservatively	O
adjusted	O
in	O
those	O
patients	O
on	O
such	O
combined	O
therapy	O
if	O
diminished	O
renal	O
function	O
is	O
detected	O
.	O
.	O

Ampicillin	B
/	O
Amoxicillin	B
:	O
An	O
increase	O
in	O
the	O
frequency	O
of	O
skin	O
rash	O
has	O
been	O
reported	O
among	O
patients	O
receiving	O
ampicillin	B
or	O
amoxicillin	B
concurrently	O
with	O
allopurinol	B
compared	O
to	O
patients	O
who	O
are	O
not	O
receiving	O
both	O
drugs	O
.	O

Cytotoxic	B
Agents	I
:	O
Enhanced	O
bone	O
marrow	O
suppression	O
by	O
cyclophosphamide	B
and	O
other	O
cytotoxic	B
agents	I
has	O
been	O
reported	O
among	O
patients	O
with	O
neoplastic	O
disease	O
,	O
except	O
leukemia	O
,	O
in	O
the	O
presence	O
of	O
allopurinol	B
.	O

However	O
,	O
in	O
a	O
well	O
-	O
controlled	O
study	O
of	O
patients	O
with	O
lymphoma	O
on	O
combination	O
therapy	O
,	O
allopurinol	B
did	O
not	O
increase	O
the	O
marrow	O
toxicity	O
of	O
patients	O
treated	O
with	O
cyclophosphamide	B
,	O
doxorubicin	B
,	O
bleomycin	B
,	O
procarbazine	B
and	O
/	O
or	O
mechlorethamine	B
.	O

Chlorpropamide	B
:	O
Chlorpropamides	O
plasma	O
half	O
-	O
life	O
may	O
be	O
prolonged	O
by	O
allopurinol	B
,	O
since	O
allopurinol	B
and	O
chlorpropamide	B
may	O
compete	O
for	O
excretion	O
in	O
the	O
renal	O
tubule	O
.	O

The	O
risk	O
of	O
hypoglycemia	O
secondary	O
to	O
this	O
mechanism	O
may	O
be	O
increased	O
if	O
allopurinol	B
and	O
chlorpropamide	B
are	O
given	O
concomitantly	O
in	O
the	O
presence	O
of	O
renal	O
insufficiency	O
.	O

Cyclosporin	B
:	O
Reports	O
indicate	O
that	O
cyclosporine	B
levels	O
may	O
be	O
increased	O
during	O
concomitant	O
treatment	O
with	O
allopurinol	B
sodium	I
for	O
injection	O
.	O

Monitoring	O
of	O
cyclosporine	B
levels	O
and	O
possible	O
adjustment	O
of	O
cyclosporine	B
dosage	O
should	O
be	O
considered	O
when	O
these	O
drugs	O
are	O
co	O
-	O
administered	O
.	O

Because	O
there	O
is	O
a	O
theoretical	O
basis	O
that	O
these	O
effects	O
may	O
be	O
additive	O
,	O
use	O
of	O
ergotamine	B
-	O
containing	O
or	O
ergot	O
-	O
type	O
medications	B
(	O
like	O
dihydroergotamine	B
or	O
methysergide	B
)	O
and	O
AXERT	B
within	O
24	O
hours	O
of	O
each	O
other	O
should	O
be	O
avoided	O
.	O

Monoamine	B
Oxidase	I
Inhibitors	I
:	O
Coadministration	O
of	O
moclobemide	B
resulted	O
in	O
a	O
27	O
%	O
decrease	O
in	O
almotriptan	B
clearance	O
and	O
an	O
increase	O
in	O
Cmax	O
of	O
approximately	O
6	O
%	O
.	O

Other	O
5	O
-	O
HT1B	O
/	O
1D	O
Agonists	B
Concomitant	O
use	O
of	O
other	O
5	O
-	O
HT1B	O
/	O
1D	O
agonists	B
within	O
24	O
hours	O
of	O
treatment	O
with	O
AXERT	B
is	O
contraindicated	O
.	O

Propanolol	B
:	O
The	O
pharmacokinetics	O
of	O
almotriptan	B
were	O
not	O
affected	O
by	O
coadministration	O
of	O
propranolol	B
.	O

Selective	B
Serotonin	I
Reuptake	I
Inhibitors	I
(	O
SSRIs	B
)	O
:	O
SSRIs	B
(	O
e	O
.	O
g	O
.	O
,	O
fluoxetine	B
,	O
fluvoxamine	B
,	O
paroxetine	B
,	O
sertraline	B
)	O
have	O
been	O
rarely	O
reported	O
to	O
cause	O
weakness	O
,	O
hyperreflexia	O
,	O
and	O
incoordination	O
when	O
coadministered	O
with	O
5	O
-	O
HT1	O
agonists	B
.	O

If	O
concomitant	O
treatment	O
with	O
AXERT	B
and	O
an	O
SSRI	B
is	O
clinically	O
warranted	O
,	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O

Verapamil	B
:	O
Coadministration	O
of	O
almotriptan	B
and	O
verapamil	B
resulted	O
in	O
a	O
24	O
%	O
increase	O
in	O
plasma	O
concentrations	O
of	O
almotriptan	B
.	O

Coadministration	O
of	O
almotriptan	B
and	O
the	O
potent	O
CYP3A4	O
inhibitor	O
ketoconazole	B
(	O
400	O
mg	O
q	O
.	O
d	O
.	O
for	O
3	O
days	O
)	O
resulted	O
in	O
an	O
approximately	O
60	O
%	O
increase	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
and	O
maximal	O
plasma	O
concentrations	O
of	O
almotriptan	B
.	O

Although	O
the	O
interaction	O
between	O
almotriptan	B
and	O
other	O
potent	O
CYP3A4	O
inhibitors	O
(	O
e	O
.	O
g	O
.	O
,	O
itraconazole	B
,	O
ritonavir	B
,	O
and	O
erythromycin	B
)	O
has	O
not	O
been	O
studied	O
,	O
increased	O
exposures	O
to	O
almotriptan	B
may	O
be	O
expected	O
when	O
almotriptan	B
is	O
used	O
concomitantly	O
with	O
these	O
medications	O
.	O

Because	O
alosetron	B
is	O
metabolized	O
by	O
a	O
variety	O
of	O
hepatic	O
CYP	O
drug	O
-	O
metabolizing	O
enzymes	O
,	O
inducers	O
or	O
inhibitors	O
of	O
these	O
enzymes	O
may	O
change	O
the	O
clearance	O
of	O
alosetron	B
.	O

In	O
a	O
pharmacokinetic	O
study	O
,	O
40	O
healthy	O
female	O
subjects	O
received	O
fluvoxamine	B
in	O
escalating	O
doses	O
from	O
50	O
to	O
200	O
mg	O
per	O
day	O
for	O
16	O
days	O
,	O
with	O
coadministration	O
of	O
alosetron	B
1	O
mg	O
on	O
the	O
last	O
day	O
.	O

Fluvoxamine	B
increased	O
mean	O
alosetron	B
plasma	O
concentrations	O
(	O
AUC	O
)	O
approximately	O
6	O
-	O
fold	O
and	O
prolonged	O
the	O
half	O
-	O
life	O
by	O
approximately	O
3	O
-	O
fold	O
.	O

Concomitant	O
administration	O
of	O
alosetron	B
and	O
fluvoxamine	B
is	O
contraindicated	O
.	O

Concomitant	O
administration	O
of	O
alosetron	B
and	O
moderate	O
CYP1A2	O
inhibitors	O
,	O
including	O
quinolone	B
antibiotics	I
and	O
cimetidine	B
,	O
has	O
not	O
been	O
evaluated	O
,	O
but	O
should	O
be	O
avoided	O
unless	O
clinically	O
necessary	O
because	O
of	O
similar	O
potential	O
drug	O
interactions	O
.	O

In	O
a	O
pharmacokinetic	O
study	O
,	O
38	O
healthy	O
female	O
subjects	O
received	O
ketoconazole	B
200	O
mg	O
twice	O
daily	O
for	O
7	O
days	O
,	O
with	O
coadministration	O
of	O
alosetron	B
1	O
mg	O
on	O
the	O
last	O
day	O
.	O

Ketoconazole	B
increased	O
mean	O
alosetron	B
plasma	O
concentrations	O
(	O
AUC	O
)	O
by	O
29	O
%	O
.	O

Caution	O
should	O
be	O
used	O
when	O
alosetron	B
and	O
ketoconazole	B
are	O
administered	O
concomitantly	O
.	O

Coadministration	O
of	O
alosetron	B
and	O
strong	O
CYP3A4	O
inhibitors	B
,	O
such	O
as	O
clarithromycin	B
,	O
telithromycin	B
,	O
protease	B
inhibitors	I
,	O
voriconazole	B
,	O
and	O
itraconazole	B
has	O
not	O
been	O
evaluated	O
but	O
should	O
be	O
undertaken	O
with	O
caution	O
because	O
of	O
similar	O
potential	O
drug	O
interactions	O
.	O

Although	O
not	O
studied	O
with	O
alosetron	B
,	O
inhibition	O
of	O
N	O
-	O
acetyltransferase	O
may	O
have	O
clinically	O
relevant	O
consequences	O
for	O
drugs	O
such	O
as	O
isoniazid	B
,	O
procainamide	B
,	O
and	O
hydralazine	B
.	O

Another	O
study	O
showed	O
that	O
alosetron	B
had	O
no	O
clinically	O
significant	O
effect	O
on	O
plasma	O
concentrations	O
of	O
the	O
oral	O
contraceptive	B
agents	I
ethinyl	I
estradiol	I
and	O
levonorgestrel	B
(	O
CYP3A4	O
substrates	O
)	O
.	O

A	O
clinical	O
interaction	O
study	O
was	O
also	O
conducted	O
with	O
alosetron	B
and	O
the	O
CYP3A4	O
substrate	O
cisapride	B
.	O

The	O
benzodiazepines	B
,	O
including	O
alprazolam	B
,	O
produce	O
additive	O
CNS	O
depressant	O
effects	O
when	O
co	O
-	O
administered	O
with	O
other	O
psychotropic	B
medications	I
,	O
anticonvulsants	B
,	O
antihistaminics	B
,	O
ethanol	B
,	O
and	O
other	O
drugs	O
which	O
themselves	O
produce	O
CNS	O
depression	O
.	O

The	O
steady	O
state	O
plasma	O
concentrations	O
of	O
imipramine	B
and	O
desipramine	B
have	O
been	O
reported	O
to	O
be	O
increased	O
an	O
average	O
of	O
31	O
%	O
and	O
20	O
%	O
,	O
respectively	O
,	O
by	O
the	O
concomitant	O
administration	O
of	O
alprazolam	B
tablets	O
in	O
doses	O
up	O
to	O
4	O
mg	O
/	O
day	O
.	O

Drugs	O
That	O
Inhibit	O
Alprazolam	B
Metabolism	O
Via	O
Cytochrome	O
P450	O
3A	O
:	O
The	O
initial	O
step	O
in	O
alprazolam	B
metabolism	O
is	O
hydroxylation	O
catalyzed	O
by	O
cytochrome	O
P450	O
3A	O
(	O
CYP	O
3A	O
)	O
.	O

Drugs	O
Demonstrated	O
to	O
be	O
CYP	O
3A	O
Inhibitors	O
of	O
Possible	O
Clinical	O
Significance	O
on	O
the	O
Basis	O
of	O
Clinical	O
Studies	O
Involving	O
Alprazolam	B
(	O
caution	O
is	O
recommended	O
during	O
coadministration	O
with	O
alprazolam	B
)	O
:	O
Coadministration	O
of	O
fluoxetine	B
with	O
alprazolam	B
increased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
alprazolam	B
by	O
46	O
%	O
,	O
decreased	O
clearance	O
by	O
21	O
%	O
,	O
increased	O
half	O
-	O
life	O
by	O
17	O
%	O
,	O
and	O
decreased	O
measured	O
psychomotor	O
performance	O
.	O

Coadministration	O
of	O
propoxyphene	B
decreased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
alprazolam	B
by	O
6	O
%	O
,	O
decreased	O
clearance	O
by	O
38	O
%	O
,	O
and	O
increased	O
half	O
-	O
life	O
by	O
58	O
%	O
.	O

Coadministration	O
of	O
oral	O
contraceptives	B
increased	O
the	O
maximum	O
plasma	O
concentration	O
of	O
alprazolam	B
by	O
18	O
%	O
,	O
decreased	O
clearance	O
by	O
22	O
%	O
,	O
and	O
increased	O
half	O
-	O
life	O
by	O
29	O
%	O
.	O

Drugs	O
and	O
other	O
substances	O
demonstrated	O
to	O
be	O
CYP	O
3A	O
inhibitors	O
on	O
the	O
basis	O
of	O
clinical	O
studies	O
involving	O
benzodiazepines	B
metabolized	O
similarly	O
to	O
alprazolam	B
or	O
on	O
the	O
basis	O
of	O
in	O
vitro	O
studies	O
with	O
alprazolam	B
or	O
other	O
benzodiazepines	B
(	O
caution	O
is	O
recommended	O
during	O
coadministration	O
with	O
alprazolam	B
)	O
:	O
Available	O
data	O
from	O
clinical	O
studies	O
of	O
benzodiazepines	B
other	O
than	O
alprazolam	B
suggest	O
a	O
possible	O
drug	O
interaction	O
with	O
alprazolam	B
for	O
the	O
following	O
:	O
diltiazem	B
,	O
isoniazid	B
,	O
macrolide	B
antibiotics	I
such	O
as	O
erythromycin	B
and	O
clarithromycin	B
,	O
and	O
grapefruit	O
juice	O
.	O

Data	O
from	O
in	O
vitro	O
studies	O
of	O
alprazolam	B
suggest	O
a	O
possible	O
drug	O
interaction	O
with	O
alprazolam	B
for	O
the	O
following	O
:	O
sertraline	B
and	O
paroxetine	B
.	O

Data	O
from	O
in	O
vitro	O
studies	O
of	O
benzodiazepines	B
other	O
than	O
alprazolam	B
suggest	O
a	O
possible	O
drug	O
interaction	O
for	O
the	O
following	O
:	O
ergotamine	B
,	O
cyclosporine	B
,	O
amiodarone	B
,	O
nicardipine	B
,	O
and	O
nifedipine	B
.	O

Standard	O
therapy	O
includes	O
antibiotics	B
,	O
such	O
as	O
penicillin	B
and	O
gentamicin	B
;	O

vasopressors	B
,	O
such	O
as	O
dopamine	B
and	O
isoproterenol	B
;	O

and	O
diuretics	B
,	O
such	O
as	O
furosemide	B
.	O

Caverject	B
:	O
The	O
potential	O
for	O
pharmacokinetic	O
drug	O
-	O
drug	O
interactions	O
between	O
alprostadil	B
and	O
other	O
agents	O
has	O
not	O
been	O
formally	O
studied	O
.	O

In	O
addition	O
to	O
bleeding	O
associated	O
with	O
heparin	B
and	O
vitamin	B
K	I
antagonists	I
,	O
drugs	O
that	O
alter	O
platelet	O
function	O
(	O
such	O
as	O
acetylsalicylic	B
acid	I
,	O
dipyridamole	B
and	O
Abciximab	B
)	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
if	O
administered	O
prior	O
to	O
,	O
during	O
,	O
or	O
after	O
Activase	B
therapy	O
.	O

Use	O
of	O
Antithrombotics	B
Aspirin	I
and	O
heparin	B
have	O
been	O
administered	O
concomitantly	O
with	O
and	O
following	O
infusions	O
of	O
Activase	B
in	O
the	O
management	O
of	O
acute	O
myocardial	O
infarction	O
or	O
pulmonary	O
embolism	O
.	O

Because	O
heparin	B
,	O
aspirin	B
,	O
or	O
Activase	B
may	O
cause	O
bleeding	O
complications	O
,	O
careful	O
monitoring	O
for	O
bleeding	O
is	O
advised	O
,	O
especially	O
at	O
arterial	O
puncture	O
sites	O
.	O

The	O
concomitant	O
use	O
of	O
heparin	B
or	O
aspirin	B
during	O
the	O
first	O
24	O
hours	O
following	O
symptom	O
onset	O
were	O
prohibited	O
in	O
The	O
NINDS	O
t	O
-	O
PA	O
Stroke	O
Trial	O
.	O

Concurrent	O
administration	O
of	B
HEXALEN	I
and	O
antidepressants	B
of	I
the	I
MAO	I
inhibitor	I
class	I
may	O
cause	O
severe	O
orthostatic	O
hypotension	O
.	O
Cimetidine	B
,	O
an	O
inhibitor	B
of	I
microsomal	O
drug	O
metabolism	O
,	O
increased	O
altretamines	O
half	O
-	O
life	O
and	O
toxicity	O
in	O
a	O
rat	O
model	O
.	O

Data	O
from	O
a	O
randomized	O
trial	O
of	O
HEXALEN	B
and	O
cisplatin	B
plus	O
or	O
minus	O
pyridoxine	B
in	O
ovarian	O
cancer	O
indicated	O
that	O
pyridoxine	B
significantly	O
reduced	O
neurotoxicity	O
;	O

however	O
,	O
it	O
adversely	O
affected	O
response	O
duration	O
suggesting	O
that	O
pyridoxine	B
should	O
not	O
be	O
administered	O
with	O
HEXALEN	B
and	O
/	O
or	O
cisplatin	B
.	O
1	O

Careful	O
observation	O
is	O
required	O
when	O
amantadine	B
is	O
administered	O
concurrently	O
with	O
central	B
nervous	I
system	I
stimulants	I
.	O

Special	O
consideration	O
should	O
be	O
given	O
to	O
the	O
administration	O
of	O
ETHYOL	B
in	O
patients	O
receiving	O
antihypertensive	B
medications	I
or	O
other	O
drugs	O
that	O
could	O
cause	O
or	O
potentiate	O
hypotension	O
.	O

When	O
amiloride	B
HCl	O
is	O
administered	O
concomitantly	O
with	O
an	O
angiotensin	O
-	O
converting	O
enzyme	B
inhibitor	I
,	O
the	O
risk	O
of	O
hyperkalemia	O
may	O
be	O
increased	O
.	O

Lithium	B
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B
because	O
they	O
reduce	O
its	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	O
toxicity	O
.	O

In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
agent	B
can	O
reduce	O
the	O
diuretic	O
,	O
natriuretic	O
,	O
and	O
antihypertensive	O
effects	O
of	O
loop	B
,	O
potassium	O
-	O
sparing	O
and	O
thiazide	B
diuretics	I
.	O

Therefore	O
,	O
when	O
MIDAMOR	B
and	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
agents	B
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B
is	O
obtained	O
.	O

Since	O
indomethacin	B
and	O
potassium	O
-	O
sparing	O
diuretics	B
,	O
including	O
MIDAMOR	B
,	O
may	O
each	O
be	O
associated	O
with	O
increased	O
serum	O
potassium	O
levels	O
,	O
the	O
potential	O
effects	O
on	O
potassium	O
kinetics	O
and	O
renal	O
function	O
should	O
be	O
considered	O
when	O
these	O
agents	O
are	O
administered	O
concurrently	O
.	O

Cytadren	B
accelerates	O
the	O
metabolism	O
of	O
dexamethasone	B
;	O

therefore	O
,	O
if	O
glucocorticoid	B
replacement	O
is	O
needed	O
,	O
hydrocortisone	B
should	O
be	O
prescribed	O
.	O

Aminoglutethimide	B
diminishes	O
the	O
effect	O
of	O
coumarin	B
and	O
warfarin	B
.	O

Renal	O
clearance	O
measurements	O
of	O
PAH	B
cannot	O
be	O
made	O
with	O
any	O
significant	O
accuracy	O
in	O
patients	O
receiving	O
sulfonamides	B
,	O
procaine	B
,	O
or	O
thiazolesulfone	B
.	O

Probenecid	B
depresses	O
tubular	O
secretion	O
of	O
certain	O
weak	O
acids	O
such	O
as	O
PAH	B
.	O

Therefore	O
,	O
patients	O
receiving	O
probenecid	B
will	O
have	O
erroneously	O
low	O
ERPF	O
and	O
Tm	O
PAH	B
values	O
.	O

It	O
is	O
,	O
however	O
,	O
possible	O
that	O
concomitant	O
use	O
of	O
other	O
known	O
photosensitizing	B
agents	I
such	O
as	O
griseofulvin	B
,	O
thiazide	B
diuretics	I
,	O
sulfonylureas	B
,	O
phenothiazines	B
,	O
sulfonamides	B
and	O
tetracyclines	B
might	O
increase	O
the	O
photosensitivity	O
reaction	O
of	O
actinic	O
keratoses	O
treated	O
with	O
the	O
LEVULAN	B
KERASTICK	I
for	O
Topical	O
Solution	O
.	O

Aminosalicylic	B
acid	I
may	O
decrease	O
the	O
amount	O
of	O
digoxin	B
(	O
Lanoxin	B
,	O
Lanoxicaps	B
)	O
that	O
gets	O
absorbed	O
into	O
your	O
body	O
.	O

In	O
the	O
case	O
that	O
you	O
are	O
taking	O
digoxin	B
while	O
taking	O
aminosalicylic	B
acid	I
,	O
higher	O
doses	O
of	O
digoxin	B
may	O
be	O
needed	O
.	O

Aminosalicylic	B
acid	I
may	O
also	O
decrease	O
the	O
absorption	O
of	O
vitamin	B
B12	I
,	O
which	O
can	O
lead	O
to	O
a	O
deficiency	O
.	O

Therefore	O
you	O
may	O
need	O
to	O
take	O
a	O
vitamin	B
B12	I
supplement	O
while	O
taking	O
aminosalicylic	B
acid	I
.	O

Amiodarone	B
is	O
metabolized	O
to	O
desethylamiodarone	B
by	O
the	O
cytochrome	O
P450	O
(	O
CYP450	O
)	O
enzyme	O
group	O
,	O
specifically	O
cytochromes	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
and	O
CYP2C8	O
.	O

In	O
view	O
of	O
the	O
long	O
and	O
variable	O
half	O
-	O
life	O
of	O
amiodarone	B
,	O
potential	O
for	O
drug	O
interactions	O
exists	O
not	O
only	O
with	O
concomitant	O
medication	O
but	O
also	O
with	O
drugs	O
administered	O
after	O
discontinuation	O
of	O
amiodarone	B
.	O

Since	O
amiodarone	B
is	O
a	O
substrate	O
for	O
CYP3A4	O
and	O
CYP2C8	O
,	O
drugs	O
/	O
substances	O
that	O
inhibit	O
these	O
isoenzymes	O
may	O
decrease	O
the	O
metabolism	O
and	O
increase	O
serum	O
concentration	O
of	O
amiodarone	B
.	O

Reported	O
examples	O
include	O
the	O
following	O
:	O
Protease	B
Inhibitors	I
:	O
Protease	B
inhibitors	I
are	O
known	O
to	O
inhibit	O
CYP3A4	O
to	O
varying	O
degrees	O
.	O

A	O
case	O
report	O
of	O
one	O
patient	O
taking	O
amiodarone	B
200	O
mg	O
and	O
indinavir	B
800	O
mg	O
three	O
times	O
a	O
day	O
resulted	O
in	O
increases	O
in	O
amiodarone	B
concentrations	O
from	O
0	O
.	O
9	O
mg	O
/	O
L	O
to	O
1	O
.	O
3	O
mg	O
/	O
L	O
.	O

Monitoring	O
for	O
amiodarone	B
toxicity	O
and	O
serial	O
measurement	O
of	O
amiodarone	B
serum	O
concentration	O
during	O
concomitant	O
protease	B
inhibitor	I
therapy	O
should	O
be	O
considered	O
.	O

Histamine	B
H2	I
antagonists	I
:	O
Cimetidine	B
inhibits	O
CYP3A4	O
and	O
can	O
increase	O
serum	O
amiodarone	B
levels	O
.	O

Other	O
substances	O
:	O
Grapefruit	O
juice	O
given	O
to	O
healthy	O
volunteers	O
increased	O
amiodarone	B
AUC	O
by	O
50	O
%	O
and	O
Cmax	O
by	O
84	O
%	O
,	O
resulting	O
in	O
increased	O
plasma	O
levels	O
of	O
amiodarone	B
.	O

This	O
information	O
should	O
be	O
considered	O
when	O
changing	O
from	O
intravenous	O
amiodarone	B
to	O
oral	O
amiodarone	B
.	O

Amiodarone	B
may	O
suppress	O
certain	O
CYP450	O
enzymes	O
,	O
including	O
CYP1A2	B
,	O
CYP2C9	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
.	O

Reported	O
examples	O
of	O
this	O
interaction	O
include	O
the	O
following	O
:	O
Immunosuppressives	O
:	O
Cyclosporine	B
(	O
CYP3A4	B
substrate	O
)	O
administered	O
in	O
combination	O
with	O
oral	O
amiodarone	B
has	O
been	O
reported	O
to	O
produce	O
persistently	O
elevated	O
plasma	O
concentrations	O
of	O
cyclosporine	B
resulting	O
in	O
elevated	O
creatinine	O
,	O
despite	O
reduction	O
in	O
dose	O
of	O
cyclosporine	B
.	O

HMG	O
-	O
CoA	O
Reductase	B
Inhibitors	I
:	O
Simvastatin	B
(	O
CYP3A4	B
substrate	O
)	O
in	O
combination	O
with	O
amiodarone	B
has	O
been	O
associated	O
with	O
reports	O
of	O
myopathy	O
/	O
rhabdomyolysis	O
.	O

Cardiovasculars	O
:	O
Cardiac	B
glycosides	I
:	O
In	O
patients	O
receiving	O
digoxin	B
therapy	O
,	O
administration	O
of	O
oral	O
amiodarone	B
regularly	O
results	O
in	O
an	O
increase	O
in	O
serum	O
digoxin	B
concentration	O
that	O
may	O
reach	O
toxic	O
levels	O
with	O
resultant	O
clinical	O
toxicity	O
.	O

Amiodarone	B
taken	O
concomitantly	O
with	O
digoxin	B
increases	O
the	O
serum	O
digoxin	B
concentration	O
by	O
70	O
%	O
after	O
one	O
day	O
.	O

On	O
administration	O
of	O
oral	O
amiodarone	B
,	O
the	O
need	O
for	O
digitalis	B
therapy	O
should	O
be	O
reviewed	O
and	O
the	O
dose	O
reduced	O
by	O
approximately	O
50	O
%	O
or	O
discontinued	O
.	O

Antiarrhythmics	B
:	O
Other	O
antiarrhythmic	B
drugs	O
,	O
such	O
as	O
quinidine	B
,	O
procainamide	B
,	O
disopyramide	B
,	O
and	O
phenytoin	B
,	O
have	O
been	O
used	O
concurrently	O
with	O
amiodarone	B
.	O

There	O
have	O
been	O
case	O
reports	O
of	O
increased	O
steady	O
-	O
state	O
levels	O
of	O
quinidine	B
,	O
procainamide	B
,	O
and	O
phenytoin	B
during	O
concomitant	O
therapy	O
with	O
amiodarone	B
.	O

Amiodarone	B
taken	O
concomitantly	O
with	O
quinidine	B
increases	O
quinidine	B
serum	O
concentration	O
by	O
33	O
%	O
after	O
two	O
days	O
.	O

Amiodarone	B
taken	O
concomitantly	O
with	O
procainamide	B
for	O
less	O
than	O
seven	O
days	O
increases	O
plasma	O
concentrations	O
of	O
procainamide	B
and	O
n	O
-	O
acetyl	O
procainamide	B
by	O
55	O
%	O
and	O
33	O
%	O
,	O
respectively	O
.	O

Quinidine	B
and	O
procainamide	O
doses	O
should	O
be	O
reduced	O
by	O
one	O
-	O
third	O
when	O
either	O
is	O
administered	O
with	O
amiodarone	B
.	O

Plasma	O
levels	O
of	O
flecainide	B
have	O
been	O
reported	O
to	O
increase	O
in	O
the	O
presence	O
of	O
oral	O
amiodarone	B
;	O

because	O
of	O
this	O
,	O
the	O
dosage	O
of	O
flecainide	B
should	O
be	O
adjusted	O
when	O
these	O
drugs	B
are	O
administered	O
concomitantly	O
.	O

Combination	O
of	O
amiodarone	B
with	O
other	O
antiarrhythmic	B
therapy	O
should	O
be	O
reserved	O
for	O
patients	O
with	O
life	O
-	O
threatening	O
ventricular	O
arrhythmias	O
who	O
are	O
incompletely	O
responsive	O
to	O
a	O
single	O
agent	O
or	O
incompletely	O
responsive	O
to	O
amiodarone	B
.	O

During	O
transfer	O
to	O
oral	O
amiodarone	B
,	O
the	O
dose	O
levels	O
of	O
previously	O
administered	O
agents	O
should	O
be	O
reduced	O
by	O
30	O
to	O
50	O
%	O
several	O
days	O
after	O
the	O
addition	O
of	O
oral	O
amiodarone	B
.	O

The	O
continued	O
need	O
for	O
the	O
other	O
antiarrhythmic	B
agent	O
should	O
be	O
reviewed	O
after	O
the	O
effects	O
of	O
amiodarone	B
have	O
been	O
established	O
,	O
and	O
discontinuation	O
ordinarily	O
should	O
be	O
attempted	O
.	O

In	O
amiodarone	B
-	O
treated	O
patients	O
who	O
require	O
additional	O
antiarrhythmic	B
therapy	O
,	O
the	O
initial	O
dose	O
of	O
such	O
agents	O
should	O
be	O
approximately	O
half	O
of	O
the	O
usual	O
recommended	O
dose	O
.	O

Antihypertensives	B
:	O
Amiodarone	B
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
-	O
receptor	B
blocking	O
agents	O
(	O
e	O
.	O
g	O
.	O
,	O
propranolol	B
,	O
a	O
CYP3A4	B
inhibitor	O
)	O
or	O
calcium	B
channel	I
antagonists	O
(	O
e	O
.	O
g	O
.	O
,	O
verapamil	B
,	O
a	O
CYP3A4	B
substrate	O
,	O
and	O
diltiazem	B
,	O
a	O
CYP3A4	B
inhibitor	O
)	O
because	O
of	O
the	O
possible	O
potentiation	O
of	O
bradycardia	O
,	O
sinus	O
arrest	O
,	O
and	O
AV	O
block	O
;	O

Anticoagulants	B
:	O
Potentiation	O
of	O
warfarin	B
-	O
type	O
(	O
CYP2C9	B
and	O
CYP3A4	B
substrate	O
)	O
anticoagulant	B
response	O
is	O
almost	O
always	O
seen	O
in	O
patients	O
receiving	O
amiodarone	B
and	O
can	O
result	O
in	O
serious	O
or	O
fatal	O
bleeding	O
.	O

Since	O
the	O
concomitant	O
administration	O
of	O
warfarin	B
with	O
amiodarone	B
increases	O
the	O
prothrombin	O
time	O
by	O
100	O
%	O
after	O
3	O
to	O
4	O
days	O
,	O
the	O
dose	O
of	O
the	O
anticoagulant	B
should	O
be	O
reduced	O
by	O
one	O
-	O
third	O
to	O
one	O
-	O
half	O
,	O
and	O
prothrombin	O
times	O
should	O
be	O
monitored	O
closely	O
.	O

Some	O
drugs	B
/	O
substances	O
are	O
known	O
to	O
accelerate	O
the	O
metabolism	O
of	O
amiodarone	B
by	O
stimulating	O
the	O
synthesis	O
of	O
CYP3A4	B
(	O
enzyme	O
induction	O
)	O
.	O

Reported	O
examples	O
of	O
this	O
interaction	O
include	O
the	O
following	O
:	O
Antibiotics	B
:	O
Rifampin	B
is	O
a	O
potent	O
inducer	O
of	O
CYP3A4	B
.	O

Administration	O
of	O
rifampin	B
concomitantly	O
with	O
oral	O
amiodarone	B
has	O
been	O
shown	O
to	O
result	O
in	O
decreases	O
in	O
serum	O
concentrations	O
of	O
amiodarone	B
and	O
desethylamiodarone	B
.	O

Since	O
amiodarone	B
is	O
a	O
substrate	O
for	O
CYP3A4	B
,	O
there	O
is	O
the	O
potential	O
that	O
the	O
use	O
of	O
St	O
.	O
John	O
s	O
Wort	O
in	O
patients	O
receiving	O
amiodarone	B
could	O
result	O
in	O
reduced	O
amiodarone	B
levels	O
.	O

Other	O
reported	O
interactions	O
with	O
amiodarone	B
:	O
Fentanyl	B
(	O
CYP3A4	B
substrate	O
)	O
in	O
combination	O
with	O
amiodarone	B
may	O
cause	O
hypotension	O
,	O
bradycardia	O
,	O
and	O
decreased	O
cardiac	O
output	O
.	O

Sinus	O
bradycardia	O
has	O
been	O
reported	O
with	O
oral	O
amiodarone	B
in	O
combination	O
with	O
lidocaine	B
(	O
CYP3A4	B
substrate	O
)	O
given	O
for	O
local	O
anesthesia	B
.	O

Seizure	O
,	O
associated	O
with	O
increased	O
lidocaine	B
concentrations	O
,	O
has	O
been	O
reported	O
with	O
concomitant	O
administration	O
of	O
intravenous	O
amiodarone	B
.	O

Dextromethorphan	B
is	O
a	O
substrate	O
for	O
both	O
CYP2D6	B
and	O
CYP3A4	B
.	O

Amiodarone	B
inhibits	O
CYP2D6	B
.	O

Cholestyramine	B
increases	O
enterohepatic	O
elimination	O
of	O
amiodarone	B
and	O
may	O
reduce	O
its	O
serum	O
levels	O
and	O
t1	B
/	O
2	O
.	O

Fluoroquinolones	B
,	O
macrolide	B
antibiotics	I
,	O
and	O
azoles	O
are	O
known	O
to	O
cause	O
QTc	O
prolongation	O
.	O

There	O
have	O
been	O
reports	O
of	O
QTc	O
prolongation	O
,	O
with	O
or	O
without	O
TdP	O
,	O
in	O
patients	O
taking	O
amiodarone	B
when	O
fluoroquinolones	B
,	O
macrolide	B
antibiotics	I
,	O
or	O
azoles	O
were	O
administered	O
concomitantly	O
.	O

Hemodynamic	O
and	O
electrophysiologic	O
interactions	O
have	O
also	O
been	O
observed	O
after	O
concomitant	O
administration	O
with	O
propranolol	B
,	O
diltiazem	B
,	O
and	O
verapamil	B
.	O

In	O
addition	O
to	O
the	O
interactions	O
noted	O
above	O
,	O
chronic	O
(	O
2	O
weeks	O
)	O
oral	O
Cordarone	B
administration	O
impairs	O
metabolism	O
of	O
phenytoin	B
,	O
dextromethorphan	B
,	O
and	O
methotrexate	B
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	B
antidepressants	I
(	O
TCAs	B
)	O
when	O
given	O
usual	O
doses	O
.	O

cimetidine	B
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	O
2D6	O
(	O
many	O
other	O
antidepressants	B
,	O
phenothiazines	B
,	O
and	O
the	O
Type	B
1C	I
antiarrhythmics	I
propafenone	I
and	O
flecainide	B
)	O
.	O

While	O
all	O
the	O
selective	O
serotonin	B
reuptake	I
inhibitors	I
(	O
SSRIs	B
)	O
,	O
e	O
.	O
g	O
.	O
,	O
fluoxetine	B
,	O
sertraline	B
,	O
and	O
paroxetine	B
,	O
inhibit	O
P450	O
2D6	O
,	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

The	O
extent	O
to	O
which	O
SSRI	B
-	O
TCA	B
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	B
involved	O
.	O

Nevertheless	O
,	O
caution	O
is	O
indicated	O
in	O
the	O
coadministration	O
of	O
TCAs	B
with	O
any	O
of	O
the	O
SSRIs	B
and	O
also	O
in	O
switching	O
from	O
one	O
class	O
to	O
the	O
other	O
.	O

Concomitant	O
use	O
of	O
tricyclic	B
antidepressants	I
with	O
drugs	O
that	O
can	O
inhibit	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B
antidepressant	I
or	O
the	O
other	O
drug	O
.	O

It	O
is	O
desirable	O
to	O
monitor	O
TCA	B
plasma	O
levels	O
whenever	O
a	O
TCA	B
is	O
going	O
to	O
be	O
coadministered	O
with	O
another	O
drug	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P450	O
2D6	O
.	O

Monoamine	B
Oxidase	I
Inhibitors	I
:	O
Guanethidine	B
or	O
similarly	O
acting	O
compounds	O
;	O

alcohol	B
,	O
barbiturates	B
and	O
other	O
CNS	B
depressants	I
;	O

and	O
disulfiram	B
When	O
amitriptyline	B
HCl	I
is	O
given	O
with	O
anticholinergic	B
agents	O
or	O
sympathomimetic	B
drugs	O
,	O
including	O
epinephrine	B
combined	O
with	O
local	O
anesthetics	B
,	O
close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
dosages	O
are	O
required	O
.	O

Hyperpyrexia	O
has	O
been	O
reported	O
when	O
amitriptyline	B
HCl	I
is	O
administered	O
with	O
anticholinergic	B
agents	O
or	O
with	O
neuroleptic	B
drugs	O
,	O
particularly	O
during	O
hot	O
weather	O
.	O

Paralytic	O
ileus	O
may	O
occur	O
in	O
patients	O
taking	O
tricyclic	B
antidepressants	I
in	O
combination	O
with	O
anticholinergic	B
-	O
type	O
drugs	O
.	O

Cimetidine	B
is	O
reported	O
to	O
reduce	O
hepatic	O
metabolism	O
of	O
certain	O
tricyclic	B
antidepressants	I
,	O
thereby	O
delaying	O
elimination	O
and	O
increasing	O
steady	O
-	O
state	O
concentrations	O
of	O
these	O
drugs	B
.	O

Clinically	O
significant	O
effects	O
have	O
been	O
reported	O
with	O
the	O
tricyclic	B
antidepressants	I
when	O
used	O
concomitantly	O
with	O
cimetidine	B
.	O

Increases	O
in	O
plasma	O
levels	O
of	O
tricyclic	B
antidepressants	I
,	O
and	O
in	O
the	O
frequency	O
and	O
severity	O
of	O
side	O
effects	O
,	O
particularly	O
anticholinergic	B
,	O
have	O
been	O
reported	O
when	O
cimetidine	B
was	O
added	O
to	O
the	O
drug	B
regimen	O
.	O

Discontinuation	O
of	O
cimetidine	B
in	O
well	O
-	O
controlled	O
patients	O
receiving	O
tricyclic	B
antidepressants	I
and	O
cimetidine	B
may	O
decrease	O
the	O
plasma	O
levels	O
and	O
efficacy	O
of	O
the	O
antidepressants	B
.	O

Transient	O
delirium	O
has	O
been	O
reported	O
in	O
patients	O
who	O
were	O
treated	O
with	O
one	O
gram	O
of	O
ethchlorvynol	B
and	O
75	O
-	O
150	O
mg	O
of	O
amitriptyline	B
HCl	I
.	O

When	O
administered	O
concurrently	O
,	O
the	O
following	O
drugs	O
may	O
interact	O
with	O
amphotericin	B
B	I
:	O
Antineoplastic	B
agents	I
:	O
may	O
enhance	O
the	O
potential	O
for	O
renal	O
toxicity	O
,	O
bronchospasm	O
and	O
hypotension	O
.	O

Antineoplastic	B
agents	I
(	O
e	O
.	O
g	O
.	O
,	O
nitrogen	B
mustard	I
,	O
etc	O
.	O
)	O
should	O
be	O
given	O
concomitantly	O
only	O
with	O
great	O
caution	O
.	O

Corticosteroids	B
and	O
Corticotropin	B
(	O
ACTH	B
)	O
:	O
may	O
potentiate	O
amphotericin	B
B	I
-	O
induced	O
hypokalemia	O
which	O
may	O
predispose	O
the	O
patient	O
to	O
cardiac	O
dysfunction	O
.	O

Digitalis	B
glycosides	I
:	O
amphotericin	B
B	I
-	O
induced	O
hypokalemia	O
may	O
potentiate	O
digitalis	B
toxicity	O
.	O

Flucytosine	B
:	O
while	O
a	O
synergistic	O
relationship	O
with	O
amphotericin	B
B	I
has	O
been	O
reported	O
,	O
concomitant	O
use	O
may	O
increase	O
the	O
toxicity	O
of	O
flucytosine	B
by	O
possibly	O
increasing	O
its	O
cellular	O
uptake	O
and	O
/	O
or	O
impairing	O
its	O
renal	O
excretion	O
.	O

Imidazoles	B
(	O
e	O
.	O
g	O
.	O
,	O
ketoconazole	B
,	O
miconazole	B
,	O
clotrimazole	B
,	O
fluconazole	B
,	O
etc	O
.	O
)	O
:	O
in	O
vitro	O
and	O
animal	O
studies	O
with	O
the	O
combination	O
of	O
amphotericin	B
B	I
and	O
imidazoles	B
suggest	O
that	O
imidazoles	B
may	O
induce	O
fungal	O
resistance	O
to	O
amphotericin	B
B	I
.	O

Other	O
nephrotoxic	O
medications	O
:	O
agents	O
such	O
as	O
aminoglycosides	B
,	O
cyclosporine	B
,	O
and	O
pentamidine	B
may	O
enhance	O
the	O
potential	O
for	O
drug	O
-	O
induced	O
renal	O
toxicity	O
,	O
and	O
should	O
be	O
used	O
concomitantly	O
only	O
with	O
great	O
caution	O
.	O

Skeletal	B
muscle	I
relaxants	I
:	O
amphotericin	B
B	I
-	O
induced	O
hypokalemia	O
may	O
enhance	O
the	O
curariform	O
effect	O
of	O
skeletal	B
muscle	I
relaxants	I
(	O
e	O
.	O
g	O
.	O
,	O
tubocurarine	B
)	O
.	O

Leukocyte	B
transfusions	I
:	O
acute	O
pulmonary	O
toxicity	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
intravenous	O
amphotericin	B
B	I
and	O
leukocyte	B
transfusions	I
.	O

Bacteriostatic	B
Antibiotics	I
:	O
Chloramphenicol	B
,	O
erythromycins	B
,	O
sulfonamides	B
,	O
or	O
tetracyclines	B
may	O
interfere	O
with	O
the	O
bactericidal	O
effect	O
of	O
penicillins	B
.	O

Probenecid	B
:	O
May	O
decrease	O
renal	O
tubular	O
secretion	O
of	O
ampicillin	B
resulting	O
in	O
increased	O
blood	O
levels	O
and	O
/	O
or	O
ampicillin	B
toxicity	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interaction	O
After	O
treatment	O
with	O
ampicillin	B
,	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
may	O
occur	O
with	O
copper	B
sulfate	I
tests	O
(	O
Benedicts	O
solution	O
,	O
Fehlings	O
solution	O
,	O
or	O
Clinitest	O
tablets	O
)	O
but	O
not	O
with	O
enzyme	O
based	O
tests	O
such	O
as	O
Clinistix	O
and	O
Glucose	O
Enzymatic	O
Test	O
Strip	O
USP	O
.	O

HIV	B
Protease	I
Inhibitors	I
:	O
The	O
effect	O
of	O
amprenavir	B
on	O
total	O
drug	O
concentrations	O
of	O
other	O
HIV	B
protease	I
inhibitors	I
in	O
subjects	O
receiving	O
both	O
agents	O
was	O
evaluated	O
using	O
comparisons	O
to	O
historical	O
data	O
.	O

Indinavir	B
steady	O
-	O
state	O
Cmax	O
,	O
A	O
.	O
C	O
.	O
and	O
Cmin	O
were	O
decreased	O
by	O
22	O
%	O
,	O
38	O
%	O
,	O
and	O
27	O
%	O
,	O
respectively	O
,	O
by	O
concomitant	O
amprenavir	B
.	O

Saquinavir	B
steady	O
-	O
state	O
Cmax	O
,	O
A	O
.	O
C	O
.	O
and	O
Cmin	O
were	O
increased	O
21	O
%	O
,	O
decreased	O
19	O
%	O
,	O
and	O
decreased	O
48	O
%	O
,	O
respectively	O
,	O
by	O
concomitant	O
amprenavir	B
.	O

Nelfinavir	B
steady	O
-	O
state	O
Cmax	O
,	O
A	O
.	O
C	O
.	O
and	O
Cmin	O
were	O
increased	O
by	O
12	O
%	O
,	O
15	O
%	O
,	O
and	O
14	O
%	O
,	O
respectively	O
,	O
by	O
concomitant	O
amprenavir	B
.	O

Methadone	B
:	O
Coadministration	O
of	O
amprenavir	B
and	O
methadone	B
can	O
decrease	O
plasma	O
levels	O
of	O
methadone	B
.	O

Coadministration	O
of	O
amprenavir	B
and	O
methadone	B
as	O
compared	O
to	O
a	O
non	O
-	O
matched	O
historicalcontrol	O
group	O
resulted	O
in	O
a	O
30	O
%	O
,	O
27	O
%	O
,	O
and	O
25	O
%	O
decrease	O
in	O
serum	O
amprenavir	B
AUC	O
,	O
Cmax	O
,	O
andCmin	O
,	O
respectively	O
.	O

Laboratory	O
Tests	O
:	O
The	O
combination	O
of	O
Amprenavir	B
and	O
low	O
-	O
dose	O
ritonavir	B
has	O
been	O
associated	O
with	O
elevations	O
of	O
cholesterol	O
and	O
triglycerides	O
,	O
SGOT	O
(	O
AST	O
)	O
,	O
and	O
SGPT	O
(	O
ALT	O
)	O
in	O
some	O
patients	O
.	O

Appropriate	O
laboratory	O
testing	O
should	O
be	O
considered	O
prior	O
to	O
initiating	O
combination	O
therapy	O
with	O
Amprenavir	B
and	O
ritonavir	B
and	O
at	O
periodic	O
intervals	O
or	O
if	O
any	O
clinical	O
signs	O
or	O
symptoms	O
of	O
hyperlipidemia	O
or	O
elevated	O
liver	O
function	O
tests	O
occur	O
during	O
therapy	O
.	O

For	O
comprehensive	O
information	O
concerning	O
laboratory	O
test	O
alterations	O
associated	O
with	O
ritonavir	B
,	O
physicians	O
should	O
refer	O
to	O
the	O
complete	O
prescribing	O
information	O
for	O
NORVIR	B
(	O
ritonavir	B
)	O
.	O

Taking	O
amyl	B
nitrite	I
after	O
drinking	O
alcohol	B
may	O
worsen	O
side	O
effects	O
and	O
may	O
cause	O
severe	O
hypotension	O
and	O
cardiovascular	O
collapse	O
.	O

In	O
vivo	O
interaction	O
studies	O
in	O
humans	O
have	O
demonstrated	O
that	O
digoxin	B
and	O
warfarin	B
do	O
not	O
affect	O
the	O
PK	O
properties	O
of	O
anagrelide	B
,	O
nor	O
does	O
anagrelide	B
affect	O
the	O
PK	O
properties	O
of	O
digoxin	B
or	O
warfarin	B
.	O

Although	O
additional	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
,	O
the	O
most	O
common	O
medications	O
used	O
concomitantly	O
with	O
anagrelide	B
in	O
clinical	O
trials	O
were	O
aspirin	B
,	O
acetaminophen	B
,	O
furosemide	B
,	O
iron	B
,	O
ranitidine	B
,	O
hydroxyurea	B
,	O
and	O
allopurinol	B
.	O

An	O
in	O
vivo	O
interaction	O
study	O
in	O
humans	O
demonstrated	O
that	O
a	O
single	O
1mg	O
dose	O
of	O
anagrelide	B
administered	O
concomitantly	O
with	O
a	O
single	O
900	O
mg	O
dose	O
of	O
aspirin	B
was	O
generally	O
well	O
tolerated	O
.	O

No	O
clinically	O
relevant	O
pharmacokinetic	O
interactions	O
between	O
anagrelide	B
and	O
acetylsalicylic	B
acid	I
were	O
observed	O
.	O

Anagrelide	B
alone	O
had	O
no	O
effect	O
on	O
platelet	O
aggregation	O
,	O
but	O
did	O
slightly	O
enhance	O
the	O
inhibition	O
of	O
platelet	O
aggregation	O
by	O
aspirin	B
.	O

It	O
is	O
known	O
that	O
CYP1A2	O
is	O
inhibited	O
by	O
several	O
medicinal	O
products	O
,	O
including	O
fluvoxamine	B
,	O
and	O
such	O
medicinal	O
products	O
could	O
theoretically	O
adversely	O
influence	O
the	O
clearance	O
of	O
anagrelide	B
.	O

Anagrelide	B
demonstrates	O
some	O
limited	O
inhibitory	O
activity	O
towards	O
CYP1A2	O
which	O
may	O
present	O
a	O
theoretical	O
potential	O
for	O
interaction	O
with	O
other	O
coadministered	O
medicinal	O
products	O
sharing	O
that	O
clearance	O
mechanism	O
e	O
.	O
g	O
.	O
theophylline	B
.	O

The	O
effects	O
of	O
medicinal	O
products	O
with	O
similar	O
properties	O
such	O
as	O
inotropes	O
milrinone	B
,	O
enoximone	B
,	O
amrinone	B
,	O
olprinone	B
and	O
cilostazol	B
may	O
be	O
exacerbated	O
by	O
anagrelide	B
.	O

There	O
is	O
a	O
single	O
case	O
report	O
,	O
which	O
suggests	O
that	O
sucralfate	B
may	O
interfere	O
with	O
anagrelide	B
absorption	O
.	O

Toxicologic	O
and	O
toxicokinetic	O
studies	O
in	O
rats	O
did	O
not	O
demonstrate	O
any	O
alterations	O
in	O
the	O
clearance	O
or	O
toxicologic	O
profile	O
of	O
either	O
methotrexate	B
or	O
Kineret	B
when	O
the	O
two	O
agents	O
were	O
administered	O
together	O
.	O

In	O
a	O
study	O
in	O
which	O
patients	O
with	O
active	O
RA	O
were	O
treated	O
for	O
up	O
to	O
24	O
weeks	O
with	O
concurrent	O
Kineret	B
and	O
etanercept	B
therapy	O
,	O
a	O
7	O
%	O
rate	O
of	O
serious	O
infections	O
was	O
observed	O
,	O
which	O
was	O
higher	O
than	O
that	O
observed	O
with	O
etanercept	B
alone	O
(	O
0	O
%	O
)	O
.	O

Two	O
percent	O
of	O
patients	O
treated	O
concurrently	O
with	O
Kineret	B
and	O
etanercept	B
developed	O
neutropenia	O
(	O
ANC	O
1	O
x	O
109	O
/	O
L	O
)	O
.	O

Anastrozole	B
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
antipyrine	B
.	O

Although	O
there	O
have	O
been	O
no	O
formal	O
interaction	O
studies	O
other	O
than	O
with	O
antipyrine	B
,	O
based	O
on	O
these	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
,	O
it	O
is	O
unlikely	O
that	O
co	O
-	O
administration	O
of	O
a	O
1	O
mg	O
dose	O
of	O
ARIMIDEX	B
with	O
other	O
drugs	O
will	O
result	O
in	O
clinically	O
significant	O
drug	O
inhibition	O
of	O
cytochrome	O
P450	O
-	O
mediated	O
metabolism	O
of	O
the	O
other	O
drugs	O
.	O

An	O
interaction	O
study	O
with	O
warfarin	B
showed	O
no	O
clinically	O
significant	O
effect	O
of	O
anastrozole	B
on	O
warfarin	B
pharmacokinetics	O
or	O
anticoagulant	O
activity	O
.	O

At	O
a	O
median	O
follow	O
-	O
up	O
of	O
33	O
months	O
,	O
the	O
combination	O
of	O
ARIMIDEX	B
and	O
tamoxifen	B
did	O
not	O
demonstrate	O
any	O
efficacy	O
benefit	O
when	O
compared	O
with	O
tamoxifen	B
in	O
all	O
patients	O
as	O
well	O
as	O
in	O
the	O
hormone	O
receptor	O
-	O
positive	O
subpopulation	O
.	O

Based	O
on	O
clinical	O
and	O
pharmacokinetic	O
results	O
from	O
the	O
ATAC	O
trial	O
,	O
tamoxifen	B
should	O
not	O
be	O
administered	O
with	O
anastrozole	B
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
Drug	O
Interactions	O
and	O
CLINICAL	O
PHARMACOLOGY	O
-	O
Clinical	O
Studies	O
-	O
Adjuvant	O
Treatment	O
of	O
Breast	O
Cancer	O
in	O
Postmenopausal	O
Women	O
subsections	O
)	O
.	O

Co	O
-	O
administration	O
of	O
anastrozole	B
and	O
tamoxifen	B
resulted	O
in	O
a	O
reduction	O
of	O
anastrozole	B
plasma	O
levels	O
by	O
27	O
%	O
compared	O
with	O
those	O
achieved	O
with	O
anastrozole	B
alone	O
.	O

Estrogen	B
-	O
containing	O
therapies	O
should	O
not	O
be	O
used	O
with	O
ARIMIDEX	B
as	O
they	O
may	O
diminish	O
its	O
pharmacologic	O
action	O
.	O

Caution	O
should	O
be	O
observed	O
when	O
anileridine	B
is	O
coadministered	O
with	O
other	O
opioids	B
,	O
sedatives	B
,	O
phenothiazines	B
,	O
or	O
anesthetics	B
,	O
as	O
these	O
agents	O
may	O
increase	O
respiratory	O
and	O
circulatory	O
depression	O
.	O

Addition	O
or	O
deletion	O
of	O
any	O
drug	O
from	O
the	O
therapeutic	O
regimen	O
of	O
patients	O
receiving	O
oral	O
anticoagulants	B
may	O
affect	O
patient	O
response	O
to	O
the	O
anticoagulant	B
.	O

For	O
example	O
,	O
since	O
cholestyramine	B
may	O
reduce	O
the	O
gastrointestinal	O
absorption	O
of	O
both	O
the	O
oral	O
anticoagulants	B
and	O
vitamin	B
K	I
,	O
the	O
net	O
effects	O
are	O
unpredictable	O
.	O

Chloral	B
hydrate	I
may	O
cause	O
an	O
increased	O
prothrombin	O
response	O
by	O
displacing	O
the	O
anticoagulant	B
from	O
protein	O
binding	O
sites	O
or	O
a	O
diminished	O
prothrombin	O
response	O
through	O
increased	O
metabolism	O
of	O
the	O
unbound	O
drug	O
by	O
hepatic	O
enzyme	O
induction	O
,	O
thus	O
leading	O
to	O
inter	O
-	O
patient	O
variation	O
in	O
ultimate	O
prothrombin	O
effect	O
.	O

Drugs	O
that	O
have	O
been	O
reported	O
to	O
diminish	O
oral	O
anticoagulant	B
response	O
,	O
ie	O
,	O
decreased	O
prothrom	O
-	O
bin	O
time	O
response	O
,	O
in	O
man	O
significantly	O
include	O
:	O
adrenocortical	B
steroids	I
;	O

Drugs	O
that	O
have	O
been	O
reported	O
to	O
diminish	O
oral	O
anticoagulant	B
response	O
,	O
ie	O
,	O
decreased	O
prothrom	O
-	O
bin	O
time	O
response	O
,	O
in	O
man	O
significantly	O
include	O
:	O
adrenocortical	B
steroids	I
;	O
alcohol	B
*	O
;	O
antacids	B
;	O
antihistamines	B
;	O
barbiturates	B
;	O
carbamazepine	B
;	O
chloral	B
hydrate	I
*	O
;	O
chlordiazepoxide	B
;	O
cholestyramine	B
;	O
diet	O
high	O
in	O
vitamin	B
K	I
;	O
diuretics	B
*	O
;	O
ethchlorvynol	B
;	O
glutethimide	B
;	O
griseofulvin	B
;	O
haloperidol	B
;	O
meprobamate	B
;	O
oral	O
contraceptives	B
;	O
paraldehyde	B
;	O
primidone	B
;	O
ranitidine	B
*	O
;	O
rifampin	B
;	O
unreliable	O
prothrombin	O
time	O
determinations	O
;	O
vitamin	B
C	I
;	O
warfarin	B
sodium	I
under	O
-	O
dosage	O
.	O

Drugs	O
that	O
reportedly	O
may	O
increase	O
oral	O
anticoagulant	B
response	O
,	O
ie	O
,	O
increased	O
prothrombin	O
response	O
,	O
in	O
man	O
include	O
:	O
alcohol	B
*	O
;	O

salicylates	B
;	O
sulfinpyrazone	B
;	O

trimethoprim	B
/	O
sulfamethoxazole	B
;	O

Drugs	O
that	O
reportedly	O
may	O
increase	O
oral	O
anticoagulant	B
response	O
,	O
ie	O
,	O
increased	O
prothrombin	O
response	O
,	O
in	O
man	O
include	O
:	O
alcohol	B
*	O
;	O
allopurinol	B
;	O
aminosalicylic	B
acid	I
;	O
amiodarone	B
;	O
anabolic	B
steroids	I
;	O
antibiotics	B
;	O
bromelains	B
;	O
chloral	B
hydrate	I
*	O
;	O
chlorpropamide	B
;	O
chymotrypsin	B
;	O
cimetidine	B
;	O
cinchophen	B
;	O
clofibrate	B
;	O
dextran	B
;	O
dextrothyroxine	B
;	O
diazoxide	B
;	O
dietary	O
deficiencies	O
;	O
diflunisal	B
;	O
disulfiram	B
;	O
drugs	B
affecting	O
blood	O
elements	O
;	O
ethacrynic	B
acid	I
;	O
fenoprofen	B
;	O
glucagon	B
;	O
hepatotoxic	O
drugs	B
;	O
ibuprofen	B
;	O
indomethacin	B
;	O
influenza	B
virus	I
vaccine	I
;	O
inhalation	O
anesthetics	B
;	O
mefenamic	B
acid	I
;	O
methyldopa	B
;	O
methylphenidate	B
;	O
metronidazole	B
;	O
miconazole	B
;	O
monoamine	B
oxidase	I
inhibitors	I
;	O
nalidixic	B
acid	I
;	O
naproxen	B
;	O
oxolinic	B
acid	I
;	O
oxyphenbutazone	B
;	O
pentoxifylline	B
;	O
phenylbutazone	B
;	O
phenyramidol	B
;	O
phenytoin	B
;	O
prolonged	B
hot	O
weather	O
;	O
prolonged	B
narcotics	I
;	O
pyrazolones	B
;	O
quinidine	B
;	O
quinine	B
;	O
ranitidine	B
*	O
;	O
salicylates	B
;	O
sulfinpyrazone	B
;	O
sulfonamides	B
,	O
long	O
acting	O
;	O
sulindac	B
;	O
thyroid	B
drugs	I
;	O
tolbutamide	B
;	O
triclofos	B
sodium	I
;	O
trimethoprim	B
/	O
sulfamethoxazole	B
;	O
unreliable	O
prothrombin	O
time	O
determinations	O
;	O
warfarin	B
sodium	I
overdosage	O
.	O

Oral	O
anticoagulants	B
may	O
potentiate	O
the	O
hypoglycemic	B
action	O
of	O
hypoglycemic	B
agents	I
,	O
eg	O
,	O
tolbutamide	B
and	O
chlorpropamide	B
,	O
by	O
inhibiting	O
their	O
metabolism	O
in	O
the	O
liver	O
.	O

Because	O
oral	O
anticoagulants	B
may	O
interfere	O
with	O
the	O
hepatic	O
metabolism	O
of	O
phenytoin	B
,	O
toxic	O
levels	O
of	O
the	O
anticonvulsant	B
may	O
occur	O
when	O
an	O
oral	O
anticoagulant	B
and	O
phenytoin	B
are	O
administered	O
concurrently	O
.	O

Drugs	O
that	O
reduce	O
the	O
number	O
of	O
blood	O
platelets	O
by	O
causing	O
bone	O
marrow	O
depression	O
(	O
such	O
as	O
antineoplastic	B
agents	I
)	O
or	O
drugs	B
which	O
inhibit	O
platelet	O
function	O
(	O
eg	O
,	O
aspirin	B
and	O
other	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	B
,	O
dipyridamole	B
,	O
hydrochloroquine	B
,	O
clofibrate	B
,	O
dextran	B
)	O
may	O
increase	O
the	O
bleeding	O
tendency	O
produced	O
by	O
anticoagulants	B
without	O
altering	O
prothrombin	O
time	O
determinations	O
.	O

The	O
beneficial	O
effects	O
on	O
arterial	O
thrombus	O
formation	O
from	O
combined	O
therapy	O
with	O
antiplatelet	B
and	O
anticoagulant	B
medication	I
must	O
be	O
weighed	O
against	O
an	O
increased	O
risk	O
of	O
inducing	O
hemorrhage	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interferences	O
:	O
Dicumarol	B
and	O
indanedione	B
anticoagulants	I
,	O
including	O
anisindione	B
,	O
or	O
their	O
metabolites	O
may	O
color	O
alkaline	O
urine	O
red	O
-	O
orange	O
,	O
which	O
may	O
interfere	O
with	O
spectrophotometrically	O
determined	O
urinary	O
laboratory	O
tests	O
.	O

5HT3	B
Antagonists	I
:	O
Based	O
on	O
reports	O
of	O
profound	O
hypotension	O
and	O
loss	O
of	O
consciousness	O
when	O
apomorphine	B
was	O
administered	O
with	O
ondansetron	B
,	O
the	O
concomitant	O
use	O
of	O
apomorphine	B
with	O
drugs	O
of	O
the	O
5HT3	B
antagonist	I
class	I
(	O
including	O
,	O
for	O
example	O
,	O
ondansetron	B
,	O
granisetron	B
,	O
dolasetron	B
,	O
palonosetron	B
,	O
and	O
alosetron	B
)	O
is	O
contraindicated	O
.	O

Antihypertensive	B
Medications	O
and	O
Vasodilators	B
:	O
The	O
following	O
adverse	O
events	O
were	O
experienced	O
more	O
commonly	O
in	O
patients	O
receiving	O
concomitant	O
antihypertensive	B
medications	I
or	O
vasodilators	B
(	O
n	O
=	O
94	O
)	O
compared	O
to	O
patients	O
not	O
receiving	O
these	O
concomitant	O
drugs	O
(	O
n	O
=	O
456	O
)	O
:	O
hypotension	O
10	O
%	O
vs	O
4	O
%	O
,	O
myocardial	O
infarction	O
3	O
%	O
vs	O
1	O
%	O
,	O
serious	O
pneumonia	O
5	O
%	O
vs	O
3	O
%	O
,	O
serious	O
falls	O
9	O
%	O
vs	O
3	O
%	O
,	O
and	O
bone	O
and	O
joint	O
injuries	O
6	O
%	O
vs	O
2	O
%	O
.	O

Dopamine	B
Antagonists	I
:	O
Since	O
apomorphine	B
is	O
a	O
dopamine	B
agonist	I
,	O
it	O
is	O
possible	O
that	O
dopamine	B
antagonists	I
,	O
such	O
as	O
the	O
neuroleptics	B
(	O
phenothiazines	B
,	O
butyrophenones	B
,	O
thioxanthenes	B
)	O
or	O
metoclopramide	B
,	O
may	O
diminish	O
the	O
effectiveness	O
of	O
APOKYN	B
.	O

Patients	O
with	O
major	O
psychotic	O
disorders	O
,	O
treated	O
with	O
neuroleptics	B
,	O
should	O
be	O
treated	O
with	O
dopamine	B
agonists	I
only	O
if	O
the	O
potential	O
benefits	O
outweigh	O
the	O
risks	O
.	O

Apraclonidine	B
should	O
not	O
be	O
used	O
in	O
patients	O
receiving	O
MAO	B
inhibitors	I
.	O
.	O

Although	O
no	O
specific	O
drug	O
interactions	O
with	O
topical	O
glaucoma	O
drugs	O
or	O
systemic	O
medications	O
were	O
identified	O
in	O
clinical	O
studies	O
of	O
IOPIDINE	B
0	O
.	O
5	O
%	O
Ophthalmic	O
Solution	O
,	O
the	O
possibility	O
of	O
an	O
additive	O
or	O
potentiating	O
effect	O
with	O
CNS	B
depressants	I
(	O
alcohol	B
,	O
barbiturates	B
,	O
opiates	B
,	O
sedatives	B
,	O
anesthetics	B
)	O
should	O
be	O
considered	O
.	O

Tricyclic	B
antidepressants	I
have	O
been	O
reported	O
to	O
blunt	O
the	O
hypotensive	O
effect	O
of	O
systemic	O
clonidine	B
.	O

An	O
additive	O
hypotensive	O
effect	O
has	O
been	O
reported	O
with	O
the	O
combination	O
of	O
systemic	O
clonidine	B
and	O
neuroleptic	B
therapy	O
.	O

Since	O
apraclonidine	B
may	O
reduce	O
pulse	O
and	O
blood	O
pressure	O
,	O
caution	O
in	O
using	O
drugs	O
such	O
as	O
beta	O
-	O
blockers	O
(	O
ophthalmic	O
and	O
systemic	O
)	O
,	O
antihypertensives	B
,	O
and	O
cardiac	B
glycosides	I
is	O
advised	O
.	O

Aprepitant	B
has	O
been	O
shown	O
to	O
induce	O
the	O
metabolism	O
of	O
S	O
(	O
-	O
)	O
warfarin	B
and	O
tolbutamide	B
,	O
which	O
are	O
metabolized	O
through	O
CYP2C9	O
.	O

Coadministration	O
of	O
Aprepitant	B
with	O
these	O
drugs	O
or	O
other	O
drugs	O
that	O
are	O
known	O
to	O
be	O
metabolized	O
by	O
CYP2C9	O
,	O
such	O
as	O
phenytoin	B
,	O
may	O
result	O
in	O
lower	O
plasma	O
concentrations	O
of	O
these	O
drugs	O
.	O

Aprepitant	B
is	O
unlikely	O
to	O
interact	O
with	O
drugs	O
that	O
are	O
substrates	O
for	O
the	O
P	O
-	O
glycoprotein	O
transporter	O
,	O
as	O
demonstrated	O
by	O
the	O
lack	O
of	O
interaction	O
of	O
Aprepitant	B
with	O
digoxin	B
in	O
a	O
clinical	O
drug	O
interaction	O
study	O
.	O

5	O
-	O
HT3	O
antagonists	B
:	O
In	O
clinical	O
drug	O
interaction	O
studies	O
,	O
aprepitant	B
did	O
not	O
have	O
clinically	O
important	O
effects	O
on	O
the	O
pharmacokinetics	O
of	O
ondansetron	B
or	O
granisetron	B
.	O

Corticosteroids	B
:	O
Dexamethasone	B
:	O
Aprepitant	B
,	O
when	O
given	O
as	O
a	O
regimen	O
of	O
125mg	O
with	O
dexamethasone	B
coadministered	O
orally	O
as	O
20	O
mg	O
on	O
Day	O
1	O
,	O
and	O
Aprepitant	B
when	O
given	O
as	O
80	O
mg	O
/	O
day	O
with	O
dexamethasone	B
coadministered	O
orally	O
as	O
8	O
mg	O
on	O
Days	O
2	O
through	O
5	O
,	O
increased	O
the	O
AUC	O
of	O
dexamethasone	B
,	O
a	O
CYP3A4	O
substrate	O
by	O
2	O
.	O
2	O
-	O
fold	O
,	O
on	O
Days	O
1	O
and	O
5	O
.	O

The	O
oral	O
dexamethasone	B
doses	O
should	O
be	O
reduced	O
by	O
approximately	O
50	O
%	O
when	O
coadministered	O
with	O
Aprepitant	B
,	O
to	O
achieve	O
exposures	O
of	O
dexamethasone	B
similar	O
to	O
those	O
obtained	O
when	O
it	O
is	O
given	O
without	O
Aprepitant	B
.	O

The	O
daily	O
dose	O
of	O
dexamethasone	B
administered	O
in	O
clinical	O
studies	O
with	O
Aprepitant	B
reflects	O
an	O
approximate	O
50	O
%	O
reduction	O
of	O
the	O
dose	O
of	O
dexamethasone	B
.	O

Aprepitant	B
,	O
when	O
given	O
as	O
a	O
regimen	O
of	O
125	O
mg	O
on	O
Day	O
1	O
and	O
80	O
mg	O
/	O
day	O
on	O
Days	O
2	O
and	O
3	O
,	O
increased	O
the	O
AUC	O
of	O
methylprednisolone	B
,	O
a	O
CYP3A4	O
substrate	O
,	O
by	O
1	O
.	O
34	O
-	O
fold	O
on	O
Day	O
1	O
and	O
by	O
2	O
.	O
5	O
-	O
fold	O
on	O
Day	O
3	O
,	O
when	O
methylprednisolone	B
was	O
coadministered	O
intravenously	O
as	O
125	O
mg	O
on	O
Day	O
1	O
and	O
orally	O
as	O
40	O
mg	O
on	O
Days	O
2	O
and	O
3	O
.	O

The	O
IV	O
methylprednisolone	B
dose	O
should	O
be	O
reduced	O
by	O
approximately	O
25	O
%	O
,	O
and	O
the	O
oral	O
methylprednisolone	B
dose	O
should	O
be	O
reduced	O
by	O
approximately	O
50	O
%	O
when	O
coadministered	O
with	O
Aprepitant	B
to	O
achieve	O
exposures	O
of	O
methylprednisolone	B
similar	O
to	O
those	O
obtained	O
when	O
it	O
is	O
given	O
without	O
Aprepitant	B
.	O

Warfarin	B
:	O
A	O
single	O
125	O
-	O
mg	O
dose	O
of	O
Aprepitant	B
was	O
administered	O
on	O
Day	O
1	O
and	O
80	O
mg	O
/	O
day	O
on	O
Days	O
2	O
and	O
3	O
to	O
healthy	O
subjects	O
who	O
were	O
stabilized	O
on	O
chronic	O
warfarin	B
therapy	O
.	O

Although	O
there	O
was	O
no	O
effect	O
of	O
Aprepitant	B
on	O
the	O
plasma	O
AUC	O
of	O
R	O
(	O
+	O
)	O
or	O
S	O
(	O
-	O
)	O
warfarin	B
determined	O
on	O
Day	O
3	O
,	O
there	O
was	O
a	O
34	O
%	O
decrease	O
in	O
S	O
(	O
-	O
)	O
warfarin	B
(	O
a	O
CYP2C9	O
substrate	O
)	O
trough	O
concentration	O
accompanied	O
by	O
a	O
14	O
%	O
decrease	O
in	O
the	O
prothrombin	O
time	O
(	O
reported	O
as	O
International	O
Normalized	O
Ratio	O
or	O
INR	O
)	O
5	O
days	O
after	O
completion	O
of	O
dosing	O
with	O
Aprepitant	B
.	O

In	O
patients	O
on	O
chronic	O
warfarin	B
therapy	O
,	O
the	O
prothrombin	O
time	O
(	O
INR	O
)	O
should	O
be	O
closely	O
monitored	O
in	O
the	O
2	O
-	O
week	O
period	O
,	O
particularly	O
at	O
7	O
to	O
10	O
days	O
,	O
following	O
initiation	O
of	O
the	O
3	O
-	O
day	O
regimen	O
of	O
Aprepitant	B
with	O
each	O
chemotherapy	O
cycle	O
.	O

Tolbutamide	B
:	O
Aprepitant	B
,	O
when	O
given	O
as	O
125	O
mg	O
on	O
Day	O
1	O
and	O
80	O
mg	O
/	O
day	O
on	O
Days	O
2	O
and	O
3	O
,	O
decreased	O
the	O
AUC	O
of	O
tolbutamide	B
(	O
a	O
CYP2C9	O
substrate	O
)	O
by	O
23	O
%	O
on	O
Day	O
4	O
,	O
28	O
%	O
on	O
Day	O
8	O
,	O
and	O
15	O
%	O
on	O
Day	O
15	O
,	O
when	O
a	O
single	O
dose	O
of	O
tolbutamide	B
500	O
mg	O
was	O
admini	O
,	O
stered	O
orally	O
prior	O
to	O
the	O
administration	O
of	O
the	O
3	O
-	O
day	O
regimen	O
of	O
Aprepitant	B
and	O
on	O
Days	O
4	O
,	O
8	O
,	O
and	O
15	O
.	O

Oral	O
contraceptives	B
:	O
Aprepitant	B
,	O
when	O
given	O
once	O
daily	O
for	O
14	O
days	O
as	O
a	O
100	O
-	O
mg	O
capsule	O
with	O
an	O
oral	O
contraceptive	B
containing	O
35	O
mcg	O
of	O
ethinyl	B
estradiol	I
and	O
1	O
mg	O
of	O
norethindrone	B
,	O
decreased	O
the	O
AUC	O
of	O
ethinyl	B
estradiol	I
by	O
43	O
%	O
,	O
and	O
decreased	O
the	O
AUC	O
of	O
norethindrone	B
by	O
8	O
%	O
;	O

therefore	O
,	O
the	O
efficacy	O
of	O
oral	O
contraceptives	B
during	O
administration	O
of	O
Aprepitant	B
may	O
be	O
reduced	O
.	O

Although	O
a	O
3	O
-	O
day	O
regimen	O
of	O
Aprepitant	B
given	O
concomitantly	O
with	O
oral	O
contraceptives	B
has	O
not	O
been	O
studied	O
,	O
alternative	O
or	O
back	O
-	O
up	O
methods	O
of	O
contraception	O
should	O
be	O
used	O
.	O

Midazolam	B
:	O
Aprepitant	B
increased	O
the	O
AUC	O
of	O
midazolam	B
,	O
a	O
sensitive	O
CYP3A4	O
substrate	O
,	O
by	O
2	O
.	O
3	O
-	O
fold	O
on	O
Day	O
1	O
and	O
3	O
.	O
3	O
-	O
fold	O
on	O
Day	O
5	O
,	O
when	O
a	O
single	O
oral	O
dose	O
of	O
midazolam	B
2	O
mg	O
was	O
coadministered	O
on	O
Day	O
1	O
and	O
Day	O
5	O
of	O
a	O
regimen	O
of	O
Aprepitant	B
125	O
mg	O
on	O
Day	O
1	O
and	O
80	O
mg	O
/	O
day	O
on	O
Days	O
2	O
through	O
5	O
.	O

The	O
potential	O
effects	O
of	O
increased	O
plasma	O
concentrations	O
of	O
midazolam	B
or	O
other	O
benzodiazepines	B
metabolized	O
via	O
CYP3A4	O
(	O
alprazolam	B
,	O
triazolam	B
)	O
should	O
be	O
considered	O
when	O
coadministering	O
these	O
agents	O
with	O
Aprepitant	B
.	O

In	O
another	O
study	O
with	O
intravenous	O
administration	O
of	O
midazolam	B
,	O
Aprepitant	B
was	O
given	O
as	O
125	O
mg	O
on	O
Day	O
1	O
and	O
80	O
mg	O
/	O
day	O
on	O
Days	O
2	O
and	O
3	O
,	O
and	O
midazolam	B
2	O
mg	O
IV	O
was	O
given	O
prior	O
to	O
the	O
administration	O
of	O
the	O
3	O
-	O
day	O
regimen	O
of	O
Aprepitant	B
and	O
on	O
Days	O
4	O
,	O
8	O
,	O
and	O
15	O
.	O

Aprepitant	B
increased	O
the	O
AUC	O
of	O
midazolam	B
by	O
25	O
%	O
on	O
Day	O
4	O
and	O
decreased	O
the	O
AUC	O
of	O
midazolam	B
by	O
19	O
%	O
on	O
Day	O
8	O
relative	O
to	O
the	O
dosing	O
of	O
Aprepitant	B
on	O
Days	O
1	O
through	O
3	O
.	O

therefore	O
,	O
coadministration	O
of	O
Aprepitant	B
with	O
drugs	O
that	O
inhibit	O
CYP3A4	O
activity	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
aprepitant	B
.	O

Consequently	O
,	O
concomitant	O
administration	O
of	O
Aprepitant	B
with	O
strong	O
CYP3A4	O
inhibitors	O
(	O
e	O
.	O
g	O
.	O
,	O
ketoconazole	B
,	O
itraconazole	B
,	O
nefazodone	B
,	O
troleandomycin	B
,	O
clarithromycin	B
,	O
ritonavir	B
,	O
nelfinavir	B
)	O
should	O
be	O
approached	O
with	O
caution	O
.	O

Because	O
moderate	O
CYP3A4	O
inhibitors	O
(	O
e	O
.	O
g	O
.	O
,	O
diltiazem	B
)	O
result	O
in	O
2	O
-	O
fold	O
increase	O
in	O
plasma	O
concentrations	O
of	O
aprepitant	B
,	O
concomitant	O
administration	O
should	O
also	O
be	O
approached	O
with	O
caution	O
.	O

therefore	O
,	O
coadministration	O
of	O
Aprepitant	B
with	O
drugs	O
that	O
strongly	O
induce	O
CYP3A4	O
activity	O
(	O
e	O
.	O
g	O
.	O
,	O
rifampin	B
,	O
carbamazepine	B
,	O
phenytoin	B
)	O
may	O
result	O
in	O
reduced	O
plasma	O
concentrations	O
of	O
aprepitant	B
that	O
may	O
result	O
in	O
decreased	O
efficacy	O
of	O
Aprepitant	B
.	O

Ketoconazole	B
:	O
When	O
a	O
single	O
125	O
-	O
mg	O
dose	O
of	O
Aprepitant	B
was	O
administered	O
on	O
Day5	O
of	O
a	O

Ketoconazole	B
:	O
When	O
a	O
single	O
125	O
-	O
mg	O
dose	O
of	O
Aprepitant	B
was	O
administered	O
on	O
Day5	O
of	O
a	O
10	O
-	O
day	O
regimen	O
of	O
400	O
mg	O
/	O
day	O
of	O
ketoconazole	B
,	O
a	O
strong	O
CYP3A4	O
inhibitor	O
,	O
the	O
AUC	O
of	O
aprepitant	B
increased	O
approximately	O
5	O
-	O
fold	O
and	O
the	O
mean	O
terminal	O
half	O
-	O
life	O
of	O
aprepitant	B
increased	O
approximately	O
3	O
-	O
fold	O
.	O

Rifampin	B
:	O
When	O
a	O
single	O
375	O
-	O
mg	O
dose	O
of	O
Aprepitant	B
was	O
administered	O
on	O
Day9	O
of	O
a	O
14	O
-	O
day	O
regimen	O
of	O
600	O
mg	O
/	O
day	O
of	O
rifampin	B
,	O
a	O
strong	O
CYP3A4	O
inducer	O
,	O
the	O
AUC	O
of	O
aprepitant	B
decreased	O
approximately	O
11	O
-	O
fold	O
and	O
the	O
mean	O
terminal	O
half	O
-	O
life	O
decreased	O
approximately	O
3	O
-	O
fold	O
.	O

Coadministration	O
of	O
Aprepitant	B
with	O
drugs	O
that	O
induce	O
CYP3A4	O
activity	O
may	O
result	O
in	O
reduced	O
plasma	O
concentrations	O
and	O
decreased	O
efficacy	O
of	O
Aprepitant	B
.	O

Diltiazem	B
:	O
In	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	O
,	O
administration	O
of	O
aprepitant	B
once	O
daily	O
,	O
as	O
a	O
tablet	O
formulation	O
comparable	O
to	O
230	O
mg	O
of	O
the	O
capsule	O
formulation	O
,	O
with	O
diltiazem	B
120	O
mg	O
3	O
times	O
daily	O
for	O
5	O
days	O
,	O
resulted	O
in	O
a	O
2	O
-	O
fold	O
increase	O
of	O
aprepitant	B
AUC	O
and	O
a	O
simultaneous	O
1	O
.	O
7	O
-	O
fold	O
increase	O
of	O
diltiazem	B
AUC	O
.	O

Paroxetine	B
:	O
Coadministration	O
of	O
once	O
daily	O
doses	O
of	O
aprepitant	B
,	O
as	O
a	O
tablet	O
formulation	O
comparable	O
to	O
85	O
mg	O
or	O
170	O
mg	O
of	O
the	O
capsule	O
formulation	O
,	O
with	O
paroxetine	B
20	O
mg	O
once	O
daily	O
,	O
resulted	O
in	O
a	O
decrease	O
in	O
AUC	O
by	O
approximately	O
25	O
%	O
and	O
Cmax	O
,	O
by	O
approximately	O
20	O
%	O
of	O
both	O
aprepitant	B
and	O
paroxetine	B
.	O

Beta	O
-	O
adrenergic	O
blocking	B
agents	I
:	O
concurrent	O
use	O
may	O
blunt	O
the	O
response	O
to	O
arbutamine	B
.	O

Beta	O
-	O
adrenergic	O
blocking	B
agents	I
should	O
be	O
withdrawn	O
at	O
least	O
48	O
hours	O
before	O
conducting	O
an	O
arbutamine	B
-	O
mediated	O
stress	O
test	O
.	O

Antiarrhythmic	B
agents	O
,	O
class	B
I	I
(	O
such	O
as	O
flecainide	B
,	O
lidocaine	B
,	O
or	O
quinidine	B
)	O
:	O
concurrent	O
use	O
with	O
arbutamine	B
may	O
have	O
a	O
proarrhythmic	O
effect	O
.	O

Antidepressants	B
(	O
tricyclic	B
)	O
,	O
atropine	B
or	O
other	O
anticholinergic	B
agents	I
,	O
or	O
digitalis	B
glycosides	I
:	O
concurrent	O
use	O
with	O
arbutamine	B
may	O
produce	O
additive	O
inotropic	O
and	O
/	O
or	O
chronotropic	O
effects	O
.	O

Anticoagulants	B
including	O
coumarin	O
derivatives	O
,	O
indandione	O
derivatives	O
,	O
and	O
platelet	B
aggregation	I
inhibitors	I
such	O
as	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
drugs	B
(	O
NSAIDs	B
)	O
,	O
and	O
aspirin	B
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
when	O
administered	O
concomitantly	O
with	O
ardeparin	B
.	O

If	O
additional	O
adrenergic	B
drugs	I
are	O
to	O
be	O
administered	O
by	O
any	O
route	O
,	O
they	O
should	O
be	O
used	O
with	O
caution	O
because	O
the	O
pharmacologically	O
predictable	O
sympathetic	O
effects	O
of	O
BROVANA	B
may	O
be	O
potentiated	O
.	O

When	O
paroxetine	B
,	O
a	O
potent	O
inhibitor	O
of	O
CYP2D6	O
,	O
was	O
co	O
-	O
administered	O
with	O
BROVANA	B
at	O
steady	O
-	O
state	O
,	O
exposure	O
to	O
either	O
drug	O
was	O
not	O
altered	O
.	O

Concomitant	O
treatment	O
with	O
methylxanthines	B
(	O
aminophylline	B
,	O
theophylline	B
)	O
,	O
steroids	B
,	O
or	O
diuretics	B
may	O
potentiate	O
any	O
hypokalemic	O
effect	O
of	O
adrenergic	B
agonists	I
.	O

The	O
ECG	O
changes	O
and	O
/	O
or	O
hypokalemia	O
that	O
may	O
result	O
from	O
the	O
administration	O
of	O
non	O
-	O
potassium	O
sparing	B
diuretics	I
(	O
such	O
as	O
loop	B
or	O
thiazide	B
diuretics	I
)	O
can	O
be	O
acutely	O
worsened	O
by	O
beta	O
-	O
agonists	O
,	O
especially	O
when	O
the	O
recommended	O
dose	O
of	O
the	O
beta	O
-	O
agonist	O
is	O
exceeded	O
.	O

Although	O
the	O
clinical	O
significance	O
of	O
these	O
effects	O
is	O
not	O
known	O
,	O
caution	O
is	O
advised	O
in	O
the	O
co	O
-	O
administration	O
of	O
beta	O
-	O
agonists	O
with	O
non	O
-	O
potassium	O
sparing	B
diuretics	I
.	O

BROVANA	B
,	O
as	O
with	O
other	O
beta2	O
-	O
agonists	B
,	O
should	O
be	O
administered	O
with	O
extreme	O
caution	O
to	O
patients	O
being	O
treated	O
with	O
monoamine	B
oxidase	I
inhibitors	I
,	O
tricyclic	B
antidepressants	I
,	O
or	O
drugs	O
known	O
to	O
prolong	O
the	O
QTc	O
interval	O
because	O
the	O
action	O
of	O
adrenergic	B
agonists	I
on	O
the	O
cardiovascular	O
system	O
may	O
be	O
potentiated	O
by	O
these	O
agents	O
.	O

The	O
concurrent	O
use	O
of	O
intravenously	O
or	O
orally	O
administered	O
methylxanthines	B
(	O
e	O
.	O
g	O
.	O
,	O
aminophylline	B
,	O
theophylline	B
)	O
by	O
patients	O
receiving	O
BROVANA	B
has	O
not	O
been	O
completely	O
evaluated	O
.	O

In	O
two	O
combined	O
12	O
-	O
week	O
placebo	O
controlled	O
trials	O
that	O
included	O
BROVANA	B
doses	O
of	O
15	O
mcg	O
twice	O
daily	O
,	O
25	O
mcg	O
twice	O
daily	O
,	O
and	O
50	O
mcg	O
once	O
daily	O
,	O
54	O
of	O
873	O
BROVANA	B
-	O
treated	O
subjects	O
received	O
concomitant	O
theophylline	B
at	O
study	O
entry	O
.	O

In	O
a	O
12	O
-	O
month	O
controlled	O
trial	O
that	O
included	O
a	O
50	O
mcg	O
once	O
daily	O
BROVANA	B
dose	O
,	O
30	O
of	O
the	O
528	O
BROVANA	B
-	O
treated	O
subjects	O
received	O
concomitant	O
theophylline	B
at	O
study	O
entry	O
.	O

Beta	O
-	O
adrenergic	O
receptor	B
antagonists	I
(	O
beta	O
-	O
blockers	O
)	O
and	O
BROVANA	B
may	O
interfere	O
with	O
the	O
effect	O
of	O
each	O
other	O
when	O
administered	O
concurrently	O
.	O

Beta	O
-	O
blockers	O
not	O
only	O
block	O
the	O
therapeutic	O
effects	O
of	O
beta	O
-	O
agonists	O
,	O
but	O
may	O
produce	O
severe	O
bronchospasm	O
in	O
COPD	O
patients	O
.	O

Heparin	B
:	O
Since	O
heparin	B
is	O
contraindicated	O
in	O
patients	O
with	O
heparin	B
-	O
induced	O
thrombocytopenia	O
,	O
the	O
co	O
-	O
administration	O
of	O
Argatroban	B
and	O
heparin	B
is	O
unlikely	O
for	O
this	O
indication	O
.	O

However	O
,	O
if	O
Argatroban	B
is	O
to	O
be	O
initiated	O
after	O
cessation	O
of	O
heparin	B
therapy	O
,	O
allow	O
sufficient	O
time	O
for	O
heparins	O
effect	O
on	O
the	O
aPTT	O
to	O
decrease	O
prior	O
to	O
initiation	O
of	O
Argatroban	B
therapy	O
.	O

Aspirin	B
/	O
Acetaminophen	B
:	O
Pharmacokinetic	O
or	O
pharmacodynamic	O
drug	O
-	O
drug	O
interactions	O
have	O
not	O
been	O
demonstrated	O
between	O
Argatroban	B
and	O
concomitantly	O
administered	O
aspirin	B
(	O
162	O
.	O
5	O
mg	O
orally	O
given	O
26	O
and	O
2	O
hours	O
prior	O
to	O
initiation	O
of	O
Argatroban	B
1	O
g	O
/	O
kg	O
/	O
min	O
.	O
over	O
4	O
hours	O
)	O
or	O
acetaminophen	B
(	O
1000	O
mg	O
orally	O
given	O
12	O
,	O
6	O
and	O
0	O
hours	O
prior	O
to	O
,	O
and	O
6	O
and	O
12	O
hours	O
subsequent	O
to	O
,	O
initiation	O
of	O
Argatroban	B
1	O
.	O
5	O
g	O
/	O
kg	O
/	O
min	O
.	O
over	O
18	O
hours	O
)	O
.	O

Oral	O
anticoagulant	B
agents	I
:	O
Pharmacokinetic	O
drug	O
-	O
drug	O
interactions	O
between	O
Argatroban	B
and	O
warfarin	B
(	O
7	O
.	O
5	O
mg	O
single	O
oral	O
dose	O
)	O
have	O
not	O
been	O
demonstrated	O
.	O

However	O
,	O
the	O
concomitant	O
use	O
of	O
Argatroban	B
and	O
warfarin	B
(	O
5	O
-	O
7	O
.	O
5	O
mg	O
initial	O
oral	O
dose	O
followed	O
by	O
2	O
.	O
5	O
-	O
6	O
mg	O
/	O
day	O
orally	O
for	O
6	O
-	O
10	O
days	O
)	O
results	O
in	O
prolongation	O
of	O
the	O
prothrombin	O
time	O
(	O
PT	O
)	O
and	O
International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
.	O

Thrombolytic	B
agents	I
:	O
The	O
safety	O
and	O
effectiveness	O
of	O
Argatroban	B
with	O
thrombolytic	B
agents	I
have	O
not	O
been	O
established	O
.	O

Co	O
-	O
administration	O
:	O
Concomitant	O
use	O
of	O
Argatroban	B
with	O
antiplatelet	B
agents	I
,	O
thrombolytics	B
,	O
and	O
other	O
anticoagulants	B
may	O
increase	O
the	O
risk	O
of	O
bleeding	O
.	O

Drug	O
-	O
drug	O
interactions	O
have	O
not	O
been	O
observed	O
between	O
Argatroban	B
and	O
digoxin	B
or	O
erythromycin	B
.	O

Drug	O
-	O
Drug	O
Interactions	O
Given	O
the	O
primary	O
CNS	O
effects	O
of	O
aripiprazole	B
,	O
caution	O
should	O
be	O
used	O
when	O
ABILIFY	B
is	O
taken	O
in	O
combination	O
with	O
other	O
centrally	B
acting	I
drugs	I
and	O
alcohol	B
.	O

1	O
-	O
adrenergic	O
receptor	O
antagonism	O
,	O
aripiprazole	B
has	O
the	O
potential	O
to	O
enhance	O
the	O
effect	O
of	O
certain	O
antihypertensive	B
agents	I
.	O

Potential	O
for	O
Other	O
Drugs	O
to	O
Affect	O
ABILIFY	B
Aripiprazole	I
is	O
not	O
a	O
substrate	O
of	O
CYP1A1	O
,	O
CYP1A2	O
,	O
CYP2A6	O
,	O
CYP2B6	O
,	O
CYP2C8	O
,	O
CYP2C9	O
,	O
CYP2C19	O
,	O
or	O
CYP2E1	O
enzymes	O
.	O

Agents	O
that	O
induce	O
CYP3A4	O
(	O
eg	O
,	O
carbamazepine	B
)	O
could	O
cause	O
an	O
increase	O
in	O
aripiprazole	B
clearance	O
and	O
lower	O
blood	O
levels	O
.	O

Inhibitors	O
of	O
CYP3A4	O
(	O
eg	O
,	O
ketoconazole	B
)	O
or	O
CYP2D6	O
(	O
eg	O
,	O
quinidine	B
,	O
fluoxetine	B
,	O
or	O
paroxetine	B
)	O
can	O
inhibit	O
aripiprazole	B
elimination	O
and	O
cause	O
increased	O
blood	O
levels	O
.	O

Ketoconazole	B
:	O
Coadministration	O
of	O
ketoconazole	B
(	O
200	O
mg	O
/	O
day	O
for	O
14	O
days	O
)	O
with	O
a	O
15	O
-	O
mg	O
single	O
dose	O
of	O
aripiprazole	B
increased	O
the	O
AUC	O
of	O
aripiprazole	B
and	O
its	O
active	O
metabolite	O
by	O
63	O
%	O
and	O
77	O
%	O
,	O
respectively	O
.	O

When	O
concomitant	O
administration	O
of	O
ketoconazole	B
with	O
aripiprazole	B
occurs	O
,	O
aripiprazole	B
dose	O
should	O
be	O
reduced	O
to	O
one	O
-	O
half	O
of	O
its	O
normal	O
dose	O
.	O

Quinidine	B
:	O
Coadministration	O
of	O
a	O
10	O
-	O
mg	O
single	O
dose	O
of	O
aripiprazole	B
with	O
quinidine	B
(	O
166	O
mg	O
/	O
day	O
for	O
13	O
days	O
)	O
,	O
a	O
potent	O
inhibitor	O
of	O
CYP2D6	O
,	O
increased	O
the	O
AUC	O
of	O
aripiprazole	B
by	O
112	O
%	O
but	O
decreased	O
the	O
AUC	O
of	O
its	O
active	O
metabolite	O
,	O
dehydroaripiprazole	B
,	O
by	O
35	O
%	O
.	O

Aripiprazole	B
dose	O
should	O
be	O
reduced	O
to	O
one	O
-	O
half	O
of	O
its	O
normal	O
dose	O
when	O
concomitant	O
administration	O
of	O
quinidine	B
with	O
aripiprazole	B
occurs	O
.	O

Other	O
significant	O
inhibitors	O
of	O
CYP2D6	O
,	O
such	O
as	O
fluoxetine	B
or	O
paroxetine	B
,	O
would	O
be	O
expected	O
to	O
have	O
similar	O
effects	O
and	O
,	O
therefore	O
,	O
should	O
be	O
accompanied	O
by	O
similar	O
dose	O
reductions	O
.	O

Carbamazepine	B
:	O
Coadministration	O
of	O
carbamazepine	B
(	O
200	O
mg	O
BID	O
)	O
,	O
a	O
potent	O
CYP3A4	O
inducer	O
,	O
with	O
aripiprazole	B
(	O
30	O
mg	O
QD	O
)	O
resulted	O
in	O
an	O
approximate	O
70	O
%	O
decrease	O
in	O
Cmax	O
and	O
AUC	O
values	O
of	O
both	O
aripiprazole	B
and	O
its	O
active	O
metabolite	O
,	O
dehydro	O
-	O
aripiprazole	B
.	O

When	O
carbamazepine	B
is	O
added	O
to	O
aripiprazole	B
therapy	O
,	O
aripiprazole	B
dose	O
should	O
be	O
doubled	O
.	O

When	O
carbamazepine	B
is	O
withdrawn	O
from	O
the	O
combination	O
therapy	O
,	O
aripiprazole	B
dose	O
should	O
then	O
be	O
reduced	O
.	O

No	O
clinically	O
significant	O
effect	O
of	O
famotidine	B
,	O
valproate	B
,	O
or	O
lithium	B
was	O
seen	O
on	O
the	O
pharmacokinetics	O
of	O
aripiprazole	B
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
:	O
Drug	O
-	O
Drug	O
Interactions	O
)	O
.	O

Potential	O
for	O
ABILIFY	B
to	O
Affect	O
Other	O
Drugs	O
Aripiprazole	B
is	O
unlikely	O
to	O
cause	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
with	O
drugs	O
metabolized	O
by	O
cytochrome	O
P450	O
enzymes	O
.	O

In	O
in	O
vivo	O
studies	O
,	O
10	O
-	O
to	O
30	O
-	O
mg	O
/	O
day	O
doses	O
of	O
aripiprazole	B
had	O
no	O
significant	O
effect	O
on	O
metabolism	O
by	O
CYP2D6	O
(	O
dextromethorphan	B
)	O
,	O
CYP2C9	O
(	O
warfarin	B
)	O
,	O
CYP2C19	O
(	O
omeprazole	B
,	O
warfarin	B
)	O
,	O
and	O
CYP3A4	O
(	O
dextromethorphan	B
)	O
substrates	O
.	O

Additionally	O
,	O
aripiprazole	B
and	O
dehydroaripiprazole	B
did	O
not	O
show	O
potential	O
for	O
altering	O
CYP1A2	O
-	O
mediated	O
metabolism	O
in	O
vitro	O
.	O

Alcohol	B
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
aripiprazole	B
coadministered	O
with	O
ethanol	B
and	O
placebo	O
coadministered	O
with	O
ethanol	B
on	O
performance	O
of	O
gross	O
motor	O
skills	O
or	O
stimulus	O
response	O
in	O
healthy	O
subjects	O
.	O

As	O
with	O
most	O
psychoactive	O
medications	O
,	O
patients	O
should	O
be	O
advised	O
to	O
avoid	O
alcohol	B
while	O
taking	O
ABILIFY	B

Caution	O
is	O
advised	O
when	O
TRISENOX	B
is	O
coadministered	O
with	O
other	O
medications	O
that	O
can	O
prolong	O
the	O
QT	O
interval	O
(	O
e	O
.	O
g	O
.	O
certain	O
antiarrhythmics	B
or	O
thioridazine	B
)	O
or	O
lead	O
to	O
electrolyte	O
abnormalities	O
(	O
such	O
as	O
diuretics	B
or	O
amphotericin	B
B	I
)	O
.	O

Tissue	O
culture	O
and	O
animal	O
studies	O
indicate	O
that	O
ELSPAR	B
can	O
diminish	O
or	O
abolish	O
the	O
effect	O
of	O
methotrexate	B
on	O
malignant	O
cells	O
.	O
14	O
This	O
effect	O
on	O
methotrexate	B
activity	O
persists	O
as	O
long	O
as	O
plasma	O
asparagine	O
levels	O
are	O
suppressed	O
.	O

These	O
results	O
would	O
seem	O
to	O
dictate	O
against	O
the	O
clinical	O
use	O
of	O
methotrexate	B
with	O
ELSPAR	B
,	O
or	O
during	O
the	O
period	O
following	O
ELSPAR	B
therapy	O
when	O
plasma	O
asparagine	O
levels	O
are	O
below	O
normal	O
.	O

Uricosuric	B
Agents	I
:	O
Aspirin	B
may	O
decrease	O
the	O
effects	O
of	O
probenecid	B
,	O
sulfinpyrazone	B
,	O
and	O
phenylbutazone	B
.	O

Alcohol	B
:	O
Has	O
a	O
synergistic	O
effect	O
with	O
aspirin	B
in	O
causing	O
gastrointestinal	O
bleeding	O
.	O

Corticosteroids	B
:	O
Concomitant	O
administration	O
with	O
aspirin	B
may	O
increase	O
the	O
risk	O
of	O
gastrointestinal	O
ulceration	O
and	O
may	O
reduce	O
serum	O
salicylate	O
levels	O
.	O

Pyrazolone	B
Derivatives	I
(	O
phenylbutazone	B
,	O
oxyphenbutazone	B
,	O
and	O
possibly	O
dipyrone	B
)	O
:	O
Concomitant	O
administration	O
with	O
aspirin	B
may	O
increase	O
the	O
risk	O
of	O
gastrointestinal	O
ulceration	O
.	O

Nonsteroidal	B
Antiinflammatory	I
Agents	O
:	O
Aspirin	B
is	O
contraindicated	O
in	O
patients	O
who	O
are	O
hypersensitive	O
to	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
agents	O
.	O

Urinary	O
Alkalinizers	O
:	O
Decrease	O
aspirin	B
effectiveness	O
by	O
increasing	O
the	O
rate	O
of	O
salicylate	B
renal	O
excretion	O
.	O

Phenobarbital	B
:	O
Decreases	O
aspirin	B
effectiveness	O
by	O
enzyme	O
induction	O
.	O

Phenytoin	B
:	O
Serum	O
phenytoin	B
levels	O
may	O
be	O
increased	O
by	O
aspirin	B
.	O

Propranolol	B
:	O
May	O
decrease	O
aspirins	B
anti	O
-	O
inflammatory	O
action	O
by	O
competing	O
for	O
the	O
same	O
receptors	O
.	O

Antacids	B
:	O
Enteric	O
Coated	O
Aspirin	B
should	O
not	O
be	O
given	O
concurrently	O
with	O
antacids	B
,	O
since	O
an	O
increase	O
in	O
the	O
pH	O
of	O
the	O
stomach	O
may	O
effect	O
the	O
enteric	O
coating	O
of	O
the	O
tablets	O
.	O

Ketoconazole	B
/	O
Itraconazole	B
,	O
Macrolides	B
,	O
Including	O
Erythromycin	B

Catecholamine	O
-	O
depleting	O
drugs	O
(	O
eg	O
,	O
reserpine	B
)	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	O
-	O
blocking	O
agents	O
.	O

Calcium	B
channel	I
blockers	I
may	O
also	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
TENORMIN	B
.	O

Beta	B
blockers	I
may	O
exacerbate	O
the	O
rebound	O
hypertension	O
which	O
can	O
follow	O
the	O
withdrawal	O
of	O
clonidine	B
.	O

If	O
the	O
two	O
drugs	O
are	O
coadministered	O
,	O
the	O
beta	B
blocker	I
should	O
be	O
withdrawn	O
several	O
days	O
before	O
the	O
gradual	O
withdrawal	O
of	O
clonidine	B
.	O

If	O
replacing	O
clonidine	B
by	O
beta	B
-	O
blocker	O
therapy	O
,	O
the	O
introduction	O
of	O
beta	B
blockers	I
should	O
be	O
delayed	O
for	O
several	O
days	O
after	O
clonidine	B
administration	O
has	O
stopped	O
.	O

Concomitant	O
use	O
of	O
prostaglandin	O
synthase	O
inhibiting	O
drugs	O
,	O
eg	O
,	O
indomethacin	B
,	O
may	O
decrease	O
the	O
hypotensive	O
effects	O
of	O
beta	B
blockers	I
.	O

Information	O
on	O
concurrent	O
usage	O
of	O
atenolol	B
and	O
aspirin	B
is	O
limited	O
.	O

Data	O
from	O
several	O
studies	O
,	O
ie	O
,	O
TIMI	O
-	O
II	O
,	O
ISIS	O
-	O
2	O
,	O
currently	O
do	O
not	O
suggest	O
any	O
clinical	O
interaction	O
between	O
aspirin	B
and	O
beta	B
blockers	I
in	O
the	O
acute	O
myocardial	O
infarction	O
setting	O
.	O

Drug	O
-	O
Drug	O
Interactions	O
Albuterol	B
-	O
STRATTERA	B
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
being	O
treated	O
with	O
systemically	O
-	O
administered	O
(	O
oral	O
or	O
intravenous	O
)	O
albuterol	B
(	O
or	O
other	O
beta2	B
agonists	I
)	O
because	O
the	O
action	O
of	O
albuterol	B
on	O
the	O
cardiovascular	O
system	O
can	O
be	O
potentiated	O
resulting	O
in	O
increases	O
in	O
heart	O
rate	O
and	O
blood	O
pressure	O
.	O

CYP2D6	O
inhibitors	O
-	O
Atomoxetine	B
is	O
primarily	O
metabolized	O
by	O
the	O
CYP2D6	O
pathway	O
to	O
4	O
-	O
hydroxyatomoxetine	O
.	O

Dosage	O
adjustment	O
of	O
STRATTERA	B
may	O
be	O
necessary	O
when	O
coadministered	O
with	O
CYP2D6	O
inhibitors	O
,	O
e	O
.	O
g	O
.	O
,	O
paroxetine	B
,	O
fluoxetine	B
,	O
and	O
quinidine	B
.	O

In	O
EM	O
individuals	O
treated	O
with	O
paroxetine	B
or	O
fluoxetine	B
,	O
the	O
AUC	O
of	O
atomoxetine	B
is	O
approximately	O
6	O
-	O
to	O
8	O
-	O
fold	O
and	O
Css	O
,	O
max	O
is	O
about	O
3	O
-	O
to	O
4	O
-	O
fold	O
greater	O
than	O
atomoxetine	B
alone	O
.	O

The	O
risk	O
of	O
myopathy	O
during	O
treatment	O
with	O
drugs	O
of	O
this	O
class	O
is	O
increased	O
with	O
concurrent	O
administration	O
of	O
cyclosporine	B
,	O
fibric	B
acid	I
derivatives	I
,	O
niacin	B
(	O
nicotinic	B
acid	I
)	O
,	O
erythromycin	B
,	O
azole	B
antifungals	I
.	O

Antacid	B
:	O
When	O
atorvastatin	B
and	O
Maalox	B
TC	I
suspension	O
were	O
coadministered	O
,	O
plasma	O
concentrations	O
of	O
atorvastatin	B
decreased	O
approximately	O
35	O
%	O
.	O

Antipyrine	B
:	O
Because	O
atorvastatin	B
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
antipyrine	B
,	O
interactions	O
with	O
other	O
drugs	B
metabolized	O
via	O
the	O
same	O
cytochrome	O
isozymes	O
are	O
not	O
expected	O
.	O

Colestipol	B
:	O
Plasma	O
concentrations	O
of	O
atorvastatin	B
decreased	O
approximately	O
25	O
%	O
when	O
colestipol	B
and	O
atorvastatin	B
were	O
coadministered	O
.	O

However	O
,	O
LDL	O
-	O
C	O
reduction	O
was	O
greater	O
when	O
atorvastatin	B
and	O
colestipol	B
were	O
coadministered	O
than	O
when	O
either	O
drug	O
was	O
given	O
alone	O
.	O

Cimetidine	B
:	O
Atorvastatin	B
plasma	O
concentrations	O
and	O
LDL	O
-	O
C	O
reduction	O
were	O
not	O
altered	O
by	O
coadministration	O
of	O
cimetidine	B
.	O

Digoxin	B
:	O
When	O
multiple	O
doses	O
of	O
atorvastatin	B
and	O
digoxin	B
were	O
coadministered	O
,	O
steady	O
-	O
state	O
plasma	O
digoxin	B
concentrations	O
increased	O
by	O
approximately	O
20	O
%	O
.	O

Erythromycin	B
:	O
In	O
healthy	O
individuals	O
,	O
plasma	O
concentrations	O
of	O
atorvastatin	B
increased	O
approximately	O
40	O
%	O
with	O
coadministration	O
of	O
atorvastatin	B
and	O
erythromycin	B
,	O
a	O
known	O
inhibitor	O
of	O
cytochrome	O
P450	O
3A4	O
.	O

Oral	O
Contraceptives	B
:	O
Coadministration	O
of	O
atorvastatin	B
and	O
an	O
oral	O
contraceptive	B
increased	O
AUC	O
values	O
for	O
norethindrone	B
and	O
ethinyl	B
estradiol	I
by	O
approximately	O
30	O
%	O
and	O
20	O
%	O
.	O

These	O
increases	O
should	O
be	O
considered	O
when	O
selecting	O
an	O
oral	O
contraceptive	B
for	O
a	O
woman	O
taking	O
atorvastatin	B
.	O

Warfarin	B
:	O
Atorvastatin	B
had	O
no	O
clinically	O
significant	O
effect	O
on	O
prothrombin	O
time	O
when	O
administered	O
to	O
patients	O
receiving	O
chronic	O
warfarin	B
treatment	O
.	O

Caution	O
should	O
be	O
exercised	O
if	O
an	O
HMG	O
-	O
CoA	O
reductase	B
inhibitor	I
is	O
administered	O
concomitantly	O
with	O
drugs	O
that	O
may	O
decrease	O
the	O
levels	O
or	O
activity	O
of	O
endogenous	O
steroid	O
hormones	O
,	O
such	O
as	O
ketoconazole	B
,	O
spironolactone	B
,	O
and	O
cimetidine	B
.	O

The	O
extent	O
of	O
plasma	O
protein	O
binding	O
of	O
atovaquone	B
in	O
human	O
plasma	O
is	O
not	O
affected	O
by	O
the	O
presence	O
of	O
therapeutic	O
concentrations	O
of	O
phenytoin	B
(	O
15	O
mcg	O
/	O
mL	O
)	O
,	O
nor	O
is	O
the	O
binding	O
of	O
phenytoin	B
affected	O
by	O
the	O
presence	O
of	O
atovaquone	B
.	O

Rifampin	B
:	O
Coadministration	O
of	O
rifampin	B
and	O
MEPRON	B
Suspension	O
results	O
in	O
a	O
significant	O
decrease	O
in	O
average	O
steady	O
-	O
state	O
plasma	O
atovaquone	B
concentrations	O
.	O

Alternatives	O
to	O
rifampin	B
should	O
be	O
considered	O
during	O
the	O
course	O
of	O
PCP	O
treatment	O
with	O
MEPRON	B
.	O

Rifabutin	B
,	O
another	O
rifamycin	B
,	O
is	O
structurally	O
similar	O
to	O
rifampin	B
and	O
may	O
possibly	O
have	O
some	O
of	O
the	O
same	O
drug	O
interactions	O
as	O
rifampin	B
.	O

No	O
interaction	O
trials	O
have	O
been	O
conducted	O
with	O
MEPRON	B
and	O
rifabutin	B
.	O

Drugs	O
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
TRACRIUM	B
include	O
:	O
enflurane	B
;	O

certain	O
antibiotics	B
,	O
especially	O
the	O
aminoglycosides	B
and	O
polymyxins	B
;	O

Drugs	O
which	O
may	O
enhance	O
the	O
neuromuscular	O
blocking	O
action	O
of	O
TRACRIUM	B
include	O
:	O
enflurane	B
;	O
isoflurane	B
;	O
halothane	B
;	O
certain	O
antibiotics	B
,	O
especially	O
the	O
aminoglycosides	B
and	O
polymyxins	B
;	O
lithium	B
;	O
magnesium	B
salts	O
;	O
procainamide	B
;	O
and	O
quinidine	B
.	O

The	O
prior	O
administration	O
of	O
succinylcholine	B
does	O
not	O
enhance	O
the	O
duration	O
,	O
but	O
quickens	O
the	O
onset	O
and	O
may	O
increase	O
the	O
depth	O
,	O
of	O
neuromuscular	O
block	O
induced	O
by	O
TRACRIUM	B
.	O

TRACRIUM	B
should	O
not	O
be	O
administered	O
until	O
a	O
patient	O
has	O
recovered	O
from	O
succinylcholine	B
-	O
induced	O
neuromuscular	O
block	O
.	O

When	O
atropine	B
and	O
pralidoxime	B
are	O
used	O
together	O
,	O
the	O
signs	O
of	O
atropinization	O
(	O
flushing	O
,	O
mydriasis	O
,	O
tachycardia	O
,	O
dryness	O
of	O
the	O
mouth	O
and	O
nose	O
)	O
may	O
occur	O
earlier	O
than	O
might	O
be	O
expected	O
than	O
when	O
atropine	B
is	O
used	O
alone	O
because	O
pralidoxime	B
may	O
potentiate	O
the	O
effect	O
of	O
atropine	B
.	O

The	O
following	O
precautions	O
should	O
be	O
kept	O
in	O
mind	O
in	O
the	O
treatment	O
of	O
anticholinesterase	O
poisoning	O
although	O
they	O
do	O
not	O
bear	O
directly	O
on	O
the	O
use	O
of	O
atropine	B
and	O
pralidoxime	B
.	O

Since	O
barbiturates	B
are	O
potentiated	O
by	O
the	O
anticholinesterases	B
,	O
they	O
should	O
be	O
used	O
cautiously	O
in	O
the	O
treatment	O
of	O
convulsions	O
.	O

Auranofin	B
should	O
be	O
avoided	O
by	O
patients	O
with	O
a	O
history	O
of	O
serious	O
reaction	O
to	O
any	O
gold	B
medication	I
,	O
including	O
Solganal	B
and	O
Myochrysine	B
.	O

Auranofin	B
should	O
not	O
be	O
used	O
together	O
with	O
penicillamine	B
(	O
Depen	B
,	O
Cuprimine	B
)	O
,	O
another	O
arthritis	O
medication	O
.	O

MAO	B
inhibitors	I
prolong	O
and	O
intensify	O
the	O
effects	O
of	O
antihistamines	B
.	O

Concomitant	O
use	O
of	O
antihistamines	B
with	O
alcohol	B
,	O
tricyclic	B
antidepressants	I
,	O
barbiturates	B
,	O
or	O
other	O
central	B
nervous	I
system	I
depressants	I
may	O
have	O
an	O
additive	O
effect	O
.	O

When	O
sympathomimetic	B
drugs	I
are	O
given	O
to	O
patients	O
receiving	O
monoamine	B
oxidase	I
inhibitors	I
,	O
hypertensive	O
reactions	O
,	O
including	O
hypertensive	O
crises	O
,	O
may	O
occur	O
.	O

The	O
antihypertensive	O
effects	O
of	O
methyldopa	B
,	O
mecamylamine	B
,	O
reserpine	B
,	O
and	O
veratrum	B
alkaloids	I
may	O
be	O
reduced	O
by	O
sympathomimetics	B
.	O

Beta	O
-	O
adrenergic	O
blocking	B
agents	I
may	O
also	O
interact	O
with	O
sympathomimetics	B
.	O

Increased	O
ectopic	O
pacemaker	O
activity	O
can	O
occur	O
when	O
pseudoephedrine	B
is	O
used	O
concomitantly	O
with	O
digitalis	B
.	O

Antacids	B
increase	O
the	O
rate	O
of	O
absorption	O
of	O
pseudoephedrine	B
,	O
while	O
kaolin	B
decreases	O
it	O
.	O

Use	O
with	O
Allopurinol	B
:	O
The	O
principal	O
pathway	O
for	O
detoxification	O
of	O
azathioprine	B
is	O
inhibited	O
by	O
allopurinol	B
.	O

Patients	O
receiving	O
azathioprine	B
and	O
allopurinol	B
concomitantly	O
should	O
have	O
a	O
dose	O
reduction	O
of	O
azathioprine	B
,	O
to	O
approximately	O
1	O
/	O
3	O
to	O
1	O
/	O
4	O
the	O
usual	O
dose	O
.	O

Use	O
with	O
Angiotensln	B
Converting	I
Enzyme	I
Inhibitors	I
:	O
The	O
use	O
of	O
angiotensin	B
converting	I
enzyme	I
inhibitors	I
to	O
control	O
hypertension	O
in	O
patients	O
on	O
azathioprine	B
has	O
been	O
reported	O
to	O
induce	O
severe	O
leukopenia	O
.	O

Co	O
-	O
administration	O
of	O
nelfinavir	B
at	O
steady	O
-	O
state	O
with	O
a	O
single	O
dose	O
of	O
azithromycin	B
.	O

Co	O
-	O
administration	O
of	O
nelfinavir	B
at	O
steady	O
-	O
state	O
with	O
a	O
single	O
dose	O
of	O
azithromycin	B
(	O
2	O
x	O
600	O
mg	O
tablets	O
)	O
results	O
in	O
increased	O
azithromycin	B
serum	O
concentrations	O
.	O

Although	O
a	O
dose	O
adjustment	O
of	O
azithromycin	B
is	O
not	O
recommended	O
when	O
administered	O
in	O
combination	O
with	O
nelfinavir	B
,	O
close	O
monitoring	O
for	O
known	O
side	O
effects	O
of	O
azithromycin	B
,	O
such	O
as	O
liver	O
enzyme	O
abnormalities	O
and	O
hearing	O
impairment	O
,	O
is	O
warranted	O
.	O

Azithromycin	B
did	O
not	O
affect	O
the	O
prothrombin	O
time	O
response	O
to	O
a	O
single	O
dose	O
of	O
warfarin	B
.	O

However	O
,	O
prudent	O
medical	O
practice	O
dictates	O
careful	O
monitoring	O
of	O
prothrombin	O
time	O
in	O
all	O
patients	O
treated	O
with	O
azithromycin	B
and	O
warfarin	B
concomitantly	O
.	O

Concurrent	O
use	O
of	O
macrolides	B
and	O
warfarin	B
in	O
clinical	O
practice	O
has	O
been	O
associated	O
with	O
increased	O
anticoagulant	O
effects	O
.	O

When	O
used	O
in	O
therapeutic	O
doses	O
,	O
azithromycin	B
had	O
a	O
modest	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
atorvastatin	B
,	O
carbamazepine	B
,	O
cetirizine	B
,	O
didanosine	B
,	O
efavirenz	B
,	O
fluconazole	B
,	O
indinavir	B
,	O
midazolam	B
,	O
rifabutin	B
,	O
sildenafil	B
,	O
theophylline	B
(	O
intravenous	O
and	O
oral	O
)	O
,	O
triazolam	B
,	O
trimethoprim	B
/	O
sulfamethoxazole	B
or	O
zidovudine	B
.	O

Co	O
-	O
administration	O
with	O
efavirenz	B
or	O
fluconazole	B
had	O
a	O
modest	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
azithromycin	B
.	O

Until	O
further	O
data	O
are	O
developed	O
regarding	O
drug	O
interactions	O
when	O
azithromycin	B
and	O
these	O
drugs	O
are	O
used	O
concomitantly	O
,	O
careful	O
monitoring	O
of	O
patients	O
is	O
advised	O
:	O
Digoxin	B
elevated	O
digoxin	B
concentrations	O
.	O

Ergotamine	B
or	O
dihydroergotamine	B
acute	O
ergot	O
toxicity	O
characterized	O
by	O
severe	O
peripheral	O
vasospasm	O
and	O
dysesthesia	O
.	O

Cyclosporine	B
,	O
hexobarbital	B
and	O
phenytoin	B
concentrations	O
.	O

Azlocillin	B
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
amikacin	B
,	O
ciprofloxacin	B
,	O
gentamicin	B
,	O
netilmicin	B
,	O
or	O
tobramycin	B
.	O

Interactions	O
attributed	O
to	O
the	O
combined	O
use	O
of	O
baclofen	B
injection	O
and	O
epidural	O
morphine	B
include	O
hypotension	O
and	O
dyspnea	O
.	O

SIDE	O
EFFECTS	O
(	O
KEMSTRO	B
)	O
The	O
most	O
common	O
adverse	O
reaction	O
during	O
treatment	O
with	O
baclofen	B
is	O
transient	O
drowsiness	O
(	O
10	O
-	O
63	O
%	O
)	O
.	O

The	O
adverse	O
experience	O
profile	O
seen	O
with	O
KEMSTROTM	B
was	O
similar	O
to	O
that	O
seen	O
with	O
baclofen	B
tablets	O
.	O

No	O
drug	O
interaction	O
studies	O
have	O
been	O
conducted	O
for	O
COLAZAL	B
,	O
however	O
the	O
use	O
of	O
orally	O
administered	O
antibiotics	B
could	O
,	O
theoretically	O
,	O
interfere	O
with	O
the	O
release	O
of	O
mesalamine	B
in	O
the	O
colon	O
.	O

No	O
dose	O
adjustment	O
is	O
necessary	O
when	O
Simulect	B
is	O
added	O
to	O
triple	O
-	O
immunosuppression	O
regimens	O
including	O
cyclosporine	B
,	O
corticosteroids	B
,	O
and	O
either	O
azathioprine	B
or	O
mycophenolate	B
mofetil	I
.	O

Total	O
body	O
clearance	O
of	O
Simulect	B
was	O
reduced	O
by	O
an	O
average	O
22	O
%	O
and	O
51	O
%	O
when	O
azathioprine	B
and	O
mycophenolate	B
mofetil	I
,	O
respectively	O
,	O
were	O
added	O
to	O
a	O
regimen	O
consisting	O
of	O
cyclosporine	B
,	O
USP	O
(	O
MODIFIED	O
)	O
and	O
corticosteroids	B
.	O

Nonetheless	O
,	O
the	O
range	O
of	O
individual	O
Simulect	B
clearance	O
values	O
in	O
the	O
presence	O
of	O
azathioprine	B
(	O
12	O
-	O
57	O
mL	O
/	O
h	O
)	O
or	O
mycophenolate	B
mofetil	I
(	O
7	O
-	O
54	O
mL	O
/	O
h	O
)	O
did	O
not	O
extend	O
outside	O
the	O
range	O
observed	O
with	O
dual	O
therapy	O
(	O
10	O
-	O
78	O
mL	O
/	O
h	O
)	O
.	O

The	O
following	O
medications	O
have	O
been	O
administered	O
in	O
clinical	O
trials	O
with	O
Simulect	B
with	O
no	O
increase	O
in	O
adverse	O
reactions	O
:	O
ATG	O
/	O
ALG	O
,	O
azathioprine	B
,	O
corticosteroids	B
,	O
cyclosporine	B
,	O
mycophenolate	B
mofetil	I
,	O
and	O
muromonab	O
-	O
CD3	O
.	O

Albuterol	B
,	O
Antihistamines	B
,	O
antidiabetic	B
drugs	I
,	O
diuretics	B
,	O
digitalis	B
.	O

Diuretics	B
:	O
Patients	O
on	O
diuretics	B
,	O
especially	O
those	O
in	O
whom	O
diuretic	O
therapy	O
was	O
recently	O
instituted	O
,	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
therapy	O
with	O
Lotensin	B
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
Lotensin	B
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	B
or	O
increasing	O
the	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
Lotensin	B
.	O

Potassium	B
Supplements	O
and	O
Potassium	B
-	O
Sparing	O
Diuretics	B
Lotensin	O
can	O
attenuate	O
potassium	O
loss	O
caused	O
by	O
thiazide	B
diuretics	I
.	O

Potassium	O
-	O
sparing	O
diuretics	B
(	O
spironolactone	B
,	O
amiloride	B
,	O
triamterene	B
,	O
and	O
others	O
)	O
or	O
potassium	B
supplements	O
can	O
increase	O
the	O
risk	O
of	O
hyperkalemia	O
.	O

Oral	O
Anticoagulants	B
Interaction	O
studies	O
with	O
warfarin	B
and	O
acenocoumarol	B
failed	O
to	O
identify	O
any	O
clinically	O
important	O
effects	O
on	O
the	O
serum	O
concentrations	O
or	O
clinical	O
effects	O
of	O
these	O
anticoagulants	B
.	O

Lithium	B
:	O
Increased	O
serum	O
lithium	B
levels	O
and	O
symptoms	O
of	O
lithium	B
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
ACE	B
inhibitors	I
during	O
therapy	O
with	O
lithium	B
.	O

If	O
a	O
diuretic	B
is	O
also	O
used	O
,	O
the	O
risk	O
of	O
lithium	B
toxicity	O
may	O
be	O
increased	O
.	O

Other	O
No	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
occurred	O
when	O
Lotensin	B
was	O
administered	O
concomitantly	O
with	O
hydrochlorothiazide	B
,	O
chlorthalidone	B
,	O
furosemide	B
,	O
digoxin	B
,	O
propranolol	B
,	O
atenolol	B
,	O
naproxen	B
,	O
or	O
cimetidine	B
.	O

Lotensin	B
has	O
been	O
used	O
concomitantly	O
with	O
beta	O
-	O
adrenergic	O
-	O
blocking	O
agents	B
,	O
calcium	O
-	O
channel	O
-	O
blocking	O
agents	B
,	O
diuretics	B
,	O
digoxin	B
,	O
and	O
hydralazine	B
,	O
without	O
evidence	O
of	O
clinically	O
important	O
adverse	O
interactions	O
.	O

Benazepril	B
,	O
like	O
other	O
ACE	B
inhibitors	I
,	O
has	O
had	O
less	O
than	O
additive	O
effects	O
with	O
beta	O
-	O
adrenergic	O
blockers	B
,	O
presumably	O
because	O
both	O
drugs	O
lower	O
blood	O
pressure	O
by	O
inhibiting	O
parts	O
of	O
the	O
renin	O
-	O
angiotensin	O
system	O

May	O
interact	O
with	O
the	O
following	O
:	O
cholestyramine	B
,	O
colestipol	B
(	O
use	O
with	O
thiazide	B
diuretics	I
may	O
prevent	O
the	O
diuretic	B
from	O
working	O
properly	O
;	O

Bentiromide	B
may	O
interact	O
with	O
acetaminophen	B
(	O
e	O
.	O
g	O
.	O
,	O
Tylenol	B
)	O
,	O
chloramphenicol	B
(	O
e	O
.	O
g	O
.	O
,	O
Chloromycetin	B
)	O
,	O
local	O
anesthetics	B
(	O
e	O
.	O
g	O
.	O
,	O
benzocaine	B
and	O
lidocaine	B
)	O
,	O
para	O
-	O
aminobenzoic	O
acid	B
(	O
PABA	B
)	O
-	O
containing	O
preparations	O
(	O
e	O
.	O
g	O
.	O
,	O
sunscreens	O
and	O
some	O
multivitamins	B
)	O
,	O
procainamide	B
(	O
e	O
.	O
g	O
.	O
,	O
Pronestyl	B
)	O
,	O
sulfonamides	B
(	O
sulfa	O
medicines	O
)	O
,	O
thiazide	B
diuretics	I
(	O
use	O
of	O
these	O
medicines	O
during	O
the	O
test	O
period	O
will	O
affect	O
the	O
test	O
results	O
)	O
,	O
and	O
pancreatic	O
supplements	O
(	O
use	O
of	O
pancreatic	O
supplements	O
may	O
give	O
false	O
test	O
results	O
)	O
.	O

Hypertensive	O
crises	O
have	O
resulted	O
when	O
sympathomimetic	B
amines	I
have	O
been	O
used	O
concomitantly	O
within14	O
days	O
following	O
use	O
of	O
monoamine	B
oxidase	I
inhibitors	I
.	O

DIDREX	B
should	O
not	O
be	O
used	O
concomitantly	O
with	O
other	O
CNS	B
stimulants	I
.	O

Amphetamines	B
may	O
decrease	O
the	O
hypotensive	O
effect	O
of	O
antihypertensives	B
.	O

Amphetamines	B
may	O
enhance	O
the	O
effects	O
of	O
tricyclic	B
antidepressants	I
.	O

Urinary	B
acidifying	I
agents	O
decrease	O
blood	O
levels	O
and	O
increase	O
excretion	O
of	O
amphetamines	B
.	O

Benzthiazide	B
may	O
interact	O
with	O
alcohol	B
,	O
blood	B
thinners	O
,	O
decongestant	B
drugs	I
(	O
allergy	O
,	O
cold	O
,	O
and	O
sinus	O
medicines	O
)	O
,	O
diabetic	O
drugs	B
,	O
lithium	B
,	O
norepinephrine	B
,	O
NSAIDs	B
like	O
Aleve	B
or	O
Ibuprofen	B
,	O
and	O
high	O
blood	B
pressure	O
medications	O
.	O

Antipsychotic	B
drugs	I
such	O
as	O
phenothiazines	B
or	O
haloperidol	B
;	O

Nitrates	B
:	O
The	O
concomitant	O
use	O
of	O
Bepridil	B
with	O
long	O
-	O
and	O
short	O
-	O
acting	O
nitrates	B
has	O
been	O
safely	O
tolerated	O
in	O
patients	O
with	O
stable	O
angina	O
pectoris	O
.	O

Sublingual	O
nitroglycerin	B
may	O
be	O
taken	O
if	O
necessary	O
for	O
the	O
control	O
of	O
acute	O
angina	O
attacks	O
during	O
Bepridil	B
therapy	O
.	O

Beta	O
-	O
blocking	O
Agents	B
:	O
The	O
concomitant	O
use	O
of	O
Bepridil	B
and	O
beta	O
-	O
blocking	O
agents	B
has	O
been	O
well	O
tolerated	O
in	O
patients	O
with	O
stable	O
angina	O
.	O

Digoxin	B
:	O
In	O
controlled	O
studies	O
in	O
healthy	O
volunteers	O
,	O
bepridil	B
hydrochloride	I
either	O
had	O
no	O
effect	O
(	O
one	O
study	O
)	O
or	O
was	O
associated	O
with	O
modest	O
increases	O
,	O
about	O
30	O
%	O
(	O
two	O
studies	O
)	O
in	O
steady	O
-	O
state	O
serum	O
digoxin	B
concentrations	O
.	O

Limited	O
clinical	O
data	O
in	O
angina	O
patients	O
receiving	O
concomitant	O
bepridil	B
hydrochloride	I
and	O
digoxin	B
therapy	O
indicate	O
no	O
discernible	O
changes	O
in	O
serum	O
digoxin	B
levels	O
.	O

Oral	O
Hypoglycemics	B
:	O
Bepridil	B
has	O
been	O
safely	O
used	O
in	O
diabetic	O
patients	O
without	O
significantly	O
lowering	O
their	O
blood	O
glucose	O
levels	O
or	O
altering	O
their	O
need	O
for	O
insulin	B
or	O
oral	O
hypoglycemic	B
agents	I
.	O

In	O
general	O
,	O
these	O
are	O
drugs	O
that	O
have	O
one	O
or	O
more	O
pharmacologic	O
activities	O
similar	O
to	O
bepridil	B
hydrochloride	I
,	O
including	O
anti	O
-	O
arrhythmic	O
agents	B
such	O
as	O
quinidine	B
and	O
procainamide	B
,	O
cardiac	B
glycosides	I
and	O
tricyclic	B
anti	O
-	O
depressants	O
.	O

Anti	O
-	O
arrhythmics	O
and	O
tricyclic	B
anti	O
-	O
depressants	O
could	O
exaggerate	O
the	O
prolongation	O
of	O
the	O
QT	O
interval	O
observed	O
with	O
bepridil	B
hydrochloride	I
.	O

Cardiac	B
glycosides	I
could	O
exaggerate	O
the	O
depression	O
of	O
AV	O
nodal	O
conduction	O
observed	O
with	O
bepridil	B
hydrochloride	I
.	O

The	O
following	O
drugs	O
have	O
been	O
coadministered	O
with	O
Kerlone	B
and	O
have	O
not	O
altered	O
its	O
pharmacokinetics	O
:	O
cimetidine	B
,	O
nifedipine	B
,	O
chlorthalidone	B
,	O
and	O
hydrochlorothiazide	B
.	O

Concomitant	O
administration	O
of	O
Kerlone	B
with	O
the	O
oral	O
anticoagulant	B
warfarin	I
has	O
been	O
shown	O
not	O
to	O
potentiate	O
the	O
anticoagulant	B
effect	O
of	O
warfarin	B
.	O

Catecholamine	O
-	O
depleting	O
drugs	O
(	O
e	O
.	O
g	O
.	O
,	O
reserpine	B
)	O
may	O
have	O
an	O
additive	O
effect	O
when	O
given	O
with	O
beta	O
-	O
blocking	O
agents	O
.	O

Should	O
it	O
be	O
decided	O
to	O
discontinue	O
therapy	O
in	O
patients	O
receiving	O
beta	O
-	O
blockers	O
and	O
clonidine	B
concurrently	O
,	O
the	O
beta	O
-	O
blocker	O
should	O
be	O
discontinued	O
slowly	O
over	O
several	O
days	O
before	O
the	O
gradual	O
withdrawal	O
of	O
clonidine	B
.	O

Literature	O
reports	O
suggest	O
that	O
oral	O
calcium	B
antagonists	I
may	O
be	O
used	O
in	O
combination	O
with	O
beta	O
-	O
adrenergic	O
blocking	B
agents	I
when	O
heart	O
function	O
is	O
normal	O
,	O
but	O
should	O
be	O
avoided	O
in	O
patients	O
with	O
impaired	O
cardiac	O
function	O
.	O

Hypotension	O
,	O
AV	O
conduction	O
disturbances	O
,	O
and	O
left	O
ventricular	O
failure	O
have	O
been	O
reported	O
in	O
some	O
patients	O
receiving	O
beta	O
-	O
adrenergic	O
blocking	B
agents	I
when	O
an	O
oral	O
calcium	B
antagonist	I
was	O
added	O
to	O
the	O
treatment	O
regimen	O
.	O

Hypotension	O
was	O
more	O
likely	O
to	O
occur	O
if	O
the	O
calcium	B
antagonist	I
were	O
a	O
dihydropyridine	B
derivative	I
,	O
e	O
.	O
g	O
.	O
,	O
nifedipine	B
,	O
while	O
left	O
ventricular	O
failure	O
and	O
AV	O
conduction	O
disturbances	O
,	O
including	O
complete	O
heart	O
block	O
,	O
were	O
more	O
likely	O
to	O
occur	O
with	O
either	O
verapamil	B
or	O
diltiazem	B
.	O

Risk	O
of	O
Anaphylactic	O
Reaction	O
:	O
Although	O
it	O
is	O
known	O
that	O
patients	O
on	O
beta	O
-	O
blockers	O
may	O
be	O
refractory	O
to	O
epinephrine	B
in	O
the	O
treatment	O
of	O
anaphylactic	O
shock	O
,	O
beta	O
-	O
blockers	O
can	O
,	O
in	O
addition	O
,	O
interfere	O
with	O
the	O
modulation	O
of	O
allergic	O
reaction	O
and	O
lead	O
to	O
an	O
increased	O
severity	O
and	O
/	O
or	O
frequency	O
of	O
attacks	O
.	O

In	O
Study	O
1	O
,	O
patients	O
with	O
colorectal	O
cancer	O
were	O
given	O
irinotecan	B
/	O
5	O
-	O
FU	O
/	O
leucovorin	B
(	O
bolus	O
-	O
IFL	O
)	O
with	O
or	O
without	O
AVASTIN	B
.	O

Irinotecan	B
concentrations	O
were	O
similar	O
in	O
patients	O
receiving	O
bolus	O
-	O
IFL	O
alone	O
and	O
in	O
combination	O
with	O
AVASTIN	B
.	O

The	O
concentrations	O
of	O
SN38	B
,	O
the	O
active	O
metabolite	O
of	O
irinotecan	B
,	O
were	O
on	O
average	O
33	O
%	O
higher	O
in	O
patients	O
receiving	O
bolus	O
-	O
IFL	O
in	O
combination	O
with	O
AVASTIN	B
when	O
compared	O
with	O
bolus	O
-	O
IFL	O
alone	O
.	O

Due	O
to	O
high	O
inter	O
-	O
patient	O
variability	O
and	O
limited	O
sampling	O
,	O
the	O
extent	O
of	O
the	O
increase	O
in	O
SN38	B
levels	O
in	O
patients	O
receiving	O
concurrent	O
irinotecan	B
and	O
AVASTIN	B
is	O
uncertain	O
.	O

On	O
the	O
basis	O
of	O
the	O
metabolism	O
of	O
bexarotene	B
by	O
cytochrome	O
P450	O
3A4	O
,	O
ketoconazole	B
,	O
itraconazole	B
,	O
erythromycin	B
,	O
gemfibrozil	B
,	O
grapefruit	O
juice	O
,	O
and	O
other	O
inhibitors	O
of	O
cytochrome	O
P450	O
3A4	O
would	O
be	O
expected	O
to	O
lead	O
to	O
an	O
increase	O
in	O
plasma	O
bexarotene	B
concentrations	O
.	O

Furthermore	O
,	O
rifampin	B
,	O
phenytoin	B
,	O
phenobarbital	B
,	O
and	O
other	O
inducers	O
of	O
cytochrome	O
P450	O
3A4	O
may	O
cause	O
a	O
reduction	O
in	O
plasma	O
bexarotene	B
concentrations	O
.	O

Concomitant	O
administration	O
of	O
Targretin	B
capsules	O
and	O
gemfibrozil	B
resulted	O
in	O
substantial	O
increases	O
in	O
plasma	O
concentrations	O
of	O
bexarotene	B
,	O
probably	O
at	O
least	O
partially	O
related	O
to	O
cytochrome	O
P450	O
3A4	O
inhibition	O
by	O
gemfibrozil	B
.	O

Under	O
similar	O
conditions	O
,	O
bexarotene	B
concentrations	O
were	O
not	O
affected	O
by	O
concomitant	O
atorvastatin	B
administration	O
.	O

Concomitant	O
administration	O
of	O
gemfibrozil	B
with	O
Targretin	B
capsules	O
is	O
not	O
recommended	O
.	O

When	O
Bezalip	B
or	O
Bezalip	B
retard	I
is	O
used	O
at	O
the	B
same	O
time	O
as	O
other	O
medicines	O
or	O
substances	O
the	B
following	O
interactions	O
must	O
be	O
taken	O
into	O
account	O
:	O
-	O
Bezalip	B
and	O
Bezalip	B
retard	I
may	O
enhance	O
the	B
action	O
of	B
anticoagulants	I
of	I
the	I
coumarin	I
type	I
.	O

For	O
this	O
reason	O
,	O
the	O
dose	O
of	O
the	O
anticoagulant	B
should	O
be	O
reduced	O
by	O
30	O
-	O
50	O
%	O
at	O
the	O
start	O
of	O
treatment	O
with	O
Bezalip	B
or	O
Bezalip	B
retard	O
and	O
then	O
titrated	O
according	O
to	O
the	O
blood	O
clotting	O
parameters	O

-	O
The	O
action	O
of	O
sulphonylureas	B
and	O
insulin	B
may	O
be	O
enhanced	O
by	O
Bezalip	B
or	O
Bezalip	B
retard	I
.	O

-	O
In	O
isolated	O
cases	O
,	O
a	O
pronounced	O
though	O
reversible	O
,	O
impairment	O
of	O
renal	O
function	O
(	O
accompanied	O
by	O
a	O
corresponding	O
increase	O
in	O
the	O
serum	O
creatinine	O
level	O
)	O
has	O
been	O
reported	O
in	O
organ	O
transplant	O
patients	O
receiving	O
immuno	O
-	O
suppressant	O
therapy	O
and	O
concomitant	O
bezafibrate	B
.	O

-	O
When	O
Bezalip	B
or	O
Bezalip	B
retard	I
is	O
used	O
concurrently	O
with	O
anion	O
-	O
exchange	O
resins	B
(	O
e	O
.	O
g	O
.	O
cholestryramine	B
)	O
,	O
an	O
interval	O
of	O
at	O
least	O
2	O
hours	O
should	O
be	O
maintained	O
between	O
the	O
two	O
medicines	O
,	O
since	O
the	O
absorption	O
of	O
Bezalip	B
or	O
Bezalip	B
retard	I
is	O
impaired	O

-	O
Perhexiline	B
hydrogen	I
maleate	I
or	O
MAO	O
-	O
inhibitors	O
(	O
with	O
hepatotoxic	O
potential	O
)	O
must	O
not	O
be	O
administered	O
together	O
with	O
Bezalip	B
or	O
Bezalip	B
retard	I
.	O

In	O
vitro	O
studies	O
have	O
shown	O
CASODEX	B
can	O
displace	O
coumarin	B
anticoagulants	O
,	O
such	O
as	O
warfarin	B
,	O
from	O
their	O
protein	O
-	O
binding	O
sites	O
.	O

It	O
is	O
recommended	O
that	O
if	O
CASODEX	B
is	O
started	O
in	O
patients	O
already	O
receiving	O
coumarin	B
anticoagulants	I
,	O
prothrombin	O
times	O
should	O
be	O
closely	O
monitored	O
and	O
adjustment	O
of	O
the	O
anticoagulant	B
dose	O
may	O
be	O
necessary	O
.	O

Drug	O
Interactions	O
:	O
The	O
central	O
anticholinergic	B
syndrome	O
can	O
occur	O
when	O
anticholinergic	B
agents	O
such	O
as	O
AKINETON	B
are	O
administered	O
concomitantly	O
with	O
drugs	O
that	O
have	O
secondary	O
anticholinergic	B
actions	O
,	O
e	O
.	O
g	O
.	O
,	O
certain	O
narcotic	B
analgesics	I
such	O
as	O
meperidine	B
,	O
the	O
phenothiazines	B
and	O
other	O
antipsychotics	B
,	O
tricyclic	B
antidepressants	I
,	O
certain	O
antiarrhythmics	B
such	O
as	O
the	O
quinidine	B
salts	O
,	O
and	O
antihistamines	B
.	O

ZEBETA	B
should	O
not	O
be	O
combined	O
with	O
other	O
beta	O
-	O
blocking	O
agents	B
.	O

Patients	O
receiving	O
catecholamine	O
-	O
depleting	O
drugs	O
,	O
such	O
as	O
reserpine	B
or	O
guanethidine	B
,	O
should	O
be	O
closely	O
monitored	O
,	O
because	O
the	O
added	O
beta	O
-	O
adrenergic	O
blocking	O
action	O
of	O
ZEBETA	B
may	O
produce	O
excessive	O
reduction	O
of	O
sympathetic	O
activity	O
.	O

In	O
patients	O
receiving	O
concurrent	O
therapy	O
with	O
clonidine	B
,	O
if	O
therapy	O
is	O
to	O
be	O
discontinued	O
,	O
it	O
is	O
suggested	O
that	O
ZEBETA	B
be	O
discontinued	O
for	O
several	O
days	O
before	O
the	O
withdrawal	O
of	O
clonidine	B
.	O

ZEBETA	B
should	O
be	O
used	O
with	O
care	O
when	O
myocardial	B
depressants	I
or	O
inhibitors	O
of	O
AV	O
conduction	O
,	O
such	O
as	O
certain	O
calcium	B
antagonists	I
(	O
particularly	O
of	O
the	O
phenylalkylamine	B
[	O
verapamil	B
]	O
and	O
benzothiazepine	B
[	O
diltiazem	B
]	O
classes	O
)	O
,	O
or	O
antiarrhythmic	B
agents	I
,	O
such	O
as	O
disopyramide	B
,	O
are	O
used	O
concurrently	O
.	O

Concurrent	O
use	O
of	O
rifampin	B
increases	O
the	O
metabolic	O
clearance	O
of	O
ZEBETA	B
,	O
resulting	O
in	O
a	O
shortened	O
elimination	O
half	O
-	O
life	O
of	O
ZEBETA	B
.	O

Pharmacokinetic	O
studies	O
document	O
no	O
clinically	O
relevant	O
interactions	O
with	O
other	O
agents	O
given	O
concomitantly	O
,	O
including	O
thiazide	B
diuretics	I
,	O
digoxin	B
,	O
and	O
cimetidine	B
.	O

There	O
was	O
no	O
effect	O
of	O
ZEBETA	B
on	O
prothrombin	O
time	O
in	O
patients	O
on	O
stable	O
doses	O
of	O
warfarin	B
.	O

If	O
you	O
are	O
also	O
using	O
a	O
steroid	B
inhaler	O
,	O
take	O
bitolterol	B
first	O
and	O
then	O
wait	O
about	O
15	O
minutes	O
before	O
using	O
the	O
steroid	B
inhaler	O
.	O

This	O
allows	O
bitolterol	B
to	O
open	O
air	O
passages	O
,	O
increasing	O
the	O
effectiveness	O
of	O
the	O
steroid	B
.	O

In	O
clinical	O
trials	O
in	O
patients	O
undergoing	O
PTCA	O
/	O
PCI	O
,	O
co	O
-	O
administration	O
of	O
Angiomax	B
with	O
heparin	B
,	O
warfarin	B
,	O
thrombolytics	B
or	O
glycoprotein	O
IIb	O
/	O
IIIa	O
inhibitors	O
was	O
associated	O
with	O
increased	O
risks	O
of	O
major	O
bleeding	O
events	O
compared	O
to	O
patients	O
not	O
receiving	O
these	O
concomitant	O
medications	O
.	O

There	O
is	O
no	O
experience	O
with	O
co	O
-	O
administration	O
of	O
Angiomax	B
and	O
plasma	O
expanders	O
such	O
as	O
dextran	B
.	O

Among	O
494	O
subjects	O
who	O
received	O
Angiomax	B
in	O
clinical	O
trials	O
and	O
were	O
tested	O
for	O
antibodies	O
,	O
2	O
subjects	O
had	O
treatment	O
-	O
emergent	O
positive	O
bivalirudin	B
antibody	O
tests	O
.	O

Certain	O
antibiotic	B
,	O
cisplatin	B
,	O
cyclosporine	B
,	O
diuretic	B
,	O
foscarnet	B
,	O
and	O
vaccines	B
.	O

Patients	O
on	O
oral	O
antidiabetic	B
agents	I
receiving	O
VELCADE	B
treatment	O
may	O
require	O
close	O
monitoring	O
of	O
their	O
blood	O
glucose	O
levels	O
and	O
adjustment	O
of	O
the	O
dose	O
of	O
their	O
antidiabetic	B
medication	I
.	O

Hormonal	B
Contraceptives	I
,	O
Including	O
Oral	O
,	O
Injectable	O
,	O
Transdermal	O
,	O
and	O
Implantable	O
Contraceptives	B
:	O
An	O
interaction	O
study	O
demonstrated	O
that	O
co	O
-	O
administration	O
of	O
bosentan	B
and	O
the	O
oral	O
hormonal	B
contraceptive	I
Ortho	O
-	O
Novum	O
produced	O
average	O
decreases	O
of	O
norethindrone	B
and	O
ethinyl	B
estradiol	I
levels	O
of	O
14	O
%	O
and	O
31	O
%	O
,	O
respectively	O
.	O

Therefore	O
,	O
hormonal	B
contraceptives	I
,	O
including	O
oral	O
,	O
injectable	O
,	O
transdermal	O
,	O
and	O
implantable	O
forms	O
,	O
may	O
not	O
be	O
reliable	O
when	O
TRACLEER	B
is	O
co	O
-	O
administered	O
.	O

Specific	O
interaction	O
studies	O
have	O
demonstrated	O
the	O
following	O
:	O
Cyclosporine	B
A	I
:	O
During	O
the	O
first	O
day	O
of	O
concomitant	O
administration	O
,	O
trough	O
concentrations	O
of	O
bosentan	B
were	O
increased	O
by	O
about	O
30	O
-	O
fold	O
.	O

Steady	O
-	O
state	O
bosentan	B
plasma	O
concentrations	O
were	O
3	O
-	O
to	O
4	O
-	O
fold	O
higher	O
than	O
in	O
the	O
absence	O
of	O
cyclosporine	B
A	I
.	O

The	O
concomitant	O
administration	O
of	O
bosentan	B
and	O
cyclosporine	B
A	I
is	O
contraindicated	O
.	O

Co	O
-	O
administration	O
of	O
bosentan	B
decreased	O
the	O
plasma	O
concentrations	O
of	O
cyclosporine	B
A	I
(	O
a	O
CYP3A4	O
substrate	O
)	O
by	O
approximately	O
50	O
%	O
.	O

Tacrolimus	B
:	O
Co	O
-	O
administration	O
of	O
tacrolimus	B
and	O
bosentan	B
has	O
not	O
been	O
studied	O
in	O
man	O
.	O

Co	O
-	O
administration	O
of	O
tacrolimus	B
and	O
bosentan	B
resulted	O
in	O
markedly	O
increased	O
plasma	O
concentrations	O
of	O
bosentan	B
in	O
animals	O
.	O

Caution	O
should	O
be	O
exercised	O
if	O
tacrolimus	B
and	O
bosentan	B
are	O
used	O
together	O
.	O

Glyburide	B
:	O
An	O
increased	O
risk	O
of	O
elevated	O
liver	O
aminotransferases	O
was	O
observed	O
in	O
patients	O
receiving	O
concomitant	O
therapy	O
with	O
glyburide	B
.	O

Therefore	O
,	O
the	O
concomitant	O
administration	O
of	O
TRACLEER	B
and	O
glyburide	B
is	O
contraindicated	O
,	O
and	O
alternative	O
hypoglycemic	B
agents	I
should	O
be	O
considered	O
.	O

Co	O
-	O
administration	O
of	O
bosentan	B
decreased	O
the	O
plasma	O
concentrations	O
of	O
glyburide	B
by	O
approximately	O
40	O
%	O
.	O

Bosentan	B
is	O
also	O
expected	O
to	O
reduce	O
plasma	O
concentrations	O
of	O
other	O
oral	O
hypoglycemic	B
agents	I
that	O
are	O
predominantly	O
metabolized	O
by	O
CYP2C9	O
or	O
CYP3A4	O
.	O

Ketoconazole	B
:	O
Co	O
-	O
administration	O
of	O
bosentan	B
125	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
and	O
ketoconazole	B
,	O
a	O
potent	O
CYP3A4	O
inhibitor	O
,	O
increased	O
the	O
plasma	O
concentrations	O
of	O
bosentan	B
by	O
approximately	O
2	O
-	O
fold	O
.	O

No	O
dose	O
adjustment	O
of	O
bosentan	B
is	O
necessary	O
,	O
but	O
increased	O
effects	O
of	O
bosentan	B
should	O
be	O
considered	O
.	O

Simvastatin	B
and	O
Other	O
Statins	B
:	O
Co	O
-	O
administration	O
of	O
bosentan	B
decreased	O
the	O
plasma	O
concentrations	O
of	O
simvastatin	B
(	O
a	O
CYP3A4	O
substrate	O
)	O
,	O
and	O
its	O
active	O
-	O
hydroxy	O
acid	O
metabolite	O
,	O
by	O
approximately	O
50	O
%	O
.	O

Bosentan	B
is	O
also	O
expected	O
to	O
reduce	O
plasma	O
concentrations	O
of	O
other	O
statins	B
that	O
have	O
significant	O
metabolism	O
by	O
CYP3A4	O
,	O
such	O
as	O
lovastatin	B
and	O
atorvastatin	B
.	O

Patients	O
using	O
CYP3A4	O
metabolized	O
statins	B
should	O
have	O
cholesterol	O
levels	O
monitored	O
after	O
TRACLEER	B
is	O
initiated	O
to	O
see	O
whether	O
the	O
statin	B
dose	O
needs	O
adjustment	O
.	O

Warfarin	B
:	O
Co	O
-	O
administration	O
of	O
bosentan	B
500	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
for	O
6	O
days	O
decreased	O
the	O
plasma	O
concentrations	O
of	O
both	O
S	O
-	O
warfarin	O
(	O
a	O
CYP2C9	O
substrate	O
)	O
and	O
R	O
-	O
warfarin	O
(	O
a	O
CYP3A4	O
substrate	O
)	O
by	O
29	O
and	O
38	O
%	O
,	O
respectively	O
.	O

Clinical	O
experience	O
with	O
concomitant	O
administration	O
of	O
bosentan	B
and	O
warfarin	B
in	O
patients	O
with	O
pulmonary	O
arterial	O
hypertension	O
did	O
not	O
show	O
clinically	O
relevant	O
changes	O
in	O
INR	O
or	O
warfarin	B
dose	O
(	O
baseline	O
vs	O
.	O
end	O
of	O
the	O
clinical	O
studies	O
)	O
,	O
and	O
the	O
need	O
to	O
change	O
the	O
warfarin	B
dose	O
during	O
the	O
trials	O
due	O
to	O
changes	O
in	O
INR	O
or	O
due	O
to	O
adverse	O
events	O
was	O
similar	O
among	O
bosentan	B
-	O
and	O
placebo	O
-	O
treated	O
patients	O
.	O

Digoxin	B
,	O
Nimodipine	B
and	O
Losartan	B
:	O
Bosentan	B
has	O
no	O
significant	O
pharmacokinetic	O
interactions	O
with	O
digoxin	B
and	O
nimodipine	B
,	O
and	O
losartan	B
has	O
no	O
significant	O
effect	O
on	O
plasma	O
levels	O
of	O
bosentan	B
.	O

Co	O
-	O
administration	O
of	O
BOTOX	B
and	O
aminoglycosides	B
or	O
other	O
agents	O
interfering	O
with	O
neuromuscular	O
transmission	O
(	O
e	O
.	O
g	O
.	O
,	O
curare	O
-	O
like	O
compounds	B
)	O
should	O
only	O
be	O
performed	O
with	O
caution	O
as	O
the	O
effect	O
of	O
the	O
toxin	B
may	O
be	O
potentiated	O
.	O

Excessive	O
neuromuscular	O
weakness	O
may	O
be	O
exacerbated	O
by	O
administration	O
of	O
another	O
botulinum	B
toxin	I
prior	O
to	O
the	O
resolution	O
of	O
the	O
effects	O
of	O
a	O
previously	O
administered	O
botulinum	B
toxin	I
.	O

Co	O
-	O
administration	O
of	O
MYOBLOC	B
and	O
aminoglycosides	B
or	O
other	O
agents	O
interfering	O
with	O
neuromuscular	O
transmission	O
(	O
e	O
.	O
g	O
.	O
,	O
curare	O
-	O
like	O
compounds	B
)	O
should	O
only	O
be	O
performed	O
with	O
caution	O
as	O
the	O
effect	O
of	O
the	O
toxin	B
may	O
be	O
potentiated	O
.	O

Digitalis	B
toxicity	O
may	O
be	O
aggravated	O
by	O
the	O
initial	O
release	O
of	O
norepinephrine	O
caused	O
by	O
Bretylium	B
Tosylate	I
Injection	O
.	O

The	O
pressor	O
effects	O
of	O
catecholamines	B
such	O
as	O
dopamine	B
or	O
norepinephrine	B
are	O
enhanced	O
by	O
Bretylium	B
Tosylate	I
.	O

Although	O
there	O
is	O
little	O
published	O
information	O
on	O
concomitant	O
administration	O
of	O
lidocaine	B
and	O
Bretylium	B
Tosylate	I
,	O
these	O
drugs	O
are	O
often	O
administered	O
concurrently	O
without	O
any	O
evidence	O
of	O
interactions	O
resulting	O
in	O
adverse	O
effects	O
or	O
diminished	O
efficacy	O
.	O

Although	O
specific	O
drug	O
interaction	O
studies	O
have	O
not	O
been	O
conducted	O
with	O
ALPHAGAN	B
P	I
,	O
the	O
possibility	O
of	O
an	O
additive	O
or	O
potentiating	O
effect	O
with	O
CNS	B
depressants	I
(	O
alcohol	B
,	O
barbiturates	B
,	O
opiates	B
,	O
sedatives	B
,	O
or	O
anesthetics	B
)	O
should	O
be	O
considered	O
.	O

Caution	O
in	O
using	O
concomitant	O
drugs	O
such	O
as	O
beta	O
-	O
blockers	O
(	O
ophthalmic	O
and	O
systemic	O
)	O
,	O
anti	O
-	O
hypertensives	O
and	O
/	O
or	O
cardiac	B
glycosides	I
is	O
advised	O
.	O

Tricyclic	B
antidepressants	I
have	O
been	O
reported	O
to	O
blunt	O
the	O
hypotensive	O
effect	O
of	O
systemic	O
clonidine	B
.	O
It	O
is	O
not	O
known	O
whether	O
the	O
concurrent	O
use	O
of	O
these	O
agents	O
with	O
ALPHAGAN	B
P	I
in	O
humans	O
can	O
lead	O
to	O
resulting	O
interference	O
with	O
the	O
IOP	O
lowering	O
effect	O
.	O

AZOPT	B
(	O
brinzolamide	B
ophthalmic	O
suspension	O
)	O
1	O
%	O
contains	O
a	O
carbonic	B
anhydrase	I
inhibitor	I
.	O

However	O
,	O
in	O
patients	O
treated	O
with	O
oral	O
carbonic	B
anhydrase	I
inhibitors	I
,	O
rare	O
instances	O
of	O
drug	O
interactions	O
have	O
occurred	O
with	O
high	O
-	O
dose	O
salicylate	B
therapy	O
.	O

Therefore	O
,	O
the	O
potential	O
for	O
such	O
drug	O
interaction	O
should	O
be	O
considered	O
in	O
patients	O
receiving	O
AZOPT	B
(	O
brinzolamide	B
ophthalmic	O
suspension	O
)	O
1	O
%	O
.	O

The	O
risk	O
of	O
using	O
bromocriptine	B
mesylate	I
in	O
combination	O
with	O
other	O
drugs	O
has	O
not	O
been	O
systematically	O
evaluated	O
,	O
but	O
alcohol	B
may	O
potentiate	O
the	O
side	O
effects	O
of	O
bromocriptine	B
mesylate	I
.	O

Bromocriptine	B
mesylate	I
may	O
interact	O
with	O
dopamine	B
antagonists	I
,	O
butyrophenones	B
,	O
and	O
certain	O
other	O
agents	O
.	O

Compounds	O
in	O
these	O
categories	O
result	O
in	O
a	O
decreased	O
efficacy	O
of	O
bromocriptine	B
mesylate	I
:	O
phenothiazines	B
,	O
haloperidol	B
,	O
metoclopramide	B
,	O
pimozide	B
.	O

Concomitant	O
use	O
of	O
bromocriptine	B
mesylate	I
with	O
other	O
ergot	B
alkaloids	I
is	O
not	O
recommended	O
.	O

Dexbrompheniramine	B
can	O
interact	O
with	O
alcohol	B
or	O
other	O
CNS	B
depressants	I
(	O
may	O
potentiate	O
the	O
CNS	B
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
antihistamines	B
)	O
,	O
anticholinergics	B
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O
(	O
anticholinergic	O
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
antihistamines	B
)	O
,	O
and	O
monoamine	B
oxidase	I
(	O
MAO	O
)	O
inhibitors	B
(	O
concurrent	O
use	O
with	O
antihistamines	B
may	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
and	O
CNS	B
depressant	O
effects	O
of	O
antihistamines	B
)	O
.	O

This	O
drug	O
may	O
interact	O
with	O
alcohol	B
or	O
other	O
CNS	B
depressants	I
(	O
may	O
potentiate	O
the	O
CNS	B
depressant	O
effects	O
of	O
either	O
these	O
medications	O
or	O
antihistamines	B
)	O
,	O
anticholinergics	B
or	O
other	O
medications	O
with	O
anticholinergic	O
activity	O
(	O
anticholinergic	O
effects	O
may	O
be	O
potentiated	O
when	O
these	O
medications	O
are	O
used	O
concurrently	O
with	O
antihistamines	B
)	O
,	O
and	O
monoamine	B
oxidase	I
(	O
MAO	O
)	O
inhibitors	B
(	O
concurrent	O
use	O
with	O
antihistamines	B
may	O
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
and	O
CNS	B
depressant	O
effects	O
of	O
antihistamines	B
)	O
.	O

Concomitant	O
oral	O
administration	O
of	O
ketoconazole	B
(	O
a	O
known	O
inhibitor	O
of	O
CYP3A4	O
activity	O
in	O
the	O
liver	O
and	O
in	O
the	O
intestinal	O
mucosa	O
)	O
caused	O
an	O
eight	O
-	O
fold	O
increase	O
of	O
the	O
systemic	O
exposure	O
to	O
oral	O
budesonide	B
.	O

If	O
treatment	O
with	O
inhibitors	O
of	O
CYP3A4	O
activity	O
(	O
such	O
as	O
ketoconazole	B
,	O
intraconazole	B
,	O
ritonavir	B
,	O
indinavir	B
,	O
saquinavir	B
,	O
erythromycin	B
,	O
etc	O
.	O
)	O
is	O
indicated	O
,	O
reduction	O
of	O
the	O
budesonide	B
dose	O
should	O
be	O
considered	O
.	O

-	O
Drugs	O
with	O
ototoxic	O
potential	O
:	O
Especially	O
in	O
the	O
presence	O
of	O
impaired	O
renal	O
function	O
,	O
the	O
use	O
of	O
parenterally	O
administered	O
bumetanide	B
in	O
patients	O
to	O
whom	O
aminoglycoside	B
antibiotics	I
are	O
also	O
being	O
given	O
should	O
be	O
avoided	O
,	O
except	O
in	O
life	O
-	O
threatening	O
conditions	O
.	O

-	O
Lithium	B
:	O
Lithium	B
should	O
generally	O
not	O
be	O
given	O
with	O
diuretics	B
(	O
such	O
as	O
bumetanide	B
)	O
because	O
they	O
reduce	O
its	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B
toxicity	O
.	O

-	O
Probenecid	B
:	O
Pretreatment	O
with	O
probenecid	B
reduces	O
both	O
the	O
natriuresis	O
and	O
hyperreninemia	O
produced	O
by	O
bumetanide	B
.	O

This	O
antagonistic	O
effect	O
of	O
probenecid	B
on	O
bumetanide	B
natriuresis	O
is	O
not	O
due	O
to	O
a	O
direct	O
action	O
on	O
sodium	O
excretion	O
but	O
is	O
probably	O
secondary	O
to	O
its	O
inhibitory	O
effect	O
on	O
renal	O
tubular	O
secretion	O
of	O
bumetanide	B
.	O

Thus	O
,	O
probenecid	B
should	O
not	O
be	O
administered	O
concurrently	O
with	O
bumetanide	B
.	O

-	O
Indomethacin	B
:	O
Indomethacin	B
blunts	O
the	O
increases	O
in	O
urine	O
volume	O
and	O
sodium	O
excretion	O
seen	O
during	O
bumetanide	B
treatment	O
and	O
inhibits	O
the	O
bumetanide	B
-	O
induced	O
increase	O
in	O
plasma	O
renin	O
activity	O
.	O

-	O
Antihypertensives	B
:	O
Bumetanide	B
may	O
potentiate	O
the	O
effect	O
of	O
various	O
antihypertensive	B
drugs	I
,	O
necessitating	O
a	O
reduction	O
in	O
the	O
dosage	O
of	O
these	O
drugs	B
.	O

-	O
Digoxin	B
:	O
Interaction	O
studies	O
in	O
humans	O
have	O
shown	O
no	O
effect	O
on	O
digoxin	B
blood	O
levels	O
.	O

-	O
Anticoagulants	B
:	O
Interaction	O
studies	O
in	O
humans	O
have	O
shown	O
bumetanide	B
to	O
have	O
no	O
effect	O
on	O
warfarin	B
metabolism	O
or	O
on	O
plasma	O
prothrombin	O
activity	O
.	O

The	O
administration	O
of	O
local	O
anesthetic	B
solutions	I
containing	O
epinephrine	B
or	O
norepinephrine	B
to	O
patients	O
receiving	O
monoamine	B
oxidase	I
inhibitors	I
or	O
tricyclic	B
antidepressants	I
may	O
produce	O
severe	O
,	O
prolonged	O
hypertension	O
.	O

Concurrent	O
administration	O
of	O
vasopressor	B
drugs	I
and	O
of	O
ergot	O
-	O
type	O
oxytocic	B
drugs	I
may	O
cause	O
severe	O
,	O
persistent	O
hypertension	O
or	O
cerebrovascular	O
accidents	O
.	O

Phenothiazines	B
and	O
butyrophenones	B
may	O
reduce	O
or	O
reverse	O
the	O
pressor	O
effect	O
of	O
epinephrine	B
.	O

Buprenorphine	B
is	O
metabolized	O
to	O
norbuprenorphine	B
by	O
cytochrome	O
CYP	O
3A4	O
.	O

Because	O
CYP	O
3A4	O
inhibitors	O
may	O
increase	O
plasma	O
concentrations	O
of	O
buprenorphine	B
,	O
patients	O
already	O
on	O
CYP	O
3A4	O
inhibitors	O
such	O
as	O
azole	B
antifungals	I
(	O
e	O
.	O
g	O
.	O

ketoconazole	B
)	O
,	O
macrolide	B
antibiotics	I
(	O
e	O
.	O
g	O
.	O
erythromycin	B
)	O
,	O
and	O
HIV	B
protease	I
inhibitors	I
(	O
e	O
.	O
g	O
.	O
ritonavir	B
,	O
indinavir	B
and	O
saquinavir	B
)	O
should	O
have	O
their	O
dose	O
of	O
SUBUTEX	B
or	O
SUBOXONE	B
adjusted	O
.	O

Based	O
on	O
anecdotal	O
reports	O
,	O
there	O
may	O
be	O
an	O
interaction	O
between	O
buprenorphine	B
and	O
benzodiazepines	B
.	O

There	O
have	O
been	O
a	O
number	O
of	O
reports	O
in	O
the	O
post	O
-	O
marketing	O
experience	O
of	O
coma	O
and	O
death	O
associated	O
with	O
the	O
concomitant	O
intravenous	O
misuse	O
of	O
buprenorphine	B
and	O
benzodiazepines	B
by	O
addicts	O
.	O

In	O
many	O
of	O
these	O
cases	O
,	O
buprenorphine	B
was	O
misused	O
by	O
self	O
-	O
injection	O
of	O
crushed	O
SUBUTEX	B
tablets	O
.	O

SUBUTEX	B
and	O
SUBOXONE	B
should	O
be	O
prescribed	O
with	O
caution	O
to	O
patients	O
on	O
benzodiazepines	B
or	O
other	O
drugs	O
that	O
act	O
on	O
the	O
central	O
nervous	O
system	O
,	O
regardless	O
of	O
whether	O
these	O
drugs	O
are	O
taken	O
on	O
the	O
advice	O
of	O
a	O
physician	O
or	O
are	O
taken	O
as	O
drugs	O
of	O
abuse	O
.	O

Patients	O
should	O
be	O
warned	O
of	O
the	O
potential	O
danger	O
of	O
the	O
intravenous	O
self	O
-	O
administration	O
of	O
benzodiazepines	B
while	O
under	O
treatment	O
with	O
SUBOXONE	B
or	O
SUBUTEX	B
.	O

Few	O
systemic	O
data	O
have	O
been	O
collected	O
on	O
the	O
metabolism	O
of	O
WELLBUTRIN	B
following	O
concomitant	O
administration	O
with	O
other	O
drugs	O
or	O
,	O
alternatively	O
,	O
the	O
effect	O
of	O
concomitant	O
administration	O
of	O
WELLBUTRIN	B
on	O
the	O
metabolism	O
of	O
other	O
drugs	O
.	O

In	O
vitro	O
studies	O
indicate	O
that	O
bupropion	B
is	O
primarily	O
metabolized	O
to	O
hydroxybupropion	B
by	O
the	O
CYP2B6	O
isoenzyme	O
.	O

Therefore	O
,	O
the	O
potential	O
exists	O
for	O
a	O
drug	O
interaction	O
between	O
WELLBUTRIN	B
and	O
drugs	O
that	O
affect	O
the	O
CYP2B6	O
isoenzyme	O
(	O
e	O
.	O
g	O
.	O
,	O
orphenadrine	B
and	O
cyclophosphamide	B
)	O
.	O

The	O
threohydrobupropion	B
metabolite	O
of	O
bupropion	B
does	O
not	O
appear	O
to	O
be	O
produced	O
by	O
the	O
cytochrome	O
P450	O
isoenzymes	O
.	O

The	O
effects	O
of	O
concomitant	O
administration	O
of	O
cimetidine	B
on	O
the	O
pharmacokinetics	O
of	O
bupropion	B
and	O
its	O
active	O
metabolites	O
were	O
studied	O
in	O
24	O
healthy	O
young	O
male	O
volunteers	O
.	O

Following	O
oral	O
administration	O
of	O
two	O
150	O
-	O
mg	O
sustained	O
-	O
release	O
tablets	O
with	O
and	O
without	O
800	O
mg	O
of	O
cimetidine	B
,	O
the	O
pharmacokinetics	O
of	O
bupropion	B
and	O
hydroxybupropion	B
were	O
unaffected	O
.	O

However	O
,	O
there	O
were	O
16	O
%	O
and	O
32	O
%	O
increases	O
in	O
the	O
AUC	O
and	O
Cmax	O
,	O
respectively	O
,	O
of	O
the	O
combined	O
moieties	O
of	O
threohydrobupropion	B
and	O
erythrohydrobupropion	B
.	O

While	O
not	O
systematically	O
studied	O
,	O
certain	O
drugs	O
may	O
induce	O
the	O
metabolism	O
of	O
bupropion	B
(	O
e	O
.	O
g	O
.	O
,	O
carbamazepine	B
,	O
phenobarbital	B
,	O
phenytoin	B
)	O
.	O

Drugs	O
Metabolized	O
by	O
Cytochrome	O
P450IID6	O
(	O
CYP2D6	O
)	O
:	O
Many	O
drugs	O
,	O
including	O
most	O
antidepressants	B
(	O
SSRIs	O
,	O
many	O
tricyclics	B
)	O
,	O
beta	O
-	O
blockers	O
,	O
antiarrhythmics	B
,	O
and	O
antipsychotics	B
are	O
metabolized	O
by	O
the	O
CYP2D6	O
isoenzyme	O
.	O

Although	O
bupropion	B
is	O
not	O
metabolized	O
by	O
this	O
isoenzyme	O
,	O
bupropion	B
and	O
hydroxybupropion	B
are	O
inhibitors	O
of	O
the	O
CYP2D6	O
isoenzyme	O
in	O
vitro	O
.	O

In	O
a	O
study	O
of	O
15	O
male	O
subjects	O
(	O
ages	O
19	O
to	O
35	O
years	O
)	O
who	O
were	O
extensive	O
metabolizers	O
of	O
the	O
CYP2D6	O
isoenzyme	O
,	O
daily	O
doses	O
of	O
bupropion	B
given	O
as	O
150	O
mg	O
twice	O
daily	O
followed	O
by	O
a	O
single	O
dose	O
of	O
50	O
mg	O
desipramine	B
increased	O
the	O
Cmax	O
,	O
AUC	O
,	O
and	O
t1	O
/	O
2	O
of	O
desipramine	B
by	O
an	O
average	O
of	O
approximately	O
2	O
-	O
,	O
5	O
-	O
and	O
2	O
-	O
fold	O
,	O
respectively	O
.	O

Therefore	O
,	O
co	O
-	O
administration	O
of	O
bupropion	B
with	O
drugs	O
that	O
are	O
metabolized	O
by	O
CYP2D6	O
isoenzyme	O
including	O
certain	O
antidepressants	B
(	O
e	O
.	O
g	O
.	O
,	O
nortriptyline	B
,	O
imipramine	B
,	O
desipramine	B
,	O
paroxetine	B
,	O
fluoxetine	B
,	O
sertraline	B
)	O
,	O
antipsychotics	B
(	O
e	O
.	O
g	O
.	O
,	O
haloperidol	B
,	O
risperidone	B
,	O
thioridazine	B
)	O
,	O
beta	O
-	O
blockers	O
(	O
e	O
.	O
g	O
.	O
,	O
metoprolol	B
)	O
,	O
and	O
Type	B
1C	I
antiarrhythmics	I
(	O
e	O
.	O
g	O
.	O
,	O
propafenone	B
,	O
flecainide	B
)	O
,	O
should	O
be	O
approached	O
with	O
caution	O
and	O
should	O
be	O
initiated	O
at	O
the	O
lower	O
end	O
of	O
the	O
dose	O
range	O
of	O
the	O
concomitant	O
medication	O
.	O

MAO	B
Inhibitors	I
:	O
Studies	O
in	O
animals	O
demonstrate	O
that	O
the	O
acute	O
toxicity	O
of	O
bupropion	B
is	O
enhanced	O
by	O
the	O
MAO	B
inhibitor	I
phenelzine	I
.	O

Levodopa	B
and	O
Amantadine	B
:	O
Limited	O
clinical	O
data	O
suggest	O
a	O
higher	O
incidence	O
of	O
adverse	O
experiences	O
in	O
patients	O
receiving	O
bupropion	B
concurrently	O
with	O
either	O
levodopa	B
or	O
amantadine	B
.	O

Administration	O
of	O
WELLBUTRIN	B
Tablets	O
to	O
patients	O
receiving	O
either	O
levodopa	B
or	O
amantadine	B
concurrently	O
should	O
be	O
undertaken	O
with	O
caution	O
,	O
using	O
small	O
initial	O
doses	O
and	O
small	O
gradual	O
dose	O
increases	O
.	O

Drugs	O
that	O
Lower	O
Seizure	O
Threshold	O
:	O
Concurrent	O
administration	O
of	O
WELLBUTRIN	B
and	O
agents	O
(	O
e	O
.	O
g	O
.	O
,	O
antipsychotics	B
,	O
other	O
antidepressants	B
,	O
theophylline	B
,	O
systemic	O
steroids	B
,	O
etc	O
.	O
)	O
that	O
lower	O
seizure	O
threshold	O
should	O
be	O
undertaken	O
only	O
with	O
extreme	O
caution	O
.	O

Alcohol	B
:	O
In	O
post	O
-	O
marketing	O
experience	O
,	O
there	O
have	O
been	O
rare	O
reports	O
of	O
adverse	O
neuropsychiatric	O
events	O
or	O
reduced	O
alcohol	B
tolerance	O
in	O
patients	O
who	O
were	O
drinking	O
alcohol	B
during	O
treatment	O
with	O
WELLBUTRIN	B
.	O

The	O
consumption	O
of	O
alcohol	B
during	O
treatment	O
with	O
WELLBUTRIN	B
should	O
be	O
minimized	O
or	O
avoided	O
(	O
also	O
see	O
a	O
href	O
=	O
bupropz	O
_	O
od	O
.	O
htm	O
#	O
CI	O
CONTRAINDICATIONS	O
)	O

It	O
is	O
recommended	O
that	O
buspirone	B
hydrochloride	I
not	O
be	O
used	O
concomitantly	O
with	O
MAO	B
inhibitors	I
Because	O
the	O
effects	O
of	O
concomitant	O
administration	O
of	O
buspirone	B
HCl	I
with	O
most	O
other	O
psychotropic	B
drugs	I
have	O
not	O
been	O
studied	O
,	O
the	O
concomitant	O
use	O
of	O
buspirone	B
HCl	I
with	O
other	O
CNS	O
-	O
active	O
drugs	B
should	O
be	O
approached	O
with	O
caution	O
.	O

There	O
is	O
one	O
report	O
suggesting	O
that	O
the	O
concomitant	O
use	O
of	O
trazodone	B
hydrochloride	I
(	O
Desyrel	B
)	O
and	O
buspirone	B
HCl	I
may	O
have	O
caused	O
3	O
-	O
to	O
6	O
-	O
fold	O
elevations	O
on	O
SGPT	O
(	O
ALT	O
)	O
in	O
a	O
few	O
patients	O
.	O

In	O
a	O
study	O
in	O
normal	O
volunteers	O
,	O
concomitant	O
administration	O
of	O
buspirone	B
HCl	I
and	O
haloperidol	B
resulted	O
in	O
increased	O
serum	O
haloperidol	B
concentrations	O
.	O

In	O
vitro	O
,	O
buspirone	B
does	O
not	O
displace	O
tightly	O
bound	O
drugs	O
like	O
phenytoin	B
,	O
propranolol	B
,	O
and	O
warfarin	B
from	O
serum	O
proteins	O
.	O

However	O
,	O
there	O
has	O
been	O
one	O
report	O
of	O
prolonged	O
prothrombin	O
time	O
when	O
buspirone	B
was	O
added	O
to	O
the	O
regimen	O
of	O
a	O
patient	O
treated	O
with	O
warfarin	B
.	O

The	O
patient	O
was	O
also	O
chronically	O
receiving	O
phenytoin	B
,	O
phenobarbital	B
,	O
digoxin	B
,	O
and	O
levothyroxine	B
sodium	I
.	O

In	O
vitro	O
,	O
buspirone	B
may	O
displace	O
less	O
firmly	O
bound	O
drugs	O
like	O
digoxin	B
.	O

Itraconazole	B
decreases	O
busulfan	B
clearance	O
by	O
up	O
to	O
25	O
%	O
,	O
and	O
may	O
produce	O
AUCs	O
1500	O
M	O
min	O
in	O
some	O
patients	O
.	O

Fluconazole	B
,	O
and	O
the	O
5	O
-	O
HT3	O
antiemetics	B
ondansetron	I
(	O
Zofran	B
)	O
and	O
granisetron	B
(	O
Kytril	B
)	O
have	O
all	O
been	O
used	O
with	O
BUSULFEX	B
.	O

Phenytoin	B
increases	O
the	O
clearance	O
of	O
busulfan	B
by	O
15	O
%	O
or	O
more	O
,	O
possibly	O
due	O
to	O
the	O
induction	O
of	O
glutathione	O
-	O
S	O
-	O
transferase	O
.	O

Since	O
the	O
pharmacokinetics	O
of	O
BUSULFEX	B
were	O
studied	O
in	O
patients	O
treated	O
with	O
phenytoin	B
,	O
the	O
clearance	O
of	O
BUSULFEX	B
at	O
the	O
recommended	O
dose	O
may	O
be	O
lower	O
and	O
exposure	O
(	O
AUC	O
)	O
higher	O
in	O
patients	O
not	O
treated	O
with	O
phenytoin	B
.	O

Because	O
busulfan	B
is	O
eliminated	O
from	O
the	O
body	O
via	O
conjugation	O
with	O
glutathione	O
,	O
use	O
of	O
acetaminophen	B
prior	O
to	O
(	O
72	O
hours	O
)	O
or	O
concurrent	O
with	O
BUSULFEX	B
may	O
result	O
in	O
reduced	O
busulfan	B
clearance	O
based	O
upon	O
the	O
known	O
property	O
of	O
acetaminophen	B
to	O
decrease	O
glutathione	O
levels	O
in	O
the	O
blood	O
and	O
tissues	O
.	O

Interactions	O
may	O
occur	O
with	O
the	O
following	O
:	O
adrenocorticoids	O
(	O
cortisone	O
-	O
like	O
medicine	O
)	O
,	O
anticoagulants	B
(	O
blood	B
thinners	O
)	O
,	O
carbamazepine	B
,	O
corticotropin	B
(	O
barbiturates	B
may	O
decrease	O
the	O
effects	O
of	O
these	O
medicines	O
)	O
,	O
central	B
nervous	I
system	I
(	O
CNS	O
)	O
depressants	B
(	O
using	O
these	O
medicines	O
with	O
barbiturates	B
may	O
result	O
in	O
increased	O
CNS	O
depressant	O
effects	O
)	O
,	O
divalproex	B
sodium	I
,	O
valproic	B
acid	I
(	O
using	O
these	O
medicines	O
with	O
barbiturates	B
may	O
change	O
the	O
amount	O
of	O
either	O
medicine	O
that	O
you	O
need	O
to	O
take	O
)	O
,	O
and	O
oral	O
contraceptives	B
containing	O
estrogens	B
(	O
barbiturates	B
may	O
decrease	O
the	O
effectiveness	O
of	O
these	O
oral	O
contraceptives	B
,	O
and	O
you	O
may	O
need	O
to	O
change	O
to	O
a	O
different	O
type	O
of	O
birth	O
control	O
)	O
.	O

The	O
CNS	O
effects	O
of	O
butalbital	B
may	O
be	O
enhanced	O
by	O
monoamine	B
oxidase	I
(	O
MAO	O
)	O
inhibitors	B
.	O

Butalbital	B
,	O
acetaminophen	B
and	O
caffeine	B
may	O
enhance	O
the	O
effects	O
of	O
:	O
other	O
narcotic	B
analgesics	O
,	O
alcohol	B
,	O
general	O
anesthetics	B
,	O
tranquilizers	B
such	O
as	O
chlordiazepoxide	B
,	O
sedative	O
-	O
hypnotics	O
,	O
or	O
other	O
CNS	B
depressants	I
,	O
causing	O
increased	O
CNS	B
depression	O
.	O

Potential	O
drug	O
interactions	O
between	O
Mentax	B
(	O
butenafine	B
HCl	I
cream	O
)	O
Cream	O
,	O
1	O
%	O
,	O
and	O
other	O
drugs	O
have	O
not	O
been	O
systematically	O
evaluated	O
.	O

Concurrent	O
use	O
of	O
butorphanol	B
with	O
central	B
nervous	I
system	I
depressants	I
(	O
e	O
.	O
g	O
.	O
,	O
alcohol	B
,	O
barbiturates	B
,	O
tranquilizers	B
,	O
and	O
antihistamines	B
)	O
may	O
result	O
in	O
increased	O
central	B
nervous	I
system	I
depressant	I
effects	O
.	O

When	O
used	O
concurrently	O
with	O
such	O
drugs	O
,	O
the	O
dose	O
of	O
butorphanol	B
should	O
be	O
the	O
smallest	O
effective	O
dose	O
and	O
the	O
frequency	O
of	O
dosing	O
reduced	O
as	O
much	O
as	O
possible	O
when	O
administered	O
concomitantly	O
with	O
drugs	O
that	O
potentiate	O
the	O
action	O
of	O
opioids	B
.	O

In	O
healthy	O
volunteers	O
,	O
the	O
pharmacokinetics	O
of	O
a	O
1	O
-	O
mg	O
dose	O
of	O
butorphanol	B
administered	O
as	O
STADOL	B
NS	I
were	O
not	O
affected	O
by	O
the	O
coadministration	O
of	O
a	O
single	O
6	O
-	O
mg	O
subcutaneous	O
dose	O
of	O
sumatriptan	B
.	O

However	O
,	O
in	O
another	O
study	O
in	O
healthy	O
volunteers	O
,	O
the	O
pharmacokinetics	O
of	O
butorphanol	B
were	O
significantly	O
altered	O
(	O
29	O
%	O
decrease	O
in	O
AUC	O
and	O
38	O
%	O
decrease	O
in	O
Cmax	O
)	O
when	O
a	O
1	O
-	O
mg	O
dose	O
of	O
STADOL	B
NS	I
was	O
administered	O
1	O
minute	O
after	O
a	O
20	O
-	O
mg	O
dose	O
of	O
sumatriptan	B
nasal	O
spray	O
.	O

When	O
the	O
STADOL	B
NS	I
was	O
administered	O
30	O
minutes	O
after	O
the	O
sumatriptan	B
nasal	O
spray	O
,	O
the	O
AUC	O
of	O
butorphanol	B
increased	O
11	O
%	O
and	O
Cmax	O
decreased	O
18	O
%	O
.	O

In	O
neither	O
case	O
were	O
the	O
pharmacokinetics	O
of	O
sumatriptan	B
affected	O
by	O
coadministration	O
with	O
STADOL	B
NS	I
.	O

These	O
results	O
suggest	O
that	O
the	O
analgesic	O
effect	O
of	O
STADOL	B
NS	I
may	O
be	O
diminished	O
when	O
it	O
is	O
administered	O
shortly	O
after	O
sumatriptan	B
nasal	O
spray	O
,	O
but	O
by	O
30	O
minutes	O
any	O
such	O
reduction	O
in	O
effect	O
should	O
be	O
minimal	O
.	O

The	O
safety	O
of	O
using	O
STADOL	B
NS	I
and	O
IMITREX	B
(	O
sumatriptan	B
)	O
Nasal	O
Spray	O
during	O
the	O
same	O
episode	O
of	O
migraine	O
has	O
not	O
been	O
established	O
.	O

The	O
pharmacokinetics	O
of	O
a	O
1	O
-	O
mg	O
dose	O
of	O
butorphanol	B
administered	O
as	O
STADOL	B
NS	I
were	O
not	O
affected	O
by	O
the	O
coadministration	O
of	O
cimetidine	B
(	O
300	O
mg	O
QID	O
)	O
.	O

Conversely	O
,	O
the	O
administration	O
of	O
STADOL	B
NS	I
(	O
1	O
mg	O
butorphanol	B
QID	O
)	O
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
a	O
300	O
-	O
mg	O
dose	O
of	O
cimetidine	B
.	O

It	O
is	O
not	O
known	O
if	O
the	O
effects	O
of	O
butorphanol	B
are	O
altered	O
by	O
concomitant	O
medications	O
that	O
affect	O
hepatic	O
metabolism	O
of	O
drugs	O
(	O
erythromycin	B
,	O
etc	O
.	O
)	O
,	O
but	O
physicians	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
that	O
a	O
smaller	O
initial	O
dose	O
and	O
longer	O
intervals	O
between	O
doses	O
may	O
be	O
needed	O
.	O

The	O
fraction	O
of	O
STADOL	B
NS	I
absorbed	O
is	O
unaffected	O
by	O
the	O
concomitant	O
administration	O
of	O
a	O
nasal	B
vasoconstrictor	I
(	O
oxymetazoline	B
)	O
,	O
but	O
the	O
rate	O
of	O
absorption	O
is	O
decreased	O
.	O

Therefore	O
,	O
a	O
slower	O
onset	O
can	O
be	O
anticipated	O
if	O
STADOL	B
NS	I
is	O
administered	O
concomitantly	O
with	O
,	O
or	O
immediately	O
following	O
,	O
a	O
nasal	B
vasoconstrictor	I
.	O

No	O
information	O
is	O
available	O
about	O
the	O
use	O
of	O
butorphanol	B
concurrently	O
with	O
MAO	B
inhibitors	I
.	O

DOSTINEX	B
should	O
not	O
be	O
administered	O
concurrently	O
with	O
D2	O
-	O
antagonists	O
,	O
such	O
as	O
phenothiazines	B
,	O
butyrophenones	B
,	O
thioxanthines	B
,	O
or	O
metoclopramide	B
.	O

Based	O
on	O
adult	O
data	O
,	O
lower	O
doses	O
of	O
caffeine	B
may	O
be	O
needed	O
following	O
coadministration	O
of	O
drugs	O
which	O
are	O
reported	O
to	O
decrease	O
caffeine	B
elimination	O
(	O
e	O
.	O
g	O
.	O
,	O
cimetidine	B
and	O
ketoconazole	B
)	O
and	O
higher	O
caffeine	B
doses	O
may	O
be	O
needed	O
following	O
coadministration	O
of	O
drugs	O
that	O
increase	O
caffeine	B
elimination	O
(	O
e	O
.	O
g	O
.	O
,	O
phenobarbital	B
and	O
phenytoin	B
)	O
.	O

Caffeine	B
administered	O
concurrently	O
with	O
ketoprofen	B
reduced	O
the	O
urine	O
volume	O
in	O
4	O
healthy	O
volunteers	O
.	O

Interconversion	O
between	O
caffeine	B
and	O
theophylline	B
has	O
been	O
reported	O
in	O
preterm	O
neonates	O
.	O

Interactions	O
for	O
vitamin	B
D	I
analogues	I
(	O
Vitamin	B
D2	I
,	O
Vitamin	B
D3	I
,	O
Calcitriol	B
,	O
and	O
Calcidiol	B
)	O
:	O
Cholestyramine	B
:	O
Cholestyramine	B
has	O
been	O
reported	O
to	O
reduce	O
intestinal	O
absorption	O
of	O
fat	B
soluble	I
vitamins	I
;	O

Phenytoin	B
/	O
Phenobarbital	B
:	O
The	O
coadministration	O
of	O
phenytoin	B
or	O
phenobarbital	B
will	O
not	O
affect	O
plasma	O
concentrations	O
of	O
vitamin	B
D	I
,	O
but	O
may	O
reduce	O
endogenous	O
plasma	O
levels	O
of	O
calcitriol	B
/	O
ergocalcitriol	O
by	O
accelerating	O
metabolism	O
.	O

Since	O
blood	O
level	O
of	O
calcitriol	B
/	O
ergocalcitriol	O
will	O
be	O
reduced	O
,	O
higher	O
doses	O
of	O
Rocaltrol	B
may	O
be	O
necessary	O
if	O
these	O
drugs	O
are	O
administered	O
simultaneously	O
.	O

Thiazides	B
:	O
Thiazides	B
are	O
known	O
to	O
induce	O
hypercalcemia	O
by	O
the	O
reduction	O
of	O
calcium	O
excretion	O
in	O
urine	O
.	O

Some	O
reports	O
have	O
shown	O
that	O
the	O
concomitant	O
administration	O
of	O
thiazides	B
with	O
vitamin	B
D	I
causes	O
hypercalcemia	O
.	O

Digitalis	B
:	O
Vitamin	B
D	I
dosage	O
must	O
be	O
determined	O
with	O
care	O
in	O
patients	O
undergoing	O
treatment	O
with	O
digitalis	B
,	O
as	O
hypercalcemia	O
in	O
such	O
patients	O
may	O
precipitate	O
cardiac	O
arrhythmias	O
.	O

Ketoconazole	B
:	O
Ketoconazole	B
may	O
inhibit	O
both	O
synthetic	O
and	O
catabolic	O
enzymes	O
of	O
vitamin	B
D	I
.	O

However	O
,	O
in	O
vivo	O
drug	O
interaction	O
studies	O
of	O
ketoconazole	B
with	O
vitamin	B
D	I
have	O
not	O
been	O
investigated	O
.	O

Corticosteroids	B
:	O
A	O
relationship	O
of	O
functional	O
antagonism	O
exists	O
between	O
vitamin	B
D	I
analogues	I
,	O
which	O
promote	O
calcium	O
absorption	O
,	O
and	O
corticosteroids	B
,	O
which	O
inhibit	O
calcium	O
absorption	O
.	O

Vitamin	B
D	I
:	O
The	O
coadministration	O
of	O
any	O
of	O
the	O
vitamin	B
D	I
analogues	I
should	O
be	O
avoided	O
as	O
this	O
could	O
create	O
possible	O
additive	O
effects	O
and	O
hypercalcemia	O
.	O

Calcium	B
Supplements	O
:	O
Uncontrolled	O
intake	O
of	O
additional	O
calcium	B
-	O
containing	O
preparations	O
should	O
be	O
avoided	O
.	O

Magnesium	B
:	O
Magnesium	B
-	O
containing	O
preparations	O
(	O
eg	O
,	O
antacids	B
)	O
may	O
cause	O
hypermagnesemia	O
and	O
should	O
therefore	O
not	O
be	O
taken	O
during	O
therapy	O
with	O
vitamin	B
D	I
by	O
patients	O
on	O
chronic	O
renal	O
dialysis	O
.	O

Interactions	O
for	O
vitamin	B
D	I
analogues	I
(	O
Vitamin	B
D2	I
,	O
Vitamin	B
D3	I
,	O
Calcitriol	B
,	O
and	O
Calcidiol	B
)	O
:	O
Cholestyramine	B
:	O
Cholestyramine	B
has	O
been	O
reported	O
to	O
reduce	O
intestinal	O
absorption	O
of	O
fat	B
soluble	I
vitamins	I
;	O

Phenytoin	B
/	O
Phenobarbital	B
:	O
The	O
coadministration	O
of	O
phenytoin	B
or	O
phenobarbital	B
will	O
not	O
affect	O
plasma	O
concentrations	O
of	O
vitamin	B
D	I
,	O
but	O
may	O
reduce	O
endogenous	O
plasma	O
levels	O
of	O
calcitriol	B
/	O
ergocalcitriol	O
by	O
accelerating	O
metabolism	O
.	O

Since	O
blood	O
level	O
of	O
calcitriol	B
/	O
ergocalcitriol	O
will	O
be	O
reduced	O
,	O
higher	O
doses	O
of	O
Rocaltrol	B
may	O
be	O
necessary	O
if	O
these	O
drugs	O
are	O
administered	O
simultaneously	O
.	O

Thiazides	B
:	O
Thiazides	B
are	O
known	O
to	O
induce	O
hypercalcemia	O
by	O
the	O
reduction	O
of	O
calcium	B
excretion	O
in	O
urine	O
.	O

Some	O
reports	O
have	O
shown	O
that	O
the	O
concomitant	O
administration	O
of	O
thiazides	B
with	O
vitamin	B
D	I
causes	O
hypercalcemia	O
.	O

Digitalis	B
:	O
Vitamin	B
D	I
dosage	O
must	O
be	O
determined	O
with	O
care	O
in	O
patients	O
undergoing	O
treatment	O
with	O
digitalis	B
,	O
as	O
hypercalcemia	O
in	O
such	O
patients	O
may	O
precipitate	O
cardiac	O
arrhythmias	O
.	O

Ketoconazole	B
:	O
Ketoconazole	B
may	O
inhibit	O
both	O
synthetic	O
and	O
catabolic	O
enzymes	O
of	O
vitamin	B
D	I
.	O

However	O
,	O
in	O
vivo	O
drug	O
interaction	O
studies	O
of	O
ketoconazole	B
with	O
vitamin	B
D	I
have	O
not	O
been	O
investigated	O
.	O

Corticosteroids	B
:	O
A	O
relationship	O
of	O
functional	O
antagonism	O
exists	O
between	O
vitamin	B
D	I
analogues	I
,	O
which	O
promote	O
calcium	O
absorption	O
,	O
and	O
corticosteroids	B
,	O
which	O
inhibit	O
calcium	O
absorption	O
.	O

Vitamin	B
D	I
:	O
The	O
coadministration	O
of	O
any	O
of	O
the	O
vitamin	B
D	I
analogues	I
should	O
be	O
avoided	O
as	O
this	O
could	O
create	O
possible	O
additive	O
effects	O
and	O
hypercalcemia	O
.	O

Calcium	B
Supplements	O
:	O
Uncontrolled	O
intake	O
of	O
additional	O
calcium	B
-	O
containing	O
preparations	O
should	O
be	O
avoided	O
.	O

Magnesium	B
:	O
Magnesium	B
-	O
containing	O
preparations	O
(	O
eg	O
,	O
antacids	B
)	O
may	O
cause	O
hypermagnesemia	O
and	O
should	O
therefore	O
not	O
be	O
taken	O
during	O
therapy	O
with	O
vitamin	B
D	I
by	O
patients	O
on	O
chronic	O
renal	O
dialysis	O
.	O

Concomitant	O
use	O
with	O
other	O
calcium	B
-	O
containing	O
medicines	O
(	O
including	O
antacids	B
)	O
may	O
cause	O
too	O
much	O
calcium	B
in	O
the	O
blood	O
or	O
urine	O
,	O
which	O
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
.	O

Using	O
calcium	B
acetate	I
with	O
digitalis	B
glycosides	I
(	O
heart	O
medicine	O
)	O
may	O
cause	O
hypercalcemia	O
(	O
too	O
much	O
calcium	B
in	O
the	O
blood	O
)	O
,	O
which	O
could	O
increase	O
the	O
chance	O
of	O
developing	O
an	O
irregular	O
heartbeat	O
.	O

May	O
interact	O
with	O
cefamandole	B
naftate	I
,	O
cephalothin	B
sodium	I
,	O
magnesium	B
sulfate	I
,	O
prednisolone	B
sodium	I
succinate	I
,	O
and	O
prochlorperazine	B
edisylate	I
.	O

No	O
significant	O
drug	O
interactions	O
have	O
been	O
reported	O
in	O
studies	O
of	O
candesartan	B
cilexetil	I
given	O
with	O
other	O
drugs	O
such	O
as	O
glyburide	B
,	O
nifedipine	B
,	O
digoxin	B
,	O
warfarin	B
,	O
hydrochlorothiazide	B
,	O
and	O
oral	O
contraceptives	B
in	O
healthy	O
volunteers	O
,	O
or	O
given	O
with	O
enalapril	B
to	O
patients	O
with	O
heart	O
failure	O
(	O
NYHA	O
class	O
II	O
and	O
III	O
)	O
.	O

Lithium	B
Reversible	O
increases	O
in	O
serum	O
lithium	B
concentrations	O
and	O
toxicity	O
have	O
been	O
reported	O
during	O
concomitant	O
administration	O
of	O
lithium	B
with	O
ACE	B
inhibitors	I
,	O
and	O
with	O
some	O
angiotensin	B
II	I
receptor	I
antagonists	I
.	O

An	O
increase	O
in	O
serum	O
lithium	B
concentration	O
has	O
been	O
reported	O
during	O
concomitant	O
administration	O
of	O
lithium	B
with	O
ATACAND	B
,	O
so	O
careful	O
monitoring	O
of	O
serum	O
lithium	B
levels	O
is	O
recommended	O
during	O
concomitant	O
use	O
.	O

Antacid	B
:	O
The	O
effect	O
of	O
an	O
aluminum	B
hydroxide	I
-	O
and	O
magnesium	B
hydroxide	I
-	O
containing	O
antacid	B
(	O
Maalox	B
)	O
*	O
on	O
the	O
pharmacokinetics	O
of	O
capecitabine	B
was	O
investigated	O
in	O
12	O
cancer	O
patients	O
.	O

There	O
was	O
a	O
small	O
increase	O
in	O
plasma	O
concentrations	O
of	O
capecitabine	B
and	O
one	O
metabolite	O
(	O
5	O
-	O
DFCR	O
)	O
;	O

there	O
was	O
no	O
effect	O
on	O
the	O
3	O
major	O
metabolites	O
(	O
5	O
-	O
DFUR	O
,	O
5	O
-	O
FU	O
and	O
FBAL	B
)	O
.	O

Coumarin	B
Anticoagulants	I
Altered	O
coagulation	O
parameters	O
and	O
/	O
or	O
bleeding	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
capecitabine	B
concomitantly	O
with	O
coumarin	O
-	O
derivative	O
anticoagulants	B
such	O
as	O
warfarin	B
and	O
phenprocoumon	B
.	O

Patients	O
taking	O
coumarin	O
-	O
derivative	O
anticoagulants	B
concomitantly	O
with	O
capecitabine	B
should	O
be	O
monitored	O
regularly	O
for	O
alterations	O
in	O
their	O
coagulation	O
parameters	O
(	O
PT	O
or	O
INR	O
)	O
.	O

Leucovorin	B
:	O
The	O
concentration	O
of	O
5	O
-	O
fluorouracil	O
is	O
increased	O
and	O
its	O
toxicity	O
may	O
be	O
enhanced	O
by	O
leucovorin	B
.	O

Deaths	O
from	O
severe	O
enterocolitis	O
,	O
diarrhea	O
,	O
and	O
dehydration	O
have	O
been	O
reported	O
in	O
elderly	O
patients	O
receiving	O
weekly	O
leucovorin	B
and	O
fluorouracil	B
.	O

Hypotension	O
Patients	O
on	O
Diuretic	B
Therapy	O
:	O
Patients	O
on	O
diuretics	B
and	O
especially	O
those	O
in	O
whom	O
diuretic	B
therapy	O
was	O
recently	O
instituted	O
,	O
as	O
well	O
as	O
those	O
on	O
severe	O
dietary	O
salt	O
restriction	O
or	O
dialysis	O
,	O
may	O
occasionally	O
experience	O
a	O
precipitous	O
reduction	O
of	O
blood	O
pressure	O
usually	O
within	O
the	O
first	O
hour	O
after	O
receiving	O
the	O
initial	O
dose	O
of	O
captopril	B
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
captopril	B
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	B
or	O
increasing	O
the	O
salt	O
intake	O
approximately	O
one	O
week	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
captopril	B
(	O
captopril	B
tablets	O
,	O
USP	O
)	O
or	O
initiating	O
therapy	O
with	O
small	O
doses	O
(	O
6	O
.	O
25	O
or	O
12	O
.	O
5	O
mg	O
)	O
.	O

Agents	O
Having	O
Vasodilator	O
Activity	O
:	O
Data	O
on	O
the	O
effect	O
of	O
concomitant	O
use	O
of	O
other	O
vasodilators	B
in	O
patients	O
receiving	O
captopril	B
for	O
heart	O
failure	O
are	O
not	O
available	O
;	O

therefore	O
,	O
nitroglycerin	B
or	O
other	O
nitrates	B
(	O
as	O
used	O
for	O
management	O
of	O
angina	O
)	O
or	O
other	O
drugs	O
having	O
vasodilator	O
activity	O
should	O
,	O
if	O
possible	O
,	O
be	O
discontinued	O
before	O
starting	O
captopril	B
.	O

Agents	O
Causing	O
Renin	O
Release	O
Captopril	B
'	O
s	O
effect	O
will	O
be	O
augmented	O
by	O
antihypertensive	B
agents	I
that	O
cause	O
renin	O
release	O
.	O

For	O
example	O
,	O
diuretics	B
(	O
e	O
.	O
g	O
.	O
,	O
thiazides	B
)	O
may	O
activate	O
the	O
renin	O
-	O
angiotensin	O
-	O
aldosterone	O
system	O
.	O

Agents	O
Affecting	O
Sympathetic	O
Activity	O
The	O
sympathetic	O
nervous	O
system	O
may	O
be	O
especially	O
important	O
in	O
supporting	O
blood	O
pressure	O
in	O
patients	O
receiving	O
captopril	B
alone	O
or	O
with	O
diuretics	B
.	O

Therefore	O
,	O
agents	B
affecting	O
sympathetic	O
activity	O
(	O
e	O
.	O
g	O
.	O
,	O
ganglionic	B
blocking	I
agents	I
or	O
adrenergic	B
neuron	I
blocking	I
agents	I
)	O
should	O
be	O
used	O
with	O
caution	O
.	O

Beta	O
-	O
adrenergic	O
blocking	B
drugs	I
add	O
some	O
further	O
antihypertensive	O
effect	O
to	O
captopril	B
,	O
but	O
the	O
overall	O
response	O
is	O
less	O
than	O
additive	O
.	O

Potassium	O
-	O
sparing	O
diuretics	B
such	O
as	O
spironolactone	B
,	O
triamterene	B
,	O
or	O
amiloride	B
,	O
or	O
potassium	B
supplements	O
should	O
be	O
given	O
only	O
for	O
documented	O
hypokalemia	O
,	O
and	O
then	O
with	O
caution	O
,	O
since	O
they	O
may	O
lead	O
to	O
a	O
significant	O
increase	O
of	O
serum	O
potassium	B
.	O

Inhibitors	O
Of	O
Endogenous	O
Prostaglandin	O
Synthesis	O
It	O
has	O
been	O
reported	O
that	O
indomethacin	B
may	O
reduce	O
the	O
antihypertensive	O
effect	O
of	O
captopril	B
,	O
especially	O
in	O
cases	O
of	O
low	O
renin	O
hypertension	O
.	O

Other	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
agents	B
(	O
e	O
.	O
g	O
.	O
,	O
aspirin	B
)	O
may	O
also	O
have	O
this	O
effect	O
.	O

Lithium	B
:	O
Increased	O
serum	O
lithium	B
levels	O
and	O
symptoms	O
of	O
lithium	B
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
concomitant	O
lithium	B
and	O
ACE	B
inhibitor	I
therapy	O
.	O

If	O
a	O
diuretic	B
is	O
also	O
used	O
,	O
it	O
may	O
increase	O
the	O
risk	O
of	O
lithium	B
toxicity	O
.	O

Cardiac	B
Glycosides	I
:	O
In	O
a	O
study	O
of	O
young	O
healthy	O
male	O
subjects	O
no	O
evidence	O
of	O
a	O
direct	O
pharmacokinetic	O
captopril	B
-	O
digoxin	B
interaction	O
could	O
be	O
found	O
.	O

Loop	B
Diuretics	I
:	O
Furosemide	B
administered	O
concurrently	O
with	O
captopril	B
does	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
captopril	B
in	O
renally	O
impaired	O
hypertensive	O
patients	O
.	O

Allopurinol	B
:	O
In	O
a	O
study	O
of	O
healthy	O
male	O
volunteers	O
no	O
significant	O
pharmacokinetic	O
interaction	O
occurred	O
when	O
captopril	B
and	O
allopurinol	B
were	O
administered	O
concomitantly	O
for	O
6	O
days	O
.	O

Agents	O
that	O
Inhibit	O
Cytochrome	O
P450	O
Isoenzymes	O
and	O
/	O
or	O
Epoxide	O
Hydrolase	O
Carbamazepine	B
is	O
metabolized	O
mainly	O
by	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
3A4	O
to	O
the	O
active	O
carbamazepine	B
10	O
,	O
11	O
-	O
epoxide	O
,	O
which	O
is	O
further	O
metabolized	O
to	O
the	O
trans	O
-	O
diol	O
by	O
epoxide	O
hydrolase	O
.	O

Agents	O
that	O
are	O
CYP3A4	O
inhibitors	B
that	O
have	O
been	O
found	O
,	O
or	O
are	O
expected	O
,	O
to	O
increase	O
plasma	O
levels	O
of	O
EQUETROTM	B
are	O
the	O
following	O
:	O
Acetazolamide	B
,	O
azole	B
antifungals	I
,	O
cimetidine	B
,	O
clarithromycin	B
(	O
1	O
)	O
,	O
dalfopristin	B
,	O
danazol	B
,	O
delavirdine	B
,	O
diltiazem	B
,	O
erythromycin	B
(	O
1	O
)	O
,	O
fluoxetine	B
,	O
fluvoxamine	B
,	O
grapefruit	O
juice	O
,	O
isoniazid	B
,	O
itraconazole	B
,	O
ketoconazole	B
,	O
loratadine	B
,	O
nefazodone	B
,	O
niacinamide	B
,	O
nicotinamide	B
,	O
protease	B
inhibitors	I
,	O
propoxyphene	B
,	O
quinine	B
,	O
quinupristin	B
,	O
troleandomycin	B
,	O
valproate	B
(	O
1	O
)	O
,	O
verapamil	B
,	O
zileuton	B
.	O

Thus	O
,	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
of	O
EQUETROTM	B
,	O
and	O
then	O
begins	O
a	O
course	O
of	O
treatment	O
with	O
one	O
of	O
these	O
CYP3A4	O
or	O
epoxide	O
hydrolase	O
inhibitors	O
,	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
reduction	O
for	O
EQUETROTM	B
may	O
be	O
necessary	O
.	O

Agents	O
that	O
are	O
CYP	O
inducers	O
that	O
have	O
been	O
found	O
,	O
or	O
are	O
expected	O
,	O
to	O
decrease	O
plasma	O
levels	O
of	O
EQUETROTM	B
are	O
the	O
following	O
:	O
Cisplatin	B
,	O
doxorubicin	B
HCL	I
,	O
felbamate	B
,	O
rifampin	B
,	O
phenobarbital	B
,	O
Phenytoin	B
(	O
2	O
)	O
,	O
primidone	B
,	O
methsuximide	B
,	O
and	O
theophylline	B
Thus	O
,	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
on	O
EQUETROTM	B
,	O
and	O
then	O
begins	O
a	O
course	O
of	O
treatment	O
with	O
one	O
of	O
these	O
CYP3A4	O
inducers	O
,	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
increase	O
for	O
EQUETROTM	B
may	O
be	O
necessary	O
.	O

Agents	O
with	O
Decreased	O
Levels	O
in	O
the	O
Presence	O
of	O
Carbamazepine	B
due	O
to	O
Induction	O
of	O
Cytochrome	O
P450	O
Enzymes	O
Carbamazepine	B
is	O
known	O
to	O
induce	O
CYP1A2	O
and	O
CYP3A4	O
.	O

Agents	O
that	O
have	O
been	O
found	O
,	O
or	O
are	O
expected	O
to	O
have	O
decreased	O
plasma	O
levels	O
in	O
the	O
presence	O
of	O
EQUETROTM	B
due	O
to	O
induction	O
of	O
CYP	O
enzymes	O
are	O
the	O
following	O
:	O
Acetaminophen	B
,	O
alprazolam	B
,	O
amitriptyline	B
,	O
bupropion	B
,	O
buspirone	B
,	O
citalopram	B
,	O
clobazam	B
,	O
clonazepam	B
,	O
clozapine	B
,	O
cyclosporin	B
,	O
delavirdine	B
,	O
desipramine	B
,	O
diazepam	B
,	O
dicumarol	B
,	O
doxycycline	B
,	O
ethosuximide	B
,	O
felbamate	B
,	O
felodipine	B
,	O
glucocorticoids	B
,	O
haloperidol	B
,	O
itraconazole	B
,	O
lamotrigine	B
,	O
levothyroxine	B
,	O
lorazepam	B
,	O
methadone	B
,	O
midazolam	B
,	O
mirtazapine	B
,	O
nortriptyline	B
,	O
olanzapine	B
,	O
oral	O
contraceptives	B
(	O
3	O
)	O
,	O
oxcarbazepine	B
,	O
Phenytoin	B
(	O
4	O
)	O
,	O
praziquantel	B
,	O
protease	B
inhibitors	I
,	O
quetiapine	B
,	O
risperidone	B
,	O
theophylline	B
,	O
topiramate	B
,	O
tiagabine	B
,	O
tramadol	B
,	O
triazolam	B
,	O
valproate	B
,	O
warfarin	B
(	O
5	O
)	O
,	O
ziprasidone	B
,	O
and	O
zonisamide	B
.	O

Agents	O
with	O
Increased	O
Levels	O
in	O
the	O
Presence	O
of	O
Carbamazepine	B
:	O
EQUETROTM	B
increases	O
the	O
plasma	O
levels	O
of	O
the	O
following	O
agents	O
:	O
Clomipramine	B
HCl	I
,	O
Phenytoin	B
(	O
6	O
)	O
,	O
and	O
primidone	B
Thus	O
,	O
if	O
a	O
patient	O
has	O
been	O
titrated	O
to	O
a	O
stable	O
dosage	O
on	O
one	O
of	O
the	O
agents	O
in	O
this	O
category	O
,	O
and	O
then	O
begins	O
a	O
course	O
of	O
the	O
treatment	O
with	O
EQUETROTM	B
,	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
a	O
dose	O
decrease	O
for	O
the	O
concomitant	O
agent	O
may	O
be	O
necessary	O
.	O

Pharmacological	O
/	O
Pharmacodynamic	O
Interactions	O
with	O
Carbamazepine	B
Concomitant	O
administration	O
of	O
carbamazepine	B
and	O
lithium	B
may	O
increase	O
the	O
risk	O
of	O
neurotoxic	O
side	O
effects	O
.	O

Given	O
the	O
anticonvulsant	O
properties	O
of	O
carbamazepine	B
,	O
EQUETROTM	B
may	O
reduce	O
the	O
thyroid	O
function	O
as	O
has	O
been	O
reported	O
with	O
other	O
anticonvulsants	B
.	O

Additionally	O
,	O
anti	O
-	O
malarial	O
drugs	B
,	O
such	O
as	O
chloroquine	B
and	O
mefloquine	B
,	O
may	O
antagonize	O
the	O
activity	O
of	O
carbamazepine	B
.	O

Because	O
of	O
its	O
primary	O
CNS	O
effect	O
,	O
caution	O
should	O
be	O
used	O
when	O
EQUETROTM	B
is	O
taken	O
with	O
other	O
centrally	B
acting	I
drugs	I
and	O
alcohol	B
.	O

Geocillin	B
(	O
carbenicillin	B
indanyl	I
sodium	I
)	O
blood	O
levels	O
may	O
be	O
increased	O
and	O
prolonged	O
by	O
concurrent	O
administration	O
of	O
probenecid	B
.	O

Caution	O
should	O
be	O
exercised	O
when	O
the	O
following	O
drugs	O
are	O
administered	O
concomitantly	O
with	O
LODOSYN	B
(	O
Carbidopa	B
)	O
given	O
with	O
levodopa	B
or	O
carbidopa	B
-	O
levodopa	B
combination	O
products	O
.	O

Dopamine	B
D2	I
receptor	I
antagonists	I
(	O
e	O
.	O
g	O
.	O
,	O
phenothiazines	B
,	O
butyrophenones	B
,	O
risperidone	B
)	O
and	O
isoniazid	B
may	O
reduce	O
the	O
therapeutic	O
effects	O
of	O
levodopa	B
.	O

In	O
addition	O
,	O
the	O
beneficial	O
effects	O
of	O
levodopa	B
in	O
Parkinsons	O
disease	O
have	O
been	O
reported	O
to	O
be	O
reversed	O
by	O
phenytoin	B
and	O
papaverine	B
.	O

Patients	O
taking	O
these	O
drugs	O
with	O
LODOSYN	B
and	O
levodopa	B
or	O
carbidopa	B
-	O
levodopa	B
combination	O
products	O
should	O
be	O
carefully	O
observed	O
for	O
loss	O
of	O
therapeutic	O
response	O
.	O

Iron	B
salts	O
may	O
reduce	O
the	O
bioavailability	O
of	O
carbidopa	B
and	O
levodopa	B
.	O

Although	O
metoclopramide	B
may	O
increase	O
the	O
bioavailability	O
of	O
levodopa	B
by	O
increasing	O
gastric	O
emptying	O
,	O
metoclopramide	B
may	O
also	O
adversely	O
affect	O
disease	O
control	O
by	O
its	O
dopamine	O
receptor	O
antagonistic	O
properties	O
.	O

Iodine	B
or	O
iodine	B
excess	O
may	O
decrease	O
the	O
effect	O
of	O
Carbimazole	B
,	O
and	O
an	O
iodine	B
deficiency	O
can	O
increase	O
the	O
effect	O
of	O
Carbimazole	B
.	O

Serum	O
concentration	O
of	O
digoxin	B
and	O
digitoxin	B
may	O
increase	O
when	O
patients	O
take	O
antithyroid	B
agents	I
.	O

Antithyroid	B
agents	I
may	O
decrease	O
thyroidal	O
uptake	O
of	O
sodium	B
iodide	I
I131	I
,	O
a	O
rebound	O
in	O
uptake	O
may	O
occur	O
up	O
to	O
5	O
days	O
after	O
sudden	O
withdrawal	O
of	O
Carbimazole	B
.	O

Antihistamines	B
may	O
enhance	O
the	O
effects	O
of	O
tricyclic	B
antidepressants	I
,	O
barbiturates	B
,	O
alcohol	B
,	O
and	O
other	O
CNS	B
depressants	I
.	O

MAO	B
inhibitors	I
prolong	O
and	O
intensify	O
the	O
anticholinergic	O
effects	O
of	O
antihistamines	B
.	O

Sympathomimetic	B
amines	I
may	O
reduce	O
the	O
antihypertensive	O
effects	O
of	O
reserpine	B
,	O
veratrum	B
alkaloids	I
,	O
methyldopa	B
and	O
mecamylamine	B
.	O

Effects	O
of	O
sympathomimetics	B
are	O
increased	O
with	O
MAO	B
inhibitors	I
and	O
beta	B
adrenergic	I
blockers	I
.	O

HEMABATE	B
may	O
augment	O
the	O
activity	O
of	O
other	O
oxytocic	B
agents	I
.	O

Ocupress	B
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
who	O
are	O
receiving	O
a	O
beta	O
-	O
adrenergic	O
blocking	B
agent	I
orally	O
because	O
of	O
the	O
potential	O
for	O
additive	O
effects	O
on	O
systemic	O
beta	O
-	O
blockade	O
.	O

Close	O
observation	O
of	O
the	O
patient	O
is	O
recommended	O
when	O
a	O
beta	O
-	O
blocker	O
is	O
administered	O
to	O
patients	O
receiving	O
catecholamine	O
-	O
depleting	O
drugs	O
such	O
as	O
reserpine	B
,	O
because	O
of	O
possible	O
additive	O
effects	O
and	O
the	O
production	O
of	O
hypotension	O
and	O
/	O
or	O
marked	O
bradycardia	O
,	O
which	O
may	O
produce	O
vertigo	O
,	O
syncope	O
,	O
or	O
postural	O
hypotension	O
.	O

poor	O
metabolizers	O
of	O
debrisoquin	B
:	O
Interactions	O
of	O
carvedilol	B
with	O
strong	O
inhibitors	O
of	O
CYP2D6	O
(	O
such	O
as	O
quinidine	B
,	O
fluoxetine	B
,	O
paroxetine	B
,	O
and	O
propafenone	B
)	O
have	O
not	O
been	O
studied	O
,	O
but	O
these	O
drugs	O
would	O
be	O
expected	O
to	O
increase	O
blood	O
levels	O
of	O
the	O
R	O
(	O
+	O
)	O
enantiomer	O
of	O
carvedilol	B
.	O

Catecholamine	O
-	O
depleting	O
Agents	O
:	O
Patients	O
taking	O
both	O
agents	B
with	I
b	O
-	O
blocking	O
properties	B
and	O
a	O
drug	O
that	O
can	O
deplete	O
catecholamines	O
(	O
e	O
.	O
g	O
.	O
,	O
reserpine	B
and	O
monoamine	B
oxidase	I
inhibitors	I
)	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
hypotension	O
and	O
/	O
or	O
severe	O
bradycardia	O
.	O

Clonidine	B
:	O
Concomitant	O
administration	O
of	O
clonidine	B
with	I
agents	I
with	I
b	O
-	O
blocking	O
properties	B
may	O
potentiate	O
blood	O
-	O
pressure	O
-	O
and	O
heart	O
-	O
rate	O
-	O
lowering	O
effects	O
.	O

When	O
concomitant	O
treatment	O
with	B
agents	I
with	I
b	O
-	O
blocking	O
properties	B
and	O
clonidine	B
is	O
to	O
be	O
terminated	O
,	O
the	O
b	O
-	O
blocking	O
agent	B
should	O
be	O
discontinued	O
first	O
.	O

Cyclosporine	B
:	O
Modest	O
increases	O
in	O
mean	O
trough	O
cyclosporine	B
concentrations	O
were	O
observed	O
following	O
initiation	O
of	O
carvedilol	B
treatment	O
in	O
21	O
renal	O
transplant	O
patients	O
suffering	O
from	O
chronic	O
vascular	O
rejection	O
.	O

In	O
about	O
30	O
%	O
of	O
patients	O
,	O
the	O
dose	O
of	O
cyclosporine	B
had	O
to	O
be	O
reduced	O
in	O
order	O
to	O
maintain	O
cyclosporine	B
concentrations	O
within	O
the	O
therapeutic	O
range	O
,	O
while	O
in	O
the	O
remainder	O
no	O
adjustment	O
was	O
needed	O
.	O

Due	O
to	O
wide	O
interindividual	O
variability	O
in	O
the	O
dose	O
adjustment	O
required	O
,	O
it	O
is	O
recommended	O
that	O
cyclosporine	B
concentrations	O
be	O
monitored	O
closely	O
after	O
initiation	O
of	O
carvedilol	B
therapy	O
and	O
that	O
the	O
dose	O
of	O
cyclosporine	B
be	O
adjusted	O
as	O
appropriate	O
.	O

Digoxin	B
:	O
Digoxin	B
concentrations	O
are	O
increased	O
by	O
about	O
15	O
%	O
when	O
digoxin	B
and	O
carvedilol	B
are	O
administered	O
concomitantly	O
.	O

Both	O
digoxin	B
and	O
COREG	B
slow	O
AV	O
conduction	O
.	O

Therefore	O
,	O
increased	O
monitoring	O
of	O
digoxin	B
is	O
recommended	O
when	O
initiating	O
,	O
adjusting	O
,	O
or	O
discontinuing	O
COREG	B
.	O

Inducers	O
and	O
Inhibitors	O
of	O
Hepatic	O
Metabolism	O
:	O
Rifampin	B
reduced	O
plasma	O
concentrations	O
of	O
carvedilol	B
by	O
about	O
70	O
%	O
.	O

Calcium	B
Channel	I
Blockers	I
:	O
Isolated	O
cases	O
of	O
conduction	O
disturbance	O
(	O
rarely	O
with	O
hemodynamic	O
compromise	O
)	O
have	O
been	O
observed	O
when	O
COREG	B
is	O
co	O
-	O
administered	O
with	O
diltiazem	B
.	O

As	O
with	B
other	O
agents	B
with	I
b	O
-	O
blocking	O
properties	B
,	O
if	O
COREG	B
is	O
to	O
be	O
administered	O
orally	O
with	B
calcium	I
channel	I
blockers	I
of	O
the	O
verapamil	B
or	O
diltiazem	B
type	O
,	O
it	O
is	O
recommended	O
that	O
ECG	O
and	O
blood	O
pressure	O
be	O
monitored	O
.	O

Insulin	B
or	O
Oral	O
Hypoglycemics	B
:	O
Agents	B
with	I
b	O
-	O
blocking	O
properties	B
may	O
enhance	O
the	O
blood	O
-	O
sugar	O
-	O
reducing	O
effect	O
of	O
insulin	B
and	O
oral	O
hypoglycemics	B
.	O

Therefore	O
,	O
in	O
patients	O
taking	O
insulin	B
or	O
oral	O
hypoglycemics	B
,	O
regular	O
monitoring	O
of	O
blood	O
glucose	O
is	O
recommended	O
.	O

Clinical	O
studies	O
in	O
healthy	O
volunteers	O
show	O
that	O
the	O
pharmacokinetics	O
of	O
CANCIDAS	B
are	O
not	O
altered	O
by	O
itraconazole	B
,	O
amphotericin	B
B	I
,	O
mycophenolate	B
,	O
nelfinavir	B
,	O
or	O
tacrolimus	B
.	O

CANCIDAS	B
has	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
itraconazole	B
,	O
amphotericin	B
B	I
,	O
or	O
the	O
active	O
metabolite	O
of	O
mycophenolate	O
.	O

CANCIDAS	B
reduced	O
the	O
blood	O
AUC0	O
-	O
12	O
of	O
tacrolimus	B
by	O
approximately	O
20	O
%	O
,	O
peak	O
blood	O
concentration	O
(	O
Cmax	O
)	O
by	O
16	O
%	O
,	O
and	O
12	O
-	O
hour	O
blood	O
concentration	O
(	O
C12hr	O
)	O
by	O
26	O
%	O
in	O
healthy	O
subjects	O
when	O
tacrolimus	B
(	O
2	O
doses	O
of	O
0	O
.	O
1	O
mg	O
/	O
kg	O
12	O
hours	O
apart	O
)	O
was	O
administered	O
on	O
the	O
10th	O
day	O
of	O
CANCIDAS	B
70	O
mg	O
daily	O
,	O
as	O
compared	O
to	O
results	O
from	O
a	O
control	O
period	O
in	O
which	O
tacrolimus	B
was	O
administered	O
alone	O
.	O

For	O
patients	O
receiving	O
both	O
therapies	O
,	O
standard	O
monitoring	O
of	O
tacrolimus	B
blood	O
concentrations	O
and	O
appropriate	O
tacrolimus	B
dosage	O
adjustments	O
are	O
recommended	O
.	O

In	O
two	O
clinical	O
studies	O
,	O
cyclosporine	B
(	O
one	O
4	O
mg	O
/	O
kg	O
dose	O
or	O
two	O
3	O
mg	O
/	O
kg	O
doses	O
)	O
increased	O
the	O
AUC	O
of	O
caspofungin	B
by	O
approximately	O
35	O
%	O
.	O

CANCIDAS	B
did	O
not	O
increase	O
the	O
plasma	O
levels	O
of	O
cyclosporine	B
.	O

There	O
were	O
transient	O
increases	O
in	O
liver	O
ALT	O
and	O
AST	O
when	O
CANCIDAS	B
and	O
cyclosporine	B
were	O
co	O
-	O
administered	O
.	O

A	O
drug	O
-	O
drug	O
interaction	O
study	O
with	O
rifampin	B
in	O
healthy	O
volunteers	O
has	O
shown	O
a	O
30	O
%	O
decrease	O
in	O
caspofungin	B
trough	O
concentrations	O
.	O

Patients	O
on	O
rifampin	B
should	O
receive	O
70	O
mg	O
of	O
CANCIDAS	B
daily	O
.	O

In	O
addition	O
,	O
results	O
from	O
regression	O
analyses	O
of	O
patient	O
pharmacokinetic	O
data	O
suggest	O
that	O
co	O
-	O
administration	O
of	O
other	O
inducers	O
of	O
drug	O
clearance	O
(	O
efavirenz	B
,	O
nevirapine	B
,	O
phenytoin	B
,	O
dexamethasone	B
,	O
or	O
carbamazepine	B
)	O
with	O
CANCIDAS	B
may	O
result	O
in	O
clinically	O
meaningful	O
reductions	O
in	O
caspofungin	B
concentrations	O
.	O

When	O
CANCIDAS	B
is	O
co	O
-	O
administered	O
with	O
inducers	O
of	O
drug	O
clearance	O
,	O
such	O
as	O
efavirenz	B
,	O
nevirapine	B
,	O
phenytoin	B
,	O
dexamethasone	B
,	O
or	O
carbamazepine	B
,	O
use	O
of	O
a	O
daily	O
dose	O
of	O
70	O
mg	O
of	O
CANCIDAS	B
should	O
be	O
considered	O

Probenecid	B
may	O
decrease	O
renal	O
tubular	O
secretion	O
of	O
cephalosporins	B
when	O
used	O
concurrently	O
,	O
resulting	O
in	O
increased	O
and	O
more	O
prolonged	O
cephalosporin	B
blood	O
levels	O
.	O

Antacids	B
(	O
aluminum	B
-	O
or	O
magnesium	B
-	O
containing	O
)	O
:	O
Concomitant	O
administration	O
of	O
300	O
-	O
mg	O
cefdinir	B
capsules	O
with	O
30	O
mL	O
Maalox	B
TC	I
suspension	O
reduces	O
the	O
rate	O
(	O
Cmax	O
)	O
and	O
extent	O
(	O
AUC	O
)	O
of	O
absorption	O
by	O
approximately	O
40	O
%	O
.	O

There	O
are	O
no	O
significant	O
effects	O
on	O
cefdinir	B
pharmacokinetics	O
if	O
the	O
antacid	B
is	O
administered	O
2	O
hours	O
before	O
or	O
2	O
hours	O
after	O
cefdinir	B
.	O

If	O
antacids	B
are	O
required	O
during	O
OMNICEF	B
therapy	O
,	O
OMNICEF	B
should	O
be	O
taken	O
at	O
least	O
2	O
hours	O
before	O
or	O
after	O
the	O
antacid	B
.	O

Probenecid	B
:	O
As	O
with	O
other	O
b	O
-	O
lactam	O
antibiotics	B
,	O
probenecid	B
inhibits	O
the	O
renal	O
excretion	O
of	O
cefdinir	B
,	O
resulting	O
in	O
an	O
approximate	O
doubling	O
in	O
A	O
.	O
C	O
.	O
a	O
54	O
%	O
increase	O
in	O
peak	O
cefdinir	B
plasma	O
levels	O
,	O
and	O
a	O
50	O
%	O
prolongation	O
in	O
the	O
apparent	O
elimination	O
half	O
-	O
life	O
.	O

Iron	B
Supplements	I
and	O
Foods	O
Fortified	O
With	O
Iron	B
Concomitant	O
administration	O
of	O
cefdinir	B
with	O
a	O
therapeutic	O
iron	B
supplement	I
containing	O
60	O
mg	O
of	O
elemental	O
iron	B
(	O
as	O
FeSO4	O
)	O
or	O
vitamins	B
supplemented	O
with	O
10	O
mg	O
of	O
elemental	O
iron	B
reduced	O
extent	O
of	O
absorption	O
by	O
80	O
%	O
and	O
31	O
%	O
,	O
respectively	O
.	O

If	O
iron	B
supplements	I
are	O
required	O
during	O
OMNICEF	B
therapy	O
,	O
OMNICEF	B
should	O
be	O
taken	O
at	O
least	O
2	O
hours	O
before	O
or	O
after	O
the	O
supplement	O
.	O

The	O
effect	O
of	O
foods	O
highly	O
fortified	O
with	O
elemental	O
iron	B
(	O
primarily	O
iron	B
-	O
fortified	O
breakfast	O
cereals	O
)	O
on	O
cefdinir	B
absorption	O
has	O
not	O
been	O
studied	O
.	O

Concomitantly	O
administered	O
iron	B
-	O
fortified	O
infant	O
formula	O
(	O
2	O
.	O
2	O
mg	O
elemental	O
iron	B
/	O
6	O
oz	O
)	O
has	O
no	O
significant	O
effect	O
on	O
cefdinir	B
pharmacokinetics	O
.	O

Therefore	O
,	O
OMNICEF	B
for	O
Oral	O
Suspension	O
can	O
be	O
administered	O
with	O
iron	B
-	O
fortified	O
infant	O
formula	O
.	O

The	O
reddish	O
color	O
is	O
due	O
to	O
the	O
formation	O
of	O
a	O
nonabsorbable	O
complex	O
between	O
cefdinir	B
or	O
its	O
breakdown	O
products	O
and	O
iron	B
in	O
the	O
gastrointestinal	O
tract	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
A	O
false	O
-	O
positive	O
reaction	O
for	O
ketones	O
in	O
the	O
urine	O
may	O
occur	O
with	O
tests	O
using	O
nitroprusside	B
,	O
but	O
not	O
with	O
those	O
using	O
nitroferricyanide	B
.	O

Oral	O
Contraceptives	B
Multiple	O
doses	O
of	O
cefditoren	B
pivoxil	I
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
ethinyl	B
estradiol	I
,	O
the	O
estrogenic	O
component	O
in	O
most	O
oral	O
contraceptives	B
.	O

Although	O
the	O
clinical	O
significance	O
is	O
not	O
known	O
,	O
it	O
is	O
not	O
recommended	O
that	O
cefditoren	B
pivoxil	I
be	O
taken	O
concomitantly	O
with	O
antacids	B
.	O

H2	O
-	O
Receptor	O
Antagonists	B
:	O
Co	O
-	O
administration	O
of	O
a	O
single	O
dose	O
of	O
intravenously	O
administered	O
famotidine	B
(	O
20	O
mg	O
)	O
reduced	O
the	O
oral	O
absorption	O
of	O
a	O
single	O
400	O
mg	O
dose	O
of	O
cefditoren	B
pivoxil	I
administered	O
following	O
a	O
meal	O
,	O
as	O
evidenced	O
by	O
a	O
27	O
%	O
decrease	O
in	O
mean	O
Cmax	O
and	O
a	O
22	O
%	O
decrease	O
in	O
mean	O
AUC	O
.	O

Although	O
the	O
clinical	O
significance	O
is	O
not	O
known	O
,	O
it	O
is	O
not	O
recommended	O
that	O
cefditoren	B
pivoxil	I
be	O
taken	O
concomitantly	O
with	O
H2	B
receptor	I
antagonists	I
.	O

Probenecid	B
:	O
As	O
with	O
other	O
b	O
-	O
lactam	O
antibiotics	B
,	O
co	O
-	O
administration	O
of	O
probenecid	B
with	O
cefditoren	B
pivoxil	I
resulted	O
in	O
an	O
increase	O
in	O
the	O
plasma	O
exposure	O
of	O
cefditoren	B
,	O
with	O
a	O
49	O
%	O
increase	O
in	O
mean	O
Cmax	O
,	O
a	O
122	O
%	O
increase	O
in	O
mean	O
AUC	O
,	O
and	O
a	O
53	O
%	O
increase	O
in	O
half	O
-	O
life	O
.	O

Renal	O
function	O
should	O
be	O
monitored	O
carefully	O
if	O
high	O
doses	O
of	O
aminoglycosides	B
are	O
to	O
be	O
administered	O
with	O
MAXIPIME	B
because	O
of	O
the	O
increased	O
potential	O
of	O
nephrotoxicity	O
and	O
ototoxicity	O
of	O
aminoglycoside	B
antibiotics	I
.	O

Nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
other	O
cephalosporins	B
with	O
potent	O
diuretics	B
such	O
as	O
furosemide	B
.	O

Carbamazepine	B
:	O
Elevated	O
carbamazepine	B
levels	O
have	O
been	O
reported	O
in	O
postmarketing	O
experience	O
when	O
SUPRAX	B
is	O
administered	O
concomitantly	O
.	O

Warfarin	B
and	O
Anticoagulants	B
:	O
Increased	O
prothrombin	O
time	O
,	O
with	O
or	O
without	O
clinical	O
bleeding	O
,	O
has	O
been	O
reported	O
when	O
cefixime	B
is	O
administered	O
concomitantly	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
A	O
false	O
-	O
positive	O
reaction	O
for	O
ketones	O
in	O
the	O
urine	O
may	O
occur	O
with	O
tests	O
using	O
nitroprusside	B
but	O
not	O
with	O
those	O
using	O
nitroferricyanide	B
.	O

Increased	O
nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
cephalosporins	B
and	O
aminoglycoside	B
antibiotics	I
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
Cephalosporins	B
,	O
including	O
cefotaxime	B
sodium	I
,	O
are	O
known	O
to	O
occasionally	O
induce	O
a	O
positive	O
direct	O
Coombs	O
test	O
.	O

If	O
CEFOTAN	B
and	O
an	O
aminoglycoside	B
are	O
used	O
concomitantly	O
,	O
renal	O
function	O
should	O
be	O
carefully	O
monitored	O
,	O
because	O
nephrotoxicity	O
may	O
be	O
potentiated	O
.	O

As	O
with	O
other	O
cephalosporins	B
,	O
high	O
concentrations	O
of	O
cefotetan	B
may	O
interfere	O
with	O
measurement	O
of	O
serum	O
and	O
urine	O
creatinine	O
levels	O
by	O
Jaffe	O
reaction	O
and	O
produce	O
false	O
increases	O
in	O
the	O
levels	O
of	O
creatinine	O
reported	O
.	O

Increased	O
nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
cephalosporins	B
and	O
aminoglycoside	B
antibiotics	I
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
As	O
with	O
cephalothin	B
,	O
high	O
concentrations	O
of	O
cefoxitin	B
(	O
100	O
micrograms	O
/	O
mL	O
)	O
may	O
interfere	O
with	O
measurement	O
of	O
serum	O
and	O
urine	O
creatinine	O
levels	O
by	O
the	O
Jaff	O
reaction	O
,	O
and	O
produce	O
false	O
increases	O
of	O
modest	O
degree	O
in	O
the	O
levels	O
of	O
creatinine	O
reported	O
.	O

Nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
aminoglycoside	B
antibiotics	I
and	O
cephalosporin	B
antibiotics	I
.	O

Concomitant	O
administration	O
of	O
probenecid	B
doubled	O
the	O
AUC	O
for	O
cefprozil	B
.	O

The	O
bioavailability	O
of	O
the	O
capsule	O
formulation	O
of	O
cefprozil	B
was	O
not	O
affected	O
when	O
administered	O
5	O
minutes	O
following	O
an	O
antacid	B
.	O

Nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
cephalosporins	B
with	O
aminoglycoside	B
antibiotics	I
or	O
potent	O
diuretics	B
such	O
as	O
furosemide	B
.	O

Renal	O
function	O
should	O
be	O
carefully	O
monitored	O
,	O
especially	O
if	O
higher	O
dosages	O
of	O
the	O
aminoglycosides	B
are	O
to	O
be	O
administered	O
or	O
if	O
therapy	O
is	O
prolonged	O
,	O
because	O
of	O
the	O
potential	O
nephrotoxicity	O
and	O
ototoxicity	O
of	O
aminoglycosidic	B
antibiotics	I
.	O

Chloramphenicol	B
has	O
been	O
shown	O
to	O
be	O
antagonistic	O
to	O
beta	O
-	O
lactam	O
antibiotics	B
,	O
including	O
ceftazidime	B
,	O
based	O
on	O
in	O
vitro	O
studies	O
and	O
time	O
kill	O
curves	O
with	O
enteric	O
gram	O
-	O
negative	O
bacilli	O
.	O

Theophylline	B
:	O
Twelve	O
healthy	O
male	O
volunteers	O
were	O
administered	O
one	O
200	O
-	O
mg	O
ceftibuten	B
capsule	O
twice	O
daily	O
for	O
6	O
days	O
.	O

With	O
the	O
morning	O
dose	O
of	O
ceftibuten	B
on	O
day	O
6	O
,	O
each	O
volunteer	O
received	O
a	O
single	O
intravenous	O
infusion	O
of	O
theophylline	B
(	O
4	O
mg	O
/	O
kg	O
)	O
.	O

The	O
effect	O
of	O
ceftibuten	B
on	O
the	O
pharmacokinetics	O
of	O
theophylline	B
administered	O
orally	O
has	O
not	O
been	O
investigated	O
.	O

Antacids	B
or	O
H	B
2	I
-	O
receptor	O
antagonists	B
:	O
The	O
effect	O
of	O
increased	O
gastric	O
pH	O
on	O
the	O
bioavailability	O
of	O
ceftibuten	B
was	O
evaluated	O
in	O
18	O
healthy	O
adult	O
volunteers	O
.	O

A	O
single	O
dose	O
of	O
liquid	O
antacid	B
did	O
not	O
affect	O
the	O
C	O
max	O
or	O
AUC	O
of	O
ceftibuten	B
;	O

however	O
,	O
150	O
mg	O
of	O
ranitidine	B
q12h	O
for	O
3	O
days	O
increased	O
the	O
ceftibuten	B
C	O
max	O
by	O
23	O
%	O
and	O
ceftibuten	B
AUC	O
by	O
16	O
%	O
.	O

The	O
results	O
of	O
assays	O
using	O
red	O
cells	O
from	O
healthy	O
subjects	O
to	O
determine	O
whether	O
ceftibuten	B
would	O
cause	O
direct	O
Coombs	O
reactions	O
in	O
vitro	O
showed	O
no	O
positive	O
reaction	O
at	O
ceftibuten	B
concentrations	O
as	O
high	O
as	O
40	O
g	O
/	O
mL	O
.	O

Although	O
the	O
occurrence	O
has	O
not	O
been	O
reported	O
with	O
Cefizox	B
,	O
nephrotoxicity	O
has	O
been	O
reported	O
following	O
concomitant	O
administration	O
of	O
other	O
cephalosporins	B
and	O
aminoglycosides	B
.	O

Clinical	O
studies	O
with	O
celecoxib	B
have	O
identified	O
potentially	O
significant	O
interactions	O
with	O
fluconazole	B
and	O
lithium	B
.	O

Experience	O
with	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
drugs	B
(	O
NSAIDs	B
)	O
suggests	O
the	O
potential	O
for	O
interactions	O
with	O
furosemide	B
and	O
ACE	B
inhibitors	I
.	O

The	O
effects	O
celecoxib	B
on	O
the	O
pharmacokinetics	O
and	O
/	O
or	O
pharmacodynamics	O
of	O
glyburide	B
,	O
ketoconazole	B
,	O
methotrexate	B
,	O
phenytoin	B
,	O
tolbutamide	B
,	O
and	O
warfarin	B
have	O
been	O
studied	O
in	O
vivo	O
and	O
clinically	O
important	O
interactions	O
have	O
not	O
been	O
found	O
.	O

ACE	B
inhibitors	I
:	O
Reports	O
suggest	O
that	O
NSAIDs	B
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
Angiotensin	B
Converting	I
Enzyme	I
(	O
ACE	B
)	O
inhibitors	B
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
CELEBREX	B
concomitantly	O
with	O
ACE	O
-	O
inhibitors	O
.	O

Furosemide	B
:	O
Clinical	O
studies	O
,	O
as	O
well	O
as	O
post	O
marketing	O
observations	O
,	O
have	O
shown	O
that	O
NSAIDs	B
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B
and	O
thiazides	B
in	O
some	O
patients	O
.	O

Aspirin	B
:	O
CELEBREX	B
can	O
be	O
used	O
with	O
low	O
dose	O
aspirin	B
.	O

However	O
,	O
concomitant	O
administration	O
of	O
aspirin	B
with	O
CELEBREX	B
may	O
result	O
in	O
an	O
increased	O
rate	O
of	O
GI	O
ulceration	O
or	O
other	O
complications	O
,	O
compared	O
to	O
use	O
of	O
CELEBREX	B
alone	O
.	O

Because	O
of	O
its	O
lack	O
of	O
platelet	O
effects	O
,	O
CELEBREX	B
is	O
not	O
a	O
substitute	O
for	O
aspirin	B
for	O
cardiovascular	O
prophylaxis	O
.	O

Fluconazole	B
:	O
Concomitant	O
administration	O
of	O
fluconazole	B
at	O
200	O
mg	O
QD	O
resulted	O
in	O
a	O
two	O
-	O
fold	O
increase	O
in	O
celecoxib	B
plasma	O
concentration	O
.	O

This	O
increase	O
is	O
due	O
to	O
the	O
inhibition	O
of	O
celecoxib	B
metabolism	O
via	O
P450	O
2C9	O
by	O
fluconazole	B
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
-	O
Pharmacokinetics	O
:	O
Metabolism	O
)	O
.	O

CELEBREX	B
should	O
be	O
introduced	O
at	O
the	O
lowest	O
recommended	O
dose	O
in	O
patients	O
receiving	O
fluconazole	B
.	O

Lithium	B
:	O
In	O
a	O
study	O
conducted	O
in	O
healthy	O
subjects	O
,	O
mean	O
steady	O
-	O
state	O
lithium	B
plasma	O
levels	O
increased	O
approximately	O
17	O
%	O
in	O
subjects	O
receiving	O
lithium	B
450	O
mg	O
BID	O
with	O
CELEBREX	B
200	O
mg	O
BID	O
as	O
compared	O
to	O
subjects	O
receiving	O
lithium	B
alone	O
.	O

Patients	O
on	O
lithium	B
treatment	O
should	O
be	O
closely	O
monitored	O
when	O
CELEBREX	B
is	O
introduced	O
or	O
withdrawn	O
.	O

Methotrexate	B
:	O
In	O
an	O
interaction	O
study	O
of	O
rheumatoid	O
arthritis	O
patients	O
taking	O
methotrexate	B
,	O
CELEBREX	B
did	O
not	O
have	O
a	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
methotrexate	B
.	O

Warfarin	B
:	O
The	O
effect	O
of	O
celecoxib	B
on	O
the	O
anti	O
-	O
coagulant	O
effect	O
of	O
warfarin	B
was	O
studied	O
in	O
a	O
group	O
of	O
healthy	O
subjects	O
receiving	O
daily	O
doses	O
of	O
2	O
-	O
5	O
mg	O
of	O
warfarin	B
.	O

In	O
these	O
subjects	O
,	O
celecoxib	B
did	O
not	O
alter	O
the	O
anticoagulant	O
effect	O
of	O
warfarin	B
as	O
determined	O
by	O
prothrombin	O
time	O
.	O

However	O
,	O
caution	O
should	O
be	O
used	O
when	O
administering	O
CELEBREX	B
with	O
warfarin	B
since	O
these	O
patients	O
are	O
at	O
increased	O
risk	O
of	O
bleeding	O
complications	O
.	O

Metformin	B
:	O
In	O
healthy	O
subjects	O
given	O
single	O
500	O
mg	O
doses	O
of	O
cephalexin	B
and	O
metformin	B
,	O
plasma	O
metformin	B
mean	O
cmax	O
and	O
AUC	O
increased	O
by	O
an	O
average	O
of	O
34	O
%	O
and	O
24	O
%	O
,	O
respectively	O
,	O
and	O
metformin	B
mean	O
renal	O
clearance	O
decreased	O
by	O
14	O
%	O
.	O

No	O
information	O
is	O
available	O
about	O
the	O
interaction	O
of	O
cephalexin	B
and	O
metformin	B
following	O
multiple	O
doses	O
of	O
either	O
drug	O
.	O

Although	O
not	O
observed	O
in	O
this	O
study	O
,	O
adverse	O
effects	O
could	O
potentially	O
arise	O
from	O
co	O
-	O
administration	O
of	O
cephalexin	B
and	O
metformin	B
by	O
inhibition	O
of	O
tubular	O
secretion	O
via	O
organic	O
cationic	O
transporter	O
systems	O
.	O

Accordingly	O
,	O
careful	O
patient	O
monitoring	O
and	O
dose	O
adjustment	O
of	O
metformin	B
is	O
recommended	O
in	O
patients	O
concomitantly	O
taking	O
cephalexin	B
and	O
metformin	B
.	O

Probenecid	B
:	O
As	O
with	O
other	O
b	O
-	O
lactams	O
,	O
the	O
renal	O
excretion	O
of	O
cephalexin	B
is	O
inhibited	O
by	O
probenecid	B
.	O

Immunosuppressive	B
Drugs	I
,	O
Fibric	B
Acid	I
Derivatives	I
,	O
Niacin	B
(	O
Nicotinic	B
Acid	I
,	O
Erythromycin	B
,	O
Azole	B
Antifungals	I
:	O
Skeletal	O
Muscle	O
.	O

ANTACID	B
(	O
Magnesium	O
-	O
Aluminum	O
Hydroxide	B
)	O
:	O
Cerivastatin	B
plasma	O
concentrations	O
were	O
not	O
affected	O
by	O
co	O
-	O
administration	O
of	O
antacid	B
.	O

CIMETlDINE	B
:	O
Cerivastatin	B
plasma	O
concentrations	O
were	O
not	O
affected	O
by	O
co	O
-	O
administration	O
of	O
cimetidine	B
.	O

CHOLESTYRAMINE	B
:	O
The	O
influence	O
of	O
the	O
bile	O
-	O
acidsequestering	O
agent	O
cholestyramine	B
on	O
the	O
pharmacokinetits	O
of	O
cerivastatin	B
sodium	I
was	O
evaluated	O
in	O
12	O
healthy	O
males	O
in	O
2	O
separate	O
randomized	O
crossover	O
studies	O
.	O

In	O
the	O
first	O
study	O
,	O
concomitant	O
administration	O
of	O
0	O
.	O
2	O
mg	O
cerivastatin	B
sodium	I
and	O
12	O
g	O
cholestyramine	B
resulted	O
in	O
decreases	O
of	O
more	O
than	O
22	O
%	O
for	O
AUC	O
and	O
40	O
%	O
for	O
Cmax	O
when	O
compared	O
to	O
dosing	O
cerivastatin	B
sodium	I
alone	O
.	O

However	O
,	O
in	O
the	O
second	O
study	O
,	O
administration	O
of	O
12	O
g	O
cholestyramine	B
1	O
hour	O
before	O
the	O
evening	O
meal	O
and	O
0	O
.	O
3	O
mg	O
cerivastatin	B
sodium	I
approximately	O
4	O
hours	O
after	O
the	O
same	O
evening	O
meal	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
cerivastatin	B
AUC	O
of	O
less	O
than	O
8	O
%	O
,	O
and	O
a	O
decrease	O
in	O
Cmax	O
of	O
about	O
30	O
%	O
when	O
compared	O
to	O
dosing	O
cerivastatin	B
sodium	I
alone	O
.	O

Therefore	O
,	O
it	O
would	O
be	O
expected	O
that	O
a	O
dosing	O
schedule	O
of	O
cerivastatin	B
sodium	I
given	O
at	O
bedtime	O
and	O
cholestyramine	B
given	O
before	O
the	O
evening	O
meal	O
would	O
not	O
result	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
clinical	O
effect	O
of	O
cerivastatin	B
sodium	I
.	O

DIGOXIN	B
:	O
Plasma	O
digoxin	B
levels	O
and	O
digoxin	B
clearance	O
at	O
steady	O
-	O
state	O
were	O
not	O
affected	O
by	O
co	O
-	O
administration	O
of	O
0	O
.	O
2	O
mg	O
cerivastatin	B
sodium	I
.	O

Cerivastatin	B
plasma	O
concentrations	O
were	O
also	O
not	O
affected	O
by	O
co	O
-	O
administration	O
of	O
digoxin	B
.	O

WARFARIN	B
:	O
Co	O
-	O
administration	O
of	O
warfarin	B
and	O
cerivastatin	B
to	O
healthy	O
volunteers	O
did	O
not	O
result	O
in	O
any	O
changes	O
in	O
prothrombin	O
time	O
or	O
clotting	O
factor	O
VII	O
when	O
compared	O
to	O
co	O
-	O
administration	O
of	O
warfarin	B
and	O
placebo	O
.	O

The	O
AUC	O
and	O
Cmax	O
of	O
both	O
the	O
(	O
R	O
)	O
and	O
(	O
S	O
)	O
isomers	O
of	O
warfarin	B
were	O
unaffected	O
by	O
concurrent	O
dosing	O
of	O
0	O
.	O
3	O
mg	O
cerivastatin	B
sodium	I
.	O

Co	O
-	O
administration	O
of	O
warfarin	B
and	O
cerivastatin	B
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
cerivastatin	B
sodium	I
.	O

ERYTHROMYCIN	B
:	O
In	O
hypercholesterolemic	O
patients	O
,	O
steady	O
-	O
state	O
cerivastatin	B
AUC	O
and	O
Cmax	O
increased	O
approximately	O
50	O
%	O
and	O
24	O
%	O
respectively	O
after	O
10	O
days	O
with	O
co	O
-	O
administration	O
of	O
erythromycin	B
,	O
a	O
known	O
inhibitor	O
of	O
cytochrome	O
P450	O
3A4	O
.	O

OTHER	O
CONCOMITANT	O
THERAPY	O
:	O
Although	O
specific	O
interaction	O
studies	O
were	O
not	O
performed	O
,	O
in	O
clinical	O
studies	O
,	O
cerivastatin	B
sodium	I
was	O
used	O
concomitantly	O
with	O
angiotensin	O
-	O
converting	B
enzyme	I
(	O
ACE	O
)	O
inhibitors	B
,	O
betablockers	B
,	O
calcium	O
-	O
channel	O
blockers	B
,	O
diuretics	B
,	O
and	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
drugs	B
(	O
NSAIDs	B
)	O
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
interactions	O
.	O

Pharmacokinetic	O
interaction	O
studies	O
with	O
cetirizine	B
in	O
adults	O
were	O
conducted	O
with	O
pseudoephedrine	B
,	O
antipyrine	B
,	O
ketoconazole	B
,	O
erythromycin	B
and	O
azithromycin	B
.	O

In	O
a	O
multiple	O
dose	O
study	O
of	O
theophylline	B
(	O
400	O
mg	O
once	O
daily	O
for	O
3	O
days	O
)	O
and	O
cetirizine	B
(	O
20	O
mg	O
once	O
daily	O
for	O
3	O
days	O
)	O
,	O
a	O
16	O
%	O
decrease	O
in	O
the	O
clearance	O
of	O
cetirizine	B
was	O
observed	O
.	O

The	O
disposition	O
of	O
theophylline	B
was	O
not	O
altered	O
by	O
concomitant	O
cetirizine	B
administration	O
.	O

Drug	O
-	O
Drug	O
Interactions	O
:	O
No	O
clinically	O
significant	O
drug	O
interactions	O
have	O
been	O
found	O
with	O
theophylline	B
at	O
a	O
low	O
dose	O
,	O
azithromycin	B
,	O
pseudoephedrine	B
,	O
ketoconazole	B
,	O
or	O
erythromycin	B
.	O

There	O
was	O
a	O
small	O
decrease	O
in	O
the	O
clearance	O
of	O
cetirizine	B
caused	O
by	O
a	O
400	O
-	O
mg	O
dose	O
of	O
theophylline	B
;	O

A	O
drug	O
interaction	O
study	O
was	O
performed	O
in	O
which	O
ERBITUX	B
was	O
administered	O
in	O
combination	O
with	O
irinotecan	B
.	O

There	O
was	O
no	O
evidence	O
of	O
any	O
pharmacokinetic	O
interactions	O
between	O
ERBITUX	B
and	O
irinotecan	B
.	O

Cevimeline	B
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
taking	O
beta	B
adrenergic	I
antagonists	I
,	O
because	O
of	O
the	O
possibility	O
of	O
conduction	O
disturbances	O
.	O

Although	O
clinical	O
studies	O
have	O
not	O
established	O
a	O
cause	O
and	O
effect	O
relationship	O
,	O
physicians	O
should	O
be	O
aware	O
that	O
variable	O
effects	O
an	O
blood	O
coagulation	O
have	O
been	O
reported	O
very	O
rarely	O
in	O
patients	O
receiving	O
oral	O
anticoagulants	B
and	O
chlordiazepoxide	B
.	O

The	O
concomitant	O
use	O
of	O
alcohol	B
or	O
other	O
central	B
nervous	I
system	I
depressants	I
may	O
have	O
an	O
additive	O
effect	O
.	O

The	O
administration	O
of	O
local	O
anesthetic	B
solutions	I
containing	O
epinephrine	B
or	O
norepinephrine	B
to	O
patients	O
receiving	O
monoamine	B
oxidase	I
inhibitors	I
,	O
tricyclic	B
antidepressants	I
or	O
phenothiazines	B
may	O
produce	O
severe	O
,	O
prolonged	O
hypotension	O
or	O
hypertension	O
.	O

Concurrent	O
administration	O
of	O
vasopressor	B
drugs	I
(	O
for	O
the	O
treatment	O
of	O
hypotension	O
related	O
to	O
obstetric	O
blocks	O
)	O
and	O
ergot	O
-	O
type	O
oxytocic	B
drugs	I
may	O
cause	O
severe	O
,	O
persistent	O
hypertension	O
or	O
cerebrovascular	O
accidents	O
.	O

Therefore	O
,	O
chloroprocaine	B
should	O
not	O
be	O
used	O
in	O
any	O
condition	O
in	O
which	O
a	O
sulfonamide	B
drug	I
is	O
being	O
employed	O
.	O

Ethoxzolamide	B
may	O
increase	O
the	O
action	O
of	O
tricyclics	B
,	O
amphetamines	B
,	O
procainamide	B
,	O
and	O
quinidine	B
.	O

It	O
may	O
increase	O
excretion	O
of	O
barbiturates	B
,	O
lithium	B
,	O
and	O
ASA	B
and	O
may	O
also	O
increase	O
the	O
toxicity	O
of	O
salicylates	B
.	O

Coadministration	O
of	O
ethoxzolamide	B
with	O
other	O
diuretics	B
,	O
amphotericin	B
B	I
,	O
and	O
corticosteroids	B
may	O
cause	O
hypokalemia	O
.	O

Acetaminophen	B
:	O
May	O
increase	O
plasma	O
concentration	O
of	O
synthetic	B
estrogens	I
,	O
possibly	O
by	O
inhibiting	O
conjugation	O
.	O

Combination	O
hormonal	B
contraceptives	I
may	O
also	O
decrease	O
the	O
plasma	O
concentration	O
of	O
acetaminophen	B
.	O

Acitretin	B
:	O
Interferes	O
with	O
the	O
contraceptive	O
effect	O
of	O
microdosed	O
progestin	B
-	O
containing	O
minipill	O
preparations	O
.	O

Aminoglutethimide	B
:	O
May	O
increase	O
CYP	O
metabolism	O
of	O
progestins	B
leading	O
to	O
possible	O
decrease	O
in	O
contraceptive	O
effectiveness	O
.	O

Antibiotics	B
(	O
ampicillin	B
,	O
tetracycline	B
)	O
:	O
Pregnancy	O
has	O
been	O
reported	O
following	O
concomitant	O
use	O
,	O
however	O
,	O
pharmacokinetic	O
studies	O
have	O
not	O
shown	O
consistent	O
effects	O
with	O
these	O
antibiotics	B
on	O
plasma	O
concentrations	O
of	O
synthetic	B
steroids	I
.	O

Anticoagulants	B
:	O
Combination	O
hormonal	B
contraceptives	I
may	O
increase	O
or	O
decrease	O
the	O
effects	O
of	O
coumarin	B
derivatives	I
.	O

Anticonvulsants	B
(	O
carbamazepine	B
,	O
felbamate	B
,	O
phenobarbital	B
,	O
phenytoin	B
,	O
topiramate	B
)	O
:	O
Increase	O
the	O
metabolism	O
of	O
ethinyl	B
estradiol	I
and	O
/	O
or	O
some	O
progestins	B
,	O
leading	O
to	O
possible	O
decrease	O
in	O
contraceptive	O
effectiveness	O
.	O

Ascorbic	B
acid	I
:	O
Doses	O
of	O
ascorbic	B
acid	I
(	O
vitamin	B
C	I
)	O
1	O
g	O
/	O
day	O
have	O
been	O
reported	O
to	O
increase	O
plasma	O
concentration	O
of	O
synthetic	B
estrogens	I
by	O
~	O
47	O
%	O
,	O
possibly	O
by	O
inhibiting	O
conjugation	O
;	O

Atorvastatin	B
:	O
Atorvastatin	B
increases	O
the	O
AUC	O
for	O
norethindrone	B
and	O
ethinyl	B
estradiol	I
.	O

Benzodiazepines	B
:	O
Combination	O
hormonal	B
contraceptives	I
may	O
decrease	O
the	O
clearance	O
of	O
some	O
benzodiazepines	B
(	O
alprazolam	B
,	O
chlordiazepoxide	B
,	O
diazepam	B
)	O
and	O
increase	O
the	O
clearance	O
of	O
others	O
(	O
lorazepam	B
,	O
oxazepam	B
,	O
temazepam	B
)	O
.	O

Clofibric	B
acid	I
:	O
Combination	O
hormonal	B
contraceptives	I
may	O
increase	O
the	O
clearance	O
of	O
clofibric	B
acid	I
.	O

Cyclosporine	B
:	O
Combination	O
hormonal	B
contraceptives	I
may	O
inhibit	O
the	O
metabolism	O
of	O
cyclosporine	B
,	O
leading	O
to	O
increased	O
plasma	O
concentrations	O
;	O

Example	O
inducers	O
include	O
aminoglutethimide	B
,	O
carbamazepine	B
,	O
nafcillin	B
,	O
nevirapine	B
,	O
phenobarbital	B
,	O
phenytoin	B
,	O
and	O
rifamycins	B
.	O

Griseofulvin	B
:	O
Griseofulvin	B
may	O
induce	O
the	O
metabolism	O
of	O
combination	B
hormonal	I
contraceptives	I
causing	O
menstrual	O
changes	O
;	O

Morphine	B
:	O
Combination	O
hormonal	B
contraceptives	I
may	O
increase	O
the	O
clearance	O
of	O
morphine	B
.	O

Non	O
-	O
nucleoside	O
reverse	B
transcriptase	I
inhibitors	I
(	O
NNRTIs	B
)	O
:	O
Nevirapine	B
may	O
decrease	O
plasma	O
levels	O
of	O
combination	B
hormonal	I
contraceptives	I
;	O

Prednisolone	B
:	O
Ethinyl	B
estradiol	I
may	O
inhibit	O
the	O
metabolism	O
of	O
prednisolone	B
,	O
leading	O
to	O
increased	O
plasma	O
concentrations	O
.	O

Protease	B
inhibitors	I
:	O
Amprenavir	B
,	O
lopinavir	B
,	O
nelfinavir	B
,	O
and	O
ritonavir	B
have	O
been	O
shown	O
to	O
decrease	O
plasma	O
levels	O
of	O
combination	B
hormonal	I
contraceptives	I
;	O

Indinavir	B
has	O
been	O
shown	O
to	O
increase	O
plasma	O
levels	O
of	O
combination	B
hormonal	I
contraceptives	I
.	O

Rifampin	B
:	O
Rifampin	B
increases	O
the	O
metabolism	O
of	O
ethinyl	B
estradiol	I
and	O
some	O
progestins	B
(	O
norethindrone	B
)	O
resulting	O
in	O
decreased	O
contraceptive	O
effectiveness	O
and	O
increased	O
menstrual	O
irregularities	O
.	O

Salicylic	B
acid	I
:	O
Combination	O
hormonal	B
contraceptives	I
may	O
increase	O
the	O
clearance	O
of	O
salicylic	B
acid	I
.	O

Selegiline	B
:	O
Combination	B
hormonal	I
contraceptives	I
may	O
increase	O
the	O
serum	O
concentration	O
of	O
selegiline	B
.	O

Theophylline	B
:	O
Ethinyl	B
estradiol	I
may	O
inhibit	O
the	O
metabolism	O
of	O
theophylline	B
,	O
leading	O
to	O
increased	O
plasma	O
concentrations	O
.	O

Tricyclic	B
antidepressants	I
(	O
amitriptyline	B
,	O
imipramine	B
,	O
nortriptyline	B
)	O
:	O
Metabolism	O
may	O
be	O
inhibited	O
by	O
combination	B
hormonal	I
contraceptives	I
,	O
increasing	O
plasma	O
levels	O
of	O
antidepressant	B
;	O

ETHANOL	B
/	O
NUTRITION	O
/	O
HERB	O
INTERACTIONS	O
:	O
Food	O
:	O
CNS	O
effects	O
of	O
caffeine	B
may	O
be	O
enhanced	O
if	O
combination	B
hormonal	I
contraceptives	I
are	O
used	O
concurrently	O
with	O
caffeine	B
.	O

Grapefruit	O
juice	O
increases	O
ethinyl	B
estradiol	I
concentrations	O
and	O
would	O
be	O
expected	O
to	O
increase	O
progesterone	B
serum	O
levels	O
as	O
well	O
;	O

There	O
have	O
been	O
isolated	O
reports	O
of	O
patients	O
experiencing	O
increases	O
in	O
their	O
prothrombin	O
times	O
when	O
etidronate	B
was	O
added	O
to	O
warfarin	B
therapy	O
.	O

ACE	O
-	O
inhibitors	O
Reports	O
suggest	O
that	O
NSAIDs	B
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
ACE	O
-	O
inhibitors	O
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	B
concomitantly	O
with	O
ACE	O
-	O
inhibitors	O
.	O

Antacids	B
:	O
The	O
concomitant	O
administration	O
of	O
antacids	B
has	O
no	O
apparent	O
effect	O
on	O
the	O
extent	O
of	O
absorption	O
of	O
Lodine	B
.	O

Aspirin	B
:	O
When	O
Lodine	B
is	O
administered	O
with	O
aspirin	B
,	O
its	O
protein	O
binding	O
is	O
reduced	O
,	O
although	O
the	O
clearance	O
of	O
free	O
etodolac	B
is	O
not	O
altered	O
.	O

however	O
,	O
as	O
with	O
other	O
NSAIDs	B
,	O
concomitant	O
administration	O
of	O
Lodine	B
and	O
aspirin	B
is	O
not	O
generally	O
recommended	O
because	O
of	O
the	O
potential	O
of	O
increased	O
adverse	O
effects	O
.	O

Cyclosporine	O
,	O
Digoxin	O
,	O
Methotrexate	O
Lodine	B
,	O
like	O
other	O
NSAIDs	B
,	O
through	O
effects	O
on	O
renal	O
prostaglandins	O
,	O
may	O
cause	O
changes	O
in	O
the	O
elimination	O
of	O
these	O
drugs	O
leading	O
to	O
elevated	O
serum	O
levels	O
of	O
cyclosporine	B
,	O
digoxin	B
,	O
methotrexate	B
,	O
and	O
increased	O
toxicity	O
.	O

Patients	O
receiving	O
these	O
drugs	O
who	O
are	O
given	O
Lodine	B
,	O
or	O
any	O
other	O
NSAID	B
,	O
and	O
particularly	O
those	O
patients	O
with	O
altered	O
renal	O
function	O
,	O
should	O
be	O
observed	O
for	O
the	O
development	O
of	O
the	O
specific	O
toxicities	O
of	O
these	O
drugs	O
.	O

Diuretics	B
:	O
Etodolac	O
has	O
no	O
apparent	O
pharmacokinetic	O
interaction	O
when	O
administered	O
with	O
furosemide	B
or	O
hydrochlorothiazide	B
.	O

Nevertheless	O
,	O
clinical	O
studies	O
,	O
as	O
well	O
as	O
postmarketing	O
observations	O
have	O
shown	O
that	O
Lodine	B
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B
and	O
thiazides	B
in	O
some	O
patients	O
.	O

Glyburide	B
:	O
Etodolac	B
has	O
no	O
apparent	O
pharmacokinetic	O
interaction	O
when	O
administered	O
with	O
glyburide	B
.	O

Lithium	B
:	O
NSAIDs	B
have	O
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	B
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	B
clearance	O
.	O

Thus	O
,	O
when	O
NSAIDs	B
and	O
lithium	B
are	O
administered	O
concurrently	O
,	O
subjects	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
of	O
lithium	B
toxicity	O
.	O

Phenylbutazone	B
:	O
Phenylbutazone	B
causes	O
increase	O
(	O
by	O
about	O
80	O
%	O
)	O
in	O
the	O
free	O
fraction	O
of	O
etodolac	B
.	O

Although	O
in	O
vivo	O
studies	O
have	O
not	O
been	O
done	O
to	O
see	O
if	O
etodolac	B
clearance	O
is	O
changed	O
by	O
coadministration	O
of	O
phenylbutazone	B
,	O
it	O
is	O
not	O
recommended	O
that	O
they	O
be	O
coadministered	O
.	O

Phenytoin	B
:	O
Etodolac	B
has	O
no	O
apparent	O
pharmacokinetic	O
interaction	O
when	O
administered	O
with	O
phenytoin	B
.	O

Warfarin	B
:	O
The	O
effects	O
of	O
warfarin	B
and	O
NSAIDs	B
on	O
GI	O
bleeding	O
are	O
synergistic	O
,	O
such	O
that	O
users	O
of	O
both	O
drugs	O
together	O
have	O
a	O
risk	O
of	O
serious	O
GI	O
bleeding	O
higher	O
than	O
that	O
of	O
users	O
of	O
either	O
drug	O
alone	O
.	O

Short	O
-	O
term	O
pharmacokinetic	O
studies	O
have	O
demonstrated	O
that	O
concomitant	O
administration	O
of	O
warfarin	B
and	O
Lodine	B
(	O
etodolac	B
capsules	O
and	O
tablets	O
)	O
results	O
in	O
reduced	O
protein	O
binding	O
of	O
warfarin	B
,	O
but	O
there	O
was	O
no	O
change	O
in	O
the	O
clearance	O
of	O
free	O
warfarin	B
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
pharmacodynamic	O
effect	O
of	O
warfarin	B
administered	O
alone	O
and	O
warfarin	B
administered	O
with	O
Lodine	B
as	O
measured	O
by	O
prothrombin	O
time	O
.	O

Thus	O
,	O
concomitant	O
therapy	O
with	O
warfarin	B
and	O
Lodine	B
should	O
not	O
require	O
dosage	O
adjustment	O
of	O
either	O
drug	O
.	O

However	O
,	O
caution	O
should	O
be	O
exercised	O
because	O
there	O
have	O
been	O
a	O
few	O
spontaneous	O
reports	O
of	O
prolonged	O
prothrombin	O
times	O
,	O
with	O
or	O
without	O
bleeding	O
,	O
in	O
etodolac	B
-	O
treated	O
patients	O
receiving	O
concomitant	O
warfarin	B
therapy	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
The	O
urine	O
of	O
patients	O
who	O
take	O
Lodine	B
can	O
give	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
urinary	O
bilirubin	O
(	O
urobilin	O
)	O
due	O
to	O
the	O
presence	O
of	O
phenolic	O
metabolites	O
of	O
etodolac	B
.	O

Probenecid	B
Prolonged	O
action	O
of	O
etomidate	B

Zimelidine	B
etomidate	I
antagonism	O

Aminophylline	B
Etomidate	I
antagonism	O

Etonogestrel	B
may	O
interact	O
with	O
the	O
following	O
medications	O
:	O
acetaminophen	B
(	O
Tylenol	B
)	O
,	O
antibiotics	B
such	O
as	O
ampicillin	B
and	O
tetracycline	B
,	O
anticonvulsants	B
(	O
Dilantin	B
,	O
Phenobarbital	B
,	O
Tegretol	B
,	O
Trileptal	B
,	O
Topamax	B
,	O
Felbatol	B
)	O
,	O
antifungals	B
(	O
Gris	O
-	O
PEG	O
,	O
Nizoral	B
,	O
Sporanox	B
)	O
,	O
atorvastatin	B
(	O
Lipitor	B
)	O
,	O
clofibrate	B
(	O
Atromid	O
-	O
S	O
)	O
,	O
cyclosporine	B
(	O
Neoral	B
,	O
Sandimmune	B
)	O
,	O
HIV	O
drugs	O
classified	O
as	O
protease	B
inhibitors	I
(	O
Agenerase	B
,	O
Crixivan	B
,	O
Fortovase	B
,	O
Invirase	B
,	O
Kaletra	B
,	O
Norvir	B
,	O
Viracept	B
)	O
,	O
morphine	B
(	O
Astramorph	B
,	O
Kadian	B
,	O
MS	B
Contin	I
)	O
,	O
phenylbutazone	B
,	O
prednisolone	B
(	O
Prelone	B
)	O
,	O
rifadin	B
(	O
rifampin	B
)	O
,	O
St	O
.	O
Johns	O
wort	O
,	O
temazepam	B
,	O
theophylline	B
(	O
Theo	O
-	O
Dur	O
)	O
,	O
and	O
vitamin	B
C	I
.	O

Caution	O
should	O
be	O
exercised	O
when	O
administering	O
ETOPOPHOS	B
with	O
drugs	O
that	O
are	O
known	O
to	O
inhibit	O
phosphatase	O
activities	O
(	O
e	O
.	O
g	O
.	O
,	O
levamisole	B
hydrochloride	I
)	O
.	O

High	O
-	O
dose	O
cyclosporin	B
A	I
resulting	O
in	O
concentrations	O
above	O
2000	O
ng	O
/	O
mL	O
administered	O
with	O
oral	O
etoposide	B
has	O
led	O
to	O
an	O
80	O
%	O
increase	O
in	O
etoposide	B
exposure	O
with	O
a	O
38	O
%	O
decrease	O
in	O
total	O
body	O
clearance	O
of	O
etoposide	B
compared	O
to	O
etoposide	B
alone	O
.	O

Exemestane	B
is	O
extensively	O
metabolized	O
by	O
CYP	O
3A4	O
,	O
but	O
coadministration	O
of	O
ketoconazole	B
,	O
a	O
potent	O
inhibitor	O
of	O
CYP	O
3A4	O
,	O
has	O
no	O
significant	O
effect	O
on	O
exemestane	B
pharmacokinetics	O
.	O

Co	O
-	O
medications	O
that	O
induce	O
CYP	O
3A4	O
(	O
e	O
.	O
g	O
.	O
,	O
rifampicin	B
,	O
phenytoin	B
,	O
carbamazepine	B
,	O
phenobarbital	B
,	O
or	O
St	O
.	O
John	O
s	O
wort	O
)	O
may	O
significantly	O
decrease	O
exposure	O
to	O
exemestane	B
.	O

Concurrent	O
use	O
with	O
probenecid	B
or	O
other	O
drugs	O
significantly	O
eliminated	O
by	O
active	O
renal	O
tubular	O
secretion	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
penciclovir	B
.	O

The	O
conversion	O
of	O
6	O
-	O
deoxy	O
penciclovir	B
to	O
penciclovir	B
is	O
catalyzed	O
by	O
aldehyde	O
oxidase	O
.	O

Compounds	O
tested	O
in	O
man	O
include	O
warfarin	B
,	O
theophylline	B
,	O
phenytoin	B
,	O
diazepam	B
,	O
aminopyrine	B
and	O
antipyrine	B
.	O

Use	O
in	O
Conjunction	O
with	O
Other	O
Antiepileptic	B
Drugs	I
:	O
The	O
addition	O
of	O
Felbatol	B
to	O
antiepileptic	B
drugs	I
(	O
AEDs	B
)	O
affects	O
the	O
steady	O
-	O
state	O
plasma	O
concentrations	O
of	O
AEDs	B
.	O

The	O
net	O
effect	O
of	O
these	O
interactions	O
is	O
summarized	O
in	O
the	O
following	O
table	O
:	O
AED	B
AED	I
Felbatol	I

Carbamazepine	B
(	O
CBZ	B
)	O

Specific	O
Effects	O
of	O
Felbatol	B
on	O
Other	O
Antiepileptic	B
Drugs	I
Phenytoin	I
:	O
Felbatol	B
causes	O
an	O
increase	O
in	O
steady	O
-	O
state	O
phenytoin	B
plasma	O
concentrations	O
.	O

In	O
10	O
otherwise	O
healthy	O
subjects	O
with	O
epilepsy	O
ingesting	O
phenytoin	B
,	O
the	O
steadystate	O
trough	O
(	O
Cmin	O
)	O
phenytoin	B
plasma	O
concentration	O
was	O
17	O
5	O
micrograms	O
/	O
mL	O
.	O

Increasing	O
the	O
felbamate	B
dose	O
to	O
1800	O
mg	O
/	O
day	O
in	O
six	O
of	O
these	O
subjects	O
increased	O
the	O
steady	O
-	O
state	O
phenytoin	B
Cmin	O
to	O
25	O
7	O
micrograms	O
/	O
mL	O
.	O

In	O
order	O
to	O
maintain	O
phenytoin	B
levels	O
,	O
limit	O
adverse	O
experiences	O
,	O
and	O
achieve	O
the	O
felbamate	B
dose	O
of	O
3600	O
mg	O
/	O
day	O
,	O
a	O
phenytoin	B
dose	O
reduction	O
of	O
approximately	O
40	O
%	O
was	O
necessary	O
for	O
eight	O
of	O
these	O
10	O
subjects	O
.	O

In	O
a	O
controlled	O
clinical	O
trial	O
,	O
a	O
20	O
%	O
reduction	O
of	O
the	O
phenytoin	B
dose	O
at	O
the	O
initiation	O
of	O
Felbatol	B
therapy	O
resulted	O
in	O
phenytoin	B
levels	O
comparable	O
to	O
those	O
prior	O
to	O
Felbatol	B
administration	O
.	O

Carbamazepine	B
:	O
Felbatol	B
causes	O
a	O
decrease	O
in	O
the	O
steady	O
-	O
state	O
carbamazepine	B
plasma	O
concentrations	O
and	O
an	O
increase	O
in	O
the	O
steady	O
-	O
state	O
carbamazepine	B
epoxide	I
plasma	O
concentration	O
.	O

In	O
nine	O
otherwise	O
healthy	O
subjects	O
with	O
epilepsy	O
ingesting	O
carbamazepine	B
,	O
the	O
steady	O
-	O
state	O
trough	O
(	O
Cmin	O
)	O
carbamazepine	B
concentration	O
was	O
8	O
2	O
micrograms	O
/	O
mL	O
.	O

The	O
carbamazepine	B
steady	O
-	O
state	O
Cmin	O
decreased	O
31	O
%	O
to	O
5	O
1	O
micrograms	O
/	O
mL	O
when	O
felbamate	B
(	O
3000	O
mg	O
/	O
day	O
,	O
divided	O
into	O
three	O
doses	O
)	O
was	O
coadministered	O
.	O

Carbamazepine	B
epoxide	I
steady	O
-	O
state	O
Cmin	O
concentrations	O
increased	O
57	O
%	O
from	O
1	O
.	O
0	O
0	O
.	O
3	O
to	O
1	O
.	O
6	O
0	O
.	O
4	O
micrograms	O
/	O
mL	O
with	O
the	O
addition	O
of	O
felbamate	B
.	O

In	O
clinical	O
trials	O
,	O
similar	O
changes	O
in	O
carbamazepine	B
and	O
carbamazepine	B
epoxide	I
were	O
seen	O
.	O

Valproate	B
:	O
Felbatol	B
causes	O
an	O
increase	O
in	O
steady	O
-	O
state	O
valproate	B
concentrations	O
.	O

In	O
four	O
subjects	O
with	O
epilepsy	O
ingesting	O
valproate	B
,	O
the	O
steady	O
-	O
state	O
trough	O
(	O
Cmin	O
)	O
valproate	B
plasma	O
concentration	O
was	O
63	O
16	O
micrograms	O
/	O
mL	O
.	O

Increasing	O
the	O
felbamate	B
dose	O
to	O
2400	O
mg	O
/	O
day	O
increased	O
the	O
steadystate	O
valproate	B
Cmin	O
to	O
96	O
25	O
micrograms	O
/	O
mL	O
.	O

Corresponding	O
values	O
for	O
free	O
valproate	B
Cmin	O
concentrations	O
were	O
7	O
3	O
,	O
9	O
4	O
,	O
and	O
11	O
6	O
micrograms	O
/	O
mL	O
for	O
0	O
,	O
1200	O
,	O
and	O
2400	O
mg	O
/	O
day	O
Felbatol	B
,	O
respectively	O
.	O

The	O
ratios	O
of	O
the	O
AUCs	O
of	O
unbound	O
valproate	B
to	O
the	O
AUCs	O
of	O
the	O
total	O
valproate	B
were	O
11	O
.	O
1	O
%	O
,	O
13	O
.	O
0	O
%	O
,	O
and	O
11	O
.	O
5	O
%	O
,	O
with	O
coadministration	O
of	O
0	O
,	O
1200	O
,	O
and	O
2400	O
mg	O
/	O
day	O
of	O
Felbatol	B
,	O
respectively	O
.	O

Phenobarbital	B
:	O
Coadministration	O
of	O
felbamate	B
with	O
phenobarbital	B
causes	O
an	O
increase	O
in	O
phenobarbital	B
plasma	O
concentrations	O
,	O
In	O
12	O
otherwise	O
healthy	O
male	O
volunteers	O
ingesting	O
phenobarbital	B
,	O
the	O
steady	O
-	O
state	O
trough	O
(	O
Cmin	O
)	O
phenobarbital	B
concentration	O
was	O
14	O
.	O
2	O
micrograms	O
/	O
mL	O
.	O

Effects	O
of	O
Other	O
Antiepileptic	B
Drugs	I
on	O
Felbatol	B
Phenytoin	I
:	O
Phenytoin	B
causes	O
an	O
approximate	O
doubling	O
of	O
the	O
clearance	O
of	O
Felbatol	B
(	O
felbamate	B
)	O
at	O
steady	O
state	O
and	O
,	O
therefore	O
,	O
the	O
addition	O
of	O
phenytoin	B
causes	O
an	O
approximate	O
45	O
%	O
decrease	O
in	O
the	O
steady	O
-	O
state	O
trough	O
concentrations	O
of	O
Felbatol	B
as	O
compared	O
to	O
the	O
same	O
dose	O
of	O
Felbatol	B
given	O
as	O
monotherapy	O
.	O

Carbamazepine	B
:	O
Carbamazepine	B
causes	O
an	O
approximate	O
50	O
%	O
increase	O
in	O
the	O
clearance	O
of	O
Felbatol	B
at	O
steady	O
state	O
and	O
,	O
therefore	O
,	O
the	O
addition	O
of	O
carbamazepine	B
results	O
in	O
an	O
approximate	O
40	O
%	O
decrease	O
in	O
the	O
steady	O
-	O
state	O
trough	O
concentrations	O
of	O
Felbatol	B
as	O
compared	O
to	O
the	O
same	O
dose	O
of	O
Felbatol	B
given	O
as	O
monotherapy	O
.	O

Valproate	B
:	O
Available	O
data	O
suggest	O
that	O
there	O
is	O
no	O
significant	O
effect	O
of	O
valproate	B
on	O
the	O
clearance	O
of	O
Felbatol	B
at	O
steady	O
state	O
,	O
Therefore	O
,	O
the	O
addition	O
of	O
valproate	B
is	O
not	O
expected	O
to	O
cause	O
a	O
clinically	O
important	O
effect	O
on	O
Felbatol	B
(	O
felbamate	B
)	O
plasma	O
concentrations	O
.	O

Phenobarbital	B
:	O
It	O
appears	O
that	O
phenobarbital	B
may	O
reduce	O
plasma	O
felbamate	B
concentrations	O
.	O

Steady	O
-	O
state	O
plasma	O
felbamate	B
concentrations	O
were	O
found	O
to	O
be	O
29	O
%	O
lower	O
than	O
the	O
mean	O
concentrations	O
of	O
a	O
group	O
of	O
newly	O
diagnosed	O
subjects	O
with	O
epilepsy	O
also	O
receiving	O
2400	O
mg	O
of	O
felbamate	B
a	O
day	O
.	O

Effects	O
of	O
Antacids	B
on	O
Felbatol	B
The	O
rate	O
and	O
extent	O
of	O
absorption	O
of	O
a	O
2400	O
mg	O
dose	O
of	O
Felbatol	B
as	O
monotherapy	O
given	O
as	O
tablets	O
was	O
not	O
affected	O
when	O
coadministered	O
with	O
antacids	B
.	O

Effects	O
of	O
Erythromycin	B
on	O
Felbatol	B
The	O
coadministration	O
of	O
erythromycin	B
(	O
1000	O
mg	O
/	O
day	O
)	O
for	O
10	O
days	O
did	O
not	O
alter	O
the	O
pharmacokinetic	O
parameters	O
of	O
Cmax	O
,	O
Cmin	O
,	O
AUC	O
,	O
CI	O
/	O
kg	O
or	O
tmax	O
at	O
felbamate	B
daily	O
doses	O
of	O
3000	O
or	O
3600	O
mg	O
/	O
day	O
in	O
10	O
otherwise	O
healthy	O
subjects	O
with	O
epilepsy	O
.	O

Effects	O
of	O
Felbatol	B
on	O
Low	O
-	O
Dose	O
Combination	B
Oral	I
Contraceptives	I
A	O
group	O
of	O
24	O
nonsmoking	O
,	O
healthy	O
white	O
female	O
volunteers	O
established	O
on	O
an	O
oral	O
contraceptive	B
regimen	O
containing	O
30	O
mg	O
ethinyl	B
estradiol	I
and	O
75	O
mg	O
gestodene	B
for	O
at	O
least	O
3	O
months	O
received	O
2400	O
mg	O
/	O
day	O
of	O
felbamate	B
from	O
midcycle	O
(	O
day	O
15	O
)	O
to	O
midcycle	O
(	O
day	O
14	O
)	O
of	O
two	O
consecutive	O
oral	O
contraceptive	B
cycles	O
.	O

Felbamate	B
treatment	O
resulted	O
in	O
a	O
42	O
%	O
decrease	O
in	O
the	O
gestodene	B
AUC	O
0	O
-	O
24	O
,	O
but	O
no	O
clinically	O
relevant	O
effect	O
was	O
observed	O
on	O
the	O
pharmacokinetic	O
parameters	O
of	O
ethinyl	B
estradiol	I
.	O

CYP3A4	B
Inhibitors	O
Felodipine	O
is	O
metabolized	O
by	O
CYP3A4	B
.	O

Co	O
-	O
administration	O
of	O
CYP3A4	O
inhibitors	O
(	O
eg	O
,	O
ketoconazole	B
,	O
itraconazole	B
,	O
erythromycin	B
,	O
grapefruit	O
juice	O
,	O
cimetidine	B
)	O
with	O
felodipine	B
may	O
lead	O
to	O
several	O
-	O
fold	O
increases	O
in	O
the	O
plasma	O
levels	O
of	O
felodipine	B
,	O
either	O
due	O
to	O
an	O
increase	O
in	O
bioavailability	O
or	O
due	O
to	O
a	O
decrease	O
in	O
metabolism	O
.	O

These	O
effects	O
have	O
been	O
observed	O
with	O
co	O
-	O
administration	O
of	O
itraconazole	B
(	O
a	O
potent	O
CYP3A4	B
inhibitor	O
)	O
.	O

Caution	O
should	O
be	O
used	O
when	O
CYP3A4	B
inhibitors	O
are	O
co	O
-	O
administered	O
with	O
felodipine	B
.	O

The	O
following	O
specific	O
interactions	O
have	O
been	O
reported	O
:	O
Itraconazole	O
Co	O
-	O
administration	O
of	O
another	O
extended	O
release	O
formulation	O
of	O
felodipine	B
with	O
itraconazole	B
resulted	O
in	O
approximately	O
8	O
-	O
fold	O
increase	O
in	O
the	O
AUC	O
,	O
more	O
than	O
6	O
-	O
fold	O
increase	O
in	O
the	O
Cmax	O
,	O
and	O
2	O
-	O
fold	O
prolongation	O
in	O
the	O
half	O
-	O
life	O
of	O
felodipine	B
.	O

Erythromycin	O
Co	O
-	O
administration	O
of	O
felodipine	B
(	O
PLENDIL	B
)	O
with	O
erythromycin	B
resulted	O
in	O
approximately	O
2	O
.	O
5	O
-	O
fold	O
increase	O
in	O
the	O
AUC	O
and	O
Cmax	O
,	O
and	O
about	O
2	O
-	O
fold	O
prolongation	O
in	O
the	O
half	O
-	O
life	O
of	O
felodipine	B
.	O

Grapefruit	O
juice	O
Co	O
-	O
administration	O
of	O
felodipine	B
with	O
grapefruit	O
juice	O
resulted	O
in	O
more	O
than	O
2	O
-	O
fold	O
increase	O
in	O
the	O
AUC	O
and	O
Cmax	O
,	O
but	O
no	O
prolongation	O
in	O
the	O
half	O
-	O
life	O
of	O
felodipine	B
.	O

Cimetidine	O
Co	O
-	O
administration	O
of	O
felodipine	B
with	O
cimetidine	B
(	O
a	O
non	O
-	O
specific	O
CYP	O
-	O
450	O
inhibitor	O
)	O
resulted	O
in	O
an	O
increase	O
of	O
approximately	O
50	O
%	O
in	O
the	O
AUC	O
and	O
the	O
Cmax	O
,	O
of	O
felodipine	B
.	O

Beta	O
-	O
Blocking	O
Agents	O
A	O
pharmacokinetic	O
study	O
of	O
felodipine	B
in	O
conjunction	O
with	O
metoprolol	B
demonstrated	O
no	O
significant	O
effects	O
on	O
the	O
pharmacokinetics	O
of	O
felodipine	B
.	O

In	O
controlled	O
clinical	O
trials	O
,	O
however	O
,	O
beta	B
blockers	I
including	O
metoprolol	B
were	O
concurrently	O
administered	O
with	O
felodipine	B
and	O
were	O
well	O
tolerated	O
.	O

Digoxin	O
When	O
given	O
concomitantly	O
with	O
PLENDIL	B
the	O
pharmacokinetics	O
of	O
digoxin	B
in	O
patients	O
with	O
heart	O
failure	O
were	O
not	O
significantly	O
altered	O
.	O

Anticonvulsants	B
:	O
In	O
a	O
pharmacokinetic	O
study	O
,	O
maximum	O
plasma	O
concentrations	O
of	O
felodipine	B
were	O
considerably	O
lower	O
in	O
epileptic	O
patients	O
on	O
long	O
-	O
term	O
anticonvulsant	B
therapy	O
(	O
eg	O
,	O
phenytoin	B
,	O
carbamazepine	B
,	O
or	O
phenobarbital	B
)	O
than	O
in	O
healthy	O
volunteers	O
.	O

Tacrolimus	O
Felodipine	B
may	O
increase	O
the	O
blood	O
concentration	O
of	O
tacrolimus	B
.	O

When	O
given	O
concomitantly	O
with	O
felodipine	B
,	O
the	O
tacrolimus	B
blood	O
concentration	O
should	O
be	O
followed	O
and	O
the	O
tacrolimus	B
dose	O
may	O
need	O
to	O
be	O
adjusted	O
.	O

Other	O
Concomitant	O
Therapy	O
In	O
healthy	O
subjects	O
there	O
were	O
no	O
clinically	O
significant	O
interactions	O
when	O
felodipine	B
was	O
given	O
concomitantly	O
with	O
indomethacin	B
or	O
spironolactone	B
.	O

Fenfluramine	B
may	O
increase	O
slightly	O
the	O
effect	O
of	O
antihypertensive	B
drugs	I
,	O
e	O
.	O
g	O
.	O
,	O
guanethidine	B
,	O
methyldopa	B
,	O
reserpine	B
.	O

Other	O
CNS	B
depressant	I
drugs	I
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
taking	O
fenfluramine	B
,	O
since	O
the	O
effects	O
may	O
be	O
additive	O
.	O

Oral	O
Anticoagulants	B
CAUTION	O
SHOULD	O
BE	O
EXERCISED	O
WHEN	O
COUMARIN	B
ANTICOAGULANTS	I
ARE	O
GIVEN	O
IN	O
CONJUNCTION	O
WITH	O
TRICOR	B
.	O

HMG	O
-	O
CoA	O
reductase	B
inhibitors	I
:	O
The	O
combined	O
use	O
of	O
TRICOR	B
and	O
HMG	O
-	O
CoA	O
reductase	B
inhibitors	I
should	O
be	O
avoided	O
unless	O
the	O
benefit	O
of	O
further	O
alterations	O
in	O
lipid	O
levels	O
is	O
likely	O
to	O
outweigh	O
the	O
increased	O
risk	O
of	O
this	O
drug	O
combination	O
.	O

Resins	B
:	O
Since	O
bile	B
acid	I
sequestrants	I
may	O
bind	O
other	O
drugs	O
given	O
concurrently	O
,	O
patients	O
should	O
take	O
TRICOR	B
at	O
least	O
1	O
hour	O
before	O
or	O
4	O
-	O
6	O
hours	O
after	O
a	O
bile	B
acid	I
binding	I
resin	I
to	O
avoid	O
impeding	O
its	O
absorption	O
.	O

Cyclosporine	B
:	O
Because	O
cyclosporine	B
can	O
produce	O
nephrotoxicity	O
with	O
decreases	O
in	O
creatinine	O
clearance	O
and	O
rises	O
in	O
serum	O
creatinine	O
,	O
and	O
because	O
renal	O
excretion	O
is	O
the	O
primary	O
elimination	O
route	O
of	O
fibrate	B
drugs	I
including	O
TRICOR	B
,	O
there	O
is	O
a	O
risk	O
that	O
an	O
interaction	O
will	O
lead	O
to	O
deterioration	O
.	O

The	O
benefits	O
and	O
risks	O
of	O
using	O
TRICOR	B
with	O
immunosuppressants	B
and	O
other	O
potentially	O
nephrotoxic	O
agents	O
should	O
be	O
carefully	O
considered	O
,	O
and	O
the	O
lowest	O
effective	O
dose	O
employed	O

Drug	O
-	O
drug	O
interactions	O
In	O
vitro	O
studies	O
using	O
human	O
liver	O
microsomes	O
indicate	O
that	O
fenofibrate	B
and	O
fenofibric	B
acid	I
are	O
not	O
inhibitors	O
of	O
cytochrome	O
(	O
CYP	O
)	O
P450	O
isoforms	O
CYP3A4	O
,	O
CYP2D6	O
,	O
CYP2E1	O
,	O
or	O
CYP1A2	O
.	O

Therefore	O
,	O
fenofibrate	B
should	O
be	O
taken	O
at	O
least	O
1	O
hour	O
before	O
or	O
4	O
-	O
6	O
hours	O
after	O
a	O
bile	B
acid	I
binding	I
resin	I
to	O
avoid	O
impeding	O
its	O
absorption	O
.	O

Concomitant	O
administration	O
of	O
fenofibrate	B
(	O
equivalent	O
to	O
145mg	O
TRICOR	B
)	O
with	O
pravastatin	B
(	O
40	O
mg	O
)	O
once	O
daily	O
for	O
10	O
days	O
has	O
been	O
shown	O
to	O
increase	O
the	O
mean	O
Cmax	O
and	O
AUC	O
values	O
for	O
pravastatin	B
by	O
36	O
%	O
(	O
range	O
from	O
69	O
%	O
decrease	O
to	O
321	O
%	O
increase	O
)	O
and	O
28	O
%	O
(	O
range	O
from	O
54	O
%	O
decrease	O
to	O
128	O
%	O
increase	O
)	O
,	O
respectively	O
,	O
and	O
for	O
3	O
-	O
hydroxy	O
-	O
iso	O
-	O
pravastatin	B
by	O
55	O
%	O
(	O
range	O
from	O
32	O
%	O
decrease	O
to	O
314	O
%	O
increase	O
)	O
and	O
39	O
%	O
(	O
range	O
from	O
24	O
%	O
decrease	O
to	O
261	O
%	O
increase	O
)	O
,	O
respectively	O
in	O
23	O
healthy	O
adults	O
.	O

A	O
single	O
dose	O
of	O
pravastatin	B
had	O
no	O
clinically	O
important	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
fenofibric	B
acid	I
.	O

Concomitant	O
administration	O
of	O
fenofibrate	B
(	O
equivalent	O
to	O
145	O
mg	O
TRICOR	B
)	O
with	O
atorvastatin	B
(	O
20	O
mg	O
)	O
once	O
daily	O
for	O
10	O
days	O
resulted	O
in	O
approximately	O
17	O
%	O
decrease	O
(	O
range	O
from	O
67	O
%	O
decrease	O
to	O
44	O
%	O
increase	O
)	O
in	O
atorvastatin	B
AUC	O
values	O
in	O
22	O
healthy	O
males	O
.	O

The	O
atorvastatin	B
Cmax	O
values	O
were	O
not	O
significantly	O
affected	O
by	O
fenofibrate	B
.	O

The	O
pharmacokinetics	O
of	O
fenofibric	B
acid	I
were	O
not	O
significantly	O
affected	O
by	O
atorvastatin	B

Drug	O
Interactions	O
with	O
Beta	O
-	O
Blockers	O
:	O
Concomitant	O
use	O
of	O
fenoldopam	B
with	O
beta	O
-	O
blockers	O
should	O
be	O
avoided	O
.	O

Drug	O
Interactions	O
,	O
General	O
:	O
Although	O
there	O
have	O
been	O
no	O
formal	O
interaction	O
studies	O
,	O
intravenous	O
fenoldopam	B
has	O
been	O
administered	O
safely	O
with	O
drugs	O
such	O
as	O
digitalis	B
and	O
sublingual	O
nitroglycerin	B
.	O

There	O
is	O
limited	O
experience	O
with	O
concomitant	O
antihypertensive	B
agents	I
such	O
as	O
alpha	O
-	O
blockers	O
,	O
calcium	B
channel	O
-	O
blockers	O
,	O
ACE	B
inhibitors	I
,	O
and	O
diuretics	B
(	O
both	O
thiazide	B
-	O
like	O
and	O
loop	O
)	O
.	O

The	O
coadministration	O
of	O
aspirin	B
decreases	O
the	O
biologic	O
half	O
-	O
life	O
of	O
fenoprofen	B
because	O
of	O
an	O
increase	O
in	O
metabolic	O
clearance	O
that	O
results	O
in	O
a	O
greater	O
amount	O
of	O
hydroxylated	B
fenoprofen	I
in	O
the	O
urine	O
.	O

Although	O
the	O
mechanism	O
of	O
interaction	O
between	O
fenoprofen	B
and	O
aspirin	B
is	O
not	O
totally	O
known	O
,	O
enzyme	O
induction	O
and	O
displacement	O
of	O
fenoprofen	B
from	O
plasma	O
albumin	O
binding	O
sites	O
are	O
possibilities	O
.	O

Because	O
Nalfon	B
has	O
not	O
been	O
shown	O
to	O
produce	O
any	O
additional	O
effect	O
beyond	O
that	O
obtained	O
with	O
aspirin	B
alone	O
and	O
because	O
aspirin	B
increases	O
the	O
rate	O
of	O
excretion	O
of	O
Nalfon	B
,	O
the	O
concomitant	O
use	O
of	O
Nalfon	B
and	O
salicylates	B
is	O
not	O
recommended	O
.	O

Chronic	O
administration	O
of	O
phenobarbital	B
,	O
a	O
known	O
enzyme	O
inducer	O
,	O
may	O
be	O
associated	O
with	O
a	O
decrease	O
in	O
the	O
plasma	O
half	O
-	O
life	O
of	O
fenoprofen	B
.	O

When	O
phenobarbital	B
is	O
added	O
to	O
or	O
withdrawn	O
from	O
treatment	O
,	O
dosage	O
adjustment	O
of	O
Nalfon	B
may	O
be	O
required	O
.	O

Patients	O
receiving	O
hydantoins	B
,	O
sulfonamides	B
,	O
or	O
sulfonylureas	B
should	O
be	O
observed	O
for	O
increased	O
activity	O
of	O
these	O
drugs	O
and	O
,	O
therefore	O
,	O
signs	O
of	O
toxicity	O
from	O
these	O
drugs	O
.	O

In	O
patients	O
receiving	O
coumarin	O
-	O
type	O
anticoagulants	B
,	O
the	O
addition	O
of	O
Nalfon	B
to	O
therapy	O
could	O
prolong	O
the	O
prothrombin	O
time	O
.	O

Patients	O
treated	O
with	O
Nalfon	B
may	O
be	O
resistant	O
to	O
the	O
effects	O
of	O
loop	B
diuretics	I
.	O

In	O
patients	O
receiving	O
Nalfon	B
and	O
a	O
steroid	B
concomitantly	O
,	O
any	O
reduction	O
in	O
steroid	B
dosage	O
should	O
be	O
gradual	O
in	O
order	O
to	O
avoid	O
the	O
possible	O
complications	O
of	O
sudden	O
steroid	B
withdrawal	O
.	O

Agents	O
Affecting	O
Cytochrome	O
P450	O
3A4	O
Isoenzyme	O
System	O
Fentanyl	B
is	O
metabolized	O
mainly	O
via	O
the	O
human	O
cytochrome	O
P450	O
3A4	O
isoenzyme	O
system	O
(	O
CYP3A4	O
)	O
,	O
therefore	O
potential	O
interactions	O
may	O
occur	O
when	O
DURAGESIC	B
is	O
given	O
concurrently	O
with	O
agents	O
that	O
affect	O
CYP3A4	O
activity	O
.	O

The	O
concomitant	O
use	O
of	O
transdermal	O
fentanyl	B
with	O
ritonavir	B
or	O
other	O
potent	O
3A4	O
inhibitors	O
such	O
as	O
ketoconazole	B
,	O
itraconazole	B
,	O
troleandomycin	B
,	O
clarithromycin	B
,	O
nelfinavir	B
,	O
and	O
nefazadone	O
may	O
result	O
in	O
an	O
increase	O
in	O
fentanyl	B
plasma	O
concentrations	O
.	O

The	O
concomitant	O
use	O
of	O
other	O
CYP3A4	O
inhibitors	O
such	O
as	O
diltiazem	B
and	O
erythromycin	B
with	O
transdermal	O
fentanyl	B
may	O
also	O
result	O
in	O
an	O
increase	O
in	O
fentanyl	B
plasma	O
concentrations	O
,	O
which	O
could	O
increase	O
or	O
prolong	O
adverse	O
drug	O
effects	O
and	O
may	O
cause	O
serious	O
respiratory	O
depression	O
.	O

Central	B
Nervous	I
System	I
Depressants	I
:	O
The	O
concomitant	O
use	O
of	O
DURAGESIC	B
(	O
fentanyl	B
transdermal	O
system	B
)	O
with	O
other	O
central	B
nervous	I
system	I
depressants	I
,	O
including	O
but	O
not	O
limited	O
to	O
other	O
opioids	B
,	O
sedatives	B
,	O
hypnotics	B
,	O
tranquilizers	B
(	O
e	O
.	O
g	O
.	O
,	O
benzodiazepines	B
)	O
,	O
general	O
anesthetics	B
,	O
phenothiazines	B
,	O
skeletal	B
muscle	I
relaxants	I
,	O
and	O
alcohol	B
,	O
may	O
cause	O
respiratory	O
depression	O
,	O
hypotension	O
,	O
and	O
profound	O
sedation	O
,	O
or	O
potentially	O
result	O
in	O
coma	O
or	O
death	O
.	O

MAO	B
Inhibitors	I
:	O
DURAGESIC	B
is	O
not	O
recommended	O
for	O
use	O
in	O
patients	O
who	O
have	O
received	O
MAOI	B
within	O
14	O
days	O
because	O
severe	O
and	O
unpredictable	O
potentiation	O
by	O
MAO	B
inhibitors	I
has	O
been	O
reported	O
with	O
opioid	B
analgesics	I

Drug	O
Interaction	O
with	O
Erythromycin	B
and	O
Ketoconazole	B
Fexofenadine	I
has	O
been	O
shown	O
to	O
exhibit	O
minimal	O
(	O
ca	O
.	O
5	O
%	O
)	O
metabolism	O
.	O

However	O
,	O
co	O
administration	O
of	O
fexofenadine	B
hydrochloride	I
with	O
either	O
ketoconazole	B
or	O
erythromycin	B
led	O
to	O
increased	O
plasma	O
concentrations	O
of	O
fexofenadine	B
.	O

Fexofenadine	B
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
either	O
erythromycin	B
or	O
ketoconazole	B
.	O

In	O
2	O
separate	O
studies	O
,	O
fexofenadine	B
hydrochloride	I
120	O
mg	O
twice	O
daily	O
(	O
240	O
mg	O
total	O
daily	O
dose	O
)	O
was	O
co	O
-	O
administered	O
with	O
either	O
erythromycin	B
500	O
mg	O
every	O
8	O
hours	O
or	O
ketoconazole	B
400	O
mg	O
once	O
daily	O
under	O
steady	O
-	O
state	O
conditions	O
to	O
healthy	O
volunteers	O
(	O
n	O
=	O
24	O
,	O
each	O
study	O
)	O
.	O

No	O
differences	O
in	O
adverse	O
events	O
or	O
QTc	O
interval	O
were	O
observed	O
when	O
subjects	O
were	O
administered	O
fexofenadine	B
hydrochloride	I
alone	O
or	O
in	O
combination	O
with	O
either	O
erythromycin	B
or	O
ketoconazole	B
.	O

The	O
findings	O
of	O
these	O
studies	O
are	O
summarized	O
in	O
the	O
following	O
table	O
:	O
Effects	O
on	O
steady	O
-	O
state	O
fexofenadine	B
pharmacokinetics	O
after	O
7	O
days	O
of	O
co	O
-	O
administration	O
with	O
fexofenadine	B
hydrochloride	I
120	O
mg	O
every	O
12	O
hours	O
(	O
two	O
times	O
the	O
recommended	O
twice	O
daily	O
dose	O
)	O
in	O
healthy	O
volunteers	O
(	O
n	O
=	O
24	O
)	O

These	O
studies	O
indicate	O
that	O
ketoconazole	B
or	O
erythromycin	B
co	O
-	O
administration	O
enhances	O
fexofenadine	B
gastrointestinal	O
absorption	O
.	O

This	O
observed	O
increase	O
in	O
the	O
bioavailability	O
of	O
fexofenadine	B
may	O
be	O
due	O
to	O
transport	O
-	O
related	O
effects	O
,	O
such	O
as	O
p	O
-	O
glycoprotein	O
.	O
in	O
vivo	O
animal	O
studies	O
also	O
suggest	O
that	O
in	O
addition	O
to	O
enhancing	O
absorption	O
,	O
ketoconazole	B
decreases	O
fexofenadine	B
gastrointestinal	O
secretion	O
,	O
while	O
erythromycin	B
may	O
also	O
decrease	O
biliary	O
excretion	O
.	O

Drug	O
Interactions	O
with	O
Antacids	B
Administration	O
of	O
120	O
mg	O
of	O
fexofenadine	B
hydrochloride	I
(	O
2	O
x	O
60	O
mg	O
capsule	O
)	O
within	O
15	O
minutes	O
of	O
an	O
aluminum	B
and	O
magnesium	B
containing	O
antacid	B
(	O
Maalox	B
)	O
decreased	O
fexofenadine	B
AUC	O
by	O
41	O
%	O
and	O
cmax	O
by	O
43	O
%	O
.	O

ALLEGRA	B
should	O
not	O
be	O
taken	O
closely	O
in	O
time	O
with	O
aluminum	B
and	O
magnesium	B
containing	O
antacids	B
.	O

Therefore	O
,	O
to	O
maximize	O
the	O
effects	O
of	O
fexofenadine	B
,	O
it	O
is	O
recommended	O
that	O
ALLEGRA	B
should	O
be	O
taken	O
with	O
water	O

Compounds	O
that	O
have	O
been	O
tested	O
in	O
man	O
include	O
antipyrine	B
,	O
digoxin	B
,	O
propranolol	B
,	O
theophylline	B
,	O
and	O
warfarin	B
and	O
no	O
clinically	O
meaningful	O
interactions	O
were	O
found	O
.	O

Other	O
concomitant	O
therapy	O
Although	O
specific	O
interaction	O
studies	O
were	O
not	O
performed	O
,	O
finasteride	B
doses	O
of	O
1	O
mg	O
or	O
more	O
were	O
concomitantly	O
used	O
in	O
clinical	O
studies	O
with	O
acetaminophen	B
,	O
acetylsalicylic	B
acid	I
,	O
a	O
-	O
blockers	B
,	O
analgesics	B
,	O
angiotensin	O
-	O
converting	O
enzyme	B
(	O
ACE	O
)	O
inhibitors	B
,	O
anticonvulsants	B
,	O
benzodiazepines	B
,	O
beta	B
blockers	I
,	O
calcium	O
-	O
channel	O
blockers	B
,	O
cardiac	O
nitrates	B
,	O
diuretics	B
,	O
H2	B
antagonists	I
,	O
HMG	O
-	O
CoA	O
reductase	B
inhibitors	I
,	O
prostaglandin	B
synthetase	I
inhibitors	I
(	O
also	O
referred	O
to	O
as	O
NSAIDs	B
)	O
,	O
and	O
quinolone	B
anti	O
-	O
infectives	O
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
interactions	O
.	O

In	O
clinical	O
studies	O
with	O
PROPECIA	B
(	O
finasteride	B
,	O
1	O
mg	O
)	O
in	O
men	O
18	O
-	O
41	O
years	O
of	O
age	O
,	O
the	O
mean	O
value	O
of	O
serum	O
prostate	O
-	O
specific	O
antigen	O
(	O
PSA	O
)	O
decreased	O
from	O
0	O
.	O
7	O
ng	O
/	O
mL	O
at	O
baseline	O
to	O
0	O
.	O
5	O
ng	O
/	O
mL	O
at	O
Month	O
12	O
.	O

Further	O
,	O
in	O
clinical	O
studies	O
with	O
PROSCAR	B
(	O
finasteride	B
,	O
5	O
mg	O
)	O
when	O
used	O
in	O
older	O
men	O
who	O
have	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
,	O
PSA	O
levels	O
are	O
decreased	O
by	O
approximately	O
50	O
%	O
.	O

TAMBOCOR	B
has	O
been	O
administered	O
to	O
patients	O
receiving	O
digitalis	B
preparations	I
or	O
beta	O
-	O
adrenergic	O
blocking	B
agents	I
without	O
adverse	O
effects	O
.	O

During	O
administration	O
of	O
multiple	O
oral	O
doses	O
of	O
TAMBOCOR	B
to	O
healthy	O
subjects	O
stabilized	O
on	O
a	O
maintenance	O
dose	O
of	O
digoxin	B
,	O
a	O
13	O
%	O
-	O
19	O
%	O
increase	O
in	O
plasma	O
digoxin	B
levels	O
occurred	O
at	O
six	O
hours	O
postdose	O
.	O

In	O
a	O
study	O
involving	O
healthy	O
subjects	O
receiving	O
TAMBOCOR	B
and	O
propranolol	B
concurrently	O
,	O
plasma	O
flecainide	B
levels	O
were	O
increased	O
about	O
20	O
%	O
and	O
propranolol	B
levels	O
were	O
increased	O
about	O
30	O
%	O
compared	O
to	O
control	O
values	O
.	O

In	O
this	O
formal	O
interaction	O
study	O
,	O
TAMBOCOR	B
and	O
propranolol	B
were	O
each	O
found	O
to	O
have	O
negative	O
inotropic	O
effects	O
;	O

The	O
effects	O
of	O
concomitant	O
administration	O
of	O
TAMBOCOR	B
and	O
propranolol	B
on	O
the	O
PR	O
interval	O
were	O
less	O
than	O
additive	O
.	O

In	O
TAMBOCOR	B
clinical	O
trials	O
,	O
patients	O
who	O
were	O
receiving	O
beta	B
blockers	I
concurrently	O
did	O
not	O
experience	O
an	O
increased	O
incidence	O
of	O
side	O
effects	O
.	O

Nevertheless	O
,	O
the	O
possibility	O
of	O
additive	O
negative	O
inotropic	O
effects	O
of	O
beta	B
blockers	I
and	O
flecainide	B
should	O
be	O
recognized	O
.	O

TAMBOCOR	B
has	O
been	O
used	O
in	O
a	O
large	O
number	O
of	O
patients	O
receiving	O
diuretics	B
without	O
apparent	O
interaction	O
.	O

Limited	O
data	O
in	O
patients	O
receiving	O
known	O
enzyme	O
inducers	O
(	O
phenytoin	B
,	O
phenobarbital	B
,	O
carbamazepine	B
)	O
indicate	O
only	O
a	O
30	O
%	O
increase	O
in	O
the	O
rate	O
of	O
flecainide	B
elimination	O
.	O

In	O
healthy	O
subjects	O
receiving	O
cimetidine	B
(	O
1	O
gm	O
daily	O
)	O
for	O
one	O
week	O
,	O
plasma	O
flecainide	B
levels	O
increased	O
by	O
about	O
30	O
%	O
and	O
half	O
-	O
life	O
increased	O
by	O
about	O
10	O
%	O
.	O

When	O
amiodarone	B
is	O
added	O
to	O
flecainide	B
therapy	O
,	O
plasma	O
flecainide	B
levels	O
may	O
increase	O
two	O
-	O
fold	O
or	O
more	O
in	O
some	O
patients	O
,	O
if	O
flecainide	B
dosage	O
is	O
not	O
reduced	O
.	O

Drugs	O
that	O
inhibit	O
cytochrome	O
P450IID6	O
,	O
such	O
as	O
quinidine	B
,	O
might	O
increase	O
the	O
plasma	O
concentrations	O
of	O
flecainide	B
in	O
patients	O
that	O
are	O
on	O
chronic	O
flecainide	B
therapy	O
;	O

There	O
has	O
been	O
little	O
experience	O
with	O
the	O
coadministration	O
of	O
TAMBOCOR	B
and	O
either	O
disopyramide	B
or	O
verapamil	B
.	O

Because	O
both	O
of	O
these	O
drugs	O
have	O
negative	O
inotropic	O
properties	O
and	O
the	O
effects	O
of	O
coadministration	O
with	O
TAMBOCOR	B
are	O
unknown	O
,	O
neither	O
disopyramide	B
nor	O
verapamil	B
should	O
be	O
administered	O
concurrently	O
with	O
TAMBOCOR	B
unless	O
,	O
in	O
the	O
judgment	O
of	O
the	O
physician	O
,	O
the	O
benefits	O
of	O
this	O
combination	O
outweigh	O
the	O
risks	O
.	O

There	O
has	O
been	O
too	O
little	O
experience	O
with	O
the	O
coadministration	O
of	O
TAMBOCOR	B
with	O
nifedipine	B
or	O
diltiazem	B
to	O
recommend	O
concomitant	O
use	O
.	O

Cytosine	B
arabinoside	I
,	O
a	O
cytostatic	B
agent	I
,	O
has	O
been	O
reported	O
to	O
inactivate	O
the	O
antifungal	O
activity	O
of	O
flucytosine	B
by	O
competitive	O
inhibition	O
.	O

The	O
use	O
of	O
FLUDARA	B
FOR	O
INJECTION	O
in	O
combination	O
with	O
pentostatin	B
is	O
not	O
recommended	O
due	O
to	O
the	O
risk	O
of	O
severe	O
pulmonary	O
toxicity	O
.	O

Amphotericin	B
B	I
or	O
potassium	O
-	O
depleting	O
diuretics	B
(	O
benzothiadiazines	B
and	O
related	O
drugs	O
,	O
ethacrynic	B
acid	I
and	O
furosemide	B
)	O
enhanced	O
hypokalemia	O
.	O

Digitalis	B
glycosides	I
enhanced	O
possibility	O
of	O
arrhythmias	O
or	O
digitalis	B
toxicity	O
associated	O
with	O
hypokalemia	O
.	O

Antidiabetic	B
drugs	I
(	O
oral	O
agents	O
and	O
insulin	B
)	O
diminished	O
antidiabetic	O
effect	O
.	O

Rarely	O
salicylate	B
toxicity	O
may	O
occur	O
in	O
patients	O
who	O
discontinue	O
steroids	B
after	O
concurrent	O
high	O
-	O
dose	O
aspirin	B
therapy	O
.	O

Monitor	O
salicylate	B
levels	O
or	O
the	O
therapeutic	O
effect	O
for	O
which	O
aspirin	B
is	O
given	O
;	O

Barbiturates	B
,	O
phenytoin	B
,	O
or	O
rifampin	B
increased	O
metabolic	O
clearance	O
of	O
fludrocortisone	B
acetate	I
because	O
of	O
the	O
induction	O
of	O
hepatic	O
enzymes	O
.	O

Observe	O
the	O
patient	O
for	O
possible	O
diminished	O
effect	O
of	O
steroid	B
and	O
increase	O
the	O
steroid	B
dosage	O
accordingly	O
.	O

Anabolic	B
steroids	I
(	O
particularly	O
C	O
-	O
17	O
alkylated	O
androgens	B
such	O
as	O
oxymetholone	B
,	O
methandrostenolone	B
,	O
norethandrolone	B
,	O
and	O
similar	O
compounds	O
)	O
enhanced	O
tendency	O
toward	O
edema	O
.	O

When	O
estrogen	B
therapy	O
is	O
initiated	O
,	O
a	O
reduction	O
in	O
corticosteroid	B
dosage	O
may	O
be	O
required	O
,	O
and	O
increased	O
amounts	O
may	O
be	O
required	O
when	O
estrogen	B
is	O
terminated	O
.	O

Interaction	O
with	O
central	B
nervous	I
system	I
depressants	I
other	O
than	O
benzodiazepines	B
has	O
not	O
been	O
specifically	O
studied	O
;	O

however	O
,	O
no	O
deleterious	O
interactions	O
were	O
seen	O
when	O
ROMAZICON	B
was	O
administered	O
after	O
narcotics	B
,	O
inhalational	O
anesthetics	B
,	O
muscle	B
relaxants	I
and	O
muscle	B
relaxant	O
antagonists	O
administered	O
in	O
conjunction	O
with	O
sedation	O
or	O
anesthesia	O
.	O

Particular	O
caution	O
is	O
necessary	O
when	O
using	O
ROMAZICON	B
in	O
cases	O
of	O
mixed	O
drug	O
overdosage	O
since	O
the	O
toxic	O
effects	O
(	O
such	O
as	O
convulsions	O
and	O
cardiac	O
dysrhythmias	O
)	O
of	O
other	O
drugs	O
taken	O
in	O
overdose	O
(	O
especially	O
cyclic	B
antidepressants	I
)	O
may	O
emerge	O
with	O
the	O
reversal	O
of	O
the	O
benzodiazepine	B
effect	O
by	O
flumazenil	B
.	O

Although	O
ROMAZICON	B
exerts	O
a	O
slight	O
intrinsic	O
anticonvulsant	O
effect	O
,	O
its	O
abrupt	O
suppression	O
of	O
the	O
protective	O
effect	O
of	O
a	O
benzodiazepine	B
agonist	O
can	O
give	O
rise	O
to	O
convulsions	O
in	O
epileptic	O
patients	O
.	O

ROMAZICON	B
blocks	O
the	O
central	O
effects	O
of	O
benzodiazepines	B
by	O
competitive	O
interaction	O
at	O
the	O
receptor	O
level	O
.	O

The	O
effects	O
of	O
nonbenzodiazepine	O
agonists	O
at	O
benzodiazepine	O
receptors	O
,	O
such	O
as	O
zopiclone	B
,	O
triazolopyridazines	O
and	O
others	O
,	O
are	O
also	O
blocked	O
by	O
ROMAZICON	B
.	O

The	O
pharmacokinetics	O
of	O
benzodiazepines	B
are	O
unaltered	O
in	O
the	O
presence	O
of	O
flumazenil	B
and	O
vice	O
versa	O
.	O

There	O
is	O
no	O
pharmacokinetic	O
interaction	O
between	O
ethanol	B
and	O
flumazenil	B
.	O

Use	O
in	O
Ambulatory	O
Patients	O
The	O
effects	O
of	O
ROMAZICON	B
may	O
wear	O
off	O
before	O
a	O
long	O
-	O
acting	O
benzodiazepine	B
is	O
completely	O
cleared	O
from	O
the	O
body	O
.	O

An	O
adequate	O
period	O
of	O
observation	O
must	O
be	O
provided	O
for	O
any	O
patient	O
in	O
whom	O
either	O
long	O
-	O
acting	O
benzodiazepines	B
(	O
such	O
as	O
diazepam	B
)	O
or	O
large	O
doses	O
of	O
short	O
-	O
acting	O
benzodiazepines	B
(	O
such	O
as	O
10	O
mg	O
of	O
midazolam	B
)	O
have	O
been	O
used	O
.	O

Because	O
of	O
the	O
increased	O
risk	O
of	O
adverse	O
reactions	O
in	O
patients	O
who	O
have	O
been	O
taking	O
benzodiazepines	B
on	O
a	O
regular	O
basis	O
,	O
it	O
is	O
particularly	O
important	O
that	O
physicians	O
query	O
patients	O
or	O
their	O
guardians	O
carefully	O
about	O
benzodiazepine	B
,	O
alcohol	B
and	O
sedative	B
use	O
as	O
part	O
of	O
the	O
history	O
prior	O
to	O
any	O
procedure	O
in	O
which	O
the	O
use	O
of	O
ROMAZICON	B
is	O
planned	O
.	O

Talk	O
to	O
your	O
doctor	O
if	O
you	O
are	O
taking	O
certain	O
antibiotics	B
such	O
as	O
erythromycin	B
,	O
clarithromycin	B
or	O
azithromycin	B
.	O

Caution	O
should	O
be	O
exercised	O
when	O
taking	O
this	O
medicine	O
certain	O
antibiotics	B
,	O
such	O
as	O
erythromycin	B
,	O
clarithromycin	B
,	O
or	O
azithromycin	B
.	O

Wait	O
5	O
weeks	O
after	O
stopping	O
escitalopram	B
before	O
starting	O
a	O
non	O
-	O
selective	O
MAO	B
inhibitor	I
.	O

Wait	O
2	O
weeks	O
after	O
stopping	O
an	O
MAO	B
inhibitor	I
before	O
starting	O
escitalopram	B
.	O

Tell	O
your	O
doctor	O
if	O
you	O
are	O
taking	O
any	O
of	O
the	O
following	O
drugs	O
:	O
blood	B
thinners	O
(	O
Coumadin	B
)	O
other	O
antidepressants	B
metoprolol	I
antihistamines	I
carbamazepine	I
(	O
Tegretol	B
)	O
cimetidine	B
(	O
Tagamet	B
)	O
estrogens	B
fluoxetine	I
(	O
Prozac	B
)	O
intraconazole	O
(	O
Sporanox	B
)	O
ketoconazole	B
(	O
Nizoral	B
)	O
levodopa	B
lithium	I
muscle	I
relaxants	I
birth	O
control	O
pills	O
sleeping	O
pills	O
thyroid	O
medications	O

Concurrent	O
administration	O
of	O
oxyphenbutazone	B
and	O
androgens	B
may	O
result	O
in	O
elevated	O
serum	O
levels	O
of	O
oxyphenbutazone	B
.	O

In	O
diabetic	O
patients	O
,	O
the	O
metabolic	O
effects	O
of	O
androgens	B
may	O
decrease	O
blood	O
glucose	O
and	O
therefore	O
,	O
insulin	B
requirements	O
.	O

Drug	O
Interactions	O
:	O
Flupenthixol	B
may	O
interact	O
with	O
some	O
drugs	O
,	O
like	O
Monoamine	B
oxidase	I
inhibitors	I
(	O
MAOI	B
)	O
:	O
MAOI	B
could	O
theoretically	O
affect	O
flupenthixol	B
pharmacodynamics	O
-	O
Arecoline	B
-	O
Eproxindine	O
-	O
Ethanol	B
:	O
Flupenthixol	B
and	O
Ethanol	B
cause	O
additive	O
CNS	O
depression	O
-	O
Tricyclic	B
antidepressants	I
:	O
Flupenthixol	B
increases	O
the	O
effect	O
of	O
Tricyclic	B
antidepressants	I

Antacids	B
:	O
Administration	O
of	O
flurbiprofen	B
to	O
volunteers	O
under	O
fasting	O
conditions	O
,	O
or	O
with	O
antacid	B
suspension	O
yielded	O
similar	O
serum	O
flurbiprofen	B
time	O
profiles	O
in	O
young	O
subjects	O
(	O
n	O
=	O
12	O
)	O
.	O

Anticoagulants	B
:	O
Flurbiprofen	B
like	O
other	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
drugs	B
,	O
has	O
been	O
shown	O
to	O
affect	O
bleeding	O
parameters	O
in	O
patients	O
receiving	O
anti	O
-	O
coagulants	O
,	O
and	O
serious	O
clinical	O
bleeding	O
has	O
been	O
reported	O
.	O

The	O
physician	O
should	O
be	O
cautious	O
when	O
administering	O
flurbiprofen	B
to	O
patients	O
taking	O
anticoagulants	B
.	O

Aspirin	B
:	O
Concurrent	O
administration	O
of	O
aspirin	B
and	O
flurbiprofen	B
resulted	O
in	O
50	O
%	O
lower	O
serum	O
flurbiprofen	B
concentrations	O
.	O

This	O
effect	O
of	O
aspirin	B
(	O
which	O
also	O
lowers	O
serum	O
concentrations	O
of	O
other	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
drugs	B
given	O
with	O
it	O
)	O
has	O
been	O
demonstrated	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
n	O
=	O
15	O
)	O
as	O
well	O
as	O
normal	O
volunteers	O
(	O
n	O
=	O
16	O
)	O
.	O

Concurrent	O
use	O
of	O
flurbiprofen	B
and	O
aspirin	B
is	O
therefore	O
not	O
recommended	O
.	O

Beta	O
-	O
adrenergic	O
Blocking	B
Agents	I
:	O
The	O
effect	O
of	O
flurbiprofen	B
on	O
blood	O
pressure	O
response	O
to	O
propranolol	B
and	O
atenolol	B
was	O
evaluated	O
in	O
men	O
with	O
mild	O
uncomplicated	O
hypertension	O
(	O
n	O
=	O
10	O
)	O
.	O

Flurbiprofen	B
pretreatment	O
attenuated	O
the	O
hypotensive	O
effect	O
of	O
a	O
single	O
dose	O
of	O
propranolol	B
but	O
not	O
atenolol	B
.	O

Flurbiprofen	B
did	O
not	O
affect	O
the	O
pharmacokinetic	O
profile	O
of	O
either	O
drug	O
,	O
and	O
the	O
mechanism	O
under	O
lying	O
the	O
interference	O
with	O
propranolols	O
hypotensive	O
effect	O
is	O
unknown	O
.	O

Patients	O
taking	O
both	O
flurbiprofen	B
and	O
a	O
beta	O
-	O
blocker	O
should	O
be	O
monitored	O
to	O
ensure	O
that	O
a	O
satisfactory	O
hypotensive	O
effect	O
is	O
achieved	O
.	O

Cimetidine	B
,	O
Ranitidine	B
:	O
In	O
normal	O
volunteers	O
(	O
n	O
=	O
9	O
)	O
,	O
pretreatment	O
with	O
cimetidine	B
or	O
ranitidine	B
did	O
not	O
affect	O
flurbiprofen	B
pharmacokinetics	O
except	O
that	O
a	O
small	O
(	O
13	O
%	O
)	O
but	O
statistically	O
significant	O
increase	O
in	O
the	O
area	O
under	O
the	O
serum	O
concentration	O
curve	O
of	O
flurbiprofen	B
resulted	O
with	O
cimetidine	B
.	O

Digoxin	B
:	O
Studies	O
of	O
concomitant	O
administration	O
of	O
flurbiprofen	B
and	O
digoxin	B
to	O
healthy	O
men	O
(	O
n	O
=	O
14	O
)	O
did	O
not	O
show	O
a	O
change	O
in	O
the	O
steady	O
state	O
serum	O
levels	O
of	O
either	O
drug	O
.	O

Diuretics	B
:	O
Studies	O
in	O
normal	O
volunteers	O
have	O
shown	O
that	O
flurbiprofen	B
like	O
other	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
drugs	B
,	O
can	O
interfere	O
with	O
the	O
effects	O
of	O
furosemide	B
.	O

Other	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
drugs	B
that	O
inhibit	O
prostaglandin	O
synthesis	O
have	O
been	O
shown	O
to	O
interfere	O
with	O
thiazide	B
diuretics	I
in	O
some	O
studies	O
and	O
with	O
potassium	O
-	O
sparing	O
diuretics	B
.	O

Patients	O
receiving	O
flurbiprofen	B
and	O
furosemide	B
or	O
other	O
diuretics	B
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
is	O
obtained	O
.	O

Oral	O
Hypoglycemic	B
Agents	I
:	O
In	O
one	O
study	O
,	O
flurbiprofen	B
was	O
given	O
to	O
adult	O
diabetics	O
who	O
were	O
already	O
receiving	O
glyburide	B
(	O
n	O
=	O
4	O
)	O
,	O
metformin	B
(	O
n	O
=	O
2	O
)	O
chlorpropamide	B
with	O
phenformin	B
(	O
n	O
=	O
3	O
)	O
or	O
glyburide	B
with	O
phenformin	B
(	O
n	O
=	O
6	O
)	O
.	O

Although	O
there	O
was	O
a	O
slight	O
reduction	O
in	O
blood	O
sugar	O
concentrations	O
during	O
concomitant	O
administration	O
of	O
flurbiprofen	B
and	O
hypoglycemic	B
agents	I
,	O
there	O
were	O
no	O
signs	O
or	O
symptoms	O
of	O
hypoglycemia	O
.	O

Increases	O
in	O
prothrombin	O
time	O
have	O
been	O
noted	O
in	O
patients	O
receiving	O
long	O
-	O
term	O
warfarin	B
therapy	O
after	O
flutamide	B
was	O
initiated	O
.	O

Therefore	O
,	O
close	O
monitoring	O
of	O
prothrombin	O
time	O
is	O
recommended	O
and	O
adjustment	O
of	O
the	O
anticoagulant	B
dose	O
may	O
be	O
necessary	O
when	O
EULEXIN	B
Capsules	O
are	O
administered	O
concomitantly	O
with	O
warfarin	B
.	O

In	O
patients	O
receiving	O
another	O
serotonin	B
reuptake	I
inhibitor	I
drug	I
in	O
combination	O
with	O
monoamine	B
oxidase	I
inhibitors	I
(	O
MAOI	B
)	O
,	O
there	O
have	O
been	O
reports	O
of	O
serious	O
,	O
sometimes	O
fatal	O
,	O
reactions	O
including	O
hyperthermia	O
,	O
rigidity	O
,	O
myoclonus	O
,	O
autonomic	O
instability	O
with	O
possible	O
rapid	O
fluctuations	O
of	O
vital	O
signs	O
,	O
and	O
mental	O
status	O
changes	O
that	O
include	O
extreme	O
agitation	O
progressing	O
to	O
delirium	O
and	O
coma	O
.	O

Therefore	O
,	O
it	O
is	O
recommended	O
that	O
Fluvoxamine	B
Tablets	O
not	O
be	O
used	O
in	O
combination	O
with	O
MAOIs	B
,	O
or	O
within	O
14	O
days	O
of	O
discontinuing	O
treatment	O
with	O
a	O
MAOI	B
.	O

After	O
stopping	O
Fluvoxamine	B
Tablets	O
,	O
at	O
least	O
2	O
weeks	O
should	O
be	O
allowed	O
before	O
starting	O
a	O
MAOI	B
.	O

Potential	O
Terfenadine	B
,	O
Astemizole	B
,	O
and	O
Cisapride	B
Interactions	O

Terfenadine	B
,	O
astemizole	B
and	O
cisapride	B
are	O
all	O
metabolized	O
by	O
the	O
cytochrome	O
P450IIIA4	O
isozyme	O
,	O
and	O
it	O
has	O
been	O
demonstrated	O
that	O
ketoconazole	B
,	O
a	O
potent	O
inhibitor	O
of	O
IIIA4	O
,	O
blocks	O
the	O
metabolism	O
of	O
these	O
drugs	O
,	O
resulting	O
in	O
increased	O
plasma	O
concentrations	O
of	O
parent	O
drug	O
.	O

Increased	O
plasma	O
concentrations	O
of	O
terfenadine	B
,	O
astemizole	B
,	O
and	O
cisapride	B
cause	O
QT	O
prolongation	O
and	O
have	O
been	O
associated	O
with	O
torsades	O
de	O
pointes	O
-	O
type	O
ventricular	O
tachycardia	O
,	O
sometimes	O
fatal	O
.	O

As	O
noted	O
below	O
,	O
a	O
sub	O
-	O
for	O
fluvoxamine	B
in	O
combination	O
with	O
alprazolam	B
,	O
a	O
drug	O
that	O
is	O
known	O
to	O
be	O
metabolized	O
by	O
the	O
IIIA4	O
isozyme	O
.	O

Although	O
it	O
has	O
not	O
been	O
definitively	O
demonstrated	O
that	O
fluvoxamine	B
is	O
a	O
potent	O
IIIA4	O
inhibitor	O
,	O
it	O
is	O
likely	O
to	O
be	O
,	O
given	O
the	O
substantial	O
interaction	O
of	O
fluvoxamine	B
with	O
alprazolam	B
.	O

Consequently	O
,	O
it	O
is	O
recommended	O
that	O
fluvoxamine	B
not	O
be	O
used	O
in	O
combination	O
with	O
either	O
terbinafine	B
,	O
astemizole	B
,	O
or	O
cisapride	B
.	O

Other	O
Potentially	O
Important	O
Drug	O
Interactions	O
:	O
Benzodiazepines	B
:	O
Benzodiazepines	B
metabolized	O
by	O
hepatic	O
oxidation	O
(	O
e	O
.	O
g	O
.	O
,	O
alprazolam	B
,	O
midazolam	B
,	O
triazolam	B
elc	O
.	O
)	O
should	O
be	O
used	O
with	O
caution	O
because	O
the	O
clearance	O
of	O
these	O
drugs	O
is	O
likely	O
to	O
be	O
reduced	O
by	O
fluvoxamine	B
.	O

The	O
clearance	O
of	O
benzodiazepines	B
metabolized	O
by	O
glucuronidation	O
(	O
e	O
.	O
g	O
.	O
,	O
lorazepam	B
,	O
oxazepam	B
,	O
temazepam	B
)	O
is	O
unlikely	O
to	O
be	O
affected	O
by	O
fluvoxamine	B
.	O

Alprazolam	B
:	O
When	O
fluvoxamine	B
maleate	I
(	O
100	O
mg	O
qd	O
)	O
and	O
alprazolam	B
(	O
1	O
mg	O
q	O
.	O
d	O
.	O
were	O
co	O
-	O
administered	O
to	O
steady	O
state	O
,	O
plasma	O
concentration	O
and	O
other	O
pharmacokinetics	O
parameters	O
(	O
AUC	O
,	O
Cmax	O
,	O
T1	O
/	O
2	O
,	O
)	O
of	O
alprazolam	B
were	O
approximately	O
twice	O
those	O
observed	O
when	O
alprazolam	B
was	O
administered	O
alone	O
;	O

This	O
interaction	O
,	O
which	O
has	O
not	O
been	O
investigated	O
using	O
higher	O
doses	O
of	O
fluvoxamine	B
,	O
may	O
be	O
more	O
pronounced	O
if	O
a	O
300	O
mg	O
daily	O
dose	O
is	O
co	O
-	O
administered	O
,	O
particularly	O
since	O
fluvoxamine	B
exhibits	O
non	O
-	O
linear	O
pharmacokinetics	O
over	O
the	O
dosage	O
range	O
100	O
-	O
300	O
mg	O
.	O
If	O
alprazolam	B
is	O
co	O
-	O
administered	O
with	O
Fluvoxamine	B
Tablets	O
,	O
the	O
initial	O
alprazolam	B
dosage	O
should	O
be	O
at	O
least	O
halved	O
and	O
titration	O
to	O
the	O
lowest	O
effective	O
dose	O
is	O
recommended	O
.	O

Diazepam	B
:	O
The	O
co	O
-	O
administration	O
of	O
Fluvoxamine	B
Tablets	O
and	O
diazepam	B
is	O
generally	O
not	O
advisable	O
.	O

Because	O
fluvoxamine	B
reduces	O
the	O
clearance	O
of	O
both	O
diazepam	B
and	O
its	O
active	O
metabolite	O
,	O
N	O
-	O
desmethyldiazepam	O
,	O
there	O
is	O
a	O
strong	O
likelihood	O
of	O
substantial	O
accumulation	O
of	O
both	O
species	O
during	O
chronic	O
co	O
-	O
administration	O
.	O

Evidence	O
supporting	O
the	O
conclusion	O
that	O
it	O
is	O
inadvisable	O
to	O
co	O
-	O
administer	O
fluvoxamine	B
and	O
diazepam	B
is	O
derived	O
from	O
a	O
study	O
in	O
which	O
healthy	O
volunteers	O
taking	O
150	O
mg	O
/	O
day	O
of	O
fluvoxamine	B
were	O
administered	O
a	O
single	O
oral	O
dose	O
of	O
10	O
mg	O
of	O
diazepam	B
.	O

In	O
these	O
subjects	O
(	O
R	O
=	O
B	O
)	O
,	O
the	O
clearance	O
of	O
diazepam	B
was	O
reduced	O
by	O
65	O
%	O
and	O
that	O
of	O
N	O
-	O
desmethyldiazepam	O
to	O
a	O
level	O
that	O
was	O
too	O
low	O
to	O
measure	O
over	O
the	O
course	O
of	O
the	O
2	O
week	O
long	O
study	O
.	O

Moreover	O
,	O
as	O
noted	O
with	O
alprazolam	B
,	O
the	O
effect	O
of	O
fluvoxamine	B
may	O
even	O
be	O
more	O
pronounced	O
when	O
it	O
is	O
administered	O
at	O
higher	O
doses	O
.	O

Accordingly	O
,	O
diazepam	B
and	O
fluvoxamine	B
should	O
not	O
ordinarily	O
be	O
co	O
-	O
administered	O
.	O

Theophylline	B
:	O
The	O
effect	O
of	O
steady	O
-	O
state	O
fluvoxamine	B
l50	O
mg	O
bid	O
on	O
the	O
pharmacokinetics	O
of	O
a	O
single	O
dose	O
of	O
Theophylline	B
(	O
375	O
mg	O
)	O
as	O
442	O
mg	O
aminophylline	B
was	O
evaluated	O
in	O
12	O
healthy	O
non	O
-	O
smoking	O
,	O
male	O
volunteers	O
.	O

Therefore	O
,	O
if	O
theophylline	B
is	O
co	O
-	O
administered	O
with	O
fluvoxamine	B
maleate	I
,	O
its	O
dose	O
should	O
be	O
reduced	O
to	O
one	O
third	O
of	O
the	O
usual	O
daily	O
maintenance	O
dose	O
and	O
plasma	O
concentrations	O
of	O
theophylline	B
should	O
to	O
monitored	O
.	O

Warfarin	B
:	O
When	O
fluvoxamine	B
maleate	I
(	O
50	O
mg	O
tid	O
)	O
was	O
administered	O
concomitantly	O
with	O
warfarin	B
for	O
two	O
weeks	O
,	O
warfarin	B
plasma	O
concentrations	O
increased	O
by	O
98	O
%	O
and	O
prothrombin	O
times	O
were	O
prolonged	O
.	O

Thus	O
patients	O
receiving	O
oral	O
anticoagulants	B
and	O
Fluvoxamine	B
Tablets	O
should	O
have	O
their	O
prothrombin	O
time	O
monitored	O
and	O
their	O
anticoagulant	B
dose	O
adjusted	O
accordingly	O
.	O

Medications	O
can	O
interfere	O
with	O
folate	O
utilization	O
,	O
including	O
:	O
anticonvulsant	B
medications	I
(	O
such	O
as	O
phenytoin	B
,	O
and	O
primidone	B
)	O
metformin	B
(	O
sometimes	O
prescribed	O
to	O
control	O
blood	O
sugar	O
in	O
type	O
2	O
diabetes	O
)	O
sulfasalazine	B
(	O
used	O
to	O
control	O
inflammation	O
associated	O
with	O
Crohns	O
disease	O
and	O
ulcerative	O
colitis	O
)	O
triamterene	B
(	O
a	O
diuretic	B
)	O
Methotrexate	B
There	O
has	O
been	O
concern	O
about	O
the	O
interaction	O
between	O
vitamin	B
B12	I
and	O
folic	B
acid	I
.	O

Therefore	O
,	O
intake	O
of	O
supplemental	O
folic	B
acid	I
should	O
not	O
exceed	O
1000	O
micrograms	O
(	O
g	O
,	O
sometimes	O
mcg	O
)	O
per	O
day	O
to	O
prevent	O
folic	B
acid	I
from	O
masking	O
symptoms	O
of	O
vitamin	O
B12	O
deficiency	O
.	O

It	O
is	O
important	O
for	O
older	O
adults	O
to	O
be	O
aware	O
of	O
the	O
relationship	O
between	O
folic	B
acid	I
and	O
vitamin	B
B12	I
because	O
they	O
are	O
at	O
greater	O
risk	O
of	O
having	O
a	O
vitamin	B
B12	I
deficiency	O
.	O

Oral	O
doses	O
of	O
Antizol	B
(	O
10	O
-	O
20	O
mg	O
/	O
kg	O
)	O
,	O
via	O
alcohol	O
dehydrogenase	O
inhibition	O
,	O
significantly	O
reduced	O
the	O
rate	O
of	O
elimination	O
of	O
ethanol	B
(	O
by	O
approximately	O
40	O
%	O
)	O
given	O
to	O
healthy	O
volunteers	O
in	O
moderate	O
doses	O
.	O

Similarly	O
,	O
ethanol	B
decreased	O
the	O
rate	O
of	O
elimination	O
of	O
Antizol	B
(	O
by	O
approximately	O
50	O
%	O
)	O
by	O
the	O
same	O
mechanism	O
.	O

Reciprocal	O
interactions	O
may	O
occur	O
with	O
concomitant	O
use	O
of	O
Antizol	B
and	O
drugs	O
that	O
increase	O
or	O
inhibit	O
the	O
cytochrome	O
P450	O
system	O
(	O
e	O
.	O
g	O
.	O
,	O
phenytoin	B
,	O
carbamazepine	B
,	O
cimetidine	B
,	O
ketoconazole	B
)	O
,	O
though	O
this	O
has	O
not	O
been	O
studied	O

In	O
clinical	O
studies	O
performed	O
with	O
Fondaparinux	B
,	O
the	O
concomitant	O
use	O
of	O
oral	O
anticoagulants	B
(	O
warfarin	B
)	O
,	O
platelet	B
inhibitors	I
(	O
acetylsalicylic	B
acid	I
)	O
,	O
NSAIDs	B
(	O
piroxicam	B
)	O
,	O
and	O
digoxin	B
did	O
not	O
significantly	O
affect	O
the	O
pharmacokinetics	O
/	O
pharmacodynamics	O
of	O
fondaparinux	B
sodium	I
.	O

In	O
addition	O
,	O
Fondaparinux	B
neither	O
influenced	O
the	O
pharmacodynamics	O
of	O
warfarin	B
,	O
acetylsalicylic	B
acid	I
,	O
piroxicam	B
,	O
and	O
digoxin	B
,	O
nor	O
the	O
pharmacokinetics	O
of	O
digoxin	B
at	O
steady	O
state	O
.	O

In	O
an	O
in	O
vitro	O
study	O
in	O
human	O
liver	O
microsomes	O
,	O
inhibition	O
of	O
CYP2A6	O
hydroxylation	O
of	O
coumarin	B
by	O
fondaparinux	B
(	O
200	O
m	O
m	O
M	O
i	O
.	O
e	O
.	O
,	O
350	O
mg	O
/	O
L	O
)	O
was	O
17	O
-	O
28	O
%	O
.	O

Since	O
fondaparinux	B
does	O
not	O
markedly	O
inhibit	O
CYP450s	O
(	O
CYP1A2	O
,	O
CYP2A6	O
,	O
CYP2C9	O
,	O
CYP2C19	O
,	O
CYP2D6	O
,	O
CYP2E1	O
,	O
or	O
CYP3A4	O
)	O
in	O
vitro	O
,	O
fondaparinux	B
sodium	I
is	O
not	O
expected	O
to	O
significantly	O
interact	O
with	O
other	O
drugs	O
in	O
vivo	O
by	O
inhibition	O
of	O
metabolism	O
mediated	O
by	O
these	O
isozymes	O
.	O

Short	O
-	O
Acting	O
beta2	O
-	O
agonists	O
:	O
Aerosol	O
bronchodilators	B
of	O
the	O
short	O
-	O
acting	O
adrenergic	O
stimulant	O
type	O
may	O
be	O
used	O
for	O
relief	O
of	O
breakthrough	O
symptoms	O
while	O
using	O
formoterol	B
.	O

Concomitant	O
administration	O
of	O
other	O
sympathomimetic	B
agents	I
may	O
potentiate	O
the	O
undesirable	O
effects	O
of	O
FORADIL	B
.	O

Monoamine	B
Oxidase	I
Inhibitors	I
and	O
Tricyclic	B
Antidepressants	I
:	O
FORADIL	B
should	O
be	O
administered	O
with	O
extreme	O
caution	O
in	O
patients	O
being	O
treated	O
with	O
monoamine	B
oxidase	I
inhibitors	I
or	O
tricyclic	B
antidepressants	I
because	O
the	O
action	O
of	O
formoterol	B
on	O
the	O
cardiovascular	O
system	O
may	O
be	O
potentiated	O
by	O
these	O
agents	O
.	O

Corticosteroids	B
,	O
Methylxanthines	B
and	O
Diuretics	B
:	O
Concomitant	O
treatment	O
with	O
xanthine	B
derivatives	I
,	O
steroids	B
,	O
or	O
diuretics	B
may	O
potentiate	O
a	O
possible	O
hypokalemic	O
effect	O
of	O
beta2	O
-	O
agonists	O
.	O

Other	O
Drugs	O
:	O
Drugs	O
such	O
as	O
quinidine	B
,	O
disopyramide	B
,	O
procainamide	B
,	O
phenothiazines	B
,	O
antihistamines	B
,	O
and	O
tricyclic	B
antidepressants	I
may	O
be	O
associated	O
with	O
QT	O
-	O
interval	O
prolongation	O
and	O
an	O
increased	O
risk	O
of	O
ventricular	O
arrhythmia	O
.	O

It	O
is	O
important	O
that	O
patients	O
understand	O
how	O
to	O
use	O
FORADIL	B
(	O
formoterol	B
fumarate	I
)	O
capsules	O
with	O
the	O
supplied	O
AerolizerTM	O
inhalation	O
device	O
and	O
how	O
it	O
should	O
be	O
used	O
in	O
relation	O
to	O
other	O
asthma	O
or	O
COPD	O
medications	O
they	O
are	O
taking	O
.	O

Acute	O
symptoms	O
should	O
be	O
treated	O
with	O
a	O
short	O
-	O
acting	O
,	O
inhaled	O
beta2	O
-	O
agonist	O
such	O
as	O
salbutamol	B
(	O
the	O
physician	O
should	O
provide	O
the	O
patient	O
with	O
such	O
medication	O
and	O
instruct	O
the	O
patient	O
in	O
how	O
it	O
should	O
be	O
used	O
)	O
.	O

FORADIL	B
should	O
not	O
be	O
used	O
as	O
a	O
substitute	O
for	O
oral	O
or	O
inhaled	O
corticosteroids	B
.	O

Guardians	O
of	O
children	O
who	O
have	O
been	O
prescribed	O
FORADIL	B
should	O
be	O
alerted	O
to	O
the	O
general	O
concern	O
regarding	O
asthma	O
therapy	O
compliance	O
,	O
especially	O
neglect	O
of	O
anti	O
-	O
inflammatory	O
therapy	O
and	O
overuse	O
of	O
short	O
-	O
acting	O
beta2	O
-	O
agonists	O
.	O

A	O
possible	O
drug	O
interaction	O
of	O
FOSCAVIR	B
and	O
intravenous	O
pentamidine	B
has	O
been	O
described	O
.	O

Concomitant	O
treatment	O
of	O
four	O
patients	O
in	O
the	O
United	O
Kingdom	O
with	O
FOSCAVIR	B
and	O
intravenous	O
pentamidine	B
may	O
have	O
caused	O
hypocalcemia	O
;	O

Because	O
of	O
foscarnets	O
tendency	O
to	O
cause	O
renal	O
impairment	O
,	O
the	O
use	O
of	O
FOSCAVIR	B
should	O
be	O
avoided	O
in	O
combination	O
with	O
potentially	O
nephrotoxic	O
drugs	O
such	O
as	O
aminoglycosides	B
,	O
amphotericin	B
B	I
and	O
intravenous	O
pentamidine	B
unless	O
the	O
potential	O
benefits	O
outweigh	O
the	O
risks	O
to	O
the	O
patient	O
.	O

Ganciclovir	B
:	O
The	O
pharmacokinetics	O
of	O
foscarnet	B
and	O
ganciclovir	B
were	O
not	O
altered	O
in	O
13	O
patients	O
receiving	O
either	O
concomitant	O
therapy	O
or	O
daily	O
alternating	O
therapy	O
for	O
maintenance	O
of	O
CMV	O
disease	O
.	O

Metoclopramide	B
:	O
When	O
coadministered	O
with	O
MONUROL	B
,	O
metoclopramide	B
,	O
a	O
drug	O
which	O
increases	O
gastrointestinal	O
motility	O
,	O
lowers	O
the	O
serum	O
concentration	O
and	O
urinary	O
excretion	O
of	O
fosfomycin	B
.	O

Cimetidine	B
:	O
Cimetidine	B
does	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
fosfomycin	B
when	O
coadministered	O
with	O
MONUROL	B
.	O

Diuretics	B
:	O
Patients	O
on	O
diuretics	B
,	O
especially	O
those	O
with	O
intravascular	O
volume	O
depletion	O
,	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
therapy	O
with	O
fosinopril	B
sodium	I
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	B
or	O
increasing	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
fosinopril	B
sodium	I
.	O

Potassium	B
Supplements	O
and	O
Potassium	B
-	O
Sparing	O
Diuretics	B
:	O
Fosinopril	B
sodium	I
can	O
attenuate	O
potassium	O
loss	O
caused	O
by	O
thiazide	B
diuretics	I
.	O

Potassium	O
-	O
sparing	O
diuretics	B
(	O
spironolactone	B
,	O
amiloride	B
,	O
triamterene	B
,	O
and	O
others	O
)	O
or	O
potassium	B
supplements	O
can	O
increase	O
the	O
risk	O
of	O
hyperkalemia	O
.	O

Lithium	B
:	O
Increased	O
serum	O
lithium	B
levels	O
and	O
symptoms	O
of	O
lithium	B
toxicity	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
ACE	B
inhibitors	I
during	O
therapy	O
with	O
lithium	B
.	O

Antacids	B
:	O
In	O
a	O
clinical	O
pharmacology	O
study	O
,	O
coadministration	O
of	O
an	O
antacid	B
(	O
aluminum	B
hydroxide	I
,	O
magnesium	B
hydroxide	I
,	O
and	O
simethicone	B
)	O
with	O
fosinopril	B
reduced	O
serum	O
levels	O
and	O
urinary	O
excretion	O
of	O
fosinoprilat	B
as	O
compared	O
with	O
fosinopril	B
administered	O
alone	O
,	O
suggesting	O
that	O
antacids	B
may	O
impair	O
absorption	O
of	O
fosinopril	B
.	O

In	O
separate	O
single	O
or	O
multiple	O
dose	O
pharmacokinetic	O
interaction	O
studies	O
with	O
chlorthalidone	B
,	O
nifedipine	B
,	O
propanolol	B
,	O
hydrochlorothiazide	B
,	O
cimetidine	B
,	O
metoclopramide	B
,	O
propantheline	B
,	O
digoxin	B
,	O
and	O
warfarin	B
,	O
the	O
bioavailability	O
of	O
fosinoprilat	B
was	O
not	O
altered	O
by	O
coadministration	O
of	O
fosinopril	B
with	O
any	O
one	O
of	O
these	O
drugs	O
.	O

In	O
a	O
study	O
with	O
concomitant	O
administration	O
of	O
aspirin	B
and	O
fosinopril	B
sodium	I
,	O
the	O
bioavailability	O
of	O
unbound	O
fosinoprilat	B
was	O
not	O
altered	O
.	O

In	O
a	O
pharmacokinetic	O
interaction	O
study	O
with	O
warfarin	B
,	O
bioavailability	O
parameters	O
,	O
the	O
degree	O
of	O
protein	O
binding	O
,	O
and	O
the	O
anticoagulant	O
effect	O
(	O
measured	O
by	O
prothrombin	O
time	O
)	O
of	O
warfarin	B
were	O
not	O
significantly	O
changed	O
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interaction	O
Fosinopril	B
may	O
cause	O
a	O
false	O
low	O
measurement	O
of	O
serum	O
digoxin	B
levels	O
with	O
the	O
Digi	O
-	O
Tab	O
RIA	O
Kit	O
for	O
Digoxin	B
.	O

No	O
drugs	O
are	O
known	O
to	O
interfere	O
with	O
the	O
conversion	O
of	O
fosphenytoin	B
to	O
phenytoin	B
.	O

Conversion	O
could	O
be	O
affected	O
by	O
alterations	O
in	O
the	O
level	O
of	O
phosphatase	O
activity	O
,	O
but	O
given	O
the	O
abundance	O
and	O
wide	O
distribution	O
of	O
phosphatases	O
in	O
the	O
body	O
it	O
is	O
unlikely	O
that	O
drugs	O
would	O
affect	O
this	O
activity	O
enough	O
to	O
affect	O
conversion	O
of	O
fosphenytoin	B
to	O
phenytoin	B
.	O

The	O
pharmacokinetics	O
and	O
protein	O
binding	O
of	O
fosphenytoin	B
,	O
phenytoin	B
,	O
and	O
diazepam	B
were	O
not	O
altered	O
when	O
diazepam	B
and	O
Cerebyx	B
were	O
concurrently	O
administered	O
in	O
single	O
submaximal	O
doses	O
.	O

The	O
most	O
significant	O
drug	O
interactions	O
following	O
administration	O
of	O
Cerebyx	B
are	O
expected	O
to	O
occur	O
with	O
drugs	O
that	O
interact	O
with	O
phenytoin	B
.	O

The	O
most	O
commonly	O
occurring	O
drug	O
interactions	O
are	O
listed	O
below	O
:	O
-	O
Drugs	O
that	O
may	O
increase	O
plasma	O
phenytoin	B
concentrations	O
include	O
:	O
acute	O
alcohol	B
intake	O
,	O
amiodarone	B
,	O
chboramphenicol	O
,	O
chlordiazepoxide	B
,	O
cimetidine	B
,	O
diazepam	B
,	O
dicumarol	B
,	O
disulfiram	B
,	O
estrogens	B
,	O
ethosuximide	B
,	O
fluoxetine	B
,	O
H2	O
-	O
antagonists	O
,	O
halothane	B
,	O
isoniazid	B
,	O
methylphenidate	B
,	O
phenothiazines	B
,	O
phenylbutazone	B
,	O
salicylates	B
,	O
succinimides	B
,	O
sulfonamides	B
,	O
tolbutamide	B
,	O
trazodone	B

-	O
Drugs	O
that	O
may	O
decrease	O
plasma	O
phenytoin	B
concentrations	O
include	O
:	O
carbamazepine	B
,	O
chronic	O
alcohol	B
abuse	O
,	O
reserpine	B

-	O
Drugs	O
that	O
may	O
either	O
increase	O
or	O
decrease	O
plasma	O
phenytoin	B
concentrations	O
include	O
:	O
phenobarbital	B
,	O
vaiproic	O
acid	O
,	O
and	O
sodium	B
valproate	I
.	O

Similarly	O
,	O
the	O
effects	O
of	O
phenytoin	B
on	O
phenobarbital	B
,	O
valproic	B
acid	I
and	O
sodium	O
plasma	O
valproate	B
concentrations	O
are	O
unpredictable	O

-	O
Although	O
not	O
a	O
true	O
drug	O
interaction	O
,	O
tricyclic	B
antidepressants	I
may	O
precipitate	O
seizures	O
in	O
susceptible	O
patients	O
and	O
Cerebyx	B
dosage	O
may	O
need	O
to	O
be	O
adjusted	O

-	O
Drugs	O
whose	O
efficacy	O
is	O
impaired	O
by	O
phenytoin	B
include	O
:	O
anticoagulants	B
,	O
corticosteroids	B
,	O
coumarin	B
,	O
digitoxin	B
,	O
doxycycline	B
,	O
estrogens	B
,	O
furosemide	B
,	O
oral	O
contraceptives	B
,	O
rifampin	B
,	O
quinidine	B
,	O
theophylline	B
,	O
vitamin	B
D	I
.	O

Care	O
should	O
be	O
taken	O
when	O
using	O
immunoanalytical	O
methods	O
to	O
measure	O
plasma	O
phenytoin	B
concentrations	O
following	O
Cerebyx	B
administration	O
.	O

Due	O
to	O
a	O
theoretical	O
risk	O
of	O
a	O
pharmacodynamic	O
interaction	O
,	O
use	O
of	O
ergotamine	B
-	O
containing	O
or	O
ergot	O
-	O
type	O
medications	B
(	O
like	O
dihydroergotamine	B
or	O
methysergide	B
)	O
and	O
FROVA	B
within	O
24	O
hours	O
of	O
each	O
other	O
should	O
be	O
avoided	O
(	O
see	O
a	O
href	O
=	O
frova	O
_	O
od	O
.	O
htm	O
#	O
CI	O
CONTRAINDICATIONS	O
)	O
.	O

Selective	B
serotonin	I
reuptake	I
inhibitors	I
(	O
SSRIs	B
)	O
(	O
e	O
.	O
g	O
.	O
,	O
fluoxetine	B
,	O
fluvoxamine	B
,	O
paroxetine	B
,	O
sertraline	B
)	O
have	O
been	O
reported	O
,	O
rarely	O
,	O
to	O
cause	O
weakness	O
,	O
hyperreflexia	O
,	O
and	O
incoordination	O
when	O
coadministered	O
with	O
5	O
-	O
HT1	O
agonists	B
.	O

If	O
concomitant	O
treatment	O
with	O
frovatriptan	B
and	O
an	O
SSRI	B
is	O
clinically	O
warranted	O
,	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O

The	O
potential	O
effects	O
of	O
fulvestrant	B
on	O
the	O
fertility	O
of	O
male	O
animals	O
were	O
not	O
studied	O
but	O
in	O
a	O
6	O
-	O
month	O
toxicology	O
study	O
,	O
male	O
rats	O
treated	O
with	O
intramuscular	O
doses	O
of	O
15	O
mg	O
/	O
kg	O
/	O
30	O
days	O
,	O
10	O
mg	O
/	O
rat	O
/	O
30	O
days	O
,	O
or	O
10	O
mg	O
/	O
rat	O
/	O
15	O
days	O
fulvestrant	B
showed	O
a	O
loss	O
of	O
spermatozoa	O
from	O
the	O
seminiferous	O
tubules	O
,	O
seminiferous	O
tubular	O
atrophy	O
,	O
and	O
degenerative	O
changes	O
in	O
the	O
epididymides	O
.	O

Furosemide	B
may	O
increase	O
the	O
ototoxic	O
potential	O
of	O
aminoglycoside	B
antibiotics	I
,	O
especially	O
in	O
the	O
presence	O
of	O
impaired	O
renal	O
function	O
.	O

Furosemide	B
should	O
not	O
be	O
used	O
concomitantly	O
with	O
ethacrynic	B
acid	I
because	O
of	O
the	O
possibility	O
of	O
ototoxicity	O
.	O

Patients	O
receiving	O
high	O
doses	O
of	O
salicylates	B
concomitantly	O
with	O
furosemide	B
,	O
as	O
in	O
rheumatic	O
disease	O
,	O
may	O
experience	O
salicylate	B
toxicity	O
at	O
lower	O
doses	O
because	O
of	O
competitive	O
renal	O
excretory	O
sites	O
.	O

Furosemide	B
has	O
a	O
tendency	O
to	O
antagonize	O
the	O
skeletal	O
muscle	O
relaxing	O
effect	O
of	O
tubocurarine	B
and	O
may	O
potentiate	O
the	O
action	O
of	O
succinylcholine	B
.	O

Lithium	B
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B
because	O
they	O
reduce	O
lithiums	O
renal	O
clearance	O
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B
toxicity	O
.	O

Furosemide	B
may	O
add	O
to	O
or	O
potentiate	O
the	O
therapeutic	O
effect	O
of	O
other	O
antihypertensive	B
drugs	I
.	O

Potentiation	O
occurs	O
with	O
ganglionic	B
or	O
peripheral	B
adrenergic	I
blocking	I
drugs	I
.	O

Furosemide	B
may	O
decrease	O
arterial	O
responsiveness	O
to	O
norepinephrine	B
.	O

Tablets	O
Simultaneous	O
administration	O
of	O
sucralfate	B
and	O
furosemide	B
tablets	O
may	O
reduce	O
the	O
natriuretic	O
and	O
antihypertensive	O
effects	O
of	O
furosemide	B
.	O

The	O
intake	O
of	O
furosemide	B
and	O
sucralfate	B
should	O
be	O
separated	O
by	O
at	O
least	O
two	O
hours	O
.	O

Tablets	O
,	O
Injection	O
,	O
and	O
Oral	O
Solution	O
One	O
study	O
in	O
six	O
subjects	O
demonstrated	O
that	O
the	O
combination	O
of	O
furosemide	B
and	O
acetylsalicylic	B
acid	I
temporarily	O
reduced	O
creatinine	O
clearance	O
in	O
patients	O
with	O
chronic	O
renal	O
insufficiency	O
.	O

There	O
are	O
case	O
reports	O
of	O
patients	O
who	O
developed	O
increased	O
BUN	O
,	O
serum	O
creatinine	O
and	O
serum	O
potassium	O
levels	O
,	O
and	O
weight	O
gain	O
when	O
furosemide	B
was	O
used	O
in	O
conjunction	O
with	O
NSAIDs	B
.	O

Literature	O
reports	O
indicate	O
that	O
coadministration	O
of	O
indomethacin	B
may	O
reduce	O
the	O
natriuretic	O
and	O
antihypertensive	O
effects	O
of	O
furosemide	B
in	O
some	O
patients	O
by	O
inhibiting	O
prostaglandin	O
synthesis	O
.	O

Patients	O
receiving	O
both	O
indomethacin	B
and	O
furosemide	B
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
diuretic	O
and	O
/	O
or	O
antihypertensive	O
effect	O
of	O
furosemide	B
is	O
achieved	O
.	O

Gabapentin	B
is	O
not	O
appreciably	O
metabolized	O
nor	O
does	O
it	O
interfere	O
with	O
the	O
metabolism	O
of	O
commonly	O
coadministered	O
antiepileptic	B
drugs	I
.	O

Phenytoin	B
:	O
In	O
a	O
single	O
(	O
400	O
mg	O
)	O
and	O
multiple	O
dose	O
(	O
400	O
mg	O
TID	O
)	O
study	O
of	O
Neurontin	B
in	O
epileptic	O
patients	O
(	O
N	O
=	O
8	O
)	O
maintained	O
on	O
phenytoin	B
monotherapy	O
for	O
at	O
least	O
2	O
months	O
,	O
gabapentin	B
had	O
no	O
effect	O
on	O
the	O
steady	O
-	O
state	O
trough	O
plasma	O
concentrations	O
of	O
phenytoin	B
and	O
phenytoin	B
had	O
no	O
effect	O
on	O
gabapentin	B
pharmacokinetics	O
.	O

Carbamazepine	B
:	O
Steady	O
-	O
state	O
trough	O
plasma	O
carbamazepine	B
and	O
carbamazepine	B
10	O
,	O
11	B
epoxide	I
concentrations	O
were	O
not	O
affected	O
by	O
concomitant	O
gabapentin	B
(	O
400	O
mg	O
TID	O
;	O

Likewise	O
,	O
gabapentin	B
pharmacokinetics	O
were	O
unaltered	O
by	O
carbamazepine	B
administration	O
.	O

Valproic	B
Acid	I
:	O
The	O
mean	O
steady	O
-	O
state	O
trough	O
serum	O
valproic	B
acid	I
concentrations	O
prior	O
to	O
and	O
during	O
concomitant	O
gabapentin	B
administration	O
(	O
400	O
mg	O
TID	O
;	O

N	O
=	O
17	O
)	O
were	O
not	O
different	O
and	O
neither	O
were	O
gabapentin	B
pharmacokinetic	O
parameters	O
affected	O
by	O
valproic	B
acid	I
.	O

Phenobarbital	B
:	O
Estimates	O
of	O
steady	O
-	O
state	O
pharmacokinetic	O
parameters	O
for	O
phenobarbital	B
or	O
gabapentin	B
(	O
300	O
mg	O
TID	O
;	O

Naproxen	B
:	O
Coadministration	O
(	O
N	O
=	O
18	O
)	O
of	O
naproxen	B
sodium	I
capsules	O
(	O
250	O
mg	O
)	O
with	O
Neurontin	B
(	O
125	O
mg	O
)	O
appears	O
to	O
increase	O
the	O
amount	O
of	O
gabapentin	B
absorbed	O
by	O
12	O
%	O
to	O
15	O
%	O
.	O

Gabapentin	B
had	O
no	O
effect	O
on	O
naproxen	B
pharmacokinetic	O
parameters	O
.	O

Hydrocodone	B
:	O
Coadministration	O
of	O
Neurontin	B
(	O
125	O
to	O
500	O
mg	O
;	O

Cmax	O
and	O
AUC	O
values	O
are	O
3	O
%	O
to	O
4	O
%	O
lower	O
,	O
respectively	O
,	O
after	O
administration	O
of	O
125	O
mg	O
Neurontin	B
and	O
21	O
%	O
to	O
22	O
%	O
lower	O
,	O
respectively	O
,	O
after	O
administration	O
of	O
500	O
mg	O
Neurontin	B
.	O

Hydrocodone	B
increases	O
gabapentin	B
AUC	O
values	O
by	O
14	O
%	O
.	O

Morphine	B
:	O
A	O
literature	O
article	O
reported	O
that	O
when	O
a	O
60	O
-	O
mg	O
controlled	O
-	O
release	O
morphine	B
capsule	O
was	O
administered	O
2	O
hours	O
prior	O
to	O
a	O
600	O
-	O
mg	O
Neurontin	B
capsule	O
(	O
N	O
=	O
12	O
)	O
,	O
mean	O
gabapentin	B
AUC	O
increased	O
by	O
44	O
%	O
compared	O
to	O
gabapentin	B
administered	O
without	O
morphine	B
.	O

Morphine	B
pharmacokinetic	O
parameter	O
values	O
were	O
not	O
affected	O
by	O
administration	O
of	O
Neurontin	B
2	O
hours	O
after	O
morphine	B
.	O

Cimetidine	B
:	O
In	O
the	O
presence	O
of	O
cimetidine	B
at	O
300	O
mg	O
QID	O
(	O
N	O
=	O
12	O
)	O
the	O
mean	O
apparent	O
oral	O
clearance	O
of	O
gabapentin	B
fell	O
by	O
14	O
%	O
and	O
creatinine	O
clearance	O
fell	O
by	O
10	O
%	O
.	O

Thus	O
cimetidine	B
appeared	O
to	O
alter	O
the	O
renal	O
excretion	O
of	O
both	O
gabapentin	B
and	O
creatinine	O
,	O
an	O
endogenous	O
marker	O
of	O
renal	O
function	O
.	O

This	O
small	O
decrease	O
in	O
excretion	O
of	O
gabapentin	B
by	O
cimetidine	B
is	O
not	O
expected	O
to	O
be	O
of	O
clinical	O
importance	O
.	O

The	O
effect	O
of	O
gabapentin	B
on	O
cimetidine	B
was	O
not	O
evaluated	O
.	O

Oral	O
Contraceptive	B
:	O
Based	O
on	O
AUC	O
and	O
half	O
-	O
life	O
,	O
multiple	O
-	O
dose	O
pharmacokinetic	O
profiles	O
of	O
norethindrone	B
and	O
ethinyl	B
estradiol	I
following	O
administration	O
of	O
tablets	O
containing	O
2	O
.	O
5	O
mg	O
of	O
norethindrone	B
acetate	I
and	O
50	O
mcg	O
of	O
ethinyl	B
estradiol	I
were	O
similar	O
with	O
and	O
without	O
coadministration	O
of	O
gabapentin	B
(	O
400	O
mg	O
TID	O
;	O

The	O
Cmax	O
of	O
norethindrone	B
was	O
13	O
%	O
higher	O
when	O
it	O
was	O
coadministered	O
with	O
gabapentin	B
;	O

Antacid	B
(	O
Maalox	B
)	O
:	O
Maalox	B
reduced	O
the	O
bioavailability	O
of	O
gabapentin	B
(	O
N	O
=	O
16	O
)	O
by	O
about	O
20	O
%	O
.	O

This	O
decrease	O
in	O
bioavailability	O
was	O
about	O
5	O
%	O
when	O
gabapentin	B
was	O
administered	O
2	O
hours	O
after	O
Maalox	B
.	O

It	O
is	O
recommended	O
that	O
gabapentin	B
be	O
taken	O
at	O
least	O
2	O
hours	O
following	O
Maalox	B
administration	O
.	O

Effect	O
of	O
Probenecid	B
:	O
Probenecid	B
is	O
a	O
blocker	O
of	O
renal	O
tubular	O
secretion	O
.	O

Gabapentin	B
pharmacokinetic	O
parameters	O
without	O
and	O
with	O
probenecid	B
were	O
comparable	O
.	O

This	O
indicates	O
that	O
gabapentin	B
does	O
not	O
undergo	O
renal	O
tubular	O
secretion	O
by	O
the	O
pathway	O
that	O
is	O
blocked	O
by	O
probenecid	B
.	O

Drug	O
/	O
Laboratory	O
Tests	O
Interactions	O
Because	O
false	O
positive	O
readings	O
were	O
reported	O
with	O
the	O
Ames	O
N	O
-	O
Multistix	O
SG	O
dipstick	O
test	O
for	O
urinary	O
protein	O
when	O
gabapentin	B
was	O
added	O
to	O
other	O
antiepileptic	B
drugs	I
,	O
the	O
more	O
specific	O
sulfosalicylic	O
acid	O
precipitation	O
procedure	O
is	O
recommended	O
to	O
determine	O
the	O
presence	O
of	O
urine	O
protein	O

In	O
patients	O
receiving	O
a	O
potent	O
CYP3A4	O
inducer	O
such	O
as	O
rifampicin	B
or	O
phenytoin	B
,	O
a	O
dose	O
increase	O
to	O
500	O
mg	O
daily	O
should	O
be	O
considered	O
in	O
the	O
absence	O
of	O
severe	O
adverse	O
drug	O
reaction	O
,	O
and	O
clinical	O
response	O
and	O
adverse	O
events	O
should	O
be	O
carefully	O
monitored	O
(	O
see	O
CLINICAL	O
PHARMACOLOGY	O
-	O
Pharmacokinetics	O
-	O
Drug	O
-	O
Drug	O
Interactions	O
and	O
DOSAGE	O
AND	O
ADMINISTRATION	O
-	O
Dosage	O
Adjustment	O
sections	O
)	O
.	O

International	O
Normalized	O
Ratio	O
(	O
INR	O
)	O
elevations	O
and	O
/	O
or	O
bleeding	O
events	O
have	O
been	O
reported	O
in	O
some	O
patients	O
taking	O
warfarin	B
while	O
on	O
IRESSA	B
therapy	O
.	O

Substances	O
that	O
are	O
potent	O
inhibitors	O
of	O
CYP3A4	O
activity	O
(	O
eg	O
,	O
ketoconazole	B
and	O
itraconazole	B
)	O
decrease	O
gefitinib	B
metabolism	O
and	O
increase	O
gefitinib	B
plasma	O
concentrations	O
.	O

Drugs	O
that	O
cause	O
significant	O
sustained	O
elevation	O
in	O
gastric	O
pH	O
(	O
histamine	B
H2	O
-	O
receptor	O
antagonists	B
such	O
as	O
ranitidine	B
or	O
cimetidine	B
)	O
may	O
reduce	O
plasma	O
concentrations	O
of	O
IRESSA	B
and	O
therefore	O
potentially	O
may	O
reduce	O
efficacy	O
.	O

Phase	O
II	O
clinical	O
trial	O
data	O
,	O
where	O
IRESSA	B
and	O
vinorelbine	B
have	O
been	O
used	O
concomitantly	O
,	O
indicate	O
that	O
IRESSA	B
may	O
exacerbate	O
the	O
neutropenic	O
effect	O
of	O
vinorelbine	B
.	O

For	O
information	O
on	O
the	O
pharmacokinetics	O
of	O
Gemzar	B
and	O
cisplatin	B
in	O
combination	O
,	O
see	O
Drug	O
Interactions	O
under	O
CLINICAL	O
PHARMACOLOGY	O
section	O
.	O

Administration	O
of	O
repeat	O
doses	O
of	O
FACTIVE	B
had	O
no	O
effect	O
on	O
the	O
repeat	O
dose	O
pharmacokinetics	O
of	O
theophylline	B
,	O
digoxin	B
or	O
an	O
ethinylestradiol	B
/	O
levonorgestrol	O
oral	O
contraceptive	B
product	I
in	O
healthy	O
subjects	O
.	O

Concomitant	O
administration	O
of	O
FACTIVE	B
and	O
calcium	B
carbonate	I
,	O
cimetidine	B
,	O
omeprazole	B
,	O
or	O
an	O
estrogen	B
/	O
progesterone	B
oral	O
contraceptive	B
produced	O
minor	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
gemifloxacin	B
,	O
which	O
were	O
considered	O
to	O
be	O
without	O
clinical	O
significance	O
.	O

Concomitant	O
administration	O
of	O
FACTIVE	B
with	O
probenecid	B
resulted	O
in	O
a	O
45	O
%	O
increase	O
in	O
systemic	O
exposure	O
to	O
gemifloxacin	B
.	O

FACTIVE	B
had	O
no	O
significant	O
effect	O
on	O
the	O
anticoagulant	O
effect	O
of	O
warfarin	B
in	O
healthy	O
subjects	O
on	O
stable	O
warfarin	B
therapy	O
.	O

However	O
,	O
because	O
some	O
quinolones	B
have	O
been	O
reported	O
to	O
enhance	O
the	O
anticoagulant	O
effects	O
of	O
warfarin	B
or	O
its	O
derivatives	O
in	O
patients	O
,	O
the	O
prothrombin	O
time	O
or	O
other	O
suitable	O
coagulation	O
test	O
should	O
be	O
closely	O
monitored	O
if	O
a	O
quinolone	B
antimicrobial	I
is	O
administered	O
concomitantly	O
with	O
warfarin	B
or	O
its	O
derivatives	O
.	O

The	O
absorption	O
of	O
oral	O
gemifloxacin	B
is	O
significantly	O
reduced	O
by	O
the	O
concomitant	O
administration	O
of	O
an	O
antacid	B
containing	O
aluminum	B
and	O
magnesium	B
.	O

Magnesium	B
-	O
and	O
/	O
or	O
aluminum	B
-	O
containing	O
antacids	B
,	O
products	O
containing	O
ferrous	B
sulfate	I
(	O
iron	B
)	O
,	O
multivitamin	B
preparations	I
containing	O
zinc	B
or	O
other	O
metal	O
cations	O
,	O
or	O
Videx	B
(	O
didanosine	B
)	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
should	O
not	O
be	O
taken	O
within	O
3	O
hours	O
before	O
or	O
2	O
hours	O
after	O
FACTIVE	B
.	O

Sucralfate	B
should	O
not	O
be	O
taken	O
within	O
2	O
hours	O
of	O
FACTIVE	B
.	O

Results	O
from	O
existing	O
clinical	O
trials	O
suggest	O
no	O
significant	O
interactions	O
between	O
COPAXONE	B
and	O
other	O
therapies	O
commonly	O
used	O
in	O
MS	O
patients	O
,	O
including	O
the	O
concurrent	O
use	O
of	O
corticosteroids	B
for	O
up	O
to	O
28	O
days	O
.	O

COPAXONE	B
has	O
not	O
been	O
formally	O
evaluated	O
in	O
combination	O
with	O
Interferon	B
beta	I
.	O

However	O
,	O
10	O
patients	O
who	O
switched	O
from	O
therapy	O
with	O
Interferon	B
beta	I
to	O
COPAXONE	B
did	O
not	O
report	O
any	O
serious	O
and	O
unexpected	O
adverse	O
reactions	O
thought	O
to	O
be	O
related	O
to	O
treatment	O
.	O

The	O
hypoglycemic	O
action	O
of	O
sulfonylureas	B
may	O
be	O
potentiated	O
by	O
certain	O
drugs	O
including	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
agents	B
and	O
other	O
drugs	O
that	O
are	O
highly	O
protein	O
bound	O
,	O
salicylates	B
,	O
sulfonamides	B
,	O
chloramphenicol	B
,	O
probenecid	B
,	O
coumarins	B
,	O
monoamine	B
oxidase	I
inhibitors	I
,	O
and	O
beta	B
adrenergic	I
blocking	I
agents	I
.	O

These	O
drugs	B
include	O
the	O
thiazides	B
and	O
other	O
diuretics	B
,	O
corticosteroids	B
,	O
phe	O
-	O
nothiazines	O
,	O
thyroid	B
products	I
,	O
estrogens	B
,	O
oral	O
contraceptives	B
,	O
phenytoin	B
,	O
nicotinic	B
acid	I
,	O
sympathomimet	O
-	O
ics	O
,	O
calcium	B
channel	I
blocking	I
drugs	I
,	O
and	O
isoniazid	B
.	O

A	O
possible	O
interaction	O
between	O
glyburide	B
and	O
ciprofloxacin	B
,	O
a	O
fluoroquinolone	B
antibiotic	I
,	O
has	O
been	O
reported	O
,	O
resulting	O
in	O
a	O
potentiation	O
of	O
the	O
hypoglycemic	O
action	O
of	O
glyburide	B
.	O

A	O
potential	O
interaction	O
between	O
oral	O
miconazole	B
and	O
oral	O
hypoglycemic	B
agents	I
leading	O
to	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
.	O

Metformin	B
:	O
In	O
a	O
single	O
-	O
dose	O
interaction	O
study	O
in	O
NIDDM	O
subjects	O
,	O
decreases	O
in	O
glyburide	B
AUC	O
and	O
Cmax	O
were	O
observed	O
,	O
but	O
were	O
highly	O
variable	O
.	O

Coadministration	O
of	O
gly	O
-	O
buride	O
and	O
metformin	B
did	O
not	O
result	O
in	O
any	O
changes	O
in	O
either	O
metformin	B
pharmacokinetics	O
or	O
pharmaco	O
-	O
dynamics	O
.	O

Before	O
taking	O
glimepiride	B
,	O
tell	O
your	O
doctor	O
if	O
you	O
are	O
taking	O
any	O
of	O
the	O
following	O
medicines	O
:	O
-	O
aspirin	B
or	O
another	O
salicylate	B
such	O
as	O
magnesium	B
/	O
choline	B
salicylate	I
(	O
Trilisate	B
)	O
,	O
salsalate	B
(	O
Disalcid	B
,	O
others	O
)	O
,	O
choline	B
salicylate	I
(	O
Arthropan	B
)	O
,	O
magnesium	B
salicylate	I
(	O
Magan	B
)	O
,	O
or	O
bismuth	B
subsalicylate	I
(	O
Pepto	O
-	O
Bismol	O
)	O
;	O

-	O
a	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
drug	B
(	O
NSAID	B
)	O
such	O
as	O
ibuprofen	B
(	O
Motrin	B
,	O
Advil	B
,	O
Nuprin	B
,	O
others	O
)	O
,	O
ketoprofen	B
(	O
Orudis	B
,	O
Orudis	B
KT	I
,	O
Oruvail	B
)	O
,	O
diclofenac	B
(	O
Voltaren	B
,	O
Cataflam	B
)	O
,	O
etodolac	B
(	O
Lodine	B
)	O
,	O
indomethacin	B
(	O
Indocin	B
)	O
,	O
nabumetone	B
(	O
Relafen	B
)	O
,	O
oxaprozin	B
(	O
Daypro	B
)	O
,	O
and	O
naproxen	B
(	O
Anaprox	B
,	O
Naprosyn	B
,	O
Aleve	B
)	O
;	O

-	O
a	O
sulfa	O
-	O
based	O
drug	O
such	O
as	O
sulfamethoxazole	B
-	O
trimethoprim	B
(	O
Bactrim	B
,	O
Septra	B
)	O
,	O
sulfisoxazole	B
(	O
Gantrisin	B
)	O
,	O
or	O
sulfasalazine	B
(	O
Azulfidine	B
)	O
;	O

-	O
a	O
monoamine	B
oxidase	I
inhibitor	I
(	O
MAOI	B
)	O
such	O
as	O
isocarboxazid	B
(	O
Marplan	B
)	O
,	O
tranylcypromine	B
(	O
Parnate	B
)	O
,	O
or	O
phenelzine	B
(	O
Nardil	B
)	O
;	O

-	O
a	O
beta	O
-	O
blocker	O
such	O
as	O
propranolol	B
(	O
Inderal	B
)	O
,	O
atenolol	B
(	O
Tenormin	B
)	O
,	O
acebutolol	B
(	O
Sectral	B
)	O
,	O
metoprolol	B
(	O
Lopressor	B
)	O
,	O
and	O
others	O
;	O

-	O
a	O
diuretic	B
(	O
water	O
pill	O
)	O
such	O
as	O
hydrochlorothiazide	B
(	O
HCTZ	B
,	O
Hydrodiuril	B
)	O
,	O
chlorothiazide	B
(	O
Diuril	B
)	O
,	O
and	O
others	O
;	O

-	O
a	O
steroid	B
medicine	I
such	O
as	O
prednisone	B
(	O
Deltasone	B
,	O
Orasone	B
,	O
others	O
)	O
,	O
methylprednisolone	B
(	O
Medrol	B
,	O
others	O
)	O
,	O
prednisolone	B
(	O
Prelone	B
,	O
Pediapred	B
,	O
others	O
)	O
,	O
and	O
others	O
;	O

-	O
a	O
phenothiazine	B
such	O
as	O
chlorpromazine	B
(	O
Thorazine	B
)	O
,	O
fluphenazine	B
(	O
Prolixin	B
,	O
Permitil	B
)	O
,	O
prochlorperazine	B
(	O
Compazine	B
)	O
,	O
promethazine	B
(	O
Phenergan	B
)	O
,	O
and	O
others	O
;	O

-	O
phenytoin	B
(	O
Dilantin	B
)	O
;	O

-	O
isoniazid	B
(	O
Nydrazid	B
)	O
;	O

-	O
rifampin	B
(	O
Rifadin	B
,	O
Rifamate	B
)	O
;	O

Immediate	O
and	O
Extended	O
Release	O
Tablets	O
The	O
hypoglycemic	O
action	O
of	O
sulfonylureas	B
may	O
be	O
potentiated	O
by	O
certain	O
drugs	O
including	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
agents	B
,	O
some	O
azoles	B
and	O
other	O
drugs	O
that	O
are	O
highly	O
protein	O
bound	O
,	O
salicylates	B
,	O
sulfonamides	B
,	O
chloramphenicol	B
,	O
probenecid	B
,	O
coumarins	B
,	O
monoamine	B
oxidase	I
inhibitors	I
,	O
and	O
beta	B
adrenergic	I
blocking	I
agents	I
.	O

In	O
vitro	O
binding	O
studies	O
with	O
human	O
serum	O
proteins	O
indicate	O
that	O
glipizide	B
binds	O
differently	O
than	O
tolbutamide	B
and	O
does	O
not	O
interact	O
with	O
salicylate	B
or	O
dicumarol	B
.	O

These	O
drugs	B
include	O
the	O
thiazides	B
and	O
other	O
diuretics	B
,	O
corticosteroids	B
,	O
phenothiazines	B
,	O
thyroid	B
products	I
,	O
estrogens	B
,	O
oral	O
contraceptives	B
,	O
phenytoin	B
,	O
nicotinic	B
acid	I
,	O
sympathomimetics	B
,	O
calcium	B
channel	I
blocking	I
drugs	I
,	O
and	O
isoniazid	B
.	O

A	O
potential	O
interaction	O
between	O
oral	O
miconazole	B
and	O
oral	O
hypoglycemic	B
agents	I
leading	O
to	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
.	O

The	O
effect	O
of	O
concomitant	O
administration	O
of	O
fluconazole	B
and	O
glipizide	B
has	O
been	O
demonstrated	O
in	O
a	O
placebo	O
-	O
controlled	O
crossover	O
study	O
in	O
normal	O
volunteers	O
.	O

All	O
subjects	O
received	O
glipizide	B
alone	O
and	O
following	O
treatment	O
with	O
100	O
mg	O
of	O
fluconazole	B
as	O
a	O
single	O
daily	O
oral	O
dose	O
for	O
seven	O
days	O
.	O

The	O
mean	O
percentage	O
increase	O
in	O
the	O
glipizide	B
AUC	O
after	O
fluconazole	B
administration	O
was	O
56	O
.	O
9	O
%	O
(	O
range	O
:	O
35	O
to	O
81	O
)	O
.	O

The	O
concurrent	O
use	O
of	O
Robinul	B
Injection	O
with	O
other	O
anticholinergics	B
or	O
medications	O
with	O
anticholinergic	O
activity	O
,	O
such	O
as	O
phenothiazines	B
,	O
antiparkinson	B
drugs	I
,	O
or	O
tricyclic	B
antidepressants	I
,	O
may	O
intensify	O
the	O
antimuscarinic	O
effects	O
and	O
may	O
result	O
in	O
an	O
increase	O
in	O
anticholinergic	O
side	O
effects	O
.	O

Concomitant	O
administration	O
of	O
Robinul	B
Injection	O
and	O
potassium	B
chloride	I
in	O
a	O
wax	O
matrix	O
may	O
increase	O
the	O
severity	O
of	O
potassium	B
chloride	I
-	O
induced	O
gastrointestinal	O
lesions	O
as	O
a	O
result	O
of	O
a	O
slower	O
gastrointestinal	O
transit	O
time	O
.	O

These	O
would	O
include	O
a	O
variety	O
of	O
preparations	O
which	O
contain	O
androgens	B
,	O
estrogens	B
,	O
progestins	B
,	O
or	O
glucocorticoids	B
.	O

The	O
gonadotropin	O
levels	O
may	O
be	O
transiently	O
elevated	O
by	O
spironolactone	B
,	O
minimally	O
elevated	O
by	O
levodopa	B
,	O
and	O
suppressed	O
by	O
oral	O
contraceptives	B
and	O
digoxin	B
.	O

The	O
response	O
to	O
Factrel	B
may	O
be	O
blunted	O
by	O
phenothiazines	B
and	O
dopamine	B
antagonists	I
which	O
cause	O
a	O
rise	O
in	O
prolactin	O
.	O

Antacids	B
,	O
Sucralfate	B
,	O
Metal	O
Cations	O
,	O
Multivitamins	B
Quinolones	I
form	O
chelates	O
with	O
alkaline	O
earth	O
and	O
transition	O
metal	O
cations	O
.	O

Administration	O
of	O
quinolones	B
with	O
antacids	B
containing	O
aluminum	B
,	O
magnesium	B
,	O
or	O
calcium	B
,	O
with	O
sucralfate	B
,	O
with	O
metal	O
cations	O
such	O
as	O
iron	B
,	O
or	O
with	O
multivitamins	B
containing	O
iron	B
or	O
zinc	B
,	O
or	O
with	O
formulations	O
containing	O
divalent	O
and	O
trivalent	O
cations	O
such	O
as	O
VIDEX	B
(	O
didanosine	B
)	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
,	O
may	O
substantially	O
interfere	O
with	O
the	O
absorption	O
of	O
quinolones	B
,	O
resulting	O
in	O
systemic	O
concentrations	O
considerably	O
lower	O
than	O
desired	O
.	O

Caffeine	B
Theobromine	I
Grepafloxacin	I
,	O
like	O
other	O
quinolones	B
,	O
may	O
inhibit	O
the	O
metabolism	O
of	O
caffeine	B
and	O
theobromine	B
.	O

In	O
some	O
patients	O
,	O
this	O
may	O
lead	O
to	O
reduced	O
clearance	O
,	O
prolongation	O
of	O
plasma	O
half	O
-	O
life	O
,	O
and	O
enhanced	O
effects	O
of	O
caffeine	B
and	O
theobromine	B
.	O

Theophylline	B
:	O
Grepafloxacin	B
is	O
a	O
competitive	O
inhibitor	O
of	O
the	O
metabolism	O
of	O
theophylline	B
.	O

Serum	O
theophylline	B
concentrations	O
increase	O
when	O
grepafloxacin	B
is	O
initiated	O
in	O
a	O
patient	O
maintained	O
on	O
theophylline	B
.	O

When	O
initiating	O
a	O
multi	O
-	O
day	O
course	O
of	O
grepafloxacin	B
in	O
a	O
patient	O
maintained	O
on	O
theophylline	B
,	O
the	O
theophylline	B
maintenance	O
dose	O
should	O
be	O
halved	O
for	O
the	O
period	O
of	O
concurrent	O
use	O
of	O
grepafloxacin	B
and	O
monitoring	O
of	O
serum	O
theophylline	B
concentrations	O
should	O
be	O
initiated	O
as	O
a	O
guide	O
to	O
further	O
dosage	O
adjustments	O
.	O

Warfarin	B
:	O
In	O
subjects	O
receiving	O
warfarin	B
,	O
no	O
significant	O
change	O
in	O
clotting	O
time	O
was	O
observed	O
when	O
grepafloxacin	B
was	O
coadministered	O
.	O

However	O
,	O
because	O
some	O
quinolones	B
have	O
been	O
reported	O
to	O
enhance	O
the	O
effects	O
of	O
warfarin	B
or	O
its	O
derivatives	O
,	O
prothrombin	O
time	O
or	O
other	O
suitable	O
anticoagulation	O
test	O
should	O
be	O
monitored	O
closely	O
if	O
a	O
quinolone	B
antimicrobial	I
is	O
administered	O
with	O
warfarin	B
or	O
its	O
derivatives	O
.	O

Drugs	O
Metabolized	O
by	O
Cytochrome	O
P450	O
Enzymes	O
The	O
drug	O
interaction	O
study	O
evaluating	O
the	O
effect	O
of	O
grepafloxacin	B
on	O
theophylline	B
indicates	O
that	O
grepafloxacin	B
inhibits	O
theophylline	B
metabolism	O
,	O
which	O
is	O
mediated	O
by	O
CYP1A2	O
.	O

substrates	O
,	O
in	O
vitro	O
data	O
suggest	O
similar	O
effects	O
of	O
grepafloxacin	B
in	O
CYP3A4	O
mediated	O
metabolism	O
and	O
theophylline	B
metabolism	O
.	O

In	O
addition	O
,	O
other	O
quinolones	B
have	O
been	O
reported	O
to	O
decrease	O
the	O
CYP3A4	O
-	O
mediated	O
metabolism	O
of	O
cyclosporine	B
.	O

include	O
terfenadine	B
,	O
astemizole	B
,	O
cisapride	B
,	O
midazolam	B
,	O
and	O
triazolam	B
.	O

Nonsteroidal	B
Anti	O
-	O
inflammatory	B
Drugs	I
(	O
NSAIDs	B
)	O
:	O
The	O
concomitant	O
administration	O
of	O
a	O
nonsteroidal	B
anti	I
inflammatory	I
drug	I
with	O
a	O
quinolone	B
may	O
increase	O
the	O
risks	O
of	O
CNS	O
stimulation	O
and	O
convulsions	O
.	O

Antidiabetic	B
Agents	I
:	O
Disturbances	O
of	O
blood	O
glucose	O
,	O
including	O
hyperglycemia	O
and	O
hypoglycemia	O
,	O
have	O
been	O
reported	O
in	O
patients	O
treated	O
concomitantly	O
with	O
quinolones	B
and	O
an	O
antidiabetic	B
agent	I
.	O

Patients	O
on	O
warfarin	O
-	O
type	O
anticoagulant	B
therapy	O
may	O
require	O
dosage	O
adjustment	O
of	O
the	O
anticoagulant	B
during	O
and	O
after	O
griseofulvin	B
therapy	O
.	O

Concomitant	O
use	O
of	O
barbiturates	B
usually	O
depresses	O
griseofulvin	B
activity	O
and	O
may	O
necessitate	O
raising	O
the	O
dosage	O
.	O

The	O
concomitant	O
administration	O
of	O
griseofulvin	B
has	O
been	O
reported	O
to	O
reduce	O
the	O
efficacy	O
of	O
oral	O
contraceptives	B
and	O
to	O
increase	O
the	O
incidence	O
of	O
breakthrough	O
bleeding	O
.	O

The	O
use	O
of	O
codeine	B
may	O
result	O
in	O
additive	O
CNS	O
depressant	O
effects	O
when	O
coadministered	O
with	O
alcohol	B
,	O
antihistamines	B
,	O
psychotropics	B
or	O
other	O
drugs	O
that	O
produce	O
CNS	O
depression	O
.	O

Serious	O
toxicity	O
may	O
result	O
if	O
dextromethorphan	B
is	O
coadministered	O
with	O
monoamine	B
oxidase	I
inhibitors	I
(	O
MAOIs	B
)	O
.	O

The	O
use	O
of	O
dextromethorphan	B
hydrobromide	I
may	O
result	O
in	O
additive	O
CNS	O
depressant	O
effects	O
when	O
coadministered	O
with	O
alcohol	B
,	O
antihistamines	B
,	O
psychotropics	B
or	O
other	O
drugs	O
that	O
produce	O
CNS	O
depression	O
.	O

The	O
potential	O
for	O
increased	O
sedation	O
when	O
guanfacine	B
is	O
given	O
with	O
other	O
CNS	O
-	O
depressant	O
drug	B
should	O
be	O
appreciated	O
.	O

The	O
administration	O
of	O
guanfacine	B
concomitantly	O
with	O
known	O
microsomal	O
enzyme	O
inducer	O
(	O
phenobarbital	B
or	O
phenytoin	B
)	O
to	O
two	O
patients	O
with	O
renal	O
impairment	O
reportedly	O
resulted	O
in	O
significant	O
reductions	O
in	O
elimination	O
half	O
-	O
life	O
and	O
plasma	O
concentration	O
.	O

TCAs	B
decrease	O
the	O
hypotensive	O
effect	O
of	O
guanfacine	B
.	O

Noncardioselective	B
beta	O
-	O
blockers	O
(	O
nadolol	B
,	O
porpranolol	O
,	O
timolol	B
)	O
may	O
exacerbate	O
rebound	O
hypertension	O
when	O
guanfacine	B
is	O
withdrawn	O
.	O

The	O
gradual	O
withdrawal	O
of	O
guafacine	B
or	O
a	O
cardioselective	B
beta	O
-	O
blocker	O
could	O
be	O
substituted	O
.	O

Anticoagulants	B
:	O
Ten	O
patients	O
who	O
were	O
stabilized	O
on	O
oral	O
anticoagulants	B
were	O
given	O
guanfacine	B
,	O
1	O
-	O
2	O
mg	O
/	O
day	O
,	O
for	O
4	O
weeks	O
.	O

In	O
several	O
well	O
-	O
controlled	O
studies	O
,	O
guanfacine	B
was	O
administered	O
together	O
with	O
diuretics	B
with	O
no	O
drug	O
interactions	O
reported	O
.	O

The	O
principal	O
drugs	B
given	O
(	O
number	O
of	O
patients	O
in	O
parentheses	O
)	O
were	O
:	O
cardiac	B
glycosides	I
(	O
115	O
)	O
,	O
sedatives	B
and	O
hypnotics	B
(	O
103	O
)	O
,	O
coronary	B
vasodilators	I
(	O
52	O
)	O
,	O
oral	O
hypoglycemics	B
(	O
45	O
)	O
,	O
cough	O
and	O
cold	O
preparations	O
(	O
45	O
)	O
,	O
NSAIDs	B
(	O
38	O
)	O
,	O
antihyperlipidemics	B
(	O
29	O
)	O
,	O
antigout	B
drugs	I
(	O
24	O
)	O
,	O
oral	O
contraceptives	B
(	O
18	O
)	O
,	O
bronchodilators	B
(	O
13	O
)	O
,	O
insulin	B
(	O
10	O
)	O
,	O
and	O
beta	B
blockers	I
(	O
10	O
)	O
.	O

An	O
encephalopathic	O
syndrome	O
(	O
characterized	O
by	O
weakness	O
,	O
lethargy	O
,	O
fever	O
,	O
tremulousness	O
and	O
confusion	O
,	O
extrapyramidal	O
symptoms	O
,	O
leukocytosis	O
,	O
elevated	O
serum	O
enzymes	O
,	O
BUN	O
,	O
and	O
FBS	O
)	O
followed	O
by	O
irreversible	O
brain	O
damage	O
has	O
occurred	O
in	O
a	O
few	O
patients	O
treated	O
with	O
lithium	B
plus	O
HALDOL	B
.	O

A	O
causal	O
relationship	O
between	O
these	O
events	O
and	O
the	O
concomitant	O
administration	O
of	O
lithium	B
and	O
HALDOL	B
has	O
not	O
been	O
established	O
;	O

As	O
with	O
other	O
antipsychotic	B
agents	I
,	O
it	O
should	O
be	O
noted	O
that	O
HALDOL	B
may	O
be	O
capable	O
of	O
potentiating	O
CNS	B
depressants	I
such	O
as	O
anesthetics	B
,	O
opiates	B
,	O
and	O
alcohol	B
.	O

In	O
a	O
study	O
of	O
12	O
schizophrenic	O
patients	O
coadministered	O
oral	O
haloperidol	B
and	O
rifampin	B
,	O
plasma	O
haloperidol	B
levels	O
were	O
decreased	O
by	O
a	O
mean	O
of	O
70	O
%	O
and	O
mean	O
scores	O
on	O
the	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
were	O
increased	O
from	O
baseline	O
.	O

In	O
5	O
other	O
schizophrenic	O
patients	O
treated	O
with	O
oral	O
haloperidol	B
and	O
rifampin	B
,	O
discontinuation	O
of	O
rifampin	B
produced	O
a	O
mean	O
3	O
.	O
3	O
-	O
fold	O
increase	O
in	O
haloperidol	B
concentrations	O
.	O

Thus	O
,	O
careful	O
monitoring	O
of	O
clinical	O
status	O
is	O
warranted	O
when	O
rifampin	B
is	O
administered	O
or	O
discontinued	O
in	O
haloperidol	B
-	O
treated	O
patients	O
.	O

FLUOTHANE	B
augments	O
the	O
action	O
of	O
non	O
-	O
depolarising	O
muscle	B
relaxants	O
and	O
the	O
muscle	B
relaxant	I
effects	O
of	O
aminoglycosides	B
.	O

FLUOTHANE	B
may	O
augment	O
the	O
hypotension	O
caused	O
by	O
the	O
ganglionic	O
-	O
blocking	O
effect	O
of	O
tubocurarine	B
.	O

Caution	O
should	O
be	O
exercised	O
during	O
the	O
administration	O
of	O
adrenaline	B
to	O
patients	O
anaesthetised	O
with	O
FLUOTHANE	B
as	O
arrhythmias	O
may	O
be	O
precipitated	O
.	O

For	O
this	O
reason	O
the	O
dose	O
of	O
adrenaline	B
should	O
be	O
restricted	O
and	O
an	O
antiarrhythmic	B
agent	I
administered	O
as	O
appropriate	O
.	O

Caution	O
should	O
also	O
be	O
applied	O
for	O
other	O
sympathomimetics	B
,	O
and	O
for	O
aminophylline	B
and	O
theophylline	B
and	O
tricyclic	B
antidepressants	I
,	O
which	O
may	O
also	O
precipitate	O
arrhythmias	O
.	O

Drug	O
Interactions	O
:	O
a	O
.	O
Drugs	O
Enhancing	O
Heparin	B
Effect	O
:	O
Oral	O
anticoagulants	B
:	O
Heparin	B
sodium	I
may	O
prolong	O
the	O
one	O
-	O
stage	O
prothrombin	O
time	O
.	O

Therefore	O
,	O
when	O
heparin	B
sodium	I
is	O
given	O
with	O
dicumarol	B
or	O
warfarin	B
sodium	I
,	O
a	O
period	O
of	O
at	O
least	O
5	O
hours	O
after	O
the	O
last	O
intravenous	O
dose	O
or	O
24	O
hours	O
after	O
the	O
last	O
subcutaneous	O
dose	O
should	O
elapse	O
before	O
blood	O
is	O
drawn	O
if	O
a	O
valid	O
prothrombin	O
time	O
is	O
to	O
be	O
obtained	O
.	O

Platelet	B
inhibitors	I
:	O
Drugs	O
such	O
as	O
acetylsalicylic	B
acid	I
,	O
dextran	B
,	O
phenylbutazone	B
,	O
ibuprofen	B
,	O
indomethacin	B
,	O
dipyridamole	B
,	O
hydroxychloroquine	B
and	O
others	O
that	O
interfere	O
with	O
platelet	O
-	O
aggregation	O
reactions	O
(	O
the	O
main	O
hemostatic	O
defense	O
of	O
heparinized	O
patients	O
)	O
may	O
induce	O
bleeding	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
heparin	B
sodium	I
.	O

The	O
anticoagulant	O
effect	O
of	O
heparin	B
is	O
enhanced	O
by	O
concurrent	O
treatment	O
with	O
antithrombin	B
III	I
(	O
human	O
)	O
in	O
patients	O
with	O
hereditary	O
antithrombin	B
III	I
deficiency	O
.	O

Thus	O
in	O
order	O
to	O
avoid	O
bleeding	O
,	O
reduced	O
dosage	O
of	O
heparin	B
is	O
recommended	O
during	O
treatment	O
with	O
antithrombin	B
III	I
(	O
human	O
)	O
.	O

Drugs	O
Decreasing	O
Heparin	B
Effect	O
:	O
Digitalis	B
,	O
tetracyclines	B
,	O
nicotine	B
,	O
or	O
antihistamines	B
may	O
partially	O
counteract	O
the	O
anticoagulant	O
action	O
of	O
heparin	B
sodium	I
.	O

Heparin	B
Sodium	I
Injection	O
should	O
not	O
be	O
mixed	O
with	O
doxorubicin	B
,	O
droperidol	B
,	O
ciprofloxacin	B
,	O
or	O
mitoxantrone	B
,	O
since	O
it	O
has	O
been	O
reported	O
that	O
these	O
drugs	O
are	O
incompatible	O
with	O
heparin	B
and	O
a	O
precipitate	O
may	O
form	O
.	O

Opioids	B
are	O
strong	O
central	B
nervous	I
system	I
depressants	I
,	O
but	O
regular	O
users	O
develop	O
physiological	O
tolerance	O
allowing	O
gradually	O
increased	O
dosages	O
.	O

In	O
combination	O
with	O
other	O
central	B
nervous	I
system	I
depressants	I
,	O
heroin	B
may	O
still	O
kill	O
even	O
experienced	O
users	O
,	O
particularly	O
if	O
their	O
tolerance	O
to	O
the	O
drug	O
has	O
reduced	O
or	O
the	O
strength	O
of	O
their	O
usual	O
dose	O
has	O
increased	O
.	O

Toxicology	O
studies	O
of	O
heroin	B
-	O
related	O
deaths	O
reveal	O
frequent	O
involvement	O
of	O
other	O
central	B
nervous	I
system	I
depressants	I
,	O
including	O
alcohol	B
,	O
benzodiazepines	B
such	O
as	O
diazepam	B
(	O
Valium	B
)	O
,	O
and	O
,	O
to	O
a	O
rising	O
degree	O
,	O
methadone	B
.	O

Ironically	O
,	O
benzodiazepines	B
are	O
often	O
used	O
in	O
the	O
treatment	O
of	O
heroin	B
addiction	O
while	O
they	O
cause	O
much	O
more	O
severe	O
withdrawal	O
symptoms	O
.	O

Cocaine	B
sometimes	O
proves	O
to	O
be	O
fatal	O
when	O
used	O
in	O
combination	O
with	O
heroin	B
.	O

Barbiturates	B
may	O
decrease	O
the	O
effectiveness	O
of	O
oral	O
contraceptives	B
,	O
certain	O
antibiotics	B
,	O
quinidine	B
,	O
theophylline	B
,	O
corticosteroids	B
,	O
anticoagulants	B
,	O
and	O
beta	B
blockers	I
.	O

MAO	B
inhibitors	I
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
hydralazine	B
.	O

When	O
other	O
potent	O
parental	O
antihypertensive	B
drugs	I
,	O
such	O
as	O
diazoxide	B
,	O
are	O
used	O
in	O
combination	O
with	O
hydralazine	B
,	O
patients	O
should	O
be	O
continuously	O
observed	O
for	O
several	O
hours	O
for	O
any	O
excessive	O
fall	O
in	O
blood	O
pressure	O
.	O

Profound	O
hypotensive	O
episodes	O
may	O
occur	O
when	O
diazoxide	B
infection	O
and	O
hydralazine	B
are	O
used	O
concomitantly	O
.	O

Beta	O
-	O
blockers	O
(	O
metoprolol	B
,	O
propranolol	B
)	O
serum	O
concentrations	O
and	O
pharmacologic	O
effects	O
may	O
be	O
increased	O
.	O

Propranolol	B
increases	O
hydralazines	O
serum	O
concentrations	O
.	O

Acebutolol	B
,	O
atenolol	B
,	O
and	O
nadolol	B
(	O
low	O
hepatic	O
clearance	O
or	O
no	O
first	O
-	O
pass	O
metabolism	O
)	O
are	O
unlikely	O
to	O
be	O
affected	O
.	O

NSAIDs	B
may	O
decrease	O
the	O
hemodynamic	O
effects	O
of	O
hydralazine	B
;	O

Alcohol	B
,	O
barbiturates	B
,	O
or	O
narcotics	B
:	O
potentiation	O
of	O
orthostatic	O
hypotension	O
may	O
occur	O
.	O

Antidiabetic	B
drugs	I
:	O
(	O
oral	O
agents	O
and	O
insulin	B
)	O
-	O
dosage	O
adjustment	O
of	O
the	O
antidiabetic	B
drug	I
may	O
be	O
required	O
.	O

Cholestyramine	B
and	O
colestipol	B
resins	I
:	O
Absorption	O
of	O
hydrochlorothiazide	B
is	O
impaired	O
in	O
the	O
presence	O
of	O
anionic	B
exchange	I
resins	I
.	O

Single	O
doses	O
of	O
either	O
cholestyramine	B
or	O
colestipol	B
resins	I
bind	O
the	O
hydrochlorothiazide	B
and	O
reduce	O
its	O
absorption	O
from	O
the	O
gastrointestinal	O
tract	O
by	O
up	O
to	O
85	O
and	O
43	O
percent	O
,	O
respectively	O
.	O

Corticosteroids	B
,	O
ACTH	B
:	O
intensified	O
electrolyte	O
depletion	O
,	O
particularly	O
hypokalemia	O
.	O

Skeletal	B
muscle	I
relaxants	I
,	O
nondepolarizing	O
(	O
e	O
.	O
g	O
.	O
,	O
tubocurarine	B
)	O
:	O
possible	O
increased	O
responsiveness	O
to	O
the	O
muscle	B
relaxant	I
.	O

Lithium	B
:	O
generally	O
should	O
not	O
be	O
given	O
with	O
diuretics	B
.	O

Diuretic	B
agents	I
reduce	O
the	O
renal	O
clearance	O
of	O
lithium	B
and	O
add	O
a	O
high	O
risk	O
of	O
lithium	B
toxicity	O
.	O

Refer	O
to	O
the	O
package	O
insert	O
for	O
lithium	B
preparations	O
before	O
use	O
of	O
such	O
preparations	O
with	O
Hydrochlorothiazide	B
.	O

Non	O
-	O
steroidal	O
Anti	O
-	O
inflammatory	O
Drugs	B
:	O
In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
agent	B
can	O
reduce	O
the	O
diuretic	O
,	O
natriuretic	O
,	O
and	O
antihypertensive	O
effects	O
of	O
loop	B
,	O
potassium	O
-	O
sparing	O
and	O
thiazide	B
diuretics	I
.	O

Therefore	O
,	O
when	O
Hydrochlorothiazide	B
and	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
agents	B
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B
is	O
obtained	O
.	O

Patients	O
receiving	O
other	O
narcotic	B
analgesics	I
,	O
antipsychotics	B
,	O
antianxiety	B
agents	I
,	O
or	O
other	O
CNS	B
depressants	I
(	O
including	O
alcohol	B
)	O
concomitantly	O
with	O
hydrocodone	B
and	O
acetaminophen	B
tablets	O
may	O
exhibit	O
an	O
additive	O
CNS	B
depression	O
.	O

The	O
use	O
of	O
MAO	B
inhibitors	I
or	O
tricyclic	B
antidepressants	I
with	O
hydrocodone	B
preparations	O
may	O
increase	O
the	O
effect	O
of	O
either	O
the	O
antidepressant	B
or	O
hydrocodone	B
.	O

The	O
concurrent	O
use	O
of	O
anticholinergics	B
with	O
hydrocodone	B
may	O
produce	O
paralytic	O
ileus	O
.	O

Antihypertensive	B
medications	I
,	O
other	O
,	O
especially	O
diazoxide	B
,	O
or	O
preanesthetic	O
and	O
anesthetic	B
agents	O
used	O
in	O
surgery	O
or	O
skeletal	O
-	O
muscle	O
relaxants	B
,	O
nondepolarizing	O
,	O
used	O
in	O
surgery	O

Amphotericin	B
B	I
or	O
Corticosteroids	B
or	O
Corticotropin	B
(	O
ACTH	B
)	O

(	O
Concurrent	O
use	O
with	O
thiazide	B
diuretics	I
may	O
enhance	O
the	O
possibility	O
of	O
digitalis	B
toxicity	O
associated	O
with	O
hypokalemia	O
.	O
)	O

for	O
adult	O
-	O
onset	O
diabetics	O
,	O
dosage	O
adjustment	O
of	O
hypoglycemic	B
medications	I
may	O
be	O
necessary	O
during	O
and	O
after	O
thiazide	B
diuretic	I
therapy	O
;	O

(	O
Concurrent	O
use	O
with	O
thiazide	B
diuretics	I
is	O
not	O
recommended	O
,	O
as	O
they	O
may	O
provoke	O
lithium	B
toxicity	O
because	O
of	O
reduced	O
renal	O
clearance	O
.	O
)	O

(	O
In	O
some	O
patients	O
,	O
the	O
steroidal	B
anti	O
-	O
inflammatory	O
agent	B
can	O
reduce	O
the	O
diuretic	O
,	O
natriuretic	O
,	O
and	O
antihypertensive	O
effects	O
of	O
loop	B
,	O
potassium	B
sparing	I
,	O
and	O
thiazide	B
diuretics	I
.	O

Therefore	O
,	O
when	O
hydroflumethiazide	B
and	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
agents	B
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B
is	O
obtained	O
.	O
)	O

(	O
Thiazides	B
may	O
decrease	O
arterial	O
responsiveness	O
to	O
norepinephrine	B
.	O

(	O
Thiazide	B
drugs	I
may	O
increase	O
the	O
responsiveness	O
to	O
tubocurarine	B
.	O
)	O

Patients	O
receiving	O
other	O
narcotic	B
analgesics	O
,	O
general	O
anesthetics	B
,	O
phenothiazines	B
,	O
tranquilizers	B
,	O
sedative	O
-	O
hypnotics	O
,	O
tricyclic	B
antidepressants	I
or	O
other	O
CNS	B
depressants	I
(	O
including	O
alcohol	B
)	O
concomitantly	O
with	O
DILAUDID	B
may	O
exhibit	O
an	O
additive	O
CNS	B
depression	O
.	O

Since	O
hydroxyurea	B
may	O
raise	O
the	O
serum	O
uric	O
acid	O
level	O
,	O
dosage	O
adjustment	O
of	O
uricosuric	B
medication	I
may	O
be	O
necessary	O

THE	O
POTENTIATING	O
ACTION	O
OF	O
HYDROXYZINE	B
MUST	O
BE	O
CONSIDERED	O
WHEN	O
THE	O
DRUG	O
IS	O
USED	O
IN	O
CONJUNCTION	O
WITH	O
CENTRAL	B
NERVOUS	I
SYSTEM	I
DEPRESSANTS	I
SUCH	O
AS	O
NARCOTICS	B
,	O
NON	O
-	O
NARCOTIC	O
ANALGESICS	B
AND	O
BARBITURATES	B
.	O

Therefore	O
when	O
central	B
nervous	I
system	I
depressants	I
are	O
administered	O
concomitantly	O
with	O
hydroxyzine	B
their	O
dosage	O
should	O
be	O
reduced	O
.	O

Patients	O
should	O
be	O
advised	O
against	O
the	O
simultaneous	O
use	O
of	O
other	O
CNS	B
depressant	I
drugs	I
,	O
and	O
cautioned	O
that	O
the	O
effect	O
of	O
alcohol	B
may	O
be	O
increased	O
.	O

Additive	O
adverse	O
effects	O
resulting	O
from	O
cholinergic	O
blockade	O
may	O
occur	O
when	O
LEVSIN	B
is	O
administered	O
concomitantly	O
with	O
other	O
antimuscarinics	B
,	O
amantadine	B
,	O
haloperidol	B
,	O
phenothiazines	B
,	O
monoamine	B
oxidase	I
(	O
MAO	O
)	O
inhibitors	B
,	O
tricyclic	B
antidepressants	I
or	O
some	O
antihistamines	B
.	O

Antacids	B
may	O
interfere	O
with	O
the	O
absorption	O
of	O
LEVSIN	B
.	O

Calcium	B
Supplements	O
/	O
Antacids	B

Products	O
containing	O
calcium	B
and	O
other	O
multivalent	O
cations	O
(	O
such	O
as	O
aluminum	B
,	O
magnesium	B
,	O
iron	B
)	O
are	O
likely	O
to	O
interfere	O
with	O
absorption	O
of	O
Ibandronate	B
.	O

Ibandronate	B
should	O
be	O
taken	O
at	O
least	O
60	O
minutes	O
before	O
any	O
oral	O
medications	O
containing	O
multivalent	O
cations	O
(	O
including	O
antacids	B
,	O
supplements	O
or	O
vitamins	B
)	O
.	O

H2	B
Blockers	I
and	O
Proton	B
Pump	I
Inhibitors	I
(	O
PPIs	B
)	O

Of	O
over	O
3500	O
patients	O
enrolled	O
in	O
the	O
Ibandronate	B
osteoporosis	O
Treatment	O
and	O
Prevention	O
Studies	O
,	O
15	O
%	O
used	O
anti	O
-	O
peptic	O
agents	O
(	O
primarily	O
H2	B
blockers	I
and	O
PPIs	B
)	O
.	O

Among	O
these	O
patients	O
,	O
the	O
incidence	O
of	O
upper	O
gastrointestinal	O
adverse	O
experiences	O
in	O
the	O
patients	O
treated	O
with	O
Ibandronate	B
150	O
mg	O
once	O
monthly	O
was	O
similar	O
to	O
that	O
in	O
patients	O
treated	O
with	O
Ibandronate	B
2	O
.	O
5	O
mg	O
once	O
daily	O
.	O

Aspirin	B
/	O
Nonsteroidal	B
Antiinflammatory	I
Drugs	O
(	O
NSAIDs	B
)	O

In	O
the	O
large	O
,	O
placebo	O
-	O
controlled	O
osteoporosis	O
Treatment	O
Study	O
,	O
aspirin	B
and	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
drugs	B
were	O
taken	O
by	O
62	O
%	O
of	O
the	O
2946	O
patients	O
.	O

Among	O
aspirin	B
or	O
NSAID	B
users	O
,	O
the	O
incidence	O
of	O
upper	O
gastrointestinal	O
adverse	O
events	O
in	O
patients	O
treated	O
with	O
ibandronate	B
2	O
.	O
5	O
mg	O
daily	O
(	O
28	O
.	O
9	O
%	O
)	O
was	O
similar	O
to	O
that	O
in	O
placebo	O
-	O
treated	O
patients	O
(	O
30	O
.	O
7	O
%	O
)	O
.	O

Similarly	O
,	O
in	O
the	O
1	O
-	O
year	O
monthly	O
comparison	O
study	O
,	O
aspirin	B
and	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
drugs	B
were	O
taken	O
by	O
39	O
%	O
of	O
the	O
1602	O
patients	O
.	O

The	O
incidence	O
of	O
upper	O
gastrointestinal	O
events	O
in	O
patients	O
concomitantly	O
taking	O
aspirin	B
or	O
NSAIDs	B
was	O
similar	O
in	O
patients	O
taking	O
ibandronate	B
2	O
.	O
5	O
mg	O
daily	O
(	O
21	O
.	O
7	O
%	O
)	O
and	O
150	O
mg	O
once	O
monthly	O
(	O
22	O
.	O
0	O
%	O
)	O
.	O

However	O
,	O
since	O
aspirin	B
,	O
NSAIDs	B
,	O
and	O
bisphosphonates	B
are	O
all	O
associated	O
with	O
gastrointestinal	O
irritation	O
,	O
caution	O
should	O
be	O
exercised	O
in	O
the	O
concomitant	O
use	O
of	O
aspirin	B
or	O
NSAIDs	B
with	O
Ibandronate	B
.	O

Coumarin	O
-	O
Type	O
Anticoagulants	B
:	O
Several	O
short	O
-	O
term	O
controlled	O
studies	O
failed	O
to	O
wshow	O
that	O
ibuprofen	B
significantly	O
affected	O
prothrombin	O
times	O
or	O
a	O
variety	O
of	O
other	O
clotting	O
factors	O
when	O
administered	O
to	O
individuals	O
on	O
coumarin	O
-	O
type	O
anticoagulants	B
.	O

However	O
,	O
because	O
bleeding	O
has	O
been	O
reported	O
when	O
ibuprofen	B
and	O
other	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
agents	B
have	O
been	O
administered	O
to	O
patients	O
on	O
coumarin	O
-	O
type	O
anticoagulants	B
,	O
the	O
physician	O
should	O
be	O
cautious	O
when	O
administering	O
ibuprofen	B
to	O
patients	O
on	O
anticoagulants	B
.	O

Aspirin	B
:	O
Animal	O
studies	O
wshow	O
that	O
aspirin	B
given	O
with	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
agents	B
,	O
including	O
ibuprofen	B
,	O
yields	O
a	O
net	O
decrease	O
in	O
anti	O
-	O
inflammatory	O
activity	O
with	O
lowered	O
blood	O
levels	O
of	O
the	O
non	O
-	O
aspirin	B
drug	O
.	O

Single	O
dose	O
bioavailability	O
studies	O
in	O
normal	O
volunteers	O
have	O
failed	O
to	O
wshow	O
an	O
effect	O
of	O
aspirin	B
on	O
ibuprofen	B
blood	O
levels	O
.	O

Methotrexate	B
:	O
Ibuprofen	B
,	O
as	O
well	O
as	O
other	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
drugs	B
,	O
probably	O
reduces	O
the	O
tubular	O
secretion	O
of	O
methotrexate	B
based	O
on	O
in	O
vitro	O
studies	O
in	O
rabbit	O
kidney	O
slices	O
.	O

This	O
may	O
indicate	O
that	O
ibuprofen	B
could	O
enhance	O
the	O
toxicity	O
of	O
methotrexate	B
.	O

Caution	O
should	O
be	O
used	O
if	O
ibuprofen	B
is	O
administered	O
concomitantly	O
with	O
methotrexate	B
.	O

H	O
-	O
2	O
Antagonists	O
:	O
In	O
studies	O
with	O
human	O
volunteers	O
,	O
co	O
-	O
administration	O
of	O
cimetidine	B
or	O
ranitidine	B
with	O
ibuprofen	B
had	O
no	O
substantive	O
effect	O
on	O
ibuprofen	B
serum	O
concentrations	O
.	O

Furosemide	B
:	O
Clinical	O
studies	O
,	O
as	O
well	O
as	O
random	O
observations	O
,	O
have	O
shown	O
that	O
ibuprofen	B
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B
and	O
thiazides	B
in	O
some	O
patients	O
.	O

During	O
concomitant	O
therapy	O
with	O
ibuprofen	B
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
renal	O
failure	O
,	O
as	O
well	O
as	O
to	O
assure	O
diuretic	B
efficacy	O
.	O

Lithium	B
:	O
Ibuprofen	B
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	B
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	B
clearance	O
in	O
a	O
study	O
of	O
eleven	O
normal	O
volunteers	O
.	O

The	O
mean	O
minimum	O
lithium	B
concentration	O
increased	O
15	O
%	O
and	O
the	O
renal	O
clearance	O
of	O
lithium	B
was	O
decreased	O
by	O
19	O
%	O
during	O
this	O
period	O
of	O
concomitant	O
drug	O
administration	O
.	O

Thus	O
,	O
when	O
ibuprofen	B
and	O
lithium	B
are	O
administered	O
concurrently	O
,	O
subjects	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
of	O
lithium	B
toxicity	O
.	O

Digoxin	B
:	O
Supraventricular	O
arrhythmias	O
may	O
mask	O
the	O
cardiotoxicity	O
associated	O
with	O
excessive	O
digoxin	B
levels	O
.	O

Coadministration	O
of	O
digoxin	B
did	O
not	O
have	O
effects	O
on	O
either	O
the	O
safety	O
or	O
efficacy	O
of	O
ibutilide	B
in	O
the	O
clinical	O
trials	O
.	O

Calcium	B
channel	I
blocking	I
agents	I
:	O
Coadministration	O
of	O
calcium	B
channel	I
blockers	I
did	O
not	O
have	O
any	O
effect	O
on	O
either	O
the	O
safety	O
or	O
efficacy	O
of	O
ibutilide	B
in	O
the	O
clinical	O
trials	O
.	O

Beta	O
-	O
adrenergic	O
blocking	B
agents	I
:	O
Coadministration	O
of	O
beta	O
-	O
adrenergic	O
blocking	B
agents	I
did	O
not	O
have	O
any	O
effect	O
on	O
either	O
the	O
safety	O
or	O
efficacy	O
of	O
ibutilide	B
in	O
the	O
clinical	O
trials	O
.	O

In	O
patients	O
using	O
cardiac	B
glycosides	I
(	O
digoxin	B
and	O
others	O
)	O
,	O
plasma	O
levels	O
of	O
calcium	O
,	O
potassium	O
and	O
magnesium	O
must	O
be	O
carefully	O
monitored	O
.	O

Insulin	B
:	O
A	O
clinical	O
study	O
in	O
6	O
insulin	B
-	O
dependent	O
diabetic	O
patients	O
demonstrated	O
no	O
effect	O
of	O
EXTRANEAL	B
on	O
insulin	B
absorption	O
from	O
the	O
peritoneal	O
cavity	O
or	O
on	O
insulins	O
ability	O
to	O
control	O
blood	O
glucose	O
when	O
insulin	B
was	O
administered	O
intraperitoneally	O
with	O
EXTRANEAL	B
.	O

However	O
,	O
appropriate	O
monitoring	O
of	O
blood	O
glucose	O
should	O
be	O
performed	O
when	O
initiating	O
EXTRANEAL	B
in	O
diabetic	O
patients	O
and	O
insulin	B
dosage	O
should	O
be	O
adjusted	O
if	O
needed	O
.	O

Heparin	B
:	O
No	O
human	O
drug	O
interaction	O
studies	O
with	O
heparin	B
were	O
conducted	O
.	O

In	O
vitro	O
studies	O
demonstrated	O
no	O
evidence	O
of	O
incompatibility	O
of	O
heparin	B
with	O
EXTRANEAL	B
.	O

Antibiotics	B
:	O
No	O
human	O
drug	O
interaction	O
studies	O
with	O
antibiotics	B
were	O
conducted	O
.	O

In	O
vitro	O
studies	O
evaluating	O
the	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
of	O
vancomycin	B
,	O
cefazolin	B
,	O
ampicillin	B
,	O
ampicillin	B
/	O
flucoxacillin	O
,	O
ceftazidime	B
,	O
gentamicin	B
,	O
and	O
amphotericin	B
demonstrated	O
no	O
evidence	O
of	O
incompatibility	O
of	O
these	O
antibiotics	B
with	O
EXTRANEAL	B
.	O

Interactions	O
may	O
occur	O
between	O
EPA	B
supplements	O
and	O
aspirin	B
and	O
other	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	B
and	O
herbs	O
such	O
as	O
garlic	O
(	O
Allium	O
sativum	O
)	O
and	O
ginkgo	B
(	O
Ginkgo	B
biloba	I
)	O
.	O

When	O
you	O
are	O
using	O
idoxuridine	B
,	O
it	O
is	O
especially	O
important	O
that	O
your	O
health	O
care	O
professional	O
know	O
if	O
you	O
are	O
using	O
the	O
following	O
:	O
Eye	O
product	O
containing	O
boric	B
acid	I
.	O

Boric	B
acid	I
may	O
interact	O
with	O
the	O
idoxuridine	B
preparation	O
causing	O
a	O
gritty	O
substance	O
to	O
form	O
or	O
may	O
interact	O
with	O
the	O
preservative	O
in	O
the	O
idoxuridine	B
preparation	O
causing	O
a	O
toxic	O
effect	O
in	O
the	O
eye	O
.	O

The	O
physician	O
should	O
be	O
alert	O
for	O
possible	O
combined	O
drug	O
actions	O
,	O
desirable	O
or	O
undesirable	O
,	O
involving	O
ifosfamide	B
even	O
though	O
ifosfamide	B
has	O
been	O
used	O
successfully	O
concurrently	O
with	O
other	O
drugs	O
,	O
including	O
other	O
cytotoxic	O
drugs	O
.	O

In	O
studies	O
in	O
normal	O
volunteers	O
,	O
there	O
was	O
no	O
pharmacodynamic	O
interaction	O
between	O
intravenous	O
iloprost	B
and	O
either	O
nifedipine	B
,	O
diltiazem	B
,	O
or	O
captopril	B
.	O

However	O
,	O
iloprost	B
has	O
the	O
potential	O
to	O
increase	O
the	O
hypotensive	O
effect	O
of	O
vasodilators	B
and	O
antihypertensive	B
agents	I
.	O

Since	O
iloprost	B
inhibits	O
platelet	O
function	O
,	O
there	O
is	O
a	O
potential	O
for	O
increased	O
risk	O
of	O
bleeding	O
,	O
particularly	O
in	O
patients	O
maintained	O
on	O
anticoagulants	B
.	O

During	O
clinical	O
trials	O
,	O
iloprost	B
was	O
used	O
concurrently	O
with	O
anticoagulants	B
,	O
diuretics	B
,	O
cardiac	B
glycosides	I
,	O
calcium	B
channel	I
blockers	I
,	O
analgesics	B
,	O
antipyretics	B
,	O
nonsteroidal	B
antiinflammatories	I
,	O
corticosteroids	B
,	O
and	O
other	O
medications	O
.	O

Intravenous	O
infusion	O
of	O
iloprost	B
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
digoxin	B
.	O

Acetylsalicylic	B
acid	I
did	O
not	O
alter	O
the	O
clearance	O
(	O
pharmacokinetics	O
)	O
of	O
iloprost	B
.	O

Drugs	O
that	O
may	O
alter	O
imatinib	B
plasma	O
concentrations	O
Drugs	O
that	O
may	O
increase	O
imatinib	B
plasma	O
concentrations	O
:	O
Caution	O
is	O
recommended	O
when	O
administering	O
Gleevec	B
with	O
inhibitors	O
of	O
the	O
CYP3A4	O
family	O
(	O
e	O
.	O
g	O
.	O
,	O
ketoconazole	B
,	O
itraconazole	B
,	O
erythromycin	B
,	O
clarithromycin	B
)	O
.	O

There	O
is	O
a	O
significant	O
increase	O
in	O
exposure	O
to	O
imatinib	B
when	O
Gleevec	B
is	O
coadministered	O
with	O
ketoconazole	B
(	O
CYP3A4	O
inhibitor	O
)	O
.	O

Drugs	O
that	O
may	O
decrease	O
imatinib	B
plasma	O
concentrations	O
:	O
Substances	O
that	O
are	O
inducers	O
of	O
CYP3A4	O
activity	O
may	O
increase	O
metabolism	O
and	O
decrease	O
imatinib	B
plasma	O
concentrations	O
.	O

Co	O
-	O
medications	O
that	O
induce	O
CYP3A4	O
(	O
e	O
.	O
g	O
.	O
,	O
dexamethasone	B
,	O
phenytoin	B
,	O
carbamazepine	B
,	O
rifampin	B
,	O
phenobarbital	B
or	O
St	O
.	O

Pretreatment	O
of	O
healthy	O
volunteers	O
with	O
multiple	O
doses	O
of	O
rifampin	B
followed	O
by	O
a	O
single	O
dose	O
of	O
Gleevec	B
,	O
increased	O
Gleevec	B
oral	O
-	O
dose	O
clearance	O
by	O
3	O
.	O
8	O
-	O
fold	O
,	O
which	O
significantly	O
(	O
p	O
0	O
.	O
05	O
)	O
decreased	O
mean	O
cmax	O
and	O
AUC	O
(	O
0	O
-	O
8	O
)	O
.	O

Drugs	O
that	O
may	O
have	O
their	O
plasma	O
concentration	O
altered	O
by	O
Gleevec	B
Gleevec	I
increases	O
the	O
mean	O
cmax	O
and	O
AUC	O
of	O
simvastatin	B
(	O
CYP3A4	O
substrate	O
)	O
2	O
-	O
and	O
3	O
.	O
5	O
-	O
fold	O
,	O
respectively	O
,	O
suggesting	O
an	O
inhibition	O
of	O
the	O
CYP3A4	O
by	O
Gleevec	B
.	O

Particular	O
caution	O
is	O
recommended	O
when	O
administering	O
Gleevec	B
with	O
CYP3A4	O
substrates	O
that	O
have	O
a	O
narrow	O
therapeutic	O
window	O
(	O
e	O
.	O
g	O
.	O
,	O
cyclosporine	B
or	O
pimozide	B
)	O
.	O

Gleevec	B
will	O
increase	O
plasmaconcentration	O
of	O
other	O
CYP3A4	O
metabolized	O
drugs	O
(	O
e	O
.	O
g	O
.	O
,	O
triazolo	O
-	O
benzodiazepines	B
,	O
dihydropyridine	B
calcium	I
channel	I
blockers	I
,	O
certain	O
HMG	O
-	O
CoA	O
reductase	B
inhibitors	I
,	O
etc	O
.	O
)	O
.	O

Because	O
warfarin	B
is	O
metabolized	O
by	O
CYP2C9	O
and	O
CYP3A4	O
,	O
patients	O
who	O
require	O
anticoagulation	O
should	O
receive	O
low	O
-	O
molecular	O
weight	O
or	O
standard	O
heparin	B
.	O

Systemic	O
exposure	O
to	O
acetaminophen	B
is	O
expected	O
to	O
be	O
increased	O
when	O
coadministered	O
with	O
Gleevec	B
.	O

Avoid	O
the	O
use	O
of	O
preparations	O
such	O
as	O
decongestants	B
and	O
local	O
anesthetics	B
which	O
contain	O
any	O
sympathomimetic	B
amine	I
(	O
e	O
.	O
g	O
.	O
,	O
epinephrine	B
,	O
norepinephrine	B
)	O
,	O
since	O
it	O
has	O
been	O
reported	O
that	O
tricyclic	B
antidepressants	I
can	O
potentiate	O
the	O
effects	O
of	O
catecholamines	O
.	O

Imipramine	B
hydrochloride	I
may	O
potentiate	O
the	O
effects	O
of	O
CNS	B
depressant	I
drugs	I
.	O

The	O
plasma	O
concentration	O
of	O
imipramine	B
may	O
increase	O
when	O
the	O
drug	O
is	O
given	O
concomitantly	O
with	O
hepatic	O
enzyme	O
inhibitors	O
(	O
e	O
.	O
g	O
.	O
,	O
cimetidine	B
,	O
fluoxetine	B
)	O
and	O
decrease	O
by	O
concomitant	O
administration	O
of	O
hepatic	O
enzyme	O
inducers	O
(	O
e	O
.	O
g	O
.	O
,	O
barbiturates	B
,	O
phenytoin	B
)	O
,	O
and	O
adjustment	O
of	O
the	O
dosage	O
of	O
imipramine	B
may	O
therefore	O
be	O
necessary	O
.	O

Poor	O
metabolizers	O
have	O
higher	O
than	O
expected	O
plasma	O
concentrations	O
of	O
tricyclic	B
antidepressants	I
(	O
TCAs	B
)	O
when	O
given	O
usual	O
doses	O
.	O

cimetidine	B
)	O
and	O
many	O
that	O
are	O
substrates	O
for	O
P450	O
2D6	O
(	O
many	O
other	O
antidepressants	B
,	O
phenothiazines	B
,	O
and	O
the	O
Type	B
1C	I
antiarrhythmics	I
propafenone	I
and	O
flecainide	B
)	O
.	O

While	O
all	O
the	O
selective	B
serotonin	I
reuptake	I
inhibitors	I
(	O
SSRIs	B
)	O
,	O
e	O
.	O
g	O
.	O
,	O
fluoxetine	B
,	O
sertraline	B
,	O
and	O
paroxetine	B
,	O
inhibit	O
P450	O
2D6	O
,	O
they	O
may	O
vary	O
in	O
the	O
extent	O
of	O
inhibition	O
.	O

The	O
extent	O
to	O
which	O
SSRI	B
-	O
TCA	B
interactions	O
may	O
pose	O
clinical	O
problems	O
will	O
depend	O
on	O
the	O
degree	O
of	O
inhibition	O
,	O
and	O
the	O
pharmacokinetics	O
of	O
the	O
SSRI	B
involved	O
.	O

Concomitant	O
use	O
of	O
tricyclic	B
antidepressants	I
with	O
drugs	O
that	O
can	O
inhibit	O
cytochrome	O
P450	O
2D6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B
antidepressant	I
or	O
the	O
other	O
drug	O
.	O

It	O
is	O
desirable	O
to	O
monitor	O
TCA	B
plasma	O
levels	O
whenever	O
a	O
TCA	B
is	O
going	O
to	O
be	O
co	O
-	O
administered	O
with	O
another	O
drug	O
known	O
to	O
be	O
an	O
inhibitor	O
of	O
P450	O
2D6	O
.	O

Drugs	O
that	O
induce	O
CYP3A4	O
activity	O
would	O
be	O
expected	O
to	O
increase	O
the	O
clearance	O
of	O
indinavir	B
,	O
resulting	O
in	O
lowered	O
plasma	O
concentrations	O
of	O
indinavir	B
.	O

Coadministration	O
of	O
CRIXIVAN	B
and	O
other	O
drugs	O
that	O
inhibit	O
CYP3A4	O
may	O
decrease	O
the	O
clearance	O
of	O
indinavir	B
and	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
indinavir	B
.	O

Antiarrhythmics	B
:	O
amiodarone	B

Ergot	O
derivatives	O
:	O
dihydroergotamine	B
,	O
ergonovine	B
,	O
ergotamine	B
,	O
methylergonovine	B

Sedative	B
/	O
hypnotics	B
:	O
midazolam	B
,	O
triazolam	B

Neuroleptic	B
:	O
pimozide	B

May	O
lead	O
to	O
loss	O
of	O
virologic	O
response	O
and	O
possible	O
resistance	O
to	O
CRIXIVAN	B
or	O
to	O
the	O
class	O
of	O
protease	B
inhibitors	I
.	O

Antimycobacterial	B
:	O
rifampin	B

May	O
lead	O
to	O
loss	O
of	O
virologic	O
response	O
and	O
possible	O
resistance	O
to	O
CRIXIVAN	B
or	O
to	O
the	O
class	O
of	O
protease	B
inhibitors	I
or	O
other	O
coadministered	O
antiretroviral	B
agents	I
.	O

HMG	O
-	O
CoA	O
Reductase	B
inhibitors	I
:	O
lovastatin	B
,	O
simvastatin	B

Protease	B
inhibitor	I
:	O
atazanavir	B

Both	O
CRIXIVAN	B
and	O
atazanavir	B
are	O
associated	O
with	O
indirect	O
(	O
unconjugated	O
)	O
hyperbilirubinemia	O
.	O

Combinations	O
of	O
these	O
drugs	O
have	O
not	O
been	O
studied	O
and	O
coadministration	O
of	O
CRIXIVAN	B
and	O
atazanavir	B
is	O
not	O
recommended	O
.	O

Dose	O
reduction	O
of	O
CRIXIVAN	B
to	O
600	O
mg	O
every	O
8	O
hours	O
should	O
be	O
considered	O
when	O
taking	O
delavirdine	B
400	O
mg	O
three	O
times	O
a	O
day	O
.	O

Indinavir	B
and	O
didanosine	B
formulations	O
containing	O
buffer	O
should	O
be	O
administered	O
at	O
least	O
one	O
hour	O
apart	O
on	O
an	O
empty	O
stomach	O
.	O

The	O
optimal	O
dose	O
of	O
indinavir	B
,	O
when	O
given	O
in	O
combination	O
with	O
efavirenz	B
,	O
is	O
not	O
known	O
.	O

Increasing	O
the	O
indinavir	B
dose	O
to	O
1000	O
mg	O
every	O
8	O
hours	O
does	O
not	O
compensate	O
for	O
the	O
increased	O
indinavir	B
metabolism	O
due	O
to	O
efavirenz	B
.	O

Indinavir	B
concentrations	O
may	O
be	O
decreased	O
in	O
the	O
presence	O
of	O
nevirapine	B
.	O

indinavir	B
concentration	O
ritonavir	B
concentration	O

Preliminary	O
clinical	O
data	O
suggest	O
that	O
the	O
incidence	O
of	O
nephrolithiasis	O
is	O
higher	O
in	O
patients	O
receiving	O
indinavir	B
in	O
combination	O
with	O
ritonavir	B
than	O
those	O
receiving	O
CRIXIVAN	B
800	O
mg	O
q8h	O
.	O

Antiarrhythmics	B
:	O
bepridil	B
,	O
lidocaine	B
(	O
systemic	O
)	O
and	O
quinidine	B

Caution	O
is	O
warranted	O
and	O
therapeutic	O
concentration	O
monitoring	O
is	O
recommended	O
for	O
antiarrhythmics	B
when	O
coadministered	O
with	O
CRIXIVAN	B
.	O

Anticonvulsants	B
:	O
carbamazepine	B
,	O
phenobarbital	B
,	O
phenytoin	B

CRIXIVAN	B
may	O
not	O
be	O
effective	O
due	O
to	O
decreased	O
indinavir	B
concentrations	O
in	O
patients	O
taking	O
these	O
agents	O
concomitantly	O
.	O

Calcium	B
Channel	I
Blockers	I
,	O
Dihydropyridine	B
:	O
e	O
.	O
g	O
.	O
,	O
felodipine	B
,	O
nifedipine	B
,	O
nicardipine	B

clarithromycin	B
concentration	O
indinavir	B
concentration	O

HMG	O
-	O
CoA	O
Reductase	B
Inhibitor	I
:	O
atorvastatin	B

Use	O
lowest	O
possible	O
dose	O
of	O
atorvastatin	B
with	O
careful	O
monitoring	O
,	O
or	O
consider	O
HMG	O
-	O
CoA	O
reductase	B
inhibitors	I
that	O
are	O
not	O
primarily	O
metabolized	O
by	O
CYP3A4	O
,	O
such	O
as	O
pravastatin	B
,	O
fluvastatin	B
,	O
or	O
rosuvastatin	B
in	O
combination	O
with	O
CRIXIVAN	B
.	O

Immunosuppressants	B
:	O
cyclosporine	B
,	O
tacrolimus	B
,	O
sirolimus	B

Dose	O
reduction	O
of	O
CRIXIVAN	B
to	O
600	O
mg	O
every	O
8	O
hours	O
is	O
recommended	O
when	O
administering	O
itraconazole	B
concurrently	O
.	O

indinavir	B
concentration	O
rifabutin	B
concentration	O

Dose	O
reduction	O
of	O
rifabutin	B
to	O
half	O
the	O
standard	O
dose	O
and	O
a	O
dose	O
increase	O
of	O
CRIXIVAN	B
to	O
1000	O
mg	O
(	O
three	O
333	O
-	O
mg	O
capsules	O
)	O
every	O
8	O
hours	O
are	O
recommended	O
when	O
rifabutin	B
and	O
CRIXIVAN	B
are	O
coadministered	O
.	O

Sildenafil	B
dose	O
should	O
not	O
exceed	O
a	O
maximum	O
of	O
25	O
mg	O
in	O
a	O
48	O
-	O
hour	O
period	O
in	O
patients	O
receiving	O
concomitant	O
indinavir	B
therapy	O
.	O

Tadalafil	B
dose	O
should	O
not	O
exceed	O
a	O
maximum	O
of	O
10	O
mg	O
in	O
a	O
72	O
-	O
hour	O
period	O
in	O
patients	O
receiving	O
concomitant	O
indinavir	B
therapy	O
.	O

Vardenafil	B
dose	O
should	O
not	O
exceed	O
a	O
maximum	O
of	O
2	O
.	O
5	O
mg	O
in	O
a	O
24	O
-	O
hour	O
period	O
in	O
patients	O
receiving	O
concomitant	O
indinavir	B
therapy	O
.	O

In	O
normal	O
volunteers	O
receiving	O
indomethacin	B
,	O
the	O
administration	O
of	O
diflunisal	B
decreased	O
the	O
renal	O
clearance	O
and	O
significantly	O
increased	O
the	O
plasma	O
levels	O
of	O
indomethacin	B
.	O

In	O
some	O
patients	O
,	O
combined	O
use	O
of	O
INDOCIN	B
and	O
diflunisal	B
has	O
been	O
associated	O
with	O
fatal	O
gastrointestinal	O
hemorrhage	O
.	O

Therefore	O
,	O
diflunisal	B
and	O
INDOCIN	B
should	O
not	O
be	O
used	O
concomitantly	O
.	O

In	O
a	O
study	O
in	O
normal	O
volunteers	O
,	O
it	O
was	O
found	O
that	O
chronic	O
concurrent	O
administration	O
of	O
3	O
.	O
6	O
g	O
of	O
aspirin	B
per	O
day	O
decreases	O
indomethacin	B
blood	O
levels	O
approximately	O
20	O
%	O
.	O

The	O
concomitant	O
use	O
of	O
INDOCIN	B
with	O
other	O
NSAIDs	B
is	O
not	O
recommended	O
due	O
to	O
the	O
increased	O
possibility	O
of	O
gastrointestinal	O
toxicity	O
,	O
with	O
little	O
or	O
no	O
increase	O
in	O
efficacy	O
.	O

Clinical	O
studies	O
have	O
shown	O
that	O
INDOCIN	B
does	O
not	O
influence	O
the	O
hypoprothrombinemia	O
produced	O
by	O
anticoagulants	B
.	O

However	O
,	O
when	O
any	O
additional	O
drug	O
,	O
including	O
INDOCIN	B
,	O
is	O
added	O
to	O
the	O
treatment	O
of	O
patients	O
on	O
anticoagulant	B
therapy	O
,	O
the	O
patients	O
should	O
be	O
observed	O
for	O
alterations	O
of	O
the	O
prothrombin	O
time	O
.	O

In	O
post	O
-	O
marketing	O
experience	O
,	O
bleeding	O
has	O
been	O
reported	O
in	O
patients	O
on	O
concomitant	O
treatment	O
with	O
anticoagulants	B
and	O
INDOCIN	B
.	O

Caution	O
should	O
be	O
exercised	O
when	O
INDOCIN	B
and	O
anticoagulants	B
are	O
administered	O
concomitantly	O
.	O

When	O
INDOCIN	B
is	O
given	O
to	O
patients	O
receiving	O
probenecid	B
,	O
the	O
plasma	O
levels	O
of	O
indomethacin	B
are	O
likely	O
to	O
be	O
increased	O
.	O

Caution	O
should	O
be	O
used	O
if	O
INDOCIN	B
is	O
administered	O
simultaneously	O
with	O
methotrexate	B
.	O

INDOCIN	B
has	O
been	O
reported	O
to	O
decrease	O
the	O
tubular	O
secretion	O
of	O
methotrexate	B
and	O
to	O
potentiate	O
its	O
toxicity	O
.	O

Administration	O
of	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	B
concomitantly	O
with	O
cyclosporine	B
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
cyclosporine	B
-	O
induced	O
toxicity	O
,	O
possibly	O
due	O
to	O
decreased	O
synthesis	O
of	O
renal	O
prostacyclin	O
.	O

NSAIDs	B
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
taking	O
cyclosporine	B
,	O
and	O
renal	O
function	O
should	O
be	O
carefully	O
monitored	O
.	O

Capsules	O
INDOCIN	B
50	O
mg	O
t	O
.	O
i	O
.	O
d	O
.	O
produced	O
a	O
clinically	O
relevant	O
elevation	O
of	O
plasma	O
lithium	B
and	O
reduction	O
in	O
renal	O
lithium	B
clearance	O
in	O
psychiatric	O
patients	O
and	O
normal	O
subjects	O
with	O
steady	O
state	O
plasma	O
lithium	B
concentrations	O
.	O

As	O
a	O
consequence	O
,	O
when	O
INDOCIN	B
and	O
lithium	B
are	O
given	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
carefully	O
observed	O
for	O
signs	O
of	O
lithium	B
toxicity	O
.	O

INDOCIN	B
given	O
concomitantly	O
with	O
digoxin	B
has	O
been	O
reported	O
to	O
increase	O
the	O
serum	O
concentration	O
and	O
prolong	O
the	O
half	O
-	O
life	O
of	O
digoxin	B
.	O

Therefore	O
,	O
when	O
INDOCIN	B
and	O
digoxin	B
are	O
used	O
concomitantly	O
,	O
serum	O
digoxin	B
levels	O
should	O
be	O
closely	O
monitored	O
.	O

In	O
some	O
patients	O
,	O
the	O
administration	O
of	O
INDOCIN	B
can	O
reduce	O
the	O
diuretic	O
,	O
natriuretic	O
,	O
and	O
antihypertensive	O
effects	O
of	O
loop	B
,	O
potassium	O
-	O
sparing	O
,	O
and	O
thiazide	B
diuretics	I
.	O

Therefore	O
,	O
when	O
INDOCIN	B
and	O
INDOCIN	B
.	O

(	O
Indomethacin	B
)	O
diuretics	B
are	O
used	O
concomitantly	O
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
to	O
determine	O
if	O
the	O
desired	O
effect	O
of	O
the	O
diuretic	B
is	O
obtained	O
.	O

INDOCIN	B
reduces	O
basal	O
plasma	O
renin	O
activity	O
(	O
PRA	O
)	O
,	O
as	O
well	O
as	O
those	O
elevations	O
of	O
PRA	O
induced	O
by	O
furosemide	B
administration	O
,	O
or	O
salt	O
or	O
volume	O
depletion	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
addition	O
of	O
triamterene	B
to	O
a	O
maintenance	O
schedule	O
of	O
INDOCIN	B
resulted	O
in	O
reversible	O
acute	O
renal	O
failure	O
in	O
two	O
of	O
four	O
healthy	O
volunteers	O
.	O

INDOCIN	B
and	O
triamterene	B
should	O
not	O
be	O
administered	O
together	O
.	O

INDOCIN	B
and	O
potassium	O
-	O
sparing	O
diuretics	B
each	O
may	O
be	O
associated	O
with	O
increased	O
serum	O
potassium	O
levels	O
.	O

The	O
potential	O
effects	O
of	O
INDOCIN	B
and	O
potassium	O
-	O
sparing	O
diuretics	B
on	O
potassium	O
kinetics	O
and	O
renal	O
function	O
should	O
be	O
considered	O
when	O
these	O
agents	O
are	O
administered	O
concurrently	O
.	O

Most	O
of	O
the	O
above	O
effects	O
concerning	O
diuretics	B
have	O
been	O
attributed	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
mechanisms	O
involving	O
inhibition	O
of	O
prostaglandin	O
synthesis	O
by	O
INDOCIN	B
.	O

Blunting	O
of	O
the	O
antihypertensive	O
effect	O
of	O
beta	O
-	O
adrenoceptor	O
blocking	B
agents	I
by	O
non	O
-	O
steroidal	O
antiinflammatory	B
drugs	I
including	O
INDOCIN	B
has	O
been	O
reported	O
.	O

INDOCIN	B
can	O
reduce	O
the	O
antihypertensive	O
effects	O
of	O
captopril	B
and	O
losartan	B
.	O

Concurrent	O
administration	O
of	O
etanercept	B
(	O
another	O
TNF	O
-	O
blocking	O
agent	O
)	O
and	O
anakinra	B
(	O
an	O
interleukin	O
-	O
1	O
antagonist	B
)	O
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
infections	O
,	O
and	O
increased	O
risk	O
of	O
neutropenia	O
and	O
no	O
additional	O
benefit	O
compared	O
to	O
these	O
medicinal	O
products	O
alone	O
.	O

Other	O
TNFa	O
-	O
blocking	O
agents	B
(	O
including	O
REMICADE	B
)	O
used	O
in	O
combination	O
with	O
anakinra	B
may	O
also	O
result	O
in	O
similar	O
toxicities	O
.	O

In	O
rheumatoid	O
arthritis	O
,	O
concomitant	O
medications	O
besides	O
MTX	B
were	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
agents	B
,	O
folic	B
acid	I
,	O
corticosteroids	B
and	O
/	O
or	O
narcotics	B
.	O

Concomitant	O
Crohn	O
s	O
disease	O
medications	O
were	O
antibiotics	B
,	O
antivirals	B
,	O
corticosteroids	B
,	O
6	O
-	O
MP	O
/	O
AZA	B
and	O
aminosalicylates	O
.	O

In	O
psoriatic	O
arthritis	O
clinical	O
trials	O
,	O
concomitant	O
medications	O
included	O
MTX	B
in	O
approximately	O
half	O
of	O
the	O
patients	O
as	O
well	O
as	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
agents	B
,	O
folic	B
acid	I
and	O
corticosteroids	B
.	O

Patients	O
with	O
Crohn	O
s	O
disease	O
who	O
received	O
immunosuppressants	B
tended	O
to	O
experience	O
fewer	O
infusion	O
reactions	O
compared	O
to	O
patients	O
on	O
no	O
immunosuppressants	B
.	O

Serum	O
infliximab	B
concentrations	O
appeared	O
to	O
be	O
unaffected	O
by	O
baseline	O
use	O
of	O
medications	O
for	O
the	O
treatment	O
of	O
Crohn	O
s	O
disease	O
including	O
corticosteroids	B
,	O
antibiotics	B
(	O
metronidazole	B
or	O
ciprofloxacin	B
)	O
and	O
aminosalicylates	O
.	O

The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
increase	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
and	O
susceptibility	O
to	O
hypoglycemia	O
:	O
oral	O
antidiabetes	O
products	O
,	O
ACE	B
inhibitors	I
,	O
disopyramide	B
,	O
fibrates	B
,	O
fluoxetine	B
,	O
MAO	B
inhibitors	I
,	O
propoxyphene	B
,	O
salicylates	B
,	O
somatostatin	B
analog	I
(	O
e	O
.	O
g	O
.	O
,	O
octreotide	B
)	O
,	O
sulfonamide	B
antibiotics	I
.	O

The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
reduce	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
of	O
insulin	B
:	O
corticosteroids	B
,	O
danazol	B
,	O
diuretics	B
,	O
sympathomimetic	B
agents	I
(	O
e	O
.	O
g	O
.	O
,	O
epinephrine	B
,	O
albuterol	B
,	O
terbutaline	B
)	O
,	O
isoniazid	B
,	O
phenothiazine	B
derivatives	I
,	O
somatropin	B
,	O
thyroid	B
hormones	I
,	O
estrogens	B
,	O
progestogens	B
(	O
e	O
.	O
g	O
.	O
,	O
in	O
oral	O
contraceptives	B
)	O
.	O

Beta	O
-	O
blockers	O
,	O
clonidine	B
,	O
lithium	B
salts	O
,	O
and	O
alcohol	B
may	O
either	O
potentiate	O
or	O
weaken	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
of	O
insulin	B
.	O

In	O
addition	O
,	O
under	O
the	O
influence	O
of	O
sympatholytic	O
medicinal	O
products	O
such	O
as	O
beta	O
-	O
blockers	O
,	O
clonidine	B
,	O
guanethidine	B
,	O
and	O
reserpine	B
,	O
the	O
signs	O
of	O
hypoglycemia	O
may	O
be	O
reduced	O
or	O
absent	O
.	O

The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
increase	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
and	O
susceptibility	O
to	O
hypoglycemia	O
:	O
oral	O
antidiabetic	B
products	I
,	O
ACE	B
inhibitors	I
,	O
disopyramide	B
,	O
fibrates	B
,	O
fluoxetine	B
,	O
monoamine	B
oxidase	I
(	O
MAO	O
)	O
inhibitors	B
,	O
propoxyphene	B
,	O
salicylates	B
,	O
somatostatin	B
analog	I
(	O
e	O
.	O
g	O
.	O
,	O
octreotide	B
)	O
,	O
sulfonamide	B
antibiotics	I
.	O

The	O
following	O
are	O
examples	O
of	O
substances	O
that	O
may	O
reduce	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
:	O
corticosteroids	B
,	O
niacin	B
,	O
danazol	B
,	O
diuretics	B
,	O
sympathomimetic	B
agents	I
(	O
e	O
.	O
g	O
.	O
,	O
epinephrine	B
,	O
salbutamol	B
,	O
terbutaline	B
)	O
,	O
isoniazid	B
,	O
phenothiazine	B
derivatives	I
,	O
somatropin	B
,	O
thyroid	B
hormones	I
,	O
estrogens	B
,	O
progestogens	B
(	O
e	O
.	O
g	O
.	O
,	O
in	O
oral	O
contraceptives	B
)	O
.	O

Beta	O
-	O
blockers	O
,	O
clonidine	B
,	O
lithium	B
salts	O
,	O
and	O
alcohol	B
may	O
either	O
potentiate	O
or	O
weaken	O
the	O
blood	O
-	O
glucose	O
-	O
lowering	O
effect	O
of	O
insulin	B
.	O

In	O
addition	O
,	O
under	O
the	O
influence	O
of	O
sympatholytic	O
medicinal	O
products	O
such	O
as	O
beta	O
-	O
blockers	O
,	O
clonidine	B
,	O
guanethidine	B
,	O
and	O
reserpine	B
,	O
the	O
signs	O
of	O
hypoglycemia	O
may	O
be	O
reduced	O
or	O
absent	O
.	O

A	O
clinical	O
study	O
in	O
healthy	O
male	O
volunteers	O
(	O
n	O
=	O
24	O
)	O
demonstrated	O
that	O
mixing	O
NovoLog	B
with	O
NPH	B
human	I
insulin	I
immediately	O
before	O
injection	O
produced	O
some	O
attenuation	O
in	O
the	O
peak	O
concentration	O
of	O
NovoLog	B
,	O
but	O
that	O
the	O
time	O
to	O
peak	O
and	O
the	O
total	O
bioavailability	O
of	O
NovoLog	B
were	O
not	O
significantly	O
affected	O
.	O

If	O
NovoLog	B
is	O
mixed	O
with	O
NPH	B
human	I
insulin	I
,	O
NovoLog	B
should	O
be	O
drawn	O
into	O
the	O
syringe	O
first	O
.	O

Because	O
there	O
are	O
no	O
data	O
on	O
the	O
compatibility	O
of	O
NovoLog	B
and	O
crystalline	O
zinc	B
insulin	I
preparations	O
,	O
NovoLog	B
should	O
not	O
be	O
mixed	O
with	O
these	O
preparations	O
.	O

The	O
effects	O
of	O
mixing	O
NovoLog	B
with	O
insulins	B
of	O
animal	O
source	O
or	O
insulin	B
preparations	O
produced	O
by	O
other	O
manufacturers	O
have	O
not	O
been	O
studied	O
.	O

When	O
used	O
in	O
external	O
subcutaneous	O
infusion	O
pumps	O
for	O
insulin	B
,	O
NovoLog	B
should	O
not	O
be	O
mixed	O
with	O
any	O
other	O
insulins	B
or	O
diluent	O
.	O

Also	O
,	O
the	O
potential	O
for	O
hepatic	O
injury	O
should	O
be	O
considered	O
when	O
Rebif	B
is	O
used	O
in	O
combination	O
with	O
other	O
products	O
associated	O
with	O
hepatic	O
injury	O
,	O
or	O
when	O
new	O
agents	O
are	O
added	O
to	O
the	O
regimen	O
of	O
patients	O
already	O
on	O
Rebif	B
.	O

Although	O
studies	O
designed	O
to	O
examine	O
drug	O
interactions	O
have	O
not	O
been	O
done	O
,	O
it	O
was	O
noted	O
that	O
corticosteroid	B
or	O
ACTH	B
treatment	O
of	O
relapses	O
for	O
periods	O
of	O
up	O
to	O
28	O
days	O
has	O
been	O
administered	O
to	O
patients	O
(	O
N	O
=	O
180	O
)	O
receiving	O
Betaseron	B
.	O

Betaseron	B
administration	O
to	O
three	O
cancer	O
patients	O
over	O
a	O
dose	O
range	O
of	O
0	O
.	O
025	O
mg	O
to	O
2	O
.	O
2	O
mg	O
led	O
to	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
antipyrine	B
elimination	O
.	O
14	O
The	O
effect	O
of	O
alternate	O
-	O
day	O
administration	O
of	O
0	O
.	O
25	O
mg	O
of	O
Betaseron	B
on	O
drug	O
metabolism	O
in	O
MS	O
patients	O
is	O
unknown	O
.	O

ATROVENT	B
Inhalation	O
Aerosol	O
has	O
been	O
used	O
concomitantly	O
with	O
other	O
drugs	O
,	O
including	O
sympathomimetic	B
bronchodilators	I
,	O
methylxanthines	B
,	O
and	O
steroids	B
,	O
commonly	O
used	O
in	O
the	O
treatment	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

With	O
the	O
exception	O
of	O
albuterol	B
,	O
there	O
are	O
no	O
formal	O
studies	O
fully	O
evaluating	O
the	O
interaction	O
effects	O
of	O
ATROVENT	B
Inhalation	O
Aerosol	O
and	O
these	O
drugs	O
with	O
respect	O
to	O
effectiveness	O
.	O

Anticholinergic	B
agents	I
:	O
Although	O
ipratropium	B
bromide	I
is	O
minimally	O
absorbed	O
into	O
the	O
systemic	O
circulation	O
,	O
there	O
is	O
some	O
potential	O
for	O
an	O
additive	O
interaction	O
with	O
concomitantly	O
used	O
anticholinergic	B
medications	I
.	O

Caution	O
is	O
therefore	O
advised	O
in	O
the	O
coadministration	O
of	O
ATROVENT	B
Inhalation	O
Aerosol	O
with	O
other	O
anticholinergic	B
-	O
containing	O
drugs	O
.	O

No	O
significant	O
drug	O
-	O
drug	O
pharmacokinetic	O
(	O
or	O
pharmacodynamic	O
)	O
interactions	O
have	O
been	O
found	O
in	O
interaction	O
studies	O
with	O
hydrochlorothiazide	B
,	O
digoxin	B
,	O
warfarin	B
,	O
and	O
nifedipine	B
.	O

In	O
vitro	O
studies	O
show	O
significant	O
inhibition	O
of	O
the	O
formation	O
of	O
oxidized	O
irbesartan	O
metabolites	O
with	O
the	O
known	O
cytochrome	O
CYP	O
2C9	O
substrates	O
/	O
inhibitors	O
sulphenazole	B
,	O
tolbutamide	B
and	O
nifedipine	B
.	O

However	O
,	O
in	O
clinical	O
studies	O
the	O
consequences	O
of	O
concomitant	O
irbesartan	B
on	O
the	O
pharmacodynamics	O
of	O
warfarin	B
were	O
negligible	O
.	O

In	O
separate	O
studies	O
of	O
patients	O
receiving	O
maintenance	O
doses	O
of	O
warfarin	B
,	O
hydrochlorothiazide	B
,	O
or	O
digoxin	B
,	O
irbesartan	B
administration	O
for	O
7	O
days	O
had	O
no	O
effect	O
on	O
the	O
pharmacodynamics	O
of	O
warfarin	B
(	O
prothrombin	O
time	O
)	O
or	O
pharmacokinetics	O
of	O
digoxin	B
.	O

The	O
pharmacokinetics	O
of	O
irbesartan	B
were	O
not	O
affected	O
by	O
coadministration	O
of	O
nifedipine	B
or	O
hydrochlorothiazide	B

The	O
adverse	O
effects	O
of	O
CAMPTOSAR	B
,	O
such	O
as	O
myelosuppression	O
and	O
diarrhea	O
,	O
would	O
be	O
expected	O
to	O
be	O
exacerbated	O
by	O
other	O
antineoplastic	B
agents	I
having	O
similar	O
adverse	O
effects	O
.	O

Lymphocytopenia	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
CAMPTOSAR	B
,	O
and	O
it	O
is	O
possible	O
that	O
the	O
administration	O
of	O
dexamethasone	B
as	O
antiemetic	O
prophylaxis	O
may	O
have	O
enhanced	O
the	O
likelihood	O
of	O
this	O
effect	O
.	O

The	O
incidence	O
of	O
akathisia	O
in	O
clinical	O
trials	O
of	O
the	O
weekly	O
dosage	O
schedule	O
was	O
greater	O
(	O
8	O
.	O
5	O
%	O
,	O
4	O
/	O
47	O
patients	O
)	O
when	O
prochlorperazine	B
was	O
administered	O
on	O
the	O
same	O
day	O
as	O
CAMPTOSAR	B
than	O
when	O
these	O
drugs	O
were	O
given	O
on	O
separate	O
days	O
(	O
1	O
.	O
3	O
%	O
,	O
1	O
/	O
80	O
patients	O
)	O
.	O

It	O
would	O
be	O
expected	O
that	O
laxative	B
use	O
during	O
therapy	O
with	O
CAMPTOSAR	B
would	O
worsen	O
the	O
incidence	O
or	O
severity	O
of	O
diarrhea	O
,	O
but	O
this	O
has	O
not	O
been	O
studied	O
.	O

In	O
view	O
of	O
the	O
potential	O
risk	O
of	O
dehydration	O
secondary	O
to	O
vomiting	O
and	O
/	O
or	O
diarrhea	O
induced	O
by	O
CAMPTOSAR	B
,	O
the	O
physician	O
may	O
wish	O
to	O
withhold	O
diuretics	B
during	O
dosing	O
with	O
CAMPTOSAR	B
and	O
,	O
certainly	O
,	O
during	O
periods	O
of	O
active	O
vomiting	O
or	O
diarrhea	O
.	O

Isocarboxazid	B
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
receiving	O
Antabuse	B
(	O
disulfiram	B
,	O
Wyeth	O
-	O
Ayerst	O
Laboratories	O
)	O
.	O

In	O
a	O
single	O
study	O
,	O
rats	O
given	O
high	O
intraperitoneal	O
doses	O
of	O
an	O
MAO	B
inhibitor	I
plus	O
disulfiram	B
experienced	O
severe	O
toxicity	O
,	O
including	O
convulsions	O
and	O
death	O
.	O

Concomitant	O
use	O
of	O
Isocarboxazid	B
and	O
other	O
psychotropic	B
agents	I
is	O
generally	O
not	O
recommended	O
because	O
of	O
possible	O
potentiating	O
effects	O
.	O

The	O
monoamine	O
oxidase	O
inhibitory	O
effects	O
of	O
Isocarboxazid	B
may	O
persist	O
for	O
a	O
substantial	O
period	O
after	O
discontinuation	O
of	O
the	O
drug	O
,	O
and	O
this	O
should	O
be	O
borne	O
in	O
mind	O
when	O
another	O
drug	O
is	O
prescribed	O
following	O
Isocarboxazid	B
.	O

May	O
interact	O
with	O
the	O
following	O
:	O
beta	O
-	O
adrenergic	B
blocking	I
agents	I
(	O
these	O
medicines	O
may	O
make	O
your	O
condition	O
worse	O
and	O
prevent	O
the	O
adrenergic	B
bronchodilators	I
from	O
working	O
properly	O
)	O
and	O
disopyramide	B
,	O
quinidine	B
,	O
phenothiazines	B
,	O
and	O
procainamide	B
(	O
these	O
medicines	O
may	O
increase	O
the	O
risk	O
of	O
heart	O
problems	O
)	O
.	O

Isoflurane	B
potentiates	O
the	O
muscle	B
relaxant	O
effect	O
of	O
all	O
muscle	B
relaxants	I
,	O
most	O
notably	O
nondepolarizing	B
muscle	I
relaxants	I
,	O
and	O
MAC	O
(	O
minimum	O
alveolar	O
concentration	O
)	O
is	O
reduced	O
by	O
concomitant	O
administration	O
of	O
N	O
2O	O
.	O

Acetaminophen	B
:	O
A	O
report	O
of	O
severe	O
acetaminophen	B
toxicity	O
was	O
reported	O
in	O
a	O
patient	O
receiving	O
Isoniazid	B
.	O

It	O
is	O
believed	O
that	O
the	O
toxicity	O
may	O
have	O
resulted	O
from	O
a	O
previously	O
unrecognized	O
interaction	O
between	O
isoniazid	B
and	O
acetaminophen	B
and	O
a	O
molecular	O
basis	O
for	O
this	O
interaction	O
has	O
been	O
proposed	O
.	O

Furthermore	O
it	O
has	O
been	O
proposed	O
that	O
isoniazid	B
resulted	O
In	O
induction	O
of	O
P	O
-	O
450IIE1	O
in	O
the	O
patients	O
liver	O
which	O
,	O
in	O
turn	O
,	O
resulted	O
in	O
a	O
greater	O
proportion	O
of	O
the	O
ingested	O
acetaminophen	B
being	O
converted	O
to	O
the	O
toxic	O
metabolites	O
.	O

Carbamazepine	B
:	O
Isoniazid	B
is	O
known	O
to	O
slow	O
the	O
metabolism	O
of	O
carbamazepine	B
and	O
increase	O
its	O
serum	O
levels	O
Carbamazepine	B
levels	O
should	O
be	O
determined	O
prior	O
to	O
concurrent	O
administration	O
with	O
isoniazid	B
,	O
signs	O
and	O
symptoms	O
of	O
carbamazepine	B
toxicity	O
should	O
be	O
monitored	O
closely	O
,	O
and	O
appropriate	O
dosage	O
adjustment	O
of	O
the	O
anticonvulsant	B
should	O
be	O
made	O
.	O

Ketoconazole	B
:	O
Potential	O
interaction	O
of	O
Ketoconazole	B
and	O
Isoniazid	B
may	O
exist	O
.	O

Phenytoin	B
:	O
Isoniazid	B
may	O
increase	O
serum	O
levels	O
of	O
phenytoin	B
.	O

To	O
avoid	O
phenytoin	B
intoxication	O
,	O
appropriate	O
adjustment	O
of	O
the	O
anticonvulsant	B
should	O
be	O
made	O
.	O

Therophylline	O
:	O
A	O
recent	O
study	O
has	O
shown	O
that	O
concomitan	O
administration	O
of	O
isoniazid	B
and	O
theophylline	B
may	O
cause	O
elevated	O
plasma	O
levels	O
of	O
theophylline	B
,	O
and	O
in	O
some	O
instances	O
a	O
slight	O
decrease	O
in	O
the	O
elimination	O
of	O
isoniazid	B
.	O

Since	O
the	O
therapeutic	O
range	O
of	O
theophylline	B
is	O
narrow	O
theophylline	B
serum	O
levels	O
should	O
be	O
monitored	O
closely	O
,	O
and	O
appropriate	O
dosage	O
adjustments	O
of	O
theophylline	B
should	O
be	O
made	O
.	O

Valproate	B
:	O
A	O
recent	O
case	O
study	O
has	O
shown	O
a	O
possible	O
increase	O
in	O
the	O
plasma	O
level	O
of	O
valproate	B
when	O
co	O
administered	O
with	O
isoniazid	B
.	O

Plasma	O
valproate	B
concentration	O
should	O
be	O
monitored	O
when	O
isoniazid	B
and	O
valproate	B
are	O
co	O
administered	O
,	O
and	O
appropriate	O
dosage	O
adjustments	O
of	O
valproate	B
should	O
be	O
made	O
.	O

Isoproterenol	B
hydrochloride	I
injection	O
and	O
epinephrine	B
should	O
not	O
be	O
administered	O
simultaneously	O
because	O
both	O
drugs	O
are	O
direct	O
cardiac	O
stimulants	O
and	O
their	O
combined	O
effects	O
may	O
induce	O
serious	O
arrhythmias	O
.	O

ISUPREL	B
should	O
be	O
used	O
with	O
caution	O
,	O
if	O
at	O
all	O
,	O
when	O
potent	O
inhalational	O
anesthetics	B
such	O
as	O
halothane	B
are	O
employed	O
because	O
of	O
potential	O
to	O
sensitize	O
the	O
myocardium	O
to	O
effects	O
of	O
sympathomimetic	B
amines	I
.	O

The	O
vasodilating	O
effects	O
of	O
isosorbide	B
dinitrate	I
may	O
be	O
additive	O
with	O
those	O
of	O
other	O
vasodilators	B
.	O

The	O
vasodilating	O
effects	O
of	O
isosorbide	B
mononitrate	I
may	O
be	O
additive	O
with	O
those	O
of	O
other	O
vasodilators	B
.	O

Marked	O
symptomatic	O
orthostatic	O
hypotension	O
has	O
been	O
reported	O
when	O
calcium	B
channel	I
blockers	I
and	O
organic	B
nitrates	I
were	O
used	O
in	O
combination	O
.	O

Vitamin	B
A	I
:	O
Because	O
of	O
the	O
relationship	O
of	O
Accutane	B
to	O
vitamin	B
A	I
,	O
patients	O
should	O
be	O
advised	O
against	O
taking	O
vitamin	B
supplements	I
containing	O
vitamin	B
A	I
to	O
avoid	O
additive	O
toxic	O
effects	O

Tetracyclines	B
:	O
Concomitant	O
treatment	O
with	O
Accutane	B
and	O
tetracyclines	B
should	O
be	O
avoided	O
because	O
Accutane	B
use	O
has	O
been	O
associated	O
with	O
a	O
number	O
of	O
cases	O
of	O
pseudotumor	O
cerebri	O
(	O
benign	O
intracranial	O
hypertension	O
)	O
,	O
some	O
of	O
which	O
involved	O
concomitant	O
use	O
of	O
tetracyclines	B

Micro	O
-	O
dosed	O
Progesterone	B
Preparations	O
:	O
Micro	O
-	O
dosed	O
progesterone	B
preparations	O
(	O
minipills	O
that	O
do	O
not	O
contain	O
an	O
estrogen	B
)	O
may	O
be	O
an	O
inadequate	O
method	O
of	O
contraception	O
during	O
Accutane	B
therapy	O
.	O

Although	O
other	O
hormonal	B
contraceptives	I
are	O
highly	O
effective	O
,	O
there	O
have	O
been	O
reports	O
of	O
pregnancy	O
from	O
women	O
who	O
have	O
used	O
combined	B
oral	I
contraceptives	I
,	O
as	O
well	O
as	O
topical	O
/	O
injectable	O
/	O
implantable	O
/	O
insertable	O
hormonal	B
birth	O
control	O
products	O
.	O

It	O
is	O
not	O
known	O
if	O
hormonal	B
contraceptives	I
differ	O
in	O
their	O
effectiveness	O
when	O
used	O
with	O
Accutane	B
.	O

Phenytoin	B
:	O
Accutane	B
has	O
not	O
been	O
shown	O
to	O
alter	O
the	O
pharmacokinetics	O
of	O
phenytoin	B
in	O
a	O
study	O
in	O
seven	O
healthy	O
volunteers	O
.	O

No	O
formal	O
clinical	O
studies	O
have	O
been	O
conducted	O
to	O
assess	O
if	O
there	O
is	O
an	O
interactive	O
effect	O
on	O
bone	O
loss	O
between	O
phenytoin	B
and	O
Accutane	B
.	O

Systemic	B
Corticosteroids	I
:	O
Systemic	B
corticosteroids	I
are	O
known	O
to	O
cause	O
osteoporosis	O
.	O

No	O
formal	O
clinical	O
studies	O
have	O
been	O
conducted	O
to	O
assess	O
if	O
there	O
is	O
an	O
interactive	O
effect	O
on	O
bone	O
loss	O
between	O
systemic	B
corticosteroids	I
and	O
Accutane	B
.	O

Nitroglycerin	B
:	O
DynaCirc	B
(	O
isradipine	B
)	O
has	O
been	O
safely	O
coadministered	O
with	O
nitroglycerin	B
.	O

Hydrochlorothiazide	B
:	O
A	O
study	O
in	O
normal	O
healthy	O
volunteers	O
has	O
shown	O
that	O
concomitant	O
administration	O
of	O
DynaCirc	B
(	O
isradipine	B
)	O
and	O
hydrochlorothiazide	B
does	O
not	O
result	O
in	O
altered	O
pharmacoktnetics	O
of	O
either	O
drug	O
.	O

In	O
a	O
study	O
in	O
hypertensive	O
patients	O
,	O
addition	O
of	O
isradipine	B
to	O
existing	O
hydrochlorothiazide	B
therapy	O
did	O
not	O
result	O
in	O
any	O
unexpected	O
adverse	O
effects	O
,	O
and	O
isradipine	B
had	O
an	O
additional	O
antihypertensive	O
effect	O
.	O

Propranolol	B
:	O
In	O
a	O
single	O
dose	O
study	O
in	O
normal	O
volunteers	O
,	O
coadministration	O
of	O
propranolol	B
had	O
a	O
small	O
effect	O
on	O
the	O
rate	O
but	O
no	O
effect	O
on	O
the	O
extent	O
of	O
isradipine	B
bioavailability	O
.	O

propranolol	B
to	O
healthy	O
volunteers	O
under	O
steady	O
-	O
state	O
conditions	O
had	O
no	O
relevant	O
effect	O
on	O
either	O
drug	O
s	O
bioavailability	O
,	O
AUC	O
and	O
Cmax	O
,	O
differences	O
were	O
20	O
%	O
between	O
isradipine	B
given	O
singly	O
and	O
in	O
combination	O
with	O
propranolol	B
,	O
and	O
between	O
propranolol	B
given	O
singly	O
and	O
in	O
combination	O
with	O
isradipine	B
.	O

Cimetidine	B
:	O
In	O
a	O
study	O
in	O
healthy	O
volunteers	O
,	O
a	O
one	O
-	O
week	O
course	O
of	O
cimetidine	B
at	O
400	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
with	O
a	O
single	O
5	O
mg	O
dose	O
of	O
isradipine	B
on	O
the	O
sixth	O
day	O
showed	O
an	O
increase	O
in	O
isradipine	B
mean	O
peak	O
plasma	O
concentrations	O
(	O
36	O
%	O
)	O
and	O
significant	O
increase	O
in	O
area	O
under	O
the	O
curve	O
(	O
50	O
%	O
)	O
.	O

If	O
isradipine	B
therapy	O
is	O
initiated	O
in	O
a	O
patient	O
currently	O
receiving	O
cimetidine	B
careful	O
monitoring	O
for	O
adverse	O
reactions	O
is	O
advised	O
and	O
downward	O
dose	O
adjustment	O
may	O
be	O
required	O
.	O

Rifampicin	B
:	O
In	O
a	O
study	O
in	O
healthy	O
volunteers	O
,	O
a	O
six	O
-	O
day	O
course	O
of	O
rifampicin	B
at	O
600	O
mg	O
/	O
day	O
followed	O
by	O
a	O
single	O
5	O
mg	O
dose	O
of	O
isradipine	B
resulted	O
in	O
a	O
reduction	O
in	O
isradipine	B
levels	O
to	O
below	O
detectable	O
limits	O
.	O

If	O
rifampicin	B
therapy	O
is	O
required	O
,	O
isradipine	B
concentrations	O
and	O
therapeutic	O
effects	O
are	O
likely	O
to	O
be	O
markedly	O
reduced	O
or	O
abolished	O
as	O
a	O
consequence	O
of	O
increased	O
metabolism	O
and	O
higher	O
clearance	O
of	O
isradipine	B
.	O

Warfarin	B
:	O
In	O
a	O
study	O
in	O
healthy	O
volunteers	O
,	O
no	O
clinically	O
relevant	O
pharmacokinetic	O
or	O
pharmacodynamic	O
interaction	O
between	O
isradipine	B
and	O
racemic	O
warfarin	B
was	O
seen	O
when	O
two	O
single	O
oral	O
doses	O
of	O
warfarin	B
(	O
0	O
.	O
7	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
were	O
administered	O
during	O
11	O
days	O
of	O
multipledose	O
treatment	O
with	O
5	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
isradipine	B
.	O

Neither	O
racemic	O
warfarin	B
nor	O
isradipine	B
binding	O
to	O
plasma	O
proteins	O
in	O
vitro	O
was	O
altered	O
by	O
the	O
addition	O
of	O
the	O
other	O
drug	O
.	O

Digoxin	B
:	O
The	O
concomitant	O
administration	O
of	O
DynaCirc	B
(	O
isradipine	B
)	O
and	O
digoxin	B
in	O
a	O
single	O
-	O
dose	O
pharmacokinetic	O
study	O
did	O
not	O
affect	O
renal	O
,	O
nonrenal	O
and	O
total	O
body	O
clearance	O
of	O
digoxin	B
.	O

Fentanyl	B
Anesthesia	O
:	O
Severe	O
hypotension	O
has	O
been	O
reported	O
during	O
fentanyl	B
anesthesia	O
with	O
concomitant	O
use	O
of	O
a	O
beta	B
blocker	I
and	O
a	O
calcium	B
channel	I
blocker	I
.	O

Even	O
though	O
such	O
interactions	O
have	O
not	O
been	O
seen	O
in	O
clinical	O
studies	O
with	O
DynaCirc	B
(	O
isradipine	B
)	O
,	O
an	O
increased	O
volume	O
of	O
circulating	O
fluids	O
might	O
be	O
required	O
if	O
such	O
an	O
interaction	O
were	O
to	O
occur	O
.	O

Both	O
itraconazole	B
and	O
its	O
major	O
metabolite	O
,	O
hydroxyitraconazole	B
,	O
are	O
inhibitors	O
of	O
the	O
cytochrome	O
P450	O
3A4	O
enzyme	O
system	O
.	O

Coadministration	O
of	O
terfenadine	B
with	O
Itraconazole	B
has	O
led	O
to	O
elevated	O
plasma	O
concentrations	O
of	O
terfenadine	B
,	O
resulting	O
in	O
rare	O
instances	O
of	O
life	O
-	O
threatening	O
cardiac	O
dysrhythmias	O
and	O
one	O
death	O
.	O

Another	O
oral	O
azole	B
antifungal	I
,	O
ketoconazole	B
,	O
inhibits	O
the	O
metabolism	O
of	O
astemizole	B
,	O
resulting	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
astemizole	B
and	O
its	O
active	O
metabolite	O
desmethylastermizole	B
which	O
may	O
prolong	O
QT	O
intervals	O
.	O

In	O
vitro	O
data	O
suggest	O
that	O
itraconazole	B
,	O
when	O
compared	O
to	O
ketoconazole	B
,	O
has	O
a	O
less	O
pronounced	O
effect	O
on	O
the	O
biotransformation	O
system	O
responsible	O
for	O
the	O
metabolism	O
of	O
astemizole	B
.	O

Based	O
on	O
the	O
chemical	O
resemblance	O
of	O
itraconazole	B
and	O
ketoconazole	B
,	O
coadministration	O
of	O
astemizole	B
with	O
itraconazole	B
is	O
contraindicated	O
.	O

Human	O
pharmacokinetics	O
data	O
indicate	O
that	O
oral	O
ketoconazole	B
potently	O
inhibits	O
the	O
metabolism	O
of	O
cisapride	B
resulting	O
in	O
an	O
eight	O
-	O
fold	O
increase	O
in	O
the	O
mean	O
AUC	O
of	O
cisapride	B
.	O

Data	O
suggest	O
that	O
coadministration	O
of	O
oral	O
ketoconazole	B
and	O
cisapride	B
can	O
result	O
in	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

In	O
vitro	O
data	O
suggest	O
that	O
itraconazole	B
also	O
markedly	O
inhibits	O
the	O
biotransformation	O
system	O
mainly	O
responsible	O
for	O
the	O
metabolism	O
of	O
cisapride	B
;	O

therefore	O
concomitant	O
administration	O
of	O
Itraconazole	B
with	O
cisapride	B
is	O
contraindicated	O
.	O

Coadministration	O
of	O
Itraconazole	B
with	O
oral	O
midazolam	B
or	O
triazolam	B
has	O
resulted	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
latter	O
two	O
drugs	O
.	O

Coadministration	O
of	O
Itraconazole	B
and	O
cyclosporine	B
,	O
tacrolimus	B
or	O
digoxin	B
has	O
led	O
to	O
increased	O
plasma	O
concentrations	O
of	O
the	O
latter	O
three	O
drugs	O
.	O

Cyclosporine	B
,	O
tacrolimus	B
and	O
digoxin	B
concentrations	O
should	O
be	O
monitored	O
at	O
the	O
initiation	O
of	O
Itraconazole	B
therapy	O
and	O
frequently	O
thereafter	O
,	O
and	O
the	O
dose	O
of	O
these	O
three	O
drug	O
products	O
adjusted	O
appropriately	O
.	O

Rhabdomyolysis	O
has	O
been	O
observed	O
in	O
patients	O
receiving	O
HMG	O
-	O
CoA	O
reductase	B
inhibitors	I
administered	O
alone	O
(	O
at	O
recommended	O
dosages	O
)	O
or	O
concomitantly	O
with	O
immunosuppressive	B
drugs	I
including	O
cyclosporine	B
.	O

When	O
Itraconazole	B
was	O
coadministered	O
with	O
phenytoin	B
,	O
rifampin	B
,	O
or	O
H2antagonists	O
,	O
reduced	O
plasma	O
concentrations	O
of	O
itraconazole	B
were	O
reported	O
.	O

The	O
physician	O
is	O
advised	O
to	O
monitor	O
the	O
plasma	O
concentrations	O
of	O
itraconazole	B
when	O
any	O
of	O
these	O
drugs	O
is	O
taken	O
concurrently	O
,	O
and	O
to	O
increase	O
the	O
dose	O
of	O
Itraconazole	B
if	O
necessary	O
.	O

Although	O
no	O
studies	O
have	O
been	O
conducted	O
,	O
concomitant	O
administration	O
of	O
Itraconazole	B
and	O
phenytoin	B
may	O
alter	O
the	O
metabolism	O
of	O
phenytoin	B
;	O

therefore	O
,	O
plasma	O
concentrations	O
of	O
phenytoin	B
should	O
also	O
be	O
monitored	O
when	O
it	O
is	O
given	O
concurrently	O
with	O
Itraconazole	B
.	O

It	O
has	O
been	O
reported	O
that	O
Itraconazole	B
enhances	O
the	O
anticoagulant	O
effect	O
of	O
coumarin	B
-	O
like	O
drugs	O
.	O

Therefore	O
,	O
prothrombin	O
time	O
should	O
be	O
carefully	O
monitored	O
in	O
patients	O
receiving	O
Itraconazole	B
and	O
coumarin	B
-	O
like	O
drugs	O
simultaneously	O
.	O

Plasma	O
concentrations	O
of	O
azole	B
antifungal	I
agents	I
are	O
reduced	O
when	O
given	O
concurrently	O
with	O
isoniazid	B
.	O

Itraconazole	B
plasma	O
concentrations	O
should	O
be	O
monitored	O
when	O
Itraconazole	B
and	O
isoniazid	B
are	O
coadministered	O
.	O

Severe	O
hypoglycemia	O
has	O
been	O
reported	O
in	O
patients	O
concomitantly	O
receiving	O
azole	B
antifungal	I
agents	I
and	O
oral	O
hypoglycemic	B
agents	I
.	O

Blood	O
glucose	O
concentrations	O
should	O
be	O
carefully	O
monitored	O
when	O
Itraconazole	B
and	O
oral	O
hypoglycemic	B
agents	I
are	O
coadministered	O
.	O

Tinnitus	O
and	O
decreased	O
hearing	O
have	O
been	O
reported	O
in	O
patients	O
concomitantly	O
receiving	O
Itraconazole	B
and	O
quinidine	B
.	O

Edema	O
has	O
been	O
reported	O
in	O
patients	O
concomitantly	O
receiving	O
Itraconazole	B
and	O
dihydropyridine	B
calcium	I
channel	I
blockers	I
.	O

The	O
results	O
from	O
a	O
study	O
in	O
which	O
eight	O
HIV	O
-	O
infected	O
individuals	O
were	O
treated	O
with	O
zidovudine	B
,	O
8	O
+	O
/	O
-	O
0	O
.	O
4	O
mg	O
/	O
kg	O
/	O
day	O
,	O
showed	O
that	O
the	O
pharmacokinetics	O
of	O
zidovudine	B
were	O
not	O
affected	O
during	O
concomitant	O
administration	O
of	O
Itraconazole	B
,	O
100	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O

In	O
vitro	O
mixing	O
of	O
an	O
aminoglycoside	B
with	O
beta	O
-	O
lactamtype	O
antibiotics	B
(	O
penicillins	B
or	O
cephalosporins	B
)	O
may	O
result	O
in	O
a	O
significant	O
mutual	O
inactivation	O
.	O

Even	O
when	O
an	O
aminoglycoside	B
and	O
a	O
penicillin	B
-	O
type	O
drug	O
are	O
administered	O
separately	O
by	O
different	O
routes	O
,	O
a	O
reduction	O
in	O
aminoglycoside	B
serum	O
half	O
-	O
life	O
or	O
serum	O
levels	O
has	O
been	O
reported	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
and	O
in	O
some	O
patients	O
with	O
normal	O
renal	O
function	O
.	O

Prolonged	O
recovery	O
time	O
may	O
occur	O
if	O
barbiturates	B
and	O
/	O
or	O
narcotics	B
are	O
used	O
concurrently	O
with	O
ketamine	B
.	O

Ketamine	B
is	O
clinically	O
compatible	O
with	O
the	O
commonly	O
used	O
general	O
and	O
local	O
anesthetic	B
agents	I
when	O
an	O
adequate	O
respiratory	O
exchange	O
is	O
maintained	O
.	O

The	O
following	O
drug	O
interactions	O
have	O
been	O
identified	O
involving	O
NIZORAL	B
Tablets	O
and	O
other	O
drugs	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
3A4	O
enzyme	O
system	O
:	O
Ketoconazole	B
tablets	O
inhibit	O
the	O
metabolism	O
of	O
terfenadine	B
,	O
resulting	O
in	O
an	O
increased	O
plasma	O
concentration	O
of	O
terfenadine	B
and	O
a	O
delay	O
in	O
the	O
elimination	O
of	O
its	O
acid	O
metabolite	O
.	O

Pharmacokinetic	O
data	O
indicate	O
that	O
oral	O
ketoconazole	B
inhibits	O
the	O
metabolism	O
of	O
astemizole	B
,	O
resulting	O
in	O
elevated	O
plasma	O
levels	O
of	O
astemizole	B
and	O
its	O
active	O
metabolite	O
desmethylastemizole	B
which	O
may	O
prolong	O
QT	O
intervals	O
.	O

Coadministration	O
of	O
astemizole	B
with	O
ketoconazole	B
tablets	O
is	O
therefore	O
contraindicated	O
.	O

Human	O
pharmacokinetics	O
data	O
indicate	O
that	O
oral	O
ketoconazole	B
potently	O
inhibits	O
the	O
metabolism	O
of	O
cisapride	B
resulting	O
in	O
a	O
mean	O
eight	O
-	O
fold	O
increase	O
in	O
AUC	O
of	O
cisapride	B
.	O

Data	O
suggest	O
that	O
coadministration	O
of	O
oral	O
ketoconazole	B
and	O
cisapride	B
can	O
result	O
in	O
prolongation	O
of	O
the	O
QT	O
interval	O
on	O
the	O
ECG	O
.	O

Therefore	O
concomitant	O
administration	O
of	O
ketoconazole	B
tablets	O
with	O
cisapride	B
is	O
contraindicated	O
.	O

Ketoconazole	B
tablets	O
may	O
alter	O
the	O
metabolism	O
of	O
cyclosporine	B
,	O
tacrolimus	B
,	O
and	O
methylprednisolone	B
,	O
resulting	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
latter	O
drugs	O
.	O

Dosage	O
adjustment	O
may	O
be	O
required	O
if	O
cyclosporine	B
,	O
tacrolimus	B
,	O
or	O
methylprednisolone	B
are	O
given	O
concomitantly	O
with	O
NIZORAL	B
Tablets	O
.	O

Coadministration	O
of	O
NIZORAL	B
Tablets	O
with	O
midazolam	B
or	O
triazolam	B
has	O
resulted	O
in	O
elevated	O
plasma	O
concentrations	O
of	O
the	O
latter	O
two	O
drugs	O
.	O

It	O
is	O
,	O
therefore	O
,	O
advisable	O
to	O
monitor	O
digoxin	B
concentrations	O
in	O
patients	O
receiving	O
ketoconazole	B
.	O

When	O
taken	O
orally	O
,	O
imidazole	B
compounds	I
like	O
ketoconazole	B
may	O
enhance	O
the	O
anticoagulant	O
effect	O
of	O
coumarin	B
-	O
like	O
drugs	O
.	O

In	O
simultaneous	O
treatment	O
with	O
imidazole	B
drugs	I
and	O
coumarin	B
drugs	I
,	O
the	O
anticoagulant	O
effect	O
should	O
be	O
carefully	O
titrated	O
and	O
monitored	O
.	O

Because	O
severe	O
hypoglycemia	O
has	O
been	O
reported	O
in	O
patients	O
concomitantly	O
receiving	O
oral	O
miconazole	B
(	O
an	O
imidazole	B
)	O
and	O
oral	O
hypoglycemic	B
agents	I
,	O
such	O
a	O
potential	O
interaction	O
involving	O
the	O
latter	O
agents	B
when	O
used	O
concomitantly	O
with	O
ketoconazole	B
tablets	O
(	O
an	O
imidazole	B
)	O
can	O
not	O
be	O
ruled	O
out	O
.	O

Concomitant	O
administration	O
of	O
ketoconazole	B
tablets	O
with	O
phenytoin	B
may	O
alter	O
the	O
metabolism	O
of	O
one	O
or	O
both	O
of	O
the	O
drugs	O
.	O

It	O
is	O
suggested	O
to	O
monitor	O
both	O
ketoconazole	B
and	O
phenytoin	B
.	O

Concomitant	O
administration	O
of	O
rifampin	B
with	O
ketoconazole	B
tablets	O
reduces	O
the	O
blood	O
levels	O
of	O
the	O
latter	O
.	O

INH	B
(	O
Isoniazid	B
)	O
is	O
also	O
reported	O
to	O
affect	O
ketoconazole	B
concentrations	O
adversely	O
.	O

After	O
the	O
coadministration	O
of	O
200	O
mg	O
oral	O
ketoconazole	B
twice	O
daily	O
and	O
one	O
20	O
mg	O
dose	O
of	O
loratadine	B
to	O
11	O
subjects	O
,	O
the	O
AUC	O
and	O
Cmax	O
of	O
loratadine	B
averaged	O
302	O
%	O
(	O
142	O
S	O
.	O
D	O
.	O
)	O
and	O
251	O
%	O
(	O
68	O
S	O
.	O
D	O
.	O
)	O
,	O
respectively	O
,	O
of	O
those	O
obtained	O
after	O
co	O
-	O
treatment	O
with	O
placebo	O
.	O

Also	O
,	O
there	O
were	O
no	O
clinically	O
significant	O
differences	O
in	O
adverse	O
events	O
when	O
loratadine	B
was	O
administered	O
with	O
or	O
without	O
ketoconazole	B
.	O

The	O
possibility	O
of	O
increased	O
interaction	O
should	O
be	O
kept	O
in	O
mind	O
when	O
Orudis	B
doses	O
greater	O
than	O
50	O
mg	O
as	O
a	O
single	O
dose	O
or	O
200	O
mg	O
of	O
ketoprofen	B
per	O
day	O
are	O
used	O
concomitantly	O
with	O
highly	O
bound	O
drugs	O
.	O

Antacids	B
:	O
Concomitant	O
administration	O
of	O
magnesium	B
hydroxide	I
and	O
aluminum	B
hydroxide	I
does	O
not	O
interfere	O
with	O
the	O
rate	O
or	O
extent	O
of	O
the	O
absorption	O
of	O
ketoprofen	B
administered	O
as	O
Orudis	B
.	O

Aspirin	B
:	O
Ketoprofen	B
does	O
not	O
alter	O
aspirin	B
absorption	O
;	O

however	O
,	O
in	O
a	O
study	O
of	O
12	O
normal	O
subjects	O
,	O
concurrent	O
administration	O
of	O
aspirin	B
decreased	O
ketoprofen	B
protein	O
binding	O
and	O
increased	O
ketoprofen	B
plasma	O
clearance	O
from	O
0	O
.	O
07	O
L	O
/	O
kg	O
/	O
h	O
without	O
aspirin	B
to	O
0	O
.	O
11	O
L	O
/	O
kg	O
/	O
h	O
with	O
aspirin	B
.	O

Therefore	O
,	O
concurrent	O
use	O
of	O
aspirin	B
and	O
ketoprofen	B
is	O
not	O
recommended	O
.	O

Diuretic	B
:	O
Hydrochlorothiazide	B
,	O
given	O
concomitantly	O
with	O
ketoprofen	B
,	O
produces	O
a	O
reduction	O
in	O
urinary	O
potassium	O
and	O
chloride	O
excretion	O
compared	O
to	O
hydrochlorothiazide	B
alone	O
.	O

Digoxin	B
:	O
In	O
a	O
study	O
in	O
12	O
patients	O
with	O
congestive	O
heart	O
failure	O
where	O
ketoprofen	B
and	O
digoxin	B
were	O
concomitantly	O
administered	O
,	O
ketoprofen	B
did	O
not	O
alter	O
the	O
serum	O
levels	O
of	O
digoxin	B
.	O

Warfarin	B
:	O
In	O
a	O
short	O
-	O
term	O
controlled	O
study	O
in	O
14	O
normal	O
volunteers	O
,	O
ketoprofen	B
did	O
not	O
significantly	O
interfere	O
with	O
the	O
effect	O
of	O
warfarin	B
on	O
prothrombin	O
time	O
.	O

Bleeding	O
from	O
a	O
number	O
of	O
sites	O
may	O
be	O
a	O
complication	O
of	O
warfarin	B
treatment	O
and	O
GI	O
bleeding	O
a	O
complication	O
of	O
ketoprofen	B
treatment	O
.	O

Because	O
prostaglandina	O
play	O
an	O
important	O
role	O
in	O
hemostasis	O
and	O
ketoprofen	B
has	O
an	O
effect	O
on	O
platelet	O
function	O
as	O
well	O
,	O
concurent	O
therapy	O
with	O
ketoprofen	B
and	O
warfarin	B
requires	O
close	O
monitoring	O
of	O
patients	O
on	O
both	O
drugs	O
.	O

Probenecid	B
:	O
Probenecid	B
increases	O
both	O
free	O
and	O
bound	O
ketoprofen	B
by	O
reducing	O
the	O
plasma	O
clearance	O
of	O
ketoprofen	B
to	O
about	O
one	O
-	O
third	O
,	O
as	O
well	O
as	O
decreasing	O
its	O
protein	O
binding	O
.	O

Therefore	O
,	O
the	O
combination	O
of	O
ketoprofen	B
and	O
probenecid	B
is	O
not	O
recommended	O
.	O

Methotrexate	B
:	O
Ketoprofen	B
,	O
like	O
other	O
NSAIDs	B
,	O
may	O
cause	O
changes	O
in	O
the	O
elimination	O
of	O
methotrexate	B
leading	O
to	O
elevated	O
serum	O
levels	O
of	O
the	O
drug	O
and	O
increased	O
toxicity	O
.	O

Lithium	B
:	O
Nonsteroidal	B
anti	O
-	O
inflammatory	O
agents	B
have	O
been	O
reported	O
to	O
increase	O
steadystate	O
plasma	O
lithium	B
levels	O
.	O

It	O
is	O
recommended	O
that	O
plasma	O
lithium	B
levels	O
be	O
monitored	O
when	O
ketoprofen	B
is	O
coadministered	O
with	O
lithium	B
.	O

Warfarin	B
,	O
Digoxin	B
,	O
Salicylate	B
,	O
and	O
Heparin	B
The	O
in	O
vitro	O
binding	O
of	O
warfarin	B
to	O
plasma	O
proteins	O
is	O
only	O
slightly	O
reduced	O
by	O
ketorolac	B
tromethamine	I
(	O
99	O
.	O
5	O
%	O
control	O
vs	O
99	O
.	O
3	O
%	O
)	O
when	O
ketorolac	B
plasma	O
concentrations	O
reach	O
5	O
to10	O
m	O
g	O
/	O
mL	O
.	O

Ketorolac	B
does	O
not	O
alter	O
digoxin	B
protein	O
binding	O
.	O

In	O
vitro	O
studies	O
indicate	O
that	O
,	O
at	O
therapeutic	O
concentrations	O
of	O
salicylate	B
(	O
300	O
m	O
g	O
/	O
mL	O
)	O
,	O
the	O
binding	O
of	O
ketorolac	B
was	O
reduced	O
from	O
approximately	O
99	O
.	O
2	O
%	O
to	O
97	O
.	O
5	O
%	O
,	O
representing	O
a	O
potential	O
twofold	O
increase	O
in	O
unbound	O
ketorolac	B
plasma	O
levels	O
.	O

Therapeutic	O
concentrations	O
of	O
digoxin	B
,	O
warfarin	B
,	O
ibuprofen	B
,	O
naproxen	B
,	O
piroxicam	B
,	O
acetaminophen	B
,	O
phenytoin	B
andtolbutamide	O
did	O
not	O
alter	O
ketorolac	B
tromethamine	I
protein	O
binding	O
.	O

In	O
a	O
study	O
involving	O
12	O
adult	O
volunteers	O
,	O
TORADOLORAL	O
was	O
coadministered	O
with	O
a	O
single	O
dose	O
of	O
25	O
mg	O
warfarin	B
,	O
causing	O
no	O
significant	O
changes	O
in	O
pharmacokinetics	O
or	O
pharmacodynamics	O
of	O
warfarin	B
.	O

In	O
another	O
study	O
,	O
TORADOLIV	O
/	O
IM	O
was	O
given	O
with	O
two	O
doses	O
of	O
5000	O
U	O
of	O
heparin	B
to	O
11	O
healthy	O
volunteers	O
,	O
resulting	O
in	O
a	O
mean	O
template	O
bleeding	O
time	O
of	O
6	O
.	O
4	O
minutes	O
(	O
3	O
.	O
2	O
to	O
11	O
.	O
4	O
min	O
)	O
compared	O
to	O
a	O
mean	O
of	O
6	O
.	O
0	O
minutes	O
(	O
3	O
.	O
4	O
to	O
7	O
.	O
5	O
min	O
)	O
for	O
heparin	B
alone	O
and	O
5	O
.	O
1	O
minutes	O
(	O
3	O
.	O
5	O
to	O
8	O
.	O
5	O
min	O
)	O
for	O
placebo	O
.	O

Although	O
these	O
results	O
do	O
not	O
indicate	O
a	O
significant	O
interaction	O
between	O
TORADOL	B
and	O
warfarin	B
or	O
heparin	B
,	O
the	O
administration	O
of	O
TORADOL	B
to	O
patients	O
taking	O
anticoagulants	B
should	O
be	O
done	O
extremely	O
cautiously	O
,	O
and	O
patients	O
should	O
be	O
closely	O
monitored	O
.	O

Furosemide	B
:	O
TORADOL	B
IV	O
/	O
IM	O
reduced	O
the	O
diuretic	B
response	O
to	O
furosemide	B
in	O
normovolemic	O
healthy	O
subjects	O
by	O
approximately	O
20	O
%	O
(	O
mean	O
sodium	O
and	O
urinary	O
output	O
decreased	O
17	O
%	O
)	O
.	O

Probenecid	B
:	O
Concomitant	O
administration	O
of	O
TORADOL	B
ORAL	O
and	O
probenecid	B
resulted	O
in	O
decreased	O
clearance	O
of	O
ketorolac	B
and	O
significant	O
increases	O
in	O
ketorolac	B
plasma	O
levels	O
(	O
total	O
AUC	O
increased	O
approximately	O
threefold	O
from	O
5	O
.	O
4	O
to	O
17	O
.	O
8	O
m	O
g	O
/	O
h	O
/	O
mL	O
)	O
and	O
terminal	O
half	O
-	O
life	O
increased	O
approximately	O
twofold	O
from	O
6	O
.	O
6	O
to	O
15	O
.	O
1	O
hours	O
.	O

Therefore	O
,	O
concomitant	O
use	O
of	O
TORADOL	B
and	O
probenecid	B
is	O
contraindicated	O
.	O

Lithium	B
:	O
Inhibition	O
of	O
renal	O
lithium	B
clearance	O
,	O
leading	O
to	O
an	O
increase	O
in	O
plasma	O
lithium	B
concentration	O
,	O
has	O
been	O
reported	O
with	O
some	O
prostaglandin	O
synthesis	O
-	O
inhibiting	O
drugs	O
.	O

The	O
effect	O
of	O
TORADOL	B
on	O
plasma	O
lithium	B
has	O
not	O
been	O
studied	O
,	O
but	O
cases	O
of	O
increased	O
lithium	B
plasma	O
levels	O
during	O
TORADOL	B
therapy	O
have	O
been	O
reported	O
.	O

Methotrexate	B
:	O
Concomitant	O
administration	O
of	O
methotrexate	B
and	O
some	O
NSAIDs	B
has	O
been	O
reported	O
to	O
reduce	O
the	O
clearance	O
of	O
methotrexate	B
,	O
enhancing	O
the	O
toxicity	O
of	O
methotrexate	B
.	O

The	O
effect	O
of	O
TORADOL	B
on	O
methotrexate	B
clearance	O
has	O
not	O
been	O
studied	O
.	O

Nondepolarizing	B
Muscle	I
Relaxants	I
:	O
In	O
postmarketing	O
experience	O
there	O
have	O
been	O
reports	O
of	O
a	O
possible	O
interaction	O
between	O
TORADOLIV	O
/	O
IM	O
and	O
nondepolarizing	B
muscle	I
relaxants	I
that	O
resulted	O
in	O
apnea	O
.	O

The	O
concurrent	O
use	O
of	O
TORADOL	B
with	O
muscle	B
relaxants	I
has	O
not	O
been	O
formally	O
studied	O
.	O

ACE	B
Inhibitors	I
:	O
Concomitant	O
use	O
of	O
ACE	B
inhibitors	I
may	O
increase	O
the	O
risk	O
of	O
renal	O
impairment	O
,	O
particularly	O
in	O
volume	O
-	O
depleted	O
patients	O
.	O

Antiepileptic	B
Drugs	I
:	O
Sporadic	O
cases	O
of	O
seizures	O
have	O
been	O
reported	O
during	O
concomitant	O
use	O
of	O
TORADOL	B
and	O
antiepileptic	B
drugs	I
(	O
phenytoin	B
,	O
carbamazepine	B
)	O
.	O

Psychoactive	B
Drugs	I
:	O
Hallucinations	O
have	O
been	O
reported	O
when	O
TORADOL	B
was	O
used	O
in	O
patients	O
taking	O
psychoactive	B
drugs	I
(	O
fluoxetine	B
,	O
thiothixene	B
,	O
alprazolam	B
)	O
.	O

Morphine	B
:	O
TORADOLIV	O
/	O
IM	O
has	O
been	O
administered	O
concurrently	O
with	O
morphine	B
in	O
several	O
clinical	O
trials	O
of	O
postoperative	O
pain	O
without	O
evidence	O
of	O
adverse	O
interactions	O
.	O

Do	O
not	O
mix	O
TORADOL	B
and	O
morphine	B
in	O
the	O
same	O
syringe	O
.	O

Cyclosporine	B
-	O
L	O
-	O
arginine	O
may	O
counteract	O
the	O
antinaturetic	O
effect	O
of	O
cyclosporin	B
.	O

Ibuprofen	B
-	O
L	O
-	O
arginine	O
may	O
increase	O
the	O
absorption	O
of	O
ibuprofen	B
if	O
taken	O
concomitantly	O
.	O

Organic	O
nitrates	B
-	O
L	O
-	O
arginine	O
supplements	O
theoretically	O
may	O
potentiate	O
the	O
effects	O
of	O
organic	O
nitrates	B
if	O
taken	O
concomitantly	O
.	O

Sildenafil	B
citrate	I
-	O
Theoretically	O
,	O
L	O
-	O
arginine	O
supplements	O
taken	O
concomitantly	O
with	O
sildenafil	B
citrate	I
,	O
may	O
potentiate	O
the	O
effects	O
of	O
the	O
drug	O
.	O

Human	B
growth	I
hormone	I
-	O
Concomitant	O
use	O
of	O
L	O
-	O
glutamine	O
and	O
human	B
growth	I
hormone	I
may	O
enhance	O
nutrient	O
absorption	O
in	O
those	O
with	O
severe	O
short	O
bowel	O
syndrome	O
.	O

Indomethacin	B
-	O
Concomitant	O
use	O
of	O
L	O
-	O
glutamine	O
and	O
indomethacin	B
may	O
ameliorate	O
increased	O
intestinal	O
permeability	O
caused	O
by	O
indomethacin	B
.	O

Methotrexate	B
-	O
There	O
is	O
one	O
report	O
that	O
methotrexate	B
may	O
decrease	O
the	O
possible	O
effectiveness	O
of	O
supplemental	O
L	O
-	O
glutamine	O
for	O
chemotherapy	O
-	O
induced	O
mucositis	O
.	O

In	O
another	O
report	O
,	O
nine	O
patients	O
with	O
breast	O
cancer	O
were	O
reported	O
to	O
have	O
decreased	O
symptoms	O
of	O
methotrexate	B
-	O
related	O
toxicity	O
when	O
given	O
supplemental	O
L	O
-	O
glutamine	O
at	O
a	O
dose	O
of	O
0	O
.	O
5	O
gram	O
/	O
kilogram	O
/	O
day	O
.	O

Paclitaxel	B
-	O
In	O
one	O
report	O
,	O
L	O
-	O
glutamine	O
at	O
a	O
dose	O
of	O
10	O
grams	O
three	O
times	O
daily	O
,	O
given	O
24	O
hours	O
after	O
receiving	O
paclitaxel	B
,	O
appeared	O
to	O
prevent	O
the	O
development	O
of	O
myalgia	O
and	O
arthralgia	O
,	O
adverse	O
reactions	O
of	O
paclitaxel	B
.	O

Medroxyprogesterone	B
Acetate	I
-	O
L	O
-	O
histidine	O
was	O
observed	O
to	O
enhance	O
(	O
in	O
tissue	O
culture	O
)	O
the	O
effect	O
of	O
medroxyprogesterone	B
acetate	I
in	O
reducing	O
the	O
number	O
of	O
human	O
breast	O
cancer	O
cells	O
that	O
were	O
in	O
the	O
S	O
phase	O
.	O

H1	B
and	O
H2	B
Blockers	I
-	O
Although	O
not	O
reported	O
,	O
L	O
-	O
histidine	O
,	O
via	O
its	O
metabolism	O
to	O
histamine	O
,	O
might	O
decrease	O
the	O
efficacy	O
of	O
H1	B
and	O
H2	B
blockers	I
.	O

Concomitant	O
use	O
of	O
calcium	B
supplements	O
and	O
L	O
-	O
lysine	O
may	O
increase	O
calcium	B
absorption	O

Acetaminophen	B
and	O
methotrexate	B
-	O
L	O
-	O
methionine	O
may	O
decrease	O
hepatic	O
toxicity	O
in	O
those	O
with	O
acetaminophen	B
overdosage	O
or	O
in	O
those	O
taking	O
methotrexate	B
.	O

Gentamicin	B
-	O
Methionine	B
may	O
protect	O
against	O
the	O
ototoxic	O
effects	O
of	O
gentamicin	B
.	O

Non	O
-	O
selective	O
monoamine	B
oxidase	I
(	O
MAO	O
)	O
inhibitors	B
-	O
including	O
phenelzine	B
sulfate	I
,	O
tranylcypromine	B
sulfate	I
and	O
pargyline	B
HC1	O
.	O

Concomitant	O
use	O
of	O
L	O
-	O
phenylalanine	O
and	O
non	O
-	O
selective	O
MAO	B
inhibitors	I
may	O
cause	O
hypertension	O
.	O

Selegiline	B
-	O
L	O
-	O
phenylalanine	O
and	O
the	O
selective	B
MAO	I
inhibitor	I
selegiline	I
may	O
have	O
synergistic	O
antidepressant	O
activity	O
if	O
used	O
concomitantly	O
.	O

Neuroleptic	B
Drugs	I
-	O
L	O
-	O
phenylalanine	O
may	O
potentiate	O
the	O
tardive	O
dyskinesia	O
side	O
reactions	O
of	O
neuroleptic	B
drugs	I
if	O
used	O
concomitantly	O
with	O
them	O
.	O

Monoamine	B
oxidase	I
(	O
MAO	O
)	O
inhibitors	B
such	O
as	O
isocarboxazid	B
(	O
e	O
.	O
g	O
.	O
,	O
Marplan	B
)	O
,	O
phenelzine	B
(	O
e	O
.	O
g	O
.	O
,	O
Nardil	B
)	O
,	O
procarbazine	B
(	O
e	O
.	O
g	O
.	O
,	O
Matulane	B
)	O
,	O
selegiline	B
(	O
e	O
.	O
g	O
.	O
,	O
Eldepryl	B
)	O
,	O
and	O
tranylcypromine	B
(	O
e	O
.	O
g	O
.	O
,	O
Parnate	B
)	O
:	O
Using	O
these	O
medicines	O
with	O
L	O
-	O
tryptophan	O
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
.	O

Non	O
-	O
selective	O
MAO	B
inhibitors	I
including	O
tranylcypromine	B
sulfate	I
,	O
phenelzine	B
sulfate	I
,	O
and	O
pargyline	B
HC1	O
:	O
Concomitant	O
use	O
of	O
L	O
-	O
tyrosine	O
and	O
non	O
-	O
selective	O
MAO	B
inhibitors	I
may	O
cause	O
hypertension	O
.	O

In	O
one	O
survey	O
,	O
2	O
.	O
3	O
%	O
of	O
patients	O
taking	O
labetalol	B
HCl	I
in	O
combination	O
with	O
tricyclic	B
antidepressants	I
experienced	O
tremor	O
,	O
as	O
compared	O
to	O
0	O
.	O
7	O
%	O
reported	O
to	O
occur	O
with	O
labetalol	B
HCl	I
alone	O
.	O

Cimetidine	B
has	O
been	O
shown	O
to	O
increase	O
the	O
bioavailability	O
of	O
labetalol	B
HCl	I
.	O

Synergism	O
has	O
been	O
shown	O
between	O
halothane	B
anesthesia	O
and	O
intravenously	O
administered	O
labetalol	B
HCl	I
.	O

During	O
controlled	O
hypotensive	O
anesthesia	O
using	O
labetalol	B
HCl	I
in	O
association	O
with	O
halothane	B
,	O
high	O
concentrations	O
(	O
3	O
%	O
or	O
above	O
)	O
of	O
halothane	B
should	O
not	O
be	O
used	O
because	O
the	O
degree	O
of	O
hypotension	O
will	O
be	O
increased	O
and	O
because	O
of	O
the	O
possibility	O
of	O
a	O
large	O
reduction	O
in	O
cardiac	O
output	O
and	O
an	O
increase	O
in	O
central	O
venous	O
pressure	O
.	O

Labetalol	B
HCl	I
blunts	O
the	O
reflex	O
tachycardia	O
produced	O
by	O
nitroglycerin	B
without	O
preventing	O
its	O
hypotensive	O
effect	O
.	O

If	O
labetalol	B
HCl	I
is	O
used	O
with	O
nitroglycerin	B
in	O
patients	O
with	O
angina	O
pectoris	O
,	O
additional	O
antihypertensive	O
effects	O
may	O
occur	O
.	O

Care	O
should	O
be	O
taken	O
if	O
labetalol	B
is	O
used	O
concomitantly	O
with	O
calcium	B
antagonists	O
of	O
the	O
verapamil	B
type	O
.	O

Labetalol	B
HCl	I
has	O
also	O
been	O
reported	O
to	O
produce	O
a	O
false	O
positive	O
test	O
for	O
amphetamine	B
when	O
screening	O
urine	O
for	O
the	O
presence	O
of	O
drugs	O
using	O
the	O
commercially	O
available	O
assay	O
methods	O
Toxi	O
-	O
Lab	O
A	O
(	O
thin	O
-	O
layer	O
chromatographic	O
assay	O
)	O
and	O
Emit	O
-	O
d	O
.	O
a	O
.	O
u	O
.	O
(	O
radioenzymatic	O
assay	O
)	O
.	O

When	O
patients	O
being	O
treated	O
with	O
labetalol	B
have	O
a	O
positive	O
urine	O
test	O
for	O
amphetamine	B
using	O
these	O
techniques	O
confirmation	O
should	O
be	O
made	O
by	O
using	O
more	O
specific	O
methods	O
such	O
as	O
a	O
gas	O
chromatographic	O
-	O
mass	O
spectrometer	O
technique	O
.	O

Results	O
of	O
preliminary	O
studies	O
in	O
humans	O
and	O
rats	O
suggest	O
that	O
nonabsorbable	O
antacids	B
given	O
concurrently	O
with	O
lactulose	B
may	O
inhibit	O
the	O
desired	O
lactulose	B
-	O
induced	O
drop	O
in	O
colonic	O
pH	O
.	O

There	O
is	O
no	O
information	O
regarding	O
the	O
effect	O
on	O
lamivudine	B
pharmacokinetics	O
of	O
higher	O
doses	O
of	O
TMP	B
/	O
SMX	B
such	O
as	O
those	O
used	O
to	O
treat	O
Pneumocystis	O
carinii	O
pneumonia	O
.	O

Lamivudine	B
and	O
zalcitabine	B
may	O
inhibit	O
the	O
intracellular	O
phosphorylation	O
of	O
one	O
another	O
.	O

Therefore	O
,	O
use	O
of	O
lamivudine	B
in	O
combination	O
with	O
zalcitabine	B
is	O
not	O
recommended	O

Studies	O
have	O
shown	O
that	O
lansoprazole	B
does	O
not	O
have	O
clinically	O
significant	O
interactions	O
with	O
other	O
drugs	O
metabolized	O
by	O
the	O
cytochrome	O
P450	O
system	O
,	O
such	O
as	O
warfarin	B
,	O
antipyrine	B
,	O
indomethacin	B
,	O
ibuprofen	B
,	O
phenytoin	B
,	O
propranolol	B
,	O
prednisone	B
,	O
diazepam	B
,	O
clarithromycin	B
,	O
or	O
terfenadine	B
in	O
healthy	O
subjects	O
.	O

When	O
lansoprazole	B
was	O
administered	O
concomitantly	O
with	O
theophylline	B
(	O
CYP1A2	O
,	O
CYP3A	O
)	O
,	O
a	O
minor	O
increase	O
(	O
10	O
%	O
)	O
in	O
the	O
clearance	O
of	O
theophylline	B
was	O
seen	O
.	O

Nonetheless	O
,	O
individual	O
patients	O
may	O
require	O
additional	O
titration	O
of	O
their	O
theophylline	B
dosage	O
when	O
lansoprazole	B
is	O
started	O
or	O
stopped	O
to	O
ensure	O
clinically	O
effective	O
blood	O
levels	O
.	O

Lansoprazole	B
has	O
also	O
been	O
shown	O
to	O
have	O
no	O
clinically	O
significant	O
interaction	O
with	O
amoxicillin	B
.	O

In	O
a	O
single	O
-	O
dose	O
crossover	O
study	O
examining	O
lansoprazole	B
30	O
mg	O
and	O
omeprazole	B
20	O
mg	O
each	O
administered	O
alone	O
and	O
concomitantly	O
with	O
sucralfate	B
1	O
gram	O
,	O
absorption	O
of	O
the	O
proton	B
pump	I
inhibitors	I
was	O
delayed	O
and	O
their	O
bioavailability	O
was	O
reduced	O
by	O
17	O
%	O
and	O
16	O
%	O
,	O
respectively	O
,	O
when	O
administered	O
concomitantly	O
with	O
sucralfate	B
.	O

Therefore	O
,	O
proton	B
pump	I
inhibitors	I
should	O
be	O
taken	O
at	O
least	O
30	O
minutes	O
prior	O
to	O
sucralfate	B
.	O

In	O
clinical	O
trials	O
,	O
antacids	B
were	O
administered	O
concomitantly	O
with	O
lansoprazole	B
delayed	O
-	O
release	O
capsules	O
;	O

therefore	O
,	O
it	O
is	O
theoretically	O
possible	O
that	O
lansoprazole	B
may	O
interfere	O
with	O
the	O
absorption	O
of	O
drugs	O
where	O
gastric	O
pH	O
is	O
an	O
important	O
determinant	O
of	O
bioavailability	O
(	O
e	O
.	O
g	O
.	O
ketoconazole	B
,	O
ampicillin	B
esters	O
,	O
iron	B
salts	O
,	O
digoxin	B
)	O
.	O

Effects	O
of	O
Lapatinib	B
on	O
Drug	O
Metabolizing	O
Enzymes	O
and	O
Drug	O
Transport	O
Systems	O
Lapatinib	B
inhibits	O
CYP3A4	O
and	O
CYP2C8	O
in	O
vitro	O
at	O
clinically	O
relevant	O
concentrations	O
.	O

Drugs	O
that	O
Inhibit	O
or	O
Induce	O
Cytochrome	O
P450	O
3A4	O
Enzymes	O
Lapatinib	B
undergoes	O
extensive	O
metabolism	O
by	O
CYP3A4	O
,	O
and	O
concomitant	O
administration	O
of	O
strong	O
inhibitors	O
or	O
inducers	O
of	O
CYP3A4	O
alter	O
lapatinib	B
concentrations	O
significantly	O
.	O

Ketoconazole	B
:	O
In	O
healthy	O
subjects	O
receiving	O
ketoconazole	B
,	O
a	O
CYP3A4	O
inhibitor	O
,	O
at	O
200	O
mg	O
twice	O
daily	O
for	O
7	O
days	O
,	O
systemic	O
exposure	O
(	O
AUC	O
)	O
to	O
lapatinib	B
was	O
increased	O
to	O
approximately	O
3	O
.	O
6	O
-	O
fold	O
of	O
control	O
and	O
half	O
-	O
life	O
increased	O
to	O
1	O
.	O
7	O
-	O
fold	O
of	O
control	O
.	O

Carbamazepine	B
:	O
In	O
healthy	O
subjects	O
receiving	O
the	O
CYP3A4	O
inducer	O
,	O
carbamazepine	B
,	O
at	O
100	O
mg	O
twice	O
daily	O
for	O
3	O
days	O
and	O
200	O
mg	O
twice	O
daily	O
for	O
17	O
days	O
,	O
systemic	O
exposure	O
(	O
AUC	O
)	O
to	O
lapatinib	B
was	O
decreased	O
approximately	O
72	O
%	O
.	O

If	O
TYKERB	B
is	O
administered	O
with	O
drugs	O
that	O
inhibit	O
Pgp	O
,	O
increased	O
concentrations	O
of	O
lapatinib	B
are	O
likely	O
,	O
and	O
caution	O
should	O
be	O
exercised	O
.	O

Other	O
Chemotherapy	O
Agents	O
In	O
a	O
separate	O
study	O
,	O
concomitant	O
administration	O
of	O
lapatinib	B
with	O
capecitabine	B
did	O
not	O
meaningfully	O
alter	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
(	O
or	O
the	O
metabolites	O
of	O
capecitabine	B
)	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
precipitation	O
occurs	O
when	O
eye	O
drops	O
containing	O
thimerosal	B
are	O
mixed	O
with	O
latanoprost	B
.	O

Cholestyramine	B
and	O
Charcoal	B
Administration	O
of	O
cholestyramine	B
or	O
activated	B
charcoal	I
in	O
patients	O
(	O
n	O
=	O
13	O
)	O
and	O
volunteers	O
(	O
n	O
=	O
96	O
)	O
resulted	O
in	O
a	O
rapid	O
and	O
significant	O
decrease	O
in	O
plasma	O
M1	O
(	O
the	O
active	O
metabolite	O
of	O
leflunomide	B
)	O
concentration	O
.	O

In	O
a	O
small	O
(	O
n	O
=	O
30	O
)	O
combination	O
study	O
of	O
ARAVA	B
with	O
methotrexate	B
,	O
a	O
2	O
-	O
to	O
3	O
-	O
fold	O
elevation	O
in	O
liver	O
enzymes	O
was	O
seen	O
in	O
5	O
of	O
30	O
patients	O
.	O

NSAIDs	B
:	O
In	O
in	O
vitro	O
studies	O
,	O
M1	O
was	O
shown	O
to	O
cause	O
increases	O
ranging	O
from	O
13	O
-	O
50	O
%	O
in	O
the	O
free	O
fraction	O
of	O
diclofenac	B
and	O
ibuprofen	B
at	O
concentrations	O
in	O
the	O
clinical	O
range	O
.	O

Tolbutamide	B
:	O
In	O
in	O
vitro	O
studies	O
,	O
M1	O
was	O
shown	O
to	O
cause	O
increases	O
ranging	O
from	O
13	O
-	O
50	O
%	O
in	O
the	O
free	O
fraction	O
of	O
tolbutamide	B
at	O
concentrations	O
in	O
the	O
clinical	O
range	O
.	O

Rifampin	B
:	O
Following	O
concomitant	O
administration	O
of	O
a	O
single	O
dose	O
of	O
ARAVA	B
to	O
subjects	O
receiving	O
multiple	O
doses	O
of	O
rifampin	B
,	O
M1	O
peak	O
levels	O
were	O
increased	O
(	O
~	O
40	O
%	O
)	O
over	O
those	O
seen	O
when	O
ARAVA	B
was	O
given	O
alone	O
.	O

Because	O
of	O
the	O
potential	O
for	O
ARAVA	B
levels	O
to	O
continue	O
to	O
increase	O
with	O
multiple	O
dosing	O
,	O
caution	O
should	O
be	O
used	O
if	O
patients	O
are	O
to	O
be	O
receiving	O
both	O
ARAVA	B
and	O
rifampin	B
.	O

Warfarin	B
:	O
Increased	O
INR	O
(	O
International	O
Normalized	O
Ratio	O
)	O
when	O
ARAVA	B
and	O
warfarin	B
were	O
co	O
-	O
administered	O
has	O
been	O
rarely	O
reported	O
.	O

Results	O
from	O
human	O
in	O
vitro	O
metabolism	O
studies	O
and	O
nonclinical	O
studies	O
show	O
that	O
REVLIMID	B
(	O
lenalidomide	B
)	O
is	O
neither	O
metabolized	O
by	O
nor	O
inhibits	O
or	O
induces	O
the	O
cytochrome	O
P450	O
pathway	O
suggesting	O
that	O
lenalidomide	B
is	O
not	O
likely	O
to	O
cause	O
or	O
be	O
subject	O
to	O
P450	O
-	O
based	O
metabolic	O
drug	O
interactions	O
in	O
man	O
.	O

Co	O
-	O
administration	O
of	O
multiple	O
doses	O
of	O
10	O
mg	O
of	O
lenalidomide	B
had	O
no	O
effect	O
on	O
the	O
single	O
dose	O
pharmacokinetics	O
of	O
R	O
-	O
and	O
S	O
-	O
warfarin	B
.	O

Co	O
-	O
administration	O
of	O
single	O
25	O
-	O
mg	O
dose	O
warfarin	B
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
total	O
lenalidomide	B
.	O

Expected	O
changes	O
in	O
laboratory	O
assessments	O
of	O
PT	O
and	O
INR	O
were	O
observed	O
after	O
warfarin	B
administration	O
,	O
but	O
these	O
changes	O
were	O
not	O
affected	O
by	O
concomitant	O
lenalidomide	B
administration	O
.	O

Concomitant	O
treatment	O
with	O
thrombolytics	B
(	O
eg	O
,	O
rt	O
-	O
PA	O
or	O
streptokinase	B
)	O
may	O
:	O
-	O
increase	O
the	O
risk	O
of	O
bleeding	O
complications	O
-	O
considerably	O
enhance	O
the	O
effect	O
of	O
REFLUDAN	B
on	O
aPTT	O
prolongation	O

Concomitant	O
treatment	O
with	O
coumarin	B
derivatives	I
(	O
vitamin	B
K	I
antagonists	I
)	O
and	O
drugs	O
that	O
affect	O
platelet	O
function	O
may	O
also	O
increase	O
the	O
risk	O
of	O
bleeding	O
.	O

Clinical	O
interaction	O
studies	O
with	O
cimetidine	B
and	O
warfarin	B
indicated	O
that	O
the	O
coadministration	O
of	O
Femara	B
with	O
these	O
drugs	O
does	O
not	O
result	O
in	O
clinically	O
-	O
significant	O
drug	O
interactions	O
.	O

(	O
See	O
CLINICAL	O
PHARMACOLOGY	O
)	O
Coadministration	O
of	O
Femara	B
and	O
tamoxifen	B
20	O
mg	O
daily	O
resulted	O
in	O
a	O
reduction	O
of	O
letrozole	B
plasma	O
levels	O
by	O
38	O
%	O
on	O
average	O
.	O

Folic	B
acid	I
in	O
large	O
amounts	O
may	O
counteract	O
the	O
antiepileptic	O
effect	O
of	O
phenobarbital	B
,	O
phenytoin	B
and	O
primidone	B
,	O
and	O
increase	O
the	O
frequency	O
of	O
seizures	O
in	O
susceptible	O
pediatric	O
patients	O
.	O

Preliminary	O
animal	O
and	O
human	O
studies	O
have	O
shown	O
that	O
small	O
quantities	O
of	O
systemically	O
administered	O
leucovorin	B
enter	O
the	O
CSF	O
primarily	O
as	O
5	O
-	O
methyltetrahydro	O
-	O
folate	O
and	O
,	O
in	O
humans	O
,	O
remain	O
1	O
to	O
3	O
orders	O
of	O
magnitude	O
lower	O
than	O
the	O
usual	O
methotrexate	B
concentrations	O
following	O
intrathecal	O
administration	O
.	O

However	O
,	O
high	O
doses	O
of	O
leucovorin	B
may	O
reduce	O
the	O
efficacy	O
of	O
intrathecally	O
administered	O
methotrexate	B
.	O

Leucovorin	B
may	O
enhance	O
the	O
toxicity	O
of	O
5	O
-	O
fluorouracil	O
.	O

ERGAMISOL	B
(	O
levamisole	B
hydrochloride	I
)	O
has	O
been	O
reported	O
to	O
produce	O
ANTABUSE	O
-	O
like	O
side	O
effects	O
when	O
given	O
concomitantly	O
with	O
alcohol	B
.	O

Because	O
of	O
reports	O
of	O
prolongation	O
of	O
the	O
prothrombin	O
time	O
beyond	O
the	O
therapeutic	O
range	O
in	O
patients	O
taking	O
concurrent	O
levamisole	B
and	O
warfarin	B
sodium	I
,	O
it	O
is	O
suggested	O
that	O
the	O
prothrombin	O
time	O
be	O
monitored	O
carefully	O
,	O
and	O
the	O
dose	O
of	O
warfarin	B
sodium	I
or	O
other	O
coumarin	B
-	O
like	O
drugs	O
should	O
be	O
adjusted	O
accordingly	O
,	O
in	O
patients	O
taking	O
both	O
drugs	O
.	O

In	O
addition	O
,	O
levetiracetam	B
does	O
not	O
affect	O
the	O
in	O
vitro	O
glucuronidation	O
of	O
valproic	B
acid	I
.	O

Potential	O
pharmacokinetic	O
interactions	O
were	O
assessed	O
in	O
clinical	O
pharmacokinetic	O
studies	O
(	O
phenytoin	B
,	O
valproate	B
,	O
oral	O
contraceptive	B
,	O
digoxin	B
,	O
warfarin	B
,	O
probenecid	B
)	O
and	O
through	O
pharmacokinetic	O
screening	O
in	O
the	O
placebo	O
-	O
controlled	O
clinical	O
studies	O
in	O
epilepsy	O
patients	O
.	O

Drug	O
-	O
Drug	O
Interactions	O
Between	O
Keppra	B
And	O
Other	O
Antiepileptic	B
Drugs	I
(	O
AEDs	B
)	O
Phenytoin	B
Keppra	I
(	O
3000	O
mg	O
daily	O
)	O
had	O
no	O
effect	O
on	O
the	O
pharmacokinetic	O
disposition	O
of	O
phenytoin	B
in	O
patients	O
with	O
refractory	O
epilepsy	O
.	O

Pharmacokinetics	O
of	O
levetiracetam	B
were	O
also	O
not	O
affected	O
by	O
phenytoin	B
.	O

Valproate	B
Keppra	I
(	O
1500	O
mg	O
twice	O
daily	O
)	O
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
valproate	B
in	O
healthy	O
volunteers	O
.	O

Valproate	B
500	O
mg	O
twice	O
daily	O
did	O
not	O
modify	O
the	O
rate	O
or	O
extent	O
of	O
levetiracetam	B
absorption	O
or	O
its	O
plasma	O
clearance	O
or	O
urinary	O
excretion	O
.	O

Potential	O
drug	O
interactions	O
between	O
Keppra	B
and	O
other	O
AEDs	B
(	O
carbamazepine	B
,	O
gabapentin	B
,	O
lamotrigine	B
,	O
phenobarbital	B
,	O
phenytoin	B
,	O
primidone	B
and	O
valproate	B
)	O
were	O
also	O
assessed	O
by	O
evaluating	O
the	O
serum	O
concentrations	O
of	O
levetiracetam	B
and	O
these	O
AEDs	B
during	O
placebo	O
-	O
controlled	O
clinical	O
studies	O
.	O

These	O
data	O
indicate	O
that	O
levetiracetam	B
does	O
not	O
influence	O
the	O
plasma	O
concentration	O
of	O
other	O
AEDs	B
and	O
that	O
these	O
AEDs	B
do	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
levetiracetam	B
.	O

Effect	O
of	O
AEDs	B
in	O
Pediatric	O
Patients	O
There	O
was	O
about	O
a	O
22	O
%	O
increase	O
of	O
apparent	O
total	O
body	O
clearance	O
of	O
levetiracetam	B
when	O
it	O
was	O
co	O
-	O
administered	O
with	O
enzyme	O
-	O
inducing	O
AEDs	B
.	O

Dose	O
adjustment	O
is	O
not	O
recommended	O
.	O
Levetiracetam	B
had	O
no	O
effect	O
on	O
plasma	O
concentrations	O
of	O
carbamazepine	B
,	O
valproate	B
,	O
topiramate	B
,	O
or	O
lamotrigine	B
.	O

Other	O
Drug	O
Interactions	O
Oral	O
Contraceptives	B
Keppra	I
(	O
500	O
mg	O
twice	O
daily	O
)	O
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
an	O
oral	O
contraceptive	B
containing	O
0	O
.	O
03	O
mg	O
ethinyl	B
estradiol	I
and	O
0	O
.	O
15	O
mg	O
levonorgestrel	B
,	O
or	O
of	O
the	O
luteinizing	O
hormone	O
and	O
progesterone	O
levels	O
,	O
indicating	O
that	O
impairment	O
of	O
contraceptive	B
efficacy	O
is	O
unlikely	O
.	O

Coadministration	O
of	O
this	O
oral	O
contraceptive	B
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
levetiracetam	B
.	O

Digoxin	B
Keppra	I
(	O
1000	O
mg	O
twice	O
daily	O
)	O
did	O
not	O
influence	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
(	O
ECG	O
)	O
of	O
digoxin	B
given	O
as	O
a	O
0	O
.	O
25	O
mg	O
dose	O
every	O
day	O
.	O

Coadministration	O
of	O
digoxin	B
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
levetiracetam	B
.	O

Warfarin	B
Keppra	I
(	O
1000	O
mg	O
twice	O
daily	O
)	O
did	O
not	O
influence	O
the	O
pharmacokinetics	O
of	O
R	B
and	O
S	B
warfarin	I
.	O

Coadministration	O
of	O
warfarin	B
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
levetiracetam	B
.	O

Probenecid	B
:	O
Probenecid	B
,	O
a	O
renal	O
tubular	O
secretion	O
blocking	O
agent	O
,	O
administered	O
at	O
a	O
dose	O
of	O
500	O
mg	O
four	O
times	O
a	O
day	O
,	O
did	O
not	O
change	O
the	O
pharmacokinetics	O
of	O
levetiracetam	B
1000	O
mg	O
twice	O
daily	O
.	O

The	O
effect	O
of	O
Keppra	B
on	O
probenecid	B
was	O
not	O
studied	O
.	O

Although	O
BETAGAN	B
used	O
alone	O
has	O
little	O
or	O
no	O
effect	O
on	O
pupil	O
size	O
,	O
mydriasis	O
resulting	O
from	O
concomitant	O
therapy	O
with	O
BETAGAN	B
and	O
epinephrine	B
may	O
occur	O
.	O

Close	O
observation	O
of	O
the	O
patient	O
is	O
recommended	O
when	O
a	O
beta	O
-	O
blocker	O
is	O
administered	O
to	O
patients	O
receiving	O
catecholamine	O
-	O
depleting	O
drugs	O
such	O
as	O
reserpine	B
,	O
because	O
of	O
possible	O
additive	O
effects	O
and	O
the	O
production	O
of	O
hypotension	O
and	O
/	O
or	O
marked	O
bradycardia	O
,	O
which	O
may	O
produce	O
vertigo	O
,	O
syncope	O
or	O
postural	O
hypotension	O
.	O

Patients	O
receiving	O
beta	O
-	O
adrenergic	O
blocking	B
agents	I
along	O
with	O
either	O
oral	O
or	O
intravenous	O
calcium	B
antagonists	I
should	O
be	O
monitored	O
for	O
possible	O
atrioventricular	O
conduction	O
disturbances	O
,	O
left	O
ventricular	O
failure	O
and	O
hypotension	O
.	O

The	O
concomitant	O
use	O
of	O
beta	O
-	O
adrenergic	O
blocking	B
agents	I
with	O
digitalis	B
and	O
calcium	B
antagonists	O
may	O
have	O
additive	O
effects	O
on	O
prolonging	O
atrioventricular	O
conduction	O
time	O
.	O

Phenothiazine	O
-	O
related	O
compounds	B
and	O
beta	O
-	O
adrenergic	O
blocking	B
agents	I
may	O
have	O
additive	O
hypotensite	O
effects	O
due	O
to	O
the	O
inhibition	O
of	O
each	O
other	O
s	O
metabolism	O
.	O

Chirocaine	B
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
receiving	O
other	O
local	O
anesthetics	B
or	O
agents	O
structurally	O
related	O
to	O
amide	O
-	O
type	O
local	O
anesthetics	B
since	O
the	O
toxic	O
effects	O
of	O
these	O
drugs	O
could	O
be	O
additive	O
.	O

In	O
vitro	O
studies	O
indicate	O
CYP3A4	O
isoform	O
and	O
CYP1A2	O
isoform	O
mediate	O
the	O
metabolism	O
of	O
levobupivacaine	B
to	O
desbutyl	B
levobupivacaine	I
and	O
3	O
-	O
hydroxy	O
levobupivacaine	B
,	O
respectively	O
.	O

Thus	O
agents	O
likely	O
to	O
be	O
concomitantly	O
administered	O
with	O
Chirocaine	B
that	O
are	O
metabolized	O
by	O
this	O
isoenzyme	O
family	O
may	O
potentially	O
interact	O
with	O
Chirocaine	B
.	O

Although	O
no	O
clinical	O
studies	O
have	O
been	O
conducted	O
,	O
it	O
is	O
likely	O
that	O
the	O
metabolism	O
of	O
levobupivacaine	B
may	O
be	O
affected	O
by	O
the	O
known	O
CYP3A4	O
inducers	O
(	O
such	O
as	O
phenytoin	B
,	O
phenobarbital	B
,	O
rifampin	B
)	O
,	O
CYP3A4	O
inhibitors	O
(	O
azole	O
antimycotics	O
e	O
.	O
g	O
.	O
,	O
ketoconazole	B
;	O

macrolide	B
antibiotics	I
e	O
.	O
g	O
.	O
,	O
erythromycin	B
;	O

and	O
calcium	B
channel	I
antagonists	I
e	O
.	O
g	O
.	O
,	O
verapamil	B
)	O
,	O
CYP1A2	O
inducers	O
(	O
omeprazole	B
)	O
and	O
CYP1A2	O
inhibitors	O
(	O
furafylline	B
and	O
clarithromycin	B
)	O
.	O

Dosage	O
adjustment	O
may	O
be	O
warranted	O
when	O
levobupivacaine	B
is	O
concurrently	O
administered	O
with	O
CYP3A4	O
inhibitors	O
and	O
CYP1A2	O
inhibitors	O
as	O
systemic	O
levobupivacaine	B
levels	O
may	O
rise	O
resulting	O
in	O
toxicity	O
.	O

However	O
,	O
the	O
systemic	O
administration	O
of	O
some	O
quinolones	B
has	O
been	O
shown	O
to	O
elevate	O
plasma	O
concentrations	O
of	O
theophylline	B
,	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	B
,	O
and	O
enhance	O
the	O
effects	O
of	O
the	O
oral	O
anticoagulant	B
warfarin	I
and	O
its	O
derivatives	O
,	O
and	O
has	O
been	O
associated	O
with	O
transient	O
elevations	O
in	O
serum	O
creatinine	O
in	O
patients	O
receiving	O
systemic	O
cyclosporine	B
concomitantly	O
.	O

Interactions	O
with	O
Other	O
CNS	O
Agents	O
:	O
Concurrent	O
use	O
of	O
Levo	O
-	O
Dromoran	O
with	O
all	O
central	B
nervous	I
system	I
depressants	I
(	O
eg	O
,	O
alcohol	B
,	O
sedatives	B
,	O
hypnotics	B
,	O
other	O
opioids	B
,	O
general	O
anesthetics	B
,	O
barbiturates	B
,	O
tricyclic	B
antidepressants	I
,	O
phenothiazines	B
,	O
tranquilizers	B
,	O
skeletal	B
muscle	I
relaxants	I
and	O
antihistamines	B
)	O
may	O
result	O
in	O
additive	O
central	B
nervous	I
system	I
depressant	O
effects	O
.	O

Although	O
no	O
interaction	O
between	O
MAO	B
inhibitors	I
and	O
Levo	O
-	O
Dromoran	O
has	O
been	O
observed	O
,	O
it	O
is	O
not	O
recommended	O
for	O
use	O
with	O
MAO	B
inhibitors	I
.	O

Most	O
cases	O
of	O
serious	O
or	O
fatal	O
adverse	O
events	O
involving	O
Levo	O
-	O
Dromoran	O
reported	O
to	O
the	O
manufacturer	O
or	O
the	O
FDA	O
have	O
involved	O
either	O
the	O
administration	O
of	O
large	O
initial	O
doses	O
or	O
too	O
frequent	O
doses	O
of	O
the	O
drug	O
to	O
nonopioid	O
tolerant	O
patients	O
,	O
or	O
the	O
simultaneous	O
administration	O
of	O
levorphanol	B
with	O
other	O
drugs	O
affecting	O
respiration	O
.	O

Interactions	O
with	O
Mixed	B
Agonist	O
/	O
Antagonist	O
Opioid	B
Analgesics	I
:	O
Agonist	O
/	O
antagonist	O
analgesics	B
(	O
eg	O
,	O
pentazocine	B
,	O
nalbuphine	B
,	O
butorphanol	B
,	O
dezocine	B
and	O
buprenorphine	B
)	O
should	O
NOT	O
be	O
administered	O
to	O
a	O
patient	O
who	O
has	O
received	O
or	O
is	O
receiving	O
a	O
course	O
of	O
therapy	O
with	O
a	O
pure	B
agonist	I
opioid	I
analgesic	I
such	O
as	O
Levo	O
-	O
Dromoran	O
.	O

In	O
opioid	B
-	O
dependent	O
patients	O
,	O
mixed	B
agonist	O
/	O
antagonist	O
analgesics	B
may	O
precipitate	O
withdrawal	O
symptoms	O
.	O

No	O
Important	O
Interactions	O
To	O
Date	O
Levosimendan	B
does	O
not	O
have	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
with	O
captopril	B
,	O
beta	O
-	O
blockers	O
,	O
felodipine	B
,	O
digoxin	B
,	O
warfarin	B
,	O
isosorbide	B
mononitrate	I
,	O
carvedilol	B
,	O
ethanol	B
or	O
itraconazole	B
.	O

Levothyroxine	B
Sodium	I
Absorption	O
:	O
The	O
following	O
agents	O
may	O
bind	O
and	O
decrease	O
absorption	O
of	O
levothyroxine	B
sodium	I
from	O
the	O
gastrointestinal	O
tract	O
:	O
aluminum	B
hydoxide	I
,	O
cholestyramine	B
resin	O
,	O
colestipol	B
hydrochloride	I
,	O
ferrous	B
sulfate	I
,	O
sodium	B
polystyrene	I
sulfonate	I
,	O
soybean	O
flour	O
(	O
e	O
.	O
g	O
.	O
,	O
infant	O
formula	O
)	O
,	O
sucralfate	B
.	O

Binding	O
to	O
Serum	O
Proteins	O
:	O
The	O
following	O
agents	O
may	O
either	O
inhibit	O
levothyroxine	B
sodium	I
binding	O
to	O
serum	O
proteins	O
or	O
alter	O
the	O
concentrations	O
of	O
serum	O
binding	O
proteins	O
:	O
androgens	B
and	O
related	O
anabolic	B
hormones	I
,	O
asparaginase	B
,	O
clofibrate	B
,	O
estrogens	B
and	O
estrogen	O
-	O
containing	O
compounds	B
,	O
5	O
-	O
fluorouracil	O
,	O
furosemide	B
,	O
glucocorticoids	B
,	O
meclofenamic	B
acid	I
,	O
mefenamic	B
acid	I
,	O
methadone	B
,	O
perphenazine	B
,	O
phenylbutazone	B
,	O
phenytoin	B
,	O
salicylates	B
,	O
tamoxifen	B
.	O

Thyroid	O
Physiology	O
:	O
The	O
following	O
agents	B
may	O
alter	O
thyroid	O
hormone	O
or	O
TSH	O
levels	O
,	O
generally	O
by	O
effects	O
on	O
thyroid	O
hormone	O
synthesis	O
,	O
secretion	O
,	O
distribution	O
,	O
metabolism	O
,	O
hormone	O
action	O
,	O
or	O
elimination	O
,	O
or	O
altered	O
TSH	O
secretion	O
:	O
aminoglutethimide	B
,	O
p	O
-	O
aminosalicylic	O
acid	B
,	O
amiodarone	B
,	O
androgens	B
and	O
related	O
anabolic	O
hormones	O
,	O
complex	O
anions	O
(	O
thiocyanate	B
,	O
perchlorate	B
,	O
pertechnetate	B
)	O
,	O
antithyroid	B
drugs	I
,	O
b	O
-	O
adrenergic	O
blocking	B
agents	I
,	O
carbamazepine	B
,	O
chloral	B
hydrate	I
,	O
diazepam	B
,	O
dopamine	B
and	O
dopamine	B
agonists	I
,	O
ethionamide	B
,	O
glucocorticoids	B
,	O
heparin	B
,	O
hepatic	O
enzyme	O
inducers	O
,	O
insulin	B
,	O
iodinated	O
cholestographic	O
agents	B
,	O
iodine	O
-	O
containing	O
compounds	B
,	O
levodopa	B
,	O
lovastatin	B
,	O
lithium	B
,	O
6	O
-	O
mercaptopurine	O
,	O
metoclopramide	B
,	O
mitotane	B
,	O
nitroprusside	B
,	O
phenobarbital	B
,	O
phenytoin	B
,	O
resorcinol	B
,	O
rifampin	B
,	O
somatostatin	B
analogs	I
,	O
sulfonamides	B
,	O
sulfonylureas	B
,	O
thiazide	B
diuretics	I
.	O

Amiodarone	B
:	O
Amiodarone	B
therapy	O
alone	O
can	O
cause	O
hypothyroidism	O
or	O
hyperthyroidism	O
.	O

Anticoagulants	B
(	O
Oral	O
)	O
:	O
The	O
hypoprothrombinemic	O
effect	O
of	O
anticoagulants	B
may	O
be	O
potentiated	O
,	O
apparently	O
by	O
increased	O
catabloism	O
of	O
vitamin	O
K	O
-	O
dependent	O
clotting	O
factors	O
.	O

Antidiabetic	B
Agents	I
(	O
Insulin	B
,	O
Sulfonylureas	B
)	O
:	O
Requirements	O
for	O
insulin	B
or	O
oral	O
antidiabetic	B
agents	I
may	O
be	O
reduced	O
in	O
hypothyroid	O
patients	O
with	O
diabetes	O
mellitus	O
and	O
may	O
subsequently	O
increase	O
with	O
the	O
initiation	O
of	O
thyroid	O
hormone	O
replacement	O
therapy	O
.	O

b	O
-	O
Adrenergic	O
Blocking	B
Agents	I
:	O
Actions	O
of	O
some	O
of	O
beta	O
-	O
blocking	O
agents	B
may	O
be	O
impaired	O
when	O
hypothyroid	O
patients	O
become	O
euthyroid	O
.	O

Cytokines	B
(	O
interferon	B
,	O
interleukin	B
)	O
:	O
Cytokines	B
have	O
been	O
reported	O
to	O
induce	O
both	O
hyperthyroidism	O
and	O
hypothyroidism	O
.	O

Digitalis	B
Glycosides	I
:	O
Therapeutic	O
effects	O
of	O
digitalis	B
glycosides	I
may	O
be	O
reduced	O
.	O

Ketamine	B
:	O
Marked	O
hypertension	O
and	O
tachycardia	O
have	O
been	O
reported	O
in	O
association	O
with	O
concomitant	O
administration	O
of	O
levothyroxine	B
sodium	I
and	O
ketamine	B
.	O

Sodium	B
Iodide	I
(	O
123I	O
and	O
131I	O
)	O
,	O
Sodium	B
Pertechnetate	I
Tc99m	I
:	O
Uptake	O
of	O
radiolabeled	O
ions	O
may	O
be	O
decreased	O
.	O

Somatrem	B
/	O
Somatropin	B
:	O
Excessive	O
concurrent	O
use	O
of	O
thyroid	B
hormone	I
may	O
accelerate	O
epiphyseal	O
closure	O
.	O

Untreated	O
hypothyroidism	O
may	O
interfere	O
with	O
the	O
growth	O
response	O
to	O
somatrem	B
or	O
somatropin	B
.	O

Theophylline	B
:	O
Theophylline	B
clearance	O
may	O
decrease	O
in	O
hypothyroid	O
patients	O
and	O
return	O
toward	O
normal	O
when	O
a	O
euthyroid	O
state	O
is	O
achieved	O
.	O

The	O
administration	O
of	O
local	O
anesthetic	B
solutions	I
containing	O
epinephrine	B
or	O
norepinephrine	B
to	O
patients	O
receiving	O
monoamine	B
oxidase	I
inhibitors	I
or	O
tricyclic	B
antidepressants	I
may	O
produce	O
severe	O
,	O
prolonged	O
hypertension	O
.	O

Phenothiazines	B
and	O
butyrophenones	B
may	O
reduce	O
or	O
reverse	O
the	O
pressor	O
effect	O
of	O
epinephrine	B
.	O

Concurrent	O
administration	O
of	O
vasopressor	B
drugs	I
(	O
for	O
the	O
treatment	O
of	O
hypotension	O
related	O
to	O
obstetric	O
blocks	O
)	O
and	O
ergot	O
-	O
type	O
oxytocic	B
drugs	I
may	O
cause	O
severe	O
,	O
persistent	O
hypertension	O
or	O
cerebrovascular	O
accidents	O
.	O

Lincomycin	B
has	O
been	O
shown	O
to	O
have	O
neuromuscular	B
blocking	I
properties	O
that	O
may	O
enhance	O
the	O
action	O
of	O
other	O
neuromuscular	B
blocking	I
agents	I
.	O

Antagonism	O
between	O
lincomycin	B
and	O
erythromycin	B
in	O
vitro	O
has	O
been	O
demonstrated	O
.	O

Therefore	O
,	O
linezolid	B
has	O
the	O
potential	O
for	O
interaction	O
with	O
adrenergic	B
and	O
serotonergic	B
agents	I
.	O

Adrenergic	B
Agents	I
:	O
Some	O
individuals	O
receiving	O
ZYVOX	B
may	O
experience	O
a	O
reversible	O
enhancement	O
of	O
the	O
pressor	O
response	O
to	O
indirect	O
-	O
acting	O
sympathomimetic	B
agents	I
,	O
vasopressor	B
or	O
dopaminergic	B
agents	I
.	O

Commonly	O
used	O
drugs	O
such	O
as	O
phenylpropanolamine	B
and	O
pseudoephedrine	B
have	O
been	O
specifically	O
studied	O
.	O

Initial	O
doses	O
of	O
adrenergic	B
agents	I
,	O
such	O
as	O
dopamine	B
or	O
epinephrine	B
,	O
should	O
be	O
reduced	O
and	O
titrated	O
to	O
achieve	O
the	O
desired	O
response	O
.	O

Serotonergic	B
Agents	I
:	O
Co	O
-	O
administration	O
of	O
linezolid	B
and	O
serotonergic	B
agents	I
was	O
not	O
associated	O
with	O
serotonin	O
syndrome	O
in	O
Phase	O
1	O
,	O
2	O
or	O
3	O
studies	O
.	O

Spontaneous	O
reports	O
of	O
serotonin	B
syndrome	O
associated	O
with	O
co	O
-	O
administration	O
of	O
ZYVOX	B
and	O
serotonergic	B
agents	I
,	O
including	O
antidepressants	B
such	O
as	O
selective	B
serotonin	I
reuptake	I
inhibitors	I
(	O
SSRIs	B
)	O
,	O
have	O
been	O
reported	O
.	O

Patients	O
who	O
are	O
treated	O
with	O
ZYVOX	B
and	O
concomitant	O
serotonergic	B
agents	I
should	O
be	O
closely	O
observed	O
for	O
signs	O
and	O
symptoms	O
of	O
serotonin	O
syndrome	O
(	O
e	O
.	O
g	O
.	O
,	O
cognitive	O
dysfunction	O
,	O
hyperpyrexia	O
,	O
hyperreflexia	O
,	O
incoordination	O
)	O
.	O

If	O
any	O
signs	O
or	O
symptoms	O
occur	O
physicians	O
should	O
consider	O
discontinuation	O
of	O
either	O
one	O
or	O
both	O
agents	B
(	O
ZYVOX	B
or	O
concomitant	O
serotonergic	B
agents	I
)	O
.	O

Oral	O
Anticoagulants	B
:	O
Thyroid	B
hormones	I
appear	O
to	O
increase	O
catabolism	O
of	O
vitamin	O
K	O
-	O
dependent	O
clotting	O
factors	O
.	O

Patients	O
stabilized	O
on	O
oral	O
anticoagulants	B
who	O
are	O
found	O
to	O
require	O
thyroid	B
replacement	O
therapy	O
should	O
be	O
watched	O
very	O
closely	O
when	O
thyroid	B
is	O
started	O
.	O

Insulin	B
or	O
Oral	O
Hypoglycemics	B
:	O
Initiating	O
thyroid	O
replacement	O
therapy	O
may	O
cause	O
increases	O
in	O
insulin	B
or	O
oral	O
hypoglycemic	B
requirements	O
.	O

Patients	O
receiving	O
insulin	B
or	O
oral	O
hypoglycemics	B
should	O
be	O
closely	O
watched	O
during	O
initiation	O
of	O
thyroid	O
replacement	O
therapy	O
.	O

Cholestyramine	B
:	O
Cholestyramine	B
binds	O
both	O
T4	B
and	O
T3	B
in	O
the	O
intestine	O
,	O
thus	O
impairing	O
absorption	O
of	O
these	O
thyroid	B
hormones	I
.	O

Therefore	O
,	O
4	O
to	O
5	O
hours	O
should	O
elapse	O
between	O
administration	O
of	O
cholestyramine	B
and	O
thyroid	B
hormones	I
.	O

Estrogen	B
,	O
Oral	O
Contraceptives	B
:	O
Estrogens	B
tend	O
to	O
increase	O
serum	O
thyroxine	O
-	O
binding	O
globulin	O
(	O
TBg	O
)	O
.	O

In	O
a	O
patient	O
with	O
a	O
nonfunctioning	O
thyroid	B
gland	O
who	O
is	O
receiving	O
thyroid	B
replacement	O
therapy	O
,	O
free	O
levothyroxine	B
may	O
be	O
decreased	O
when	O
estrogens	B
are	O
started	O
thus	O
increasing	O
thyroid	B
requirements	O
.	O

Therefore	O
,	O
patients	O
without	O
a	O
functioning	O
thyroid	B
gland	O
who	O
are	O
on	O
thyroid	B
replacement	O
therapy	O
may	O
need	O
to	O
increase	O
their	O
thyroid	B
dose	O
if	O
estrogens	B
or	O
estrogen	B
-	O
containing	O
oral	O
contraceptives	B
are	O
given	O
.	O

Tricyclic	B
Antidepressants	I
:	O
Use	O
of	O
thyroid	B
products	I
with	O
imipramine	B
and	O
other	O
tricyclic	B
antidepressants	I
may	O
increase	O
receptor	O
sensitivity	O
and	O
enhance	O
antidepressant	O
activity	O
transient	O
cardiac	O
arrhythmias	O
have	O
been	O
observed	O
.	O

Digitalis	B
:	O
Thyroid	B
preparations	I
may	O
potentiate	O
the	O
toxic	O
effects	O
of	O
digitalis	B
.	O

Ketamine	B
:	O
When	O
administered	O
to	O
patients	O
on	O
a	O
thyroid	B
preparation	I
,	O
this	O
parenteral	O
anesthetic	B
may	O
cause	O
hypertension	O
and	O
tachycardia	O
.	O

Vasopressors	O
:	O
Thyroxine	B
increases	O
the	O
adrenergic	O
effect	O
of	O
catecholamines	O
such	O
as	O
epinephrine	B
and	O
norepinephrine	B
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
The	O
following	O
drugs	O
or	O
moieties	O
are	O
known	O
to	O
interfere	O
with	O
laboratory	O
tests	O
performed	O
in	O
patients	O
on	O
thyroid	B
hormone	I
therapy	O
:	O
androgens	B
,	O
corticosteroids	B
,	O
estrogens	B
,	O
oral	O
contraceptives	B
containing	O
estrogens	B
,	O
iodine	B
-	O
containing	O
preparations	O
and	O
the	O
numerous	O
preparations	O
containing	O
salicylates	B
.	O

Pregnancy	O
estrogens	B
and	O
estrogen	B
-	O
containing	O
oral	O
contraceptives	B
increase	O
TBg	O
concentrations	O
.	O

Decreases	O
in	O
TBg	O
concentrations	O
are	O
observed	O
in	O
nephrosis	O
,	O
acromegaly	O
and	O
after	O
androgen	B
or	O
corticosteroid	B
therapy	O
.	O

Urinary	O
acidifying	O
agents	O
These	O
agents	O
(	O
ammonium	B
chloride	I
,	O
sodium	B
acid	I
phosphate	I
,	O
etc	O
.	O
)	O
increase	O
the	O
concentration	O
of	O
the	O
ionized	O
species	O
of	O
the	O
amphetamine	B
molecule	O
,	O
thereby	O
increasing	O
urinary	O
excretion	O
.	O

Adrenergic	B
blockers	I
Adrenergic	I
blockers	I
are	O
inhibited	O
by	O
amphetamines	B
.	O

Antidepressants	B
,	O
tricyclic	B
Amphetamines	I
may	O
enhance	O
the	O
activity	O
of	O
tricyclic	B
antidepressants	I
or	O
sympathomimetic	B
agents	I
;	O

d	O
-	O
amphetamine	O
with	O
desipramine	B
or	O
protriptyline	B
and	O
possibly	O
other	O
tricyclics	B
cause	O
striking	O
and	O
sustained	O
increases	O
in	O
the	O
concentration	O
of	O
d	O
-	O
amphetamine	O
in	O
the	O
brain	O
;	O

MAO	B
inhibitors	I
MAOI	I
antidepressants	I
,	O
as	O
well	O
as	O
a	O
metabolite	O
of	O
furazolidone	B
,	O
slow	O
amphetamine	B
metabolism	O
.	O

Antihistamines	B
:	O
Amphetamines	B
may	O
counteract	O
the	O
sedative	O
effect	O
of	O
antihistamines	B
.	O

Antihypertensives	B
:	O
Amphetamines	B
may	O
antagonize	O
the	O
hypotensive	O
effects	O
of	O
antihypertensives	B
.	O

Chlorpromazine	B
:	O
Chlorpromazine	B
blocks	O
dopamine	O
and	O
norepinephrine	O
receptors	O
,	O
thus	O
inhibiting	O
the	O
central	O
stimulant	O
effects	O
of	O
amphetamines	B
and	O
can	O
be	O
used	O
to	O
treat	O
amphetamine	B
poisoning	O
.	O

Ethosuximide	B
:	O
Amphetamines	B
may	O
delay	O
intestinal	O
absorption	O
of	O
ethosuximide	B
.	O

Haloperidol	B
:	O
Haloperidol	B
blocks	O
dopamine	O
receptors	O
,	O
thus	O
inhibiting	O
the	O
central	O
stimulant	O
effects	O
of	O
amphetamines	B
.	O

Lithium	B
carbonate	I
:	O
The	O
anorectic	O
and	O
stimulatory	O
effects	O
of	O
amphetamines	B
may	O
be	O
inhibited	O
by	O
lithium	B
carbonate	I
.	O

Meperidine	B
:	O
Amphetamines	B
potentiate	O
the	O
analgesic	O
effect	O
of	O
meperidine	B
.	O

Methenamine	B
therapy	O
Urinary	O
excretion	O
of	O
amphetamines	B
is	O
increased	O
,	O
and	O
efficacy	O
is	O
reduced	O
by	O
acidifying	O
agents	O
used	O
in	O
methenamine	B
therapy	O
.	O

Norepinephrine	B
:	O
Amphetamines	B
enhance	O
the	O
adrenergic	O
effect	O
of	O
norepinephrine	B
.	O

Phenobarbital	B
:	O
Amphetamines	B
may	O
delay	O
intestinal	O
absorption	O
of	O
phenobarbital	B
;	O

Phenytoin	B
:	O
Amphetamines	B
may	O
delay	O
intestinal	O
absorption	O
of	O
phenytoin	B
;	O

Propoxyphene	B
:	O
In	O
cases	O
of	O
propoxyphene	B
overdosage	O
,	O
amphetamine	B
CNS	O
stimulation	O
is	O
potentiated	O
and	O
fatal	O
convulsions	O
can	O
occur	O
.	O

Veratrum	B
alkaloids	I
:	O
Amphetamines	B
inhibit	O
the	O
hypotensive	O
effect	O
of	O
veratrum	B
alkaloids	I
.	O

Hypotension	O
-	O
Patients	O
on	O
Diuretic	O
Therapy	O
:	O
Patients	O
on	O
diuretics	B
,	O
and	O
especially	O
those	O
in	O
whom	O
diuretic	O
therapy	O
was	O
recently	O
instituted	O
,	O
may	O
occasionally	O
experience	O
an	O
excessive	O
reduction	O
of	O
blood	O
pressure	O
after	O
initiation	O
of	O
therapy	O
with	O
PRINIVIL	B
.	O

The	O
possibility	O
of	O
hypotensive	O
effects	O
with	O
PRINIVIL	B
can	O
be	O
minimized	O
by	O
either	O
discontinuing	O
the	O
diuretic	B
or	O
increasing	O
the	O
salt	O
intake	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
PRINIVIL	B
.	O

If	O
it	O
is	O
necessary	O
to	O
continue	O
the	O
diuretic	B
,	O
initiate	O
therapy	O
with	O
PRINIVIL	B
at	O
a	O
dose	O
of	O
5	O
mg	O
daily	O
,	O
and	O
provide	O
close	O
medical	O
supervision	O
after	O
the	O
initial	O
dose	O
until	O
blood	O
pressure	O
has	O
stabilized	O
.	O

When	O
a	O
diuretic	B
is	O
added	O
to	O
the	O
therapy	O
of	O
a	O
patient	O
receiving	O
PRINIVIL	B
,	O
an	O
additional	O
antihypertensive	O
effect	O
is	O
usually	O
observed	O
.	O

Studies	O
with	O
ACE	B
inhibitors	I
in	O
combination	O
with	O
diuretics	B
indicate	O
that	O
the	O
dose	O
of	O
the	O
ACE	B
inhibitor	I
can	O
be	O
reduced	O
when	O
it	O
is	O
given	O
with	O
a	O
diuretic	B
.	O

Non	O
-	O
steroidal	O
Anti	O
-	O
inflammatory	O
Agents	B
:	O
In	O
some	O
patients	O
with	O
compromised	O
renal	O
function	O
who	O
are	O
being	O
treated	O
with	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	B
,	O
the	O
co	O
-	O
administration	O
of	O
lisinopril	B
may	O
result	O
in	O
a	O
further	O
deterioration	O
of	O
renal	O
function	O
.	O

Reports	O
suggest	O
that	O
NSAIDs	B
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
ACE	B
inhibitors	I
,	O
including	O
lisinopril	B
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	B
concomitantly	O
with	O
ACE	B
inhibitors	I
.	O

In	O
a	O
study	O
in	O
36	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	O
where	O
the	O
antihypertensive	O
effects	O
of	O
PRINIVIL	B
alone	O
were	O
compared	O
to	O
PRINIVIL	B
given	O
concomitantly	O
with	O
indomethacin	B
,	O
the	O
use	O
of	O
indomethacin	B
was	O
associated	O
with	O
a	O
reduced	O
antihypertensive	O
effect	O
,	O
although	O
the	O
difference	O
between	O
the	O
two	O
regimens	O
was	O
not	O
significant	O
.	O

Other	O
Agents	O
:	O
PRINIVIL	B
has	O
been	O
used	O
concomitantly	O
with	O
nitrates	B
and	O
/	O
or	O
digoxin	B
without	O
evidence	O
of	O
clinically	O
significant	O
adverse	O
interactions	O
.	O

No	O
clinically	O
important	O
pharmacokinetic	O
interactions	O
occurred	O
when	O
PRINIVIL	B
was	O
used	O
concomitantly	O
with	O
propranolol	B
or	O
hydrochlorothiazide	B
.	O

Agents	O
Increasing	O
Serum	O
Potassium	O
:	O
PRINIVIL	B
attenuates	O
potassium	O
loss	O
caused	O
by	O
thiazide	O
-	O
type	O
diuretics	B
.	O

Use	O
of	O
PRINIVIL	B
with	O
potassium	B
-	O
sparing	O
diuretics	B
(	O
e	O
.	O
g	O
.	O
,	O
spironolactone	B
,	O
triamterene	B
,	O
or	O
amiloride	B
)	O
,	O
potassium	B
supplements	O
,	O
or	O
potassium	B
-	O
containing	O
salt	O
substitutes	O
may	O
lead	O
to	O
significant	O
increases	O
in	O
serum	O
potassium	B
.	O

Lithium	B
:	O
Lithium	B
toxicity	O
has	O
been	O
reported	O
in	O
patients	O
receiving	O
lithium	B
concomitantly	O
with	O
drugs	O
which	O
cause	O
elimination	O
of	O
sodium	O
,	O
including	O
ACE	B
inhibitors	I
.	O

Lithium	B
toxicity	O
was	O
usually	O
reversible	O
upon	O
discontinuation	O
of	O
lithium	B
and	O
the	O
ACE	B
inhibitor	I
.	O

It	O
is	O
recommended	O
that	O
serum	O
lithium	B
levels	O
be	O
monitored	O
frequently	O
if	O
PRINIVIL	B
is	O
administered	O
concomitantly	O
with	O
lithium	B
.	O

-	O
Lofexidine	B
may	O
enhance	O
the	O
CNS	O
depressive	O
effects	O
of	O
alcohol	B
,	O
barbiturates	B
and	O
other	O
sedatives	B

-	O
Lofexidine	B
may	O
enhance	O
the	O
effects	O
of	O
anti	O
-	O
hypertensive	O
drug	B
therapy	O

-	O
Concomitant	O
use	O
of	O
tricyclic	B
antidepressants	I
may	O
reduce	O
the	O
efficacy	O
of	O
lofexidine	B
.	O

Theophylline	B
:	O
In	O
three	O
pharmacokinetic	O
studies	O
including	O
46	O
normal	O
,	O
healthy	O
subjects	O
,	O
theophylline	B
clearance	O
and	O
concentration	O
were	O
not	O
significantly	O
altered	O
by	O
the	O
addition	O
of	O
lomefloxacin	B
.	O

In	O
clinical	O
studies	O
where	O
patients	O
were	O
on	O
chronic	O
theophylline	B
therapy	O
,	O
lomefloxacin	B
had	O
no	O
measurable	O
effect	O
on	O
the	O
mean	O
distribution	O
of	O
theophylline	B
concentrations	O
or	O
the	O
mean	O
estimates	O
of	O
theophylline	B
clearance	O
.	O

Antacids	B
and	O
sucralfate	B
:	O
Sucralfate	B
and	O
antacids	B
containing	O
magnesium	B
or	O
aluminum	B
,	O
as	O
well	O
as	O
formulations	O
containing	O
divalent	O
and	O
trivalent	O
cations	O
such	O
as	O
Videx	B
(	O
didanosine	B
)	O
,	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
can	O
form	O
chelation	O
complexes	O
with	O
lomefloxacin	B
and	O
interfere	O
with	O
its	O
bioavailability	O
.	O

Sucralfate	B
administered	O
2	O
hours	O
before	O
lomefloxacin	B
resulted	O
in	O
a	O
slower	O
absorption	O
(	O
mean	O
C	O
max	O
decreased	O
by	O
30	O
%	O
and	O
mean	O
T	O
max	O
increased	O
by	O
1	O
hour	O
)	O
and	O
a	O
lesser	O
extent	O
of	O
absorption	O
(	O
mean	O
AUC	O
decreased	O
by	O
approximately	O
25	O
%	O
)	O
.	O

Magnesium	B
-	O
and	O
aluminum	B
-	O
containing	O
antacids	B
,	O
administered	O
concomitantly	O
with	O
lomefloxacin	B
,	O
significantly	O
decreased	O
the	O
bioavailability	O
(	O
48	O
%	O
)	O
of	O
lomefloxacin	B
.	O

Separating	O
the	O
doses	O
of	O
antacid	B
and	O
lomefloxacin	B
minimizes	O
this	O
decrease	O
in	O
bioavailability	O
;	O

therefore	O
,	O
administration	O
of	O
these	O
agents	O
should	O
precede	O
lomefloxacin	B
dosing	O
by	O
4	O
hours	O
or	O
follow	O
lomefloxacin	B
dosing	O
by	O
at	O
least	O
2	O
hours	O
.	O

Caffeine	B
:	O
Two	O
hundred	O
mg	O
of	O
caffeine	B
(	O
equivalent	O
to	O
1	O
to	O
3	O
cups	O
of	O
American	O
coffee	O
)	O
was	O
administered	O
to	O
16	O
normal	O
,	O
healthy	O
volunteers	O
who	O
had	O
achieved	O
steady	O
-	O
state	O
blood	O
concentrations	O
of	O
lomefloxacin	B
after	O
being	O
dosed	O
at	O
400	O
mg	O
qd	O
.	O

This	O
did	O
not	O
result	O
in	O
any	O
statistically	O
or	O
clinically	O
relevant	O
changes	O
in	O
the	O
pharmacokinetic	O
parameters	O
of	O
either	O
caffeine	B
or	O
its	O
major	O
metabolite	O
,	O
paraxanthine	B
.	O

Other	O
quinolones	B
have	O
demonstrated	O
moderate	O
to	O
marked	O
interference	O
with	O
the	O
metabolism	O
of	O
caffeine	B
,	O
resulting	O
in	O
a	O
reduced	O
clearance	O
,	O
a	O
prolongation	O
of	O
plasma	O
half	O
-	O
life	O
,	O
and	O
an	O
increase	O
in	O
symptoms	O
that	O
accompany	O
high	O
levels	O
of	O
caffeine	B
.	O

Cimetidine	B
:	O
Cimetidine	B
has	O
been	O
demonstrated	O
to	O
interfere	O
with	O
the	O
elimination	O
of	O
other	O
quinolones	B
.	O

The	O
interaction	O
between	O
lomefloxacin	B
and	O
cimetidine	B
has	O
not	O
been	O
studied	O
.	O

Cyclosporine	B
:	O
Elevated	O
serum	O
levels	O
of	O
cyclosporine	B
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
cyclosporine	B
with	O
other	O
members	O
of	O
the	O
quinolone	B
class	I
.	O

Interaction	O
between	O
lomefloxacin	B
and	O
cyclosporine	B
has	O
not	O
been	O
studied	O
.	O

Omeprazole	B
:	O
No	O
clinically	O
significant	O
changes	O
in	O
lomefloxacin	B
pharmacokinetics	O
(	O
AUC	O
,	O
C	O
max	O
,	O
or	O
T	O
max	O
)	O
were	O
observed	O
when	O
a	O
single	O
dose	O
of	O
lomefloxacin	B
400	O
mg	O
was	O
given	O
after	O
multiple	O
doses	O
of	O
omeprazole	B
(	O
20	O
mg	O
qd	O
)	O
in	O
13	O
healthy	O
volunteers	O
.	O

Phenytoin	B
:	O
No	O
significant	O
differences	O
were	O
observed	O
in	O
mean	O
phenytoin	B
AUC	O
,	O
C	O
max	O
,	O
C	O
min	O
or	O
T	O
max	O
(	O
although	O
C	O
max	O
increased	O
by	O
11	O
%	O
)	O
when	O
extended	O
phenytoin	B
sodium	I
capsules	O
(	O
100	O
mg	O
tid	O
)	O
were	O
coadministered	O
with	O
lomefloxacin	B
(	O
400	O
mg	O
qd	O
)	O
for	O
five	O
days	O
in	O
15	O
healthy	O
males	O
.	O

Lomefloxacin	B
is	O
unlikely	O
to	O
have	O
a	O
significant	O
effect	O
on	O
phenytoin	B
metabolism	O
.	O

Probenecid	B
:	O
Probenecid	B
slows	O
the	O
renal	O
elimination	O
of	O
lome	O
-	O
floxacin	O
.	O

Terfenadine	B
:	O
No	O
clinically	O
significant	O
changes	O
occurred	O
in	O
heart	O
rate	O
or	O
corrected	O
QT	O
intervals	O
,	O
or	O
in	O
terfenadine	B
metabolite	O
or	O
lomefloxacin	B
pharmacokinetics	O
,	O
during	O
concurrent	O
administration	O
of	O
lomefloxacin	B
and	O
terfenadine	B
at	O
steady	O
-	O
state	O
in	O
28	O
healthy	O
males	O
.	O

Warfarin	B
:	O
Quinolones	B
may	O
enhance	O
the	O
effects	O
of	O
the	O
oral	O
anticoagulant	B
,	O
warfarin	B
,	O
or	O
its	O
derivatives	O
.	O

However	O
,	O
no	O
clinically	O
or	O
statistically	O
significant	O
differences	O
in	O
prothrombin	O
time	O
ratio	O
or	O
warfarin	B
enantiomer	O
pharmacokinetics	O
were	O
observed	O
in	O
a	O
small	O
study	O
of	O
7	O
healthy	O
males	O
who	O
received	O
both	O
warfarin	B
and	O
lomefloxacin	B
under	O
steady	O
-	O
state	O
conditions	O
.	O

Probenecid	B
:	O
As	O
with	O
other	O
b	O
-	O
lactam	O
antibiotics	B
,	O
renal	O
excretion	O
of	O
loracarbef	B
is	O
inhibited	O
by	O
probenecid	B
and	O
resulted	O
in	O
an	O
approximate	O
80	O
%	O
increase	O
in	O
the	O
AUC	O
for	O
loracarbef	B
.	O

Loratadine	B
(	O
10	O
mg	O
once	O
daily	O
)	O
has	O
been	O
coadministered	O
with	O
therapeutic	O
doses	O
of	O
erythromycin	B
,	O
cimetidine	B
,	O
and	O
ketoconazole	B
in	O
controlled	O
clinical	O
pharmacology	O
studies	O
in	O
adult	O
volunteers	O
.	O

Although	O
increased	O
plasma	O
concentrations	O
(	O
AUC	O
0	O
-	O
24	O
hrs	O
)	O
of	O
loratadine	B
and	O
/	O
or	O
descarboethoxyloratadine	B
were	O
observed	O
following	O
coadministration	O
of	O
loratadine	B
with	O
each	O
of	O
these	O
drugs	O
in	O
normal	O
volunteers	O
(	O
n	O
=	O
24	O
in	O
each	O
study	O
)	O
,	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
safety	O
profile	O
of	O
loratadine	B
,	O
as	O
assessed	O
by	O
electrocardiographic	O
parameters	O
,	O
clinical	O
laboratory	O
tests	O
,	O
vital	O
signs	O
,	O
and	O
adverse	O
events	O
.	O

No	O
effects	O
on	O
plasma	O
concentrations	O
of	O
cimetidine	B
or	O
ketoconazole	B
were	O
observed	O
.	O

Plasma	O
concentrations	O
(	O
AUC	O
0	O
-	O
24	O
hrs	O
)	O
of	O
erythromycin	B
decreased	O
15	O
%	O
with	O
coadministration	O
of	O
loratadine	B
relative	O
to	O
that	O
observed	O
with	O
erythromycin	B
alone	O
.	O

TABLE	O
1	O
Effects	O
on	O
Plasma	O
Concentrations	O
(	O
AUC	O
0	O
-	O
24	O
hrs	O
)	O
of	O
Loratadine	B
and	O
Descarboethoxyloratadine	B
After	O
10	O
Days	O
of	O
Coadministration	O
(	O
Loratadine	B
10	O
mg	O
)	O
in	O
Normal	O
Volunteers	O

Loratadine	B
Descarboethoxyloratadine	I

There	O
does	O
not	O
appear	O
to	O
be	O
an	O
increase	O
in	O
adverse	O
events	O
in	O
subjects	O
who	O
received	O
oral	O
contraceptives	B
and	O
loratadine	B
.	O

Tablets	O
:	O
The	O
benzodiazepines	B
,	O
including	O
lorazepam	B
,	O
produce	O
CNS	O
-	O
depressant	O
effects	O
when	O
administered	O
with	O
such	O
medications	O
as	O
barbiturates	B
or	O
alcohol	B
.	O

Injection	O
:	O
Lorazepam	B
injection	O
,	O
like	O
other	O
injectable	O
benzodiazepines	B
,	O
produces	O
depression	O
of	O
the	O
central	O
nervous	O
system	O
when	O
administered	O
with	O
ethyl	B
alcohol	I
,	O
phenothiazines	B
,	O
barbiturates	B
,	O
MAO	B
inhibitors	I
,	O
and	O
other	O
antidepressants	B
.	O
When	O
scopolamine	B
is	O
used	O
concomitantly	O
with	O
injectable	O
lorazepam	B
,	O
an	O
increased	O
incidence	O
of	O
sedation	O
,	O
hallucinations	O
,	O
and	O
irrational	O
behavior	O
has	O
been	O
observed	O
.	O

No	O
significant	O
drug	O
-	O
drug	O
pharmacokinetic	O
interactions	O
have	O
been	O
found	O
in	O
interaction	O
studies	O
with	O
hydrochlorothiazide	B
,	O
digoxin	B
,	O
warfarin	B
,	O
cimetidine	B
and	O
phenobarbital	B
.	O

Rifampin	B
,	O
an	O
inducer	O
of	O
drug	O
metabolism	O
,	O
decreased	O
the	O
concentrations	O
of	O
losartan	B
and	O
its	O
active	O
metabolite	O
.	O

Ketoconazole	B
did	O
not	O
affect	O
the	O
conversion	O
of	O
losartan	B
to	O
the	O
active	O
metabolite	O
after	O
intravenous	O
administration	O
of	O
losartan	B
,	O
and	O
erythromycin	B
had	O
no	O
clinically	O
significant	O
effect	O
after	O
oral	O
administration	O
.	O

Fluconazole	B
,	O
an	O
inhibitor	O
of	O
P450	O
2C9	O
,	O
decreased	O
active	O
metabolite	O
concentration	O
and	O
increased	O
losartan	B
concentration	O
.	O

As	O
with	O
other	O
drugs	O
that	O
block	O
angiotensin	O
II	O
or	O
its	O
effects	O
,	O
concomitant	O
use	O
of	O
potassium	B
-	O
sparing	O
diuretics	B
(	O
e	O
.	O
g	O
.	O
,	O
spironolactone	B
,	O
triamterene	B
,	O
amiloride	B
)	O
,	O
potassium	B
supplements	O
,	O
or	O
salt	O
substitutes	O
containing	O
potassium	B
may	O
lead	O
to	O
increases	O
in	O
serum	O
potassium	B
.	O

As	O
with	O
other	O
antihypertensive	B
agents	I
,	O
the	O
antihypertensive	B
effect	O
of	O
losartan	B
may	O
be	O
blunted	O
by	O
the	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	B
indomethacin	I

Itraconazole	B
Ketoconazole	I
Erythromycin	I
Clarithromycin	I
Telithromycin	I
HIV	I
protease	I
inhibitors	I
Nefazodone	I
Cyclosporine	I
Large	O
quantities	O
of	O
grapefruit	O
juice	O
(	O
1	O
quart	O
daily	O
)	O

Gemfibrozil	B
Other	O
fibrates	B
Niacin	I
(	O
nicotinic	B
acid	I
)	O
(	O
=	O
1	O
g	O
/	O
day	O
)	O

Danazol	B
:	O
The	O
risk	O
of	O
myopathy	O
/	O
rhabdomyolysis	O
is	O
increased	O
by	O
concomitant	O
administration	O
of	O
danazol	B
particularly	O
with	O
higher	O
doses	O
of	O
lovastatin	B
(	O
see	O
WARNINGS	O
,	O
Myopathy	O
/	O
Rhabdomyolysis	O
)	O
.	O

Amiodarone	B
or	O
Verapamil	B
:	O
The	O
risk	O
of	O
myopathy	O
/	O
rhabdomyolysis	O
is	O
increased	O
when	O
either	O
amiodarone	B
or	O
verapamil	B
is	O
used	O
concomitantly	O
with	O
a	O
closely	O
related	O
member	O
of	O
the	O
HMG	O
-	O
CoA	O
reductase	B
inhibitor	I
class	I
(	O
see	O
WARNINGS	O
,	O
Myopathy	O
/	O
Rhabdomyolysis	O
)	O
.	O

Coumarin	B
Anticoagulants	O
:	O
In	O
a	O
small	O
clinical	O
trial	O
in	O
which	O
lovastatin	B
was	O
administered	O
to	O
warfarin	B
treated	O
patients	O
,	O
no	O
effect	O
on	O
prothrombin	O
time	O
was	O
detected	O
.	O

However	O
,	O
another	O
HMG	O
-	O
CoA	O
reductase	B
inhibitor	I
has	O
been	O
found	O
to	O
produce	O
a	O
less	O
than	O
two	O
-	O
second	O
increase	O
in	O
prothrombin	O
time	O
in	O
healthy	O
volunteers	O
receiving	O
low	O
doses	O
of	O
warfarin	B
.	O

Also	O
,	O
bleeding	O
and	O
/	O
or	O
increased	O
prothrombin	O
time	O
have	O
been	O
reported	O
in	O
a	O
few	O
patients	O
taking	O
coumarin	B
anticoagulants	O
concomitantly	O
with	O
lovastatin	B
.	O

It	O
is	O
recommended	O
that	O
in	O
patients	O
taking	O
anticoagulants	B
,	O
prothrombin	O
time	O
be	O
determined	O
before	O
starting	O
lovastatin	B
and	O
frequently	O
enough	O
during	O
early	O
therapy	O
to	O
insure	O
that	O
no	O
significant	O
alteration	O
of	O
prothrombin	O
time	O
occurs	O
.	O

Lovastatin	B
therapy	O
has	O
not	O
been	O
associated	O
with	O
bleeding	O
or	O
with	O
changes	O
in	O
prothrombin	O
time	O
in	O
patients	O
not	O
taking	O
anticoagulants	B
.	O

Propranolol	B
:	O
In	O
normal	O
volunteers	O
,	O
there	O
was	O
no	O
clinically	O
significant	O
pharmacokinetic	O
or	O
pharmacodynamic	O
interaction	O
with	O
concomitant	O
administration	O
of	O
single	O
doses	O
of	O
lovastatin	B
and	O
propranolol	B
.	O

Digoxin	B
:	O
In	O
patients	O
with	O
hypercholesterolemia	O
,	O
concomitant	O
administration	O
of	O
lovastatin	B
and	O
digoxin	B
resulted	O
in	O
no	O
effect	O
on	O
digoxin	B
plasma	O
concentrations	O
.	O

Oral	O
Hypoglycemic	B
Agents	I
:	O
In	O
pharmacokinetic	O
studies	O
of	O
MEVACOR	B
in	O
hypercholesterolemic	O
noninsulin	O
dependent	O
diabetic	O
patients	O
,	O
there	O
was	O
no	O
drug	O
interaction	O
with	O
glipizide	B
or	O
with	O
chlorpropamide	B

There	O
have	O
been	O
rare	O
reports	O
of	O
significant	O
respiratory	O
depression	O
,	O
stupor	O
and	O
/	O
or	O
hypotension	O
with	O
the	O
concomitant	O
use	O
of	O
loxapine	B
and	O
lorazepam	B
.	O

The	O
absorption	O
of	O
lymecycline	B
may	O
be	O
affected	O
by	O
the	O
simultaneous	O
administration	O
of	O
indigestion	O
remedies	O
,	O
iron	B
or	O
zinc	B
supplements	O
.	O

Oral	O
contraceptives	B
may	O
be	O
less	O
effective	O
while	O
you	O
are	O
taking	O
lymecycline	B
.	O

Warfarin	B
:	O
Meclofenamate	B
sodium	I
enhances	O
the	O
effect	O
of	O
warfarin	B
.	O

Therefore	O
,	O
when	O
meclofenamate	B
sodium	I
is	O
given	O
to	O
a	O
patient	O
receiving	O
warfarin	B
,	O
the	O
dosage	O
of	O
warfarin	B
should	O
be	O
reduced	O
to	O
prevent	O
excessive	O
prolongation	O
of	O
the	O
prothrombin	O
time	O
.	O

Aspirin	B
:	O
Concurrent	O
administration	O
of	O
aspirin	B
may	O
lower	O
meclofenamate	B
sodium	I
plasma	O
levels	O
,	O
possibly	O
by	O
competing	O
for	O
protein	O
-	O
binding	O
sites	O
.	O

The	O
urinary	O
excretion	O
of	O
meclofenamate	B
sodium	I
is	O
unaffected	O
by	O
aspirin	B
,	O
indicating	O
no	O
change	O
in	O
meclofenamate	B
sodium	I
absorption	O
.	O

Meclofenamate	B
sodium	I
does	O
not	O
affect	O
serum	O
salicylate	B
levels	O
.	O

Propoxyphene	B
:	O
The	O
concurrent	O
administration	O
of	O
propoxyphene	B
hydrochloride	I
does	O
not	O
affect	O
the	O
bioavailability	O
of	O
meclofenamate	B
sodium	I
.	O

Antacids	B
:	O
Concomitant	O
administration	O
of	O
aluminum	B
and	O
magnesium	B
hydroxides	O
does	O
not	O
interfere	O
with	O
absorption	O
of	O
meclofenamate	B
sodium	I
.	O

Aspirin	B
:	O
As	O
with	O
other	O
NSAIDs	B
,	O
concomitant	O
administration	O
of	O
Ponstel	B
and	O
aspirin	B
is	O
not	O
generally	O
recommended	O
because	O
of	O
the	O
potential	O
of	O
increased	O
adverse	O
effects	O
.	O

Methotrexate	B
:	O
NSAIDs	B
have	O
been	O
reported	O
to	O
competitively	O
inhibit	O
methotrexate	B
accumulation	O
in	O
rabbit	O
kidney	O
slices	O
.	O

Caution	O
should	O
be	O
used	O
when	O
NSAIDs	B
are	O
administered	O
concomitantly	O
with	O
methotrexate	B
.	O

ACE	B
inhibitors	I
:	O
Reports	O
suggest	O
that	O
NSAIDs	B
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
ACE	B
inhibitors	I
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
NSAIDs	B
concomitantly	O
with	O
ACE	B
inhibitors	I
.	O

Furosemide	B
:	O
Clinical	O
studies	O
,	O
as	O
well	O
as	O
post	O
-	O
marketing	O
observations	O
,	O
have	O
shown	O
that	O
NSAIDs	B
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B
and	O
thiazides	B
in	O
some	O
patients	O
.	O

During	O
concomitant	O
therapy	O
of	O
Ponstel	B
with	O
furosemide	B
,	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
signs	O
of	O
renal	O
failure	O
,	O
as	O
well	O
as	O
to	O
assure	O
diuretic	O
efficacy	O
.	O

Lithium	B
:	O
NSAIDs	B
have	O
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	B
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	B
clearance	O
.	O

Thus	O
,	O
when	O
NSAIDs	B
and	O
lithium	B
are	O
administered	O
concurrently	O
,	O
subjects	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
of	O
lithium	B
toxicity	O
.	O

Warfarin	B
:	O
The	O
effects	O
of	O
warfarin	B
and	O
NSAIDs	B
on	O
GI	O
bleeding	O
are	O
synergistic	O
,	O
such	O
that	O
users	O
of	O
both	O
drugs	O
together	O
have	O
a	O
risk	O
of	O
serious	O
GI	O
bleeding	O
higher	O
than	O
users	O
of	O
either	O
drug	O
alone	O
.	O

Antacids	B
:	O
In	O
a	O
single	O
dose	O
study	O
(	O
n	O
=	O
6	O
)	O
,	O
ingestion	O
of	O
an	O
antacid	B
containing	O
1	O
.	O
7	O
-	O
gram	O
of	O
magnesium	B
hydroxide	I
with	O
500	O
-	O
mg	O
of	O
mefenamic	B
acid	I
increased	O
the	O
Cmax	O
and	O
AUC	O
of	O
mefenamic	B
acid	I
by	O
125	O
%	O
and	O
36	O
%	O
,	O
respectively	O
.	O
A	O
number	O
of	O
compounds	O
are	O
inhibitors	O
of	O
CYP2C9	O
including	O
fluconazole	B
,	O
lovastatin	B
and	O
trimethoprim	B
.	O

There	O
is	O
one	O
report	O
of	O
cardiopulmonary	O
arrest	O
,	O
with	O
full	O
recovery	O
,	O
in	O
a	O
patient	O
who	O
was	O
taking	O
a	O
beta	B
blocker	I
(	O
propranolol	B
)	O
.	O

Because	O
of	O
the	O
danger	O
of	O
a	O
potentially	O
fatal	O
prolongation	O
of	O
the	O
QTc	O
interval	O
,	O
halofantrine	B
must	O
not	O
be	O
given	O
simultaneously	O
with	O
or	O
subsequent	O
to	O
Mefloquine	B
.	O

Concomitant	O
administration	O
of	O
Mefloquine	B
and	O
other	O
related	O
compounds	O
(	O
eg	O
,	O
quinine	B
,	O
quinidine	B
and	O
chloroquine	B
)	O
may	O
produce	O
electrocardiographic	O
abnormalities	O
and	O
increase	O
the	O
risk	O
of	O
convulsions	O
.	O

This	O
appears	O
to	O
be	O
the	O
only	O
clinically	O
relevant	O
interaction	O
of	O
this	O
kind	O
with	O
Mefloquine	B
,	O
although	O
theoretically	O
,	O
coadministration	O
of	O
other	O
drugs	O
known	O
to	O
alter	O
cardiac	O
conduction	O
(	O
eg	O
,	O
anti	O
-	O
arrhythmic	O
or	O
beta	O
-	O
adrenergic	O
blocking	B
agents	I
,	O
calcium	B
channel	I
blockers	I
,	O
antihistamines	B
or	O
H1	O
-	O
blocking	B
agents	I
,	O
tricyclic	B
antidepressants	I
and	O
phenothiazines	B
)	O
might	O
also	O
contribute	O
to	O
a	O
prolongation	O
of	O
the	O
QTc	O
interval	O
.	O

In	O
patients	O
taking	O
an	O
anticonvulsant	B
(	O
eg	O
,	O
valproic	B
acid	I
,	O
carbamazepine	B
,	O
phenobarbital	B
or	O
phenytoin	B
)	O
,	O
the	O
concomitant	O
use	O
of	O
Mefloquine	B
may	O
reduce	O
seizure	O
control	O
by	O
lowering	O
the	O
plasma	O
levels	O
of	O
the	O
anticonvulsant	B
.	O

When	O
Mefloquine	B
is	O
taken	O
concurrently	O
with	O
oral	O
live	B
typhoid	I
vaccines	I
,	O
attenuation	O
of	O
immunization	O
cannot	O
be	O
excluded	O
.	O

Nevertheless	O
,	O
the	O
effects	O
of	O
Mefloquine	B
on	O
travelers	O
receiving	O
comedication	O
,	O
particularly	O
diabetics	O
or	O
patients	O
using	O
anticoagulants	B
,	O
should	O
be	O
checked	O
before	O
departure	O
.	O

In	O
clinical	O
trials	O
,	O
the	O
concomitant	O
administration	O
of	O
sulfadoxine	B
and	O
pyrimethamine	B
did	O
not	O
alter	O
the	O
adverse	O
reaction	O
profile	O
.	O

Broad	O
-	O
Spectrum	O
Antibiotics	B
-	O
Broad	O
-	O
spectrum	O
antibiotics	B
may	O
sterilize	O
the	O
bowel	O
and	O
decrease	O
the	O
vitamin	B
K	I
contribution	O
to	O
the	O
body	O
by	O
the	O
intestinal	O
microflora	O
.	O

Cephalosporins	B
-	O
Cephalosporins	B
containing	O
side	O
chains	O
of	O
N	O
-	O
methylthiotetrazole	O
(	O
cefmenoxime	B
,	O
cefoperazone	B
,	O
cefotetan	B
,	O
cefamandole	B
,	O
latamoxef	B
)	O
or	O
methylthiadiazole	O
(	O
cefazolin	B
)	O
can	O
cause	O
vitamin	O
K	O
deficiency	O
and	O
hypoprothrombinemia	O
.	O

Cholestyramine	B
-	O
Concomitant	O
intake	O
of	O
cholestyramine	B
and	O
vitamin	B
K	I
may	O
reduce	O
the	O
absorption	O
of	O
vitamin	B
K	I
.	O

Colestipol	B
-	O
Concomitant	O
intake	O
of	O
colestipol	B
and	O
vitamin	B
K	I
may	O
reduce	O
the	O
absorption	O
of	O
vitamin	B
K	I
.	O

Mineral	B
Oil	I
-	O
Concomitant	O
intake	O
of	O
mineral	B
oil	I
and	O
vitamin	B
K	I
may	O
reduce	O
the	O
absorption	O
of	O
vitamin	B
K	I
.	O

Orlistat	B
-	O
Orlistat	B
may	O
decrease	O
the	O
absorption	O
of	O
vitamin	B
K	I
.	O

Salicylates	B
-	O
Salicylates	B
in	O
large	O
doses	O
may	O
inhibit	O
vitamin	O
K	O
epoxide	O
reductase	O
resulting	O
in	O
vitamin	O
K	O
deficiency	O
.	O

Warfarin	B
-	O
Vitamin	B
K	I
can	O
antagonize	O
the	O
effect	O
of	O
warfarin	B

Nabilone	B
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
who	O
are	O
taking	O
other	O
psychoactive	B
drugs	I
or	O
CNS	B
depressants	I
,	O
including	O
alcohol	B
,	O
barbiturates	B
and	O
narcotic	B
analgesics	I
,	O
or	O
to	O
those	O
with	O
a	O
history	O
of	O
psychiatric	O
disorder	O
(	O
including	O
manic	O
-	O
depressive	O
illness	O
and	O
schizophrenia	O
)	O
.	O

Nabilone	B
has	O
been	O
shown	O
to	O
have	O
an	O
additive	O
CNS	O
depressant	O
effect	O
when	O
given	O
with	O
either	O
diazepam	B
,	O
secobarbitone	B
sodium	I
,	O
alcohol	B
or	O
codeine	B
.	O

Caution	O
should	O
be	O
exercised	O
when	O
administering	O
nabumetone	B
with	O
warfarin	B
since	O
interactions	O
have	O
been	O
seen	O
with	O
other	O
NSAIDs	B
.	O

Concomitant	O
administration	O
of	O
an	O
aluminum	B
-	O
containing	O
antacid	B
had	O
no	O
significant	O
effect	O
in	O
the	O
bioavailability	O
of	O
6MNA	B
.	O

When	O
administered	O
concurrently	O
,	O
the	O
following	O
drugs	O
may	O
interact	O
with	O
beta	O
-	O
adrenergic	O
receptor	B
blocking	I
agents	I
:	O
Anesthetics	B
,	O
general	O
:	O
exaggeration	O
of	O
the	O
hypotension	O
induced	O
by	O
general	O
anesthetics	B
.	O

Antidiabetic	B
drugs	I
(	O
oral	O
agents	O
and	O
insulin	B
)	O
:	O
hypoglycemia	O
or	O
hyperglycemia	O
;	O

Tetracycline	B
,	O
a	O
bacteriostatic	B
antibiotic	I
,	O
may	O
antagonize	O
the	O
bactericidal	O
effect	O
of	O
penicillin	B
and	O
concurrent	O
use	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O

Elevated	O
plasma	O
levels	O
of	O
theophylline	B
have	O
been	O
reported	O
with	O
concomitant	O
quinolone	B
use	O
.	O

There	O
have	O
been	O
reports	O
of	O
theophylline	B
-	O
related	O
side	O
effects	O
in	O
patients	O
on	O
concomitant	O
therapy	O
with	O
quinolones	B
and	O
theophylline	B
.	O

Therefore	O
,	O
monitoring	O
of	O
theophylline	B
plasma	O
levels	O
should	O
be	O
considered	O
and	O
dosage	O
of	O
theophylline	B
adjusted	O
,	O
as	O
required	O
.	O

Quinolones	B
have	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	B
.	O

Quinolones	B
,	O
including	O
nalidixic	B
acid	I
,	O
may	O
enhance	O
the	O
effects	O
of	O
the	O
oral	O
anticoagulant	B
warfarin	I
or	O
its	O
derivatives	O
.	O

Nitrofurantoin	B
interferes	O
with	O
the	O
therapeutic	O
action	O
of	O
nalidixic	B
acid	I
.	O

Antacids	B
containing	O
magnesium	B
,	O
aluminum	B
,	O
or	O
calcium	B
;	O

sucralfate	B
or	O
divalent	O
or	O
trivalent	O
cations	O
such	O
as	O
iron	B
;	O

multivitamins	B
containing	O
zinc	B
;	O

and	O
Videx	B
,	O
(	O
Didanosine	B
)	O
,	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
may	O
substantially	O
interfere	O
with	O
the	O
absorption	O
of	O
quinolones	B
,	O
resulting	O
in	O
systemic	O
levels	O
considerably	O
lower	O
than	O
desired	O
.	O

Elevated	O
serum	O
levels	O
of	O
cyclosporine	B
have	O
been	O
reported	O
with	O
the	O
concomitant	O
use	O
of	O
some	O
quinolones	B
and	O
cyclosporine	B
.	O

Therefore	O
,	O
cyclosporine	B
serum	O
levels	O
should	O
be	O
monitored	O
and	O
appropriate	O
cyclosporine	B
dosage	O
adjustments	O
made	O
when	O
these	O
drugs	O
are	O
used	O
concomitantly	O
.	O

Studies	O
to	O
evaluate	O
possible	O
interactions	O
between	O
REVIA	B
and	O
drugs	O
other	O
than	O
opiates	B
have	O
not	O
been	O
performed	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
concomitant	O
use	O
of	O
REVIA	B
and	O
disulfiram	B
is	O
unknown	O
,	O
and	O
the	O
concomitant	O
use	O
of	O
two	O
potentially	O
hepatotoxic	O
medications	O
is	O
not	O
ordinarily	O
recommended	O
unless	O
the	O
probable	O
benefits	O
outweigh	O
the	O
known	O
risks	O
.	O

Lethargy	O
and	O
somnolence	O
have	O
been	O
reported	O
following	O
doses	O
of	O
REVIA	B
and	O
thioridazine	B
.	O

Patients	O
taking	O
REVIA	B
may	O
not	O
benefit	O
from	O
opioid	B
containing	O
medicines	O
,	O
such	O
as	O
cough	O
and	O
cold	O
preparations	O
,	O
antidiarrheal	O
preparations	O
,	O
and	O
opioid	B
analgesics	I
.	O

In	O
an	O
emergency	O
situation	O
when	O
opioid	B
analgesia	O
must	O
be	O
administered	O
to	O
a	O
patient	O
receiving	O
REVIA	B
,	O
the	O
amount	O
of	O
opioid	B
required	O
may	O
be	O
greater	O
than	O
usual	O
,	O
and	O
the	O
resulting	O
respiratory	O
depression	O
may	O
be	O
deeper	O
and	O
more	O
prolonged	O
.	O

The	O
use	O
of	O
NSAIDs	B
in	O
patients	O
who	O
are	O
receiving	O
ACE	B
inhibitors	I
may	O
potentiate	O
renal	O
disease	O
states	O
.	O

Similarly	O
,	O
patients	O
receiving	O
the	O
drug	O
and	O
a	O
hydantoin	B
,	O
sulfonamide	B
or	O
sulfonylurea	B
should	O
be	O
observed	O
for	O
signs	O
of	O
toxicity	O
to	O
these	O
drugs	O
.	O

Concomitant	O
administration	O
of	O
naproxen	B
and	O
aspirin	B
is	O
not	O
recommended	O
because	O
naproxen	B
is	O
displaced	O
from	O
its	O
binding	O
sites	O
during	O
the	O
concomitant	O
administration	O
of	O
aspirin	B
,	O
resulting	O
in	O
lower	O
plasma	O
concentrations	O
and	O
peak	O
plasma	O
levels	O
.	O

Inhibition	O
of	O
renal	O
lithium	B
clearance	O
leading	O
to	O
increases	O
in	O
plasma	O
lithium	B
concentrations	O
has	O
also	O
been	O
reported	O
.	O

Naproxen	B
and	O
other	O
NSAIDs	B
can	O
reduce	O
the	O
antihypertensive	O
effect	O
of	O
propranolol	B
and	O
other	O
beta	O
-	O
blockers	O
.	O

Probenecid	B
given	O
concurrently	O
increases	O
naproxen	B
anion	O
plasma	O
levels	O
and	O
extends	O
its	O
plasma	O
half	O
-	O
life	O
significantly	O
.	O

Caution	O
should	O
be	O
used	O
if	O
naproxen	B
is	O
administered	O
concomitantly	O
with	O
methotrexate	B
.	O

Naproxen	B
,	O
naproxen	B
sodium	I
and	O
other	O
NSAIDs	B
have	O
been	O
reported	O
to	O
reduce	O
the	O
tubular	O
secretion	O
of	O
methotrexate	B
in	O
an	O
animal	O
model	O
,	O
possibly	O
increasing	O
the	O
toxicity	O
of	O
methotrexate	B
.	O

Because	O
there	O
is	O
a	O
theoretical	O
basis	O
that	O
these	O
effects	O
may	O
be	O
additive	O
,	O
use	O
of	O
ergotamine	B
-	O
containing	O
or	O
ergot	O
-	O
type	O
medications	B
(	O
like	O
dihydroergotamine	B
or	O
methysergide	B
)	O
and	O
naratriptan	B
within	O
24	O
hours	O
is	O
contraindicated	O
.	O

The	O
administration	O
of	O
naratriptan	B
with	O
other	O
5	O
-	O
HT1	O
agonists	B
has	O
not	O
been	O
evaluated	O
in	O
migraine	O
patients	O
.	O

Because	O
their	O
vasospastic	O
effects	O
may	O
be	O
additive	O
,	O
coadministration	O
of	O
naratriptan	B
and	O
other	O
5	O
-	O
HT1	O
agonists	B
within	O
24	O
hours	O
of	O
each	O
other	O
is	O
not	O
recommended	O
.	O

Selective	B
serotonin	I
reuptake	I
inhibitors	I
(	O
SSRIs	B
)	O
(	O
e	O
.	O
g	O
.	O
,	O
fluoxetine	B
,	O
fluvoxamine	B
,	O
paroxetine	B
,	O
sertraline	B
)	O
have	O
been	O
reported	O
,	O
rarely	O
,	O
to	O
cause	O
weakness	O
,	O
hyperreflexia	O
,	O
and	O
incoordination	O
when	O
coadministered	O
with	O
5	O
-	O
HTv	O
agonists	O
.	O

If	O
concomitant	O
treatment	O
with	O
naratriptan	B
and	O
an	O
SSRI	B
is	O
clinically	O
warranted	O
,	O
appropriate	O
observation	O
of	O
the	O
patient	O
is	O
advised	O
.	O

After	O
multiple	O
dosing	O
,	O
interferon	B
beta	O
-	O
1a	O
(	O
AVONEX	B
30	O
mcg	O
IM	O
once	O
weekly	O
)	O
reduced	O
TYSABRI	B
clearance	O
by	O
approximately	O
30	O
%	O
.	O

The	O
similarity	O
of	O
the	O
TYSABRI	B
-	O
associated	O
adverse	O
event	O
profile	O
between	O
Study	O
1	O
(	O
without	O
co	O
-	O
administered	O
AVONEX	B
)	O
and	O
Study	O
2	O
(	O
with	O
co	O
-	O
administered	O
AVONEX	B
)	O
indicates	O
that	O
this	O
alteration	O
in	O
clearance	O
does	O
not	O
necessitate	O
reduction	O
of	O
the	O
TYSABRI	B
dose	O
to	O
maintain	O
safety	O
,	O
General	O
)	O
.	O

Results	O
of	O
studies	O
in	O
multiple	O
sclerosis	O
patients	O
taking	O
TYSABRI	B
and	O
concomitant	O
interferon	B
beta	O
-	O
1a	O
(	O
AVONEX	B
30	O
mcg	O
IM	O
once	O
weekly	O
)	O
or	O
glatiramer	B
acetate	I
were	O
inconclusive	O
with	O
regard	O
to	O
the	O
need	O
for	O
dose	O
adjustment	O
of	O
the	O
beta	O
-	O
interferon	B
or	O
glatiramer	B
acetate	I
.	O

Starlix	B
is	O
a	O
potential	O
inhibitor	O
of	O
the	O
CYP2C9	O
isoenzyme	O
in	O
vivo	O
as	O
indicated	O
by	O
its	O
ability	O
to	O
inhibit	O
the	O
in	O
vitro	O
metabolism	O
of	O
tolbutamide	B
.	O

Glyburide	B
:	O
In	O
a	O
randomized	O
,	O
multiple	O
-	O
dose	O
crossover	O
study	O
,	O
patients	O
with	O
Type	O
2	O
diabetes	O
were	O
administered	O
120	O
mg	O
Starlix	B
three	O
times	O
a	O
day	O
before	O
meals	O
for	O
1	O
day	O
in	O
combination	O
with	O
glyburide	B
10	O
mg	O
daily	O
.	O

Metformin	B
:	O
When	O
Starlix	B
120	O
mg	O
three	O
times	O
daily	O
before	O
meals	O
was	O
administered	O
in	O
combination	O
with	O
metformin	B
500	O
mg	O
three	O
times	O
daily	O
to	O
patients	O
with	O
Type	O
2	O
diabetes	O
,	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Digoxin	B
:	O
When	O
Starlix	B
120	O
mg	O
before	O
meals	O
was	O
administered	O
in	O
combination	O
with	O
a	O
single	O
1	O
-	O
mg	O
dose	O
of	O
digoxin	B
to	O
healthy	O
volunteers	O
,	O
there	O
were	O
no	O
clinically	O
relevant	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Warfarin	B
:	O
When	O
healthy	O
subjects	O
were	O
administered	O
Starlix	B
120	O
mg	O
three	O
times	O
daily	O
before	O
meals	O
for	O
four	O
days	O
in	O
combination	O
with	O
a	O
single	O
dose	O
of	O
warfarin	B
30	O
mg	O
on	O
day	O
2	O
,	O
there	O
were	O
no	O
alterations	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

Diclofenac	B
:	O
Administration	O
of	O
morning	O
and	O
lunch	O
doses	O
of	O
Starlix	B
120	O
mg	O
in	O
combination	O
with	O
a	O
single	O
75	O
-	O
mg	O
dose	O
of	O
diclofenac	B
in	O
healthy	O
volunteers	O
resulted	O
in	O
no	O
significant	O
changes	O
to	O
the	O
pharmacokinetics	O
of	O
either	O
agent	O
.	O

In	O
vitro	O
displacement	O
studies	O
with	O
highly	O
protein	O
-	O
bound	O
drugs	O
such	O
as	O
furosemide	B
,	O
propranolol	B
,	O
captopril	B
,	O
nicardipine	B
,	O
pravastatin	B
,	O
glyburide	B
,	O
warfarin	B
,	O
phenytoin	B
,	O
acetylsalicylic	B
acid	I
,	O
tolbutamide	B
,	O
and	O
metformin	B
showed	O
no	O
influence	O
on	O
the	O
extent	O
of	O
nateglinide	B
protein	O
binding	O
.	O

Similarly	O
,	O
nateglinide	B
had	O
no	O
influence	O
on	O
the	O
serum	O
protein	O
binding	O
of	O
propranolol	B
,	O
glyburide	B
,	O
nicardipine	B
,	O
warfarin	B
,	O
phenytoin	B
,	O
acetylsalicylic	B
acid	I
,	O
and	O
tolbutamide	B
in	O
vitro	O
.	O

Certain	O
drugs	B
,	O
including	O
nonsteroidal	B
anti	O
-	O
inflammatory	O
agents	B
(	O
NSAIDs	B
)	O
,	O
salicylates	B
,	O
monoamine	B
oxidase	I
inhibitors	I
,	O
and	O
non	O
-	O
selective	O
beta	O
-	O
adrenergic	O
-	O
blocking	O
agents	B
may	O
potentiate	O
the	O
hypoglycemic	O
action	O
of	O
Starlix	B
and	O
other	O
oral	O
antidiabetic	B
drugs	I
.	O

Certain	O
drugs	B
including	O
thiazides	B
,	O
corticosteroids	B
,	O
thyroid	B
products	I
,	O
and	O
sympathomimetics	B
may	O
reduce	O
the	O
hypoglycemic	O
action	O
of	O
Starlix	B
and	O
other	O
oral	O
antidiabetic	B
drugs	I
.	O

In	O
clinical	O
studies	O
,	O
Tilade	B
has	O
been	O
co	O
-	O
administered	O
with	O
other	O
anti	O
-	O
asthma	O
medications	O
,	O
including	O
inhaled	O
and	O
oral	O
bronchodilators	B
,	O
and	O
inhaled	O
corticosteroids	B
,	O
with	O
no	O
evidence	O
of	O
increased	O
frequency	O
of	O
adverse	O
events	O
or	O
laboratory	O
abnormalities	O
.	O

Coadministration	O
of	O
VIRACEPT	B
and	O
drugs	O
primarily	O
metabolized	O
by	O
CYP3A	O
(	O
e	O
.	O
g	O
.	O
,	O
dihydropyridine	B
calcium	I
channel	I
blockers	I
)	O
may	O
result	O
in	O
increased	O
plasma	O
concentrations	O
of	O
the	O
other	O
drug	O
that	O
could	O
increase	O
or	O
prolong	O
both	O
its	O
therapeutic	O
and	O
adverse	O
effects	O
.	O

Coadministration	O
of	O
VIRACEPT	B
and	O
drugs	O
that	O
induce	O
CYP3A	O
may	O
decrease	O
nelfinavir	B
plasma	O
concentrations	O
and	O
reduce	O
its	O
therapeutic	O
effect	O
.	O

Coadministration	O
of	O
VIRACEPT	B
and	O
drugs	O
that	O
inhibit	O
CYP3A	O
may	O
increase	O
nelfinavir	B
plasma	O
concentrations	O
.	O

Based	O
on	O
known	O
metabolic	O
profiles	O
,	O
clinically	O
significant	O
drug	O
interactions	O
are	O
not	O
expected	O
between	O
VIRACEPT	B
and	O
dapsone	B
,	O
trimethoprim	B
/	O
sulfamethoxazole	B
,	O
clarithromycin	B
,	O
erythromycin	B
,	O
itraconazole	B
or	O
fluconazole	B
.	O

Drugs	O
That	O
Should	O
Not	O
Be	O
Coadministered	O
With	O
VIRACEPT	B
Antiarrhythmics	I
:	O
amiodarone	B
,	O
quinidine	B
Antihistamines	I
:	O
astemizole	B
,	O
terfenadine	B
Antimigraine	O
:	O
ergot	B
derivatives	I
Antimycobacterial	I
agents	I
:	O
rifampin	B
Benzodiazepines	I
midazolam	I
,	O
triazolam	B
GI	O
motility	O
agents	B
:	O
cisapride	B

Drugs	O
Which	O
Require	O
a	O
Dose	O
Reduction	O
When	O
Coadminstered	O
With	O
VIRACEPT	B
Antimycobacterial	I
agents	I
:	O
rifabutin	B

*	O
This	O
table	O
is	O
not	O
all	O
inclusive	O
*	O
*	O
VIRACEPT	B
may	O
not	O
be	O
effective	O
due	O
to	O
decreased	O
nelfinavir	B
plasma	O
concentrations	O
in	O
patients	O
taking	O
these	O
agents	O
concomitantly	O

Terfenadine	B
:	O
Administration	O
of	O
terfenadine	B
with	O
VIRACEPT	B
resulted	O
in	O
the	O
appearance	O
of	O
unchanged	O
terfenadine	B
in	O
plasma	O
;	O

therefore	O
,	O
VIRACEPT	B
should	O
not	O
be	O
administered	O
concurrently	O
with	O
terfenadine	B
because	O
of	O
the	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
cardiac	O
arrhythmias	O
.	O

Because	O
a	O
similar	O
interaction	O
is	O
likely	O
,	O
VIRACEPT	B
should	O
also	O
not	O
be	O
administered	O
concurrently	O
with	O
astemizole	B
.	O

Indinavir	B
:	O
Coadministration	O
of	O
indinavir	B
with	O
VIRACEPT	B
resulted	O
in	O
an	O
83	O
%	O
increase	O
in	O
nelfinavir	B
plasma	O
AUC	O
and	O
a	O
51	O
%	O
increase	O
in	O
indinavir	B
plasma	O
A	O
.	O
C	O
.	O

Ritonavir	B
:	O
Coadministration	O
of	O
ritonavir	B
with	O
VIRACEPT	B
resulted	O
in	O
a	O
152	O
%	O
increase	O
in	O
nelfinavir	B
plasma	O
AUC	O
and	O
very	O
little	O
change	O
in	O
ritonavir	B
plasma	O
A	O
.	O
C	O
.	O

Saquinavir	B
:	O
Coadministration	O
of	O
saquinavir	B
(	O
using	O
an	O
experimental	O
soft	O
-	O
gelatin	O
capsule	O
formulation	O
of	O
saquinavir	B
1200mg	O
)	O
with	O
VIRACEPT	B
resulted	O
in	O
an	O
18	O
%	O
increase	O
in	O
nelfinavir	B
plasma	O
AUC	O
and	O
a	O
4	O
-	O
fold	O
increase	O
in	O
saquinavir	B
plasma	O
A	O
.	O
C	O
.	O

Ketoconazole	B
:	O
Coadministration	O
of	O
ketoconazole	B
with	O
VIRACEPT	B
resulted	O
in	O
a	O
35	O
%	O
increase	O
in	O
nelfinavir	B
plasma	O
A	O
.	O
C	O
.	O

This	O
change	O
was	O
not	O
considered	O
clinically	O
significant	O
and	O
no	O
dose	O
adjustment	O
is	O
needed	O
when	O
ketoconazole	B
and	O
VIRACEPT	B
are	O
coadministered	O
.	O

Didanosine	B
:	O
It	O
is	O
recommended	O
that	O
didanosine	B
be	O
administered	O
on	O
an	O
empty	O
stomach	O
;	O

therefore	O
,	O
nelfinavir	B
should	O
be	O
administered	O
(	O
with	O
food	O
)	O
one	O
hour	O
after	O
or	O
more	O
than	O
two	O
hours	O
before	O
didanosine	B
.	O

A	O
dose	O
adjustment	O
is	O
not	O
needed	O
when	O
zidovudine	B
is	O
administered	O
with	O
VIRACEPT	B
.	O

Little	O
or	O
no	O
change	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
drug	O
was	O
observed	O
when	O
VIRACEPT	B
was	O
coadministered	O
with	O
lamivudine	B
or	O
stavudine	B
.	O

Rifabutin	B
:	O
Coadministration	O
of	O
rifabutin	B
and	O
VIRACEPT	B
resulted	O
in	O
a	O
32	O
%	O
decrease	O
in	O
nelfinavir	B
plasma	O
AUC	O
and	O
a	O
207	O
%	O
increase	O
in	O
rifabutin	B
plasma	O
A	O
.	O
C	O
.	O

It	O
is	O
recommended	O
that	O
the	O
dose	O
of	O
rifabutin	B
be	O
reduced	O
to	O
one	O
-	O
half	O
the	O
usual	O
dose	O
when	O
administered	O
with	O
VIRACEPT	B
.	O

Rifampin	B
:	O
Coadministration	O
of	O
rifampin	B
and	O
VIRACEPT	B
resulted	O
in	O
an	O
82	O
%	O
decrease	O
in	O
nelfinavir	B
plasma	O
A	O
.	O
C	O
.	O

VIRACEPT	B
and	O
rifampin	B
should	O
not	O
be	O
coadministered	O
.	O

Ethinyl	B
Estradiol	I
and	O
Norethindrone	B
:	O
Coadministration	O
of	O
VIRACEPT	B
with	O
OVCON	O
-	O
35	O
resulted	O
in	O
a	O
47	O
%	O
decrease	O
in	O
ethinyl	B
estradiol	I
and	O
an	O
18	O
%	O
decrease	O
in	O
norethindrone	B
plasma	O
concentrations	O
.	O

Caution	O
should	O
also	O
be	O
taken	O
in	O
concurrent	O
or	O
serial	O
use	O
of	O
other	O
aminoglycosides	B
and	O
polymyxins	B
because	O
they	O
may	O
enhance	O
neomycin	B
s	O
nephrotoxicity	O
and	O
/	O
or	O
ototoxicity	O
and	O
potentiate	O
neomycin	B
sulfate	I
neuromuscular	O
blocking	O
effects	O
.	O

Oral	O
neomycin	B
inhibits	O
the	O
gastrointestinal	O
absorption	O
of	O
penicillin	B
V	I
,	O
oral	O
vitamin	B
B	O
-	O
12	O
,	O
methotrexate	B
and	O
5	O
-	O
fluorouracil	O
.	O

Oral	O
neomycin	B
sulfate	I
may	O
enhance	O
the	O
effect	O
of	O
coumarin	B
in	O
anticoagulants	B
by	O
decreasing	O
vitamin	O
K	O
availability	O
.	O

Certain	O
antibiotics	B
,	O
especially	O
neomycin	B
,	O
streptomycin	B
and	O
kanamycin	B
,	O
have	O
a	O
mild	O
but	O
definite	O
nondepolarizing	O
blocking	O
action	O
which	O
may	O
accentuate	O
neuromuscular	O
block	O
.	O

These	O
antibiotics	B
should	O
be	O
used	O
in	O
the	O
myasthenic	O
patient	O
only	O
where	O
definitely	O
indicated	O
,	O
and	O
then	O
careful	O
adjustment	O
should	O
be	O
made	O
of	O
adjunctive	O
anticholinesterase	B
dosage	O
.	O

Local	O
and	O
some	O
general	O
anesthetics	B
,	O
antiarrhythmic	B
agents	I
and	O
other	O
drugs	O
that	O
interfere	O
with	O
neuromuscular	O
transmission	O
should	O
be	O
used	O
cautiously	O
,	O
if	O
at	O
all	O
,	O
in	O
patients	O
with	O
myasthenia	O
gravis	O
;	O

The	O
co	O
-	O
administration	O
of	O
Natrecor	B
with	O
IV	O
vasodilators	B
such	O
as	O
nitroglycerin	B
,	O
nitroprusside	B
,	O
milrinone	B
,	O
or	O
IV	O
ACE	B
inhibitors	I
has	O
not	O
been	O
evaluated	O
(	O
these	O
drugs	O
were	O
not	O
co	O
-	O
administered	O
with	O
Natrecor	B
in	O
clinical	O
trials	O
)	O
.	O

Netilmicin	B
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
potent	O
loop	B
diuretics	I
such	O
as	O
furosemide	B
and	O
ethacrynic	B
acid	I
as	O
the	O
potential	O
for	O
ototoxicity	O
is	O
enhanced	O
by	O
the	O
combination	O
.	O

The	O
in	O
vitro	O
interaction	O
between	O
nevirapine	B
and	O
the	O
antithrombotic	B
agent	I
warfarin	I
is	O
complex	O
.	O

When	O
warfarin	B
is	O
co	O
-	O
administered	O
with	O
nevirapine	B
,	O
anticoagulation	O
levels	O
should	O
be	O
monitored	O
frequently	O
.	O

Clarithromycin	B
exposure	O
was	O
significantly	O
decreased	O
by	O
nevirapine	B
;	O

Alternatives	O
to	O
clarithromycin	B
,	O
such	O
as	O
azithromycin	B
,	O
should	O
be	O
considered	O
.	O

Ethinyl	B
estradiol	I
and	O
Norethindrone	B

Ethinyl	B
estradiol	I
Norethindrone	I

Oral	O
contraceptives	B
and	O
other	O
hormonalmethods	O
of	O
birth	O
control	O
should	O
not	O
be	O
usedas	O
the	O
sole	O
method	O
of	O
contraception	O
inwomen	O
taking	O
nevirapine	B
,	O
since	O
nevirapinemay	O
lower	O
the	O
plasma	O
levels	O
of	O
thesemedications	O
.	O

Nevirapine	B
and	O
ketoconazole	B
should	O
not	O
beadministered	O
concomitantly	O
becausedecreases	O
in	O
ketoconazole	B
plasmaconcentrations	O
may	O
reduce	O
the	O
efficacy	O
of	O
the	O
drug	O
.	O

Lopinavir	B
/	O
Ritonavir	B

A	O
dose	O
increase	O
of	O
lopinavir	B
/	O
ritonavir	B
to	O
533	O
/	O
133	O
mg	O
twice	O
daily	O
with	O
food	O
isrecommended	O
in	O
combination	O
with	O
nevirapine	B
.	O

Methadone	B
levels	O
may	O
be	O
decreased	O
;	O
increased	O
dosages	O
may	O
be	O
required	O
to	O
prevent	O
symptoms	O
of	O
opiate	B
withdrawal	O
.	O
Methadone	B
maintained	O
patients	O
beginning	O
nevirapine	B
therapy	O
should	O
be	O
monitored	O
forevidence	O
of	O
withdrawal	O
and	O
methadone	B
dose	O
should	O
be	O
adjusted	O
accordingly	O
.	O

The	O
appropriate	O
dose	O
for	O
nelfinavir	B
incombination	O
with	O
nevirapine	B
,	O
with	O
respectto	O
safety	O
and	O
efficacy	O
,	O
has	O
not	O
been	O
established	O
.	O

Nevirapine	B
and	O
rifampin	B
should	O
not	O
beadministered	O
concomitantly	O
becausedecreases	O
in	O
nevirapine	B
plasmaconcentrations	O
may	O
reduce	O
the	O
efficacy	O
ofthe	O
drug	O
.	O

Physicians	O
needing	O
to	O
treatpatients	O
co	O
-	O
infected	O
with	O
tuberculosis	O
andusing	O
a	O
nevirapine	B
containing	O
regimen	O
mayuse	O
rifabutin	B
instead	O
.	O

aBased	O
on	O
reports	O
of	O
narcotic	O
withdrawal	O
syndrome	O
in	O
patients	O
treated	O
with	O
nevirapine	B
and	O
methadone	B
concurrently	O
,	O
and	O
evidence	O
of	O
decreased	O
plasma	O
concentrations	O
of	O
methadone	B
.	O

Amiodarone	B
,	O
disopyramide	B
,	O
lidocaine	B

Carbamazepine	B
,	O
clonazepam	B
,	O
ethosuximide	B

Diltiazem	B
,	O
nifedipine	B
,	O
verapamil	B

Cyclosporin	B
,	O
tacrolimus	B
,	O
sirolimus	B

Interactions	O
for	O
Vitamin	B
B3	I
(	O
Niacin	B
)	O
:	O
Antihypertensive	B
Therapy	O
:	O
Nicotinic	B
acid	I
may	O
potentiate	O
the	O
effects	O
of	O
ganglionic	B
blocking	I
agents	I
and	O
vasoactive	O
drugs	O
resulting	O
in	O
postural	O
hypotension	O
.	O

Aspirin	B
:	O
Concomitant	O
aspirin	B
may	O
decrease	O
the	O
metabolic	O
clearance	O
of	O
nicotinic	B
acid	I
.	O

Beta	O
-	O
Blockers	O
:	O
In	O
controlled	O
clinical	O
studies	O
,	O
adrenergic	B
beta	O
-	O
receptor	O
blockers	B
have	O
been	O
frequently	O
administered	O
concomitantly	O
with	O
nicardipine	B
HCl	I
.	O

Cimetidine	B
:	O
Cimetidine	B
increases	O
nicardipine	B
HCl	I
plasma	O
levels	O
.	O

Digoxin	B
:	O
Some	O
calcium	B
blockers	I
may	O
increase	O
the	O
concentration	O
of	O
digitalis	B
preparations	I
in	O
the	O
blood	O
.	O

Nicardipine	B
HCl	I
usually	O
does	O
not	O
alter	O
the	O
plasma	O
levels	O
of	O
digoxin	B
,	O
however	O
,	O
serum	O
digoxin	B
levels	O
should	O
be	O
evaluated	O
after	O
concomitant	O
therapy	O
with	O
nicardipine	B
HCl	I
is	O
initiated	O
.	O

Maalox	B
*	O
Coadministration	O
of	O
Maalox	B
TC	I
had	O
no	O
effect	O
on	O
nicardipine	B
HCl	I
absorption	O
.	O

Cyclosporine	B
:	O
Concomitant	O
administration	O
of	O
nicardipine	B
and	O
cyclosporine	B
levels	O
.	O

Plasma	O
concentrations	O
of	O
cyclosporine	B
should	O
therefore	O
be	O
closely	O
monitored	O
,	O
and	O
its	O
dosage	O
reduced	O
accordingly	O
,	O
in	O
patients	O
treated	O
with	O
nicardipine	B
.	O

When	O
therapeutic	O
concentrations	O
of	O
furosemide	B
,	O
propranolol	B
,	O
dipyridamole	B
,	O
warfarin	B
,	O
quinidine	B
,	O
or	O
naproxen	B
were	O
added	O
to	O
human	O
plasma	O
(	O
in	O
vitro	O
)	O
,	O
the	O
plasma	O
protein	O
binding	O
of	O
nicardipine	B
HCl	I
was	O
not	O
altered	O
.	O

Physiological	O
changes	O
resulting	O
from	O
smoking	O
cessation	O
,	O
with	O
or	O
without	O
nicotine	B
replacement	O
,	O
may	O
alter	O
the	O
pharmacokinetics	O
of	O
certain	O
concomitant	O
medications	O
,	O
such	O
as	O
tricyclic	B
antidepressants	I
and	O
theophylline	B
.	O

Beta	O
-	O
adrenergic	O
Blocking	B
Agents	I
:	O
Experience	O
in	O
over	O
1400	O
patients	O
in	O
a	O
non	O
-	O
comparative	O
clinical	O
trial	O
has	O
shown	O
that	O
concomitant	O
administration	O
of	O
nifedipine	B
and	O
beta	O
-	O
blocking	O
agents	B
is	O
usually	O
well	O
tolerated	O
,	O
but	O
there	O
have	O
been	O
occasional	O
literature	O
reports	O
suggesting	O
that	O
the	O
combination	O
may	O
increase	O
the	O
likelihood	O
of	O
congestive	O
heart	O
failure	O
,	O
severe	O
hypotension	O
or	O
exacerbation	O
of	O
angina	O
.	O

Long	O
Acting	O
Nitrates	B
:	O
Nifedipine	B
may	O
be	O
safely	O
co	O
-	O
administered	O
with	O
nitrates	B
,	O
but	O
there	O
have	O
been	O
no	O
controlled	O
studies	O
to	O
evaluate	O
the	O
antianginal	O
effectiveness	O
of	O
this	O
combination	O
.	O

Digitalis	B
:	O
Immediate	O
Release	O
Capsules	O
:	O
Since	O
there	O
have	O
been	O
isolated	O
reports	O
of	O
patients	O
with	O
elevated	O
digoxin	B
levels	O
,	O
and	O
there	O
is	O
a	O
possible	O
interaction	O
between	O
digoxin	B
and	O
nifedipine	B
,	O
it	O
is	O
recommended	O
that	O
digoxin	B
levels	O
be	O
monitored	O
when	O
initiating	O
,	O
adjusting	O
,	O
and	O
discontinuing	O
nifedipine	B
to	O
avoid	O
possible	O
over	O
-	O
or	O
under	O
-	O
digitalization	O
.	O

Extended	O
Release	O
Tablets	O
:	O
Administration	O
of	O
nifedipine	B
with	O
digoxin	B
increased	O
digoxin	B
levels	O
in	O
9	O
of	O
12	O
normal	O
volunteers	O
.	O

Since	O
there	O
have	O
been	O
isolated	O
reports	O
of	O
patients	O
with	O
elevated	O
digoxin	B
levels	O
,	O
it	O
is	O
recommended	O
that	O
digoxin	B
levels	O
be	O
monitored	O
when	O
initiating	O
,	O
adjusting	O
,	O
and	O
discontinuing	O
nifedipine	B
to	O
avoid	O
possible	O
over	O
-	O
or	O
under	O
-	O
digitalization	O
.	O

Quinidine	B
:	O
Immediate	O
Release	O
Capsules	O
:	O
There	O
have	O
been	O
rare	O
reports	O
of	O
an	O
interaction	O
between	O
quinidine	B
and	O
nifedipine	B
(	O
with	O
a	O
decreased	O
plasma	O
level	O
of	O
quinidine	B
)	O
.	O

Coumarin	B
Anticoagulants	I
:	O
There	O
have	O
been	O
rare	O
reports	O
of	O
increased	O
prothrombin	O
time	O
in	O
patients	O
taking	O
coumarin	B
anticoagulants	I
to	O
whom	O
nifedipine	B
was	O
administered	O
.	O

Cimetidine	B
:	O
A	O
study	O
in	O
6	O
healthy	O
volunteers	O
has	O
shown	O
a	O
significant	O
increase	O
in	O
peak	O
nifedipine	B
plasma	O
levels	O
(	O
80	O
%	O
)	O
and	O
area	O
-	O
under	O
-	O
the	O
-	O
curve	O
(	O
74	O
%	O
)	O
after	O
a	O
1	O
week	O
course	O
of	O
cimetidine	B
at	O
1000	O
mg	O
per	O
day	O
and	O
nifedipine	B
at	O
40	O
mg	O
per	O
day	O
.	O

The	O
effect	O
may	O
be	O
mediated	O
by	O
the	O
known	O
inhibition	O
of	O
cimetidine	B
on	O
hepatic	O
cytochrome	O
P	O
-	O
450	O
,	O
the	O
enzyme	O
system	O
probably	O
responsible	O
for	O
the	O
first	O
-	O
pass	O
metabolism	O
of	O
nifedipine	B
.	O

If	O
nifedipine	B
therapy	O
is	O
initiated	O
in	O
a	O
patient	O
currently	O
receiving	O
cimetidine	B
,	O
cautious	O
titration	O
is	O
advised	O
.	O

Consequently	O
,	O
drugs	O
with	O
a	O
low	O
therapeutic	O
margin	O
,	O
such	O
as	O
vitamin	B
K	I
antagonists	I
,	O
phenytoin	B
,	O
and	O
theophylline	B
,	O
could	O
have	O
a	O
delayed	O
elimination	O
and	O
increases	O
in	O
their	O
serum	O
half	O
-	O
life	O
leading	O
to	O
a	O
toxic	O
level	O
.	O

For	O
example	O
,	O
when	O
vitamin	B
K	I
antagonists	I
are	O
administered	O
concomitantly	O
with	O
nilutamide	B
,	O
prothrombin	O
time	O
should	O
be	O
carefully	O
monitored	O
and	O
if	O
necessary	O
,	O
the	O
dosage	O
of	O
vitamin	B
K	I
antagonists	I
should	O
be	O
reduced	O
.	O

It	O
is	O
possible	O
that	O
the	O
cardiovascular	O
action	O
of	O
other	O
calcium	B
channel	I
blockers	I
could	O
be	O
enhanced	O
by	O
the	O
addition	O
of	O
Nimotop	B
.	O

In	O
Europe	O
,	O
Nimotop	B
was	O
observed	O
to	O
occasionally	O
intensify	O
the	O
effect	O
of	O
antihypertensive	B
compounds	I
taken	O
concomitantly	O
by	O
patients	O
suffering	O
from	O
hypertension	O
;	O

A	O
study	O
in	O
eight	O
healthy	O
volunteers	O
has	O
shown	O
a	O
50	O
%	O
increase	O
in	O
mean	O
peak	O
nimodipine	B
plasma	O
concentrations	O
and	O
a	O
90	O
%	O
increase	O
in	O
mean	O
area	O
under	O
the	O
curve	O
,	O
after	O
a	O
one	O
week	O
course	O
of	O
cimetidine	B
at	O
1	O
,	O
000	O
mg	O
/	O
day	O
and	O
nimodipine	B
at	O
90	O
mg	O
/	O
day	O
.	O

This	O
effect	O
may	O
be	O
mediated	O
by	O
the	O
known	O
inhibition	O
of	O
hepatic	O
cytochrome	O
P	O
-	O
450	O
by	O
cimetidine	B
,	O
which	O
could	O
decrease	O
first	O
pass	O
metabolism	O
of	O
nimodipine	B
.	O

A	O
30	O
to	O
45	O
%	O
increase	O
in	O
AUC	O
and	O
Cmax	O
of	O
nisoldipine	B
was	O
observed	O
with	O
concomitant	O
administration	O
of	O
cimetidine	B
400	I
mg	I
twice	O
daily	O
.	O

Ranitidine	B
150	O
mg	O
twice	O
daily	O
did	O
not	O
interact	O
significantly	O
with	O
nisoldipine	B
(	O
AUC	O
was	O
decreased	O
by	O
15	O
-	O
20	O
%	O
)	O
.	O

Coadministration	O
of	O
phenytoin	B
with	O
40	O
mg	O
SULAR	B
tablets	O
in	O
epileptic	O
patients	O
lowered	O
the	O
nisoldipine	B
plasma	O
concentrations	O
to	O
undetectable	O
levels	O
.	O

Coadministration	O
of	O
SULAR	B
with	O
phenytoin	B
or	O
any	O
known	O
CYP3A4	O
inducer	O
should	O
be	O
avoided	O
and	O
alternative	O
antihypertensive	B
therapy	O
should	O
be	O
considered	O
.	O

Pharmacokinetic	O
interactions	O
between	O
nisoldipine	B
and	O
beta	O
-	O
blockers	O
(	O
atenolol	B
,	O
propranolol	B
)	O
were	O
variable	O
and	O
not	O
significant	O
.	O

Propranolol	B
attenuated	O
the	O
heart	O
rate	O
increase	O
following	O
administration	O
of	O
immediate	O
release	O
nisoldipine	B
.	O

The	O
blood	O
pressure	O
effect	O
of	O
SULAR	B
tended	O
to	O
be	O
greater	O
in	O
patients	O
on	O
atenolol	B
than	O
in	O
patients	O
on	O
no	O
other	O
antihypertensive	B
therapy	O
.	O

Quinidine	B
at	O
648	O
mg	O
bid	O
decreased	O
the	O
bioavailability	O
(	O
AUC	O
)	O
of	O
nisoldipine	B
by	O
26	O
%	O
,	O
but	O
not	O
the	O
peak	O
concentration	O
.	O

The	O
immediate	O
release	O
,	O
but	O
not	O
the	O
coat	O
-	O
core	O
formulation	O
of	O
nisoldipine	B
increased	O
plasma	O
quinidine	B
concentrations	O
by	O
about	O
20	O
%	O
.	O

No	O
significant	O
interactions	O
were	O
found	O
between	O
nisoldipine	B
and	O
warfarin	B
or	O
digoxin	B
.	O

Therefore	O
,	O
caution	O
should	O
be	O
used	O
when	O
administering	O
nitazoxanide	B
concurrently	O
with	O
other	O
highly	O
plasma	O
protein	O
-	O
bound	O
drugs	O
with	O
narrow	O
therapeutic	O
indices	O
,	O
as	O
competition	O
for	O
binding	O
sites	O
may	O
occur	O
(	O
e	O
.	O
g	O
.	O
,	O
warfarin	B
)	O
.	O

INOmax	B
has	O
been	O
administered	O
with	O
tolazoline	B
,	O
dopamine	B
,	O
dobutamine	B
,	O
steroids	B
,	O
surfactant	B
,	O
and	O
high	O
-	O
frequency	O
ventilation	O
.	O

Although	O
there	O
are	O
no	O
study	O
data	O
to	O
evaluate	O
the	O
possibility	O
,	O
nitric	B
oxide	I
donor	I
compounds	I
,	O
including	O
sodium	B
nitroprusside	I
and	O
nitroglycerin	B
,	O
may	O
have	O
an	O
additive	O
effect	O
with	O
INOmax	B
on	O
the	O
risk	O
of	O
developing	O
methemoglobinemia	O
.	O

Antacids	B
containing	O
magnesium	B
trisilicate	I
,	O
when	O
administered	O
concomitantly	O
with	O
nitrofurantoin	B
,	O
reduce	O
both	O
the	O
rate	O
and	O
extent	O
of	O
absorption	O
.	O

The	O
mechanism	O
for	O
this	O
interaction	O
probably	O
is	O
adsorption	O
of	O
nitrofurantoin	B
onto	O
the	O
surface	O
of	O
magnesium	B
trisilicate	I
.	O

Uricosuric	B
drugs	I
,	O
such	O
as	O
probenecid	B
and	O
sulfinpyrazone	B
,	O
can	O
inhibit	O
renal	O
tubular	O
secretion	O
of	O
nitrofurantoin	B
.	O

The	O
resulting	O
increase	O
in	O
nitrofurantoin	B
serum	O
levels	O
may	O
increase	O
toxicity	O
,	O
and	O
the	O
decreased	O
urinary	O
levels	O
could	O
lessen	O
its	O
efficacy	O
as	O
a	O
urinary	O
tract	O
antibacterial	B
.	O

The	O
vasodilating	O
effects	O
of	O
nitroglycerin	B
may	O
be	O
additive	O
with	O
those	O
of	O
other	O
vasodilators	B
.	O

Marked	O
symptomatic	O
orthostatic	O
hypotension	O
has	O
been	O
reported	O
when	O
calcium	B
channel	I
blockers	I
and	O
organic	O
nitrates	B
were	O
used	O
in	O
combination	O
.	O

The	O
hypotensive	B
effect	O
of	O
sodium	B
nitroprusside	I
is	O
augmented	O
by	O
that	O
of	O
most	O
other	O
hypotensive	B
drugs	I
,	O
including	O
ganglionic	B
blocking	I
agents	I
,	O
negative	O
inotropic	O
agents	B
,	O
and	O
inhaled	O
anesthetics	B
.	O

No	O
interactions	O
have	O
been	O
observed	O
between	O
nizatidine	B
and	O
theophylline	B
,	O
chlordiazepoxide	B
,	O
lorazepam	B
,	O
lidocaine	B
,	O
phenytoin	B
,	O
and	O
warfarin	B
.	O

In	O
patients	O
given	O
very	O
high	O
doses	O
(	O
3900	O
mg	O
)	O
of	O
aspirin	B
daily	O
,	O
increases	O
in	O
serum	O
salicylate	B
levels	O
were	O
seen	O
when	O
nizatidine	B
,	O
150	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
,	O
was	O
administered	O
concurrently	O
.	O

The	O
effectiveness	O
of	O
progestin	B
-	O
only	O
pills	O
is	O
reduced	O
by	O
hepatic	O
enzyme	O
-	O
inducing	O
drugs	O
such	O
as	O
the	O
anticonvulsants	B
phenytoin	I
,	O
carbamazepine	B
,	O
and	O
barbiturates	B
,	O
and	O
the	O
antituberculosis	B
drug	I
rifampin	I
.	O

Elevated	O
plasma	O
levels	O
of	O
theophylline	B
have	O
been	O
reported	O
with	O
concomitant	O
quinolone	B
use	O
.	O

There	O
have	O
been	O
reports	O
of	O
theophylline	B
-	O
related	O
side	O
effects	O
in	O
patients	O
on	O
concomitant	O
therapy	O
with	O
norfloxacin	B
and	O
theophylline	B
.	O

Therefore	O
,	O
monitoring	O
of	O
theophylline	B
plasma	O
levels	O
should	O
be	O
considered	O
and	O
dosage	O
of	O
theophylline	B
adjusted	O
as	O
required	O
.	O

Elevated	O
serum	O
levels	O
of	O
cyclosporine	B
have	O
been	O
reported	O
with	O
concomitant	O
use	O
of	O
cyclosporine	B
with	O
norfloxacin	B
.	O

Therefore	O
,	O
cyclosporine	B
serum	O
levels	O
should	O
be	O
monitored	O
and	O
appropriate	O
cyclosporine	B
dosage	O
adjustments	O
made	O
when	O
these	O
drugs	O
are	O
used	O
concomitantly	O
.	O

Quinolones	B
,	O
including	O
norfloxacin	B
,	O
may	O
enhance	O
the	O
effects	O
of	O
oral	O
anticoagulants	B
,	O
including	O
warfarin	B
or	O
its	O
derivatives	O
or	O
similar	O
agents	O
.	O

The	O
concomitant	O
administration	O
of	O
quinolones	B
including	O
norfloxacin	B
with	O
glyburide	B
(	O
a	O
sulfonylurea	B
agent	I
)	O
has	O
,	O
on	O
rare	O
occasions	O
,	O
resulted	O
in	O
severe	O
hypoglycemia	O
.	O

Diminished	O
urinary	O
excretion	O
of	O
norfloxacin	B
has	O
been	O
reported	O
during	O
the	O
concomitant	O
administration	O
of	O
probenecid	B
and	O
norfloxacin	B
.	O

The	O
concomitant	O
use	O
of	O
nitrofurantoin	B
is	O
not	O
recommended	O
since	O
nitrofurantoin	B
may	O
antagonize	O
the	O
antibacterial	O
effect	O
of	O
Norfloxacin	B
in	O
the	O
urinary	O
tract	O
.	O

Multivitamins	B
,	O
or	O
other	O
products	O
containing	O
iron	B
or	O
zinc	B
,	O
antacids	B
or	O
sucralfate	B
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
,	O
or	O
within	O
2	O
hours	O
of	O
,	O
the	O
administration	O
of	O
norfloxacin	B
,	O
because	O
they	O
may	O
interfere	O
with	O
absorption	O
resulting	O
in	O
lower	O
serum	O
and	O
urine	O
levels	O
of	O
norfloxacin	B
.	O

Videx	B
(	O
Didanosine	B
)	O
chewable	O
/	O
buffered	O
tablets	O
or	O
the	O
pediatric	O
powder	O
for	O
oral	O
solution	O
should	O
not	O
be	O
administered	O
concomitantly	O
with	O
,	O
or	O
within	O
2	O
hours	O
of	O
,	O
the	O
administration	O
of	O
norfloxacin	B
,	O
because	O
these	O
products	O
may	O
interfere	O
with	O
absorption	O
resulting	O
in	O
lower	O
serum	O
and	O
urine	O
levels	O
of	O
norfloxacin	B
.	O

Some	O
quinolones	B
have	O
also	O
been	O
shown	O
to	O
interfere	O
with	O
the	O
metabolism	O
of	O
caffeine	B
.	O

A	O
similar	O
association	O
,	O
though	O
less	O
marked	O
,	O
has	O
been	O
suggested	O
with	O
barbiturates	B
,	O
phenylbutazone	B
,	O
phenytoin	B
sodium	I
,	O
carbamazepine	B
,	O
griseofulvin	B
,	O
topiramate	B
,	O
and	O
possibly	O
with	O
ampicillin	B
and	O
tetracyclines	B
72	O
.	O

A	O
possible	O
interaction	O
has	O
been	O
suggested	O
with	O
hormonal	B
contraceptives	I
and	O
the	O
herbal	O
supplement	O
St	O
.	O
Johns	O
Wort	O
based	O
on	O
some	O
reports	O
of	O
oral	O
contraceptive	B
users	O
experiencing	O
breakthrough	O
bleeding	O
shortly	O
after	O
starting	O
St	O
.	O
Johns	O
Wort	O
.	O

Steady	O
-	O
state	O
serum	O
concentrations	O
of	O
tricyclic	B
antidepressants	I
are	O
reported	O
to	O
fluctuate	O
significantly	O
when	O
cimetidine	B
is	O
either	O
added	O
or	O
deleted	O
from	O
the	O
drug	O
regimen	O
.	O

Serious	O
anticholinergic	O
symptoms	O
(	O
severe	O
dry	O
mouth	O
,	O
urinary	O
retention	O
,	O
blurred	O
vision	O
)	O
have	O
been	O
associated	O
with	O
elevations	O
in	O
the	O
serum	O
levels	O
of	O
tricyclic	B
antidepressants	I
when	O
cimetidine	B
is	O
added	O
to	O
the	O
drug	O
regimen	O
.	O

In	O
addition	O
,	O
higher	O
-	O
than	O
expected	O
steady	O
-	O
state	O
serum	O
concentrations	O
of	O
tricyclic	B
antidepressants	I
have	O
been	O
observed	O
when	O
therapy	O
is	O
initiated	O
in	O
patients	O
already	O
taking	O
cimetidine	B
.	O

In	O
well	O
-	O
controlled	O
patients	O
undergoing	O
concurrent	O
therapy	O
with	O
cimetidine	B
,	O
a	O
decrease	O
in	O
the	O
steady	O
-	O
state	O
serum	O
concentrations	O
of	O
tricyclic	B
antidepressants	I
may	O
occur	O
when	O
cime	O
-	O
tidine	O
therapy	O
is	O
discontinued	O
.	O

The	O
therapeutic	O
efficacy	O
of	O
tricyclic	B
antidepressants	I
may	O
be	O
compromised	O
in	O
these	O
patients	O
when	O
cimetidine	B
is	O
discontinued	O
.	O

There	O
have	O
been	O
greater	O
than	O
2	O
-	O
fold	O
increases	O
in	O
previously	O
stable	O
plasma	O
levels	O
of	O
other	O
antidepressants	B
,	O
including	O
nortriptyline	B
,	O
when	O
fluoxetine	B
hydrochloride	I
has	O
been	O
administered	O
in	O
combination	O
with	O
these	O
agents	O
.	O

Fluoxetine	B
and	O
its	O
active	O
metabolite	O
,	O
norfluoxe	O
-	O
tine	O
,	O
have	O
long	O
half	O
-	O
lives	O
(	O
4	O
to	O
16	O
days	O
for	O
norfluoxetine	B
)	O
,	O
that	O
may	O
affect	O
strategies	O
during	O
conversion	O
from	O
one	O
drug	O
to	O
the	O
other	O
.	O

Administration	O
of	O
reserpine	B
during	O
therapy	O
with	O
a	O
tricyclic	B
antidepressant	I
has	O
been	O
shown	O
to	O
produce	O
a	O
stimulating	O
effect	O
in	O
some	O
depressed	O
patients	O
.	O

Close	O
supervision	O
and	O
careful	O
adjustment	O
of	O
the	O
dosage	O
are	O
required	O
when	O
nortriptyline	B
hydrochloride	I
is	O
used	O
with	O
other	O
anticholinergic	B
drugs	I
or	O
sympathomimetic	B
drugs	I
.	O

Such	O
individuals	O
are	O
referred	O
to	O
as	O
poor	O
metabolizers	O
of	O
drugs	O
such	O
as	O
debrisoquin	B
,	O
dextromethorphan	B
,	O
and	O
the	O
tricyclic	B
antidepressants	I
.	O

In	O
addition	O
,	O
certain	O
drugs	O
that	O
are	O
metabolized	O
by	O
this	O
isoenzyme	O
,	O
including	O
many	O
antidepressants	B
(	O
tricyclic	B
antidepressants	I
,	O
selective	B
serotonin	I
reuptake	I
inhibitors	I
,	O
and	O
others	O
)	O
,	O
may	O
inhibit	O
the	O
activity	O
of	O
this	O
isoenzyme	O
,	O
and	O
thus	O
may	O
make	O
normal	O
metab	O
-	O
olizers	O
resemble	O
poor	O
metabolizers	O
with	O
regard	O
to	O
concomitant	O
therapy	O
with	O
other	O
drugs	O
metabolized	O
by	O
this	O
enzyme	O
system	O
,	O
leading	O
to	O
drug	O
interactions	O
.	O

Concomitant	O
use	O
of	O
tricyclic	B
antidepressants	I
with	O
other	O
drugs	O
metabolized	O
by	O
cytochrome	O
P450IID6	O
may	O
require	O
lower	O
doses	O
than	O
usually	O
prescribed	O
for	O
either	O
the	O
tricyclic	B
antidepressant	I
or	O
the	O
other	O
drug	O
.	O

Therefore	O
,	O
co	O
-	O
administration	O
of	O
tricyclic	B
antidepressants	I
with	O
other	O
drugs	O
that	O
are	O
metabolized	O
by	O
this	O
isoenzyme	O
,	O
including	O
other	O
antidepressants	B
,	O
phenothiazines	B
,	O
carbamazepine	B
,	O
and	O
Type	B
1C	I
antiarrhythmics	I
(	O
eg	O
,	O
propafenone	B
,	O
flecainide	B
,	O
and	O
encainide	B
)	O
,	O
or	O
that	O
inhibit	O
this	O
enzyme	O
(	O
eg	O
,	O
quinidine	B
)	O
,	O
should	O
be	O
approached	O
with	O
caution	O
.	O

In	O
addition	O
,	O
several	O
AED	B
s	O
that	O
are	O
cytochrome	O
P450	O
inducers	O
can	O
decrease	O
plasma	O
concentrations	O
of	O
oxcarbazepine	B
and	O
MHD	B
.	O

Results	O
demonstrate	O
that	O
oxcarbazepine	B
and	O
its	O
pharmacologically	O
active	O
10	O
-	O
monohydroxy	O
metabolite	O
(	O
MHD	B
)	O
have	O
little	O
or	O
no	O
capacity	O
to	O
function	O
as	O
inhibitors	O
for	O
most	O
of	O
the	O
human	O
cytochrome	O
P450	O
enzymes	O
evaluated	O
(	O
CYP1A2	O
,	O
CYP2A6	O
,	O
CYP2C9	O
,	O
CYP2D6	O
,	O
CYP2E1	O
,	O
CYP4A9	O
and	O
CYP4A11	O
)	O
with	O
the	O
exception	O
of	O
CYP2C19	O
and	O
CYP3A4	O
/	O
5	O
.	O

Although	O
inhibition	O
of	O
CYP	O
3A4	O
/	O
5	O
by	O
OXC	B
and	O
MHD	B
did	O
occur	O
at	O
high	O
concentrations	O
,	O
it	O
is	O
not	O
likely	O
to	O
be	O
of	O
clinical	O
significance	O
.	O

The	O
inhibition	O
of	O
CYP	O
-	O
2C19	O
by	O
OXC	B
and	O
MHD	B
,	O
however	O
,	O
is	O
clinically	O
relevant	O
.	O

Increases	O
of	O
22	O
%	O
with	O
MHD	B
and	O
47	O
%	O
with	O
oxcarbazepine	B
were	O
observed	O
.	O

As	O
MHD	B
,	O
the	O
predominant	O
plasma	O
substrate	O
,	O
is	O
only	O
a	O
weak	O
inducer	O
of	O
UDP	O
-	O
glucuronyl	O
transferase	O
,	O
it	O
is	O
unlikely	O
to	O
have	O
an	O
effect	O
on	O
drugs	O
that	O
are	O
mainly	O
eliminated	O
by	O
conjugation	O
through	O
UDP	O
-	O
glucuronyl	O
transferase	O
(	O
e	O
.	O
g	O
.	O
,	O
valproic	B
acid	I
,	O
lamotrigine	B
)	O
.	O

In	O
addition	O
,	O
oxcarbazepine	B
and	O
MHD	B
induce	O
a	O
subgroup	O
of	O
the	O
cytochrome	O
P450	O
3A	O
family	O
(	O
CYP3A4	O
and	O
CYP3A5	O
)	O
responsible	O
for	O
the	O
metabolism	O
of	O
dihydropyridine	B
calcium	I
antagonists	I
and	O
oral	O
contraceptives	B
,	O
resulting	O
in	O
a	O
lower	O
plasma	O
concentration	O
of	O
these	O
drugs	O
.	O

Antiepileptic	B
drugs	I
:	O
Potential	O
interactions	O
between	O
Trileptal	B
and	O
other	O
AEDs	B
were	O
assessed	O
in	O
clinical	O
studies	O
.	O

Influence	O
of	O
Trileptal	B
on	O
AED	B
Concentration	O
(	O
Mean	O
change	O
,	O
90	O
%	O
Confidence	O
Interval	O
)	O

Influence	O
of	O
AED	B
On	O
MHD	B
Concentration	O
(	O
Mean	O
change	O
,	O
90	O
%	O
Confidence	O
Interval	O
)	O

1	O
-	O
nc	O
denotes	O
a	O
mean	O
change	O
of	O
less	O
than	O
10	O
%	O
2	O
-	O
Pediatrics	O
3	O
-	O
Mean	O
increase	O
in	O
adults	O
at	O
high	O
Trileptal	B
doses	O
In	O
vivo	O
,	O
the	O
plasma	O
levels	O
of	O
phenytoin	B
increased	O
by	O
up	O
to	O
40	O
%	O
,	O
when	O
Trileptal	B
was	O
given	O
at	O
doses	O
above	O
1200	O
mg	O
/	O
day	O
.	O

Therefore	O
,	O
when	O
using	O
doses	O
of	O
Trileptal	B
greater	O
than	O
1200	O
mg	O
/	O
day	O
during	O
adjunctive	O
therapy	O
,	O
a	O
decrease	O
in	O
the	O
dose	O
of	O
phenytoin	B
may	O
be	O
required	O
.	O

The	O
increase	O
of	O
phenobarbital	B
level	O
,	O
however	O
,	O
is	O
small	O
(	O
15	O
%	O
)	O
when	O
given	O
with	O
Trileptal	B
.	O

Strong	O
inducers	O
of	O
cytochrome	O
P450	O
enzymes	O
(	O
i	O
.	O
e	O
.	O
carbamazepine	B
,	O
phenytoin	B
and	O
phenobarbital	B
)	O
have	O
been	O
shown	O
to	O
decrease	O
the	O
plasma	O
levels	O
of	O
MHD	B
(	O
29	O
-	O
40	O
%	O
)	O
.	O

Hormonal	O
contraceptives	B
Co	O
-	O
administration	O
of	O
Trileptal	B
with	O
an	O
oral	O
contraceptive	B
has	O
been	O
shown	O
to	O
influence	O
the	O
plasma	O
concentrations	O
of	O
the	O
two	O
hormonal	O
components	O
,	O
ethinylestradiol	B
(	O
EE	O
)	O
and	O
levonorgestrel	B
(	O
LNG	O
)	O
.	O

Therefore	O
,	O
concurrent	O
use	O
of	O
Trileptal	B
with	O
hormonal	B
contraceptives	I
may	O
render	O
these	O
contraceptives	B
less	O
effective	O
.	O

Calcium	B
Antagonists	O
:	O
After	O
repeated	O
co	O
-	O
administration	O
of	O
Trileptal	B
,	O
the	O
AUC	O
of	O
felodipine	B
was	O
lowered	O
by	O
28	O
%	O
[	O
90	O
%	O
CI	O
:	O
20	O
-	O
33	O
]	O
.	O

Verapamil	B
produced	O
a	O
decrease	O
of	O
20	O
%	O
[	O
90	O
%	O
CI	O
:	O
18	O
-	O
27	O
]	O
of	O
the	O
plasma	O
levels	O
of	O
MHD	B
.	O

Other	O
drug	O
interactions	O
Cimetidine	B
,	O
erythromycin	B
and	O
dextropropoxyphene	B
had	O
no	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
MHD	B
.	O

Results	O
with	O
warfarin	B
wshow	O
no	O
evidence	O
of	O
interaction	O
with	O
either	O
single	O
or	O
repeated	O
doses	O
of	O
Trileptal	B
.	O

In	O
a	O
Phase	O
I	O
trial	O
using	O
escalating	O
doses	O
of	O
TAXOL	B
(	O
110	O
-	O
200	O
mg	O
/	O
m2	O
)	O
and	O
cisplatin	B
(	O
50	O
or	O
75	O
mg	O
/	O
m2	O
)	O
given	O
as	O
sequential	O
infusions	O
,	O
myelosuppression	O
was	O
more	O
profound	O
when	O
TAXOL	B
was	O
given	O
after	O
cisplatin	B
than	O
with	O
the	O
alternate	O
sequence	O
(	O
ie	O
,	O
TAXOL	B
before	O
cisplatin	B
)	O
.	O

Pharmacokinetic	O
data	O
from	O
these	O
patients	O
demonstrated	O
a	O
decrease	O
in	O
paclitaxel	B
clearance	O
of	O
approximately	O
33	O
%	O
when	O
TAXOL	B
was	O
administered	O
following	O
cisplatin	B
.	O

Potential	O
interactions	O
between	O
TAXOL	B
,	O
a	O
substrate	O
of	O
CYP3A4	O
,	O
and	O
protease	B
inhibitors	I
(	O
ritonavir	B
,	O
saquinavir	B
,	O
indinavir	B
,	O
and	O
nelfinavir	B
)	O
,	O
which	O
are	O
substrates	O
and	O
/	O
or	O
inhibitors	B
of	O
CYP3A4	O
,	O
have	O
not	O
been	O
evaluated	O
in	O
clinical	O
trials	O
.	O

Reports	O
in	O
the	O
literature	O
suggest	O
that	O
plasma	O
levels	O
of	O
doxorubicin	B
(	O
and	O
its	O
active	O
metabolite	O
doxorubicinol	B
)	O
may	O
be	O
increased	O
when	O
paclitaxel	B
and	O
doxorubicin	B
are	O
used	O
in	O
combination	O
.	O

Hypersensitivity	O
Reactions	O
:	O
Patients	O
with	O
a	O
history	O
of	O
severe	O
hypersensitivity	O
reactions	O
to	O
products	O
containing	O
Cremophor	O
EL	O
(	O
eg	O
,	O
cyclosporin	B
for	O
injection	O
concentrate	O
and	O
teniposide	B
for	O
injection	O
concentrate	O
)	O
should	O
not	O
be	O
treated	O
with	O
TAXOL	B
.	O

In	O
order	O
to	O
avoid	O
the	O
occurrence	O
of	O
severe	O
hypersensitivity	O
reactions	O
,	O
all	O
patients	O
treated	O
with	O
TAXOL	B
should	O
be	O
premedicated	O
with	O
corticosteroids	B
(	O
such	O
as	O
dexamethasone	B
)	O
,	O
diphen	O
-	O
hydramine	O
and	O
H2	B
antagonists	I
(	O
such	O
as	O
cimetidine	B
or	O
ranitidine	B
)	O
.	O

However	O
,	O
severe	O
reactions	O
,	O
such	O
as	O
hypotension	O
requiring	O
treatment	O
,	O
dyspnea	O
requiring	O
bronchodilators	B
,	O
angioedema	O
,	O
or	O
generalized	O
urticaria	O
require	O
immediate	O
discontinuation	O
of	O
TAXOL	B
and	O
aggressive	O
symptomatic	O
therapy	O
.	O

Treatment	O
with	O
PEGASYS	B
once	O
weekly	O
for	O
4	O
weeks	O
in	O
healthy	O
subjects	O
was	O
associated	O
with	O
an	O
inhibition	O
of	O
P450	O
1A2	O
and	O
a	O
25	O
%	O
increase	O
in	O
theophylline	B
AUC	O
.	O

Theophylline	B
serum	O
levels	O
should	O
be	O
monitored	O
and	O
appropriate	O
dose	O
adjustments	O
considered	O
for	O
patients	O
given	O
both	O
theophylline	B
and	O
PEGASYS	B
.	O

In	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
treated	O
with	O
PEGASYS	B
in	O
combination	O
with	O
COPEGUS	B
,	O
PEGASYS	B
treatment	O
did	O
not	O
affect	O
ribavirin	B
distribution	O
or	O
clearance	O
.	O

Nucleoside	O
Analogues	O
Didanosine	B
Co	O
-	O
administration	O
of	O
COPEGUS	B
and	O
didanosine	B
is	O
not	O
recommended	O
.	O

Stavudine	B
and	O
Zidovudine	B
Ribavirin	I
can	O
antagonize	O
the	O
in	O
vitro	O
antiviral	O
activity	O
of	O
stavudine	B
and	O
zidovudine	B
against	O
HIV	O
.	O

Use	O
With	O
Ribavirin	B
Ribavirin	I
is	O
genotoxic	O
and	O
mutagenic	O
.	O

Pregnancy	O
:	O
Category	O
X	O
:	O
Use	O
With	O
Ribavirin	B
(	O
see	O
CONTRAINDICATIONS	O
)	O
Significant	O
teratogenic	O
and	O
/	O
or	O
embryocidal	O
effects	O
have	O
been	O
demonstrated	O
in	O
all	O
animal	O
species	O
exposed	O
to	O
ribavirin	B
.	O

Nursing	O
Mothers	O
It	O
is	O
not	O
known	O
whether	O
peginterferon	B
or	O
ribavirin	B
or	O
its	O
components	O
are	O
excreted	O
in	O
human	O
milk	O
.	O

The	O
effect	O
of	O
orally	O
ingested	O
peginterferon	B
or	O
ribavirin	B
from	O
breast	O
milk	O
on	O
the	O
nursing	O
infant	O
has	O
not	O
been	O
evaluated	O
.	O

Because	O
of	O
the	O
potential	O
for	O
adverse	O
reactions	O
from	O
the	O
drugs	O
in	O
nursing	O
infants	O
,	O
a	O
decision	O
must	O
be	O
made	O
whether	O
to	O
discontinue	O
nursing	O
or	O
discontinue	O
PEGASYS	B
and	O
COPEGUS	B
treatment	O
.	O

Pediatric	O
Use	O
The	O
safety	O
and	O
effectiveness	O
of	O
PEGASYS	B
,	O
alone	O
or	O
in	O
combination	O
with	O
COPEGUS	B
in	O
patients	O
below	O
the	O
age	O
of	O
18	O
years	O
have	O
not	O
been	O
established	O
.	O

PEGASYS	B
contains	O
benzyl	B
alcohol	I
.	O

Clinical	O
studies	O
of	O
PEGASYS	B
alone	O
or	O
in	O
combination	O
with	O
COPEGUS	B
did	O
not	O
include	O
sufficient	O
numbers	O
of	O
subjects	O
aged	O
65	O
or	O
over	O
to	O
determine	O
whether	O
they	O
respond	O
differently	O
from	O
younger	O
subjects	O
.	O

Adverse	O
reactions	O
related	O
to	O
alpha	B
interferons	O
,	O
such	O
as	O
CNS	O
,	O
cardiac	O
,	O
and	O
systemic	O
(	O
eg	O
,	O
flu	O
-	O
like	O
)	O
effects	O
may	O
be	O
more	O
severe	O
in	O
the	O
elderly	O
and	O
caution	O
should	O
be	O
exercised	O
in	O
the	O
use	O
of	O
PEGASYS	B
in	O
this	O
population	O
.	O

PEGASYS	B
and	O
COPEGUS	B
are	O
excreted	O
by	O
the	O
kidney	O
,	O
and	O
the	O
risk	O
of	O
toxic	O
reactions	O
to	O
this	O
therapy	O
may	O
be	O
greater	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
.	O

PEGASYS	B
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
creatinine	O
clearance	O
50	O
mL	O
/	O
min	O
and	O
COPEGUS	B
should	O
not	O
be	O
administered	O
to	O
patients	O
with	O
creatinine	O
clearance	O
50	O
mL	O
/	O
min	O

Aminoglycosides	B
:	O
The	O
mixing	O
of	O
piperacillin	B
with	O
an	O
aminoglycoside	B
in	O
vitro	O
can	O
result	O
in	O
substantial	O
inactivation	O
of	O
the	O
aminoglycoside	B
.	O

Vecuronium	B
:	O
When	O
used	O
in	O
the	O
perioperative	O
period	O
,	O
piperacillin	B
has	O
been	O
implicated	O
in	O
the	O
prolongation	O
of	O
the	O
neuromuscular	O
blockade	O
of	O
vecuronium	B
.	O

In	O
one	O
controlled	O
clinical	O
study	O
,	O
the	O
ureidopenicillins	O
,	O
including	O
piperacillin	B
,	O
were	O
reported	O
to	O
prolong	O
the	O
action	O
of	O
vecuronium	B
.	O

Due	O
to	O
their	O
similar	O
mechanism	O
of	O
action	O
,	O
it	O
is	O
expected	O
that	O
the	O
neuromuscular	O
blockade	O
produced	O
by	O
any	O
of	O
the	O
non	O
-	O
depolarizing	O
muscle	B
relaxants	I
could	O
be	O
prolonged	O
in	O
the	O
presence	O
of	O
piperacillin	B
.	O

Probenecid	B
:	O
The	O
oral	O
combination	O
of	O
probenecid	B
before	O
intramuscular	O
injection	O
of	O
PIPRACIL	B
produces	O
an	O
increase	O
in	O
piperacillin	B
peak	O
serum	O
level	O
of	O
about	O
30	O
%	O
.	O

Anticoagulants	B
:	O
Coagulation	O
parameters	O
should	O
be	O
tested	O
more	O
frequently	O
and	O
monitored	O
regularly	O
during	O
simultaneous	O
administration	O
of	O
high	O
doses	O
of	O
heparin	B
,	O
oral	O
anticoagulants	B
,	O
or	O
other	O
drugs	O
that	O
may	O
affect	O
the	O
blood	O
coagulation	O
system	O
or	O
the	O
thrombocyte	O
function	O
.	O

Methotrexate	B
:	O
Piperacillin	B
sodium	I
may	O
reduce	O
the	O
excretion	O
of	O
methotrexate	B
.	O

Drug	O
/	O
Laboratory	O
Test	O
Interactions	O
As	O
with	O
other	O
penicillins	B
,	O
the	O
administration	O
of	O
PIPRACIL	B
may	O
result	O
in	O
a	O
false	O
-	O
positive	O
reaction	O
for	O
glucose	O
in	O
the	O
urine	O
using	O
a	O
copper	O
-	O
reduction	O
method	O
.	O

There	O
have	O
been	O
reports	O
of	O
positive	O
test	O
results	O
using	O
the	O
Bio	O
-	O
Rad	O
Laboratories	O
Platelia	O
Aspergillus	O
EIA	O
test	O
in	O
patients	O
receiving	O
piperacillin	B
/	O
tazobactam	B
injection	O
who	O
were	O
subsequently	O
found	O
to	O
be	O
free	O
of	O
Aspergillus	O
infection	O
.	O

Phenothiazines	B
-	O
Taking	O
piperazine	B
and	O
a	O
phenothiazine	B
together	O
may	O
increase	O
the	O
risk	O
of	O
convulsions	O
(	O
seizures	O
)	O
.	O

Pyrantel	B
(	O
e	O
.	O
g	O
.	O
,	O
Antiminth	B
)	O
-	O
Taking	O
piperazine	B
and	O
pyrantel	B
together	O
may	O
decrease	O
the	O
effects	O
of	O
piperazine	B
.	O

ACE	B
inhibitors	I
:	O
Reports	O
suggest	O
that	O
NSAIDs	B
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
Angiotensin	B
Converting	I
Enzyme	I
(	O
ACE	B
)	O
inhibitors	B
.	O

In	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	O
,	O
administration	O
of	O
25	O
mg	O
daily	O
of	O
VIOXX	B
with	O
the	O
ACE	B
inhibitor	I
benazepril	I
,	O
10	O
to	O
40	O
mg	O
for	O
4	O
weeks	O
,	O
was	O
associated	O
with	O
an	O
average	O
increase	O
in	O
mean	O
arterial	O
pressure	O
of	O
about	O
3	O
mm	O
Hg	O
compared	O
to	O
ACE	B
inhibitor	I
alone	O
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
VIOXX	B
concomitantly	O
with	O
ACE	B
inhibitors	I
.	O

Aspirin	B
:	O
Concomitant	O
administration	O
of	O
low	O
-	O
dose	O
aspirin	B
with	O
VIOXX	B
may	O
result	O
in	O
an	O
increased	O
rate	O
of	O
GI	O
ulceration	O
or	O
other	O
complications	O
,	O
compared	O
to	O
use	O
of	O
VIOXX	B
alone	O
.	O

In	O
a	O
12	O
-	O
week	O
endoscopy	O
study	O
conducted	O
in	O
OA	O
patients	O
there	O
was	O
no	O
difference	O
in	O
the	O
cumulative	O
incidence	O
of	O
endoscopic	O
gastroduodenal	O
ulcers	O
in	O
patients	O
taking	O
low	O
-	O
dose	O
(	O
81	O
mg	O
)	O
enteric	O
coated	O
aspirin	B
plus	O
VIOXX	B
25	O
mg	O
daily	O
,	O
as	O
compared	O
to	O
those	O
taking	O
ibuprofen	B
2400	O
mg	O
daily	O
alone	O
.	O

Patients	O
taking	O
low	O
-	O
dose	O
aspirin	B
plus	O
ibuprofen	B
were	O
not	O
studied	O
.	O

At	O
steady	O
state	O
,	O
VIOXX	B
50	O
mg	O
once	O
daily	O
had	O
no	O
effect	O
on	O
the	O
anti	O
-	O
platelet	O
activity	O
of	O
low	O
-	O
dose	O
(	O
81	O
mg	O
once	O
daily	O
)	O
aspirin	B
,	O
as	O
assessed	O
by	O
ex	O
vivo	O
platelet	O
aggregation	O
and	O
serum	O
TXB2	O
generation	O
in	O
clotting	O
blood	O
.	O

Because	O
of	O
its	O
lack	O
of	O
platelet	O
effects	O
,	O
VIOXX	B
is	O
not	O
a	O
substitute	O
for	O
aspirin	B
for	O
cardiovascular	O
prophylaxis	O
.	O

Prospective	O
,	O
long	O
-	O
term	O
studies	O
on	O
concomitant	O
administration	O
of	O
VIOXX	B
and	O
aspirin	B
have	O
not	O
been	O
conducted	O
.	O

Cimetidine	B
:	O
Co	O
-	O
administration	O
with	O
high	O
doses	O
of	O
cimetidine	B
[	O
800	O
mg	O
twice	O
daily	O
]	O
increased	O
the	O
Cmax	O
of	O
rofecoxib	B
by	O
21	O
%	O
,	O
the	O
AUC0	O
-	O
120hr	O
by	O
23	O
%	O
and	O
the	O
t1	O
/	O
2	O
by	O
15	O
%	O
.	O

Digoxin	B
:	O
Rofecoxib	B
75	O
mg	O
once	O
daily	O
for	O
11	O
days	O
does	O
not	O
alter	O
the	O
plasma	O
concentration	O
profile	O
or	O
renal	O
elimination	O
of	O
digoxin	B
after	O
a	O
single	O
0	O
.	O
5	O
mg	O
oral	O
dose	O
.	O

Furosemide	B
:	O
Clinical	O
studies	O
,	O
as	O
well	O
as	O
post	O
-	O
marketing	O
observations	O
,	O
have	O
shown	O
that	O
NSAIDs	B
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B
and	O
thiazides	B
in	O
some	O
patients	O
.	O

Ketoconazole	B
:	O
Ketoconazole	B
400	O
mg	O
daily	O
did	O
not	O
have	O
any	O
clinically	O
important	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
rofecoxib	B
.	O

Lithium	B
:	O
NSAIDs	B
have	O
produced	O
an	O
elevation	O
of	O
plasma	O
lithium	B
levels	O
and	O
a	O
reduction	O
in	O
renal	O
lithium	B
clearance	O
.	O

Thus	O
,	O
when	O
VIOXX	B
and	O
lithium	B
are	O
administered	O
concurrently	O
,	O
subjects	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
of	O
lithium	B
toxicity	O
.	O

Methotrexate	B
VIOXX	I
12	O
.	O
5	O
,	O
25	O
,	O
and	O
50	O
mg	O
,	O
each	O
dose	O
administered	O
once	O
daily	O
for	O
7	O
days	O
,	O
had	O
no	O
effect	O
on	O
the	O
plasma	O
concentration	O
of	O
methotrexate	B
as	O
measured	O
by	O
AUC0	O
-	O
24hr	O
in	O
patients	O
receiving	O
single	O
weekly	O
methotrexate	B
doses	O
of	O
7	O
.	O
5	O
to	O
20	O
mg	O
for	O
rheumatoid	O
arthritis	O
.	O

At	O
higher	O
than	O
recommended	O
doses	O
,	O
VIOXX	B
75	O
mg	O
administered	O
once	O
daily	O
for	O
10	O
days	O
increased	O
plasma	O
concentrations	O
by	O
23	O
%	O
as	O
measured	O
by	O
AUC0	O
-	O
24hr	O
in	O
patients	O
receiving	O
methotrexate	B
7	O
.	O
5	O
to	O
15	O
mg	O
/	O
week	O
for	O
rheumatoid	O
arthritis	O
.	O

At	O
24	O
hours	O
postdose	O
,	O
a	O
similar	O
proportion	O
of	O
patients	O
treated	O
with	O
methotrexate	B
alone	O
(	O
94	O
%	O
)	O
and	O
subsequently	O
treated	O
with	O
methotrexate	B
co	O
-	O
administered	O
with	O
75	O
mg	O
of	O
rofecoxib	B
(	O
88	O
%	O
)	O
had	O
methotrexate	B
plasma	O
concentrations	O
below	O
the	O
measurable	O
limit	O
(	O
5	O
ng	O
/	O
mL	O
)	O
.	O

Standard	O
monitoring	O
of	O
methotrexate	B
-	O
related	O
toxicity	O
should	O
be	O
continued	O
if	O
VIOXX	B
and	O
methotrexate	B
are	O
administered	O
concomitantly	O
.	O

Oral	O
Contraceptives	B
Rofecoxib	I
did	O
not	O
have	O
any	O
clinically	O
important	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
ethinyl	B
estradiol	I
and	O
norethindrone	B
.	O

Prednisone	B
/	O
prednisolone	B
:	O
Rofecoxib	B
did	O
not	O
have	O
any	O
clinically	O
important	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
prednisolone	B
or	O
prednisone	B
.	O

Rifampin	B
:	O
Co	O
-	O
administration	O
of	O
VIOXX	B
with	O
rifampin	B
600	O
mg	O
daily	O
,	O
a	O
potent	O
inducer	O
of	O
hepatic	O
metabolism	O
,	O
produced	O
an	O
approximate	O
50	O
%	O
decrease	O
in	O
rofecoxib	B
plasma	O
concentrations	O
.	O

Therefore	O
,	O
a	O
starting	O
daily	O
dose	O
of	O
25	O
mg	O
of	O
VIOXX	B
should	O
be	O
considered	O
for	O
the	O
treatment	O
of	O
osteoarthritis	O
when	O
VIOXX	B
is	O
co	O
-	O
administered	O
with	O
potent	O
inducers	O
of	O
hepatic	O
metabolism	O
.	O

Theophylline	B
VIOXX	I
12	O
.	O
5	O
,	O
25	O
,	O
and	O
50	O
mg	O
administered	O
once	O
daily	O
for	O
7	O
days	O
increased	O
plasma	O
theophylline	B
concentrations	O
(	O
AUC	O
(	O
0	O
-	O
)	O
)	O
by	O
38	O
to	O
60	O
%	O
in	O
healthy	O
subjects	O
administered	O
a	O
single	O
300	O
-	O
mg	O
dose	O
of	O
theophylline	B
.	O

Adequate	O
monitoring	O
of	O
theophylline	B
plasma	O
concentrations	O
should	O
be	O
considered	O
when	O
therapy	O
with	O
VIOXX	B
is	O
initiated	O
or	O
changed	O
in	O
patients	O
receiving	O
theophylline	B
.	O

Therefore	O
,	O
there	O
is	O
a	O
potential	O
for	O
an	O
interaction	O
with	O
other	O
drugs	O
that	O
are	O
metabolized	O
by	O
CYP	O
1A2	O
(	O
e	O
.	O
g	O
.	O
,	O
amitriptyline	B
,	O
tacrine	B
,	O
and	O
zileuton	B
)	O
.	O

Warfarin	B
:	O
Anticoagulant	O
activity	O
should	O
be	O
monitored	O
,	O
particularly	O
in	O
the	O
first	O
few	O
days	O
after	O
initiating	O
or	O
changing	O
VIOXX	B
therapy	O
in	O
patients	O
receiving	O
warfarin	B
or	O
similar	O
agents	O
,	O
since	O
these	O
patients	O
are	O
at	O
an	O
increased	O
risk	O
of	O
bleeding	O
complications	O
.	O

In	O
single	O
and	O
multiple	O
dose	O
studies	O
in	O
healthy	O
subjects	O
receiving	O
both	O
warfarin	B
and	O
rofecoxib	B
,	O
prothrombin	O
time	O
(	O
measured	O
as	O
INR	O
)	O
was	O
increased	O
by	O
approximately	O
8	O
%	O
to	O
11	O
%	O
.	O

In	O
post	O
-	O
marketing	O
experience	O
,	O
bleeding	O
events	O
have	O
been	O
reported	O
,	O
predominantly	O
in	O
the	O
elderly	O
,	O
in	O
association	O
with	O
increases	O
in	O
prothrombin	O
time	O
in	O
patients	O
receiving	O
VIOXX	B
concurrently	O
with	O
warfarin	B
.	O

Several	O
drug	O
interaction	O
studies	O
have	O
been	O
completed	O
with	O
both	O
INVIRASE	B
and	O
FORTOVASE	B
.	O

Observations	O
from	O
drug	O
interaction	O
studies	O
with	O
FORTOVASE	B
may	O
not	O
be	O
predictive	O
for	O
INVIRASE	B
.	O

Because	O
ritonavir	B
is	O
coadministered	O
,	O
prescribers	O
should	O
also	O
refer	O
to	O
the	O
prescribing	O
information	O
for	O
ritonavir	B
regarding	O
drug	O
interactions	O
associated	O
with	O
this	O
agent	O
.	O

Additional	O
drugs	O
that	O
are	O
not	O
recommended	O
for	O
coadministration	O
with	O
INVIRASE	B
and	O
ritonavir	B
are	O
included	O
below	O
.	O

Drugs	O
That	O
Should	O
Not	O
Be	O
Coadministered	O
With	O
INVIRASE	B
/	O
Ritonavir	B

Antiarrhythmics	B
:	O
Amiodarone	B
,	O
bepridil	B
,	O
flecainide	B
,	O
propafenone	B
,	O
quinidine	B
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
.	O

Antihistamines	B
:	O
astemizole	B
*	O
,	O
terfenadine	B
*	O
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
cardiac	O
arrhythmias	O
.	O

Ergot	B
Derivatives	I
:	O
Dihydroergotamine	B
,	O
ergonovine	B
,	O
ergotamine	B
,	O
methylergonovine	B
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
acute	O
ergot	B
toxicity	O
characterized	O
by	O
peripheral	O
vasospasm	O
and	O
ischemia	O
of	O
the	O
extremities	O
and	O
other	O
tissues	O
.	O

Antimycobacterial	B
Agents	I
:	O
rifampin	B
CONTRAINDICATED	O
since	O
the	O
coadministration	O
of	O
this	O
product	O
with	O
saquinavir	B
in	O
an	O
antiretroviral	B
regimen	O
reduces	O
the	O
plasma	O
concentrations	O
of	O
saquinavir	B
.	O

Garlic	O
Capsules	O
Garlic	O
capsules	O
should	O
not	O
be	O
used	O
while	O
taking	O
saquinavir	B
(	O
FORTOVASE	B
)	O
as	O
the	O
sole	O
protease	B
inhibitor	I
due	O
to	O
the	O
risk	O
of	O
decreased	O
saquinavir	B
plasma	O
concentrations	O
.	O

No	O
data	O
are	O
available	O
for	O
the	O
coadministration	O
of	O
INVIRASE	B
/	O
ritonavir	B
or	O
FORTOVASE	B
/	O
ritonavir	B
and	O
garlic	O
capsules	O
.	O

HMG	O
-	O
CoA	O
Reductase	B
Inhibitors	I
:	O
lovastatin	B
,	O
simvastatin	B
WARNING	O
potential	O
for	O
serious	O
reactions	O
such	O
as	O
risk	O
of	O
myopathy	O
including	O
rhabdomyolysis	O
.	O

Sedatives	B
/	O
Hypnotics	B
:	O
triazolam	B
,	O
midazolam	B
CONTRAINDICATED	O
due	O
to	O
potential	O
for	O
serious	O
and	O
/	O
or	O
life	O
-	O
threatening	O
reactions	O
such	O
as	O
prolonged	O
or	O
increased	O
sedation	O
or	O
respiratory	O
depression	O
.	O

Although	O
specific	O
studies	O
have	O
not	O
been	O
performed	O
,	O
coadministration	O
with	O
drugs	O
that	O
are	O
mainly	O
metabolized	O
by	O
CYP3A4	O
(	O
eg	O
,	O
calcium	B
channel	I
blockers	I
,	O
dapsone	B
,	O
disopyramide	B
,	O
quinine	B
,	O
amiodarone	B
,	O
quinidine	B
,	O
warfarin	B
,	O
tacrolimus	B
,	O
cyclosporine	B
,	O
ergot	B
derivatives	I
,	O
pimozide	B
,	O
carbamazepine	B
,	O
fentanyl	B
,	O
alfentanyl	B
,	O
alprazolam	B
,	O
and	O
triazolam	B
)	O
may	O
have	O
elevated	O
plasma	O
concentrations	O
when	O
coadministered	O
with	O
saquinavir	B
;	O

Since	O
INVIRASE	B
is	O
coadministered	O
with	O
ritonavir	B
,	O
the	O
ritonavir	B
label	O
should	O
be	O
reviewed	O
for	O
additional	O
drugs	O
that	O
should	O
not	O
be	O
coadministered	O
.	O

Coadministration	O
with	O
compounds	O
that	O
are	O
potent	O
inducers	O
of	O
CYP3A4	O
(	O
eg	O
,	O
phenobarbital	B
,	O
phenytoin	B
,	O
dexamethasone	B
,	O
carbamazepine	B
)	O
may	O
result	O
in	O
decreased	O
plasma	O
levels	O
of	O
saquinavir	B
.	O

Sulfacetamide	B
preparations	O
are	O
incompatible	O
with	O
silver	B
preparations	O
.	O

Sulfapyridine	B
may	O
interact	O
with	O
any	O
of	O
the	O
following	O
:	O
-	O
Acetaminophen	B
(	O
e	O
.	O
g	O
.	O
,	O
Tylenol	B
)	O
(	O
with	O
long	O
-	O
term	O
,	O
high	O
-	O
dose	O
use	O
)	O
or	O

-	O
Amiodarone	B
(	O
e	O
.	O
g	O
.	O
,	O
Cordarone	B
)	O
or	O

-	O
Anabolic	B
steroids	I
(	O
nandrolone	B
[	O
e	O
.	O
g	O
.	O
,	O
Anabolin	B
]	O
,	O
oxandrolone	B
[	O
e	O
.	O
g	O
.	O
,	O
Anavar	B
]	O
,	O
oxymetholone	B
[	O
e	O
.	O
g	O
.	O
,	O
Anadrol	B
]	O
,	O
stanozolol	B
[	O
e	O
.	O
g	O
.	O
,	O
Winstrol	B
]	O
)	O
or	O

-	O
Carbamazepine	B
(	O
e	O
.	O
g	O
.	O
,	O
Tegretol	B
)	O
or	O

-	O
Carmustine	B
(	O
e	O
.	O
g	O
.	O
,	O
BiCNU	B
)	O
or	O

-	O
Chloroquine	B
(	O
e	O
.	O
g	O
.	O
,	O
Aralen	B
)	O
or	O

-	O
Dantrolene	B
(	O
e	O
.	O
g	O
.	O
,	O
Dantrium	B
)	O
or	O

-	O
Daunorubicin	B
(	O
e	O
.	O
g	O
.	O
,	O
Cerubidine	B
)	O
or	O

-	O
Disulfiram	B
(	O
e	O
.	O
g	O
.	O
,	O
Antabuse	B
)	O
or	O

-	O
Divalproex	B
(	O
e	O
.	O
g	O
.	O
,	O
Depakote	B
)	O
or	O

-	O
Etretinate	B
(	O
e	O
.	O
g	O
.	O
,	O
Tegison	B
)	O
or	O

-	O
Hydroxychloroquine	B
(	O
e	O
.	O
g	O
.	O
,	O
Plaquenil	B
)	O
or	O

-	O
Mercaptopurine	B
(	O
e	O
.	O
g	O
.	O
,	O
Purinethol	B
)	O
or	O

-	O
Naltrexone	B
(	O
e	O
.	O
g	O
.	O
,	O
Trexan	B
)	O
(	O
with	O
long	O
-	O
term	O
,	O
high	O
-	O
dose	O
use	O
)	O
or	O

-	O
Oral	O
contraceptives	B
(	O
birth	O
control	O
pills	O
)	O
containing	O
estrogen	B
or	O

-	O
Phenothiazines	B
(	O
acetophenazine	B
[	O
e	O
.	O
g	O
.	O
,	O
Tindal	B
]	O
,	O
chlorpromazine	B
[	O
e	O
.	O
g	O
.	O
,	O
Thorazine	B
]	O
,	O
fluphenazine	B
[	O
e	O
.	O
g	O
.	O
,	O
Prolixin	B
]	O
,	O
mesoridazine	B
[	O
e	O
.	O
g	O
.	O
,	O
Serentil	B
]	O
,	O
perphenazine	B
[	O
e	O
.	O
g	O
.	O
,	O
Trilafon	B
]	O
,	O
prochlorperazine	B
[	O
e	O
.	O
g	O
.	O
,	O
Compazine	B
]	O
,	O
promazine	B
[	O
e	O
.	O
g	O
.	O
,	O
Sparine	B
]	O
,	O
promethazine	B
[	O
e	O
.	O
g	O
.	O
,	O
Phenergan	B
]	O
,	O
thioridazine	B
[	O
e	O
.	O
g	O
.	O
,	O
Mellaril	B
]	O
,	O
trifluoperazine	B
[	O
e	O
.	O
g	O
.	O
,	O
Stelazine	B
]	O
,	O
triflupromazine	B
[	O
e	O
.	O
g	O
.	O
,	O
Vesprin	B
]	O
,	O
trimeprazine	B
[	O
e	O
.	O
g	O
.	O
,	O
Temaril	B
]	O
)	O
or	O

-	O
Plicamycin	B
(	O
e	O
.	O
g	O
.	O
,	O
Mithracin	B
)	O
or	O

-	O
Valproic	B
acid	I
(	O
e	O
.	O
g	O
.	O
,	O
Depakene	B
)	O
Use	O
of	O
sulfapyridine	B
with	O
these	O
medicines	O
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
liver	O

-	O
Acetohydroxamic	B
acid	I
(	O
e	O
.	O
g	O
.	O
,	O
Lithostat	B
)	O
or	O

-	O
Furazolidone	B
(	O
e	O
.	O
g	O
.	O
,	O
Furoxone	B
)	O
or	O

-	O
Nitrofurantoin	B
(	O
e	O
.	O
g	O
.	O
,	O
Furadantin	B
)	O
or	O

-	O
Procainamide	B
(	O
e	O
.	O
g	O
.	O
,	O
Pronestyl	B
)	O
or	O

-	O
Quinidine	B
(	O
e	O
.	O
g	O
.	O
,	O
Quinidex	B
)	O
or	O

-	O
Quinine	B
(	O
e	O
.	O
g	O
.	O
,	O
Quinamm	B
)	O
or	O

-	O
Sulfoxone	B
(	O
e	O
.	O
g	O
.	O
,	O
Diasone	B
)	O
or	O

-	O
Vitamin	B
K	I
(	O
e	O
.	O
g	O
.	O
,	O
AquaMEPHYTON	B
,	O
Synkayvite	B
)	O
Use	O
of	O
sulfapyridine	B
with	O
these	O
medicines	O
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
blood	O

-	O
Anticoagulants	B
(	O
blood	B
thinners	O
)	O
or	O

-	O
Ethotoin	B
(	O
e	O
.	O
g	O
.	O
,	O
Peganone	B
)	O
or	O

-	O
Mephenytoin	B
(	O
e	O
.	O
g	O
.	O
,	O
Mesantoin	B
)	O
Use	O
of	O
sulfapyridine	B
with	O
these	O
medicines	O
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
of	O
these	O
medicines	O

-	O
Antidiabetics	B
,	O
oral	O
(	O
diabetes	O
medicine	O
you	O
take	O
by	O
mouth	O
)	O
Use	O
of	O
oral	O
antidiabetics	B
with	O
sulfapyridine	B
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
blood	O
and	O
/	O
or	O
the	O
side	O
effects	O
or	O
oral	O
antidiabetics	B

-	O
Methotrexate	B
(	O
e	O
.	O
g	O
.	O
,	O
Mexate	B
)	O
Use	O
of	O
methotrexate	B
with	O
sulfapyridine	B
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
liver	O
and	O
/	O
or	O
the	O
side	O
effects	O
of	O
methotrexate	B

-	O
Methyldopa	B
(	O
e	O
.	O
g	O
.	O
,	O
Aldomet	B
)	O
Use	O
of	O
methyldopa	B
with	O
sulfapyridine	B
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
liver	O
and	O
/	O
or	O
the	O
blood	O

-	O
Phenytoin	B
(	O
e	O
.	O
g	O
.	O
,	O
Dilantin	B
)	O
Use	O
of	O
phenytoin	B
with	O
sulfapyridine	B
may	O
increase	O
the	O
chance	O
of	O
side	O
effects	O
affecting	O
the	O
liver	O
and	O
/	O
or	O
the	O
side	O
effects	O
of	O
phenytoin	B

In	O
evaluating	O
the	O
potential	O
for	O
interactions	O
among	O
co	O
-	O
administered	O
antiepilepsy	O
drugs	O
(	O
AEDs	B
)	O
,	O
whether	O
or	O
not	O
an	O
AED	B
induces	O
or	O
does	O
not	O
induce	O
metabolic	O
enzymes	O
is	O
an	O
important	O
consideration	O
.	O

Phenytoin	B
,	O
phenobarbital	B
and	O
carbamazepine	B
are	O
ge	O
nerally	O
classified	O
as	O
enzyme	O
inducers	O
;	O

valproate	B
and	O
gabapentin	B
are	O
not	O
.	O

GABITRIL	B
is	O
considered	O
to	O
be	O
a	O
non	O
-	O
enzyme	O
inducing	O
AED	B
.	O

Effects	O
of	O
GABITRIL	B
on	O
other	O
Antiepilepsy	O
Drugs	O
(	O
AEDs	B
)	O
:	O
Phenytoin	B
:	O
Tiagabine	B
had	O
no	O
effect	O
on	O
the	O
steady	O
-	O
state	O
plasma	O
concentrations	O
of	O
phenytoin	B
in	O
patients	O
with	O
epilepsy	O
.	O

Carbamazepine	B
:	O
Tiagabine	B
had	O
no	O
effect	O
on	O
the	O
steady	O
-	O
state	O
plasma	O
concentrations	O
of	O
carbamazepine	B
or	O
its	O
epoxide	O
metabolite	O
in	O
patients	O
with	O
epilepsy	O
.	O

Valproate	B
:	O
Tiagabine	B
causes	O
a	O
slight	O
decrease	O
(	O
about	O
10	O
%	O
)	O
in	O
steady	O
-	O
state	O
valproate	B
concentrations	O
.	O

Phenobarbital	B
or	O
Primidone	B
:	O
No	O
formal	O
pharmacokinetic	O
studies	O
have	O
been	O
performed	O
examining	O
the	O
addition	O
of	O
tiagabine	B
to	O
regimens	O
containing	O
phenobarbital	B
or	O
primidone	B
.	O

The	O
addition	O
of	O
tiagabine	B
in	O
a	O
limited	O
number	O
of	O
patients	O
in	O
three	O
well	O
-	O
controlled	O
studies	O
caused	O
no	O
systematic	O
changes	O
in	O
phenobarbital	B
or	O
primidone	B
concentrations	O
when	O
compared	O
to	O
placebo	O
.	O

Effects	O
of	O
other	O
Antiepilepsy	O
Drugs	O
(	O
AEDs	B
)	O
on	O
GABITRIL	B
:	O
Carbamazepine	B
:	O
Population	O
pharmacokinetic	O
analyses	O
indicate	O
that	O
tiagabine	B
clearance	O
is	O
60	O
%	O
greater	O
in	O
patients	O
taking	O
carbamazepine	B
with	O
or	O
without	O
other	O
enzyme	O
-	O
inducing	O
AEDs	B
.	O

Phenytoin	B
:	O
Population	O
pharmacokinetic	O
analyses	O
indicate	O
that	O
tiagabine	B
clearance	O
is	O
60	O
%	O
greater	O
in	O
patients	O
taking	O
phenytoin	B
with	O
or	O
without	O
other	O
enzyme	O
-	O
inducing	O
AEDs	B
.	O

Phenobarbital	B
(	O
Primidone	B
)	O
:	O
Population	O
pharmacokinetic	O
analyses	O
indicate	O
that	O
tiagabine	B
clearance	O
is	O
60	O
%	O
greater	O
in	O
patients	O
taking	O
phenobarbital	B
(	O
primidone	B
)	O
with	O
or	O
without	O
other	O
enzyme	O
-	O
inducing	O
AEDs	B
.	O

Valproate	B
:	O
The	O
addition	O
of	O
tiagabine	B
to	O
patients	O
taking	O
valproate	B
chronically	O
had	O
no	O
effect	O
on	O
tiagabine	B
pharmacokinetics	O
,	O
but	O
valproate	B
significantly	O
decreased	O
tiagabine	B
binding	O
in	O
vitro	O
from	O
96	O
.	O
3	O
to	O
94	O
.	O
8	O
%	O
,	O
which	O
resulted	O
in	O
an	O
increase	O
of	O
approximately	O
40	O
%	O
in	O
the	O
free	O
tiagabine	B
concentration	O
.	O

Interaction	O
of	O
GABITRIL	B
with	O
Other	O
Drugs	O
:	O
Cimetidine	B
:	O
Co	O
-	O
administration	O
of	O
cimetidine	B
(	O
800	O
mg	O
/	O
day	O
)	O
to	O
patients	O
taking	O
tiagabine	B
chronically	O
had	O
no	O
effect	O
on	O
tiagabine	B
pharmacokinetics	O
.	O

Theophylline	B
:	O
A	O
single	O
10	O
mg	O
dose	O
of	O
tiagabine	B
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
theophylline	B
at	O
steady	O
state	O
.	O

Warfarin	B
:	O
No	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
steady	O
-	O
state	O
pharmacokinetics	O
of	O
R	O
-	O
warfarin	O
or	O
S	O
-	O
warfarin	O
with	O
the	O
addition	O
of	O
tiagabine	B
given	O
as	O
a	O
single	O
dose	O
.	O

Digoxin	B
:	O
Concomitant	O
administration	O
of	O
tiagabine	B
did	O
not	O
affect	O
the	O
steady	O
-	O
state	O
pharmacokinetics	O
of	O
digoxin	B
or	O
the	O
mean	O
daily	O
trough	O
serum	O
level	O
of	O
digoxin	B
.	O

Ethanol	B
or	O
Triazolam	B
:	O
No	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
pharmacokinetics	O
of	O
triazolam	B
(	O
0	O
.	O
125	O
mg	O
)	O
and	O
tiagabine	B
(	O
10	O
mg	O
)	O
when	O
given	O
together	O
as	O
a	O
single	O
dose	O
.	O

The	O
pharmacokinetics	O
of	O
ethanol	B
were	O
not	O
affected	O
by	O
multiple	O
-	O
dose	O
administration	O
of	O
tiagabine	B
.	O

Tiagabine	B
has	O
shown	O
no	O
clinically	O
important	O
potentiation	O
of	O
the	O
pharmacodynamic	O
effects	O
of	O
triazo	O
lam	O
or	O
alcohol	B
.	O

Because	O
of	O
the	O
possible	O
additive	O
effects	O
of	O
drugs	O
that	O
may	O
depress	O
the	O
nervous	O
system	O
,	O
ethanol	B
or	O
triazolam	B
should	O
be	O
used	O
cautiously	O
in	O
combination	O
with	O
tiagabine	B
.	O

Oral	O
Contraceptives	B
:	O
Multiple	O
dose	O
administration	O
of	O
tiagabine	B
(	O
8	O
mg	O
/	O
day	O
monotherapy	O
)	O
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
oral	O
contraceptives	B
in	O
healthy	O
women	O
of	O
childbearing	O
age	O
.	O

Antipyrine	B
:	O
Antipyrine	B
pharmacokinetics	O
were	O
not	O
significantly	O
different	O
before	O
and	O
after	O
tiagabine	B
multiple	O
-	O
dose	O
regimens	O
.	O

This	O
indicates	O
that	O
tiagabine	B
does	O
not	O
cause	O
induction	O
or	O
inhibition	O
of	O
the	O
hepatic	O
microsomal	O
enzyme	O
systems	O
responsible	O
for	O
the	O
metabolism	O
of	O
antipyrine	B
.	O

Interaction	O
of	O
GABITRIL	B
with	O
Highly	O
Protein	O
Bound	O
Drugs	O
:	O
In	O
vitro	O
data	O
showed	O
that	O
tiagabine	B
is	O
96	O
%	O
bound	O
to	O
human	O
plasma	O
protein	O
and	O
therefore	O
has	O
the	O
potential	O
to	O
interact	O
with	O
other	O
highly	O
protein	O
bound	O
compounds	O
.	O

The	O
drug	O
interaction	O
studies	O
with	O
valdecoxib	B
were	O
performed	O
both	O
with	O
valdecoxib	B
and	O
a	O
rapidly	O
hydrolyzed	O
intravenous	O
prodrug	O
form	O
.	O

Aspirin	B
:	O
Concomitant	O
administration	O
of	O
aspirin	B
with	O
valdecoxib	B
may	O
result	O
in	O
an	O
increased	O
risk	O
of	O
GI	O
ulceration	O
and	O
complications	O
compared	O
to	O
valdecoxib	B
alone	O
.	O

Because	O
of	O
its	O
lack	O
of	O
anti	O
-	O
platelet	O
effect	O
valdecoxib	B
is	O
not	O
a	O
substitute	O
for	O
aspirin	B
for	O
cardiovascular	O
prophylaxis	O
.	O

In	O
a	O
parallel	O
group	O
drug	O
interaction	O
study	O
comparing	O
the	O
intravenous	O
prodrug	O
form	O
of	O
valdecoxib	B
at	O
40	O
mg	O
BID	O
(	O
n	O
=	O
10	O
)	O
vs	O
placebo	O
(	O
n	O
=	O
9	O
)	O
,	O
valdecoxib	B
had	O
no	O
effect	O
on	O
in	O
vitro	O
aspirin	B
-	O
mediated	O
inhibition	O
of	O
arachidonate	O
-	O
or	O
collagen	O
-	O
stimulated	O
platelet	O
aggregation	O
.	O

Methotrexate	B
:	O
Valdecoxib	B
10	I
mg	I
BID	O
did	O
not	O
show	O
a	O
significant	O
effect	O
on	O
the	O
plasma	O
exposure	O
or	O
renal	O
clearance	O
of	O
methotrexate	B
.	O

ACE	O
-	O
inhibitors	O
:	O
Reports	O
suggest	O
that	O
NSAIDs	B
may	O
diminish	O
the	O
antihypertensive	O
effect	O
of	O
ACE	O
-	O
inhibitors	O
.	O

This	O
interaction	O
should	O
be	O
given	O
consideration	O
in	O
patients	O
taking	O
BEXTRA	B
concomitantly	O
with	O
ACE	O
-	O
inhibitors	O
.	O

Furosemide	B
:	O
Clinical	O
studies	O
,	O
as	O
well	O
as	O
post	O
-	O
marketing	O
observations	O
,	O
have	O
shown	O
that	O
NSAIDs	B
can	O
reduce	O
the	O
natriuretic	O
effect	O
of	O
furosemide	B
and	O
thiazides	B
in	O
some	O
patients	O
.	O

Anticonvulsants	B
(	O
Phenytoin	B
)	O
:	O
Steady	O
state	O
plasma	O
exposure	O
(	O
AUC	O
)	O
of	O
valdecoxib	B
(	O
40	O
mg	O
BID	O
for	O
12	O
days	O
)	O
was	O
decreased	O
by	O
27	O
%	O
when	O
co	O
-	O
administered	O
with	O
multiple	O
doses	O
(	O
300	O
mg	O
QD	O
for	O
12	O
days	O
)	O
of	O
phenytoin	B
(	O
a	O
CYP	O
3A4	O
inducer	O
)	O
.	O

Patients	O
already	O
stabilized	O
on	O
valdecoxib	B
should	O
be	O
closely	O
monitored	O
for	O
loss	O
of	O
symptom	O
control	O
with	O
phenytoin	B
coadministration	O
.	O

Valdecoxib	B
did	O
not	O
have	O
a	O
statistically	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
of	O
phenytoin	B
(	O
a	O
CYP	O
2C9	O
and	O
CYP	O
2C19	O
substrate	O
)	O
.	O

Dextromethorphan	B
:	O
Dextromethorphan	B
is	O
primarily	O
metabolized	O
by	O
CYP	O
2D6	O
and	O
to	O
a	O
lesser	O
extent	O
by	O
3A4	O
.	O

Coadministration	O
with	O
valdecoxib	B
(	O
40	O
mg	O
BID	O
for	O
7	O
days	O
)	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
dextromethorphan	B
plasma	O
levels	O
suggesting	O
that	O
,	O
at	O
these	O
doses	O
,	O
valdecoxib	B
is	O
a	O
weak	O
inhibitor	O
of	O
2D6	O
.	O

Even	O
so	O
dextromethorphan	B
plasma	O
concentrations	O
in	O
the	O
presence	O
of	O
high	O
doses	O
of	O
valdecoxib	B
were	O
almost	O
5	O
-	O
fold	O
lower	O
than	O
those	O
seen	O
in	O
CYP	O
2D6	O
poor	O
metabolizers	O
suggesting	O
that	O
dose	O
adjustment	O
is	O
not	O
necessary	O
.	O

Lithium	B
:	O
Valdecoxib	B
40	O
mg	O
BID	O
for	O
7	O
days	O
produced	O
significant	O
decreases	O
in	O
lithium	B
serum	O
clearance	O
(	O
25	O
%	O
)	O
and	O
renal	O
clearance	O
(	O
30	O
%	O
)	O
with	O
a	O
34	O
%	O
higher	O
serum	O
exposure	O
compared	O
to	O
lithium	B
alone	O
.	O

Lithium	B
serum	O
concentrations	O
should	O
be	O
monitored	O
closely	O
when	O
initiating	O
or	O
changing	O
therapy	O
with	O
BEXTRA	B
in	O
patients	O
receiving	O
lithium	B
.	O

Lithium	B
carbonate	I
(	O
450	O
mg	O
BID	O
for	O
7	O
days	O
)	O
had	O
no	O
effect	O
on	O
valdecoxib	B
pharmacokinetics	O
.	O

Warfarin	B
:	O
The	O
effect	O
of	O
valdecoxib	B
on	O
the	O
anticoagulant	O
effect	O
of	O
warfarin	B
(	O
1	O
-	O
8	O
mg	O
/	O
day	O
)	O
was	O
studied	O
in	O
healthy	O
subjects	O
by	O
coadministration	O
of	O
BEXTRA	B
40	O
mg	O
BID	O
for	O
7	O
days	O
.	O

Valdecoxib	B
caused	O
a	O
statistically	O
significant	O
increase	O
in	O
plasma	O
exposures	O
of	O
R	O
-	O
warfarin	B
and	O
S	O
-	O
warfarin	B
(	O
12	O
%	O
and	O
15	O
%	O
,	O
respectively	O
)	O
,	O
and	O
in	O
the	O
pharmacodynamic	O
effects	O
(	O
prothrombin	O
time	O
,	O
measured	O
as	O
INR	O
)	O
of	O
warfarin	B
.	O

Anticoagulant	B
therapy	O
should	O
be	O
monitored	O
,	O
particularly	O
during	O
the	O
first	O
few	O
weeks	O
,	O
after	O
initiating	O
therapy	O
with	O
BEXTRA	B
in	O
patients	O
receiving	O
warfarin	B
or	O
similar	O
agents	O
.	O

Fluconazole	B
and	O
Ketoconazole	B
:	O
Ketoconazole	B
and	O
fluconazole	B
are	O
predominantly	O
CYP	O
3A4	O
and	O
2C9	O
inhibitors	O
,	O
respectively	O
.	O

Concomitant	O
single	O
dose	O
administration	O
of	O
valdecoxib	B
20	O
mg	O
with	O
multiple	O
doses	O
of	O
ketoconazole	B
and	O
fluconazole	B
produced	O
a	O
significant	O
increase	O
in	O
exposure	O
of	O
valdecoxib	B
.	O

Plasma	O
exposure	O
(	O
AUC	O
)	O
to	O
valdecoxib	B
was	O
increased	O
62	O
%	O
when	O
coadministered	O
with	O
fluconazole	B
and	O
38	O
%	O
when	O
coadministered	O
with	O
ketoconazole	B
.	O

Glyburide	B
:	O
Glyburide	B
is	O
a	O
CYP	O
2C9	O
substrate	O
.	O

Coadministration	O
of	O
valdecoxib	B
(	O
10	O
mg	O
BID	O
for	O
7	O
days	O
)	O
with	O
glyburide	B
(	O
5	O
mg	O
QD	O
or	O
10	O
mg	O
BID	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
(	O
exposure	O
)	O
of	O
glyburide	B
.	O

Coadministration	O
of	O
valdecoxib	B
(	O
40	O
mg	O
BID	O
(	O
day	O
1	O
)	O
and	O
40	O
mg	O
QD	O
(	O
days	O
2	O
-	O
7	O
)	O
)	O
with	O
glyburide	B
(	O
5	O
mg	O
QD	O
)	O
did	O
not	O
affect	O
either	O
the	O
pharmacokinetics	O
(	O
exposure	O
)	O
or	O
the	O
pharmacodynamics	O
(	O
blood	O
glucose	O
and	O
insulin	O
levels	O
)	O
of	O
glyburide	B
.	O

Coadministration	O
of	O
valdecoxib	B
(	O
40	O
mg	O
BID	O
(	O
day	O
1	O
)	O
and	O
40	O
mg	O
QD	O
(	O
days	O
2	O
-	O
7	O
)	O
)	O
with	O
glyburide	B
(	O
10	O
mg	O
glyburide	B
BID	O
)	O
resulted	O
in	O
21	O
%	O
increase	O
in	O
glyburide	B
AUC0	O
-	O
12	O
and	O
a	O
16	O
%	O
increase	O
in	O
glyburide	B
Cmax	O
leading	O
to	O
a	O
16	O
%	O
decrease	O
in	O
glucose	O
AUC0	O
-	O
24	O
.	O

Because	O
changes	O
in	O
glucose	O
concentrations	O
with	O
valdecoxib	B
coadministration	O
were	O
within	O
the	O
normal	O
variability	O
and	O
individual	O
glucose	O
concentrations	O
were	O
above	O
or	O
near	O
70	O
mg	O
/	O
dL	O
,	O
dose	O
adjustment	O
for	O
glyburide	B
(	O
5	O
mg	O
QD	O
and	O
10	O
mg	O
BID	O
)	O
with	O
valdecoxib	B
coadministration	O
(	O
up	O
to	O
40	O
mg	O
QD	O
)	O
is	O
not	O
indicated	O
.	O

Coadministration	O
of	O
glyburide	B
with	O
doses	O
higher	O
than	O
40	O
mg	O
valdecoxib	B
(	O
e	O
.	O
g	O
.	O
,	O
40	O
mg	O
BID	O
)	O
have	O
not	O
been	O
studied	O
.	O

Omeprazole	B
:	O
Omeprazole	B
is	O
a	O
CYP	O
3A4	O
substrate	O
and	O
CYP	O
2C19	O
substrate	O
and	O
inhibitor	O
.	O

Valdecoxib	B
steady	O
state	O
plasma	O
concentrations	O
(	O
40	O
mg	O
BID	O
)	O
were	O
not	O
affected	O
significantly	O
with	O
multiple	O
doses	O
of	O
omeprazole	B
(	O
40	O
mg	O
QD	O
)	O
.	O

Coadministration	O
with	O
valdecoxib	B
increased	O
exposure	O
of	O
omeprazole	B
(	O
AUC	O
)	O
by	O
46	O
%	O
.	O

Drugs	O
whose	O
absorption	O
is	O
sensitive	O
to	O
pH	O
may	O
be	O
negatively	O
impacted	O
by	O
concomitant	O
administration	O
of	O
omeprazole	B
and	O
valdecoxib	B
.	O

However	O
,	O
because	O
higher	O
doses	O
(	O
up	O
to	O
360	O
mg	O
QD	O
)	O
of	O
omeprazole	B
are	O
tolerated	O
in	O
Zollinger	O
-	O
Ellison	O
(	O
ZE	O
)	O
patients	O
,	O
no	O
dose	O
adjustment	O
for	O
omeprazole	B
is	O
recommended	O
at	O
current	O
doses	O
.	O

Coadministration	O
of	O
valdecoxib	B
with	O
doses	O
higher	O
than	O
40	O
mg	O
QD	O
omeprazole	B
has	O
not	O
been	O
studied	O
.	O

Oral	O
Contraceptives	B
:	O
Valdecoxib	B
(	O
40	O
mg	O
BID	O
)	O
did	O
not	O
induce	O
the	O
metabolism	O
of	O
the	O
combination	O
oral	O
contraceptive	B
norethindrone	I
/	O
ethinyl	B
estradiol	I
(	O
1	O
mg	O
/	O
35	O
mcg	O
combination	O
,	O
Ortho	O
-	O
Novum	O
1	O
/	O
35	O
)	O
.	O

Coadministration	O
of	O
valdecoxib	B
and	O
Ortho	O
-	O
Novum	O
1	O
/	O
35	O
increased	O
the	O
exposure	O
of	O
norethindrone	B
and	O
ethinyl	B
estradiol	I
by	O
20	O
%	O
and	O
34	O
%	O
,	O
respectively	O
.	O

These	O
increased	O
exposures	O
of	O
norethindrone	B
and	O
ethinyl	B
estradiol	I
should	O
be	O
taken	O
into	O
consideration	O
when	O
selecting	O
an	O
oral	O
contraceptive	B
for	O
women	O
taking	O
valdecoxib	B
.	O

Diazepam	B
:	O
Diazepam	B
(	O
Valium	B
)	O
is	O
a	O
CYP	O
3A4	O
and	O
CYP	O
2C19	O
substrate	O
.	O

Plasma	O
exposure	O
of	O
diazepam	B
(	O
10	O
mg	O
BID	O
)	O
was	O
increased	O
by	O
28	O
%	O
following	O
administration	O
of	O
valdecoxib	B
(	O
40	O
mg	O
BID	O
)	O
for	O
12	O
days	O
,	O
while	O
plasma	O
exposure	O
of	O
valdecoxib	B
(	O
40	O
mg	O
BID	O
)	O
was	O
not	O
substantially	O
increased	O
following	O
administration	O
of	O
diazepam	B
(	O
10	O
mg	O
BID	O
)	O
for	O
12	O
days	O
.	O

Although	O
the	O
magnitude	O
of	O
changes	O
in	O
diazepam	B
plasma	O
exposure	O
when	O
coadministered	O
with	O
valdecoxib	B
were	O
not	O
sufficient	O
to	O
warrant	O
dosage	O
adjustments	O
,	O
patients	O
may	O
experience	O
enhanced	O
sedative	O
side	O
effects	O
caused	O
by	O
increased	O
exposure	O
of	O
diazepam	B
under	O
this	O
circumstance	O
.	O

Cimetidine	B
(	O
400	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
had	O
no	O
effect	O
on	O
vardenafil	B
bioavailability	O
(	O
AUC	O
)	O
and	O
maximum	O
concentration	O
(	O
Cmax	O
)	O
of	O
vardenafil	B
when	O
co	O
-	O
administered	O
with	O
20	O
mg	O
Vardenafil	B
in	O
healthy	O
volunteers	O
.	O

Erythromycin	B
(	O
500	O
mg	O
t	O
.	O
i	O
.	O
d	O
)	O
produced	O
a	O
4	O
-	O
fold	O
increase	O
in	O
vardenafil	B
AUC	O
and	O
a	O
3	O
-	O
fold	O
increase	O
in	O
Cmax	O
when	O
co	O
-	O
administered	O
with	O
Vardenafil	B
5	O
mg	O
in	O
healthy	O
volunteers	O
.	O

It	O
is	O
recommended	O
not	O
to	O
exceed	O
a	O
single	O
5	O
mg	O
dose	O
of	O
Vardenafil	B
in	O
a	O
24	O
-	O
hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
erythromycin	B
.	O

Ketoconazole	B
(	O
200	O
mg	O
once	O
daily	O
)	O
produced	O
a	O
10	O
-	O
fold	O
increase	O
in	O
vardenafil	B
AUC	O
and	O
a	O
4	O
-	O
fold	O
increase	O
in	O
Cmax	O
when	O
co	O
-	O
administered	O
with	O
Vardenafil	B
(	O
5	O
mg	O
)	O
in	O
healthy	O
volunteers	O
.	O

A	O
5	O
-	O
mg	O
Vardenafil	B
dose	O
should	O
not	O
be	O
exceeded	O
when	O
used	O
in	O
combination	O
with	O
200	O
mg	O
once	O
daily	O
ketoconazole	B
.	O

Since	O
higher	O
doses	O
of	O
ketoconazole	B
(	O
400	O
mg	O
daily	O
)	O
may	O
result	O
in	O
higher	O
increases	O
in	O
Cmax	O
and	O
AUC	O
,	O
a	O
single	O
2	O
.	O
5	O
mg	O
dose	O
of	O
Vardenafil	B
should	O
not	O
be	O
exceeded	O
in	O
a	O
24	O
-	O
hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
ketoconazole	B
400	O
mg	O
daily	O
.	O

HIV	B
Protease	I
Inhibitors	I
:	O
Indinavir	B
(	O
800	O
mg	O
t	O
.	O
i	O
.	O
d	O
.	O
)	O
co	O
-	O
administered	O
with	O
Vardenafil	B
10	O
mg	O
resulted	O
in	O
a	O
16	O
-	O
fold	O
increase	O
in	O
vardenafil	B
AUC	O
,	O
a	O
7	O
-	O
fold	O
increase	O
in	O
vardenafil	B
Cmax	O
and	O
a	O
2	O
-	O
fold	O
increase	O
in	O
vardenafil	B
half	O
-	O
life	O
.	O

It	O
is	O
recommended	O
not	O
to	O
exceed	O
a	O
single	O
2	O
.	O
5	O
mg	O
Vardenafil	B
dose	O
in	O
a	O
24	O
-	O
hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
indinavir	B
.	O

Ritonavir	B
(	O
600	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
co	O
-	O
administered	O
with	O
Vardenafil	B
5	O
mg	O
resulted	O
in	O
a	O
49	O
-	O
fold	O
increase	O
in	O
vardenafil	B
AUC	O
and	O
a	O
13	O
-	O
fold	O
increase	O
in	O
vardenafil	B
Cmax	O
.	O

The	O
interaction	O
is	O
a	O
consequence	O
of	O
blocking	O
hepatic	O
metabolism	O
of	O
vardenafil	B
by	O
ritonavir	B
,	O
a	O
highly	O
potent	O
CYP3A4	O
inhibitor	O
,	O
which	O
also	O
inhibits	O
CYP2C9	O
.	O

Ritonavir	B
significantly	O
prolonged	O
the	O
half	O
-	O
life	O
of	O
vardenafil	B
to	O
26	O
hours	O
.	O

Consequently	O
,	O
it	O
is	O
recommended	O
not	O
to	O
exceed	O
a	O
single	O
2	O
.	O
5	O
mg	O
Vardenafil	B
dose	O
in	O
a	O
72	O
-	O
hour	O
period	O
when	O
used	O
in	O
combination	O
with	O
ritonavir	B
.	O

Other	O
Drug	O
Interactions	O
:	O
No	O
pharmacokinetic	O
interactions	O
were	O
observed	O
between	O
vardenafil	B
and	O
the	O
following	O
drugs	O
:	O
glyburide	B
,	O
warfarin	B
,	O
digoxin	B
,	O
Maalox	B
,	O
and	O
ranitidine	B
.	O

In	O
the	O
warfarin	B
study	O
,	O
vardenafil	B
had	O
no	O
effect	O
on	O
the	O
prothrombin	O
time	O
or	O
other	O
pharmacodynamic	O
parameters	O
.	O

In	O
vivo	O
studies	O
:	O
Nitrates	B
:	O
The	O
blood	O
pressure	O
lowering	O
effects	O
of	O
sublingual	O
nitrates	B
(	O
0	O
.	O
4	O
mg	O
)	O
taken	O
1	O
and	O
4	O
hours	O
after	O
vardenafil	B
and	O
increases	O
in	O
heart	O
rate	O
when	O
taken	O
at	O
1	O
,	O
4	O
and	O
8	O
hours	O
were	O
potentiated	O
by	O
a	O
20	O
mg	O
dose	O
of	O
Vardenafil	B
in	O
healthy	O
middle	O
-	O
aged	O
subjects	O
.	O

These	O
effects	O
were	O
not	O
observed	O
when	O
Vardenafil	B
20	O
mg	O
was	O
taken	O
24	O
hours	O
before	O
the	O
NTG	B
.	O

Potentiation	O
of	O
the	O
hypotensive	O
effects	O
of	O
nitrates	B
for	O
patients	O
with	O
ischemic	O
heart	O
disease	O
has	O
not	O
been	O
evaluated	O
,	O
and	O
concomitant	O
use	O
of	O
Vardenafil	B
and	O
nitrates	B
is	O
contraindicated	O
.	O

Nifedipine	B
:	O
Vardenafil	B
20	O
mg	O
,	O
when	O
co	O
-	O
administered	O
with	O
slow	O
-	O
release	O
nifedipine	B
30	O
mg	O
or	O
60	O
mg	O
once	O
daily	O
,	O
did	O
not	O
affect	O
the	O
relative	O
bioavailability	O
(	O
AUC	O
)	O
or	O
maximum	O
concentration	O
(	O
Cmax	O
)	O
of	O
nifedipine	B
,	O
a	O
drug	O
that	O
is	O
metabolized	O
via	O
CYP3A4	O
.	O

Nifedipine	B
did	O
not	O
alter	O
the	O
plasma	O
levels	O
of	O
Vardenafil	B
when	O
taken	O
in	O
combination	O
.	O

In	O
these	O
patients	O
whose	O
hypertension	O
was	O
controlled	O
with	O
nifedipine	B
,	O
Vardenafil	B
20	O
mg	O
produced	O
mean	O
additional	O
supine	O
systolic	O
/	O
diastolic	O
blood	O
pressure	O
reductions	O
of	O
6	O
/	O
5	O
mm	O
Hg	O
compared	O
to	O
placebo	O
.	O

Alpha	O
-	O
blockers	O
:	O
When	O
Vardenafil	B
10	O
or	O
20	O
mg	O
was	O
given	O
to	O
healthy	O
volunteers	O
either	O
simultaneously	O
or	O
6	O
hours	O
after	O
a	O
10	O
mg	O
dose	O
of	O
terazosin	B
,	O
significant	O
hypotension	O
developed	O
in	O
a	O
substantial	O
number	O
of	O
subjects	O
.	O

With	O
simultaneous	O
dosing	O
of	O
Vardenafil	B
10	O
mg	O
and	O
terazosin	B
10	O
mg	O
,	O
6	O
of	O
8	O
subjects	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
of	O
less	O
than	O
85	O
mm	O
Hg	O
.	O

With	O
simultaneous	O
dosing	O
of	O
Vardenafil	B
20	O
mg	O
and	O
terazosin	B
10	O
mg	O
,	O
2	O
of	O
9	O
subjects	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
of	O
less	O
than	O
85	O
mm	O
Hg	O
.	O

When	O
Vardenafil	B
dosing	O
was	O
separated	O
from	O
terazosin	B
10	O
mg	O
by	O
6	O
hours	O
,	O
7	O
of	O
28	O
subjects	O
who	O
received	O
20	O
mg	O
of	O
Vardenafil	B
experienced	O
a	O
decrease	O
in	O
standing	O
systolic	O
blood	O
pressure	O
below	O
85	O
mm	O
Hg	O
.	O

In	O
a	O
similar	O
study	O
with	O
tamsulosin	B
in	O
healthy	O
volunteers	O
,	O
1	O
of	O
24	O
subjects	O
dosed	O
with	O
Vardenafil	B
20	O
mg	O
and	O
tamsulosin	B
0	O
.	O
4	O
mg	O
separated	O
by	O
6	O
hours	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
below	O
85	O
mm	O
Hg	O
.	O

Two	O
of	O
16	O
subjects	O
dosed	O
simultaneously	O
with	O
Vardenafil	B
10	O
mg	O
and	O
tamsulosin	B
0	O
.	O
4	O
mg	O
experienced	O
a	O
standing	O
systolic	O
blood	O
pressure	O
below	O
85	O
mm	O
Hg	O
.	O

The	O
administration	O
of	O
lower	O
doses	O
of	O
Vardenafil	B
with	O
alpha	O
-	O
blockers	O
has	O
not	O
been	O
completely	O
evaluated	O
to	O
determine	O
if	O
they	O
can	O
be	O
safely	O
administered	O
together	O
.	O

Based	O
on	O
these	O
data	O
,	O
Vardenafil	B
should	O
not	O
be	O
used	O
in	O
patients	O
on	O
alpha	O
-	O
blocker	O
therapy	O
.	O

Ritonavir	B
and	O
indinavir	B
:	O
Upon	O
concomitant	O
administration	O
of	O
5	O
mg	O
of	O
Vardenafil	B
with	O
600	O
mg	O
BID	O
ritonavir	B
,	O
the	O
Cmax	O
and	O
AUC	O
of	O
ritonavir	B
were	O
reduced	O
by	O
approximately	O
20	O
%	O
.	O

Upon	O
administration	O
of	O
10	O
mg	O
of	O
Vardenafil	B
with	O
800	O
mg	O
TID	O
indinavir	B
,	O
the	O
Cmax	O
and	O
AUC	O
of	O
indinavir	B
were	O
reduced	O
by	O
40	O
%	O
and	O
30	O
%	O
,	O
respectively	O
.	O

Alcohol	B
:	O
Alcohol	B
(	O
0	O
.	O
5	O
g	O
/	O
kg	O
body	O
weight	O
:	O
approximately	O
40	O
mL	O
of	O
absolute	O
alcohol	O
in	O
a	O
70	O
kg	O
person	O
)	O
and	O
vardenafil	B
plasma	O
levels	O
were	O
not	O
altered	O
when	O
dosed	O
simultaneously	O
.	O

Vardenafil	B
(	O
20	O
mg	O
)	O
did	O
not	O
potentiate	O
the	O
hypotensive	O
effects	O
of	O
alcohol	B
during	O
the	O
4	O
-	O
hour	O
observation	O
period	O
in	O
healthy	O
volunteers	O
when	O
administered	O
with	O
alcohol	B
(	O
0	O
.	O
5	O
g	O
/	O
kg	O
body	O
weight	O
)	O
.	O

Aspirin	B
:	O
Vardenafil	B
(	O
10	O
mg	O
and	O
20	O
mg	O
)	O
did	O
not	O
potentiate	O
the	O
increase	O
in	O
bleeding	O
time	O
caused	O
by	O
aspirin	B
(	O
two	O
81	O
mg	O
tablets	O
)	O
.	O

Other	O
interactions	O
:	O
Vardenafil	B
had	O
no	O
effect	O
on	O
the	O
pharmacodynamics	O
of	O
glyburide	B
(	O
glucose	O
and	O
insulin	O
concentrations	O
)	O
and	O
warfarin	B
(	O
prothrombin	O
time	O
or	O
other	O
pharmacodynamic	O
parameters	O
)	O
.	O

Zidovudine	B
:	O
There	O
is	O
no	O
significant	O
pharmacokinetic	O
interaction	O
between	O
ZDV	B
and	O
zalcitabine	B
which	O
has	O
been	O
confirmed	O
clinically	O
.	O

Zalcitabine	B
also	O
has	O
no	O
significant	O
effect	O
on	O
the	O
intracellular	O
phosphorylation	O
of	O
ZDV	B
,	O
as	O
shown	O
in	O
vitro	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
or	O
in	O
two	O
other	O
cell	O
lines	O
(	O
U937	O
and	O
Molt	O
-	O
4	O
)	O
.	O

In	O
the	O
same	O
study	O
it	O
was	O
shown	O
that	O
didanosine	B
and	O
stavudine	B
had	O
no	O
significant	O
effect	O
on	O
the	O
intracellular	O
phosphorylation	O
of	O
zalcitabine	B
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Lamivudine	B
:	O
In	O
vitro	O
studies	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
U937	O
and	O
Molt	O
-	O
4	O
cells	O
revealed	O
that	O
lamivudine	B
significantly	O
inhibited	O
zalcitabine	B
phosphorylation	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O

Zalcitabine	B
inhibited	O
lamivudine	B
phosphorylation	O
at	O
high	O
concentration	O
ratios	O
(	O
10	O
and	O
100	O
)	O
;	O

however	O
,	O
it	O
is	O
considered	O
to	O
be	O
unlikely	O
that	O
this	O
decrease	O
of	O
phosphorylated	O
lamivudine	B
concentration	O
is	O
of	O
clinical	O
significance	O
,	O
as	O
lamivudine	B
is	O
a	O
more	O
efficient	O
substrate	O
for	O
deoxycytidine	O
kinase	O
than	O
zalcitabine	B
.	O

These	O
in	O
vitro	O
studies	O
suggest	O
that	O
concomitant	O
administration	O
of	O
zalcitabine	B
and	O
lamivudine	B
in	O
humans	O
may	O
result	O
in	O
sub	O
-	O
therapeutic	O
concentrations	O
of	O
active	O
phosphorylated	O
zalcitabine	B
,	O
which	O
may	O
lead	O
to	O
a	O
decreased	O
antiretroviral	B
effect	O
of	O
zalcitabine	B
.	O

Concomitant	O
use	O
of	O
zalcitabine	B
and	O
lamivudine	B
is	O
not	O
recommended	O
.	O

Saquinavir	B
:	O
The	O
combination	O
of	O
HIVID	B
,	O
saquinavir	B
,	O
and	O
ZDV	B
has	O
been	O
studied	O
(	O
as	O
triple	O
combination	O
)	O
in	O
adults	O
.	O

Drugs	O
that	O
have	O
been	O
associated	O
with	O
peripheral	O
neuropathy	O
include	O
antiretroviral	B
nucleoside	I
analogues	I
,	O
chloramphenicol	B
,	O
cisplatin	B
,	O
dapsone	B
,	O
disulfiram	B
,	O
ethionamide	B
,	O
glutethimide	B
,	O
gold	B
,	O
hydralazine	B
,	O
iodoquinol	B
,	O
isoniazid	B
,	O
metronidazole	B
,	O
nitrofurantoin	B
,	O
phenytoin	B
,	O
ribavirin	B
,	O
and	O
vincristine	B
.	O

Concomitant	O
use	O
of	O
HIVID	B
with	O
didanosine	B
is	O
not	O
recommended	O
.	O

Intravenous	O
Pentamidine	B
:	O
Treatment	O
with	O
HIVID	B
should	O
be	O
interrupted	O
when	O
the	O
use	O
of	O
a	O
drug	O
that	O
has	O
the	O
potential	O
to	O
cause	O
pancreatitis	O
is	O
required	O
.	O

Death	O
due	O
to	O
fulminant	O
pancreatitis	O
possibly	O
related	O
to	O
intravenous	O
pentamidine	B
and	O
HIVID	B
has	O
been	O
reported	O
.	O

If	O
intravenous	O
pentamidine	B
is	O
required	O
to	O
treat	O
Pneumocystis	O
carinii	O
pneumonia	O
,	O
treatment	O
with	O
HIVID	B
should	O
be	O
interrupted	O
.	O

Amphotericin	B
,	O
Foscarnet	B
,	O
and	O
Aminoglycosides	B
:	O
Drugs	O
such	O
as	O
amphotericin	B
,	O
foscarnet	B
,	O
and	O
aminoglycosides	B
may	O
increase	O
the	O
risk	O
of	O
developing	O
peripheral	O
neuropathy	O
or	O
other	O
HIVID	B
-	O
associated	O
adverse	O
events	O
by	O
interfering	O
with	O
the	O
renal	O
clearance	O
of	O
zalcitabine	B
(	O
thereby	O
raising	O
systemic	O
exposure	O
)	O
.	O

Probenecid	B
or	O
Cimetidine	B
:	O
Concomitant	O
administration	O
of	O
probenecid	B
or	O
cimetidine	B
decreases	O
the	O
elimination	O
of	O
zalcitabine	B
,	O
most	O
likely	O
by	O
inhibition	O
of	O
renal	O
tubular	O
secretion	O
of	O
zalcitabine	B
.	O

Patients	O
receiving	O
these	O
drugs	O
in	O
combination	O
with	O
zalcitabine	B
should	O
be	O
monitored	O
for	O
signs	O
of	O
toxicity	O
and	O
the	O
dose	O
of	O
zalcitabine	B
reduced	O
if	O
warranted	O
.	O

Magnesium	B
/	O
Aluminum	B
-	O
containing	O
Antacid	B
Products	I
:	O
Absorption	O
of	O
zalcitabine	B
is	O
moderately	O
reduced	O
(	O
approximately	O
25	O
%	O
)	O
when	O
coadministered	O
with	O
magnesium	B
/	O
aluminum	B
-	O
containing	O
antacid	B
products	I
.	O

The	O
clinical	O
significance	O
of	O
this	O
reduction	O
is	O
not	O
known	O
,	O
hence	O
zalcitabine	B
is	O
not	O
recommended	O
to	O
be	O
ingested	O
simultaneously	O
with	O
magnesium	B
/	O
aluminum	B
-	O
containing	O
antacids	B
.	O

Metoclopramide	B
:	O
Bioavailability	O
is	O
mildly	O
reduced	O
(	O
approximately	O
10	O
%	O
)	O
when	O
zalcitabine	B
and	O
metoclopramide	B
are	O
coadministered	O
.	O

Doxorubicin	B
:	O
Doxorubicin	B
caused	O
a	O
decrease	O
in	O
zalcitabine	B
phosphorylation	O
(	O
50	O
%	O
inhibition	O
of	O
total	O
phosphate	O
formation	O
)	O
in	O
U937	O
/	O
Molt	O
4	O
cells	O
.	O

CNS	O
-	O
Active	O
Drugs	O
Ethanol	B
:	O
Sonata	B
10	O
mg	O
potentiated	O
the	O
CNS	O
-	O
impairing	O
effects	O
of	O
ethanol	B
0	O
.	O
75	O
g	O
/	O
kg	O
on	O
balance	O
testing	O
and	O
reaction	O
time	O
for	O
1	O
hour	O
after	O
ethanol	B
administration	O
and	O
on	O
the	O
digit	O
symbol	O
substitution	O
test	O
(	O
DSST	O
)	O
,	O
symbol	O
copying	O
test	O
,	O
and	O
the	O
variability	O
component	O
of	O
the	O
divided	O
attention	O
test	O
for	O
2	O
.	O
5	O
hours	O
after	O
ethanol	B
administration	O
.	O

zaleplon	B
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
ethanol	B
.	O

Imipramine	B
:	O
Coadministration	O
of	O
single	O
doses	O
of	O
Sonata	B
20	O
mg	O
and	O
imipramine	B
75	O
mg	O
produced	O
additive	O
effects	O
on	O
decreased	O
alertness	O
and	O
impaired	O
psychomotor	O
performance	O
for	O
2	O
to	O
4	O
hours	O
after	O
administration	O
.	O

Paroxetine	B
:	O
Coadministration	O
of	O
a	O
single	O
dose	O
of	O
Sonata	B
20	O
mg	O
and	O
paroxetine	B
20	O
mg	O
daily	O
for	O
7	O
days	O
did	O
not	O
produce	O
any	O
interaction	O
on	O
psychomotor	O
performance	O
.	O

Additionally	O
,	O
paroxetine	B
did	O
not	O
alter	O
the	O
pharmacokinetics	O
of	O
Sonata	B
,	O
reflecting	O
the	O
absence	O
of	O
a	O
role	O
of	O
CYP2D6	O
in	O
zaleplon	B
s	O
metabolism	O
.	O

Thioridazine	B
:	O
Coadministration	O
of	O
single	O
doses	O
of	O
Sonata	B
20	O
mg	O
and	O
thioridazine	B
50	O
mg	O
produced	O
additive	O
effects	O
on	O
decreased	O
alertness	O
and	O
impaired	O
psychomotor	O
performance	O
for	O
2	O
to	O
4	O
hours	O
after	O
administration	O
.	O

Venlafaxine	B
:	O
Coadministration	O
of	O
a	O
single	O
dose	O
of	O
zaleplon	B
10	O
mg	O
and	O
multiple	O
doses	O
of	O
venlafaxine	B
ER	O
(	O
extended	O
release	O
)	O
150	O
mg	O
did	O
not	O
result	O
in	O
any	O
significant	O
changes	O
in	O
the	O
pharmacokinetics	O
of	O
either	O
zaleplon	B
or	O
venlafaxine	B
.	O

In	O
addition	O
,	O
there	O
was	O
no	O
pharmacodynamic	O
interaction	O
as	O
a	O
result	O
of	O
coadministration	O
of	O
zaleplon	B
and	O
venlafaxine	B
ER	O
.	O

Promethazine	B
:	O
Coadministration	O
of	O
a	O
single	O
dose	O
of	O
zaleplon	B
and	O
promethazine	B
(	O
10	O
and	O
25	O
mg	O
,	O
respectively	O
)	O
resulted	O
in	O
a	O
15	O
%	O
decrease	O
in	O
maximal	O
plasma	O
concentrations	O
of	O
zaleplon	B
,	O
but	O
no	O
change	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
.	O

However	O
,	O
the	O
pharmacodynamics	O
of	O
coadministration	O
of	O
zaleplon	B
and	O
promethazine	B
have	O
not	O
been	O
evaluated	O
.	O

Drugs	O
That	O
Induce	O
CYP3A4	O
Rifampin	B
:	O
CYP3A4	O
is	O
ordinarily	O
a	O
minor	O
metabolizing	O
enzyme	O
of	O
zaleplon	B
.	O

Multiple	O
-	O
dose	O
administration	O
of	O
the	O
potent	O
CYP3A4	O
inducer	O
rifampin	B
(	O
600	O
mg	O
every	O
24	O
hours	O
,	O
q24h	O
,	O
for	O
14	O
days	O
)	O
,	O
however	O
,	O
reduced	O
zaleplon	B
Cmax	O
and	O
AUC	O
by	O
approximately	O
80	O
%	O
.	O

An	O
alternative	O
non	O
-	O
CYP3A4	O
substrate	O
hypnotic	B
agent	I
may	O
be	O
considered	O
in	O
patients	O
taking	O
CYP3A4	O
inducers	O
such	O
as	O
rifampin	B
,	O
phenytoin	B
,	O
carbamazepine	B
,	O
and	O
phenobarbital	B
.	O

Drugs	O
That	O
Inhibit	O
CYP3A4	O
CYP3A4	O
is	O
a	O
minor	O
metabolic	O
pathway	O
for	O
the	O
elimination	O
of	O
zaleplon	B
because	O
the	O
sum	O
of	O
desethylzaleplon	O
(	O
formed	O
via	O
CYP3A4	O
in	O
vitro	O
)	O
and	O
its	O
metabolites	O
,	O
5	O
-	O
oxo	O
-	O
desethylzaleplon	O
and	O
5	O
-	O
oxo	O
-	O
desethylzaleplon	O
glucuronide	B
,	O
account	O
for	O
only	O
9	O
%	O
of	O
the	O
urinary	O
recovery	O
of	O
a	O
zaleplon	B
dose	O
.	O

Coadministration	O
of	O
single	O
,	O
oral	O
doses	O
of	O
zaleplon	B
with	O
erythromycin	B
(	O
10	O
mg	O
and	O
800	O
mg	O
,	O
respectively	O
)	O
,	O
a	O
strong	O
,	O
selective	O
CYP3A4	O
inhibitor	O
produced	O
a	O
34	O
%	O
increase	O
in	O
zaleplons	O
maximal	O
plasma	O
concentrations	O
and	O
a	O
20	O
%	O
increase	O
in	O
the	O
area	O
under	O
the	O
plasma	O
concentration	O
-	O
time	O
curve	O
.	O

Other	O
strong	O
selective	O
CYP3A4	O
inhibitors	O
such	O
as	O
ketoconazole	B
can	O
also	O
be	O
expected	O
to	O
increase	O
the	O
exposure	O
of	O
zaleplon	B
.	O

Diphenhydramine	B
:	O
Diphenhydramine	B
is	O
reported	O
to	O
be	O
a	O
weak	O
inhibitor	O
of	O
aldehyde	O
oxidase	O
in	O
rat	O
liver	O
,	O
but	O
its	O
inhibitory	O
effects	O
in	O
human	O
liver	O
are	O
not	O
known	O
.	O

There	O
is	O
no	O
pharmacokinetic	O
interaction	O
between	O
zaleplon	B
and	O
diphenhydramine	B
following	O
the	O
administration	O
of	O
a	O
single	O
dose	O
(	O
10	O
mg	O
and	O
50	O
mg	O
,	O
respectively	O
)	O
of	O
each	O
drug	O
.	O

Drugs	O
That	O
Inhibit	O
Both	O
Aldehyde	O
Oxidase	O
and	O
CYP3A4	O
Cimetidine	B
:	O
Cimetidine	B
inhibits	O
both	O
aldehyde	O
oxidase	O
(	O
in	O
vitro	O
)	O
and	O
CYP3A4	O
(	O
in	O
vitro	O
and	O
in	O
vivo	O
)	O
,	O
the	O
primary	O
and	O
secondary	O
enzymes	O
,	O
respectively	O
,	O
responsible	O
for	O
zaleplon	B
metabolism	O
.	O

Concomitant	O
administration	O
of	O
Sonata	B
(	O
10	O
mg	O
)	O
and	O
cimetidine	B
(	O
800	O
mg	O
)	O
produced	O
an	O
85	O
%	O
increase	O
in	O
the	O
mean	O
Cmax	O
and	O
AUC	O
of	O
zaleplon	B
.	O

Drugs	O
with	O
a	O
Narrow	O
Therapeutic	O
Index	O
Digoxin	B
:	O
Sonata	B
(	O
10	O
mg	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetic	O
or	O
pharmacodynamic	O
profile	O
of	O
digoxin	B
(	O
0	O
.	O
375	O
mg	O
q24h	O
for	O
8	O
days	O
)	O
.	O

Warfarin	B
:	O
Multiple	O
oral	O
doses	O
of	O
Sonata	B
(	O
20	O
mg	O
q24h	O
for	O
13	O
days	O
)	O
did	O
not	O
affect	O
the	O
pharmacokinetics	O
of	O
warfarin	B
(	O
R	O
+	O
)	O
-	O
or	O
(	O
S	O
-	O
)	O
-	O
enantiomers	O
or	O
the	O
pharmacodynamics	O
(	O
prothrombin	O
time	O
)	O
following	O
a	O
single	O
25	O
-	O
mg	O
oral	O
dose	O
of	O
warfarin	B
.	O

Drugs	O
That	O
Alter	O
Renal	O
Excretion	O
Ibuprofen	B
:	O
Ibuprofen	B
is	O
known	O
to	O
affect	O
renal	O
function	O
and	O
,	O
consequently	O
,	O
alter	O
the	O
renal	O
excretion	O
of	O
other	O
drugs	O
.	O

There	O
was	O
no	O
apparent	O
pharmacokinetic	O
interaction	O
between	O
zaleplon	B
and	O
ibuprofen	B
following	O
single	O
dose	O
administration	O
(	O
10	O
mg	O
and	O
600	O
mg	O
,	O
respectively	O
)	O
of	O
each	O
drug	O
.	O

This	O
was	O
expected	O
because	O
zaleplon	B
is	O
primarily	O
metabolized	O
and	O
renal	O
excretion	O
of	O
unchanged	O
zaleplon	B
accounts	O
for	O
less	O
than	O
1	O
%	O
of	O
the	O
administered	O
dose	O
.	O

